Clustering O 0 5.958143901807489e-06
of O 0 1.346638356380936e-07
missense O 0 2.751829924818594e-06
mutations O 0 2.6499996863549313e-08
in O 0 2.2762005613685687e-08
the O 0 6.93637048243545e-06
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
gene O 0 1.2338553005974973e-06
in O 0 4.6458406899319016e-08
a O 0 1.0435768871275286e-07
sporadic B-Disease 0 7.904995072749443e-06
T I-Disease 0 0.01717166230082512
- I-Disease 1 0.7820743918418884
cell I-Disease 1 0.9998513460159302
leukaemia I-Disease 1 1.0
. O 0 5.201363819651306e-07

Ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 0.9999997615814209
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 4.499125694223949e-08
is O 0 8.517094252091795e-10
a O 0 4.102456596655202e-09
recessive B-Disease 0 2.095401328006119e-07
multi I-Disease 1 0.8603073954582214
- I-Disease 1 1.0
system I-Disease 0 0.169301375746727
disorder I-Disease 1 0.9654417037963867
caused O 0 1.0628269819790148e-07
by O 0 6.260199025831525e-10
mutations O 0 5.125725954790994e-10
in O 0 2.1313406595169226e-09
the O 0 3.149888883058338e-08
ATM O 0 9.817335012485273e-06
gene O 0 6.077452319175336e-09
at O 0 1.5528134156284068e-07
11q22 O 0 9.89441559795523e-07
- O 0 1.1353350828358089e-06
q23 O 0 5.32061039848486e-06
( O 0 1.818019654820091e-07
ref O 0 1.1877316410391359e-06
. O 0 1.1741299044132347e-09
3 O 0 3.971570095018251e-08
) O 0 3.401289694338061e-09
. O 0 6.576358124732451e-09

The O 0 3.663558914013265e-07
risk O 0 4.0372930243393057e-07
of O 0 1.9821028729438694e-07
cancer B-Disease 0 1.80809020093875e-05
, O 0 5.211295395213256e-09
especially O 0 3.9056438083662215e-08
lymphoid B-Disease 1 0.9999833106994629
neoplasias I-Disease 1 0.9999911785125732
, O 0 7.1596644168892e-09
is O 0 8.553315833381703e-10
substantially O 0 1.2260107595807312e-08
elevated O 0 7.647695809964716e-08
in O 0 6.400818364227234e-08
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 2.9154179514989664e-07
and O 0 6.602635660435396e-10
has O 0 1.0816524759205137e-10
long O 0 1.6209367181829748e-10
been O 0 1.3415553390405677e-10
associated O 0 4.325640401425801e-10
with O 0 1.4894261379794216e-09
chromosomal O 1 1.0
instability O 1 1.0
. O 0 1.4896052107360447e-06

By O 0 1.109518095177009e-07
analysing O 0 6.453558398789028e-06
tumour B-Disease 1 1.0
DNA O 0 7.4424910678772e-08
from O 0 1.9820560748229354e-09
patients O 0 5.8010315301393334e-11
with O 0 1.286722377952243e-11
sporadic B-Disease 0 4.343664272710157e-07
T I-Disease 0 0.00013682626013178378
- I-Disease 0 0.00015095065464265645
cell I-Disease 0 0.0008852403261698782
prolymphocytic I-Disease 0 0.0017699752934277058
leukaemia I-Disease 1 0.9999998807907104
( O 0 1.2548302663617505e-07
T B-Disease 0 1.1918061773030786e-06
- I-Disease 0 1.28824899547908e-06
PLL I-Disease 0 0.0003692795289680362
) O 0 9.228744990430471e-10
, O 0 3.082056831971158e-11
a O 0 5.702999184009627e-10
rare O 0 4.261536901140062e-09
clonal B-Disease 0 1.1449208159319824e-06
malignancy I-Disease 0 4.4079890358261764e-05
with O 0 7.597152351657144e-10
similarities O 0 5.851994444583397e-08
to O 0 7.693646608686322e-09
a O 0 5.344209697000224e-08
mature B-Disease 0 1.9283520202861837e-07
T I-Disease 0 1.7569921055837767e-06
- I-Disease 0 8.112964451356675e-07
cell I-Disease 0 2.207504849138786e-06
leukaemia I-Disease 0 0.0006449579959735274
seen O 0 5.061340502265921e-08
in O 0 1.4367897094302862e-08
A B-Disease 1 1.0
- I-Disease 1 0.8000326752662659
T I-Disease 1 1.0
, O 0 3.7846095701787874e-10
we O 0 2.415428412838594e-10
demonstrate O 0 7.504232790722654e-10
a O 0 3.5201566661591244e-10
high O 0 5.230282873469605e-10
frequency O 0 6.780738193157276e-10
of O 0 2.6241102624169343e-09
ATM O 0 3.899573925991717e-07
mutations O 0 3.834778272704398e-09
in O 0 7.537391155665318e-08
T B-Disease 0 1.7358788682031445e-05
- I-Disease 0 5.379262438509613e-05
PLL I-Disease 0 0.009822247549891472
. O 0 3.6837528227806615e-07

In O 0 1.346769238352863e-07
marked O 0 4.9080995268013794e-08
contrast O 0 1.1609563088654795e-08
to O 0 1.965450246999012e-09
the O 0 1.2852502173643643e-08
ATM O 0 8.636106372250651e-07
mutation O 0 1.5564042277205203e-09
pattern O 0 1.7279697672734073e-08
in O 0 6.107458716542169e-08
A B-Disease 1 1.0
- I-Disease 1 0.9999561309814453
T I-Disease 1 1.0
, O 0 2.497488604813469e-10
the O 0 3.5286401578460413e-10
most O 0 6.890153378402708e-12
frequent O 0 7.30832269701942e-11
nucleotide O 0 1.968026436260928e-10
changes O 0 1.2840842972261513e-11
in O 0 1.7178597433442633e-10
this O 0 1.9616750446260767e-09
leukaemia B-Disease 0 0.0003913685504812747
were O 0 1.0511601544749283e-07
missense O 0 6.11488849244779e-06
mutations O 0 9.783025234355591e-08
. O 0 8.369413961872851e-08

These O 0 1.6317386553055258e-07
clustered O 0 7.436977398356248e-07
in O 0 6.617327130697959e-09
the O 0 7.117645584031607e-09
region O 0 2.1405409000863074e-08
corresponding O 0 8.328424172532323e-08
to O 0 3.106062607116655e-08
the O 0 2.8419293585102423e-07
kinase O 0 0.00011784815433202311
domain O 0 8.083926417157272e-08
, O 0 8.705004599096622e-12
which O 0 2.376227903680417e-12
is O 0 3.2084508660989997e-12
highly O 0 1.1408238936860826e-10
conserved O 0 5.286903803636278e-09
in O 0 9.360788588708147e-09
ATM O 0 2.3189809326140676e-06
- O 0 2.820909905665303e-08
related O 0 1.927156567660404e-08
proteins O 0 1.9235457671129552e-09
in O 0 6.284512021892397e-09
mouse O 0 2.203528204347549e-08
, O 0 6.212153708107238e-11
yeast O 0 1.0086139035081487e-08
and O 0 6.431803090123367e-09
Drosophila O 0 1.1888898825418437e-06
. O 0 1.7457427503586587e-08

The O 0 4.2503293684603705e-07
resulting O 0 1.4749588217455312e-07
amino O 0 9.551045110356426e-08
- O 0 4.006531284517223e-08
acid O 0 6.1730056621911444e-09
substitutions O 0 9.521411215018816e-09
are O 0 6.432928634225732e-10
predicted O 0 1.0936170191655492e-08
to O 0 1.4197689246486789e-08
interfere O 0 1.7102040317240608e-07
with O 0 7.183766470575392e-09
ATP O 0 0.0004908267874270678
binding O 0 6.267552521421749e-08
or O 0 3.8152570880356507e-08
substrate O 0 1.882340399106397e-07
recognition O 0 9.345877316491169e-08
. O 0 9.320172011939576e-08

Two O 0 2.5606030362723686e-07
of O 0 1.5678216414016788e-07
seventeen O 0 6.725204571012e-07
mutated O 0 2.0441812864646636e-07
T B-Disease 0 4.78666470371536e-06
- I-Disease 0 1.7257553963645478e-06
PLL I-Disease 0 0.0002064781729131937
samples O 0 2.250458663866084e-08
had O 0 2.4197284176352696e-08
a O 0 1.4528390046564255e-08
previously O 0 2.487564643161022e-08
reported O 0 1.9204311740850244e-07
A B-Disease 1 1.0
- I-Disease 1 0.9988227486610413
T I-Disease 1 0.9999996423721313
allele O 0 2.643893992626545e-07
. O 0 1.2146989547545672e-07

In O 0 1.0173337727792386e-07
contrast O 0 1.3234307871812234e-08
, O 0 8.713866850307284e-10
no O 0 1.5177020751266923e-09
mutations O 0 4.948957910144713e-10
were O 0 3.6247442825043663e-09
detected O 0 3.81670339777429e-09
in O 0 1.8116214084429316e-09
the O 0 1.5110593665212946e-08
p53 O 0 4.1945583006963716e-08
gene O 0 1.3504953821907861e-09
, O 0 2.0494625441180858e-10
suggesting O 0 1.0218958124141864e-08
that O 0 2.9422275726886937e-10
this O 0 3.152623762048279e-08
tumour B-Disease 1 1.0
suppressor O 0 0.0001610855688340962
is O 0 2.879728677740445e-10
not O 0 2.893988000629566e-11
frequently O 0 9.383051974287682e-11
altered O 0 7.678675473243857e-10
in O 0 1.975293040246129e-09
this O 0 1.4774387047111759e-08
leukaemia B-Disease 0 0.004372558556497097
. O 0 8.28245276807138e-08

Occasional O 0 3.523820123518817e-05
missense O 0 3.6537370760925114e-05
mutations O 0 3.9262584294874614e-08
in O 0 4.770067718595783e-08
ATM O 0 4.9204718379769474e-06
were O 0 2.0432741720810554e-08
also O 0 5.096985611352522e-10
found O 0 8.989411992565977e-10
in O 0 5.759869026178421e-09
tumour B-Disease 1 1.0
DNA O 0 2.7313882711155202e-08
from O 0 9.709644199773493e-10
patients O 0 3.4357655609440485e-11
with O 0 2.1020405902016925e-11
B B-Disease 0 6.143101472844137e-06
- I-Disease 0 6.56025658827275e-05
cell I-Disease 0 0.3991895914077759
non I-Disease 1 0.9998055100440979
- I-Disease 1 0.846448540687561
Hodgkins I-Disease 1 1.0
lymphomas I-Disease 0 1.2118230188207235e-05
( O 0 2.6630202487609722e-09
B B-Disease 0 2.8976268495739532e-08
- I-Disease 0 2.8986204547720718e-09
NHL I-Disease 0 4.934937081202406e-08
) O 0 4.19601853263174e-10
and O 0 1.2942327765053108e-10
a O 0 1.002574112618504e-08
B B-Disease 0 3.603198877044633e-07
- I-Disease 0 2.3872999577179144e-07
NHL I-Disease 0 3.934129381377716e-06
cell O 0 2.5838829969870858e-05
line O 0 8.33230785701744e-07
. O 0 9.615072826818505e-08

The O 0 1.6259492952030996e-07
evidence O 0 1.6466064778342115e-07
of O 0 1.6957926618488273e-08
a O 0 1.9423409547414394e-09
significant O 0 8.35200797411062e-10
proportion O 0 1.969078677888092e-09
of O 0 1.9273661777674533e-08
loss O 0 2.340801614764132e-07
- O 0 1.968974494559461e-08
of O 0 8.01549390416767e-07
- O 0 3.356876447924151e-07
function O 0 1.7564782694989844e-07
mutations O 0 1.2097105539510267e-09
and O 0 1.5389223229078652e-10
a O 0 2.1055255317037336e-09
complete O 0 3.477304488797017e-08
absence O 0 9.611955675836725e-08
of O 0 4.826194555107577e-08
the O 0 4.444722367935583e-09
normal O 0 2.4225037975611485e-08
copy O 0 1.6158789861719924e-08
of O 0 2.1376767023184584e-08
ATM O 0 1.451126792062496e-07
in O 0 5.903547095620354e-10
the O 0 5.561812121968046e-10
majority O 0 9.831890857014969e-11
of O 0 8.42007086276908e-09
mutated O 0 1.544390926255801e-07
tumours B-Disease 1 1.0
establishes O 0 1.6290285032027896e-07
somatic O 0 8.180028743254297e-08
inactivation O 0 1.26051418192219e-07
of O 0 9.403827050391556e-09
this O 0 3.382261692941313e-10
gene O 0 9.632497577349852e-11
in O 0 4.538890374661264e-10
the O 0 3.2430704788311004e-09
pathogenesis O 0 7.880314115027431e-06
of O 0 4.413019723870093e-06
sporadic B-Disease 0 0.0003108525415882468
T I-Disease 0 0.10350997000932693
- I-Disease 0 0.00046018764260225
PLL I-Disease 1 0.9969276785850525
and O 0 2.8112832062276993e-09
suggests O 0 1.597418908261261e-08
that O 0 3.40837968959562e-10
ATM O 0 3.24962968534237e-07
acts O 0 4.433360345501569e-09
as O 0 1.5208092563057107e-08
a O 0 5.349360208128928e-07
tumour B-Disease 1 1.0
suppressor O 0 0.00015291421732399613
. O 0 3.289377659143611e-08

As O 0 1.0607834610709688e-07
constitutional O 0 5.218042176124982e-08
DNA O 0 3.271127013704245e-08
was O 0 1.1196219951159492e-08
not O 0 4.9774594168550124e-11
available O 0 3.093926226327426e-10
, O 0 1.725550674569476e-10
a O 0 2.2115829168001255e-08
putative O 0 1.990225791814737e-05
hereditary O 1 0.9994729161262512
predisposition O 1 0.8151559829711914
to O 0 2.687015694391448e-05
T B-Disease 1 0.962293267250061
- I-Disease 0 0.0016159896040335298
PLL I-Disease 1 0.9571298956871033
will O 0 5.049246354360548e-09
require O 0 1.6501010557945506e-09
further O 0 6.3525429361277475e-09
investigation O 0 6.526054363575895e-08
. O 0 1.5003951414627181e-09
. O 0 9.636697662074312e-09

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
protein O 0 0.00011634392285486683
kinase O 0 1.763158979883883e-05
is O 0 7.528027506920054e-11
involved O 0 7.574490340500617e-11
in O 0 6.623748077805303e-11
the O 0 3.4777655755213743e-10
modulation O 0 1.523049353302497e-09
of O 0 3.6652059165476203e-09
the O 0 1.9742843804237964e-08
Ca2 O 0 8.55928192322608e-06
+ O 0 6.020609930601495e-07
homeostasis O 0 2.0411823697941145e-06
in O 0 1.9753541025124832e-08
skeletal O 0 0.0016204925486817956
muscle O 0 6.226704044820508e-06
cells O 0 3.5785467389359837e-06
. O 0 5.324897855985e-08

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9913376569747925
DM B-Disease 1 1.0
) O 0 6.576823086135164e-09
, O 0 5.902756061715309e-11
the O 0 2.674456489604182e-10
most O 0 4.2730438631899403e-10
prevalent O 0 2.523815510357963e-06
muscular B-Disease 0 0.035453539341688156
disorder I-Disease 0 0.0001579047238919884
in O 0 2.7307827110689686e-09
adults O 0 1.210012867680632e-09
, O 0 1.838496993533667e-10
is O 0 3.738456488822095e-10
caused O 0 8.039378052160373e-09
by O 0 3.267720760646853e-09
( O 0 2.5724290253492654e-08
CTG O 0 1.55698023718287e-06
) O 0 8.581553800901531e-10
n O 0 1.035411845151657e-08
- O 0 2.1139880956866364e-09
repeat O 0 2.8092839166049544e-09
expansion O 0 3.6082996590636185e-09
in O 0 5.271173497689574e-10
a O 0 1.6967688365454592e-09
gene O 0 2.0360557684284686e-10
encoding O 0 1.4568229955713718e-09
a O 0 1.3193050207860324e-08
protein O 0 2.5895761268657225e-07
kinase O 0 3.5772456612903625e-05
( O 0 5.980984951747814e-08
DM B-Disease 1 1.0
protein O 0 4.334672212280566e-07
kinase O 0 1.0417627436254406e-06
; O 0 1.7242608729706177e-10
DMPK O 0 5.047593276685802e-07
) O 0 3.2178432141094504e-10
and O 0 2.845390069394771e-11
involves O 0 1.782694769580928e-09
changes O 0 1.8836874282612825e-09
in O 0 2.317825043007815e-08
cytoarchitecture O 0 7.086734512995463e-06
and O 0 6.966653387507904e-08
ion O 0 4.165604696027003e-05
homeostasis O 0 0.09876077622175217
. O 0 4.6368640482796764e-07

To O 0 1.2177703467841638e-07
obtain O 0 1.5934000430206652e-07
clues O 0 1.1440138223406393e-06
to O 0 1.3145293742411468e-09
the O 0 1.701776497498031e-09
normal O 0 4.803382580575999e-08
biological O 0 5.3852616588301316e-08
role O 0 6.91855888135251e-08
of O 0 7.019197596491722e-07
DMPK O 0 0.00017155485693365335
in O 0 6.287799436677233e-08
cellular O 0 8.865122680390414e-08
ion O 0 3.52848275042561e-07
homeostasis O 0 0.00022814443218521774
, O 0 1.885664513423535e-09
we O 0 2.150369216025183e-09
have O 0 9.660022087798481e-11
compared O 0 2.3226819079180672e-10
the O 0 9.310427429021217e-10
resting O 0 5.8512796385912225e-08
[ O 0 1.026835434458917e-07
Ca2 O 0 1.5151567822613288e-07
+ O 0 1.128848747811162e-08
] O 0 3.2952283124387804e-09
i O 0 7.615141850436657e-10
, O 0 1.5780023121525488e-11
the O 0 1.7582689471051793e-10
amplitude O 0 3.301588780146858e-09
and O 0 1.0568136643573922e-10
shape O 0 1.1201986893638605e-08
of O 0 5.1852225624315906e-08
depolarization O 0 6.902478588699523e-08
- O 0 1.2022670148326142e-07
induced O 0 1.0839728474820731e-06
Ca2 O 0 9.428378007214633e-07
+ O 0 2.3071379473549314e-08
transients O 0 5.854011941863746e-09
, O 0 8.554335191590656e-12
and O 0 3.035275156215711e-11
the O 0 7.120031786378433e-10
content O 0 2.3241057967027245e-09
of O 0 1.437934855630374e-07
ATP O 0 5.085472821519943e-06
- O 0 1.3583033364739094e-07
driven O 0 2.5194191266564303e-07
ion O 0 4.983916923606557e-08
pumps O 0 3.3707049595932403e-08
in O 0 3.0759812474911996e-09
cultured O 0 7.273247319972143e-07
skeletal O 0 1.6458778191008605e-05
muscle O 0 3.499033951470665e-08
cells O 0 3.385020974633335e-08
of O 0 1.3655502506537687e-08
wild O 0 1.8080209551740722e-09
- O 0 3.0232429892862456e-09
type O 0 1.190297904685167e-08
and O 0 6.283382703031748e-10
DMPK O 0 2.591752945590997e-06
[ O 0 1.9377539217657613e-07
- O 0 9.731083849828792e-08
/ O 0 6.545452038153599e-07
- O 0 6.325100230242242e-07
] O 0 6.977730890866951e-07
knockout O 0 1.6055086234700866e-05
mice O 0 4.641147825168446e-06
. O 0 2.184700242935378e-08

In O 0 1.2071008086422808e-06
vitro O 0 7.212917125798413e-07
- O 0 5.198908681336434e-08
differentiated O 0 4.296364153333343e-08
DMPK O 0 1.8092061509378254e-05
[ O 0 1.3004222410017974e-06
- O 0 9.013951967062894e-07
/ O 0 4.0284189708472695e-06
- O 0 1.4208370657797786e-06
] O 0 2.635252087657136e-07
myotubes O 0 6.109533501330588e-07
exhibit O 0 8.684436281214403e-09
a O 0 2.5097290912157177e-09
higher O 0 7.2927761607388675e-09
resting O 0 1.3534464926578949e-07
[ O 0 1.4076972831844614e-07
Ca2 O 0 4.95640676945186e-07
+ O 0 2.034283674845483e-08
] O 0 7.807146928939801e-09
i O 0 2.781431307496973e-09
than O 0 3.264959136384249e-10
do O 0 5.132594349532837e-10
wild O 0 2.9401816536989145e-09
- O 0 1.2822873429740866e-08
type O 0 5.484191589744114e-08
myotubes O 0 1.6078786302387016e-06
because O 0 2.8047970612732342e-09
of O 0 7.691109082941239e-09
an O 0 4.683533560978503e-10
altered O 0 2.505190277446445e-09
open O 0 1.85463324697821e-08
probability O 0 5.09872215559426e-08
of O 0 1.494931289869328e-08
voltage O 0 2.2941360811046252e-08
- O 0 1.2942561689044396e-08
dependent O 0 6.3437916253406e-08
l O 0 8.797807815597025e-09
- O 0 8.835202014445542e-10
type O 0 4.706433465173632e-09
Ca2 O 0 4.731998970441964e-08
+ O 0 2.2263186849613703e-09
and O 0 2.91123514184477e-10
Na O 0 1.344368683930952e-06
+ O 0 4.370527761921039e-08
channels O 0 1.4015323124283441e-08
. O 0 8.343414847900021e-09

The O 0 1.311179175900179e-06
mutant O 0 8.604267236478336e-07
myotubes O 0 2.330484903723118e-06
exhibit O 0 1.4189025066002614e-08
smaller O 0 1.2351946132582725e-09
and O 0 5.197970942560914e-10
slower O 0 5.357743049216879e-08
Ca2 O 0 4.3380754277677624e-07
+ O 0 7.1646915067447026e-09
responses O 0 2.06501274413462e-10
upon O 0 1.978290420368012e-09
triggering O 0 5.238871558788105e-09
by O 0 1.4659489178114882e-09
acetylcholine O 0 1.9396917139147263e-07
or O 0 3.962261629908426e-09
high O 0 1.4870424891455514e-08
external O 0 3.0669906436742167e-07
K O 0 4.04702541345614e-06
+ O 0 5.116008310324105e-07
. O 0 2.1687077023102574e-08

In O 0 1.0278544948505441e-07
addition O 0 9.525080280070597e-09
, O 0 2.7586372075560917e-10
we O 0 1.9283569185901683e-10
observed O 0 5.047895990095697e-10
that O 0 1.031072709850589e-11
these O 0 3.646474788787657e-10
Ca2 O 0 6.115012638474582e-07
+ O 0 2.2429173895943677e-07
transients O 0 6.874991242966644e-08
partially O 0 9.556488933526452e-09
result O 0 2.2663772247799585e-10
from O 0 1.8240400856406325e-10
an O 0 4.575726256228485e-11
influx O 0 4.780801310388938e-10
of O 0 6.4994321036238034e-09
extracellular O 0 2.26741121878149e-07
Ca2 O 0 3.588809249777114e-07
+ O 0 3.498358269737878e-09
through O 0 2.295000300911454e-10
the O 0 1.5059572477937877e-09
l O 0 7.188234896204904e-09
- O 0 1.5963704802501866e-09
type O 0 1.3827383682496475e-08
Ca2 O 0 8.568213161197491e-07
+ O 0 5.576168149445948e-08
channel O 0 5.0622865899185854e-08
. O 0 6.4056275839163845e-09

Neither O 0 3.7995059756212868e-06
the O 0 5.948697889834875e-08
content O 0 1.0356705715253156e-08
nor O 0 7.119628442353587e-09
the O 0 1.6962284909993741e-09
activity O 0 1.4867362452264388e-08
of O 0 3.165868633914215e-08
Na O 0 8.072314585660934e-07
+ O 0 3.859906172465344e-08
/ O 0 1.1381778186603242e-08
K O 0 9.506752007837349e-08
+ O 0 2.4093203876418556e-08
ATPase O 0 4.789993681697524e-07
and O 0 9.141133960888226e-10
sarcoplasmic O 0 1.3210622000769945e-06
reticulum O 0 7.3074545525742e-07
Ca2 O 0 4.511474003265903e-07
+ O 0 4.4759470796407186e-08
- O 0 2.0530798394702288e-08
ATPase O 0 4.159141099080443e-06
are O 0 1.072201633034453e-10
affected O 0 1.3422163380738539e-09
by O 0 4.2732986038629406e-09
DMPK O 0 0.0013835560530424118
absence O 0 3.422153167775832e-05
. O 0 5.767456627836509e-07

In O 0 1.864669911810779e-07
conclusion O 0 1.4979974594098167e-07
, O 0 6.436782218344206e-10
our O 0 4.601830472239499e-09
data O 0 1.724861320440141e-08
suggest O 0 6.485302961323214e-09
that O 0 1.4960307992417654e-10
DMPK O 0 2.118737938872073e-06
is O 0 1.6727234042335226e-09
involved O 0 5.597647678712292e-09
in O 0 4.125526142928493e-09
modulating O 0 1.215611007410189e-07
the O 0 4.088973160065734e-09
initial O 0 1.6815340231346454e-08
events O 0 3.225292255493173e-09
of O 0 5.819411619256698e-09
excitation O 0 1.1763461316149915e-06
- O 0 8.793080269242637e-06
contraction O 0 1.7602893649382167e-06
coupling O 0 2.4294820377690485e-07
in O 0 1.2188503539789508e-08
skeletal O 0 9.6187497547362e-05
muscle O 0 2.5167992134811357e-07
. O 0 7.313433414424253e-09
. O 0 2.7033177474322656e-08

Constitutional O 0 4.6933582780184224e-05
RB1 O 0 0.13412024080753326
- O 0 2.5252793420804664e-06
gene O 0 8.005790697040993e-09
mutations O 0 7.087581077591665e-10
in O 0 2.756917194535191e-10
patients O 0 9.77200889651364e-11
with O 0 2.7576678787721853e-11
isolated O 0 2.1154146452317946e-06
unilateral B-Disease 0 8.372828688152367e-07
retinoblastoma I-Disease 1 0.9999812841415405
. O 0 9.860456202659407e-07

In O 0 8.002098894621668e-08
most O 0 4.04318384328306e-10
patients O 0 1.5056177138372817e-10
with O 0 6.15041073626088e-11
isolated O 0 1.6999483420931938e-07
unilateral B-Disease 0 6.669370122835971e-08
retinoblastoma I-Disease 1 0.9992050528526306
, O 0 1.237064939374477e-08
tumor B-Disease 0 6.559751454915386e-06
development O 0 3.5181063395839374e-08
is O 0 7.050579564626958e-11
initiated O 0 5.440303763037946e-10
by O 0 9.655914262607368e-11
somatic O 0 2.940097498793648e-09
inactivation O 0 5.859351670522983e-09
of O 0 9.758435171036695e-10
both O 0 5.304079397916439e-11
alleles O 0 1.1246461401048791e-10
of O 0 3.6176717177482942e-09
the O 0 6.44543689531929e-08
RB1 O 0 7.73995925555937e-05
gene O 0 1.1724760184961269e-07
. O 0 3.580699470262516e-08

However O 0 2.6311187184546725e-07
, O 0 5.987257356565578e-10
some O 0 5.023018112559896e-11
of O 0 3.512537483096878e-10
these O 0 1.3912607177424263e-10
patients O 0 4.3692896523062075e-10
can O 0 7.094357323822464e-10
transmit O 0 1.1180495818052805e-07
retinoblastoma B-Disease 1 0.9994383454322815
predisposition O 1 0.9999837875366211
to O 0 1.1114964593161858e-07
their O 0 3.8190282936056974e-08
offspring O 0 2.1668559213594563e-07
. O 0 1.2448141184506767e-08

To O 0 2.5896348176956963e-08
determine O 0 7.740335483674698e-09
the O 0 1.1960915591302523e-09
frequency O 0 4.5600483389307556e-09
and O 0 1.3857415215312585e-10
nature O 0 1.3664518405676063e-08
of O 0 1.9917434812555257e-08
constitutional O 0 1.367450863654085e-07
RB1 O 0 0.0004325633926782757
- O 0 9.284917013019367e-08
gene O 0 7.412535585338276e-10
mutations O 0 6.39152550330202e-11
in O 0 4.544622664304221e-11
patients O 0 1.0960001135817965e-11
with O 0 8.76052008713657e-12
isolated O 0 3.685593696900469e-08
unilateral B-Disease 0 2.060199477682545e-08
retinoblastoma I-Disease 0 1.8823358914232813e-05
, O 0 2.738678450686649e-10
we O 0 2.6554158871761047e-10
analyzed O 0 5.0742610113729825e-09
DNA O 0 1.0259579852345269e-08
from O 0 1.114714631711422e-08
peripheral O 0 4.629767715869093e-07
blood O 0 1.814243333342347e-08
and O 0 5.321666662894131e-09
from O 0 1.5347855253367015e-07
tumor B-Disease 0 0.00048676319420337677
tissue O 0 1.605775105417706e-05
. O 0 1.5429688460244506e-07

The O 0 5.485823066919693e-07
analysis O 0 1.817321191310839e-07
of O 0 4.7641307787671394e-07
tumors B-Disease 1 1.0
from O 0 6.151886111638305e-08
54 O 0 8.993553279879052e-08
( O 0 1.0077270129471572e-09
71 O 0 4.449778323589726e-09
% O 0 6.145860903528089e-11
) O 0 8.608495860595866e-12
of O 0 1.323866016811337e-10
76 O 0 1.4425369343484817e-08
informative O 0 6.370515137632538e-08
patients O 0 1.3962672129608222e-09
showed O 0 3.1951976620092637e-09
loss O 0 3.861408259808741e-08
of O 0 1.7573495370015735e-07
constitutional O 0 8.873274168763601e-07
heterozygosity O 1 0.9999867677688599
( O 0 0.00045144293108023703
LOH O 1 0.9992609620094299
) O 0 1.1179361436575164e-08
at O 0 1.0961673524434445e-07
intragenic O 0 8.061112566792872e-06
loci O 0 5.752054335061985e-07
. O 0 1.0806702732679696e-07

Three O 0 2.739356261827197e-07
of O 0 2.1379298686952097e-07
13 O 0 2.6251134386257036e-06
uninformative O 0 0.050980739295482635
patients O 0 5.206619562159176e-07
had O 0 7.165638038486577e-08
constitutional O 0 7.462276130354439e-07
deletions O 0 2.8404003842297243e-06
. O 0 3.0443308673966385e-07

For O 0 3.894351863209522e-08
39 O 0 5.062962671331661e-08
randomly O 0 1.1355323792372474e-08
selected O 0 1.334860826318618e-07
tumors B-Disease 1 1.0
, O 0 6.821776565857363e-08
SSCP O 0 0.0012929263757541776
, O 0 2.2113718856076048e-08
hetero O 0 2.5432268557779025e-06
- O 0 2.201440096882834e-08
duplex O 0 3.1089641083781316e-07
analysis O 0 3.381753987952152e-09
, O 0 3.104020512845196e-11
sequencing O 0 3.0020153030108077e-10
, O 0 6.043519851228751e-11
and O 0 9.248176530141095e-11
Southern O 0 2.1974548403136396e-08
blot O 0 1.025722212943947e-06
analysis O 0 4.2311754100410326e-08
were O 0 2.3007911131855963e-09
used O 0 2.7783067513276194e-10
to O 0 3.1075525486201627e-10
identify O 0 1.2851080199993703e-08
mutations O 0 6.243367067781946e-08
. O 0 1.4078423760111036e-07

Mutations O 0 6.510452408292622e-07
were O 0 4.132773767651088e-08
detected O 0 1.416128547759854e-08
in O 0 2.9154985092816332e-09
21 O 0 5.62356916589124e-08
( O 0 4.381626173000086e-09
91 O 0 4.447489487802159e-08
% O 0 1.5326019342509767e-09
) O 0 2.132827942036286e-10
of O 0 1.2004987226532648e-08
23 O 0 0.00019003661873284727
tumors B-Disease 1 1.0
with O 1 0.8729587197303772
LOH O 1 1.0
. O 0 1.8937555523734773e-06

In O 0 3.735245854841196e-07
6 O 0 1.1399163213354768e-07
( O 0 1.1288718848589951e-09
38 O 0 4.605843262339704e-09
% O 0 2.6466528968427383e-10
) O 0 3.811934448649801e-11
of O 0 3.231671596992669e-09
16 O 0 8.682321094966028e-06
tumors B-Disease 1 1.0
without O 1 0.9999990463256836
LOH O 1 1.0
, O 0 1.5235055439433154e-09
one O 0 7.997361661793434e-10
mutation O 0 1.22828455739743e-10
was O 0 5.882228037989989e-09
detected O 0 1.568099872173434e-09
, O 0 2.4274074070240736e-11
and O 0 3.124441677604395e-11
in O 0 9.37443456194842e-10
9 O 0 5.694439764170056e-08
( O 0 9.624330221669197e-10
56 O 0 5.342494890925309e-09
% O 0 3.122412051137502e-10
) O 0 4.283895460588383e-11
of O 0 1.4626392319527781e-09
the O 0 2.1228306934517605e-07
tumors B-Disease 1 1.0
without O 1 0.9999963045120239
LOH O 1 1.0
, O 0 5.842831773961166e-10
both O 0 1.756934736585336e-10
mutations O 0 1.496468282624619e-09
were O 0 5.568777883269149e-09
found O 0 1.2498912127512085e-08
. O 0 2.2999104842824636e-08

Thus O 0 1.5119522913664696e-06
, O 0 5.194365826355352e-09
a O 0 5.8977538408555574e-09
total O 0 4.861057778526856e-09
of O 0 6.041497524478245e-09
45 O 0 9.44859479545812e-09
mutations O 0 1.088470202859071e-09
were O 0 9.816235824189334e-09
identified O 0 7.68143664231502e-08
in O 0 2.1562601659752545e-07
tumors B-Disease 1 1.0
of O 0 0.0004686552274506539
36 O 0 0.00026494701160117984
patients O 0 6.253420110624575e-07
. O 0 6.004921004887365e-08

Thirty O 0 2.542718721088022e-05
- O 0 3.17833240615073e-07
nine O 0 9.33460029273192e-08
of O 0 4.0624048125437184e-08
the O 0 8.426593645083358e-09
mutations O 0 2.2730712867513603e-09
- O 0 8.932603101641234e-09
including O 0 1.2321191844577584e-09
34 O 0 4.5134708415162095e-08
small O 0 3.133522330500682e-09
mutations O 0 8.151379016219096e-10
, O 0 1.428170637307602e-10
2 O 0 1.7181335465465963e-08
large O 0 4.416093268844179e-09
structural O 0 1.8619242837303318e-05
alterations O 0 3.134343273814011e-07
, O 0 9.315187510239298e-10
and O 0 1.7236106986118216e-09
hypermethylation O 0 3.973187631345354e-05
in O 0 5.345229396880313e-07
3 O 0 0.04845498502254486
tumors O 1 1.0
- O 0 5.460715897243062e-07
were O 0 5.552730719671217e-09
not O 0 1.1959883083889622e-10
detected O 0 1.029091256654624e-09
in O 0 5.990247187170894e-11
the O 0 4.3055806142611175e-10
corresponding O 0 4.0984385663023204e-08
peripheral O 0 8.883891950972611e-07
blood O 0 9.256925181944098e-08
DNA O 0 2.8285560915719543e-07
. O 0 1.1816839062817053e-08

In O 0 5.638992206513649e-07
6 O 0 3.0119352345536754e-07
( O 0 3.2625890877824304e-09
17 O 0 4.4813437405366585e-09
% O 0 3.1472013883870886e-10
) O 0 2.8050136866020203e-11
of O 0 2.2825237533385945e-10
the O 0 1.0152994001089155e-09
36 O 0 5.271369829529249e-08
patients O 0 2.063238246918786e-09
, O 0 1.7669156415767162e-10
a O 0 1.803605376160533e-09
mutation O 0 4.17765905202927e-10
was O 0 7.4400610117209e-09
detected O 0 5.851890527708292e-09
in O 0 3.123388769843416e-10
constitutional O 0 3.792575142824717e-09
DNA O 0 3.6950660309287287e-09
, O 0 3.4020904149389963e-11
and O 0 2.8235056653835855e-11
1 O 0 2.271597576708473e-09
of O 0 5.905112510085075e-10
these O 0 4.904208289469025e-11
mutations O 0 2.884334993069615e-10
is O 0 2.172199503602812e-10
known O 0 2.979511637413168e-10
to O 0 1.8807823354283215e-10
be O 0 3.9301506493671923e-10
associated O 0 2.717699176812971e-09
with O 0 7.065728557797968e-10
reduced O 0 5.090375339023012e-07
expressivity O 0 0.00012622649956028908
. O 0 3.042484877369134e-07

The O 0 5.965837885923975e-07
presence O 0 2.7072394104266095e-08
of O 0 4.6083059146440064e-08
a O 0 1.573472374616358e-08
constitutional O 0 9.651191845705398e-09
mutation O 0 9.281774793201691e-10
was O 0 8.846572363552241e-09
not O 0 3.6719478152535956e-11
associated O 0 3.2068023236853094e-10
with O 0 2.849990729525409e-11
an O 0 1.3003723653426391e-09
early O 0 7.52542206328144e-09
age O 0 4.514460982818491e-08
at O 0 1.6729228491385584e-07
treatment O 0 9.020180868901662e-08
. O 0 3.5942750997719486e-08

In O 0 3.425079242447282e-08
1 O 0 7.961421033542138e-08
patient O 0 1.7544651953471657e-08
, O 0 3.6420538807035996e-10
somatic O 0 3.5370504747334053e-07
mosaicism O 0 0.0001725307374726981
was O 0 4.442835077611562e-08
demonstrated O 0 1.5756279614365098e-09
by O 0 3.565122502768858e-11
molecular O 0 8.677957796798808e-10
analysis O 0 1.8088859576881333e-10
of O 0 1.7004063435077654e-10
DNA O 0 6.283682463248397e-10
and O 0 3.95062316194128e-10
RNA O 0 1.0133811656487524e-07
from O 0 2.5821526250524585e-08
peripheral O 0 5.164266895008041e-06
blood O 0 7.857177592995868e-07
. O 0 2.0617628138097643e-07

In O 0 4.819599439542799e-07
2 O 0 3.9463654388782743e-07
patients O 0 1.1349947648398029e-09
without O 0 6.264869734096123e-10
a O 0 2.3428430306893233e-09
detectable O 0 2.261795941649325e-07
mutation O 0 1.9704686771149227e-09
in O 0 6.475957992080339e-09
peripheral O 0 7.082916908984771e-06
blood O 0 9.292115237258258e-07
, O 0 2.7556266601891366e-08
mosaicism O 1 0.8313868045806885
was O 0 1.3984715678816428e-06
suggested O 0 9.913360798918802e-09
because O 0 1.168883434488066e-09
1 O 0 4.155591426524552e-09
of O 0 1.6168123506687948e-09
the O 0 8.205996770982438e-09
patients O 0 6.994761037049102e-08
showed O 0 1.1526484740898013e-05
multifocal O 1 1.0
tumors B-Disease 1 1.0
and O 0 5.7165962630278955e-08
the O 0 2.2678841915535486e-08
other O 0 1.2429955675852256e-10
later O 0 2.8160487275386004e-09
developed O 0 4.191341496095902e-09
bilateral B-Disease 0 9.149599122793006e-07
retinoblastoma I-Disease 0 0.06173710152506828
. O 0 3.801231684974482e-07

In O 0 2.445507902848476e-07
conclusion O 0 3.2391005788667826e-07
, O 0 3.223594724488521e-09
our O 0 2.651840169676234e-08
results O 0 1.1377761843789358e-08
emphasize O 0 9.274982559759337e-09
that O 0 1.43547340680783e-10
the O 0 7.764967002721335e-10
manifestation O 0 3.5603029857611546e-08
and O 0 4.174751655483533e-10
transmissibility O 0 1.057784629665548e-06
of O 0 2.2772296048856333e-08
retinoblastoma B-Disease 0 2.5156859919661656e-06
depend O 0 2.9607404528064762e-08
on O 0 7.524216805165906e-09
the O 0 1.1605459926400385e-09
nature O 0 1.089814816168655e-08
of O 0 2.8376427874121646e-09
the O 0 3.7322508972259527e-10
first O 0 4.582995372093279e-10
mutation O 0 7.26145532592426e-11
, O 0 7.941265700583955e-12
its O 0 1.2468605141424671e-11
time O 0 1.939541027784486e-10
in O 0 6.148009323858616e-10
development O 0 2.5191253527623303e-08
, O 0 1.1934588040052319e-10
and O 0 3.581910115735276e-11
the O 0 2.2239493580045178e-10
number O 0 1.5416663778911044e-10
and O 0 2.269257004527958e-11
types O 0 2.9051444583316766e-10
of O 0 7.162532789095621e-09
cells O 0 2.061943948916678e-09
that O 0 2.2819697520493065e-11
are O 0 5.214601667136165e-11
affected O 0 2.972155299652002e-10
. O 0 7.164086546218584e-10
. O 0 1.3385686337130664e-08

Hereditary B-Disease 1 1.0
deficiency I-Disease 1 1.0
of I-Disease 1 0.9999970197677612
the I-Disease 0 4.379271558718756e-05
fifth I-Disease 0 5.6731812946964055e-05
component I-Disease 0 2.8576852855621837e-05
of I-Disease 0 4.256034117133822e-06
complement I-Disease 0 1.2443854302546242e-06
in O 0 1.7635962876738631e-06
man O 0 0.0001825799117796123
. O 0 1.4750841046407004e-06

I O 0 0.0018332325853407383
. O 0 5.0161506806034595e-06

Clinical O 1 0.5132013559341431
, O 0 7.650584876728317e-08
immunochemical O 0 3.0170462196110748e-05
, O 0 1.0095839719781452e-08
and O 0 5.733322261392004e-09
family O 0 1.8716235672400217e-07
studies O 0 8.355774525625748e-07
. O 0 6.427500665040498e-08

The O 0 6.727437380504853e-07
first O 0 7.522081801880631e-08
recognized O 0 4.357924865416862e-08
human O 0 1.1515047049215354e-07
kindred O 0 0.0020030548330396414
with O 0 4.5053516828374995e-07
hereditary B-Disease 1 1.0
deficiency I-Disease 1 1.0
of I-Disease 1 1.0
the I-Disease 0 0.0002231881080660969
fifth I-Disease 0 8.589925710111856e-05
component I-Disease 0 3.016819027834572e-05
of I-Disease 0 2.2652555344393477e-05
complement I-Disease 0 2.0874123947578482e-05
( O 0 5.6903900258475915e-05
C5 O 1 0.9710630774497986
) O 0 1.936068727559359e-08
is O 0 2.9170672544154286e-09
described O 0 2.614986271964881e-07
. O 0 2.4619231453471e-07

The O 0 5.627975497191073e-06
proband O 0 3.675208427011967e-05
, O 0 2.8067628221606356e-08
a O 0 7.268532442594733e-08
20 O 0 1.4068491793750582e-07
- O 0 1.4415522109345602e-08
year O 0 4.5481332477947944e-08
- O 0 1.4265120285017474e-07
old O 0 3.3808984767347283e-07
black O 0 1.9233191039802477e-08
female O 0 2.433952595026767e-08
with O 0 4.043257106900455e-08
systemic B-Disease 1 1.0
lupus I-Disease 1 1.0
erythematosus I-Disease 1 1.0
since O 0 1.1108686521765776e-05
age O 0 1.1562457302716211e-06
11 O 0 3.746326910913922e-07
, O 0 1.635646174058536e-09
lacked O 0 6.119983595453959e-07
serum O 0 3.2067771371657727e-06
hemolytic O 0 0.06403724104166031
complement O 0 5.043516011937754e-06
activity O 1 0.6790209412574768
, O 0 6.48782305656681e-10
even O 0 8.092079784027817e-10
during O 0 3.73092348127102e-08
remission O 0 4.233510480844416e-06
. O 0 2.469779225577895e-08

C5 O 0 0.05131453648209572
was O 0 6.883723017381271e-06
undetectable O 0 9.869895620795432e-06
in O 0 6.634618188172681e-08
her O 0 3.352534250211647e-08
serum O 0 8.284222019483423e-08
by O 0 3.5157834421539746e-09
both O 0 5.6598516984252e-09
immunodiffusion O 0 3.5162997846782673e-06
and O 0 2.3407540794551096e-08
hemolytic O 0 0.025130189955234528
assays O 0 4.1937644709832966e-05
. O 0 6.690519853691512e-07

Other O 0 2.4768082695914018e-08
complement O 0 1.3370478946228559e-08
components O 0 1.939022240549093e-07
were O 0 3.8538445323865744e-08
normal O 0 8.840402188070584e-08
during O 0 3.1304114855856824e-08
remission O 0 1.8067036080537946e-06
of O 0 4.527188082192879e-07
lupus O 0 6.242271979317593e-07
, O 0 1.5899678240671733e-09
but O 0 9.683792434600491e-09
C1 O 0 0.00014460789680015296
, O 0 3.884278143573283e-08
C4 O 0 0.0005698098102584481
, O 0 1.546910866068174e-08
C2 O 0 5.382907602324849e-06
, O 0 4.923915053467454e-09
and O 0 9.423595237478821e-09
C3 O 0 0.09023438394069672
levels O 0 2.327592119399924e-05
fell O 1 0.8699708580970764
during O 0 3.960450158047024e-06
exacerbations O 1 0.8939003944396973
. O 0 5.646488716593012e-07

A O 0 2.6851148504647426e-05
younger O 0 8.095467762814224e-08
half O 0 8.525960737415517e-08
- O 0 4.565659708077874e-07
sister O 0 2.357344101255876e-06
, O 0 6.413451991704733e-09
who O 0 6.961762721857667e-09
had O 0 1.2661467962971074e-07
no O 0 5.126841529090598e-07
underlying O 1 0.9999997615814209
disease O 1 0.9969666600227356
, O 0 4.332190162159577e-09
was O 0 2.047675025096396e-06
also O 0 1.518121850452303e-09
found O 0 1.3072484206233526e-09
to O 0 3.149196681206945e-09
lack O 0 2.8265867513255216e-06
immunochemically O 0 0.0007767928764224052
detectable O 0 0.16878530383110046
C5 O 0 0.0072522819973528385
. O 0 1.0388840365749274e-07

By O 0 4.580838321999181e-06
hemolytic O 0 0.042163871228694916
assay O 0 1.4409288269234821e-05
, O 0 6.435300292650936e-09
she O 0 2.4826054545457055e-09
exhibited O 0 1.4836003536800035e-08
1 O 0 1.5901437677712238e-07
- O 0 6.358203741285706e-09
2 O 0 1.2270284344140236e-08
% O 0 1.584644637731003e-10
of O 0 2.598067316839092e-10
the O 0 1.1102961883224793e-09
normal O 0 1.3516755359432864e-07
serum O 0 3.2449813147650275e-07
C5 O 0 4.787852049048524e-06
level O 0 2.7802656177300378e-08
and O 0 3.061772016477171e-11
normal O 0 2.4174573454160964e-09
concentrations O 0 2.0288344337870967e-09
of O 0 3.4944416804627565e-10
other O 0 1.68047017273798e-11
complement O 0 1.8630847975487086e-09
components O 0 1.0003988393236796e-07
. O 0 7.063012930075274e-08

C5 O 0 0.0019935283344238997
levels O 0 5.676730552295339e-07
of O 0 8.389023520294359e-08
other O 0 2.341806748518138e-09
family O 0 1.0831854524440132e-08
members O 0 9.060435179897297e-10
were O 0 7.67102292797972e-09
either O 0 8.524330574743999e-09
normal O 0 1.2765725898589153e-07
or O 0 2.851526792468917e-09
approximately O 0 1.2834856510934856e-09
half O 0 2.42498487956766e-09
- O 0 5.81827963586079e-09
normal O 0 9.002799394863814e-09
, O 0 2.480761603085302e-11
consistent O 0 2.157608092190344e-09
with O 0 5.379935733018648e-11
autosomal O 0 8.943927554128095e-08
codominant O 0 2.446746236728359e-07
inheritance O 0 3.2002187566604334e-08
of O 0 1.2441685015573967e-08
the O 0 1.9714548216143157e-08
gene O 0 1.265843678766032e-07
determining O 0 0.00011992072541033849
C5 B-Disease 1 1.0
deficiency I-Disease 1 1.0
. O 0 1.506336502643535e-06

Normal O 0 0.0019158425275236368
hemolytic O 1 0.9929283261299133
titers O 0 0.004653771407902241
were O 0 1.5931765346977045e-06
restored O 0 4.2035844671772793e-07
to O 0 7.243355248931493e-09
both O 0 1.1722665504976248e-08
homozygous O 0 9.119187780015636e-06
C5 B-Disease 1 1.0
- I-Disease 1 1.0
deficient I-Disease 1 1.0
( O 0 6.528403446282027e-06
C5D B-Disease 1 1.0
) O 0 4.412878951143284e-08
sera O 0 3.8380372302526666e-07
by O 0 6.561379911618204e-11
addition O 0 3.799052461506136e-10
of O 0 5.558940419092551e-09
highly O 0 2.97194873155604e-08
purified O 0 2.735797352215741e-06
human O 0 1.2742485751005006e-06
C5 O 0 0.0006156836752779782
. O 0 7.450586281265714e-08

In O 0 5.882320692762733e-07
specific O 0 1.3504167384326138e-07
C5 O 0 0.0006304786656983197
titrations O 0 2.8507063689175993e-05
, O 0 1.1516222420127065e-09
however O 0 1.2031595719719235e-09
, O 0 2.4074250926098273e-10
it O 0 8.009951729670561e-11
was O 0 1.4417859794946253e-08
noted O 0 1.545954475545841e-09
that O 0 9.074400085518075e-12
when O 0 5.921475115799879e-11
limited O 0 3.773883705537884e-10
amounts O 0 3.3097729001951848e-09
of O 0 1.4234353784559062e-07
C5 O 0 2.1264921088004485e-05
were O 0 3.735886977551672e-08
assayed O 0 6.757542223567725e-07
in O 0 2.9250344368847436e-09
the O 0 2.3191064624228375e-09
presence O 0 1.182722697556926e-09
of O 0 2.5710166440262583e-08
low O 0 1.933089777139685e-07
dilutions O 0 9.192076504405122e-06
of O 0 7.116670417417481e-07
either O 0 5.614450401481008e-06
C5D B-Disease 1 1.0
serum O 0 6.108576781116426e-05
, O 0 4.403863052004908e-09
curving O 0 6.920182471503722e-08
rather O 0 1.3629578576868084e-09
than O 0 1.3083402417013446e-10
linear O 0 4.267491249265731e-09
dose O 0 9.950927193358439e-09
- O 0 6.42258379812688e-09
response O 0 6.598909196853242e-10
plots O 0 3.269536463790246e-08
were O 0 3.611701160366465e-09
consistently O 0 1.1500264074371103e-09
obtained O 0 1.2260358284166273e-09
, O 0 3.6963595378969316e-11
suggesting O 0 9.551491819692615e-10
some O 0 6.2581183291055e-11
inhibitory O 0 4.102098571934221e-08
effect O 0 2.1693406182521358e-08
. O 0 1.2781996794331008e-08

Further O 0 4.1736532807590265e-07
studies O 0 6.045060985115924e-08
suggested O 0 3.079063226607559e-09
that O 0 2.669879595185165e-10
low O 0 1.5949811427162786e-07
dilutions O 0 1.2888086530438159e-05
of O 0 3.042753860427183e-06
C5D B-Disease 1 1.0
serum O 0 2.2511342194775352e-06
contain O 0 6.148200615285759e-09
a O 0 4.673095244100978e-09
factor O 0 1.8735759610422065e-09
( O 0 4.971083614191407e-11
or O 0 2.1333895761088684e-10
factors O 0 1.897570989228825e-09
) O 0 2.3205387611469064e-10
interfering O 0 7.509449062581552e-09
at O 0 1.873369548377468e-08
some O 0 2.460701642448271e-10
step O 0 4.083096527551788e-09
in O 0 3.3724911752130993e-09
the O 0 3.139374626925928e-08
hemolytic O 0 0.0001142347464337945
assay O 0 7.324378202611115e-06
of O 0 3.723035115399398e-05
C5 O 1 0.9782439470291138
, O 0 1.0002491057647944e-09
rather O 0 1.246569292234767e-09
than O 0 2.9216706831647343e-10
a O 0 2.6910418338133013e-09
true O 0 1.2835261031796108e-07
C5 O 0 3.0429593607550487e-05
inhibitor O 0 4.4366112206262187e-07
or O 0 1.0729986676949466e-08
inactivator O 0 2.06021718440752e-06
. O 0 8.191019418291035e-08

Of O 0 1.910812443384202e-06
clinical O 0 3.935759377782233e-05
interest O 0 9.784695976122748e-06
are O 0 3.8853431583163456e-09
( O 0 6.928140283690709e-10
a O 0 1.0471928879596248e-09
) O 0 2.5647138926498947e-11
the O 0 1.181398728844485e-10
documentation O 0 1.950536017147897e-07
of O 0 1.4377319246250408e-07
membranous O 1 1.0
glomerulonephritis B-Disease 1 1.0
, O 0 0.00011522745626280084
vasculitis B-Disease 1 1.0
, O 0 4.5357708700066723e-07
and O 0 6.960862265259493e-06
arthritis B-Disease 1 1.0
in O 0 2.1604480480164057e-06
an O 0 2.0675771850164892e-07
individual O 0 7.051436341498629e-07
lacking O 0 0.0013747881166636944
C5 O 0 0.015234722755849361
( O 0 8.250285787880784e-09
and O 0 1.6197747310098265e-10
its O 0 1.5621859361658608e-09
biologic O 0 1.893143917186535e-07
functions O 0 6.783820616362846e-09
) O 0 4.5793497466251054e-11
, O 0 2.5392134575530356e-11
and O 0 1.209225636289446e-10
( O 0 6.3683383011436945e-09
b O 0 3.703690154566175e-08
) O 0 1.0895149227252432e-09
a O 0 2.5229129896331415e-09
remarkable O 0 3.234022472042852e-08
propensity O 0 2.462540749093023e-07
to O 0 3.2805851368777894e-09
bacterial B-Disease 1 1.0
infections I-Disease 1 1.0
in O 0 5.819503456905295e-08
the O 0 3.109969171077864e-08
proband O 0 1.2309299108892446e-06
, O 0 1.808775490497183e-10
even O 0 4.566188052668174e-11
during O 0 1.1162650803697716e-09
periods O 0 1.0502923686317445e-07
of O 0 5.6639795076307564e-08
low O 0 1.1434832458689925e-07
- O 0 3.682029570128975e-09
dose O 0 3.5849637924911804e-08
or O 0 1.3814670518641492e-09
alternate O 0 2.159646017574346e-09
- O 0 9.036450698829412e-09
day O 0 4.094258443387844e-08
corticosteroid O 0 2.1985462808515877e-05
therapy O 0 0.00014680287858936936
. O 0 4.170100353917405e-08

Other O 0 6.347688952246244e-08
observations O 0 1.1804728501374484e-06
indicate O 0 1.942638760965565e-07
that O 0 8.958909725187425e-10
the O 0 5.450228002246149e-08
C5D B-Disease 1 1.0
state O 0 2.872742221882163e-08
is O 0 1.4426875249995419e-09
compatible O 0 1.7042548483559017e-09
with O 0 6.409629771386705e-11
normal O 0 2.2448861614066118e-07
coagulation O 0 5.851458126926445e-07
function O 0 1.515811476338058e-07
and O 0 5.315465290145482e-10
the O 0 5.921096501992906e-09
capacity O 0 1.7648730477048957e-08
to O 0 1.548761829894829e-08
mount O 0 1.7531910998513922e-05
a O 0 1.3689922297999146e-06
neutrophilic O 1 0.9981535077095032
leukocytosis O 0 0.16082775592803955
during O 0 5.513692030945094e-06
pyogenic B-Disease 1 0.7916804552078247
infection I-Disease 0 1.5499061191803776e-05
. O 0 3.242625057353621e-09
. O 0 1.3665300002685399e-08

Susceptibility O 0 0.005085937678813934
to O 0 4.983545750292251e-06
ankylosing B-Disease 1 1.0
spondylitis I-Disease 1 1.0
in O 0 4.2304822272853926e-05
twins O 0 2.9540867672039894e-06
: O 0 1.5649863627231753e-09
the O 0 1.7988849299044318e-09
role O 0 1.0921390902751682e-08
of O 0 2.2622037931796513e-07
genes O 0 2.6580384115959532e-08
, O 0 5.441873618394766e-09
HLA O 0 2.0914753804390784e-06
, O 0 9.5256935672694e-10
and O 0 6.228683679943003e-10
the O 0 6.409528907624917e-08
environment O 0 8.571270200263825e-07
. O 0 1.0923520932237807e-07

OBJECTIVE O 0 6.6988097387366e-05
To O 0 8.08973865673579e-09
determine O 0 2.1503034908221252e-09
the O 0 3.889552568914212e-10
relative O 0 1.4239671664029174e-08
effects O 0 1.5494208582822466e-08
of O 0 4.249216534191191e-09
genetic O 0 6.1599854106475505e-09
and O 0 2.7114366307756654e-11
environmental O 0 7.804820123524792e-10
factors O 0 5.465410901628331e-10
in O 0 1.547236783139283e-10
susceptibility O 0 9.151975888244124e-08
to O 0 6.134182228834106e-08
ankylosing B-Disease 1 1.0
spondylitis I-Disease 1 1.0
( O 1 0.5899880528450012
AS B-Disease 1 0.9999998807907104
) O 0 6.140313590918822e-09
. O 0 4.235525263851514e-09

METHODS O 0 5.668422090820968e-05
Twins O 0 4.008907126262784e-05
with O 0 8.601435119715006e-09
AS B-Disease 1 1.0
were O 0 9.190529226543731e-08
identified O 0 9.481287754908863e-09
from O 0 3.648549906642984e-09
the O 0 8.071351587091158e-09
Royal O 0 1.4614440260629635e-05
National O 0 5.273922397464048e-06
Hospital O 1 0.9987367987632751
for O 0 2.1778318171072897e-07
Rheumatic B-Disease 1 1.0
Diseases I-Disease 1 1.0
database O 1 0.9999713897705078
. O 0 4.3208706301811617e-07

Clinical O 0 0.00015715368499513716
and O 0 4.038068546208251e-09
radiographic O 0 1.6453835769425496e-06
examinations O 0 7.128284323698608e-06
were O 0 1.1233138863531167e-08
performed O 0 9.339756745774253e-10
to O 0 1.711648878188754e-10
establish O 0 7.339663099514837e-09
diagnoses O 0 1.261073379055233e-07
, O 0 3.183728836120281e-10
and O 0 1.7220400660988844e-09
disease O 0 2.6469540443940787e-06
severity O 0 9.996938752010465e-05
was O 0 1.0096496225742158e-06
assessed O 0 4.7227477040223675e-08
using O 0 3.792138825176039e-10
a O 0 2.3962015704981354e-10
combination O 0 1.2230338963803433e-10
of O 0 1.0803293815087045e-09
validated O 0 4.132150976943194e-08
scoring O 0 2.9595492279099744e-08
systems O 0 1.7979327537887002e-07
. O 0 3.75964752663549e-08

HLA O 0 6.321780529106036e-05
typing O 0 9.048662263921869e-07
for O 0 3.6619447030261654e-08
HLA O 0 5.070965016784612e-07
- O 0 7.404657509368917e-08
B27 O 0 5.511886342901562e-07
, O 0 8.807226059559525e-09
HLA O 0 1.46260163091938e-07
- O 0 2.671023402456285e-08
B60 O 0 2.7486618137118057e-07
, O 0 2.067784610204626e-09
and O 0 1.4577492990497376e-08
HLA O 0 3.551412737579085e-05
- O 0 2.1578394807875156e-05
DR1 O 1 0.7291457653045654
was O 0 1.1152339141062839e-07
performed O 0 2.9599935835733504e-09
by O 0 9.54633705418928e-10
polymerase O 0 2.1335504030162156e-08
chain O 0 2.319685998841692e-09
reaction O 0 6.091790960560672e-11
with O 0 3.6314534712644786e-11
sequence O 0 2.4833157752368606e-09
- O 0 2.26209850850978e-09
specific O 0 3.9868824908140255e-10
primers O 0 4.877329207175762e-09
, O 0 1.1551679057753006e-10
and O 0 3.2809965855307155e-10
zygosity O 0 4.7515800360997673e-07
was O 0 8.515949190268657e-08
assessed O 0 8.458609812578288e-08
using O 0 1.6953237036432256e-08
microsatellite O 0 7.185267804743489e-06
markers O 0 4.446357593224093e-07
. O 0 6.345219816239478e-08

Genetic O 0 2.381165904807858e-05
and O 0 4.576612422368953e-09
environmental O 0 1.6751444675833227e-08
variance O 0 9.346872609228285e-09
components O 0 3.710676210744168e-08
were O 0 8.267139861573014e-09
assessed O 0 1.878324873416659e-08
with O 0 2.5468152586860526e-10
the O 0 1.0019700624752659e-08
program O 0 6.63509922560479e-08
Mx O 0 5.785625489806989e-07
, O 0 2.1628797711170655e-11
using O 0 6.346032727089224e-11
data O 0 1.1423072487914965e-09
from O 0 1.0520471993569203e-10
this O 0 2.1720338028163866e-10
and O 0 6.767723881306864e-11
previous O 0 1.1714126557649251e-08
studies O 0 5.540332193021413e-09
of O 0 1.0291428154118876e-08
twins O 0 1.3864917036698898e-07
with O 0 7.79512365767232e-09
AS B-Disease 1 1.0
. O 0 3.014550316038367e-07

RESULTS O 0 3.0957885428506415e-06
Six O 0 1.9929866823531484e-07
of O 0 1.4002368686760747e-07
8 O 0 2.9274415282998234e-06
monozygotic O 0 8.707366941962391e-05
( O 0 1.6892769281184883e-06
MZ O 0 0.0017542379209771752
) O 0 6.579306877085855e-09
twin O 0 1.221400225404068e-07
pairs O 0 5.6315738738987875e-09
were O 0 5.964625415799674e-08
disease O 0 4.935002948514011e-07
concordant O 0 3.0854339456709567e-06
, O 0 9.829289604468272e-10
compared O 0 2.358796713508582e-09
with O 0 1.9624711578014598e-10
4 O 0 1.1783476594473541e-07
of O 0 5.6183164787171336e-08
15 O 0 4.373913498056936e-08
B27 O 0 2.4931608777478687e-07
- O 0 1.0349305767931583e-07
positive O 0 3.235583534433317e-08
dizygotic O 0 8.481143595417961e-05
( O 0 1.7008143515795382e-07
DZ O 0 5.513609357876703e-05
) O 0 2.425206924172585e-09
twin O 0 3.653314806228991e-08
pairs O 0 1.64423863413532e-09
( O 0 1.2245728875370787e-09
27 O 0 1.5446376622207936e-08
% O 0 1.1906583496923417e-09
) O 0 1.309868463694741e-10
and O 0 2.1171103758987897e-10
4 O 0 1.1540949174104753e-07
of O 0 9.923483048623893e-07
32 O 0 2.0724563000840135e-05
DZ O 1 0.9666905403137207
twin O 0 4.690444256993942e-06
pairs O 0 1.826060902487825e-08
overall O 0 1.5564651789645723e-07
( O 0 2.1171921993357046e-09
12 O 0 1.7384053085933715e-09
. O 0 2.5485731580676685e-11
5 O 0 1.7917178851689641e-09
% O 0 1.8233511922538526e-10
) O 0 1.8599627393811602e-10
. O 0 1.7078505276657552e-09

Nonsignificant O 0 0.00048458503442816436
increases O 0 8.95966962843886e-08
in O 0 2.9679365631807286e-09
similarity O 0 5.827808902125753e-09
with O 0 6.169585675674938e-11
regard O 0 9.721953908581327e-09
to O 0 3.680117877102873e-10
age O 0 1.3497750472879488e-08
at O 0 1.1099520236257376e-07
disease O 0 1.5858201152241236e-07
onset O 0 6.625456308029243e-07
and O 0 3.9957339520446666e-11
all O 0 3.548819571541628e-11
of O 0 1.656963038998427e-10
the O 0 4.2622502749445346e-10
disease O 0 5.056934870850682e-10
severity O 0 7.447980010510946e-10
scores O 0 2.169955048980654e-10
assessed O 0 6.239552208242571e-10
were O 0 1.4090842381797586e-10
noted O 0 2.932977194447517e-10
in O 0 1.3875434135002251e-09
disease O 0 1.2667145199429797e-07
- O 0 4.121097276765795e-07
concordant O 0 8.055799116846174e-05
MZ O 0 0.0021305556874722242
twins O 0 6.345570113808208e-07
compared O 0 1.239677338560341e-08
with O 0 2.669122478593522e-09
concordant O 0 0.000831424433272332
DZ O 1 0.999258816242218
twins O 0 0.00019027467351406813
. O 0 7.73731244407827e-07

HLA O 0 0.0009896415285766125
- O 0 8.749181688472163e-06
B27 O 0 5.193326160224387e-06
and O 0 1.7973595944908993e-08
B60 O 0 1.2328672482908587e-06
were O 0 1.1261219512448406e-08
associated O 0 6.7961627436829986e-09
with O 0 4.771473216536037e-10
the O 0 3.0348923019118956e-07
disease O 0 5.54561847820878e-05
in O 0 7.169629157033341e-08
probands O 0 0.00017244390619453043
, O 0 3.552749205937289e-10
and O 0 4.9298207877024325e-11
the O 0 7.93739629578738e-10
rate O 0 2.6184370227610998e-08
of O 0 4.069637959958072e-09
disease O 0 7.059592377345325e-08
concordance O 0 2.5603955577935267e-07
was O 0 1.4162338857204304e-08
significantly O 0 1.3045956537283132e-09
increased O 0 4.738499370660065e-09
among O 0 2.6998641100561827e-09
DZ O 0 5.196752681513317e-05
twin O 0 1.5406044440169353e-07
pairs O 0 7.739461294065109e-10
in O 0 9.114827226319733e-10
which O 0 2.3036837715206815e-10
the O 0 6.33636343394528e-09
co O 0 5.026428198107169e-07
- O 0 1.6398961122376932e-07
twin O 0 5.213003646531433e-07
was O 0 7.643291866088475e-08
positive O 0 1.7174018873689079e-09
for O 0 1.075458833099674e-09
both O 0 5.384910295447298e-09
B27 O 0 4.179742063570302e-06
and O 0 1.7423771225821838e-07
DR1 O 1 0.9665188789367676
. O 0 3.897347085057845e-07

Additive O 0 3.992380243289517e-06
genetic O 0 4.699519706719002e-08
effects O 0 5.935788394140218e-08
were O 0 3.5198364223276712e-09
estimated O 0 1.6555572190934953e-10
to O 0 4.6623628568998043e-11
contribute O 0 2.46962617023172e-10
97 O 0 1.0388701099373066e-07
% O 0 1.4302370399121855e-10
of O 0 1.2253782710747174e-10
the O 0 4.6922129376403277e-11
population O 0 8.512895249834784e-12
variance O 0 5.24042809146863e-10
. O 0 3.5468741277355775e-09

CONCLUSION O 0 1.9231274563935585e-05
Susceptibility O 0 9.72398484009318e-05
to O 0 3.4709302099145134e-08
AS B-Disease 1 1.0
is O 0 2.383403474581769e-09
largely O 0 2.9555706770878487e-09
genetically O 0 1.6503362565423174e-10
determined O 0 2.6202142677789197e-09
, O 0 1.271002469938054e-10
and O 0 7.774521998404893e-11
the O 0 1.258745552235041e-08
environmental O 0 4.9386091660608145e-08
trigger O 0 3.309709839527386e-09
for O 0 3.255184177763937e-10
the O 0 2.322126135823055e-08
disease O 0 3.9910132727527525e-06
is O 0 2.5375506140790094e-09
probably O 0 2.2520308107232268e-07
ubiquitous O 0 4.6876576220711286e-07
. O 0 2.865278148078687e-08

HLA O 0 0.000831707613542676
- O 0 2.038196498688194e-06
B27 O 0 2.7908974971069256e-06
accounts O 0 4.104321504883046e-08
for O 0 6.306964395186299e-10
a O 0 6.481827963256137e-09
minority O 0 6.578726452488581e-10
of O 0 4.72056571609869e-09
the O 0 5.183103279904344e-09
overall O 0 2.359252846417803e-07
genetic O 0 1.5601089842220972e-07
susceptibility O 0 1.8885816643887665e-07
to O 0 2.5895358746197417e-08
AS B-Disease 1 1.0
. O 0 2.2760210072192422e-07

Cell O 0 3.146513336105272e-05
cycle O 0 1.2541032674562302e-06
- O 0 3.104827897004725e-07
dependent O 0 5.651882020174526e-07
colocalization O 0 1.5757301525809453e-06
of O 0 1.863277958591425e-07
BARD1 O 0 0.0001268163468921557
and O 0 1.0274345818572783e-08
BRCA1 O 0 2.6640021744128717e-08
proteins O 0 5.503592581668215e-10
in O 0 2.5083939370063035e-09
discrete O 0 1.6162172755684878e-07
nuclear O 0 1.1483564776426647e-05
domains O 0 3.867825580528006e-05
. O 0 1.1803957988831826e-07

Germ O 0 0.007218732964247465
- O 0 1.970764969883021e-05
line O 0 2.301084833788991e-07
mutations O 0 8.686507513289143e-09
of O 0 1.3351850292053768e-08
the O 0 1.3780314134237415e-07
BRCA1 O 0 4.755310669679602e-07
gene O 0 8.533652007258752e-09
predispose O 0 1.2383461012177577e-07
women O 0 6.357667170497905e-10
to O 0 3.84618170645723e-10
early O 0 1.9025155495455692e-07
- O 0 1.021006301016314e-05
onset O 1 1.0
breast B-Disease 1 1.0
and I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
by O 0 9.797273037293053e-08
compromising O 0 2.4000178200367372e-06
the O 0 7.886619357577729e-09
genes O 0 2.6489976878707466e-09
presumptive O 0 4.606082626423813e-08
function O 0 1.4004420734181622e-08
as O 0 3.4503739865243688e-09
a O 0 6.271737618135376e-08
tumor B-Disease 0 5.958218025625683e-06
suppressor O 0 1.5077513126016129e-05
. O 0 3.010010729553869e-08

Although O 0 1.5644073414478044e-07
the O 0 3.076845445093568e-08
biochemical O 0 2.0928960111632477e-06
properties O 0 1.1881443242600653e-05
of O 0 1.398239533045853e-06
BRCA1 O 0 3.3379231467733916e-07
polypeptides O 0 1.2008518979200744e-07
are O 0 1.9694607056308655e-10
not O 0 1.3187324843233483e-10
understood O 0 1.2528645898512991e-09
, O 0 2.690310300923482e-11
their O 0 4.5103573653726414e-11
expression O 0 7.642803612206706e-10
pattern O 0 2.5008266568704585e-09
and O 0 2.2195718873962988e-10
subcellular O 0 3.419092081458075e-06
localization O 0 6.042629365765606e-07
suggest O 0 1.0175333464701453e-08
a O 0 2.1792345705762273e-09
role O 0 5.416999293572644e-09
in O 0 2.369710649929857e-08
cell O 0 3.964451934734825e-06
- O 0 5.905534976591298e-07
cycle O 0 6.33039053354878e-06
regulation O 0 1.949754704355655e-07
. O 0 1.0696087571204771e-08

When O 0 6.737375883858476e-07
resting O 0 1.381299261993263e-05
cells O 0 4.642178055291879e-07
are O 0 3.2442457609249686e-09
induced O 0 6.412415132217575e-08
to O 0 1.514134040370152e-09
proliferate O 0 2.1373260494783608e-08
, O 0 1.0885760071133177e-09
the O 0 4.943318643313432e-09
steady O 0 1.935295358634903e-06
- O 0 5.141552072984723e-09
state O 0 3.809065285409474e-10
levels O 0 1.956716122464286e-09
of O 0 2.6507567252309627e-09
BRCA1 O 0 2.132186427417082e-09
increase O 0 1.7233534044258647e-10
in O 0 7.022185055660657e-10
late O 0 1.7183718625801703e-07
G1 O 0 3.128036496491404e-07
and O 0 7.407344182475128e-11
reach O 0 9.005165502173895e-10
a O 0 6.285779674541914e-10
maximum O 0 3.778653390185127e-09
during O 0 7.045680483486194e-09
S O 0 2.586500897905353e-07
phase O 0 3.300797857264115e-07
. O 0 4.794449282030655e-08

Moreover O 0 4.187276374523208e-07
, O 0 8.848963783947283e-10
in O 0 2.8453059908173373e-09
S O 0 1.48701474245172e-07
phase O 0 9.411760970579053e-08
cells O 0 7.922913169977619e-08
, O 0 6.128726415255414e-10
BRCA1 O 0 8.829209363625523e-09
polypeptides O 0 2.5095722833157197e-08
are O 0 1.5204305869875867e-10
hyperphosphorylated O 0 2.9434431780828163e-08
and O 0 2.516452879408604e-10
accumulate O 0 6.476538416677613e-09
into O 0 1.1579994740884558e-08
discrete O 0 3.3697908747853944e-06
subnuclear O 0 3.3569631341379136e-05
foci O 0 3.922861651517451e-05
termed O 0 9.994554375225562e-07
" O 0 3.625144131547131e-07
BRCA1 O 0 1.3418873834325495e-07
nuclear O 0 1.7057537888831575e-06
dots O 0 3.575919890863588e-06
. O 0 1.4899589473316155e-07

" O 0 1.306884951191023e-05
BRCA1 O 0 1.8543432815931737e-05
associates O 0 1.662539943936281e-05
in O 0 2.7026990423451025e-08
vivo O 0 5.192962362343678e-07
with O 0 5.130577629408606e-10
a O 0 1.548517332139454e-07
structurally O 0 6.88029058437678e-06
related O 0 2.0849474822171032e-06
protein O 0 3.3178363082697615e-05
termed O 0 3.561934136087075e-05
BARD1 O 1 0.9695306420326233
. O 0 4.783830149790447e-07

Here O 0 8.093682481558062e-06
we O 0 6.674676455986628e-08
show O 0 1.5688096155486164e-08
that O 0 2.471558235850324e-10
the O 0 1.1651688502922752e-08
steady O 0 1.6576165080550709e-06
- O 0 9.343734674871484e-09
state O 0 8.200250478651583e-10
levels O 0 5.41345634985646e-09
of O 0 2.346569871747306e-08
BARD1 O 0 1.6885594959603623e-05
, O 0 1.9247559102097966e-10
unlike O 0 2.123605458148603e-10
those O 0 5.2872619477062344e-11
of O 0 1.2750481781509393e-09
BRCA1 O 0 3.9104700033654183e-10
, O 0 1.163747917476421e-11
remain O 0 6.195909896256069e-10
relatively O 0 1.668876148386289e-10
constant O 0 3.599137432530597e-09
during O 0 1.1021187518167608e-08
cell O 0 1.6892288101644226e-07
cycle O 0 8.033446761146479e-07
progression O 0 1.1221981139897252e-06
. O 0 1.7549805164662757e-08

However O 0 1.8280004496773472e-06
, O 0 9.74908616058201e-08
immunostaining O 0 3.2151623599929735e-05
revealed O 0 4.000547050964087e-06
that O 0 2.0791675936493448e-08
BARD1 O 0 0.0001516791235189885
resides O 0 2.8699193990178173e-06
within O 0 1.0526267146815371e-07
BRCA1 O 0 5.182631923617009e-08
nuclear O 0 9.271242902286758e-07
dots O 0 7.70295969232393e-08
during O 0 4.1028343389371e-08
S O 0 2.6910132078228344e-07
phase O 0 5.496527677451013e-08
of O 0 1.92306988111568e-08
the O 0 5.296411753619168e-09
cell O 0 2.444621038932837e-08
cycle O 0 7.811689961556567e-09
, O 0 2.449083644218142e-11
but O 0 3.269300802299924e-11
not O 0 2.465512516369728e-10
during O 0 1.1636409169568651e-08
the O 0 2.9780656163325148e-08
G1 O 0 1.2308911436775816e-06
phase O 0 2.806388863518805e-07
. O 0 7.060561557636902e-08

Nevertheless O 0 7.03289970260812e-06
, O 0 7.759126674500294e-08
BARD1 O 0 2.933743417088408e-05
polypeptides O 0 4.3881024680558767e-07
are O 0 4.692161659214378e-10
found O 0 5.378522627275117e-10
exclusively O 0 1.9530099759634822e-09
in O 0 1.3875354198944478e-09
the O 0 3.6302796324605424e-09
nuclear O 0 6.743739788817038e-08
fractions O 0 6.247298500738907e-08
of O 0 5.70666109922513e-08
both O 0 3.394652781096852e-09
G1 O 0 6.337502611586388e-08
- O 0 2.8738040835918355e-09
and O 0 8.348455815543332e-10
S O 0 1.3355229100397992e-07
- O 0 6.501328808639073e-09
phase O 0 2.0576004544636817e-07
cells O 0 1.3015410615935252e-07
. O 0 2.3707009688678227e-08

Therefore O 0 2.0820752411054855e-07
, O 0 3.377956803163329e-09
progression O 0 7.143189861835708e-08
to O 0 6.155745246871902e-09
S O 0 7.218649216156336e-07
phase O 0 3.031340156667284e-07
is O 0 1.0634423341926436e-09
accompanied O 0 4.552713317451662e-09
by O 0 6.479624059529954e-10
the O 0 3.421303462758374e-09
aggregation O 0 8.828148878592401e-09
of O 0 9.675761525329563e-09
nuclear O 0 1.5732271094748285e-06
BARD1 O 0 0.0012390021001920104
polypeptides O 0 2.8762790407199645e-06
into O 0 1.360310051268243e-07
BRCA1 O 0 2.268473195954357e-07
nuclear O 0 4.108561824978096e-06
dots O 0 2.3660447823203867e-06
. O 0 1.2622056999589404e-07

This O 0 2.0365766317809175e-07
cell O 0 1.43189041068581e-07
cycle O 0 2.681580610897072e-07
- O 0 1.4492513855657307e-07
dependent O 0 2.4977990165098163e-07
colocalization O 0 1.071213432624063e-06
of O 0 2.0183570370591042e-07
BARD1 O 0 0.0006365605513565242
and O 0 1.9879291102142815e-08
BRCA1 O 0 8.106021454068468e-08
indicates O 0 7.617633457357442e-08
a O 0 4.905654105158419e-09
role O 0 2.2951327505182917e-09
for O 0 3.922169700132372e-09
BARD1 O 0 8.374937169719487e-05
in O 0 3.2925606774369953e-07
BRCA1 O 0 1.8656550082596368e-06
- O 0 6.637366368522635e-06
mediated O 0 6.369294715113938e-05
tumor B-Disease 0 0.0669172927737236
suppression O 0 3.392832513782196e-05
. O 0 5.524590918071226e-08

Ethnic O 0 1.9083724112078926e-07
differences O 0 1.5705288092249248e-07
in O 0 1.5668007335989387e-07
the O 0 5.862025886926858e-07
HFE O 0 0.00030824635177850723
codon O 0 4.741363227367401e-06
282 O 0 3.1533177207165863e-06
( O 0 2.2514339548251883e-07
Cys O 0 0.003893024753779173
/ O 0 1.924670687003527e-05
Tyr O 0 4.436234667082317e-05
) O 0 2.492428130551616e-08
polymorphism O 0 8.208894541894551e-07
. O 0 4.485690041633461e-08

Recent O 0 6.468405331361282e-07
studies O 0 5.2068177325281795e-08
have O 0 4.69225103216786e-10
shown O 0 1.1296284796458167e-08
that O 0 4.723540669715476e-08
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
( O 1 0.9999988079071045
HH B-Disease 1 0.9999998807907104
) O 0 4.7177395323672044e-09
is O 0 4.016910692961062e-10
likely O 0 7.171633287228474e-10
to O 0 1.28884103389737e-09
be O 0 9.10840203260932e-09
caused O 0 5.799181579391188e-08
by O 0 5.4947846273023515e-09
homozygosity O 0 2.4410951482423116e-06
for O 0 8.251623384580853e-09
a O 0 7.078320152231754e-08
Cys282Tyr O 0 5.240881364443339e-06
mutation O 0 3.6022278493419435e-09
in O 0 5.8250080314792285e-09
the O 0 1.1448363324007005e-07
HFE O 0 0.0005248041707091033
gene O 0 9.255494859417013e-08
located O 0 1.5304796363579953e-07
4 O 0 6.655936886090785e-07
. O 0 5.7307882883606e-08

5 O 0 3.4245233109686524e-05
Mb O 0 0.0006931745447218418
telomeric O 0 1.6399368178099394e-05
to O 0 5.111648420097481e-07
HLA O 0 2.137752562703099e-05
- O 0 1.711323079689464e-06
A O 0 3.658493369584903e-06
. O 0 8.636256865202085e-08

Population O 0 1.5221898186368321e-09
studies O 0 1.1727265825101085e-09
of O 0 8.503572845874885e-10
this O 0 1.4357526278985233e-10
polymorphism O 0 8.421693564741872e-09
are O 0 4.427449379340587e-11
facilitated O 0 1.954627348865756e-09
by O 0 1.5208424797297226e-10
the O 0 1.5307087819493859e-09
fact O 0 2.998806314380431e-09
that O 0 7.150213754414381e-11
the O 0 3.6911425027597033e-09
Cys282Tyr O 0 5.353960659704171e-06
mutation O 0 3.768390044456282e-09
creates O 0 9.664546496424009e-09
a O 0 4.1291020380640475e-08
Rsal O 0 2.7507083359523676e-05
restriction O 0 1.9450747856808448e-07
site O 0 2.343092972978411e-07
. O 0 1.938355964625771e-08

We O 0 1.9608724244335463e-07
have O 0 9.78193415157591e-10
studied O 0 1.4526422731364619e-08
the O 0 1.2151248007796767e-08
codon O 0 1.607187272156807e-07
282 O 0 4.0057216210698243e-07
( O 0 8.904200399229012e-08
Cys O 0 0.003813620889559388
/ O 0 2.70196255769406e-06
Tyr O 0 3.753361170311109e-06
) O 0 2.387433306605402e-10
polymorphism O 0 5.339986230978866e-10
in O 0 8.496981764027911e-12
different O 0 9.725982172414938e-12
ethnic O 0 8.66043070590905e-10
groups O 0 9.159669134284343e-10
. O 0 1.1983482650634869e-08

In O 0 4.78607091736194e-07
agreement O 0 4.373354656195261e-08
with O 0 2.2997426185611403e-09
previous O 0 3.272656670105789e-07
observations O 0 1.179450009658467e-06
the O 0 2.533011311811606e-08
Tyr O 0 4.06614435632946e-06
allele O 0 8.712675025890348e-09
appeared O 0 9.951857116163865e-09
to O 0 7.716245975508684e-10
be O 0 1.3705804269292798e-09
rare O 0 5.495895738505396e-09
or O 0 2.2165490776160368e-08
absent O 0 1.0548214390837529e-07
in O 0 9.373491316466698e-09
Asiatic O 0 5.992031674395548e-06
( O 0 6.583348977073911e-09
Indian O 0 2.4543949095345852e-08
, O 0 2.1232206270926923e-10
Chinese O 0 1.779003433455273e-08
) O 0 1.3022208311674888e-10
populations O 0 7.697646686732895e-11
. O 0 1.115856407274407e-09

The O 0 5.116638135405083e-07
highest O 0 1.40696585049227e-07
allele O 0 3.0197446765356517e-09
frequency O 0 4.17547019182507e-09
( O 0 2.5125057590003053e-10
7 O 0 1.3700603984645454e-09
. O 0 3.4998563075427924e-11
5 O 0 1.7152937958897496e-09
% O 0 2.2395159338106652e-10
) O 0 2.531085063761651e-11
was O 0 1.321913800644836e-09
found O 0 6.150085440914665e-10
in O 0 5.52843548717874e-09
Swedes O 0 7.153947194638022e-07
. O 0 2.0828159108532418e-07

Saamis O 0 0.00035992360790260136
( O 0 1.276502104019528e-07
2 O 0 1.3187846548134985e-07
% O 0 2.9057944939125946e-09
) O 0 1.459781739931998e-10
and O 0 3.0738450673695183e-10
Mordvinians O 0 5.988816269564268e-07
( O 0 2.285805544843811e-09
1 O 0 4.119173002692378e-09
. O 0 3.7185563656061404e-11
8 O 0 1.7969439269904797e-09
% O 0 8.971781650934929e-11
) O 0 4.233774789086375e-12
had O 0 1.7651531278306543e-11
significantly O 0 2.8152135136960688e-11
lower O 0 4.979902046287066e-10
frequencies O 0 8.748056168350615e-10
of O 0 1.005538674547779e-08
the O 0 3.289358829761113e-08
Tyr O 0 1.4261001524573658e-05
allele O 0 1.1489817097753985e-07
. O 0 2.813387212086127e-08

Comparisons O 0 8.65418101625437e-08
with O 0 1.2187655051842938e-10
allele O 0 9.185509575182493e-10
frequencies O 0 3.949887084075954e-09
based O 0 9.869793871075672e-10
on O 0 3.1887563700649935e-09
prevalence O 0 1.844241666049129e-07
estimates O 0 6.656176054775642e-09
of O 0 5.1849060156428095e-08
HH B-Disease 1 0.9999945163726807
showed O 0 4.866301992478839e-07
some O 0 2.093073048214933e-09
disagreements O 0 4.8303569144536596e-08
with O 0 1.091425907984167e-10
the O 0 2.4636053197468755e-09
RFLP O 0 1.2489645939695038e-07
data O 0 5.564722016515589e-09
, O 0 2.3213965472113074e-11
particularly O 0 1.650049819001964e-10
in O 0 9.259746747147801e-09
Finns O 0 5.655948825733503e-06
. O 0 2.418353801658668e-07

The O 0 2.913129492299049e-06
newly O 0 7.711963917245157e-06
described O 0 1.6895839507924393e-05
HFE O 0 0.2879258096218109
marker O 0 2.7012488317268435e-06
provides O 0 1.751472744615512e-08
a O 0 1.2517228364927746e-09
new O 0 2.0653632970546454e-10
approach O 0 2.107213070701164e-09
to O 0 1.4701594108768035e-10
the O 0 1.404266258830944e-09
screening O 0 3.0845943577162416e-09
of O 0 2.4897869366213854e-07
HH B-Disease 1 0.9999992847442627
as O 0 1.3284381594758088e-08
well O 0 1.8754779951279943e-09
as O 0 7.125411927155767e-10
studies O 0 4.567934919208483e-09
of O 0 2.7366799937311725e-09
the O 0 2.1337487332573346e-09
relationship O 0 3.080533161892163e-08
between O 0 3.373457602151575e-08
the O 0 1.1672737088019858e-07
HFE O 0 0.000549808144569397
Tyr O 0 1.8576160982775036e-06
allele O 0 3.6266653569150265e-10
and O 0 2.292815937110504e-11
different O 0 2.691728229198276e-10
disorders O 1 0.9581176042556763
including O 0 4.386838838854601e-07
cancer B-Disease 1 1.0

Autosomal B-Disease 1 1.0
dominant I-Disease 1 0.9999967813491821
neurohypophyseal I-Disease 1 1.0
diabetes I-Disease 1 1.0
insipidus I-Disease 1 0.9999980926513672
associated O 0 7.368294774323658e-08
with O 0 4.35331798387395e-10
a O 0 2.7874072827671625e-08
missense O 0 1.6414419690136128e-07
mutation O 0 3.164138673295014e-10
encoding O 0 2.0948902612616394e-09
Gly23 O 0 8.273514708889707e-07
- O 0 1.0203084457316436e-06
- O 0 7.711184480285738e-06
> O 0 3.6490223465079907e-06
Val O 0 1.221666479978012e-05
in O 0 1.7802466345528956e-07
neurophysin O 0 0.00025364922476001084
II O 1 0.5963698625564575
. O 0 1.3115655974615947e-06

Autosomal B-Disease 1 1.0
dominant I-Disease 1 1.0
neurohypophyseal I-Disease 1 1.0
diabetes I-Disease 1 1.0
insipidus I-Disease 1 1.0
( O 0 3.727141665876843e-05
ADNDI B-Disease 1 0.9999971389770508
) O 0 2.2003405319992453e-08
is O 0 1.2148206884887713e-09
an O 0 1.8786437294693314e-08
inherited B-Disease 1 1.0
disease I-Disease 1 1.0
caused O 1 1.0
by O 0 3.8115406368888216e-06
progressive O 1 1.0
degeneration O 1 1.0
of O 0 2.3556945052405354e-06
the O 0 3.327218962567713e-07
magnocellular O 0 0.0012016959954053164
neurons O 0 4.092653398402035e-06
of O 0 3.9465686541007017e-07
the O 0 2.766494446859724e-07
hypothalamus O 0 6.501828920590924e-06
leading O 0 9.927840238788121e-08
to O 0 1.0016943940982515e-09
decreased O 0 1.9291026376322407e-07
ability O 0 6.508570904451005e-10
to O 0 1.8799967138605211e-10
produce O 0 4.338728820663107e-10
the O 0 5.4143236560832975e-09
hormone O 0 1.1645846065277965e-08
arginine O 0 1.3528929798667377e-07
vasopressin O 0 3.187153083672456e-07
( O 0 2.0895110086627255e-09
AVP O 0 4.861922775489802e-07
) O 0 1.7347509539966666e-10
. O 0 8.02423794077356e-10

Affected O 0 8.544557204004377e-07
individuals O 0 4.958238264407555e-09
are O 0 3.919034818888889e-10
not O 0 8.684515329093756e-10
symptomatic O 0 1.6652950307616265e-07
at O 0 3.96681585357328e-08
birth O 0 3.345092736140032e-08
, O 0 1.968195190160671e-10
but O 0 1.1676595801368705e-10
usually O 0 4.618291082891801e-09
develop O 0 4.536118467513006e-06
diabetes B-Disease 1 1.0
insipidus I-Disease 1 0.9999954700469971
at O 0 8.221843927458394e-06
1 O 0 1.3250998563307803e-05
- O 0 5.348666718418826e-07
6 O 0 1.3505213019016082e-06
yr O 0 4.485838144319132e-05
of O 0 5.791245527575484e-08
age O 0 1.828211679821834e-07
. O 0 8.856604694074122e-08

The O 0 1.290004547627177e-06
genetic O 0 2.8523470518848626e-06
locus O 0 4.3228408230788773e-07
of O 0 3.606787402077316e-08
the O 0 6.234537863747391e-08
disease O 0 3.2280252071359428e-06
is O 0 1.6922738765856593e-08
the O 0 4.059988611970766e-07
AVP O 0 0.0001916078763315454
- O 0 5.518013495020568e-07
neurophysin O 0 1.0942348126263823e-05
II O 0 0.000849773408845067
( O 0 2.0575514270149142e-07
NPII O 0 5.015850183553994e-05
) O 0 3.272823123623425e-09
gene O 0 3.772142320723759e-10
, O 0 3.856103283905732e-11
and O 0 2.090434769730365e-10
mutations O 0 2.5931079505880916e-09
that O 0 8.326622169541054e-10
cause O 0 1.2763404129145783e-06
ADNDI B-Disease 1 0.9985710382461548
have O 0 4.601610648080623e-09
been O 0 5.50346657135492e-10
found O 0 9.428278296974568e-11
in O 0 5.853693224588952e-11
both O 0 1.0421632307133777e-10
the O 0 2.2886410544487035e-09
signal O 0 5.377892264846196e-08
peptide O 0 5.919448042845943e-09
of O 0 2.4332795334203183e-08
the O 0 6.123217133335856e-08
prepro O 0 6.346080044750124e-05
- O 0 0.0002159938885597512
AVP O 0 0.006369114387780428
- O 0 6.057935479475418e-06
NPII O 0 0.00012921259622089565
precursor O 0 6.990512133597804e-07
and O 0 3.6860980934250165e-09
within O 0 6.701196753056138e-08
NPII O 0 0.0004448069375939667
itself O 0 1.7651464645496162e-07
. O 0 9.67938262874668e-08

An O 0 8.09180789929087e-07
affected O 0 2.0578163173468056e-07
girl O 0 1.8882733456848655e-06
who O 0 1.1441678715584658e-08
presented O 0 8.357657321766965e-08
at O 0 1.1209850754312356e-06
9 O 0 4.306578773594083e-07
months O 0 1.3460728531811128e-08
of O 0 1.9394949646311943e-08
age O 0 4.843420597921977e-08
and O 0 8.277107332865796e-10
her O 0 1.0005262396362014e-08
similarly O 0 4.214717463923989e-09
affected O 0 1.9517476523844834e-09
younger O 0 2.363768958346668e-09
brother O 0 3.1728268368169665e-07
and O 0 1.3316752145442479e-08
father O 0 7.642117338946264e-07
were O 0 1.6466474050957913e-07
all O 0 1.3886342076219194e-09
found O 0 7.650840516681967e-10
to O 0 3.0756161506495516e-10
have O 0 1.2831276319236196e-10
a O 0 2.3271087279397307e-09
novel O 0 2.0689531865514255e-08
missense O 0 1.8239067856029578e-07
mutation O 0 1.0880487621989232e-09
( O 0 9.532872269346626e-10
G1758 O 0 6.871540669806109e-09
- O 0 2.7362689891674563e-08
- O 0 2.926744571141171e-07
> O 0 4.6655009100504685e-07
T O 0 3.732126430122662e-08
) O 0 1.0544538853185514e-10
encoding O 0 1.5959708554724727e-10
the O 0 9.089116126403951e-10
amino O 0 1.5114709484009836e-09
acid O 0 1.4204019072039387e-09
substitution O 0 4.104937723070634e-09
Gly23 O 0 1.6502535800100304e-06
- O 0 3.5328771446074825e-06
- O 0 6.660605777142337e-06
> O 0 7.150508281483781e-06
Val O 0 1.4259234376368113e-05
within O 0 8.497045200783759e-07
NPII O 0 0.0034219231456518173
. O 0 8.725249358576548e-07

The O 0 5.464352170747588e-07
mutation O 0 1.3863933112645555e-08
was O 0 5.304502437297742e-08
confirmed O 0 1.8619621400262076e-09
by O 0 7.345065111685756e-10
restriction O 0 3.6786548918144035e-08
endonuclease O 0 1.1693855412886478e-06
analysis O 0 4.124607855260365e-08
. O 0 1.53425219195924e-08

A O 0 6.655709876213223e-05
T1 O 0 0.0003022942109964788
- O 0 1.9505246484641248e-07
weighted O 0 1.9244536986207095e-07
magnetic O 0 4.878676236330648e-07
resonance O 0 2.774926315396442e-07
imaging O 0 1.2976050811630557e-06
of O 0 1.4896335187586374e-07
the O 0 1.5096311472007073e-06
fathers O 0 0.003693903563544154
pituitary O 0 0.0002502668939996511
gland O 0 6.456953656197584e-07
demonstrates O 0 2.4736309001127665e-08
an O 0 3.373842094589463e-09
attenuated O 0 3.4967104056704557e-06
posterior O 0 2.043325366685167e-05
pituitary O 0 4.158975571044721e-05
bright O 0 2.3233637875819113e-06
spot O 0 1.5324059859267436e-05
. O 0 3.245881998736877e-07

This O 0 9.744383078214014e-08
mutation O 0 8.2948439228403e-09
may O 0 1.0747104317587741e-09
be O 0 2.3584084685168705e-10
valuable O 0 1.2343215338717073e-08
for O 0 2.4111979080032597e-10
developing O 0 6.671568630878255e-09
models O 0 2.6183670343016274e-08
of O 0 4.656557166526909e-07
dominantly B-Disease 1 0.9999791383743286
inherited I-Disease 1 1.0
neurodegeneration I-Disease 1 1.0
, O 0 8.551921126809248e-08
as O 0 1.3410852428563658e-09
the O 0 6.412286257528876e-10
early O 0 6.516499784225971e-09
age O 0 1.4524235147916897e-08
of O 0 1.6796972701627055e-08
onset O 0 0.00037748421891592443
of O 0 1.5601641507601016e-06
symptoms O 1 0.9818423986434937
suggests O 0 3.778887105454487e-07
that O 0 7.89440735005087e-11
this O 0 2.1173768294246997e-10
mutation O 0 2.7588425988156473e-10
may O 0 2.801726628476331e-10
be O 0 1.304764213339027e-10
particularly O 0 1.7365849036554692e-10
deleterious O 0 5.968037619652478e-09
to O 0 2.054246106553137e-09
the O 0 2.7860307838523113e-08
magnocellular O 0 1.7737569578457624e-05
neuron O 0 3.4199008496216265e-06
. O 0 4.9807975521787284e-09
. O 0 1.672137450725586e-08

Frequent O 0 7.2487591751269065e-06
inactivation O 0 8.825255463307258e-06
of O 0 3.279526936239563e-05
PTEN O 1 0.9999998807907104
/ O 1 0.872266411781311
MMAC1 O 1 0.9999499320983887
in O 0 1.7972452042158693e-06
primary O 1 1.0
prostate B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 2.5299243588960962e-06

Sporadic B-Disease 1 1.0
prostate I-Disease 1 1.0
carcinoma I-Disease 1 1.0
is O 0 1.9365920422842464e-07
the O 0 6.562888010819279e-09
most O 0 1.843261654421724e-10
common O 0 3.4889005573468523e-10
male B-Disease 0 3.975766826869176e-09
cancer I-Disease 0 4.005031417619875e-09
in O 0 3.797069769717609e-09
the O 0 3.1933712563159133e-08
Western O 0 1.0731504573868733e-07
world O 0 1.9261341410725663e-09
, O 0 5.2207616701993587e-11
yet O 0 2.322026459999904e-10
many O 0 1.4048488067297527e-11
of O 0 1.6957327209077278e-10
the O 0 6.028670895830146e-10
major O 0 7.91777399200555e-09
genetic O 0 5.888054488423222e-09
events O 0 1.1943840361183788e-09
involved O 0 1.6948636938352024e-09
in O 0 5.907219158274302e-10
the O 0 2.2995934045866306e-09
progression O 0 1.6975005223685002e-07
of O 0 2.7376458877625964e-09
this O 0 5.79294057168056e-10
often O 0 3.601272835496161e-09
fatal O 0 2.5622844987083226e-05
cancer B-Disease 0 2.0696754290838726e-05
remain O 0 4.239001100359019e-06
to O 0 9.508761777965447e-09
be O 0 6.070098379495903e-08
elucidated O 0 0.0003979489265475422
. O 0 1.5702622135904676e-07

Numerous O 0 6.750149623258039e-06
cytogenetic O 0 0.04350212216377258
and O 0 5.6839684958731596e-08
allelotype O 0 0.0001036891553667374
studies O 0 1.5518629652433447e-06
have O 0 2.508958596436628e-09
reported O 0 1.5985497370252233e-08
frequent O 0 1.4680649584875027e-08
loss O 0 2.0562548286306992e-07
of O 0 1.7069417026505107e-06
heterozygosity O 1 0.999982476234436
on O 0 6.553853017976508e-05
chromosomal O 1 0.8767873048782349
arm O 0 0.000643621722701937
10q O 0 8.114735101116821e-05
in O 0 1.0329304132028483e-06
sporadic B-Disease 1 1.0
prostate I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 6.287077667366248e-06

Deletion O 0 1.5529067241004668e-05
mapping O 0 1.5544313782811514e-06
studies O 0 6.200502156161747e-08
have O 0 6.051181777877446e-10
unambiguously O 0 1.5609655790171928e-08
identified O 0 3.709160312226345e-09
a O 0 4.612656923086433e-09
region O 0 3.989889307831618e-09
of O 0 1.982320299021012e-07
chromosome O 0 1.1230503105252865e-06
10q23 O 0 7.091264819791832e-07
to O 0 3.3103031427117457e-09
be O 0 1.3807163190548977e-09
the O 0 7.159172810133896e-09
minimal O 0 1.0131451517736423e-06
area O 0 5.598355556912793e-08
of O 0 1.3761980710569333e-07
loss O 0 9.434311323275324e-06
. O 0 4.7303657879638195e-07

A O 0 2.7215576210437575e-06
new O 0 1.0914440906617529e-07
tumor B-Disease 0 8.310385965160094e-06
suppressor O 0 9.556349141348619e-06
gene O 0 4.050010460332487e-08
, O 0 1.0847360343291257e-08
PTEN O 0 0.0014300558250397444
/ O 0 1.6500742276548408e-05
MMAC1 O 0 0.07043717056512833
, O 0 1.2208188238105322e-08
was O 0 5.080510732113908e-07
isolated O 0 2.376387584490658e-07
recently O 0 1.897035417641746e-09
at O 0 6.152904852285701e-09
this O 0 1.5732579128346913e-10
region O 0 5.848027062604899e-10
of O 0 1.317914133380782e-08
chromosome O 0 3.853374153095501e-08
10q23 O 0 1.5396439323467348e-07
and O 0 9.406118106625172e-10
found O 0 1.1690284296150821e-09
to O 0 2.617360772561028e-10
be O 0 1.1163966279204018e-10
inactivated O 0 1.5412936482661621e-09
by O 0 2.6020993693087746e-10
mutation O 0 5.031881022965479e-10
in O 0 1.3711451973819067e-09
three O 0 2.3631530154943903e-07
prostate B-Disease 1 1.0
cancer I-Disease 1 1.0
cell O 1 0.9999997615814209
lines O 0 1.728051188365498e-06
. O 0 6.570305544073562e-08

We O 0 4.258086789832305e-07
screened O 0 2.1472835669555934e-06
80 O 0 5.277021500660339e-06
prostate B-Disease 0 0.037733208388090134
tumors I-Disease 1 1.0
by O 0 7.677288138552285e-09
microsatellite O 0 1.1297447599645238e-06
analysis O 0 4.7460249064101845e-09
and O 0 4.204916970174111e-11
found O 0 1.6480722342393506e-09
chromosome O 0 2.4261520792379088e-08
10q23 O 0 6.723166023903104e-08
to O 0 5.090809107599625e-09
be O 0 7.013474689898658e-09
deleted O 0 1.282212025444096e-07
in O 0 1.4744876430938803e-09
23 O 0 3.8000422364348196e-08
cases O 0 1.224645895803178e-08
. O 0 3.739258858104222e-08

We O 0 1.7300037313816574e-07
then O 0 8.565287146211631e-09
proceeded O 0 1.4426827732449965e-08
with O 0 2.4907655798989126e-11
sequence O 0 2.7302673455409376e-09
analysis O 0 3.875721077406524e-09
of O 0 2.795264020249988e-09
the O 0 6.4190568416222504e-09
entire O 0 1.181036964226223e-06
PTEN O 0 0.0005653290427289903
/ O 0 1.6511745570824132e-06
MMAC1 O 0 3.548534732544795e-05
coding O 0 1.5355527693827753e-07
region O 0 2.5935875669347297e-09
and O 0 8.118046512795019e-11
tested O 0 6.429383692108104e-10
for O 0 6.333750190989917e-10
homozygous O 0 1.3107844587523232e-08
deletion O 0 2.097933160527532e-09
with O 0 1.969737740969979e-11
new O 0 1.9170263154677514e-09
intragenic O 0 4.795830591319827e-06
markers O 0 2.819360744865662e-08
in O 0 2.3708701668567755e-10
these O 0 5.132630431781138e-11
23 O 0 5.8131548463791205e-09
cases O 0 2.669192367132922e-10
with O 0 2.7085897413847704e-10
10q23 O 0 8.842610441206489e-06
loss O 0 0.0006644795648753643
of O 0 0.0005151223158463836
heterozygosity O 1 0.9999983310699463
. O 0 3.923716576537117e-06

The O 0 4.435883340647706e-07
identification O 0 4.5304098250653624e-08
of O 0 4.027301869768962e-08
the O 0 8.144393603970457e-08
second O 0 7.288585948117543e-07
mutational O 0 5.198653525440022e-06
event O 0 4.152812849156362e-08
in O 0 2.413794497613253e-09
10 O 0 3.663207071014085e-09
( O 0 5.360272781196329e-10
43 O 0 1.8407655844043802e-08
% O 0 1.3800455889168006e-08
) O 0 4.8102403837901875e-08
tumors B-Disease 1 1.0
establishes O 0 5.067017627879977e-05
PTEN O 1 0.999994158744812
/ O 0 0.00029679122962988913
MMAC1 O 0 0.0012194296577945352
as O 0 1.7137118391019612e-08
a O 0 1.1221211515533014e-08
main O 0 8.693933573056256e-09
inactivation O 0 3.43780257594517e-08
target O 0 7.96327004337627e-09
of O 0 1.7710608091192626e-08
10q O 0 1.5650444993298152e-06
loss O 0 2.4304817998199724e-06
in O 0 3.408403017601813e-07
sporadic B-Disease 1 1.0
prostate I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 8.51604582408072e-08
. O 0 1.9753617408468926e-08

Risk O 0 2.1060701328678988e-05
reversals O 0 2.3104555566533236e-06
in O 0 3.2245972558797575e-09
predictive O 0 3.125930803093979e-08
testing O 0 1.6542702763189254e-09
for O 0 3.193072828366894e-08
Huntington B-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 5.504043656401336e-07

The O 0 5.527742175104322e-08
first O 0 4.07281408598692e-09
predictive O 0 8.728359368603833e-09
testing O 0 4.254404606385265e-10
for O 0 5.60411050898324e-09
Huntington B-Disease 1 1.0
disease I-Disease 1 1.0
( O 0 2.0022453384171968e-07
HD B-Disease 0 1.7253076975976e-06
) O 0 1.7036298760597646e-10
was O 0 3.490311928366907e-10
based O 0 1.4052508288953103e-11
on O 0 2.818771882573401e-10
analysis O 0 7.529151191398853e-10
of O 0 3.896725719876315e-10
linked O 0 6.304225141917641e-09
polymorphic O 0 2.1927991866732555e-08
DNA O 0 1.985602260390351e-08
markers O 0 4.823155208555363e-09
to O 0 1.6332012131581308e-10
estimate O 0 3.2189928500514498e-09
the O 0 5.834256966430473e-10
likelihood O 0 8.451026545230889e-09
of O 0 1.6068154806703205e-08
inheriting O 0 7.044540950573719e-08
the O 0 5.612786235786871e-09
mutation O 0 4.3184847364763357e-10
for O 0 1.8580597060946502e-09
HD B-Disease 0 2.284348056491581e-06
. O 0 7.656803546751689e-08

Limits O 0 3.163146686802065e-07
to O 0 1.2342713517909942e-09
accuracy O 0 1.2389114623090336e-08
included O 0 4.4372666652137127e-10
recombination O 0 1.019576534311284e-09
between O 0 7.835412318968338e-10
the O 0 2.415337263528272e-09
DNA O 0 1.4872609810367976e-08
markers O 0 1.8908581367327315e-09
and O 0 4.889609550584595e-11
the O 0 6.344027525528873e-10
mutation O 0 1.0504477288009184e-09
, O 0 1.80357007106835e-10
pedigree O 0 1.1247245801371264e-08
structure O 0 1.2737314314392734e-08
, O 0 7.031898674458859e-11
and O 0 2.6466922403711735e-11
whether O 0 9.511871845724329e-11
DNA O 0 6.3070726419312e-10
samples O 0 1.2656223291607205e-10
were O 0 1.0195280175651078e-09
available O 0 6.958705833781664e-10
from O 0 3.2420746087780117e-09
family O 0 1.2753285538735781e-08
members O 0 3.753999333611091e-09
. O 0 3.8629995202654754e-08

With O 0 3.1606479655721387e-09
direct O 0 9.753342133933529e-09
tests O 0 1.515433473153749e-10
for O 0 2.240840568656921e-10
the O 0 5.7159832422826184e-09
HD B-Disease 0 1.4194989716997952e-06
mutation O 0 1.3964402967303613e-09
, O 0 3.9058017237136866e-11
we O 0 1.2213600963928428e-10
have O 0 2.9802545847834594e-11
assessed O 0 1.6245434997230745e-09
the O 0 6.849776301720567e-10
accuracy O 0 1.2221677891943727e-08
of O 0 1.670268590103774e-09
results O 0 4.528643016143974e-10
obtained O 0 1.5202262559910196e-08
by O 0 2.464122239587141e-09
linkage O 0 7.555556180705025e-08
approaches O 0 4.142826526276622e-09
when O 0 1.0053483601168978e-09
requested O 0 1.5346092396839595e-08
to O 0 4.816223864168023e-09
do O 0 1.1845423530942867e-09
so O 0 2.330581005960397e-10
by O 0 1.2109774294444264e-10
the O 0 1.1406482425257991e-09
test O 0 1.8558636849519417e-09
individuals O 0 2.442023916415792e-09
. O 0 1.979646313543526e-08

For O 0 6.942379116026132e-08
six O 0 8.451510602469625e-09
such O 0 3.371833368071009e-10
individuals O 0 1.3713127300363226e-09
, O 0 3.244887691877807e-10
there O 0 1.9242134552399648e-09
was O 0 3.169046181028534e-08
significant O 0 5.841497507930171e-09
disparity O 0 3.6678653003718864e-08
between O 0 6.5083765043993935e-09
the O 0 1.0719267251602105e-08
tests O 0 5.957915494292365e-09
. O 0 2.164633094992041e-08

Three O 0 1.7719447669151123e-06
went O 0 9.553027666697744e-07
from O 0 1.3061574044570534e-08
a O 0 2.5996811814366083e-08
decreased O 0 2.407374040558352e-06
risk O 0 1.8413448543697086e-08
to O 0 2.6458152335706586e-10
an O 0 1.676993821586592e-10
increased O 0 3.168585172019789e-09
risk O 0 1.8079321151276417e-08
, O 0 1.6060755503310986e-10
while O 0 3.357547850857401e-10
in O 0 6.933824070465278e-10
another O 0 1.6949091019569096e-09
three O 0 2.7285582127056784e-10
the O 0 1.3468991477694203e-09
risk O 0 2.4221249006473045e-08
was O 0 2.9382749744399916e-07
decreased O 0 3.381450824235799e-06
. O 0 7.24833384424528e-08

Knowledge O 0 0.0011411833111196756
of O 0 1.0353377319916035e-06
the O 0 2.503691653998885e-08
potential O 0 1.3733156833950488e-08
reasons O 0 6.620116899114237e-09
for O 0 9.69106322967761e-11
these O 0 2.4189494157722535e-11
changes O 0 5.2595813121447677e-11
in O 0 6.503346750008632e-10
results O 0 6.849201206193811e-10
and O 0 5.530939595210782e-11
impact O 0 2.518518726901675e-09
of O 0 8.143081209333047e-10
these O 0 9.92697452018021e-11
risk O 0 2.073622162868105e-09
reversals O 0 1.0984964049498558e-08
on O 0 6.924757434134676e-10
both O 0 1.1958696533032054e-10
patients O 0 1.2365589108220831e-10
and O 0 4.699359998361352e-11
the O 0 4.1711163412117e-09
counseling O 0 2.039069535442195e-08
team O 0 6.703849697586861e-10
can O 0 3.495314870871624e-10
assist O 0 1.439008467940539e-08
in O 0 5.433307137536758e-09
the O 0 1.1151207957027509e-08
development O 0 7.630823262161357e-08
of O 0 7.360552167767764e-09
strategies O 0 2.451348013465804e-09
for O 0 2.424881961893277e-10
the O 0 3.303169737733924e-09
prevention O 0 2.3823865547001333e-08
and O 0 6.629966714521984e-11
, O 0 1.6776007666363668e-11
where O 0 6.961570209185197e-11
necessary O 0 9.429601099952833e-09
, O 0 7.869185303377435e-10
management O 0 3.004905479997433e-08
of O 0 7.390403400364676e-09
a O 0 1.0318355947447344e-08
risk O 0 1.2560666284855415e-08
reversal O 0 1.1790790566124087e-08
in O 0 1.6436513261552932e-10
any O 0 2.370798002360175e-10
predictive O 0 2.5688191573891572e-09
testing O 0 1.2369480439922143e-10
program O 0 5.33040001027274e-10
. O 0 6.494356441510973e-11
. O 0 2.1394295224297366e-09

A O 0 1.2961926358912024e-06
novel O 0 1.4368394829489262e-07
common O 0 6.62757093650157e-09
missense O 0 1.148043452303682e-06
mutation O 0 4.614099768929236e-09
G301C O 0 5.1731802841459285e-08
in O 0 4.901408168223043e-09
the O 0 2.66719997199516e-08
N O 0 3.275484004916507e-06
- O 0 2.972748802676506e-07
acetylgalactosamine O 0 6.294811100815423e-06
- O 0 2.2414342311094515e-06
6 O 0 5.359334863896947e-06
- O 0 2.2931085652544425e-07
sulfate O 0 1.0277196906827157e-06
sulfatase O 0 0.0003041251911781728
gene O 0 1.130215139255597e-07
in O 0 1.1871196647916804e-07
mucopolysaccharidosis B-Disease 0 0.0008549559279344976
IVA I-Disease 1 0.9999539852142334
. O 0 2.0571856111928355e-06

Mucopolysaccharidosis B-Disease 0 0.04522683843970299
IVA I-Disease 1 0.9999977350234985
( O 0 3.3147367503261194e-05
MPS B-Disease 1 1.0
IVA I-Disease 1 1.0
) O 0 3.234917045347174e-08
is O 0 8.250894412142884e-10
an O 0 7.738799823187037e-09
autosomal B-Disease 1 0.9999983310699463
recessive I-Disease 1 1.0
lysosomal I-Disease 1 1.0
storage I-Disease 1 1.0
disorder I-Disease 1 1.0
caused O 1 0.9990031123161316
by O 0 9.073811924054098e-08
a O 0 2.5605208065826446e-05
genetic B-Disease 1 1.0
defect I-Disease 1 1.0
in O 0 1.063402351064724e-06
N O 0 1.350693764834432e-05
- O 0 3.9025616160870413e-07
acetylgalactosamine O 0 7.131099209800595e-06
- O 0 4.760079264087835e-06
6 O 0 5.628304643323645e-05
- O 0 3.6246817671781173e-06
sulfate O 0 1.238612094311975e-05
sulfatase O 1 0.997020423412323
( O 0 8.485658895551751e-07
GALNS O 0 0.00030234811129048467
) O 0 3.951727478579414e-08
. O 0 2.846974211934139e-08

In O 0 3.150598502088542e-07
previous O 0 1.4642483847637777e-07
studies O 0 4.090332339501401e-08
, O 0 1.9039869680881338e-10
we O 0 4.661075414524873e-10
have O 0 1.5766906877323628e-11
found O 0 5.6799499131843234e-11
two O 0 3.91881596617516e-11
common O 0 6.58394519459371e-11
mutations O 0 1.45398526552043e-10
in O 0 6.273410235735355e-09
Caucasians O 0 5.9587819123407826e-08
and O 0 3.997994380000591e-09
Japanese O 0 2.4235117962234654e-05
, O 0 3.754350164086873e-09
respectively O 0 4.048644370868715e-07
. O 0 9.925700794610748e-08

To O 0 2.4524302943973453e-07
characterize O 0 9.624299082133803e-07
the O 0 1.8020898551185383e-08
mutational O 0 2.4593632588221226e-06
spectrum O 0 1.5374502781995147e-09
in O 0 3.0477943085971404e-11
various O 0 5.4525904624735944e-11
ethnic O 0 7.488073355821356e-11
groups O 0 2.1589025706036935e-11
, O 0 1.61681674992753e-11
mutations O 0 2.687151369473728e-11
in O 0 2.1696240637414377e-10
the O 0 5.586917595223895e-09
GALNS O 0 7.176728104241192e-06
gene O 0 1.028002460934374e-09
in O 0 3.146956917277066e-09
Colombian O 0 1.912201469167485e-06
MPS B-Disease 1 1.0
IVA I-Disease 1 1.0
patients O 0 9.642676701560049e-08
were O 0 7.683187974727446e-10
investigated O 0 1.0424862750824104e-08
, O 0 2.8699995505143683e-11
and O 0 2.903226443973228e-11
genetic O 0 1.1980276770628961e-09
backgrounds O 0 1.7030981069865447e-09
were O 0 6.681332709312926e-10
extensively O 0 2.2280846612154903e-10
analyzed O 0 5.148614867778178e-10
to O 0 2.445139576923161e-11
identify O 0 1.0365984459692612e-10
racial O 0 1.4633165512645263e-10
origin O 0 7.983975980341285e-11
, O 0 1.347247226973769e-11
based O 0 2.8715654853961325e-11
on O 0 2.4079210847460786e-10
mitochondrial O 0 9.061437711288534e-10
DNA O 0 5.136628900004325e-10
( O 0 7.853871719643024e-11
mtDNA O 0 5.194690233523147e-10
) O 0 3.6787475843347295e-11
lineages O 0 4.62143434631912e-10
. O 0 1.2787549907855578e-09

Three O 0 3.880972201386612e-07
novel O 0 1.5935655710563879e-06
missense O 0 3.386755270184949e-05
mutations O 0 1.5376240725117896e-08
never O 0 3.1585223325691913e-08
identified O 0 8.180836452709173e-09
previously O 0 9.053599647756982e-09
in O 0 3.994326536194137e-10
other O 0 1.1225160384542576e-10
populations O 0 6.270448743572743e-11
and O 0 1.0879300238464396e-10
found O 0 1.103639069022222e-09
in O 0 1.6011335590704334e-09
16 O 0 1.2242044711285871e-08
out O 0 4.4860448689121313e-10
of O 0 1.1328672222532532e-08
19 O 0 1.6167058447535965e-07
Colombian O 0 9.881186997517943e-06
MPS B-Disease 1 1.0
IVA I-Disease 1 1.0
unrelated O 0 2.2610915948462207e-06
alleles O 0 2.069141746829928e-09
account O 0 2.5164061945304184e-09
for O 0 5.196979513399924e-10
84 O 0 1.9989350619198376e-07
. O 0 3.240741008880832e-08

2 O 0 1.8538021322456188e-06
% O 0 8.65541593952912e-09
of O 0 4.4530641396534065e-09
the O 0 1.444868558131418e-09
alleles O 0 2.6454619050930717e-10
in O 0 8.032736698027065e-10
this O 0 7.090285580879652e-10
study O 0 1.2718039066328402e-08
. O 0 7.865063267331607e-09

The O 0 1.7277907318202779e-06
G301C O 0 3.3129310850199545e-06
and O 0 6.517929751481688e-09
S162F O 0 5.213068448028935e-07
mutations O 0 4.298124078871979e-09
account O 0 8.698826547970384e-09
for O 0 6.7864478481283186e-09
68 O 0 1.0029873465100536e-06
. O 0 1.7788481443403725e-07

4 O 0 4.9088762352766935e-06
% O 0 1.9517150562364805e-08
and O 0 1.8482193553381876e-09
10 O 0 8.046637844927318e-08
. O 0 3.2068911082205886e-08

5 O 0 4.826300141758111e-07
% O 0 5.333697927767389e-09
of O 0 1.7174510702488988e-09
mutations O 0 4.908684569926436e-10
, O 0 1.2383928604808858e-10
respectively O 0 7.560467807365967e-09
, O 0 6.3625676949286e-10
whereas O 0 5.03967312326381e-09
the O 0 9.61750856731669e-09
remaining O 0 7.009979299255065e-07
F69V O 0 6.899250001879409e-05
is O 0 1.4679214510593397e-09
limited O 0 4.332873504431234e-10
to O 0 5.116974066687874e-10
a O 0 6.435422417183645e-09
single O 0 3.727977038181507e-09
allele O 0 1.114300118842948e-08
. O 0 1.48708796388064e-08

The O 0 1.4767407208182703e-07
skewed O 0 2.486414985014562e-07
prevalence O 0 7.675256341599379e-08
of O 0 4.128690722637884e-09
G301C O 0 3.185043695452805e-08
in O 0 2.9144184288121266e-10
only O 0 2.3727883546875717e-10
Colombian O 0 1.0566030717029662e-08
patients O 0 1.0841785108572921e-10
and O 0 9.206074270962095e-12
haplotype O 0 1.3457973624397823e-09
analysis O 0 9.306854592550096e-11
by O 0 1.0629850298593535e-11
restriction O 0 1.2276335503713653e-10
fragment O 0 1.3199688009279953e-09
length O 0 1.4652612456700354e-09
polymorphisms O 0 1.1829083490511039e-08
in O 0 6.514221939646347e-10
the O 0 1.4497774536437191e-08
GALNS O 0 0.00019878223247360438
gene O 0 2.7655204348775442e-08
suggest O 0 9.482228335855325e-09
that O 0 5.929838564622258e-11
G301C O 0 6.607869806884992e-08
originated O 0 1.0021841134744136e-08
from O 0 1.143918515467135e-09
a O 0 5.974096772831672e-09
common O 0 3.836841511173361e-09
ancestor O 0 5.935816602686828e-07
. O 0 8.211574709093838e-08

Investigation O 0 1.769242953741923e-05
of O 0 9.679567369857978e-08
the O 0 8.194016132279103e-09
genetic O 0 1.1564456059431905e-08
background O 0 4.671099063102702e-09
by O 0 1.6477193220953978e-10
means O 0 7.380373645560212e-09
of O 0 4.923992946714861e-08
mtDNA O 0 1.86907286092719e-07
lineages O 0 6.622541626200018e-09
indicate O 0 6.461925439182892e-10
that O 0 4.535510855774305e-12
all O 0 3.5881460996867176e-11
our O 0 6.223566106910994e-10
patients O 0 4.89800144887198e-11
are O 0 3.0812557366699522e-12
probably O 0 3.0628599656523647e-10
of O 0 3.422674366149181e-09
native O 0 2.5593962504899537e-08
American O 0 1.3272258456709096e-06
descent O 0 5.114583836984821e-05

Low O 0 1.3924096720074886e-06
frequency O 0 8.49498889010647e-08
of O 0 7.599681595138463e-08
BRCA1 O 0 4.822279038307897e-07
germline O 0 1.3944841157353949e-06
mutations O 0 2.6558666377241025e-10
in O 0 2.684243105566253e-10
45 O 0 3.025240147280783e-08
German O 1 0.9999996423721313
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 4.175053163635312e-06
. O 0 1.1303288971475922e-08

In O 0 4.5672926773931977e-08
this O 0 4.156104904673441e-10
study O 0 4.036865008938406e-10
we O 0 1.0471803979505978e-10
investigated O 0 7.136867985479967e-09
45 O 0 1.9869169420871913e-08
German O 1 0.9954327344894409
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 3.7927918583591236e-09
for O 0 1.3588222214089285e-10
germline O 0 2.431783912015817e-07
mutations O 0 2.5420446303492383e-10
in O 0 4.337611658744578e-10
the O 0 3.810600723852531e-09
BRCA1 O 0 3.0578139131876014e-08
gene O 0 5.258684154796356e-09
. O 0 5.577792006050686e-09

We O 0 1.9500524217619386e-07
identified O 0 7.66990027045722e-08
four O 0 4.740969572480935e-08
germline O 0 4.492686912271893e-06
mutations O 0 2.6127282559684772e-09
in O 0 1.8180078553697854e-09
three O 0 1.1174798864033164e-08
breast B-Disease 0 0.0002216468274127692
cancer I-Disease 0 5.606716513284482e-05
families O 0 4.251040408576046e-09
and O 0 4.512622775454389e-10
in O 0 1.5372934569768404e-07
one O 1 0.9970169067382812
breast B-Disease 1 1.0
- I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
family O 0 0.37569698691368103
. O 0 2.3148481395618425e-11
among O 0 1.5871507667158946e-12
these O 0 4.564261728984276e-12
were O 0 2.566398760173172e-10
one O 0 4.885883364558197e-10
frameshift O 0 5.6173515616819714e-08
mutation O 0 8.567321158059471e-11
, O 0 3.418592839365964e-11
one O 0 3.772120393819023e-10
nonsense O 0 6.319432799273272e-08
mutation O 0 4.163571154514045e-10
, O 0 1.5146300880175545e-10
one O 0 1.2758144540825356e-09
novel O 0 4.466634351274479e-08
splice O 0 7.334991778407129e-07
site O 0 1.3681782817798194e-08
mutation O 0 2.690640210634143e-10
, O 0 4.722884930363769e-11
and O 0 1.6410639513964043e-10
one O 0 1.5416736331985703e-08
missense O 0 1.195935965370154e-05
mutation O 0 1.4411568827199517e-07
. O 0 7.22273370001858e-08

The O 0 5.719208729715319e-06
missense O 0 4.064757013111375e-05
mutation O 0 4.1824947061286366e-08
was O 0 2.2376252672984265e-07
also O 0 4.658231578247296e-10
found O 0 8.409569707268361e-10
in O 0 7.59185514453975e-09
2 O 0 1.806917452995549e-06
. O 0 2.3552581751573598e-07

8 O 0 3.2229527278104797e-06
% O 0 1.2155676465397391e-08
of O 0 4.168149825289902e-09
the O 0 1.778354574710761e-09
general O 0 5.704862360289553e-09
population O 0 1.713497677080511e-10
, O 0 1.1303019631370148e-10
suggesting O 0 4.8154888965257214e-09
that O 0 2.811114188649988e-11
it O 0 3.980899984656894e-11
is O 0 1.4300732820160533e-10
not O 0 4.477300197258671e-10
disease O 0 6.1962559527728445e-09
associated O 0 2.1728979504587187e-08
. O 0 9.062033257123403e-08

The O 0 1.0055121890673036e-07
average O 0 2.692182832220169e-08
age O 0 3.6545815262911674e-09
of O 0 8.626556358137805e-09
disease O 0 1.2964967481821077e-06
onset O 0 0.0001396456646034494
in O 0 3.105124823932215e-09
those O 0 1.1957653756056175e-09
families O 0 2.2249770914584133e-09
harbouring O 0 1.262268142454559e-05
causative O 0 1.4543935321853496e-05
mutations O 0 7.91078491602093e-09
was O 0 1.3820296373978636e-07
between O 0 2.4456097591496473e-08
32 O 0 2.6495555971450813e-07
. O 0 4.202574288569849e-08

3 O 0 1.804311978048645e-06
and O 0 1.8787655875485143e-08
37 O 0 1.048992544383509e-06
. O 0 1.4266916537053476e-07

4 O 0 1.183327981379989e-06
years O 0 2.4495871997487484e-08
, O 0 8.363214010209674e-10
whereas O 0 5.597263097456562e-09
the O 0 2.720791592025762e-08
family O 0 5.385030021898274e-07
harbouring O 0 7.183552952483296e-05
the O 0 3.490815174700401e-07
missense O 0 1.6218918972299434e-05
mutation O 0 6.6002465715087055e-09
had O 0 5.287973170453597e-09
an O 0 6.176841815808132e-10
average O 0 1.1998874782648272e-08
age O 0 4.170980894002696e-09
of O 0 1.9893919045443909e-07
onset O 0 0.0006987655651755631
of O 0 1.6037914974731393e-05
51 O 0 1.2578722817124799e-05
. O 0 2.2617916783929104e-07

2 O 0 1.1764082955778576e-05
years O 0 5.39981499514397e-07
. O 0 2.708012232233159e-07

These O 0 8.056435518710714e-08
findings O 0 1.1245985120922342e-07
show O 0 4.4739159932305483e-08
that O 0 1.1322142112746292e-09
BRCA1 O 0 1.8006947044568733e-08
is O 0 1.8670689438948784e-09
implicated O 0 1.7279369046718784e-08
in O 0 1.7859994594360273e-09
a O 0 1.5514013407269545e-09
small O 0 3.3364175311412225e-10
fraction O 0 1.4307023121773454e-08
of O 0 3.413997546886094e-05
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 2.6200814318144694e-07
suggesting O 0 1.5963217414594055e-09
the O 0 5.7571721695515166e-11
involvement O 0 1.0471430389458192e-09
of O 0 7.817946290344935e-10
another O 0 9.647432852588622e-10
susceptibility O 0 6.630327842316319e-09
gene O 0 2.7677404812465056e-09
( O 0 5.517995393944375e-09
s O 0 2.183471821126659e-07
) O 0 5.034564409811537e-08

Paternal O 0 0.11277204751968384
transmission O 1 0.9995061159133911
of O 1 0.9996768236160278
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 2.193093314417638e-05

We O 0 7.216191875158984e-07
report O 0 4.7478017961566366e-08
a O 0 2.399033416367047e-09
rare O 0 1.1458795023955304e-09
case O 0 2.710896174207278e-09
of O 0 8.884927638064255e-08
paternally O 1 0.999997615814209
transmitted O 1 1.0
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9362378716468811
DM B-Disease 1 1.0
) O 0 7.355811248999089e-08
. O 0 1.790758652475688e-08

The O 0 6.787292932131095e-06
proband O 0 8.758071635384113e-05
is O 0 2.4449567703754838e-08
a O 0 1.2665557491686741e-08
23 O 0 1.1304108760157305e-08
year O 0 1.2829424189675365e-09
old O 0 5.9761106285805e-07
, O 0 7.378884703257427e-08
mentally B-Disease 1 1.0
retarded I-Disease 1 1.0
male O 0 0.0001210656701005064
who O 0 7.74649819845763e-08
suffers O 0 0.2763453722000122
severe O 1 0.9999983310699463
muscular B-Disease 1 1.0
weakness I-Disease 1 1.0
. O 0 3.864211976178922e-06

He O 0 8.449916890640452e-07
presented O 0 2.3253046776972042e-07
with O 0 4.39836682630812e-08
respiratory O 1 1.0
and O 0 2.0353573404463532e-07
feeding O 0 0.00032919005025178194
difficulties O 1 0.9989678859710693
at O 0 0.00028782771551050246
birth O 0 1.953490027517546e-05
. O 0 1.0213915402346174e-07

His O 0 6.058929557184456e-06
two O 0 1.0182378673562198e-06
sibs O 1 0.9997617602348328
suffer O 0 1.0658884093572851e-05
from O 0 5.577943511525518e-07
childhood O 1 0.9999983310699463
onset O 1 1.0
DM B-Disease 1 1.0
. O 0 5.92325613979483e-06

Their O 0 1.261119336959382e-06
late O 0 3.838175871351268e-06
father O 0 8.082706699497066e-07
had O 0 3.410685067706254e-08
the O 0 4.718927471003553e-09
adult O 0 8.304659182556406e-09
type O 0 1.642275009317018e-07
of O 0 0.00013454338477458805
DM B-Disease 1 1.0
, O 0 1.9186659372394388e-08
with O 0 1.6108653300150877e-09
onset O 0 0.00255629513412714
around O 0 7.267784241093977e-08
30 O 0 3.995808484091867e-08
years O 0 1.0369435088364298e-08
. O 0 2.072721549950529e-08

Only O 0 2.7478588293661232e-08
six O 0 1.710354080586285e-09
other O 0 1.0485310536489933e-11
cases O 0 5.7886303389542704e-11
of O 0 3.178130203451701e-09
paternal O 0 1.7755170119926333e-05
transmission O 1 0.999627947807312
of O 1 1.0
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
have O 0 4.093519601156004e-05
been O 0 4.3930516113732665e-08
reported O 0 2.5346155396732684e-08
recently O 0 2.705205837116864e-08
. O 0 2.7913976907711913e-08

We O 0 1.3596927317394147e-07
review O 0 7.684891834003338e-09
the O 0 7.50520645631525e-10
sex O 0 4.068479719787632e-10
related O 0 1.2327328047234687e-09
effects O 0 1.643718938737493e-08
on O 0 3.633239131772825e-08
transmission O 0 2.83177741948748e-05
of O 0 0.011593721807003021
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 0 1.7630143702263013e-05

Decreased O 0 0.0011720218462869525
fertility O 0 1.421380488864088e-06
of O 0 2.2183750392201773e-09
males O 0 6.285057196908639e-11
with O 0 2.6757715834713203e-11
adult O 0 6.712851075008075e-08
onset O 1 0.9999567270278931
DM B-Disease 1 1.0
and O 0 1.0510695425125505e-08
contraction O 0 1.6878713893220265e-07
of O 0 1.602056154403897e-09
the O 0 7.105014354635841e-10
repeat O 0 1.4305489015598027e-09
upon O 0 2.527777986927049e-09
male O 0 3.98372224097443e-09
transmission O 0 9.227301700498458e-10
contribute O 0 1.4974410600387955e-10
to O 0 1.75039219230122e-10
the O 0 6.733580359963298e-10
almost O 0 1.6180340400850923e-09
absent O 0 4.672765729907269e-09
occurrence O 0 3.22278315145752e-09
of O 0 8.732435330394139e-10
paternal O 0 1.4639566359164746e-07
transmission O 0 4.063295364176156e-06
of O 0 0.0011897457297891378
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 0 8.428408909821883e-05

Also O 0 3.0644588377981563e-07
the O 0 4.402219033750043e-08
fathers O 0 2.9559623726527207e-07
of O 0 2.2685895828544744e-08
the O 0 2.121219289108467e-08
reported O 0 2.324218257854227e-07
congenitally O 0 0.00015005686145741493
affected O 0 1.5001097253275475e-08
children O 0 2.2061805715622995e-09
showed O 0 1.7714189226580856e-08
, O 0 2.4109220175816404e-10
on O 0 8.671758422451603e-09
average O 0 6.602137858635615e-08
, O 0 9.157240521417975e-10
shorter O 0 2.2893938478318887e-07
CTG O 0 0.00031299603870138526
repeat O 0 2.0483391836023657e-06
lengths O 0 8.077797247096896e-06
and O 0 6.47819020649365e-10
hence O 0 5.650014678337811e-09
less O 0 8.864859957213866e-10
severe O 0 2.5507800316404428e-08
clinical O 0 2.6828439558812534e-07
symptoms O 0 4.5063742959428055e-08
than O 0 1.0893668606071216e-10
the O 0 3.690316940918592e-10
mothers O 0 6.548642739190313e-10
of O 0 4.660302144188222e-10
children O 0 5.94356563965448e-10
with O 0 1.4639042866804175e-08
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 0 1.6399977539549582e-05

We O 0 6.666647891506727e-07
conclude O 0 1.3460954733091057e-06
that O 0 7.376686372850827e-09
paternal O 0 5.506314209924312e-06
transmission O 0 0.00010854908032342792
of O 0 0.028307998552918434
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
is O 0 3.3235894534300314e-06
rare O 0 1.634362156721636e-08
and O 0 1.913532943209617e-10
preferentially O 0 3.854959906846034e-09
occurs O 0 2.003435639608142e-09
with O 0 1.0179264375853592e-10
onset O 0 0.022442398592829704
of O 1 0.5729257464408875
DM B-Disease 1 1.0
past O 0 8.25230188183923e-07
30 O 0 8.64591154225991e-09
years O 0 4.953368271110037e-10
in O 0 4.1794126492966654e-10
the O 0 1.3883031391159761e-09
father O 0 2.717809266528093e-08
. O 0 3.4069578269679823e-09
. O 0 1.3209012550419175e-08

The O 0 4.196208919893252e-06
RB1 O 0 0.000494185893330723
gene O 0 1.2973036866981147e-08
mutation O 0 1.3831624734450543e-09
in O 0 1.2150408457145545e-09
a O 0 1.851565123445198e-08
child O 0 1.7031013044288557e-07
with O 0 1.402800506866697e-07
ectopic B-Disease 1 1.0
intracranial I-Disease 1 1.0
retinoblastoma I-Disease 1 1.0
. O 0 2.053115349553991e-05

The O 0 5.855974450241774e-06
RB1 O 0 0.006503253243863583
gene O 0 1.265515408022111e-07
mutation O 0 1.2441186747480515e-08
was O 0 4.2371112840555725e-08
investigated O 0 1.4641059919995314e-07
in O 0 1.0533493188802368e-08
a O 0 2.847169788822157e-08
child O 0 3.8289266512947506e-07
with O 0 7.498746157352798e-08
ectopic B-Disease 1 1.0
intracranial I-Disease 1 1.0
retinoblastoma I-Disease 1 0.9988875985145569
using O 0 8.884894242555674e-08
DNA O 0 4.0917917942806525e-08
obtained O 0 1.8573306448388394e-08
from O 0 2.609008342702168e-09
both O 0 5.943009973030655e-10
the O 0 1.455351839041441e-08
pineal B-Disease 0 0.09024006128311157
and I-Disease 0 1.4640208689797873e-07
retinal I-Disease 1 0.9999967813491821
tumours I-Disease 1 1.0
of O 0 1.0312913218513131e-05
the O 0 3.376657673470618e-07
patient O 0 7.419575013045687e-06
. O 0 4.309076473418827e-08

A O 0 1.2663978850468993e-05
nonsense O 0 4.466078280529473e-06
mutation O 0 2.311480962191581e-08
in O 0 1.2588560416304517e-08
exon O 0 1.1651272302515281e-07
17 O 0 1.0316648513253313e-07
( O 0 1.1207543337832249e-08
codon O 0 7.724602113512447e-08
556 O 0 8.853463384639326e-08
) O 0 1.4331213993301617e-09
of O 0 2.1042941611426613e-08
the O 0 3.199615150606405e-07
RB1 O 0 0.002524222480133176
gene O 0 4.0988297200783563e-08
was O 0 1.8390132083823119e-07
found O 0 1.6621645171355226e-09
to O 0 4.214498472432382e-10
be O 0 1.4477485876795981e-09
present O 0 8.66388827347464e-09
homozygously O 0 8.156663170666434e-06
in O 0 1.7950902986285655e-07
both O 0 5.748348286260807e-08
the O 0 1.1624339322224841e-06
retinal B-Disease 0 0.0009391749044880271
and I-Disease 0 6.429670662555509e-08
the I-Disease 0 2.9667889975826256e-06
pineal I-Disease 1 1.0
tumours I-Disease 1 1.0
. O 0 5.791200692328857e-07

The O 0 1.8490125341941166e-07
same O 0 7.614390895582801e-09
mutation O 0 1.5048001733575234e-09
was O 0 1.3908641349758e-08
present O 0 1.53770840505274e-09
heterozygously O 0 2.399387710738665e-07
in O 0 6.313731315543691e-09
the O 0 8.225899073011078e-09
DNA O 0 8.31288371472283e-09
from O 0 8.085075386965457e-10
the O 0 1.1340578476293217e-09
constitutional O 0 4.5643817614404725e-09
cells O 0 1.065997179416911e-09
of O 0 1.1147587297699602e-09
the O 0 1.8062665807505596e-09
patient O 0 5.162249294698995e-08
, O 0 1.7854297207353653e-10
proving O 0 5.686212745104058e-08
it O 0 4.26115878693345e-11
to O 0 1.5344409076689658e-10
be O 0 1.0155415397505863e-09
of O 0 2.0856337101804456e-08
germline O 0 4.7335834096884355e-06
origin O 0 1.0135899231045187e-07
. O 0 6.087107351504528e-08

The O 0 8.089160701274523e-07
initial O 0 3.040315448288311e-07
mutation O 0 1.477272437711008e-08
was O 0 6.389352336100274e-08
shown O 0 4.825216226578277e-09
to O 0 2.3192567866203717e-09
have O 0 6.169070809747268e-10
occurred O 0 5.234969080447627e-08
in O 0 1.3975808288435587e-09
the O 0 1.403742100336558e-08
paternally O 0 3.641541070464882e-06
derived O 0 9.104155651584733e-07
RB1 O 0 7.717878179391846e-05
allele O 0 1.9829461450626695e-07
. O 0 6.387561057863422e-08

The O 0 1.415246231317724e-07
mutation O 0 1.57686734780782e-08
is O 0 8.039542365168018e-10
in O 0 4.4717102243296836e-10
an O 0 8.20510104304617e-10
area O 0 1.0768695268836836e-08
of O 0 1.926991188838656e-08
the O 0 3.316833385724749e-08
gene O 0 6.198513702315722e-09
that O 0 8.001236895260888e-10
encodes O 0 5.895290922097729e-09
the O 0 7.567404480823825e-10
protein O 0 5.28849719572122e-09
- O 0 2.0426731417444444e-09
binding O 0 3.918565916194439e-09
region O 0 2.532750187356214e-08
known O 0 8.794959427405047e-08
as O 0 1.9140202311973553e-08
the O 0 1.008681635994435e-07
pocket O 0 0.000305911002214998
region O 0 4.040205112687545e-07
and O 0 1.0000264616394361e-08
has O 0 9.618549290379974e-10
been O 0 1.0680935025320082e-09
detected O 0 1.3810034227290657e-09
in O 0 5.846005624032813e-11
other O 0 4.679304686783237e-12
cases O 0 7.010859254252821e-11
of O 0 7.244529864891547e-09
retinoblastoma B-Disease 0 1.6591046005487442e-05
. O 0 3.572854012645621e-08
. O 0 4.940342535064701e-08

Low O 0 1.36837043100968e-05
levels O 0 3.2279191941597674e-07
of O 0 1.435263214943916e-07
beta O 0 2.242103391836281e-06
hexosaminidase O 0 9.55051405071572e-07
A O 0 3.5289666300286626e-08
in O 0 5.404808267606143e-10
healthy O 0 3.2373599356816385e-09
individuals O 0 6.072070624085768e-11
with O 0 5.487374790669186e-11
apparent O 0 0.001775466720573604
deficiency O 1 1.0
of O 0 0.0003227858687750995
this O 0 2.2927842735498416e-08
enzyme O 0 2.0693526892046066e-07
. O 0 1.5958264043547388e-08

Appreciable O 0 0.0007308201165869832
beta O 0 4.866777817369439e-05
hexosaminidase O 0 4.787920988746919e-05
A O 0 6.866709099995205e-06
( O 0 4.667191788598757e-08
hex O 0 2.2565550352737773e-06
A O 0 5.989912779114093e-07
) O 0 1.027749663151667e-09
activity O 0 8.617413449485412e-09
has O 0 8.302687010131038e-11
been O 0 3.44858280820759e-10
detected O 0 4.7889536780587605e-09
in O 0 2.6919353413035196e-09
cultured O 0 3.4978860639967024e-05
skin O 0 3.87713844247628e-05
fibroblasts O 1 0.788009762763977
and O 0 7.388532452523577e-08
melanoma B-Disease 1 0.9957064986228943
tissue O 0 1.0217943327006651e-06
from O 0 1.544334260472624e-08
healthy O 0 1.897219590318855e-07
individuals O 0 1.8929717515714373e-10
previously O 0 3.3043985325775793e-09
reported O 0 2.9863176376210276e-09
as O 0 3.5292727074143215e-10
having O 0 1.8341913232688967e-07
deficiency B-Disease 1 0.9987605810165405
of I-Disease 0 0.0023556877858936787
hex I-Disease 0 0.00022624684788752347
A I-Disease 0 6.045754048500385e-07
activity O 0 6.524648199501826e-08
indistinguishable O 0 7.659224365852424e-09
from O 0 1.0312345422036628e-10
that O 0 6.215599649556092e-12
of O 0 6.346472236629097e-10
patients O 0 3.948062154979226e-10
with O 0 2.5385876512018513e-08
Tay B-Disease 1 1.0
- I-Disease 1 1.0
Sachs I-Disease 1 1.0
disease I-Disease 1 1.0
( O 0 1.177318517875392e-05
TSD B-Disease 1 0.9937322735786438
) O 0 4.574328471562694e-08
. O 0 1.8203369478442255e-08

Identification O 0 2.6074783363583265e-06
and O 0 4.239843676145938e-08
quantitation O 0 0.0011363670928403735
of O 0 0.00014338149048853666
hex O 0 0.004345256835222244
A O 0 2.9585124138975516e-05
, O 0 2.484680239334125e-09
amounting O 0 3.3030082136065175e-07
to O 0 1.2694215456576785e-08
3 O 0 6.515850259347644e-07
. O 0 6.404457764119798e-08

5 O 0 3.438453404669417e-06
% O 0 9.622227281624873e-08
- O 0 6.453605294609588e-08
6 O 0 4.211320856484235e-07
. O 0 7.014119773884886e-08

9 O 0 1.5281736978067784e-06
% O 0 9.866202965724824e-09
of O 0 6.784403261406169e-09
total O 0 2.9457178030156683e-08
beta O 0 4.091608900580468e-07
hexosaminidase O 0 6.113519930295297e-07
activity O 0 6.263656473493029e-07
, O 0 2.290395373361065e-10
has O 0 3.846905780036103e-11
been O 0 1.354924783480982e-10
obtained O 0 1.410671468526914e-09
by O 0 1.903109225764865e-09
cellulose O 0 6.287152132244955e-07
acetate O 0 7.557588332929299e-08
gel O 0 5.133049540972934e-08
electrophoresis O 0 1.2256909087682288e-07
, O 0 7.4319910225995045e-09
DEAE O 0 1.6238296666415408e-05
- O 0 1.0898937716774526e-06
cellulose O 0 2.023959950747667e-06
ion O 0 2.4279959234263515e-06
- O 0 1.6276668247883208e-05
exchange O 0 0.0002336911129532382
chromatography O 0 0.004676359705626965
, O 0 1.0593135613135019e-07
radial O 0 3.6057331271877047e-06
immunodiffusion O 0 1.595800495124422e-05
, O 0 1.610770894444613e-08
and O 0 4.187499769159331e-08
radioimmunoassay O 0 0.000957248208578676
. O 0 7.826971000213234e-07

Previous O 0 0.00026872125454247
family O 0 6.980538955758675e-07
studies O 0 4.095812755622319e-08
suggested O 0 9.282412061217826e-10
that O 0 4.610846860569895e-12
these O 0 1.84335220698717e-11
individuals O 0 7.932730861082149e-11
may O 0 8.298194353884014e-10
be O 0 1.0070717593180234e-09
compound O 0 9.67085753700303e-08
heterozygotes O 0 8.671328544096468e-09
for O 0 1.0622863005904648e-10
the O 0 1.522700854295067e-09
common O 0 2.7567135241213236e-09
mutant O 0 2.467896251800994e-07
TSD B-Disease 0 4.945526598021388e-05
gene O 0 2.0702588532373056e-09
and O 0 8.434577342120164e-11
a O 0 2.575756719025435e-09
rare O 0 3.2961460227909356e-09
( O 0 1.7134070828817016e-09
allelic O 0 4.661960417706723e-08
) O 0 5.170583516900251e-09
mutant O 0 8.925114514113375e-08
gene O 0 3.085331456986751e-08
. O 0 1.7182417266781158e-08

Thus O 0 7.739939178463828e-07
, O 0 1.6195902396987094e-09
the O 0 3.2904738933581257e-09
postulated O 0 6.15329497577477e-07
rate O 0 4.8679630992864986e-08
mutant O 0 2.5852473939380616e-08
gene O 0 9.511332832445873e-10
appears O 0 1.5234735695202062e-09
to O 0 1.565427371064132e-10
code O 0 1.3122490594152936e-10
for O 0 6.572978966667975e-11
the O 0 7.738250595856755e-10
expression O 0 1.717506803444735e-09
of O 0 3.3659621756498836e-09
low O 0 9.606563544650726e-09
amounts O 0 8.063150147563647e-09
of O 0 1.3217814398558403e-07
hex O 0 9.58562122832518e-06
A O 0 2.2269582586886827e-06
. O 0 4.352641624905118e-08

Heterozygotes O 0 7.946601544972509e-05
for O 0 1.6976080985386943e-08
the O 0 2.0448648996307384e-08
rare O 0 1.7523246853556884e-08
mutant O 0 6.498467541860009e-08
may O 0 1.392817305934102e-09
be O 0 1.8163846815522078e-10
indistinguishable O 0 2.651798336472666e-09
from O 0 2.693782974461101e-10
heterozygotes O 0 1.1380019593332236e-08
for O 0 3.7556591170329057e-10
the O 0 1.0130309924250014e-08
common O 0 3.3350207928606324e-08
TSD B-Disease 0 0.00024896321701817214
mutant O 0 2.133470616172417e-06
. O 0 4.6169805756335336e-08

However O 0 1.024036606622758e-07
, O 0 1.1844677461070319e-09
direct O 0 1.3922283770284594e-08
visualization O 0 7.3086785050691105e-06
and O 0 1.5760013738486123e-08
quantitation O 1 0.5731207728385925
of O 0 0.0006744713173247874
hex O 0 0.0016211214242503047
A O 0 6.797007472414407e-07
by O 0 3.3183489289712043e-10
the O 0 7.624559872354553e-10
methods O 0 3.658263914019244e-09
described O 0 2.2911612607146026e-09
may O 0 1.0138306860696389e-09
prevent O 0 1.3800158793486617e-09
false O 0 2.988923242241981e-08
- O 0 4.659140184770649e-09
positive O 0 1.4518521940232176e-09
prenatal O 0 5.305124659571447e-07
diagnosis O 0 1.6144271342000138e-07
of O 0 4.6590979962957135e-08
TSD B-Disease 0 0.03180719539523125
in O 0 6.607820068893488e-08
fetuses O 0 4.3452266140775464e-07
having O 0 2.1393164573169088e-08
the O 0 3.838980688897209e-08
incomplete O 0 7.977364475664217e-06
hex B-Disease 0 0.00012033275561407208
A I-Disease 0 2.589759424154181e-05
deficiency I-Disease 1 0.9978354573249817
of O 0 5.272900307318196e-05
the O 0 8.815345040602551e-07
type O 0 8.636454731458798e-05
described O 0 3.139351179015648e-07
in O 0 1.7553153597305027e-08
the O 0 5.543315495515344e-08
four O 0 7.622357145464775e-08
healthy O 0 2.5461264385739923e-07
individuals O 0 1.263640143633893e-07

The O 0 5.3223052418616135e-06
tumor B-Disease 0 8.546499884687364e-05
suppressor O 0 4.2203038901789114e-05
gene O 0 2.484940466729313e-07
Smad4 O 0 0.00011767792602768168
/ O 0 3.5484908949001692e-06
Dpc4 O 0 1.2937958672409877e-05
is O 0 6.067777946761055e-10
required O 0 4.179946389015754e-10
for O 0 4.636098727139881e-10
gastrulation O 0 2.2876915295455547e-07
and O 0 7.321958039874232e-10
later O 0 7.021827119757518e-09
for O 0 2.8408648766742317e-09
anterior O 0 1.7721896483635646e-06
development O 0 1.7330564787698677e-06
of O 0 6.952960234229977e-07
the O 0 1.7005839936246048e-07
mouse O 0 7.554646686003252e-07
embryo O 0 1.5519250951001595e-07
. O 0 1.1296931390347709e-08

Mutations O 0 7.904308176875929e-07
in O 0 6.692613396808156e-08
the O 0 4.861217917095928e-07
SMAD4 O 1 0.9995751976966858
/ O 0 0.33229371905326843
DPC4 O 1 0.9845261573791504
tumor B-Disease 0 0.00016512841102667153
suppressor O 0 5.875951501366217e-06
gene O 0 2.656268094369807e-09
, O 0 6.9356465015602e-11
a O 0 4.561874877850869e-09
key O 0 6.914495997989434e-08
signal O 0 1.4822518323853728e-07
transducer O 0 2.4001658971428697e-07
in O 0 2.2283408451784226e-09
most O 0 8.124914074869594e-10
TGFbeta O 0 1.170259747595992e-05
- O 0 3.005043538450991e-07
related O 0 1.278916215596837e-06
pathways O 0 4.0284234614773595e-08
, O 0 1.5684004442406696e-11
are O 0 2.7802228835110965e-12
involved O 0 8.627863701260452e-11
in O 0 3.779776491796838e-10
50 O 0 1.1092913254628911e-08
% O 0 5.199728647653501e-09
of O 0 1.4271611803451378e-07
pancreatic B-Disease 1 1.0
cancers I-Disease 1 0.9999998807907104
. O 0 1.7777368839233532e-06

Homozygous O 0 0.0005918945535086095
Smad4 O 0 0.004801786504685879
mutant O 0 2.1440326236188412e-05
mice O 0 5.327600547389011e-07
die O 0 2.6418341292355763e-08
before O 0 1.7915001038204537e-08
day O 0 1.9428611608418578e-07
7 O 0 1.0960665122183855e-06
. O 0 5.706236549940513e-08

5 O 0 6.037633738742443e-06
of O 0 1.6733821439629537e-06
embryogenesis O 0 3.816463868133724e-05
. O 0 6.758586437172198e-07

Mutant O 0 1.9544291717465967e-05
embryos O 0 1.1830904611542792e-07
have O 0 3.474145415793828e-10
reduced O 0 5.077046560941767e-10
size O 0 5.895740784467307e-09
, O 0 1.4876148091147456e-09
fail O 0 4.9077531372176963e-08
to O 0 3.4903685275367025e-08
gastrulate O 0 2.6946574507746845e-05
or O 0 1.5052809487769991e-07
express O 0 4.1465440858701186e-08
a O 0 6.043055122972874e-08
mesodermal O 0 4.63893911728519e-06
marker O 0 6.755686854376108e-08
, O 0 1.8755126618419382e-10
and O 0 3.6241065703990216e-10
show O 0 1.366660882240467e-07
abnormal O 0 4.518432979239151e-05
visceral O 0 4.9402015065425076e-06
endoderm O 0 0.00013875702279619873
development O 0 3.5000803109142e-06
. O 0 1.2233132906658284e-07

Growth B-Disease 1 1.0
retardation I-Disease 1 1.0
of O 0 2.094017509080004e-05
the O 0 1.4362821048052865e-06
Smad4 O 1 0.9990299940109253
- O 0 0.0003253669710829854
deficient O 0 4.151227585680317e-06
embryos O 0 4.348133852971614e-09
results O 0 6.721005973986394e-10
from O 0 2.360613648999532e-10
reduced O 0 1.8937815760011745e-09
cell O 0 4.10819041007926e-08
proliferation O 0 1.6470078634256424e-08
rather O 0 9.515234156154406e-10
than O 0 8.429783954211345e-11
increased O 0 2.4543280741085027e-09
apoptosis O 0 2.0005445833248814e-07
. O 0 3.9463627921065836e-09

Aggregation O 0 1.3350241715670563e-05
of O 0 3.3829076073743636e-07
mutant O 0 5.378679361456307e-06
Smad4 O 0 0.01403822097927332
ES O 0 0.0005527346511371434
cells O 0 1.359074408568972e-09
with O 0 4.255960514565338e-11
wild O 0 1.7533535734415295e-09
- O 0 2.1793146842696842e-08
type O 0 1.9474838097721658e-07
tetraploid O 0 1.3532219782064203e-05
morulae O 0 0.00016422192857135087
rescues O 0 7.593836016894784e-06
the O 0 7.138382329685555e-08
gastrulation B-Disease 0 0.00029314495623111725
defect I-Disease 0 7.214115612441674e-05
. O 0 1.2605552512923168e-07

These O 0 6.202300539825956e-08
results O 0 1.9955153973683082e-08
indicate O 0 3.5100498507745215e-08
that O 0 6.472817837277489e-10
Smad4 O 0 1.345008627140487e-06
is O 0 1.2641319102613124e-09
initially O 0 1.1828716894868307e-09
required O 0 4.1390571525745656e-10
for O 0 1.9971051201661538e-10
the O 0 1.8680343938370925e-09
differentiation O 0 1.6314158912678067e-08
of O 0 8.16739653686227e-09
the O 0 1.165157836879871e-08
visceral O 0 1.577954265030712e-07
endoderm O 0 6.341359721773188e-07
and O 0 2.0688170621063762e-10
that O 0 1.1284128492716761e-10
the O 0 2.728429482345973e-09
gastrulation B-Disease 0 3.410546696613892e-06
defect I-Disease 0 6.867206252536562e-07
in O 0 3.987416619111173e-09
the O 0 8.345244495444604e-09
epiblast O 0 8.259708920377307e-06
is O 0 2.1004877837071945e-09
secondary O 0 9.357756880490342e-08
and O 0 3.1484517215574215e-09
non O 0 4.0851351513992995e-05
- O 0 7.98101827967912e-05
cell O 0 0.0001282344601349905
autonomous O 0 8.611782504885923e-06
. O 0 1.0388205851086241e-07

Rescued O 0 0.0014467851724475622
embryos O 0 2.5108827230724273e-06
show O 0 5.528675046662102e-07
severe O 0 4.616197657014709e-06
anterior O 0 3.601896241889335e-05
truncations O 0 0.21405449509620667
, O 0 2.434905184145464e-07
indicating O 0 3.5050870792474598e-06
a O 0 2.1324360943708598e-07
second O 0 1.0043104481383125e-07
important O 0 6.200514235388255e-08
role O 0 1.5443231404788094e-07
for O 0 7.496801401885023e-08
Smad4 O 0 0.10201604664325714
in O 0 7.522324949604808e-07
anterior O 0 0.00019927069661207497
patterning O 0 0.00016737465921323746
during O 0 2.2632646505371667e-05
embryogenesis O 0 0.00032872840529307723
. O 0 4.4393959797162097e-07

Prevalence O 0 5.4003459808882326e-05
of O 0 2.1494950885880826e-07
p16 O 0 1.2016415666948888e-06
and O 0 2.8783475158888905e-08
CDK4 O 1 0.6639816761016846
germline O 0 0.0008285740623250604
mutations O 0 1.9746195789593912e-08
in O 0 7.163407644839026e-09
48 O 0 2.3161815931871388e-07
melanoma B-Disease 0 0.0027188200037926435
- O 0 1.2131181392760482e-05
prone O 0 3.877689323417144e-06
families O 0 8.038596455151037e-09
in O 0 2.1936692462531937e-08
France O 0 4.664638709073188e-06
. O 0 1.5649491160729667e-06

The O 0 8.662570508022327e-06
French O 0 0.0011203911853954196
Familial B-Disease 1 1.0
Melanoma I-Disease 1 1.0
Study O 0 0.00038242185837589204
Group O 0 3.335428573336685e-07
. O 0 2.4375253815378528e-08

Germline O 0 0.013376740738749504
mutations O 0 2.201155382408615e-07
in O 0 1.8258868195175637e-08
the O 0 2.628705253471253e-08
p16 O 0 3.2351584877687856e-07
and O 0 1.3086536299056206e-08
CDK4 O 0 0.0010625104187056422
genes O 0 5.083689558205151e-08
have O 0 5.443085426826144e-10
been O 0 1.2537586524530298e-09
reported O 0 1.5519695528709576e-09
in O 0 9.262356437389485e-10
a O 0 1.1884988104782224e-08
subset O 0 2.7298710847389884e-07
of O 0 2.6215332127321744e-07
melanoma B-Disease 0 0.008654706180095673
pedigrees O 0 4.978932793164859e-06
, O 0 4.3169284813515674e-10
but O 0 5.383261544866791e-11
their O 0 2.3148051531141078e-10
prevalence O 0 4.1016608776089925e-08
is O 0 3.908857265644272e-11
not O 0 5.529431773565463e-11
well O 0 1.1256189313968434e-09
known O 0 1.5206497394615326e-08
. O 0 2.3450439812222612e-08

We O 0 2.3762900980273116e-07
searched O 0 3.818428240265348e-07
for O 0 2.8793454287523446e-09
such O 0 6.365605820235487e-09
germline O 0 2.9470853405655362e-05
mutations O 0 1.2157670425949618e-08
in O 0 6.707217004020549e-09
48 O 0 3.413728393297788e-07
French O 0 0.00013890276022721082
melanoma B-Disease 1 0.9999994039535522
- O 0 0.0008813192253001034
prone O 0 3.792877123487415e-06
families O 0 8.546890417626685e-10
selected O 0 1.2215960465411513e-09
according O 0 1.7171104538249438e-09
to O 0 1.0586763687925327e-09
two O 0 4.6424075694773137e-10
major O 0 6.2441869452811716e-09
criteria O 0 9.408006818034664e-09
families O 0 2.2800784871268576e-10
with O 0 3.235121892597448e-11
at O 0 1.778952452013982e-08
least O 0 2.0790198451692277e-09
three O 0 2.4449822721983594e-10
affected O 0 2.673900545424601e-10
members O 0 3.015783178739184e-10
( O 0 1.3552122757332086e-09
n O 0 3.6084600196772953e-08
= O 0 5.679882875142539e-08
20 O 0 7.381274702566998e-09
) O 0 1.0889389390200677e-10
or O 0 2.388294284560999e-10
families O 0 2.399712893674799e-11
with O 0 5.657252877960817e-12
two O 0 5.587703078013817e-10
affected O 0 2.6588380386272092e-09
members O 0 5.48669720767947e-10
, O 0 2.367580576034811e-10
one O 0 5.260888391589447e-10
of O 0 1.879266520177225e-09
them O 0 3.537980741707969e-10
affected O 0 1.7905017468677897e-09
before O 0 3.4191898201640925e-09
the O 0 4.44985470693382e-09
age O 0 7.646845823217063e-09
of O 0 2.0321314408988655e-08
50 O 0 4.769801442705557e-09
( O 0 2.2177140679424667e-10
n O 0 3.040272700260971e-09
= O 0 7.333170071177619e-09
28 O 0 2.166271606540704e-09
) O 0 3.475330093150042e-11
, O 0 4.332555581659792e-12
and O 0 5.400783553016764e-12
one O 0 3.398925585429424e-11
additional O 0 3.086552680109378e-10
minor O 0 8.257310213366509e-08
criterion O 0 4.9907130232895724e-06
. O 0 1.2594388465458906e-07

Sixteen O 0 6.406726697605336e-06
different O 0 3.826961858521827e-08
p16 O 0 5.617428087134613e-06
germline O 0 4.596610597218387e-05
mutations O 0 1.1367589536348532e-08
were O 0 2.219187722474203e-09
found O 0 4.027904954018169e-10
in O 0 2.617975003449402e-10
21 O 0 5.944861047879613e-09
families O 0 3.609461340925435e-10
, O 0 6.775447564111303e-11
while O 0 1.8911070487348525e-09
one O 0 1.0385705628834785e-08
germline O 0 4.605539288604632e-06
mutation O 0 3.6258507307707077e-09
, O 0 8.846297583353646e-10
Arg24His O 0 7.18716637493344e-06
, O 0 1.3349857885813776e-09
was O 0 4.850113555221469e-08
detected O 0 2.780780050670728e-08
in O 0 8.643850080147786e-09
the O 0 1.9820764407540992e-07
CDK4 O 0 0.002702396595850587
gene O 0 2.9132999657122127e-07
. O 0 6.299395494124838e-08

The O 0 5.7204793790788244e-08
frequency O 0 7.349262176603588e-08
of O 0 1.795358528511315e-08
p16 O 0 1.7378002326040587e-07
gene O 0 2.7085551579375533e-09
mutation O 0 1.7152176901014116e-10
in O 0 1.0072306877439985e-10
our O 0 6.570525235005675e-10
sample O 0 1.1148006823225032e-10
( O 0 7.799949575115761e-11
44 O 0 4.925209129424957e-10
% O 0 2.370834084608475e-10
) O 0 2.9850674015952094e-11
is O 0 5.725641748915988e-12
among O 0 2.3176701443444747e-12
the O 0 5.942497188771156e-11
highest O 0 3.6444465223439693e-09
rates O 0 1.6707497607626465e-09
yet O 0 3.6804900793718787e-10
reported O 0 1.4118962665676804e-09
and O 0 1.2209479260949507e-10
the O 0 3.8665355361899856e-09
CDK4 O 0 6.695934189338004e-06
mutation O 0 1.7984560507500191e-09
is O 0 1.8902945875254318e-10
the O 0 1.1583407150128622e-10
second O 0 1.2879931565734637e-09
mutation O 0 5.067130603997327e-10
detected O 0 2.5435444861443557e-09
in O 0 3.3731134552184017e-10
this O 0 1.2064732546335222e-09
gene O 0 2.734890092170872e-09
worldwide O 0 6.999456125811321e-09
. O 0 8.356919600771562e-09

In O 0 4.266793780516309e-07
summary O 0 2.981649004141218e-06
, O 0 1.2035817897881884e-09
our O 0 1.210701583431728e-08
results O 0 6.903213112252615e-09
show O 0 8.895233882810771e-09
frequent O 0 8.53339177098178e-09
involvement O 0 2.3311434560469024e-08
of O 0 1.775816649285389e-08
the O 0 1.662197135487986e-08
p16 O 0 2.1488085621967912e-07
gene O 0 4.849028734099647e-09
in O 0 9.893565078300526e-09
familial B-Disease 0 4.049242488690652e-05
melanoma I-Disease 0 0.0001006577440421097
and O 0 2.3944117799601372e-09
confirm O 0 5.0786887584308715e-08
the O 0 3.103438928064861e-08
role O 0 1.646898653007156e-07
of O 0 1.3113842669554288e-06
the O 0 3.452983321494685e-07
CDK4 O 0 0.003175124991685152
gene O 0 7.838914406477215e-09
as O 0 2.549932265338839e-09
a O 0 4.046589907602538e-08
melanoma B-Disease 0 5.12907536176499e-05
- O 0 4.5668980419577565e-06
predisposing O 0 7.928147533675656e-05
gene O 0 4.280920506971597e-08
. O 0 4.508073914166744e-09
. O 0 2.5885828591754034e-08

Progression O 0 0.00012510585656855255
of O 0 1.1966487818426685e-06
somatic O 0 3.369172918610275e-05
CTG O 0 0.0004520842048805207
repeat O 0 3.018416805389279e-07
length O 0 1.0860568444570617e-08
heterogeneity O 0 1.4334835896079312e-07
in O 0 1.616349831756736e-09
the O 0 2.2703716684446817e-09
blood O 0 1.5886591597791266e-08
cells O 0 7.097449383763887e-08
of O 0 4.373698629933642e-06
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 0 8.214657282223925e-05
. O 0 9.813802215319356e-09

The O 0 1.4414895588288346e-07
genetic O 0 5.2073239942274085e-08
basis O 0 3.5354688066036033e-07
of O 0 1.1899222954525612e-05
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.013682191260159016
DM B-Disease 1 1.0
) O 0 6.207031777449856e-09
is O 0 1.809196403801394e-10
the O 0 3.442976459488989e-10
expansion O 0 5.594787300111648e-09
of O 0 2.2044234881946068e-08
an O 0 1.309040520425242e-08
unstable O 0 1.2948438779858407e-05
CTG O 0 0.0005341940559446812
repeat O 0 4.7510951617368846e-07
in O 0 5.299827687821335e-09
the O 0 1.5807671616130392e-08
34 O 0 2.4998175263135636e-07
UTR O 0 5.112047801958397e-05
of O 0 5.87002546126314e-07
the O 0 2.282118202856509e-06
DM B-Disease 1 1.0
protein O 0 6.431071597035043e-06
kinase O 0 1.0118539648829028e-05
gene O 0 1.813969086050804e-09
on O 0 4.676224740762791e-09
chromosome O 0 6.150372655611136e-08
19 O 0 3.185961929830228e-07
. O 0 6.213525693965494e-08

One O 0 6.570405162165116e-07
of O 0 7.55727143086915e-08
the O 0 3.362113787375165e-08
principal O 0 1.0684967492124997e-05
features O 0 5.046380024964492e-08
of O 0 6.576963187399087e-07
the O 0 6.485499397967942e-06
DM B-Disease 1 1.0
mutation O 0 4.1756795354785936e-08
is O 0 8.249777527780111e-10
an O 0 2.0943059786393547e-10
extraordinarily O 0 2.264426512965656e-08
high O 0 2.061736559255678e-08
level O 0 1.0033375019702362e-06
of O 0 7.332375844271155e-07
somatic O 0 0.0001437062892364338
mosaicism O 1 0.9486221671104431
, O 0 1.896543366797232e-09
due O 0 3.24887921010486e-08
to O 0 8.185608302291314e-10
an O 0 5.553310589156979e-10
extremely O 0 2.774198870625355e-09
high O 0 4.8502220018065145e-09
degree O 0 9.979115702662966e-07
of O 0 2.057101511354631e-08
somatic O 0 8.384846523767919e-07
instability O 0 1.3156028444427648e-07
both O 0 6.457991780228767e-11
within O 0 3.7818678744194756e-10
and O 0 2.15225441635436e-11
between O 0 1.891719281221782e-10
different O 0 2.3103723101325357e-10
tissues O 0 8.032193221652051e-08
. O 0 3.4897229994612644e-08

This O 0 4.2178561443506624e-07
instability O 0 2.151467242583749e-06
appears O 0 6.3332606714539e-08
to O 0 1.4399273995380213e-09
be O 0 1.726697229642582e-09
biased O 0 8.330184542160168e-09
towards O 0 1.050646125655419e-09
further O 0 1.0377423365071081e-09
expansion O 0 4.660793528898921e-09
and O 0 1.3958643962919126e-10
continuous O 0 1.2378065150642215e-07
throughout O 0 1.4205564502489665e-09
the O 0 1.0291678620433231e-09
life O 0 3.8273832991819745e-09
of O 0 1.3345580196499895e-09
an O 0 1.6034064354020217e-10
individual O 0 3.7673533737070386e-10
, O 0 8.543969004515262e-11
features O 0 6.079826087024287e-10
that O 0 8.458792000176629e-11
could O 0 2.5396651448517105e-10
be O 0 4.3199019361672697e-10
associated O 0 1.57103652309587e-09
with O 0 2.5126445368783834e-10
the O 0 2.476374163506989e-07
progressive O 0 9.277086974179838e-06
nature O 0 1.97770333443259e-07
of O 0 3.430060857567696e-08
the O 0 3.5347131444041224e-08
disease O 0 6.97492964718549e-07
. O 0 2.1217976708953756e-08

Although O 0 4.084913740598495e-08
increasing O 0 1.9616274826717017e-08
measured O 0 1.1485671080890825e-08
allele O 0 8.315543809089831e-10
size O 0 6.437764210609487e-10
between O 0 2.6189150847955034e-09
patients O 0 2.011178068528352e-08
clearly O 0 8.339293700032613e-09
correlates O 0 4.4735063653433826e-08
with O 0 8.978161963879572e-12
an O 0 1.6244021752709337e-11
increased O 0 1.6223780652246944e-10
severity O 0 9.398196887389076e-09
of O 0 2.9190876382756414e-09
symptoms O 0 5.5128751341726456e-08
and O 0 5.1833058678507626e-11
an O 0 1.9106433449267435e-11
earlier O 0 9.371819292836037e-11
age O 0 3.3261493559422206e-10
of O 0 7.839702220735489e-10
onset O 0 2.99668094783101e-08
, O 0 1.8510363380963568e-11
this O 0 9.153598885813796e-12
correlation O 0 1.4811765147726419e-09
is O 0 4.902232699638409e-12
not O 0 2.0370285319648573e-12
precise O 0 1.4819104277030704e-10
and O 0 1.3323388399488767e-11
measured O 0 5.964802540781022e-10
allele O 0 1.346770056587232e-10
length O 0 1.1470646654743177e-09
cannot O 0 1.5779588746767104e-09
be O 0 5.058614083175428e-10
used O 0 3.4898992029575027e-10
as O 0 1.0223724644653487e-10
an O 0 2.3015668537684775e-10
accurate O 0 3.808234083635398e-08
predictor O 0 5.121387971485092e-07
of O 0 4.746640414055037e-09
age O 0 5.4599979648628505e-08
of O 0 1.0906995839832234e-06
onset O 0 0.01751820556819439
. O 0 3.8939847968322283e-07

In O 0 1.2530794890608377e-07
order O 0 1.1576990921469132e-08
to O 0 1.4470417086798193e-09
further O 0 6.1716871613271e-09
characterize O 0 3.1947851653058024e-07
the O 0 4.097406858249997e-08
dynamics O 0 6.776304417144274e-06
of O 0 4.616841397364624e-05
DM B-Disease 1 1.0
CTG O 1 0.7617120146751404
repeat O 0 1.3691176263819216e-06
somatic O 0 1.866007323769736e-06
instability O 0 5.032759986534074e-07
, O 0 2.0460333427507749e-10
we O 0 4.3150677475622956e-10
have O 0 6.917045408671996e-11
studied O 0 3.0438989107040015e-09
repeat O 0 2.186708369933399e-09
length O 0 4.111580520493874e-10
changes O 0 5.0607146945269577e-11
over O 0 9.612400458935966e-11
time O 0 9.739246076279073e-10
in O 0 2.2389234910491496e-09
111 O 0 5.972714006929891e-06
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 0 4.1302167241852317e-10
with O 0 3.515527983739136e-13
varying O 0 1.4730450192956823e-10
clinical O 0 2.814219257629702e-08
severity O 0 9.081066565386209e-08
and O 0 3.313297192164555e-09
CTG O 0 1.107409752876265e-05
repeat O 0 1.0189413757188959e-08
size O 0 9.166257752823981e-10
over O 0 1.7605442104162705e-10
time O 0 1.8794589495829683e-10
intervals O 0 3.4105791524297047e-09
of O 0 4.906075101729357e-09
1 O 0 1.6760775878310596e-08
- O 0 8.605111290194145e-09
7 O 0 3.547634008782552e-08
years O 0 1.3785776964425622e-08
. O 0 2.2034734925568955e-08

We O 0 4.616047704075754e-07
have O 0 2.8184021783062008e-09
found O 0 1.2055462184079602e-09
a O 0 3.262919046065349e-09
direct O 0 8.854201816177465e-09
progression O 0 1.5960644361712184e-07
of O 0 8.338227885928973e-09
the O 0 3.5777008022819246e-09
size O 0 7.750219133129121e-09
heterogeneity O 0 3.790472291598235e-08
over O 0 8.825264963263635e-10
time O 0 3.105640189460246e-09
related O 0 1.3718234548321107e-08
to O 0 2.7767983468152124e-09
initial O 0 1.0281798523692487e-07
CTG O 0 1.1387201993784402e-05
repeat O 0 2.5637886480467387e-08
size O 0 2.6337978464852085e-09
and O 0 9.23074741643326e-11
the O 0 1.0075579259805068e-09
time O 0 2.8664792761645685e-09
interval O 0 3.483657806668816e-08
and O 0 2.061974341271977e-10
always O 0 1.537744331869817e-08
biased O 0 4.6678504617148064e-08
towards O 0 1.5346151016615295e-08
further O 0 1.9048826516154804e-08
expansion O 0 2.6211884573967836e-07
. O 0 8.052548849946106e-08

Attempts O 0 4.296862243791111e-06
to O 0 7.564016968331089e-09
mathematically O 0 9.103886782213522e-07
model O 0 9.938847966850517e-08
the O 0 3.189116526414182e-08
dynamics O 0 6.966174623812549e-06
have O 0 3.3761726747627563e-09
proved O 0 1.0227952174091115e-07
only O 0 1.2906441471116636e-09
partially O 0 3.0758009472720005e-08
successful O 0 4.3285308670704126e-09
suggesting O 0 1.4149911242711255e-09
that O 0 2.117972464077411e-12
individual O 0 7.966174594975506e-12
specific O 0 1.8858714936897947e-11
genetic O 0 3.0587266053316853e-10
and O 0 2.2245263964215667e-10
/ O 0 3.4316124697397754e-07
or O 0 1.53193617791203e-08
environmental O 0 3.881167742747493e-08
factors O 0 1.5195421809721665e-08
also O 0 1.1092689961023083e-10
play O 0 1.6423924442676707e-09
a O 0 1.3996809933303211e-08
role O 0 1.9361795722261377e-08
in O 0 2.7675518765590823e-08
somatic O 0 3.0299549962364836e-06
mosaicism O 0 3.993034624727443e-05
. O 0 6.607098868016692e-09
. O 0 2.750160632558618e-08

Aspartylglucosaminuria B-Disease 1 1.0
among O 0 1.9550368506315863e-06
Palestinian O 0 0.0002781988005153835
Arabs O 0 7.307410214707488e-06
. O 0 1.8003365198637766e-07

Aspartylglucosaminuria B-Disease 1 1.0
( O 1 0.9999287128448486
AGU B-Disease 1 1.0
) O 0 1.6625838483719235e-08
is O 0 4.916864693171874e-10
a O 0 3.314751140237604e-09
rare O 0 3.0176479981491866e-07
disorder B-Disease 1 0.9999996423721313
of I-Disease 1 0.9999936819076538
glycoprotein I-Disease 1 1.0
metabolism I-Disease 1 1.0
caused O 0 2.0140696506132372e-05
by O 0 1.2146653682876263e-09
the O 0 2.2556283951757905e-08
deficiency B-Disease 1 0.9968262910842896
of I-Disease 0 3.0328314096550457e-05
the I-Disease 0 4.777588856086368e-06
lysosomal I-Disease 1 0.9999967813491821
enzyme I-Disease 0 7.168998308770824e-06
aspartylglucosaminidase I-Disease 0 4.964276376995258e-05
( O 0 1.7054840384389536e-07
AGA O 0 6.838516128482297e-05
) O 0 3.26053140042859e-08
. O 0 2.99506375256442e-08

AGU B-Disease 1 1.0
is O 0 3.1107259701457224e-07
inherited O 0 8.170442924892996e-06
as O 0 5.059699503817683e-08
an O 0 1.0470140665574945e-07
autosomal O 1 0.9855896830558777
recessive O 0 0.00021363278210628778
trait O 0 4.496647761698114e-06
and O 0 3.34651417688292e-09
occurs O 0 3.8831224458135694e-08
with O 0 1.9642611148729117e-10
a O 0 2.513658436953392e-08
high O 0 1.8346425179061043e-07
frequency O 0 1.2530652782061225e-07
in O 0 2.043180735711303e-08
Finland O 0 7.33562842469837e-07
because O 0 7.788005795816844e-09
of O 0 2.6589466983750754e-07
a O 0 1.0469562283788036e-07
founder O 0 1.174190856545465e-06
effect O 0 1.6483190279359405e-07
. O 0 4.512997620054193e-08

While O 0 2.8136591367911024e-07
very O 0 4.537299869156186e-09
few O 0 9.934996825222697e-09
patients O 0 3.478297871950531e-09
with O 0 3.2125158089257866e-09
AGU B-Disease 1 1.0
have O 0 3.071989951308751e-08
been O 0 3.297611517183441e-09
reported O 0 1.3922940578225962e-09
from O 0 8.181862409806229e-10
non O 0 1.1692534940266341e-07
- O 0 2.8869248325236185e-08
Finnish O 0 9.188282092509326e-06
origin O 0 4.517234231116163e-08
, O 0 2.74058198357352e-09
we O 0 2.7569884153422208e-08
diagnosed O 0 7.597566764161456e-06
the O 0 2.0825888569220297e-08
disorder O 0 1.7464609527451103e-06
in O 0 3.700052264576925e-09
8 O 0 3.076610965990767e-08
patients O 0 8.18675960356785e-11
originating O 0 2.5279456306037673e-10
from O 0 2.19137943902048e-10
3 O 0 6.1989391397787585e-09
unrelated O 0 2.620065586711462e-08
families O 0 2.0114100662826928e-10
, O 0 2.53983847842143e-11
all O 0 2.1202624378435786e-10
Palestinian O 0 9.976279216061812e-06
Arabs O 0 1.4690257010840924e-08
from O 0 1.6463755914131184e-09
the O 0 2.2230302043624306e-09
region O 0 8.179978472355742e-09
of O 0 9.406610246287528e-08
Jerusalem O 0 0.00019233510829508305
. O 0 1.916513951982779e-07

The O 0 8.922277743295126e-07
clinical O 0 0.0003098515444435179
diagnosis O 1 0.9996151924133301
of O 0 0.035512927919626236
AGU B-Disease 1 1.0
is O 0 1.8992615480328823e-07
often O 0 1.1408941569257536e-09
difficult O 0 4.876436143774754e-09
, O 0 6.850661010693315e-11
in O 0 5.066917996288112e-10
particular O 0 1.8345220897941772e-09
early O 0 1.3618880245758191e-08
in O 0 8.978788268443338e-10
the O 0 2.665103471244379e-09
course O 0 4.9279016423042776e-08
of O 0 2.22476503886071e-09
the O 0 3.9834864296039996e-09
disease O 0 2.348633998394689e-08
, O 0 1.9016923452630508e-11
and O 0 2.7196458626810305e-11
most O 0 4.0171154597201664e-11
of O 0 5.079052178835752e-10
the O 0 5.81173553726444e-09
patients O 0 3.867819398095662e-09
are O 0 1.746327110696555e-10
diagnosed O 0 1.6797066848539544e-08
after O 0 7.089125730885826e-09
the O 0 1.5069435477244042e-08
age O 0 4.7930409863283785e-08
of O 0 6.868319957220592e-08
5 O 0 4.5376570056987475e-08
years O 0 1.0801485039735326e-08
. O 0 1.4059419406464713e-08

However O 0 2.67953538468646e-07
, O 0 1.3180617708385967e-09
since O 0 2.286524969363768e-09
these O 0 2.0028385894210743e-10
patients O 0 3.9239261839796313e-10
excrete O 0 6.917038497533667e-09
early O 0 1.7138940267003022e-09
large O 0 1.3590685521425172e-10
amounts O 0 1.4925259916864775e-09
of O 0 4.717337276360922e-08
aspartylglucosamine O 0 7.400117283395957e-07
in O 0 3.634984091505089e-09
urine O 0 1.006202010600532e-09
, O 0 8.757133213022072e-11
biochemical O 0 3.796193581706575e-09
screening O 0 1.6141131764513261e-09
is O 0 6.217835135657879e-10
easy O 0 1.936688365233863e-09
by O 0 7.893011244597403e-10
urine O 0 8.285325314716374e-09
chromatography O 0 4.518502464634366e-06
. O 0 2.0466325523216256e-08
. O 0 4.956349641815905e-08

Detection O 0 1.690717795099772e-06
of O 0 2.8414842034862886e-08
heterozygous O 0 1.922974490753404e-08
carriers O 0 2.3659010861543095e-10
of O 0 2.0249926180326838e-08
the O 0 4.574385911837453e-06
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 0.00016043134382925928
ATM O 0 1.4422101230593398e-05
) O 0 6.430057597484051e-10
gene O 0 8.924471578408699e-11
by O 0 7.008416624820768e-10
G2 O 0 1.2705633025689167e-06
phase O 0 6.764551017113263e-07
chromosomal O 0 1.0438907338539138e-05
radiosensitivity O 0 1.6171517927432433e-05
of O 0 1.091430112865055e-05
peripheral O 0 0.0018638204783201218
blood O 0 3.353290230734274e-05
lymphocytes O 0 1.1890216228493955e-05
. O 0 1.7266198426568735e-07

In O 0 0.00012196937314001843
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 0.9999998807907104
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 3.456705854887332e-08
patients O 0 8.438105214558789e-10
, O 0 2.584257460802597e-11
mutations O 0 8.331971917963088e-11
in O 0 6.137476638023998e-10
a O 0 2.2086352746697457e-09
single O 0 9.288610991475821e-10
gene O 0 5.8041748490778033e-11
, O 0 2.5123608055066526e-11
ATM O 0 4.2073622807947686e-08
, O 0 7.763093119728115e-12
result O 0 2.644251206884718e-10
in O 0 4.423714283774416e-09
an O 0 9.935981506714597e-05
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
syndrome I-Disease 1 1.0
that O 0 1.988247610995586e-08
embraces O 0 4.7587698226436714e-09
a O 0 4.949609611060168e-10
variety O 0 8.519428912334703e-11
of O 0 1.46580427795584e-08
clinical O 0 3.0600742775277467e-06
features O 0 4.031819322847241e-09
and O 0 4.2592435134380935e-10
manifests O 0 7.288024050922104e-08
extreme O 0 1.1474961638668901e-06
radiosensitivity O 0 3.4686112485360354e-05
and O 0 1.1126648047365961e-08
a O 0 5.0682960051062764e-08
strong O 0 1.8773899768120828e-08
pre O 0 3.0190462894097436e-06
- O 0 4.318060859986872e-07
disposition O 0 9.510154086456168e-06
to O 0 1.7411744579476363e-07
malignancy B-Disease 0 0.1668204963207245
. O 0 2.048183631586653e-07

Heterozygotes O 0 1.51098684000317e-05
for O 0 2.7507850219876673e-08
the O 0 5.964444227402055e-08
ATM O 0 1.619533395569306e-05
gene O 0 2.9629365627670268e-09
have O 0 1.9834012210395713e-10
no O 0 8.537489604165671e-10
clinical O 0 1.2990815534408284e-08
expression O 0 8.758528124985787e-09
of O 0 2.538172566346475e-06
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
but O 0 5.068419017817405e-09
may O 0 1.3966275247412341e-08
be O 0 9.527950872723068e-09
cancer B-Disease 0 1.8799741496877687e-07
prone O 0 8.190625955251107e-09
with O 0 2.1485424550604648e-11
a O 0 4.879599391216516e-09
moderate O 0 5.342922992923604e-09
increase O 0 3.7752084791620177e-10
in O 0 1.3209787708134968e-09
in O 0 1.3374076068828344e-08
vitro O 0 3.949022357119247e-06
radiosensitivity O 0 4.304995854909066e-06
. O 0 5.1140911949687506e-08

We O 0 1.7336851954041776e-07
performed O 0 3.226998401828496e-08
a O 0 8.183352662172183e-08
blind O 0 7.113386573109892e-07
chromosomal O 0 6.343186100821185e-07
analysis O 0 5.021215088163444e-08
on O 0 3.014020677483131e-08
G2 O 0 8.290606956506963e-07
- O 0 1.334334687186356e-08
phase O 0 7.955409841997607e-08
lymphocytes O 0 8.926846817303158e-09
from O 0 2.8828239795331e-09
7 O 0 1.2520808923000004e-07
unrelated O 0 4.410490873851813e-06
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 7.491955500427139e-08
, O 0 4.4905734686295773e-10
13 O 0 4.6429882161191927e-08
obligate O 0 1.1138346280858968e-06
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
heterozygotes O 0 6.797259857194149e-07
( O 0 3.9445394173220905e-10
parents O 0 5.183365542338336e-11
of O 0 3.6752847987209236e-10
the O 0 7.849023653250242e-10
patients O 0 1.249174930162411e-10
) O 0 3.582757354680943e-11
, O 0 2.4698602538175685e-11
and O 0 1.1537652777615648e-10
14 O 0 1.7650279460212914e-08
normal O 0 4.566918221371452e-08
controls O 0 3.2870677291185757e-09
following O 0 1.4943546400303376e-09
X O 0 7.82860638537386e-07
- O 0 3.200595566354991e-09
irradiation O 0 9.769819619975806e-09
with O 0 1.4608569909313474e-10
1 O 0 1.2544509786494018e-07
Gy O 0 7.337835995713249e-06
in O 0 6.211881009576814e-11
order O 0 3.0794592570382306e-11
to O 0 1.5033757225224598e-11
evaluate O 0 9.39279765077572e-10
this O 0 3.657585068150837e-10
cytogenetic O 0 6.06555033755285e-07
method O 0 6.594319756914047e-09
as O 0 3.452577668205947e-10
a O 0 1.1654750498024669e-09
tool O 0 1.7263161566916096e-08
for O 0 1.4890959298963224e-10
detection O 0 4.542732057188914e-08
of O 0 1.2399142690355802e-07
ATM O 0 6.870873767184094e-05
carriers O 0 3.7250430295898695e-08
. O 0 1.535016878051465e-07

Both O 0 1.2859724847658072e-05
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
homozygotes O 0 0.0011852955212816596
and O 0 8.884246227580661e-09
heterozygotes O 0 4.1255211158386373e-07
showed O 0 5.827842208816492e-09
significantly O 0 4.338000791914709e-10
increased O 0 3.2164443330984227e-10
levels O 0 4.137646225643721e-09
of O 0 1.0665468508364029e-08
radiation O 0 3.75897107005585e-05
- O 0 1.2259672530490207e-06
induced O 0 1.2112475815229118e-05
chromatid O 0 0.0006228084093891084
damage O 0 9.842145800575963e-07
relative O 0 1.6277101622108603e-07
to O 0 6.683104070148715e-10
that O 0 2.0359468277941772e-10
of O 0 8.39054070667089e-09
normal O 0 3.4350898658885853e-07
controls O 0 9.025085034863878e-08
. O 0 1.2721434572426915e-08

These O 0 3.527122771629365e-08
results O 0 2.7305757654971785e-08
show O 0 1.4890860988714394e-08
that O 0 2.2732435378536309e-10
the O 0 6.1527405392780565e-09
G2 O 0 4.530368187261047e-06
- O 0 7.921432398916295e-08
phase O 0 1.2105950872864923e-06
chromosomal O 0 1.6615809727227315e-05
radiosensitivity O 0 6.279581157286884e-06
assay O 0 6.026262155955919e-08
can O 0 7.352227715529125e-10
be O 0 2.7830057702793454e-10
used O 0 2.069416998873308e-10
for O 0 1.9059455402814507e-10
the O 0 6.872864499740672e-09
detection O 0 1.3235776918918418e-07
of O 0 6.865379418741213e-06
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
heterozygotes O 0 6.506414501927793e-05
. O 0 8.894134140291499e-08

In O 0 7.935435775152655e-08
combination O 0 8.36838864870515e-09
with O 0 7.419042047374091e-10
molecular O 0 1.5083565813256428e-05
genetic O 0 5.628045073535759e-06
analyses O 0 5.804891856087124e-08
, O 0 8.39382938155886e-11
this O 0 8.166765874673132e-11
test O 0 1.0800217664641565e-10
may O 0 1.467649196618126e-10
be O 0 5.031542543720846e-11
of O 0 2.896242690120232e-10
value O 0 1.2575905872225235e-09
in O 0 1.2508487301499116e-10
studies O 0 7.756691955407291e-10
of O 0 1.0233074387855368e-09
familial B-Disease 0 1.1183374937218105e-07
and I-Disease 0 4.4294698464675264e-10
sporadic I-Disease 0 4.095234089618316e-06
cancers I-Disease 0 5.2158356993459165e-06
aimed O 0 7.48948352224943e-08
at O 0 3.8436112959061575e-08
determination O 0 7.095551701752356e-09
of O 0 2.302621870953203e-09
the O 0 1.8556893521815e-10
potential O 0 3.621853927882057e-10
involvement O 0 1.016879469517562e-08
of O 0 4.792245889007063e-08
ATM O 0 1.589081875863485e-05
mutations O 0 3.0771725167966224e-09
in O 0 3.5804177400677872e-09
tumor B-Disease 0 3.3715459721861407e-06
risk O 0 7.951678071549395e-08
or O 0 3.3304297097913604e-09
development O 0 2.1905000480160197e-08
. O 0 7.193443063435723e-10
. O 0 1.1956245771216345e-08

Ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
: O 0 8.165998366393978e-08
identification O 0 1.870905563805536e-08
and O 0 1.6609594255534432e-10
detection O 0 8.22922956444927e-08
of O 0 6.477109195657249e-07
founder O 0 0.0005902126431465149
- O 0 4.1014970975084e-07
effect O 0 1.075394138183583e-07
mutations O 0 2.156793410534874e-09
in O 0 7.180557259900411e-10
the O 0 3.2153171236615208e-09
ATM O 0 1.9229125314268458e-07
gene O 0 5.276582643043426e-11
in O 0 2.3339030361113622e-11
ethnic O 0 5.942519393231649e-11
populations O 0 2.745252358771211e-10
. O 0 1.5574258549477804e-09

To O 0 4.499743511132692e-08
facilitate O 0 1.5897473559789432e-08
the O 0 4.852905188812429e-09
evaluation O 0 1.6645789457925275e-07
of O 0 3.3232615237466234e-07
ATM O 0 0.00015504194016102701
heterozygotes O 0 2.52801157785143e-07
for O 0 1.010631689446484e-09
susceptibility O 0 1.021775375420475e-07
to O 0 7.738087948183647e-10
other O 0 2.934762433071114e-10
diseases O 0 3.3776243071770296e-05
, O 0 2.0540921741307727e-10
such O 0 2.789994901775117e-10
as O 0 4.7321254470489293e-08
breast B-Disease 0 0.16230671107769012
cancer I-Disease 0 0.037081170827150345
, O 0 1.2721331765774835e-09
we O 0 4.343574833143293e-09
have O 0 1.588405934560555e-10
attempted O 0 2.07058681311878e-09
to O 0 9.83661763154231e-11
define O 0 3.273670223791214e-10
the O 0 1.051934858664616e-10
most O 0 2.118061368655555e-12
common O 0 2.62323062577563e-12
mutations O 0 3.856660650558563e-12
and O 0 2.303431100372788e-12
their O 0 2.913044458430214e-11
frequencies O 0 1.3836874979133995e-09
in O 0 4.8130122110023876e-08
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 0.999998927116394
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 3.227655254178785e-09
homozygotes O 0 3.766229283996836e-08
from O 0 1.628640972084483e-10
10 O 0 1.690868833836845e-10
ethnic O 0 6.298714327890309e-11
populations O 0 3.4235345114375093e-10
. O 0 3.888664501516814e-09

Both O 0 5.342293718513247e-08
genomic O 0 2.658525488641317e-07
mutations O 0 4.869836978116382e-09
and O 0 1.498672574928861e-10
their O 0 3.1248903464842215e-10
effects O 0 1.8421809855340143e-08
on O 0 4.6062236691568614e-08
cDNA O 0 6.631088353969972e-07
were O 0 1.8179635574711028e-08
characterized O 0 4.095859651442879e-08
. O 0 3.58047422821528e-08

Protein O 0 1.016872647596756e-05
- O 0 3.0456666877398675e-07
truncation O 0 1.8216414900962263e-06
testing O 0 1.4091233069279951e-08
of O 0 2.799993303881365e-08
the O 0 1.7246279071514437e-08
entire O 0 6.567761943188088e-07
ATM O 0 5.3183475756668486e-06
cDNA O 0 1.797800734948396e-07
detected O 0 4.757598759397297e-09
92 O 0 6.5226672951723685e-09
( O 0 1.1826521706392867e-10
66 O 0 8.30362556492048e-10
% O 0 1.095586885102584e-10
) O 0 3.5455988839361297e-11
truncating O 0 1.3575957247269343e-08
mutations O 0 2.76429934498168e-10
in O 0 7.435290161339481e-10
140 O 0 6.073906710923893e-09
mutant O 0 9.20161102868633e-09
alleles O 0 1.107027025604168e-09
screened O 0 2.229387696672802e-08
. O 0 2.153091216428038e-08

The O 0 1.5573217524433858e-06
haplotyping O 0 0.0002922157582361251
of O 0 7.683786975576368e-07
patients O 0 3.1966379765435704e-08
with O 0 2.884351368859228e-10
identical O 0 8.543123612980708e-07
mutations O 0 3.1843640613260504e-07
indicates O 0 7.814761602276121e-07
that O 0 1.4317162733146205e-10
almost O 0 4.927633301399226e-10
all O 0 3.821135421966382e-11
of O 0 9.102747028366664e-11
these O 0 4.6424474507700264e-12
represent O 0 1.3483866800889643e-10
common O 0 3.29635180262855e-10
ancestry O 0 4.483991788983843e-10
and O 0 1.787111951478959e-11
that O 0 3.3622226097013153e-12
very O 0 7.401328161460441e-11
few O 0 4.613464055225336e-10
spontaneously O 0 1.6000505809188326e-08
recurring O 0 5.600823897111695e-06
ATM O 0 2.8247757654753514e-05
mutations O 0 3.5702790057712264e-08
exist O 0 3.180100236477301e-07
. O 0 1.1980561964719527e-07

Assays O 0 1.012969278235687e-06
requiring O 0 2.7293143300965994e-09
minimal O 0 1.582420239287785e-08
amounts O 0 5.26333754358177e-10
of O 0 2.3341144572697203e-09
genomic O 0 1.001685401291752e-08
DNA O 0 3.596845266073956e-09
were O 0 2.4209262372565377e-10
designed O 0 7.905693460985574e-11
to O 0 2.4250334379471994e-11
allow O 0 4.977212045287338e-11
rapid O 0 3.7161124177842453e-10
screening O 0 9.630917591207933e-11
for O 0 4.880339188328975e-11
common O 0 1.7933649010259956e-10
ethnic O 0 6.807900909677755e-10
mutations O 0 7.1035950455211605e-09
. O 0 6.71695943310624e-09

These O 0 8.641921844798617e-09
rapid O 0 3.565692097140527e-08
assays O 0 5.704418981622439e-08
detected O 0 5.854146056805121e-09
mutations O 0 1.7682641462180015e-10
in O 0 1.2280315653256935e-10
76 O 0 7.14070758078833e-09
% O 0 4.180544799226027e-10
of O 0 3.245328894507793e-09
Costa O 0 6.219204351509688e-08
Rican O 0 3.3235625096494914e-07
patients O 0 2.390496689486099e-09
( O 0 7.195470608234444e-11
3 O 0 5.635492628108807e-10
) O 0 1.0498817960835627e-11
, O 0 5.9545771091684685e-12
50 O 0 9.163281244894961e-11
% O 0 6.135624647241045e-11
of O 0 7.830854853452252e-10
Norwegian O 0 1.2711688214039896e-05
patients O 0 1.017385908852475e-08
( O 0 2.71000583085268e-10
1 O 0 4.8149377818162975e-09
) O 0 4.3781638037199144e-11
, O 0 1.6096598012826924e-11
25 O 0 4.424429156379972e-10
% O 0 1.2709587549064594e-10
of O 0 8.161039621867872e-10
Polish O 0 1.9542561346952425e-07
patients O 0 3.4351216982031474e-08
( O 0 7.071579988249255e-10
4 O 0 4.218247973142297e-09
) O 0 2.0380594781266304e-11
, O 0 5.491989675532327e-12
and O 0 1.8853391070550174e-11
14 O 0 9.790744881499336e-10
% O 0 7.962168424580085e-11
of O 0 4.00315836035503e-10
Italian O 0 1.8794393596976988e-08
patients O 0 1.5426053767697567e-09
( O 0 2.536373333583697e-10
1 O 0 1.1170685709771533e-08
) O 0 7.944390284508884e-11
, O 0 1.3644885568653287e-11
as O 0 6.529320140113981e-11
well O 0 1.1420213386070799e-10
as O 0 8.400043161049808e-11
in O 0 1.7410158037467482e-10
patients O 0 1.5834390743041382e-10
of O 0 4.977283474261185e-09
Amish O 0 6.216647307155654e-06
/ O 0 1.7025374745571753e-06
Mennonite O 0 1.5006188732513692e-05
and O 0 1.047522513175636e-09
Irish O 0 6.552158993144985e-08
English O 0 2.41490624830476e-07
backgrounds O 0 2.710474689138209e-07
. O 0 7.52993329911078e-08

Additional O 0 2.600289406018419e-07
mutations O 0 2.9109658683523776e-08
were O 0 1.4772612466629198e-08
observed O 0 7.86185339052281e-09
in O 0 1.379629832598539e-08
Japanese O 0 5.60114949621493e-06
, O 0 4.403694742194375e-09
Utah O 0 8.224990324379178e-07
Mormon O 0 3.5642582929540367e-07
, O 0 8.408892332445461e-11
and O 0 7.00357549732189e-11
African O 0 6.725561441101036e-09
American O 0 4.975198208967413e-08
patients O 0 1.087723600079471e-08
. O 0 1.1132272881297922e-08

These O 0 1.0939237959917136e-08
assays O 0 1.2176141872544122e-08
should O 0 1.0617313972449693e-10
facilitate O 0 5.409613867968233e-10
screening O 0 7.304201132818378e-10
for O 0 1.467619714645707e-08
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
heterozygotes O 0 4.92995582135336e-07
in O 0 2.975751867140275e-10
the O 0 2.2314701475512067e-10
populations O 0 2.2061909590864737e-11
studied O 0 4.146795351545052e-09
. O 0 7.072456509327196e-10
. O 0 6.889980141977503e-09

The O 0 1.0464522347319871e-05
von B-Disease 1 0.9999591112136841
Hippel I-Disease 1 0.9999996423721313
- I-Disease 1 0.9999866485595703
Lindau I-Disease 1 0.9999994039535522
tumor I-Disease 0 0.010020814836025238
suppressor O 0 1.1445340533100534e-05
gene O 0 1.3453586023004505e-09
is O 0 5.766744720636652e-11
required O 0 2.3056268005916536e-10
for O 0 1.0343158551862075e-09
cell O 0 1.9768511094753194e-07
cycle O 0 3.087745596985769e-07
exit O 0 2.5103288336936203e-08
upon O 0 1.0511677750457693e-08
serum O 0 7.654115279365215e-07
withdrawal O 0 2.8717488476104336e-07
. O 0 1.4781412005504535e-07

The O 0 1.235721697412373e-06
inactivation O 0 4.4868720578961074e-06
of O 0 1.2707390624200343e-06
the O 0 1.5682284129070467e-06
von B-Disease 1 0.9999982118606567
Hippel I-Disease 1 1.0
- I-Disease 1 1.0
Lindau I-Disease 1 1.0
( I-Disease 0 8.086301386356354e-05
VHL I-Disease 1 0.9996640682220459
) I-Disease 0 6.063942805667466e-07
tumor I-Disease 0 2.6212304874206893e-05
suppressor O 0 2.3876329578342848e-05
gene O 0 1.126179949295647e-08
predisposes O 0 3.6465340969016324e-08
affected O 0 2.325022258053977e-10
individuals O 0 5.450947679341844e-11
to O 0 1.114766681742374e-10
the O 0 1.3961053646482924e-08
human O 0 0.0005799029604531825
VHL B-Disease 1 1.0
cancer I-Disease 1 1.0
syndrome I-Disease 1 1.0
and O 0 8.923978223052131e-11
is O 0 4.248482468605097e-11
associated O 0 6.180424505508597e-10
with O 0 6.382964157225501e-10
sporadic B-Disease 1 0.9999988079071045
renal I-Disease 1 1.0
cell I-Disease 1 1.0
carcinomas I-Disease 1 1.0
( O 0 0.0019804639741778374
RCC B-Disease 1 0.9999953508377075
) O 0 6.434713384351198e-08
and O 0 3.120289449043412e-08
brain B-Disease 1 0.9998642206192017
hemangioblastomas I-Disease 1 0.8302367925643921
. O 0 1.2641237390198512e-06

VHL O 0 0.005262733902782202
- O 0 2.7639978725346737e-05
negative O 0 2.06288723347825e-06
786 O 0 1.1940248441533186e-05
- O 0 1.4996599020378198e-06
0 O 0 2.2721887660281936e-07
RCC B-Disease 0 4.5158139982959256e-05
cells O 0 1.0646976278394504e-07
are O 0 1.7208942049151688e-09
tumorigenic O 0 1.954000481418916e-06
in O 0 1.2810362193249603e-07
nude O 0 0.0008828615536913276
mice O 0 1.5595838931403705e-07
which O 0 1.6907204802851794e-10
is O 0 1.3943052268317047e-10
suppressed O 0 4.663434527429899e-09
by O 0 2.1295110119723404e-10
the O 0 3.797461012311487e-09
reintroduction O 0 7.100427978912194e-08
of O 0 1.0138354156197238e-07
VHL B-Disease 0 4.8932346544461325e-05
. O 0 2.781287378184061e-07

Remarkably O 0 0.0009086754289455712
, O 0 1.8511122634734534e-09
this O 0 1.6188420048912633e-10
occurs O 0 1.093476753588618e-09
without O 0 1.9897830050297216e-09
affecting O 0 2.5788733371001626e-09
the O 0 5.086904786288926e-10
growth O 0 3.994031327891889e-09
rate O 0 5.823608706378991e-09
and O 0 2.3153130801478738e-10
cell O 0 2.273128707486194e-08
cycle O 0 1.5246255813394782e-08
profile O 0 3.984844954008082e-10
of O 0 4.450302626413105e-10
these O 0 1.2531603532650593e-10
cells O 0 1.1272129896156002e-09
in O 0 1.6471106700777227e-09
culture O 0 5.131816394055022e-08
. O 0 1.4063094688765432e-08

The O 0 2.666137561391224e-06
786 O 0 6.1334262682066765e-06
- O 0 4.2438446712367295e-07
0 O 0 1.0070245792803689e-07
cell O 0 1.4894241395779773e-08
line O 0 3.876992948903535e-09
, O 0 5.622745671840512e-11
like O 0 2.2320149895005414e-10
many O 0 2.8789814976448724e-10
cancer B-Disease 0 3.612557364363056e-08
cells O 0 1.6092201349238167e-08
, O 0 3.5320338320765643e-10
fails O 0 8.696934727936423e-09
to O 0 2.780534691382286e-09
exit O 0 2.2361932749959124e-08
the O 0 7.058485351763011e-09
cell O 0 3.786736257893608e-08
cycle O 0 2.9308216298318257e-08
upon O 0 1.4087900623849237e-08
serum O 0 5.04616878060915e-07
withdrawal O 0 2.3879692889750004e-07
. O 0 5.9483802772319905e-08

Here O 0 5.032437002228107e-06
, O 0 3.922155045188447e-09
it O 0 3.7391978402467885e-10
is O 0 2.982018798558528e-10
shown O 0 1.0615982537487412e-09
that O 0 2.6681132303529864e-10
reintroduction O 0 8.838846987657689e-09
of O 0 2.049189928854389e-09
the O 0 3.060946163202516e-09
wild O 0 7.768719001433055e-09
- O 0 4.28979696209808e-08
type O 0 1.2789708137006528e-07
VHL B-Disease 0 5.655572022078559e-05
gene O 0 1.3210499361093753e-08
restores O 0 4.439268863620782e-08
the O 0 1.9346724222657485e-09
ability O 0 2.9402489332142068e-09
of O 0 2.04241956680562e-07
VHL O 0 0.00326616526581347
- O 0 0.0002271971316076815
negative O 0 3.6116489354753867e-06
RCC B-Disease 0 0.0007770108641125262
cancer I-Disease 0 1.434986671711158e-07
cells O 0 2.704291235389178e-09
to O 0 3.5264063891204955e-10
exit O 0 4.49469750307685e-09
the O 0 1.0773086867033044e-09
cell O 0 6.762569171314681e-09
cycle O 0 1.0632786207054323e-08
and O 0 3.071635445994758e-10
enter O 0 2.580883062819339e-07
G0 O 0 0.010007290169596672
/ O 0 3.641822695499286e-05
quiescence O 0 0.00010613708582241088
in O 0 2.903557572153659e-08
low O 0 2.9802146173096844e-07
serum O 0 2.3477616650779964e-06
. O 0 4.082016502593433e-08

Both O 0 2.3598363441124093e-06
VHL O 0 0.00018180010374635458
- O 0 1.332914848717337e-06
positive O 0 2.7267764934890693e-08
and O 0 9.081340124339476e-09
VHL O 0 0.00017620634753257036
- O 0 3.1016900265967706e-06
negative O 0 5.385409735936264e-07
RCC B-Disease 0 4.0520702896174043e-05
cells O 0 3.4812398297390246e-08
exit O 0 4.1334025091543936e-09
the O 0 3.1603404337943175e-09
cell O 0 1.7521976758416713e-08
cycle O 0 1.5875716741220458e-08
by O 0 1.9607848678049322e-09
contact O 0 2.0066202068846906e-06
inhibition O 0 1.79134622158017e-05
. O 0 6.013562625639679e-08

The O 0 4.075232482136926e-06
cyclin O 0 0.00010714287782320753
- O 0 2.834731276379898e-06
dependent O 0 4.726361112261657e-06
kinase O 0 8.35472656035563e-06
inhibitor O 0 6.799562157766559e-08
, O 0 1.0604401384783912e-10
p27 O 0 6.141697639350241e-08
, O 0 1.8587287264892893e-10
accumulates O 0 1.9954734753468983e-08
upon O 0 8.954541108607827e-09
serum O 0 1.055499652125036e-07
withdrawal O 0 1.6298328020525332e-08
, O 0 3.351744437551929e-10
only O 0 3.9171887955546936e-10
in O 0 4.08748201952136e-10
the O 0 1.4952384885802417e-09
presence O 0 6.771630367552461e-09
of O 0 3.4141157811973244e-07
VHL B-Disease 0 0.0005145047907717526
, O 0 6.08579275862553e-09
as O 0 1.4612923093793029e-09
a O 0 2.570250456912504e-09
result O 0 1.4912396872901468e-09
of O 0 4.157930444392832e-09
the O 0 3.802381964845836e-09
stabilization O 0 8.794137329459772e-08
of O 0 2.542855384035647e-07
the O 0 1.0436087904963642e-07
protein O 0 2.581010960511776e-07
. O 0 3.1971438829714316e-08

We O 0 5.375522391659615e-07
propose O 0 4.3594379661726634e-08
that O 0 6.155249088202197e-10
the O 0 9.20406861837364e-09
loss O 0 8.645420024322448e-08
of O 0 1.0560776075863032e-07
wild O 0 1.0967278285534121e-07
- O 0 4.6257426333795593e-07
type O 0 1.4653983271273319e-06
VHL B-Disease 0 0.00016278076509479433
gene O 0 7.040467764340974e-09
results O 0 2.397158249678455e-09
in O 0 7.849232930290384e-10
a O 0 2.958006950493086e-09
specific O 0 5.864125629528871e-09
cellular O 0 2.0206529427468922e-07
defect O 0 1.5460118163446168e-07
in O 0 4.740867698416196e-09
serum O 0 3.565846327546751e-06
- O 0 0.0007305064937099814
dependent O 0 0.021845808252692223
growth O 0 9.289681912605374e-08
control O 0 6.583273481908236e-09
, O 0 6.76792996645581e-11
which O 0 6.427356563643016e-11
may O 0 3.929700731486463e-10
initiate O 0 1.0858787646839119e-08
tumor B-Disease 0 6.94421942171175e-07
formation O 0 1.6205434860694368e-07
. O 0 1.2570448859605676e-07

This O 0 1.9785693439189345e-07
is O 0 1.2098982260511093e-08
corrected O 0 1.1087649909313768e-07
by O 0 7.639203714049358e-10
the O 0 4.816334442381276e-09
reintroduction O 0 6.427596233038457e-09
of O 0 9.191788663542866e-09
wild O 0 2.3832773976550925e-08
- O 0 2.9131444989616284e-07
type O 0 2.3155114377004793e-06
VHL B-Disease 1 0.8320780396461487
, O 0 8.087905456477529e-08
implicating O 0 0.03794172406196594
VHL B-Disease 0 0.008514541201293468
as O 0 1.741070754235352e-08
the O 0 3.945211268785442e-09
first O 0 1.075547562123802e-08
tumor B-Disease 0 1.2699160834017675e-07
suppressor O 0 7.889030229080163e-08
involved O 0 2.1551567197519717e-09
in O 0 9.978367021545864e-10
the O 0 4.8352677417540235e-09
regulation O 0 1.2982987129817047e-08
of O 0 5.650879941754283e-08
cell O 0 2.1297697117006464e-07
cycle O 0 2.2270253907663573e-07
exit O 0 1.0336655087428426e-08
, O 0 5.326250898662899e-11
which O 0 3.843048448914921e-11
is O 0 1.7139455132930692e-10
consistent O 0 7.798633738786975e-09
with O 0 8.34030344787351e-11
its O 0 2.6865800695219377e-09
gatekeeper O 0 3.748456549601542e-07
function O 0 4.733729852546276e-09
in O 0 2.1586041842880377e-09
the O 0 2.629276885102172e-08
kidney O 0 3.398306716917432e-06
. O 0 3.4139440163727386e-09
. O 0 2.1076763445648794e-08

Piebaldism B-Disease 1 1.0
with O 0 0.03337966278195381
deafness B-Disease 1 1.0
: O 0 1.6268333524749323e-07
molecular O 0 6.285246172410552e-07
evidence O 0 1.2957252693013288e-07
for O 0 2.5779585133278715e-09
an O 0 9.8150936267416e-09
expanded O 0 1.563291789352661e-06
syndrome O 1 0.9999414682388306
. O 0 1.986508237905582e-07

In O 0 5.251731067801302e-07
a O 0 1.1982356795670057e-07
South O 0 9.125689359734679e-08
African O 0 3.072728560482574e-08
girl O 0 1.4796420373386354e-06
of O 0 3.8589092810070724e-07
Xhosa O 0 0.0005043994169682264
stock O 0 1.4226617395252106e-07
with O 0 4.324609004235924e-10
severe O 0 0.00024179925094358623
piebaldism B-Disease 1 0.9979378581047058
and O 0 3.4296954254386947e-07
profound O 1 1.0
congenital O 1 1.0
sensorineural B-Disease 1 1.0
deafness I-Disease 1 1.0
we O 0 3.604030496262567e-07
identified O 0 2.6008862619164574e-08
a O 0 6.715524580869214e-09
novel O 0 3.648830215752241e-08
missense O 0 3.782816975217429e-07
substitution O 0 1.1786787545986499e-08
at O 0 1.4598445119418102e-08
a O 0 3.195703257574678e-09
highly O 0 2.8003124263875634e-09
conserved O 0 6.37530419567156e-08
residue O 0 4.898756742477417e-07
in O 0 8.725313804802681e-09
the O 0 2.3538316185067742e-08
intracellular O 0 1.4873331565468106e-05
kinase O 0 3.11222393065691e-05
domain O 0 2.0341019535408122e-07
of O 0 2.8798194051660175e-08
the O 0 5.571575201201995e-08
KIT O 0 0.00013519037747755647
proto O 0 0.0006892146775498986
- O 0 6.347774615278468e-05
oncogene O 0 0.0008008342119865119
, O 0 1.5890712745658675e-08
R796G O 0 4.870596512773773e-06
. O 0 1.5310693868286762e-07

Though O 0 5.470763426274061e-06
auditory B-Disease 0 0.10470540821552277
anomalies I-Disease 1 0.9806603789329529
have O 0 8.770230763843756e-09
been O 0 7.281656611013432e-09
observed O 0 2.2564716317674538e-08
in O 0 4.346668447396951e-08
mice O 0 6.953644060558872e-08
with O 0 6.303572663846069e-10
dominant O 0 5.81607423555397e-07
white O 0 3.808858650700131e-08
spotting O 0 7.72522616898641e-05
( O 0 1.5613608184139594e-06
W O 0 0.024752678349614143
) O 0 2.6950790488200482e-09
due O 0 2.3851464803215094e-08
to O 0 6.5778760216517185e-09
KIT O 0 0.0022090559359639883
mutations O 0 5.467085793497972e-05
, O 0 2.9881878162996145e-06
deafness B-Disease 1 1.0
is O 0 1.1871598815105244e-08
not O 0 9.37227184749645e-10
typical O 0 2.3045430452839355e-08
in O 0 7.68237029546981e-09
human O 0 8.065845236160385e-08
piebaldism B-Disease 0 1.9267528841737658e-05
. O 0 6.435241317603868e-08

Thus O 0 4.3444805442049983e-07
, O 0 1.001251193066821e-09
the O 0 3.767017808797846e-09
occurrence O 0 4.68641610495979e-06
of O 0 0.000383309117751196
sensorineural B-Disease 1 1.0
deafness I-Disease 1 1.0
in O 0 6.381716275427607e-07
this O 0 2.103839547018538e-09
patient O 0 1.484526102046857e-08
extends O 0 1.700993512709914e-10
considerably O 0 8.322219996470537e-11
the O 0 2.48454989221214e-11
phenotypic O 0 1.0059870714229646e-09
range O 0 1.0545669892891851e-09
of O 0 4.890053251216386e-09
piebaldism B-Disease 0 2.434524617456191e-07
due O 0 3.5879462956245334e-08
to O 0 2.0743102790987678e-09
KIT O 0 6.676465318378177e-07
gene O 0 1.7870863677771354e-09
mutation O 0 4.09142109081273e-10
in O 0 1.3569109724720363e-10
humans O 0 9.910974263505068e-10
and O 0 3.0434099684839566e-10
tightens O 0 3.444784679729196e-09
the O 0 2.0849158510749533e-10
clinical O 0 2.1087862123181367e-08
similarity O 0 1.1666276833466327e-08
between O 0 1.1206303440758347e-08
piebaldism B-Disease 0 2.9012769573455444e-06
and O 0 1.7759639592274112e-10
the O 0 1.4370650502915083e-10
various O 0 8.829402486920657e-11
forms O 0 1.965139162507512e-09
of O 0 3.0978646918811137e-06
Waardenburg B-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 1.3868879378264864e-08
. O 0 3.53880764691894e-08

Cycloheximide O 0 0.0006434147944673896
facilitates O 0 7.980621035130753e-07
the O 0 1.2503060808910504e-08
identification O 0 3.4886710409409716e-08
of O 0 4.1932782579579e-08
aberrant O 0 3.9471407831115357e-07
transcripts O 0 3.631965057593334e-07
resulting O 0 3.526006153720118e-08
from O 0 1.900491319872799e-08
a O 0 4.0578818527592375e-08
novel O 0 4.082036753061402e-07
splice O 0 2.9606669613713166e-06
- O 0 8.022271913432633e-08
site O 0 2.121219289108467e-08
mutation O 0 2.3785895475469943e-09
in O 0 6.09408612461948e-09
COL17A1 O 0 0.0001897588517749682
in O 0 2.855060365902773e-08
a O 0 8.406659190995924e-08
patient O 0 3.5848481161337986e-07
with O 0 4.650944962492076e-09
generalized O 1 0.9973492622375488
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 0.9999996423721313
. O 0 1.1694793329297681e-06

Patients O 0 4.5427418626786675e-06
with O 0 1.3221691297360394e-08
generalized O 1 0.9974820017814636
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 1.0
often O 0 8.479767998892385e-09
show O 0 4.677723541846035e-09
decreased O 0 1.3678213406365103e-07
expression O 0 5.639323230610671e-09
of O 0 7.17281389839286e-09
type O 0 2.602430129172717e-07
XVII O 0 0.0006735594943165779
collagen O 0 7.731950063316617e-06
, O 0 9.913512677428571e-09
a O 0 6.303481825398194e-08
transmembrane O 0 1.8815322846421623e-06
hemidesmosomal O 0 1.3359947388380533e-06
protein O 0 4.839745315621258e-08
encoded O 0 3.0535304063050717e-08
by O 0 8.417035957108965e-09
COL17A1 O 0 5.900636097067036e-05
. O 0 1.7889054504394153e-07

This O 0 2.939048613370687e-07
report O 0 1.0345062406713623e-07
documents O 0 1.4076786669647845e-07
a O 0 6.478555292233068e-08
novel O 0 3.6461486274674826e-07
splice O 0 3.801220600507804e-06
- O 0 1.1411987799192502e-07
site O 0 3.5683864751945293e-08
mutation O 0 3.6427785232717724e-09
in O 0 1.0248178305971578e-08
COL17A1 O 0 0.0006783278076909482
in O 0 1.807859817404278e-08
a O 0 1.008262344726063e-07
patient O 0 3.1201889783005754e-07
with O 0 1.5980490264411173e-09
generalized O 1 0.9999927282333374
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 0.9999986886978149
, O 0 1.7868648782837226e-09
and O 0 1.4573198203748916e-10
applies O 0 1.534661064894749e-09
a O 0 8.937370843398185e-10
new O 0 2.932826204116168e-10
methodology O 0 4.063566905188054e-08
to O 0 2.6647462014750545e-10
define O 0 4.011583509822003e-09
and O 0 2.8048974254346604e-10
characterize O 0 1.455291425145333e-07
the O 0 1.4631617695215482e-08
resulting O 0 9.361845343391906e-08
mRNA O 0 4.5957366978655045e-07
splice O 0 9.26407494716841e-07
variants O 0 1.4266693604270131e-08
. O 0 1.491883594439969e-08

Mutational O 0 0.003114015096798539
analysis O 0 1.70543182775873e-06
of O 0 4.550988137452805e-07
COL17A1 O 0 0.00040822618757374585
identified O 0 1.369068058920675e-06
a O 0 3.098568583936867e-07
maternally O 0 1.0113543567058514e-06
inherited O 0 5.55187671125168e-06
G O 0 0.00010920294153038412
- O 0 8.45184604258975e-06
to O 0 1.8286473277839832e-06
- O 0 0.0001258810661965981
T O 0 3.329678293084726e-05
transversion O 0 1.1796630133176222e-05
at O 0 8.950674441621231e-07
the O 0 4.433616140886443e-08
- O 0 2.7322846207766815e-08
1 O 0 1.0287683949172788e-07
position O 0 1.5230014582812146e-07
of O 0 1.423339028860937e-07
exon O 0 7.3065763217528e-07
32 O 0 2.555828473305155e-07
. O 0 4.8864571056128625e-08

This O 0 7.702929565311933e-07
acceptor O 0 5.883161975361872e-07
splice O 0 1.6636180589557625e-05
- O 0 1.041819359670626e-06
site O 0 2.6767361305246595e-07
mutation O 0 1.0211048007136014e-08
led O 0 8.071490142924631e-09
to O 0 5.570594652226646e-09
the O 0 2.2912804098496053e-08
formation O 0 6.220343493623659e-07
of O 0 5.793531454401091e-05
aberrant O 0 7.600044682476437e-06
transcripts O 0 1.016830879052577e-06
present O 0 7.4403017080726386e-09
at O 0 5.979524786425827e-08
extremely O 0 3.5618043625618157e-08
low O 0 2.808193073633447e-07
levels O 0 3.3271112442889716e-07
. O 0 5.246003809133981e-08

Based O 0 1.24824475733476e-06
on O 0 7.687533809530578e-08
our O 0 2.5325279651156052e-08
recent O 0 3.117884617154232e-09
finding O 0 1.572545293981875e-08
that O 0 7.467652607395792e-10
cycloheximide O 0 2.4107835088216234e-06
stabilized O 0 5.022957793698879e-06
mutant O 0 5.558370617109176e-07
COL17A1 O 0 2.014672827499453e-05
transcripts O 0 3.301106232811435e-07
in O 0 2.008535782138665e-09
keratinocytes O 0 3.789843461277087e-08
homozygous O 0 1.1110148356863192e-08
for O 0 6.830206400465499e-10
a O 0 2.0794015398450938e-08
frameshift O 0 1.5481423361052293e-06
mutation O 0 1.2904274315772568e-09
, O 0 1.2143266947539644e-10
the O 0 1.1358870510846941e-09
effects O 0 1.823242428145022e-07
of O 0 1.5901830465736566e-06
the O 0 2.2044849856683868e-07
splice O 0 1.2309122894293978e-06
- O 0 4.708159551114477e-08
site O 0 1.0782033932343893e-08
mutation O 0 3.6558067684211437e-10
on O 0 3.564833539471124e-09
splicing O 0 7.840364801836586e-09
of O 0 4.755423788083135e-08
COL17A1 O 0 1.0863160241569858e-05
transcripts O 0 2.1293919871823164e-07
were O 0 1.3219315642132301e-09
determined O 0 1.903512458767409e-09
using O 0 9.981241388956619e-10
reverse O 0 1.1749796691162828e-08
transcriptase O 0 2.0127822963900144e-08
polymerase O 0 1.087308731939629e-08
chain O 0 4.008967824375986e-09
reaction O 0 2.954977373903489e-10
of O 0 2.2599650151278183e-08
total O 0 6.101811322878348e-08
RNA O 0 1.916155838443956e-07
from O 0 2.5626334387851557e-09
keratinocytes O 0 3.0952751473023454e-08
incubated O 0 7.039060534452801e-08
for O 0 2.0907668929481815e-09
2 O 0 6.029986820976774e-08
. O 0 1.3978347368492905e-08

5 O 0 6.358852715493413e-06
h O 0 6.043102303010528e-07
in O 0 1.2145038752464643e-08
the O 0 6.882860947854397e-09
presence O 0 1.3643163043752793e-08
or O 0 1.8993825179336454e-08
absence O 0 1.3630383932650147e-07
of O 0 1.6469159902499086e-07
10 O 0 1.5502816097523464e-07
microg O 0 1.8844018541130936e-06
cycloheximide O 0 2.8761855901393574e-06
per O 0 5.085950078864698e-07
ml O 0 9.789854402697529e-07
. O 0 2.3615619682004763e-08

Using O 0 2.7927188739340636e-07
this O 0 4.796495645109644e-09
approach O 0 3.226973532832744e-08
, O 0 8.516038429995376e-10
an O 0 3.754156985280588e-09
abnormally O 0 6.853761078673415e-07
spliced O 0 7.549116958216473e-07
transcript O 0 5.825788775837282e-06
was O 0 3.0799111527812784e-07
identified O 0 7.332359608369643e-09
that O 0 3.434421844139557e-11
contains O 0 1.2781058156274838e-10
an O 0 1.616820705097055e-10
extra O 0 2.26134377889764e-09
264 O 0 1.175257580143807e-08
bases O 0 7.224356668444898e-09
upstream O 0 1.5144401288580411e-07
from O 0 3.497164113852591e-09
exon O 0 1.7640887861603005e-08
32 O 0 4.203069003949622e-09
, O 0 5.0667223888689605e-11
resulting O 0 8.060101475138026e-10
in O 0 1.7909628224899166e-09
a O 0 2.0694033153745295e-08
premature O 0 9.746668894194954e-08
termination O 0 3.059634821056534e-07
codon O 0 6.171648578856548e-07
27 O 0 8.774514981269022e-07
bp O 0 3.2845862278918503e-06
downstream O 0 9.253232065020711e-07
from O 0 6.150619213940445e-08
the O 0 3.807232076269429e-07
cryptic O 0 3.655661203083582e-05
splice O 0 3.056279820157215e-05
site O 0 2.1039948023826582e-06
. O 0 7.092835119237861e-08

Three O 0 1.0127355380973313e-06
other O 0 9.305532344683343e-09
splice O 0 7.210661578938016e-07
variants O 0 1.2076825761653254e-08
, O 0 4.5178502605658366e-10
including O 0 3.0908767212345367e-10
one O 0 2.1745218958812984e-09
derived O 0 1.818060724190218e-08
from O 0 1.702540153303289e-08
the O 0 2.6133079700230155e-08
skipping O 0 1.6016207382563152e-07
of O 0 2.4951302179943013e-07
exon O 0 1.288823767708891e-07
32 O 0 9.336523731917623e-08
, O 0 1.5223001748054799e-09
were O 0 1.9896626568538522e-08
also O 0 5.3859579018933346e-09
identified O 0 1.2493197232288367e-07
. O 0 1.1612135608629615e-07

These O 0 4.3692857332189305e-08
results O 0 9.052546268151218e-09
indicate O 0 1.2236278656985178e-08
the O 0 2.0517478827031255e-09
usefulness O 0 8.62723510408614e-08
of O 0 4.614557624904592e-09
cycloheximide O 0 2.1536625638418627e-07
treatment O 0 1.222013157331503e-09
in O 0 2.6972737932062785e-10
evaluating O 0 2.27058394308699e-09
the O 0 1.790286474623315e-09
abnormal O 0 5.0782237082103165e-08
processing O 0 5.179993323167764e-08
of O 0 1.6746355413488345e-07
mRNA O 0 8.384400729255503e-08
due O 0 1.932240110136263e-07
to O 0 1.592618303902782e-08
splice O 0 6.912655408086721e-07
- O 0 3.3425671119857725e-08
site O 0 1.4387394386972119e-08
mutations O 0 1.4625910205179338e-10
, O 0 3.810378748636545e-11
because O 0 7.432554016695292e-10
( O 0 1.1166063629275413e-08
i O 0 1.5461151292583963e-07
) O 0 1.564193219394383e-08
aberrant O 0 1.6949947223565687e-07
splicing O 0 1.8116223188258118e-08
often O 0 5.924256640810199e-10
generates O 0 1.246609815375166e-09
a O 0 3.023923556000341e-09
premature O 0 2.3214974831375912e-08
termination O 0 8.413331897827447e-08
codon O 0 1.1978140435076057e-07
, O 0 2.363511830694165e-09
( O 0 2.7629776244708637e-09
ii O 0 8.584164845615305e-08
) O 0 5.4753046541122785e-09
transcripts O 0 1.0930023108812748e-07
with O 0 2.5630719768798826e-10
premature O 0 5.078330787000596e-07
termination O 0 6.285833364927385e-07
codons O 0 4.689804100621586e-08
can O 0 6.994101409141251e-10
occur O 0 4.120532359763729e-09
at O 0 1.6832787252951675e-07
low O 0 1.1425930779296323e-06
or O 0 9.12833275634739e-09
undetectable O 0 8.022777109317758e-08
levels O 0 1.1208611816471148e-08
due O 0 2.2945910060911956e-08
to O 0 6.426823961902528e-09
nonsense O 0 2.526358002796769e-07
- O 0 2.0783270215929406e-08
mediated O 0 4.6714308865603016e-08
mRNA O 0 1.3385355046580116e-08
decay O 0 2.919183650362811e-08
, O 0 2.2943688615661983e-11
and O 0 3.719627730824904e-11
( O 0 3.3235239560447383e-10
iii O 0 9.862289651607625e-09
) O 0 3.8729183748920093e-10
the O 0 9.362498554210674e-10
levels O 0 8.392925465727785e-09
of O 0 2.275127197748361e-09
these O 0 5.287748017224203e-10
transcripts O 0 5.62801183434658e-08
can O 0 3.8095379628622084e-10
be O 0 6.318197631749456e-10
increased O 0 4.215778837135531e-09
by O 0 1.0971040076412919e-08
cycloheximide O 0 3.5894281609216705e-05
. O 0 4.508699760208401e-07

A O 0 4.372480816527968e-06
deletion O 0 4.935294555252767e-07
mutation O 0 1.0031709685165424e-08
in O 0 1.0265315708579692e-08
COL17A1 O 0 5.341629366739653e-05
in O 0 1.4715075380422604e-08
five O 0 1.61497943906852e-08
Austrian O 0 4.258482476870995e-06
families O 0 3.909427892523354e-09
with O 0 1.0243071946192117e-09
generalized O 0 0.000777345267124474
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 0.9999985694885254
represents O 0 8.928144978881392e-08
propagation O 0 8.841057592690049e-07
of O 0 2.482961924954452e-08
an O 0 1.9408679108323668e-08
ancestral O 0 6.980845228099497e-06
allele O 0 2.5497882916170056e-07
. O 0 2.0340360151749337e-07

Patients O 0 7.479999112547375e-06
with O 0 1.5184932422585007e-08
generalized O 1 0.9751123785972595
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 1.0
, O 0 4.426212729669032e-09
a O 0 1.9800381334533768e-09
usually O 0 4.390659780195705e-10
nonlethal O 0 8.522773953245633e-08
form O 0 2.8274923735693847e-08
of O 0 0.0006336895166896284
junctional B-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 1.0
, O 0 9.760115382562162e-09
have O 0 8.895669756370239e-10
generalized O 0 8.139905816051396e-08
blistering B-Disease 0 9.796840458875522e-07
, O 0 4.168024503314882e-08
nail B-Disease 1 0.9999961853027344
dystrophy I-Disease 1 1.0
, O 0 8.284900445687526e-07
patchy B-Disease 1 1.0
alopecia I-Disease 1 1.0
, O 0 1.6932931430346798e-06
and O 0 0.0006569905090145767
dental B-Disease 1 1.0
abnormalities I-Disease 1 1.0
. O 0 0.007602734956890345

Skin B-Disease 1 0.9977326393127441
fragility I-Disease 1 0.9908973574638367
in O 0 1.934691695737456e-08
most O 0 2.1932820837289313e-10
cases O 0 2.6873780978320383e-10
is O 0 5.4689430067922373e-11
due O 0 1.051377762628647e-09
to O 0 3.3446431735306703e-10
mutations O 0 3.043682805792258e-10
in O 0 3.849505991748714e-10
the O 0 2.272277921377963e-09
gene O 0 8.239147142319325e-10
encoding O 0 3.3950804390059375e-09
type O 0 7.675768642911862e-08
XVII O 0 0.00021675846073776484
collagen O 0 5.0736947741825134e-05
( O 0 1.1299763400529628e-06
COL17A1 O 0 0.0003032074891962111
) O 0 4.333109515641809e-08
. O 0 2.593302461662006e-08

Recently O 0 1.277883075090358e-05
, O 0 9.311586168792019e-09
we O 0 8.449383415154443e-09
reported O 0 6.084214465573723e-09
five O 0 2.664839238164518e-09
Austrian O 0 8.123090537992539e-07
families O 0 1.0370261316339224e-09
with O 0 3.94267424264072e-10
generalized O 0 0.0016487137181684375
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 1.0
who O 0 2.8928923256898997e-07
share O 0 1.848679289651045e-07
the O 0 1.0249413406882013e-07
same O 0 4.825167820854404e-07
COL17A1 O 0 0.0012783074053004384
mutation O 0 5.453081826090056e-07
. O 0 1.102667894770093e-07

Affected O 0 4.152892927322682e-07
individuals O 0 8.266095030684539e-10
in O 0 7.825614600776021e-10
three O 0 5.877526243480702e-10
families O 0 2.307465746254067e-10
are O 0 4.74455370824689e-11
homozygous O 0 9.082011254157862e-10
for O 0 1.138409588818945e-09
4003delTC O 0 7.528569057058121e-08
, O 0 8.42106273601928e-10
whereas O 0 5.798382662902668e-09
those O 0 1.078785061281451e-09
in O 0 1.5319179258455051e-09
two O 0 1.7128776175212579e-09
others O 0 4.115866758525044e-09
are O 0 2.3459016951221656e-09
compound O 0 2.3234922537085367e-06
heterozygotes O 0 5.743674591940362e-06
. O 0 3.007813234034984e-07

To O 0 4.101801209799305e-08
determine O 0 1.6992602880350205e-08
if O 0 2.1142543271679415e-09
the O 0 5.0928878891909335e-09
occurrence O 0 2.0742545814300684e-07
of O 0 1.0477828382704502e-08
4003delTC O 0 1.4596607478267742e-08
in O 0 2.0755203111733067e-10
these O 0 4.304724285364436e-11
unrelated O 0 6.337209867979254e-09
families O 0 3.0545058149478166e-10
signifies O 0 3.492704347962672e-09
propagation O 0 6.963040277696564e-08
of O 0 6.002250696468536e-09
an O 0 5.26571986014801e-09
ancestral O 0 5.473792725751991e-07
allele O 0 1.0998990163102462e-08
or O 0 5.239034450710278e-08
a O 0 7.62575993462633e-08
mutational O 0 1.1158589586557355e-05
hot O 0 3.7983070910740935e-07
spot O 0 5.5414126620689785e-08
, O 0 3.542558746350011e-10
haplotypes O 0 1.3332992487846695e-08
were O 0 1.8485578623383958e-09
determined O 0 2.3584771913220948e-09
for O 0 1.8021095726794556e-09
polymorphisms O 0 1.6674307801167743e-07
both O 0 3.255254288347942e-09
within O 0 5.385702479543397e-07
and O 0 7.988908379275017e-08
flanking O 0 1.9735141904675402e-05
COL17A1 O 1 0.9490697979927063
. O 0 1.04022990399244e-06

Five O 0 7.1299091359833255e-06
intragenic O 0 0.00010130974987987429
polymorphisms O 0 3.441271246629185e-06
were O 0 8.430262710135139e-08
chosen O 0 1.906681923458109e-08
based O 0 1.7785929173896875e-08
on O 0 2.0151414048541483e-07
their O 0 9.295335701153817e-08
informativeness O 0 4.7387409722432494e-05
. O 0 3.898789486811438e-07

One O 0 2.8242001803846506e-07
of O 0 5.192110563712049e-08
these O 0 1.9572536924528094e-09
, O 0 7.221376829846804e-10
not O 0 1.2817317207591827e-09
previously O 0 7.166757853838135e-08
reported O 0 1.6267775038159016e-07
, O 0 6.2333227468514e-09
was O 0 1.4540999018208822e-06
2988 O 0 1.7664577171672136e-05
A O 0 2.441387186991051e-05
or O 0 1.6227781429734023e-07
C O 0 8.406180313613731e-06
that O 0 6.437616550947212e-10
introduces O 0 3.9824912256847256e-09
a O 0 2.406811194788361e-09
new O 0 4.322695812408739e-10
restriction O 0 4.415806831303826e-09
site O 0 8.328182588002164e-09
for O 0 1.8268960788603295e-09
Eco0109 O 0 1.3124451925250469e-06
I O 0 2.3129679902922362e-05
. O 0 3.7074545389259583e-07

All O 0 2.225558404234107e-07
the O 0 4.890148730396504e-08
4003delTC O 0 4.97778955832473e-07
alleles O 0 9.559570024464392e-09
showed O 0 1.0317962484407417e-08
the O 0 1.8180944527657061e-09
same O 0 2.6490785121069393e-09
haplotype O 0 1.3806827681150935e-08
for O 0 1.4759192479285588e-10
these O 0 4.777492845775555e-10
five O 0 1.2907433344366837e-08
polymorphic O 0 1.2725796239010378e-07
markers O 0 2.3904894419501943e-07
. O 0 4.783688822840304e-08

Fourteen O 0 2.076062446576543e-05
microsatellite O 0 7.734418613836169e-05
polymorphisms O 0 3.9128053685999475e-06
were O 0 2.0963142333130236e-08
selected O 0 2.1680821582492626e-09
based O 0 1.0901371361171641e-08
on O 0 3.541900284176336e-08
their O 0 1.43583633871458e-08
high O 0 2.2196255144990573e-07
heterozygosity O 0 6.105803913669661e-05
and O 0 4.722168878146249e-09
their O 0 2.28992491635438e-09
location O 0 1.9038515119973454e-07
within O 0 6.088326642839093e-08
10q23 O 0 1.256477276001533e-06
- O 0 1.81330085524678e-06
q25 O 0 2.6130242986255325e-05
near O 0 2.5250039470847696e-05
COL17A1 O 0 0.0010055359452962875
. O 0 5.664032869390212e-07

Three O 0 2.318767542419664e-07
families O 0 7.93228593920503e-09
shared O 0 2.26455455276664e-07
microsatellite O 0 8.707416418474168e-05
polymorphisms O 0 2.0121880879742093e-05
covering O 0 7.756824743410107e-06
at O 0 7.001020094321575e-06
most O 0 6.236533067749406e-09
19 O 0 5.6485305321984924e-08
cM O 0 7.292055670404807e-08
, O 0 4.1137926398704394e-10
whereas O 0 5.271558300989909e-09
the O 0 4.742197301510487e-09
others O 0 6.558217302554681e-10
shared O 0 1.5289696175813106e-09
smaller O 0 1.8600657125666942e-10
regions O 0 1.9047570465335895e-10
consistent O 0 2.965062195769974e-09
with O 0 2.5278910908976826e-11
cross O 0 7.182191286148054e-09
- O 0 1.1134332567053207e-08
over O 0 7.174971727863522e-10
events O 0 1.298456564491346e-09
during O 0 1.4806060821825895e-09
passage O 0 3.3572036262086158e-09
of O 0 1.8296639203718712e-10
this O 0 9.972364080346185e-12
mutation O 0 9.683333995758048e-12
through O 0 4.2950549367093416e-11
several O 0 1.8911890109496454e-10
generations O 0 6.7148460125565634e-09
. O 0 1.546084860137853e-08

These O 0 2.7805626245935855e-08
results O 0 2.0234406150620998e-08
indicate O 0 1.645943115136106e-08
that O 0 9.711843135251641e-11
4003delTC O 0 3.805416781688109e-08
occurs O 0 1.3314916946782773e-09
on O 0 2.3372150881328935e-09
a O 0 5.092712473953043e-09
single O 0 5.995797192070995e-09
ancestral O 0 6.437143440507498e-08
allele O 0 4.423866162284185e-09
. O 0 2.915887753474067e-09
. O 0 2.0507707532146924e-08

The O 0 2.3197683276521275e-06
haptoglobin O 0 0.0001458768965676427
- O 0 3.0449336918536574e-06
gene O 0 2.9484384711508937e-08
deletion O 0 1.2982039265807543e-07
responsible O 0 7.850618999327708e-08
for O 0 5.243862943871136e-08
anhaptoglobinemia B-Disease 0 0.0006728331791236997
. O 0 1.6596205796304275e-06

We O 0 3.015611298451404e-07
have O 0 1.1518529463572236e-09
found O 0 1.2856933295779527e-09
an O 0 4.28631685700509e-10
allelic O 0 7.723158290673382e-08
deletion O 0 7.685803637969002e-08
of O 0 3.246674680212891e-07
the O 0 7.545791049778927e-07
haptoglobin O 0 0.0023672294337302446
( O 0 1.7949532775674015e-06
Hp O 0 1.1397742127883248e-05
) O 0 1.8470459606234613e-09
gene O 0 3.2967858998311783e-10
from O 0 1.3323504521878249e-09
an O 0 2.0242503229184194e-09
individual O 0 2.034445722998157e-09
with O 0 7.409217239739974e-09
anhaptoglobinemia B-Disease 0 0.0003634704917203635
. O 0 1.0830923429239192e-06

The O 0 5.341445103113074e-06
Hp O 0 1.8836450180970132e-05
gene O 0 2.181018476932195e-09
cluster O 0 1.7707119104315439e-09
consists O 0 2.235560847552165e-09
of O 0 1.2824909845221555e-07
coding O 0 4.3208556235185824e-06
regions O 0 3.994292541165123e-08
of O 0 4.881696895608911e-06
the O 0 2.439037871226901e-06
alpha O 0 5.445362694445066e-05
chain O 0 9.258231870035161e-08
and O 0 4.810676301758576e-10
beta O 0 1.3916289276494354e-07
chain O 0 5.434851235719407e-09
of O 0 2.225079009932074e-09
the O 0 7.239156829541571e-09
haptoglobin O 0 4.148781499679899e-06
gene O 0 1.7533377416611984e-08
( O 0 3.2508118419372067e-09
Hp O 0 8.162542286527241e-08
) O 0 7.968792292700755e-11
and O 0 4.589799026954999e-11
of O 0 5.021337123878311e-09
the O 0 2.7357053511423146e-08
alpha O 0 2.287373717990704e-06
chain O 0 1.0258214189207138e-07
and O 0 1.920928083265494e-09
beta O 0 3.0875250445205893e-07
chain O 0 1.7970887000728908e-08
of O 0 5.0370689841372496e-09
the O 0 1.0020636764807023e-08
haptoglobin O 0 7.291955171240261e-06
- O 0 5.904352065044804e-07
related O 0 5.467406936077168e-07
gene O 0 2.8887646053021854e-08
( O 0 4.920591933910146e-09
Hpr O 0 7.170859817051678e-07
) O 0 8.453747701864245e-10
, O 0 1.4510485868424183e-10
in O 0 2.2889075079746135e-09
tandem O 0 1.9515258031788107e-07
from O 0 1.0248533754975142e-07
the O 0 1.9246536453465524e-07
5 O 0 5.863042815690278e-07
side O 0 1.5344299697517272e-07
. O 0 1.1183374937218105e-07

Southern O 0 2.974145900225267e-06
blot O 0 7.580536930618109e-06
and O 0 1.7445877631416806e-08
PCR O 0 3.3347382100146206e-07
analyses O 0 1.0830681418383392e-07
have O 0 4.4641768059960896e-10
indicated O 0 1.327930876371397e-09
that O 0 4.991444063628947e-11
the O 0 5.546927361876897e-10
individual O 0 1.5267453967737765e-10
with O 0 8.220291114469092e-11
anhaptoglobinemia B-Disease 0 2.5202072606589354e-07
was O 0 9.258319977334395e-08
homozygous O 0 1.635614976791544e-09
for O 0 1.2000396509836975e-10
the O 0 8.429306141977122e-10
gene O 0 1.0336216327289094e-09
deletion O 0 2.163955015177521e-09
and O 0 1.7636092586315044e-10
that O 0 9.893687258344386e-11
the O 0 8.739737822338611e-09
gene O 0 4.603111669609916e-09
deletion O 0 9.869685513308468e-09
was O 0 8.41660607875383e-08
included O 0 8.631494630151337e-09
at O 0 1.5630070038241684e-07
least O 0 1.594457188502929e-08
from O 0 1.094541524082615e-08
the O 0 7.407044222418335e-08
promoter O 0 3.3073688427975867e-06
region O 0 2.2791298306401586e-06
of O 0 0.0014653444522991776
Hp O 0 0.0016338885761797428
to O 0 1.5887916049450723e-07
Hpr O 0 6.795131776016206e-05
alpha O 0 3.1747140383231454e-06
but O 0 1.555276685216711e-09
not O 0 1.1397131016721573e-09
to O 0 5.6087410271743465e-09
Hpr O 0 9.231522199115716e-06
beta O 0 2.7031792342313565e-06
( O 0 3.014124416722552e-08
Hpdel O 0 2.7318942557030823e-06
) O 0 5.490635945903932e-09
. O 0 1.1629841978333388e-08

In O 0 4.244694764565793e-07
addition O 0 1.744042066320617e-08
, O 0 3.1674010081417237e-09
we O 0 2.5269730752341957e-09
found O 0 2.175766677936508e-09
seven O 0 2.0803565536908764e-09
individuals O 0 1.8831622372594836e-10
with O 0 8.090053627007876e-11
hypohaptoglobinemia B-Disease 0 1.2589023299369728e-06
in O 0 1.1454037718294785e-08
three O 0 5.80391512627898e-09
families O 0 2.3179831387665217e-09
, O 0 1.2979135821655774e-10
and O 0 1.4109749479906952e-10
the O 0 7.969530813056735e-09
genotypes O 0 1.0517035775592376e-07
of O 0 2.76423975265061e-07
six O 0 9.352422125630255e-08
of O 0 1.435508210079206e-07
the O 0 1.7428583021228405e-08
seven O 0 1.3475061955148249e-08
individuals O 0 3.0322619415379393e-10
were O 0 2.7085809151117246e-09
found O 0 1.557746709401897e-09
to O 0 2.7772804056525047e-09
be O 0 6.077791425695978e-08
Hp2 O 0 0.029816195368766785
/ O 0 0.0024934050161391497
Hpdel O 0 0.36093100905418396
. O 0 7.149758971536357e-07

The O 0 9.345161515739164e-07
phenotypes O 0 6.527250207000179e-07
and O 0 1.9865749045777648e-09
genotypes O 0 1.2927296211273642e-07
in O 0 4.450898760666178e-09
one O 0 1.0673419925666394e-09
of O 0 2.392348541491174e-09
these O 0 2.0673891765188301e-10
three O 0 1.1556005041768458e-09
families O 0 9.81042913572594e-10
showed O 0 6.851137879237967e-09
the O 0 1.4982312279698817e-08
father O 0 8.571942800017496e-08
to O 0 1.57873341066761e-08
be O 0 3.51434366052672e-08
hypohaptoglobinemic B-Disease 0 4.458358489500824e-06
( O 0 1.7247717210011615e-07
Hp2 O 0 1.1285492291790433e-05
) O 0 4.7941544067953146e-09
and O 0 2.640638818718344e-09
Hp2 O 0 0.0005164560861885548
/ O 0 5.6647477322258055e-05
Hpdel O 0 0.0028282764833420515
, O 0 2.1589222853890533e-08
the O 0 6.562365229001443e-08
mother O 0 1.1925207843432872e-07
to O 0 5.362463806335427e-09
be O 0 9.73109859359056e-09
Hp2 O 0 1.7938699556907522e-06
- O 0 6.305671007567071e-08
1 O 0 2.183059564231371e-07
and O 0 4.2469801009303865e-09
Hp1 O 0 0.0003525378997437656
/ O 0 3.494303655315889e-06
Hp2 O 0 4.6496741560986266e-05
, O 0 1.0914201764578024e-09
one O 0 5.694184568305616e-10
of O 0 2.479340288630283e-09
the O 0 1.9289243535780543e-09
two O 0 6.848809297466119e-10
children O 0 3.969476136678196e-10
to O 0 4.2603159888798814e-10
be O 0 8.38681213366499e-09
hypohaptoglobinemic B-Disease 0 1.5065547813719604e-06
( O 0 8.604408918699846e-08
Hp2 O 0 8.010878445929848e-06
) O 0 4.197837633057588e-09
and O 0 3.876578613670745e-09
Hp2 O 0 0.00029739257297478616
/ O 0 4.7330231609521434e-05
Hpdel O 0 0.012115671299397945
, O 0 3.3037053093210034e-09
and O 0 4.27281571235838e-10
the O 0 4.0250882626935436e-09
other O 0 2.108719865390185e-10
child O 0 4.772750195058961e-09
to O 0 3.4246070423904484e-09
be O 0 1.620589173967346e-08
Hp1 O 0 1.1550781891855877e-05
and O 0 4.9046274597230877e-08
Hp1 O 1 0.9920182824134827
/ O 0 0.00028860423481091857
Hpdel O 0 0.0027049793861806393
, O 0 7.3980190862243944e-09
showing O 0 7.564452886299478e-08
an O 0 2.6317390489083436e-09
anomalous O 0 6.406115062418394e-06
inheritance O 0 2.7548389880394097e-06
of O 0 9.652144399296958e-06
Hp O 0 0.0004142922116443515
phenotypes O 0 2.0817337542666792e-07
in O 0 4.770638550866124e-09
the O 0 8.34540347938173e-09
child O 0 5.025871985253616e-08
with O 0 9.11361475175454e-09
Hp1 O 1 0.7324506640434265
. O 0 9.463257697461813e-07

The O 0 3.265888517489657e-05
Hp2 O 1 0.9968881011009216
/ O 0 0.005608740728348494
Hpdel O 0 0.1040782555937767
individuals O 0 6.436714272695099e-08
had O 0 2.0232516106943876e-08
an O 0 8.178492327814979e-10
extremely O 0 5.219970233838467e-09
low O 0 4.813912113377228e-08
level O 0 7.698963031543826e-07
of O 0 3.754445856429811e-07
Hp O 0 1.487535428168485e-06
( O 0 1.0140279727011148e-09
mean O 0 3.71447694824667e-09
+ O 0 3.49285755874007e-09
/ O 0 1.0125783544978617e-09
- O 0 1.9076520363370264e-09
SD O 0 4.988986290754838e-08
= O 0 3.1326619076565976e-09
0 O 0 1.2975348573363021e-10
. O 0 8.375753215994486e-12
049 O 0 9.371989406758985e-09
+ O 0 9.438718695520265e-10
/ O 0 3.754412614132008e-10
- O 0 5.539145808697299e-10
0 O 0 4.2560360791199514e-10
. O 0 2.6601847460949735e-11
043 O 0 4.518362928251918e-08
mg O 0 1.3573342450001746e-08
/ O 0 2.0978609960309313e-09
ml O 0 8.722879640821191e-10
; O 0 1.9899366876519053e-11
n O 0 2.5787700863588725e-09
= O 0 4.6223980199044945e-09
6 O 0 2.2802797428056465e-09
) O 0 3.90489307555697e-11
, O 0 7.968576319627996e-12
compared O 0 1.181130609984038e-10
with O 0 1.254302738062929e-11
the O 0 2.6547943843269195e-09
level O 0 1.322788847346601e-07
( O 0 2.5474664044899953e-10
1 O 0 5.917830669943669e-10
. O 0 1.7281551190073685e-11
64 O 0 2.881931915332814e-10
+ O 0 1.082462008916707e-09
/ O 0 7.849232930290384e-10
- O 0 7.413850089399432e-10
1 O 0 4.174984802318704e-09
. O 0 1.7026650922513653e-10
07 O 0 4.064535730208263e-08
mg O 0 6.415607600729345e-08
/ O 0 1.229589141615861e-08
ml O 0 2.6853812506999475e-09
) O 0 4.205436780063687e-12
obtained O 0 9.069715811715895e-11
from O 0 1.267690258321963e-10
52 O 0 2.8541931040848567e-09
healthy O 0 3.430739470289268e-09
volunteers O 0 4.406005338353225e-09
having O 0 5.6993076924527486e-08
phenotype O 0 4.4207138216734165e-07
Hp2 O 0 3.460338484728709e-05
, O 0 2.817429400892024e-09
whereas O 0 1.1717880887829324e-08
the O 0 1.5961063581926282e-08
serum O 0 9.283559165851329e-07
Hp O 0 2.5605936571082566e-06
level O 0 1.6151940940289933e-07
of O 0 5.771261690767915e-09
an O 0 1.2960464923494897e-09
individual O 0 6.31093510783387e-10
with O 0 1.826955253747542e-09
Hp1 O 0 0.0003898574213963002
/ O 0 1.4348569493449759e-05
Hpdel O 0 7.341148739214987e-05
was O 0 1.3801753766529146e-06
0 O 0 2.2350211281718657e-07
. O 0 2.3392678016875834e-08

50 O 0 1.3926606925451779e-06
mg O 0 3.451216571193072e-06
/ O 0 1.2285152024560375e-06
ml O 0 2.474986047218408e-07
, O 0 1.8472105789424376e-10
which O 0 1.63274272574343e-11
was O 0 2.608446125762498e-09
approximately O 0 2.888794758959534e-10
half O 0 2.4025170741737156e-10
the O 0 1.1617331541202702e-09
level O 0 2.6038253508886555e-07
of O 0 1.3018899380767834e-07
Hp O 0 2.5771469154278748e-06
in O 0 1.434571661462769e-08
control O 0 3.057849369270116e-07
sera O 0 4.393153631099267e-06
from O 0 9.190491034871684e-09
the O 0 2.029571000150554e-08
Hp1 O 0 4.6499990276061e-06
phenotype O 0 2.102168039641583e-08
( O 0 2.441896962412926e-10
1 O 0 1.0513897530373129e-09
. O 0 3.3234460322661974e-11
26 O 0 3.0510836079855608e-09
+ O 0 1.6290674365038171e-09
/ O 0 7.086729536531777e-10
- O 0 3.218444954988797e-10
0 O 0 1.5261805708099985e-10
. O 0 5.802057619075374e-12
33 O 0 5.995622331944617e-10
mg O 0 6.258530582670119e-09
/ O 0 1.5797445573895175e-09
ml O 0 9.95219462396335e-10
; O 0 2.927956488374406e-11
n O 0 3.330054898498247e-09
= O 0 5.858401763703114e-09
9 O 0 7.186014450155653e-09
) O 0 1.1471647243244121e-10
, O 0 3.9991576022968545e-11
showing O 0 6.4121437048925145e-09
a O 0 7.909080501633525e-09
gene O 0 1.3450378588686362e-09
- O 0 6.5508820590309824e-09
dosage O 0 8.523602446075529e-08
effect O 0 1.6675404879151756e-07
. O 0 4.300176215110696e-08

The O 0 3.053507384720433e-07
other O 0 3.5732816705547066e-09
allele O 0 1.4628213307332771e-08
( O 0 3.7311085776536856e-08
Hp2 O 0 1.0851460501726251e-05
) O 0 3.153704630776133e-09
of O 0 1.5784442197741555e-08
individuals O 0 6.59362831001431e-09
with O 0 9.94091120531948e-09
Hp2 O 1 0.9999998807907104
/ O 1 0.9643129110336304
Hpdel O 0 0.4149739444255829
was O 0 5.913757377129514e-07
found O 0 9.082028462614744e-10
to O 0 1.332184501601219e-10
have O 0 2.8866999068899446e-11
, O 0 1.0542985755257472e-11
in O 0 1.5185179502719137e-10
all O 0 6.240861716300117e-10
exons O 0 3.8868628315924525e-09
, O 0 3.139681223340851e-11
no O 0 8.85473361300626e-11
mutation O 0 8.314330994518837e-12
, O 0 6.222764491192745e-12
by O 0 8.273220303278706e-11
DNA O 0 7.030215964931585e-09
sequencing O 0 2.719100500314653e-08
. O 0 1.8287098058067386e-08

On O 0 2.6760087621369166e-06
the O 0 2.7605191021962128e-08
basis O 0 4.45054467945738e-07
of O 0 2.8392683759648207e-08
the O 0 5.250846424331712e-09
present O 0 3.912919321891195e-09
study O 0 5.747545106515872e-09
, O 0 1.0006512979332527e-10
the O 0 4.4422882039540923e-10
mechanism O 0 3.181413177344439e-08
of O 0 5.782801437703711e-08
anhaptoglobinemia B-Disease 0 1.315181748395844e-06
and O 0 8.297070808183094e-10
the O 0 4.89380402868278e-09
mechanism O 0 1.7283396402945073e-07
of O 0 5.6275393234273e-08
anomalous O 0 3.0172446713550016e-05
inheritance O 0 2.7723681341740303e-06
of O 0 8.709738722245675e-06
Hp O 0 0.00021068447676952928
phenotypes O 0 6.972621804379742e-07
were O 0 9.159676750414292e-08
well O 0 5.80522439008746e-08
explained O 0 2.4245111944765085e-06
. O 0 4.464496612399671e-07

However O 0 3.022319390311168e-07
, O 0 1.5566239408570937e-09
the O 0 5.820565807113098e-09
mechanism O 0 2.5285999072366394e-07
of O 0 6.533452960866271e-07
hypohaptoglobinemia B-Disease 0 0.0014509048778563738
remains O 0 2.8603408281924203e-05
unknown O 0 0.0002864766283892095

ATM O 0 0.00016612412582617253
mutations O 0 5.684933057636954e-08
and O 0 3.529193826068422e-09
phenotypes O 0 2.991749170178082e-06
in O 0 9.580293408362195e-06
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
families O 0 1.2486299965530634e-05
in O 0 1.797736715047904e-08
the O 0 2.127032949772456e-08
British O 0 1.9992744171304366e-07
Isles O 0 1.5175529597399873e-06
: O 0 1.1437374380918186e-09
expression O 0 2.368466978097672e-09
of O 0 2.3811588256705818e-09
mutant O 0 1.7140518338010224e-08
ATM O 0 2.882677847537707e-07
and O 0 4.7970946659425806e-11
the O 0 3.9129621764999456e-10
risk O 0 5.453563378665649e-09
of O 0 4.900447692079979e-08
leukemia B-Disease 1 1.0
, O 0 1.719539432087913e-05
lymphoma B-Disease 1 1.0
, O 0 5.075433819001773e-06
and O 0 1.5977509974618442e-05
breast B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 4.0765189623925835e-06

We O 0 1.5080081539053936e-07
report O 0 1.565679852433277e-08
the O 0 1.008123029500041e-09
spectrum O 0 1.5099033134902129e-09
of O 0 3.504156254052759e-08
59 O 0 4.773407908942318e-07
ATM O 0 2.7515463898453163e-06
mutations O 0 2.2498052310027106e-09
observed O 0 2.6616099546572514e-08
in O 0 2.3129281601086404e-07
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 0.9999943971633911
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 7.38775396413871e-09
patients O 0 1.0805951689007998e-09
in O 0 8.194919187687333e-10
the O 0 2.5421345029030817e-08
British O 0 2.470345634719706e-06
Isles O 0 5.911099651711993e-05
. O 0 1.486369711756197e-07

Of O 0 6.7997507358086295e-06
51 O 0 3.6011622341902694e-06
ATM O 0 2.263072383357212e-05
mutations O 0 5.1025521585756906e-09
identified O 0 6.072295999359767e-09
in O 0 2.4488853167525804e-09
families O 0 1.7367116633693058e-09
native O 0 1.8689145786510153e-09
to O 0 1.3849074109728576e-09
the O 0 1.6740585806473973e-08
British O 0 6.868004902571556e-07
Isles O 0 5.803457952424651e-06
, O 0 1.5914181084042411e-09
11 O 0 3.9066719637048664e-08
were O 0 2.7561839033296565e-08
founder O 0 6.757678079338802e-07
mutations O 0 3.018840732949002e-09
, O 0 2.627670026011941e-10
and O 0 5.131458591378646e-10
2 O 0 8.466939505069604e-08
of O 0 2.422804179502691e-08
these O 0 6.715470401985613e-10
11 O 0 1.537506832960389e-08
conferred O 0 1.599294030540932e-08
a O 0 1.0810466966049148e-09
milder O 0 5.748111986392246e-10
clinical O 0 4.2414267653612114e-09
phenotype O 0 1.0345329037875217e-09
with O 0 7.872315646584305e-12
respect O 0 3.917920987639434e-10
to O 0 3.4231444345778073e-09
both O 0 1.0646915171719229e-07
cerebellar B-Disease 1 1.0
degeneration I-Disease 1 1.0
and O 0 1.1644284825251816e-07
cellular O 0 1.2400270179568906e-06
features O 0 4.1163872310789884e-08
. O 0 4.9775422894526855e-08

We O 0 3.7940930042168475e-07
report O 0 8.297965337078494e-08
, O 0 7.656825729007721e-10
in O 0 2.0519825838505312e-09
two O 0 5.201246100483559e-09
A B-Disease 1 1.0
- I-Disease 1 0.9647350907325745
T I-Disease 1 1.0
families O 0 8.30787527661414e-09
, O 0 2.7194971274902e-10
an O 0 1.8501098431045193e-09
ATM O 0 1.7230190962891356e-07
mutation O 0 3.8245501210454336e-10
( O 0 5.30143207111422e-10
7271T O 0 1.1252845766307473e-08
- O 0 2.6913410167139773e-08
- O 0 7.685391665290808e-07
> O 0 1.6591079656791408e-06
G O 0 2.9682437343581114e-06
) O 0 9.341966089593257e-10
that O 0 2.5655944382863005e-11
may O 0 4.357056104797863e-10
be O 0 2.480256833248262e-10
associated O 0 8.335599988029685e-10
with O 0 3.6932304436909646e-11
an O 0 3.90872528788222e-10
increased O 0 4.897819483318244e-09
risk O 0 1.4749826959814527e-07
of O 0 2.097230691333607e-07
breast B-Disease 0 0.4060458242893219
cancer I-Disease 0 8.090402843663469e-06
in O 0 1.0343952361324682e-08
both O 0 7.740468710437653e-09
homozygotes O 0 2.7458163458504714e-06
and O 0 1.3789767105976125e-09
heterozygotes O 0 3.69777524156234e-08
( O 0 2.347453897932894e-10
relative O 0 1.1244543074440116e-08
risk O 0 1.459339871168197e-09
12 O 0 8.324922973201865e-10
. O 0 2.532016957212946e-11
7 O 0 9.906476750032311e-10
; O 0 9.796548988694198e-11
P O 0 4.879257744505594e-07
= O 0 4.5566597606239156e-08
. O 0 1.663070653412646e-10
0025 O 0 3.5167784062650753e-07
) O 0 9.314685828210045e-11
, O 0 6.8905736151647634e-12
although O 0 1.6120623932969202e-11
there O 0 2.463246828732224e-10
is O 0 2.6824517607160203e-10
a O 0 2.311537183885548e-09
less O 0 1.0341486778031594e-08
severe O 0 1.4355222447193228e-05
A B-Disease 1 1.0
- I-Disease 1 0.9999984502792358
T I-Disease 1 1.0
phenotype O 0 7.021628789516399e-08
in O 0 2.514744801285218e-10
terms O 0 1.6391533685933268e-09
of O 0 1.6455342644050575e-09
the O 0 1.3109637819752606e-09
degree O 0 6.4601599660818465e-06
of O 0 1.8083068198393448e-06
cerebellar B-Disease 1 1.0
degeneration I-Disease 1 1.0
. O 0 6.249932198443275e-07

This O 0 1.0400538030808093e-07
mutation O 0 4.0424685820994455e-09
( O 0 7.488391018384277e-10
7271T O 0 7.369443721927382e-09
- O 0 1.2506137458956346e-08
- O 0 1.3220827099758026e-07
> O 0 2.3424875905675435e-07
G O 0 3.2535524496779544e-07
) O 0 5.601831776225197e-10
also O 0 4.583098137111996e-11
allows O 0 3.63732481634127e-11
expression O 0 5.054929252956697e-10
of O 0 2.864413373160346e-09
full O 0 1.1837840929729282e-08
- O 0 4.340471448927019e-08
length O 0 5.538686664863235e-08
ATM O 0 1.9678179796756012e-06
protein O 0 8.74217143120859e-09
at O 0 6.443123812260865e-09
a O 0 1.2023267936811521e-09
level O 0 1.243338143552819e-08
comparable O 0 4.0212055907318245e-09
with O 0 2.380865643525354e-11
that O 0 4.165085984442207e-11
in O 0 1.4420630245481902e-09
unaffected O 0 2.3565657158997055e-07
individuals O 0 3.823676930636566e-09
. O 0 1.4465016739961811e-08

In O 0 1.8360533715622296e-07
addition O 0 1.1040058645050976e-08
, O 0 8.09926015143958e-10
we O 0 3.2184157561232496e-09
have O 0 5.676930592279916e-10
studied O 0 9.926306887564351e-08
18 O 0 5.785719622508623e-06
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 2.2932784560225628e-08
, O 0 1.4124524466696542e-11
in O 0 7.125924850193144e-11
15 O 0 1.3654297692511363e-09
families O 0 1.2641072910657414e-10
, O 0 3.3218872097506846e-11
who O 0 1.3830693534888638e-10
developed O 0 5.383741807918341e-08
leukemia B-Disease 1 1.0
, O 0 0.0016870051622390747
lymphoma B-Disease 1 1.0
, O 0 3.730256503331475e-05
preleukemic O 1 0.9999642372131348
T O 1 0.9956555366516113
- O 0 0.0007334193796850741
cell O 0 0.002772858366370201
proliferation O 1 0.9382284879684448
, O 0 3.661811831534578e-08
or O 0 0.00012942729517817497
Hodgkin B-Disease 1 1.0
lymphoma I-Disease 1 1.0
, O 0 4.284522958641901e-08
mostly O 0 6.7458474362069865e-09
in O 0 1.0264982641672304e-08
childhood O 0 5.469781535794027e-05
. O 0 2.7569785743253306e-07

A O 0 1.715977418825787e-06
wide O 0 7.246395927751337e-09
variety O 0 1.3633505435706184e-09
of O 0 5.5924537889495696e-08
ATM O 0 3.6830329008807894e-06
mutation O 0 4.117238772138876e-10
types O 0 3.340218657221783e-10
, O 0 3.8542502522886934e-11
including O 0 2.383465924626904e-10
missense O 0 3.6245019146008417e-06
mutations O 0 1.209718281103278e-08
and O 0 2.2123411991259445e-09
in O 0 1.278106367408327e-07
- O 0 1.383978087687865e-06
frame O 0 4.040024214191362e-05
deletions O 0 8.583985078303158e-08
, O 0 6.99979962881514e-10
were O 0 8.881500868085368e-09
seen O 0 1.3315228031274273e-08
in O 0 1.2156713413702391e-09
these O 0 1.920605452454538e-09
patients O 0 1.7056734691323072e-08
. O 0 2.8307626465107205e-08

We O 0 1.3829040881319088e-06
also O 0 5.686383808267692e-09
show O 0 6.942786789920774e-09
that O 0 1.6684974235570138e-10
25 O 0 4.32326707766606e-09
% O 0 1.4502524736670352e-09
of O 0 5.9852962586148806e-09
all O 0 1.63542228648339e-08
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 9.065383110851144e-09
carried O 0 1.550271355732491e-09
in O 0 1.004582195207604e-08
- O 0 1.2697732643118798e-07
frame O 0 6.1401028688123915e-06
deletions O 0 4.4856645331492473e-07
or O 0 9.658119637379059e-08
missense O 0 2.688591621335945e-06
mutations O 0 9.10499675654819e-09
, O 0 4.945240328346756e-10
many O 0 1.4433969297567018e-10
of O 0 3.572211637603573e-09
which O 0 5.118145351978853e-10
were O 0 5.080313947303239e-09
also O 0 1.8067274065725059e-10
associated O 0 7.97170052191376e-10
with O 0 4.816478327285267e-10
expression O 0 3.4055886999340146e-08
of O 0 2.944044865671458e-07
mutant O 0 1.199572579935193e-06
ATM O 0 5.415420309873298e-05
protein O 0 1.6252795376203721e-07
. O 0 1.5696686617161504e-08

The O 0 7.909814485174138e-06
DMPK O 0 0.0022511188872158527
gene O 0 2.1141228501164733e-07
of O 0 1.4252923108415416e-07
severely O 0 0.28931924700737
affected O 0 0.00018616984016261995
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 0 0.11124681681394577
is O 0 4.246315743472451e-09
hypermethylated O 0 1.6609886870355695e-06
proximal O 0 1.1988452115474502e-06
to O 0 3.240794743675224e-09
the O 0 8.950784113892496e-09
largely O 0 9.862819894124186e-08
expanded O 0 1.2973065111054893e-07
CTG O 0 5.5289263400482014e-05
repeat O 0 1.917299641718273e-06
. O 0 1.0270685635305199e-07

Using O 0 6.02290697315766e-07
methylation O 0 1.3310145732248202e-06
- O 0 3.3453295600338606e-07
sensitive O 0 7.09287462541397e-07
restriction O 0 3.4053549313739495e-08
enzymes O 0 1.3959237099570032e-09
, O 0 5.0202501877816275e-11
we O 0 7.546878122433043e-10
characterized O 0 4.0945140611370334e-09
the O 0 5.981530382115352e-09
methylation O 0 7.987171102286084e-08
pattern O 0 8.264400719326659e-08
on O 0 1.1139728250952885e-08
the O 0 5.453459017701334e-09
5 O 0 1.6357342147443887e-08
side O 0 2.3922159808620336e-09
of O 0 2.506740237606664e-08
the O 0 1.5863797386828082e-07
CTG O 0 0.00020455858611967415
repeat O 0 2.2633690832662978e-07
in O 0 7.910136545774549e-09
the O 0 1.5853780510610704e-08
DMPK O 0 1.3843073247699067e-05
gene O 0 1.481769928979304e-09
of O 0 2.7211741748800478e-09
normal O 0 1.8059608919429593e-08
individuals O 0 7.767748250175899e-11
and O 0 2.385593111942086e-11
of O 0 5.687305737467341e-09
patients O 0 6.488408477167695e-09
affected O 0 2.2201700478063913e-09
with O 0 1.9717141697128682e-08
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
, O 0 4.376765172509067e-09
showing O 0 3.6331492481167516e-08
expansions O 0 2.418907030232731e-08
of O 0 9.561757607912114e-09
the O 0 1.6848920481038476e-08
repetitive O 0 8.147948733494559e-07
sequence O 0 1.3261146136755997e-07
. O 0 3.603432219279057e-08

The O 0 8.490151799378509e-07
gene O 0 2.6310376100013855e-08
segment O 0 5.124509883103201e-08
analyzed O 0 1.8541944868388782e-08
corresponds O 0 2.0602270112135557e-08
to O 0 1.947151773151745e-09
the O 0 2.669205301231159e-08
genomic O 0 8.124639521156496e-07
SacI O 0 0.00022616163187194616
- O 0 3.899600073964393e-07
HindIII O 0 7.1100071181717794e-06
fragment O 0 1.9655530536510923e-07
carrying O 0 2.5664942171488292e-08
exons O 0 5.4879691901987826e-08
11 O 0 1.1440351244118574e-07
- O 0 7.885599728751913e-08
15 O 0 1.3080277483368263e-07
. O 0 5.253633972301941e-08

There O 0 2.4296952005897765e-07
is O 0 5.80954173656778e-09
constitutive O 0 5.401834073381906e-07
methylation O 0 4.111832367925672e-07
in O 0 2.7462975893399744e-08
intron O 0 2.8498645860963734e-06
12 O 0 4.3354408063578376e-08
at O 0 2.2989894432612346e-08
restriction O 0 4.951934862162943e-09
sites O 0 1.088640400048746e-09
of O 0 9.685344082299707e-09
SacII O 0 5.855918516317615e-06
and O 0 1.8981909377657757e-08
HhaI O 0 7.136781641747802e-05
, O 0 7.0371521943002335e-09
localized O 0 5.447682127623921e-08
1 O 0 4.89533782399576e-08
, O 0 2.35589991959273e-10
159 O 0 1.95507476874468e-09
- O 0 1.911144797972497e-09
1 O 0 1.8400600154677704e-08
, O 0 3.6760983146422177e-10
232 O 0 2.8119229611434093e-08
bp O 0 1.4795628544561623e-07
upstream O 0 1.6494765020524937e-07
of O 0 3.738638554295903e-08
the O 0 8.518304639437702e-08
CTG O 0 0.0001602214470040053
repeat O 0 2.3170123597537895e-07
, O 0 1.2962492190737862e-09
whereas O 0 2.7865658669412596e-09
most O 0 1.6314763429114976e-10
, O 0 2.3665906040415408e-11
if O 0 8.143510865643577e-11
not O 0 1.3184005276389854e-10
all O 0 3.4962352457590384e-10
, O 0 7.23412510450494e-11
of O 0 7.222740738832556e-10
the O 0 6.557567266973763e-10
other O 0 1.0488936108554725e-10
sites O 0 4.827499289206116e-09
of O 0 2.8007946184516186e-08
SacII O 0 2.5168254069285467e-05
, O 0 3.1287761714793305e-08
HhaI O 0 4.967373388353735e-05
, O 0 4.463702296675365e-09
and O 0 2.970213186515025e-09
HpaII O 0 2.130500797647983e-05
in O 0 3.509666335332895e-09
this O 0 4.5171522078391035e-10
region O 0 3.2361746615805487e-09
are O 0 5.284250259585122e-10
unmethylated O 0 3.4051996067319124e-07
, O 0 2.334946125337467e-10
in O 0 4.2555814427913674e-10
normal O 0 2.9416414193406126e-08
individuals O 0 1.365871860059542e-10
and O 0 3.2036217428865754e-11
most O 0 2.6831769445179177e-11
of O 0 8.073610668901665e-10
the O 0 4.361855765466771e-09
patients O 0 3.112726965071033e-09
. O 0 5.465017327566102e-09

In O 0 2.5974711093113e-07
a O 0 9.964583824739748e-09
number O 0 1.0975576003602328e-09
of O 0 1.7591085255119765e-09
young O 0 1.292479345771369e-09
and O 0 2.1323898202751934e-09
severely O 0 5.896698894503061e-06
affected O 0 6.857491907652502e-09
patients O 0 4.945523435218036e-10
, O 0 2.991291242482319e-11
however O 0 1.966067864067611e-10
, O 0 8.088880953938116e-11
complete O 0 1.2640892776971668e-08
methylation O 0 2.027450562991362e-08
of O 0 1.6358583376785418e-09
these O 0 7.31729121739022e-11
restriction O 0 4.980120205111405e-10
sites O 0 3.9232003756772826e-10
was O 0 1.6276324732444891e-09
found O 0 8.347974395084279e-11
in O 0 2.3744997634800313e-10
the O 0 1.7236928551156439e-09
mutated O 0 5.235765154765204e-09
allele O 0 1.5675233555612067e-08
. O 0 1.9158939323915547e-08

In O 0 1.030129155310533e-07
most O 0 2.663516629475282e-10
of O 0 4.5897138867267984e-10
these O 0 7.781612854085296e-11
patients O 0 3.5672667597630436e-10
, O 0 3.449515326159336e-11
the O 0 5.65421653941911e-10
onset O 0 1.3113144632370677e-05
of O 0 3.75719679368558e-07
the O 0 2.559082531661261e-06
disease O 1 0.9999990463256836
was O 1 0.999347984790802
congenital O 1 1.0
. O 0 1.0677762247723876e-06

Preliminary O 0 7.359778919635573e-06
in O 0 5.375768523663282e-07
vivo O 0 0.00014926742005627602
footprinting O 0 0.0007020332268439233
data O 0 1.4781721802137326e-07
gave O 0 2.931401343886364e-09
evidence O 0 6.648233519257474e-09
for O 0 5.162037464145897e-10
protein O 0 1.4263020098326251e-08
- O 0 1.4521492452956863e-08
DNA O 0 2.7736872354466868e-08
contact O 0 4.0041101101451204e-07
in O 0 1.88550739466109e-08
normal O 0 4.236580025462899e-06
genes O 0 2.3394596482262386e-08
at O 0 5.709459216518553e-08
an O 0 9.792785249373992e-09
Sp1 O 0 1.4843130884401035e-06
consensus O 0 1.9093640446499194e-08
binding O 0 5.14339637547323e-09
site O 0 5.685161141855133e-08
upstream O 0 1.1424651802371955e-07
of O 0 3.349766686255862e-08
the O 0 8.779774418599118e-08
CTG O 0 0.000214301937376149
repeat O 0 3.1470401040678553e-07
and O 0 5.017237181270673e-10
for O 0 2.663054499141282e-10
a O 0 4.758803351379015e-10
significant O 0 2.3160905138208676e-10
reduction O 0 1.6037956518388796e-09
of O 0 4.5674384274718705e-09
this O 0 4.864449953956296e-10
interaction O 0 1.2129805604388366e-08
in O 0 1.2359109291537607e-09
cells O 0 8.443804544455702e-10
with O 0 5.965528071527615e-11
a O 0 4.4386929687334487e-08
hypermethylated O 0 1.1048231499444228e-05
DMPK O 0 0.00021371916227508336
gene O 0 5.327732210957947e-08
. O 0 2.984296365582395e-09
. O 0 1.6303612682122548e-08

The O 0 0.00018787245790008456
hemochromatosis B-Disease 1 1.0
gene O 0 3.51812741428148e-06
product O 0 1.5285409915577475e-07
complexes O 0 6.051001832929614e-08
with O 0 5.84318815555207e-10
the O 0 1.891481815619045e-07
transferrin O 0 0.00011365248064976186
receptor O 0 2.4067310278041987e-06
and O 0 9.286538205088846e-10
lowers O 0 1.8774471755023114e-08
its O 0 7.944268853865566e-11
affinity O 0 1.6784889034227035e-09
for O 0 2.1275015082977689e-10
ligand O 0 8.210556501353494e-08
binding O 0 1.1616406503378585e-08
. O 0 2.359072226454373e-08

We O 0 7.445030973940447e-07
recently O 0 6.826773812917963e-08
reported O 0 2.1960806506626795e-08
the O 0 4.315498181028943e-09
positional O 0 1.3425939471289894e-07
cloning O 0 2.577856506036369e-08
of O 0 1.1809064837109418e-08
a O 0 1.363348633987016e-08
candidate O 0 2.5515245027918354e-08
gene O 0 1.2742519572839228e-07
for O 0 9.022328413266223e-06
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
called O 1 1.0
HFE O 1 1.0
. O 0 8.453656619167305e-07

The O 0 5.847832085237314e-07
gene O 0 1.847148922706765e-08
product O 0 7.502190868535763e-09
, O 0 4.1038633602497043e-10
a O 0 1.6904543542750616e-08
member O 0 2.1797678328994152e-08
of O 0 2.3526966685949446e-07
the O 0 1.5886234905337915e-07
major O 0 1.0590666761345346e-06
histocompatibility O 0 6.605623639188707e-05
complex O 1 0.7822130918502808
class O 0 1.6652944395900704e-05
I O 0 7.628637831658125e-05
- O 0 1.4333210174299893e-06
like O 0 3.104682377852441e-08
family O 0 9.88881510011197e-08
, O 0 8.870272849570426e-10
was O 0 1.4639341827660246e-07
found O 0 5.409678482948266e-09
to O 0 2.3112196601005053e-09
have O 0 7.522017453354124e-10
a O 0 5.530491620220346e-09
mutation O 0 3.380320467982756e-10
, O 0 4.5662776337884736e-10
Cys O 0 7.856781849113759e-06
- O 0 2.438802653159655e-07
282 O 0 5.437528329821362e-07
- O 0 1.3713154203287559e-06
- O 0 1.7997252825807664e-06
> O 0 7.520595772803063e-07
Tyr O 0 2.8941417440364603e-06
( O 0 8.896501313415683e-10
C282Y O 0 6.588071865820666e-09
) O 0 2.545041608015275e-11
, O 0 1.927542327140319e-12
in O 0 4.002392861579551e-11
85 O 0 2.976610291582915e-09
% O 0 2.5634924738504594e-10
of O 0 1.7224474069266194e-09
patient O 0 9.691630964425713e-08
chromosomes O 0 1.671266005587313e-07
. O 0 4.60206948105224e-08

This O 0 1.3364224571432715e-07
mutation O 0 1.8504142218489505e-08
eliminates O 0 5.118326384945249e-08
the O 0 9.690055868816216e-09
ability O 0 1.5494622473966047e-08
of O 0 7.90514491200156e-07
HFE O 0 0.001968243159353733
to O 0 4.782794960078718e-08
associate O 0 9.083930763154058e-07
with O 0 1.225544887795138e-09
beta2 O 0 2.639054218889214e-05
- O 0 1.3235741789685562e-05
microglobulin O 0 5.7204066251870245e-05
( O 0 6.57612275745123e-08
beta2m O 0 8.485982903039258e-07
) O 0 1.4353646049514168e-09
and O 0 2.890117312137619e-10
prevents O 0 1.8547003932667394e-08
cell O 0 3.071614628424868e-06
- O 0 2.015246309383656e-06
surface O 0 8.723580685909837e-05
expression O 0 5.444069756777026e-05
. O 0 1.6325402896200103e-07

A O 0 1.7179281712742522e-05
second O 0 2.672364303180075e-07
mutation O 0 5.119641599549141e-09
that O 0 4.4628487017028817e-10
has O 0 2.2343747685393822e-10
no O 0 9.104575426910344e-10
effect O 0 6.393104712287823e-09
on O 0 6.564869181602262e-08
beta2m O 0 4.236377662891755e-06
association O 0 4.808112308296586e-08
, O 0 5.026914440264818e-09
H63D O 0 4.998269287170842e-05
, O 0 3.1430935631959755e-09
was O 0 6.866132906679923e-08
found O 0 1.5772456674056912e-09
in O 0 5.584560036631103e-10
eight O 0 6.974025801298467e-10
out O 0 5.554949555897082e-11
of O 0 7.364227561090786e-10
nine O 0 6.338007896289355e-09
patients O 0 4.623664784375592e-10
heterozygous O 0 1.2738182730842595e-09
for O 0 6.384351936006283e-10
the O 0 1.1457013471272148e-07
C282Y O 0 1.920343675010372e-05
mutant O 0 5.906914338993374e-06
. O 0 1.5312707546399906e-07

In O 0 8.565765341472797e-08
this O 0 1.0825693674831882e-09
report O 0 2.927121878215644e-09
, O 0 7.387661316027305e-11
we O 0 1.7282185404976502e-10
demonstrate O 0 4.901099526222197e-09
in O 0 5.110899703453242e-09
cultured O 0 1.605342845323321e-07
293 O 0 2.47842990575009e-07
cells O 0 2.4964244005332148e-08
overexpressing O 0 2.0984962247894146e-06
wild O 0 1.438783403528987e-08
- O 0 5.5900752471416126e-08
type O 0 4.3911077796110476e-07
or O 0 1.1225517937418772e-07
mutant O 0 1.6272845186904306e-06
HFE O 0 8.76663689268753e-05
proteins O 0 1.2133501980926553e-09
that O 0 4.242312404145743e-11
both O 0 1.0129913574630223e-10
the O 0 8.437380794035221e-10
wild O 0 7.740232454978013e-09
- O 0 5.1574467363479926e-08
type O 0 3.218025028672855e-07
and O 0 2.2213697548068012e-08
H63D O 0 0.3512504994869232
HFE O 0 0.0008699847385287285
proteins O 0 6.22144469275554e-09
form O 0 4.206686110563851e-09
stable O 0 2.0256243260519113e-06
complexes O 0 3.921566005260502e-08
with O 0 4.785545848484674e-10
the O 0 8.111170757274522e-08
transferrin O 0 4.054354576510377e-05
receptor O 0 8.038481610128656e-06
( O 0 2.752642913605996e-08
TfR O 0 8.667578185850289e-06
) O 0 6.8853553969461245e-09
. O 0 1.2081825317977746e-08

The O 0 2.116823452524841e-06
C282Y O 0 6.644174391112756e-06
mutation O 0 2.9956236602401987e-08
nearly O 0 3.8492533604994605e-08
completely O 0 1.2351014788691828e-07
prevents O 0 8.279512186959437e-09
the O 0 3.3199776261483294e-09
association O 0 8.589876365761029e-09
of O 0 2.5615205956341924e-08
the O 0 9.550261381718883e-08
mutant O 0 6.430679604818579e-06
HFE O 0 0.00034533647703938186
protein O 0 3.9442277000034665e-08
with O 0 3.370303203187319e-10
the O 0 9.943967427261668e-08
TfR O 0 0.002467573154717684
. O 0 2.4191982106458454e-07

Studies O 0 1.746737507346552e-05
on O 0 3.450475389854546e-07
cell O 0 1.5508658179896884e-06
- O 0 8.782989624478432e-08
associated O 0 9.892965380231544e-08
transferrin O 0 3.1097074497665744e-06
at O 0 8.290213315831352e-08
37 O 0 1.942623484296746e-08
degrees O 0 8.269673230643093e-07
C O 0 1.030573798743717e-06
suggest O 0 8.328103540122811e-09
that O 0 1.488857370723906e-10
the O 0 2.8955260411578365e-09
overexpressed O 0 1.6559937421334325e-06
wild O 0 4.167571532320835e-08
- O 0 7.66250138894975e-08
type O 0 7.22719804002736e-08
HFE O 0 5.706419688067399e-05
protein O 0 1.9311121590703806e-08
decreases O 0 8.228252745823283e-09
the O 0 2.1439545971890794e-10
affinity O 0 2.462045678441882e-09
of O 0 7.041474958668914e-09
the O 0 2.3036333729464786e-08
TfR O 0 5.0193528295494616e-05
for O 0 4.9256744460990376e-08
transferrin O 0 2.0733103156089783e-05
. O 0 9.383136756468957e-08

The O 0 4.662630453822203e-05
overexpressed O 1 0.9315789937973022
H63D O 1 0.9944217801094055
protein O 0 6.419460078177508e-06
does O 0 1.0900658153900622e-09
not O 0 1.4306135442954115e-10
have O 0 3.2627848339794596e-11
this O 0 2.452051756085538e-11
effect O 0 1.0171563591399035e-09
, O 0 1.0843460157561324e-10
providing O 0 7.277473068612039e-10
the O 0 6.127955365364812e-10
first O 0 8.068761214730102e-10
direct O 0 4.3280995454253457e-10
evidence O 0 1.2198615451097794e-09
for O 0 5.089891702558802e-11
a O 0 1.7546181174665776e-09
functional O 0 1.318640130421045e-07
consequence O 0 1.24587160144074e-07
of O 0 2.639320761943509e-08
the O 0 4.172678202962743e-08
H63D O 0 6.917591235833243e-05
mutation O 0 7.073042951333264e-08
. O 0 1.7521642803330906e-08

Addition O 0 6.218944008651306e-07
of O 0 3.4139887361561705e-07
soluble O 0 3.593786232158891e-06
wild O 0 8.008120175873046e-07
- O 0 2.020182910200674e-05
type O 0 0.029318321496248245
HFE O 1 1.0
/ O 1 0.9998351335525513
beta2m O 0 0.0009976336732506752
heterodimers O 0 2.6575409719953313e-05
to O 0 5.782415257726825e-08
cultured O 0 4.671922397392336e-06
cells O 0 8.652398264530348e-08
also O 0 3.8507252941855086e-10
decreased O 0 2.5266274406021694e-08
the O 0 1.5471933734190202e-09
apparent O 0 4.7038422934519986e-08
affinity O 0 2.0201627037863545e-08
of O 0 1.1244607023286335e-08
the O 0 1.1025496959859993e-08
TfR O 0 4.457856903172797e-06
for O 0 4.622818239319315e-10
its O 0 2.331790593945726e-10
ligand O 0 3.799156100825485e-09
under O 0 3.593252140277059e-09
steady O 0 2.7784480494119634e-07
- O 0 1.1743606087577518e-09
state O 0 1.1305434366448708e-10
conditions O 0 2.05217820514747e-09
, O 0 3.437876025524922e-11
both O 0 5.2086869539724745e-11
in O 0 2.2764153062571069e-10
293 O 0 5.217482001995677e-09
cells O 0 1.9313828314437842e-10
and O 0 6.20500179016048e-11
in O 0 1.3543473009747231e-08
HeLa O 0 0.00019160476222168654
cells O 0 1.8082465658153524e-07
. O 0 2.7492479404145342e-08

Furthermore O 0 1.278155423278804e-06
, O 0 2.164239676361035e-09
at O 0 1.0544046524785244e-08
4 O 0 1.8018218028714728e-08
degrees O 0 4.0977360526994744e-07
C O 0 2.2885338069045247e-07
, O 0 1.7198727164657868e-10
the O 0 2.892793560249629e-09
added O 0 1.371920266279858e-08
soluble O 0 2.4562876888012397e-07
complex O 0 4.240280588874157e-07
of O 0 9.264189770874509e-07
HFE O 1 0.9985361099243164
/ O 0 0.00015790412726346403
beta2m O 0 3.772995114559308e-05
inhibited O 0 4.810626137441432e-07
binding O 0 1.3951789945565451e-08
of O 0 5.4764772272619666e-08
transferrin O 0 2.80623044091044e-06
to O 0 6.56694751910436e-08
HeLa O 0 0.00034432855318300426
cell O 0 4.833172170037869e-06
TfR O 0 8.199294097721577e-05
in O 0 5.313370188275712e-09
a O 0 1.3315837321670188e-08
concentration O 0 1.0526550795475487e-05
- O 0 3.3682601952023106e-07
dependent O 0 3.2909846936490794e-07
manner O 0 7.51871027659945e-08
. O 0 2.7882155251290897e-08

Scatchard O 0 0.0006901427987031639
plots O 0 4.045632522320375e-06
of O 0 1.2764606083237595e-07
these O 0 6.188118462091552e-09
data O 0 2.9103784981998615e-07
indicate O 0 2.8981354205370735e-08
that O 0 2.506154450632181e-10
the O 0 6.596748036713507e-09
added O 0 1.983505271141439e-08
heterodimer O 0 2.3054077757933555e-07
substantially O 0 5.055066587544843e-09
reduced O 0 1.8118494482521896e-09
the O 0 7.285764769271452e-10
affinity O 0 2.249531760867285e-08
of O 0 5.5755187133854633e-08
TfR O 0 3.3391730539733544e-05
for O 0 2.5138552572911976e-08
transferrin O 0 2.7506348487804644e-05
. O 0 2.364383959729821e-07

These O 0 5.761454247021902e-08
results O 0 4.1439587761260555e-08
establish O 0 4.702128819644713e-08
a O 0 5.490785426331968e-08
molecular O 0 2.775929317522241e-07
link O 0 3.3237748198189365e-07
between O 0 1.3940463361450384e-07
HFE O 1 0.9924496412277222
and O 0 3.6942786607596645e-08
a O 0 1.815774055557995e-07
key O 0 2.260262874642649e-07
protein O 0 3.2137368322082693e-08
involved O 0 5.082564769054443e-08
in O 0 1.0436759900755987e-08
iron O 0 2.9498973162844777e-05
transport O 0 2.7206106096855365e-06
, O 0 1.6042156048001743e-08
the O 0 5.485279075401195e-07
TfR O 1 0.9999790191650391
, O 0 1.0857829080279657e-09
and O 0 1.4151713134680222e-10
raise O 0 1.2004569560630785e-09
the O 0 6.455839751673409e-10
possibility O 0 2.8458324585756145e-09
that O 0 3.74858651064347e-11
alterations O 0 2.855140568414072e-09
in O 0 2.905493623472921e-10
this O 0 1.4612248910861325e-10
regulatory O 0 1.9327139888503098e-09
mechanism O 0 9.558312363822097e-09
may O 0 5.376276646096301e-10
play O 0 1.7038582766915056e-09
a O 0 5.1917212751106945e-09
role O 0 3.968040118706995e-09
in O 0 3.993460229168022e-09
the O 0 3.276290883036381e-08
pathogenesis O 1 0.9998453855514526
of O 1 0.9999843835830688
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
. O 0 5.01958274981007e-05
. O 0 2.798896616695856e-07

Genomic O 0 1.2337891348579433e-05
organization O 0 1.6219009069118329e-07
of O 0 2.0727023297695268e-07
the O 0 2.7821283765661065e-07
UBE3A O 0 0.0025896201841533184
/ O 0 6.352039690682432e-06
E6 O 0 6.960277687539929e-07
- O 0 7.256868883587231e-08
AP O 0 1.6117655832204036e-06
gene O 0 6.851370026872416e-10
and O 0 1.7182923139902329e-10
related O 0 1.1100833319233061e-07
pseudogenes O 0 4.286646344553446e-06
. O 0 1.8557254577444837e-07

The O 0 3.938878307963023e-06
UBE3A O 0 0.001670005964115262
gene O 0 4.205577113225445e-07
encodes O 0 8.90453932811397e-08
the O 0 2.360422612923685e-08
E6 O 0 4.850844561588019e-07
- O 0 2.1746438960690284e-07
AP O 0 3.1502691854257137e-05
ubiquitin O 0 1.5849052488192683e-06
- O 0 1.2497813486334053e-06
protein O 0 2.1101607217133278e-07
ligase O 0 2.654021784564975e-07
and O 0 4.215585658329246e-09
has O 0 5.501304967125975e-10
recently O 0 1.949054251326743e-09
been O 0 8.79810557741223e-10
shown O 0 3.559898764660119e-10
to O 0 1.398027943411151e-10
be O 0 4.4055326053893396e-10
mutated O 0 2.0054780947020845e-08
in O 0 4.232515209423582e-07
Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 1 0.7328543066978455
who O 0 1.9225417702273262e-08
lack O 0 4.330178853706457e-06
15q11 O 0 1.3111256521369796e-05
- O 0 7.911443390185013e-06
q13 O 0 1.6342195522156544e-05
deletions O 0 1.3536225651478162e-06
or O 0 1.6140192826696875e-07
chromosome O 0 1.4634571243732353e-06
15 O 0 2.906960162363248e-06
paternal O 0 0.0740545392036438
uniparental B-Disease 1 0.9999997615814209
disomy I-Disease 1 0.9333859086036682
. O 0 1.823049274207733e-06

Previous O 0 3.552601992851123e-05
UBE3A O 0 0.0008376915939152241
cDNA O 0 1.4109074982115999e-05
analysis O 0 2.686540412355498e-08
has O 0 3.749952431908454e-11
shown O 0 1.6199414032413983e-10
a O 0 2.050300373923619e-09
coding O 0 1.301239027640122e-08
region O 0 1.817071826337724e-09
of O 0 1.8163241577440203e-08
approximately O 0 4.4788677655560605e-08
2 O 0 3.3751479122656747e-07
. O 0 2.677332666678467e-08

6 O 0 3.85007297154516e-05
kb O 0 6.804072472732514e-05
and O 0 7.014277603190067e-09
a O 0 4.7003531733480486e-08
3 O 0 2.463000896568701e-07
- O 0 9.301454895194183e-08
untranslated O 0 3.72782742488198e-05
region O 0 9.012115498308049e-08
( O 0 1.568067631296799e-08
UTR O 0 4.166688086115755e-06
) O 0 1.0224217028564908e-09
of O 0 6.2203175943409406e-09
< O 0 1.751009222061839e-07
50 O 0 5.021663085358341e-09
bp O 0 1.2390769299486237e-08
, O 0 3.1325390198455594e-11
whereas O 0 7.761872256040192e-10
Northern O 0 1.4343328746946327e-09
analysis O 0 4.577651591120002e-09
has O 0 5.560684551708661e-11
indicated O 0 4.3742093280840777e-10
mRNA O 0 7.026270676391277e-10
sizes O 0 3.801335912712034e-10
of O 0 9.116431165523409e-09
5 O 0 8.516208538367209e-08
- O 0 7.952739622396621e-08
8 O 0 4.0174629134526185e-07
kb O 0 1.84009568329202e-05
. O 0 4.91479781317139e-08

We O 0 1.3416442357083724e-07
have O 0 2.1112511738863304e-10
analyzed O 0 4.076684767539973e-09
additional O 0 7.2223587110897824e-09
cDNA O 0 5.116725674270128e-07
clones O 0 8.974460286026442e-09
and O 0 4.936294775714778e-11
provide O 0 2.178626723470245e-10
evidence O 0 4.269876896501046e-09
for O 0 1.856765713403874e-10
an O 0 5.235902267308745e-10
additional O 0 4.124487862355863e-09
0 O 0 7.110985933422853e-08
. O 0 1.3678494781288464e-08

5 O 0 3.0302817322080955e-06
kb O 0 7.232766620290931e-06
of O 0 1.8412875135709328e-07
5 O 0 4.939862492392422e-07
- O 0 1.0304179909326194e-07
UTR O 0 1.1185299626959022e-05
and O 0 2.9419877645153747e-09
> O 0 3.03902787379684e-08
2 O 0 1.5424795662966062e-08
kb O 0 7.261181167450559e-07
of O 0 8.961514907923629e-08
3 O 0 7.151463705667993e-07
- O 0 1.767644221217779e-06
UTR O 0 0.00011258052109042183
. O 0 1.447537272269983e-07

We O 0 5.602050805464387e-07
have O 0 1.4653618318760664e-09
established O 0 1.2134102611582875e-09
the O 0 4.5008033411342296e-10
genomic O 0 7.49855733062077e-09
organization O 0 4.415949828029397e-09
of O 0 2.4829901690281986e-08
UBE3A O 0 4.182517386652762e-06
and O 0 4.2678960365805096e-10
the O 0 2.434559664976632e-09
sequence O 0 9.474581119661707e-09
of O 0 5.063416352868444e-08
intron O 0 2.4177068098651944e-06
- O 0 1.5069442724779947e-06
exon O 0 1.650876924941258e-06
borders O 0 8.82328734519433e-08
. O 0 1.3620481809084595e-07

We O 0 2.4773692075541476e-06
have O 0 8.283191910152254e-09
also O 0 6.201442692699288e-10
mapped O 0 1.1834455193593385e-08
two O 0 6.044237332858415e-10
highly O 0 7.197509699352622e-09
homologous O 0 1.3518491215336326e-08
processed O 0 1.8971304527326538e-08
pseudogenes O 0 3.4915811397695506e-07
, O 0 4.380356521949125e-09
UBE3AP1 O 0 3.505877612042241e-05
and O 0 4.532406805424216e-08
UBE3AP2 O 0 0.0014638241846114397
, O 0 4.538260878206302e-09
to O 0 2.735985882296177e-09
chromosomes O 0 2.239171070783641e-09
2 O 0 4.605008818714396e-09
and O 0 5.034643188461807e-11
21 O 0 1.8528185652399998e-09
, O 0 5.956068971357809e-11
respectively O 0 1.8839569904116615e-09
, O 0 3.4735873899460756e-11
and O 0 5.6416309124340813e-11
determined O 0 2.545942345832941e-09
their O 0 1.066737476129731e-09
genomic O 0 2.108162888703191e-08
organization O 0 1.435617313916282e-08
. O 0 1.3896390704815076e-08

These O 0 5.0226425685195863e-08
results O 0 7.908536936440669e-09
will O 0 4.747305326624485e-11
form O 0 4.827264282747379e-11
the O 0 1.988158387922212e-10
basis O 0 1.8515148303421824e-09
for O 0 3.224347872032851e-11
studies O 0 6.742550962002269e-10
of O 0 5.69717162335337e-10
mutation O 0 3.234124079654066e-10
and O 0 3.5228969741396554e-10
imprinting O 0 1.0389032922830665e-06
of O 0 2.430748281767592e-06
UBE3A O 1 0.7160163521766663
. O 0 1.5252006733135204e-06

Mutation O 0 1.32383775053313e-07
spectrum O 0 8.568735054836907e-09
and O 0 9.854218552263205e-10
genotype O 0 1.6498037780365848e-07
- O 0 4.4540602317511e-08
phenotype O 0 2.782408969892458e-08
analyses O 0 3.3986196967816795e-08
in O 0 4.2711723047261785e-09
Cowden B-Disease 1 0.9828441143035889
disease I-Disease 0 2.5886283765430562e-05
and O 0 1.7463554158325678e-08
Bannayan B-Disease 1 1.0
- I-Disease 1 1.0
Zonana I-Disease 1 1.0
syndrome I-Disease 1 1.0
, O 0 2.5860151797729714e-09
two O 0 1.680341377152672e-08
hamartoma B-Disease 1 0.9999322891235352
syndromes I-Disease 0 0.013881208375096321
with O 0 1.172788529402169e-06
germline O 1 1.0
PTEN O 1 0.999998927116394
mutation O 0 1.4554831295754411e-06
. O 0 8.921421112972894e-08

The O 0 0.00011400404764572158
tumour B-Disease 1 1.0
suppressor O 1 0.9995909333229065
gene O 0 2.5311915123893414e-06
PTEN O 0 2.1797903173137456e-05
, O 0 4.3596995458194954e-10
which O 0 1.5419016063944468e-10
maps O 0 1.3485347061248376e-08
to O 0 1.0776359360420429e-08
10q23 O 0 1.2874020285380539e-05
. O 0 5.43231408300926e-07

3 O 0 7.091941256476275e-07
and O 0 2.8364739446118392e-09
encodes O 0 3.915205581961345e-08
a O 0 4.323588598253991e-09
403 O 0 1.1388553211588714e-08
amino O 0 9.119665911327957e-09
acid O 0 1.4558488636851052e-08
dual O 0 4.181900692401541e-07
specificity O 0 2.1560188088187715e-06
phosphatase O 1 0.9679003953933716
( O 0 3.433727329138492e-07
protein O 0 1.1681605656121974e-06
tyrosine O 0 2.8711101549561135e-06
phosphatase O 0 2.127022298736847e-06
; O 0 8.627654701776066e-10
PTPase O 0 1.5174298368947348e-06
) O 0 9.259406574813056e-10
, O 0 1.0322970950271682e-10
was O 0 2.0018209312411273e-08
shown O 0 5.7637814521172e-09
recently O 0 4.947922072062738e-09
to O 0 9.26126064726418e-10
play O 0 8.196142431415865e-09
a O 0 1.8466558060481475e-08
broad O 0 8.873239032425317e-09
role O 0 2.6394870289436767e-08
in O 0 2.5880794396471174e-08
human O 0 2.068950095690525e-07
malignancy B-Disease 0 0.00035600614501163363
. O 0 4.458463109813238e-08

Somatic O 0 0.021366683766245842
PTEN O 0 0.0047836387529969215
deletions O 0 5.155657163413707e-07
and O 0 1.1627195872776497e-09
mutations O 0 1.3479013460937495e-09
were O 0 1.3614327443178809e-09
observed O 0 9.206715390064346e-10
in O 0 1.9277033302955715e-09
sporadic B-Disease 0 0.00010463134094607085
breast I-Disease 1 0.9998996257781982
, I-Disease 0 4.914703595204628e-07
brain I-Disease 1 1.0
, I-Disease 0 3.304381834823289e-07
prostate I-Disease 1 0.9999998807907104
and I-Disease 0 0.04367275536060333
kidney I-Disease 1 1.0
cancer I-Disease 1 1.0
cell O 1 0.9999998807907104
lines O 0 5.004836367561438e-08
and O 0 1.1516261555488683e-10
in O 0 9.33512600553854e-10
several O 0 3.324679642702222e-09
primary O 0 0.2120218127965927
tumours B-Disease 1 1.0
such O 0 1.3381015406821462e-08
as O 0 8.271445949503686e-06
endometrial B-Disease 1 1.0
carcinomas I-Disease 1 1.0
, O 1 0.8745935559272766
malignant B-Disease 1 1.0
melanoma I-Disease 1 1.0
and O 1 1.0
thyroid B-Disease 1 1.0
tumours I-Disease 1 1.0
. O 0 2.7520096409716643e-05

In O 0 2.47891193794203e-07
addition O 0 2.9768617793024532e-08
, O 0 2.6399050057079876e-08
PTEN O 0 0.0002373694151174277
was O 0 1.8672965040877898e-07
identified O 0 1.0244757930877313e-08
as O 0 7.481310015933218e-10
the O 0 2.073657690004893e-09
susceptibility O 0 5.024903870776143e-08
gene O 0 1.323240739203868e-09
for O 0 1.5256546026520823e-09
two O 0 1.219743950287011e-07
hamartoma B-Disease 1 1.0
syndromes I-Disease 1 1.0
Cowden B-Disease 1 1.0
disease I-Disease 1 0.9999996423721313
( O 0 1.1798532995044297e-07
CD B-Disease 0 2.538153012210387e-06
; O 0 8.42007086276908e-09
MIM O 0 0.00018964236369356513
158350 O 0 2.891564918172662e-06
) O 0 2.6179112211366373e-09
and O 0 1.3486728400735615e-09
Bannayan B-Disease 0 0.00031279082759283483
- I-Disease 0 0.00083635636838153
Zonana I-Disease 1 0.9996883869171143
( I-Disease 0 1.8243257500216714e-06
BZS I-Disease 0 0.0016098935157060623
) I-Disease 0 2.624872408318879e-08
or I-Disease 0 1.6705147487527938e-08
Ruvalcaba I-Disease 0 1.2007689292659052e-05
- I-Disease 0 1.8403006833977997e-06
Riley I-Disease 0 6.272365135373548e-05
- I-Disease 1 0.980219304561615
Smith I-Disease 1 0.9999792575836182
syndrome I-Disease 1 1.0
( O 0 3.279771044617519e-05
MIM O 1 0.9998742341995239
153480 O 0 0.0008292453712783754
) O 0 1.6556495552322303e-07
. O 0 5.966219163155984e-08

Constitutive O 0 1.5122930562938564e-05
DNA O 0 9.900742981017174e-08
from O 0 4.44233272389738e-09
37 O 0 1.6459621221542875e-08
CD B-Disease 0 7.908796106903537e-08
families O 0 2.313176733492739e-10
and O 0 1.0826638197070082e-10
seven O 0 1.4499904388287632e-08
BZS B-Disease 0 0.0006496055866591632
families O 0 2.138862420508758e-09
was O 0 4.0026737480047814e-08
screened O 0 5.366579713950159e-08
for O 0 1.286961719415558e-07
germline O 1 0.9946413040161133
PTEN O 0 0.3457798659801483
mutations O 0 1.1988933010798064e-06
. O 0 1.1105280606216184e-07

PTEN O 0 0.07277632504701614
mutations O 0 2.5432117922719044e-07
were O 0 2.5217021359935643e-08
identified O 0 4.466359282417898e-09
in O 0 1.7675771957215147e-09
30 O 0 1.0791683102695515e-08
of O 0 2.4796678488314683e-08
37 O 0 2.1553223206183247e-08
( O 0 5.163839356114863e-10
81 O 0 2.139111332510879e-09
% O 0 8.31412855228919e-11
) O 0 2.1131313712730027e-11
CD B-Disease 0 3.4408313975831106e-09
families O 0 3.57940344031249e-11
, O 0 1.2249477474024495e-11
including O 0 1.2885871536472138e-10
missense O 0 8.752000439926633e-07
and O 0 1.184963327460764e-08
nonsense O 0 2.1315312551450916e-05
point O 0 7.249909117490461e-07
mutations O 0 3.908704915289718e-09
, O 0 1.3151681133027893e-10
deletions O 0 2.2224493356759467e-09
, O 0 1.998000376257636e-10
insertions O 0 3.100794288002362e-08
, O 0 1.8203984986087107e-09
a O 0 1.3293536937908357e-07
deletion O 0 4.282837835489772e-06
/ O 0 1.669447919994127e-05
insertion O 0 2.160120402550092e-06
and O 0 1.2732982668239856e-07
splice O 0 0.0007554664625786245
site O 0 5.828550911246566e-06
mutations O 0 4.244010654019803e-07
. O 0 2.1421138285404595e-07

These O 0 4.862553382167789e-08
mutations O 0 1.9593912270465808e-08
were O 0 1.8797800649394958e-08
scattered O 0 3.5238279849636456e-08
over O 0 5.684496429125829e-09
the O 0 1.2653628367331748e-08
entire O 0 1.6132483438013878e-07
length O 0 6.570392940830061e-08
of O 0 4.0327756778424373e-07
PTEN O 0 1.6903382856980897e-05
, O 0 5.121426616128133e-10
with O 0 2.5625527741435228e-11
the O 0 7.032710414023313e-09
exception O 0 1.8864209749835936e-08
of O 0 1.1566705815369005e-08
the O 0 3.5033596024192093e-09
first O 0 9.437463255324019e-09
, O 0 4.644967466216343e-10
fourth O 0 6.372581395908128e-08
and O 0 6.238960459370446e-09
last O 0 3.868360636261059e-07
exons O 0 1.6593926375207957e-06
. O 0 2.409591957075463e-07

A O 0 2.3968954337760806e-05
hot O 0 3.8110172226879513e-06
spot O 0 7.196770752671e-07
for O 0 1.9662047989754683e-08
PTEN O 0 4.216490196995437e-05
mutation O 0 4.357922467335129e-09
in O 0 3.5752110161269e-09
CD B-Disease 0 4.067103418492479e-07
was O 0 9.545162527047069e-08
identified O 0 7.9764497229462e-09
in O 0 7.46556239050733e-09
exon O 0 3.2794982729456024e-08
5 O 0 6.288996434733463e-09
that O 0 3.1304844133606125e-11
contains O 0 4.62993060557082e-10
the O 0 1.7667288076950172e-08
PTPase O 0 0.0001978253130801022
core O 0 1.9686891391756944e-05
motif O 0 1.2651426573029312e-07
, O 0 7.915802735514177e-11
with O 0 1.3582334042194777e-11
13 O 0 5.619470666573534e-09
of O 0 1.099014035332857e-08
30 O 0 4.586268254058723e-09
( O 0 4.472801851118646e-10
43 O 0 2.1422756901756657e-09
% O 0 1.8426148107320017e-10
) O 0 1.0259257332556615e-10
CD B-Disease 0 1.1110043551809667e-08
mutations O 0 9.446444737548632e-10
identified O 0 3.9963174991441974e-09
in O 0 2.8058244616602224e-09
this O 0 1.2250898073773442e-08
exon O 0 6.382738888532913e-07
. O 0 9.016929425342823e-08

Seven O 0 5.296487870509736e-06
of O 0 3.8257110190897947e-07
30 O 0 1.1539375321945045e-07
( O 0 4.0555510061324185e-09
23 O 0 3.590335495573527e-08
% O 0 2.1399682026412847e-09
) O 0 9.896462122016558e-11
were O 0 3.9879319291280524e-10
within O 0 3.6910228207176488e-09
the O 0 2.3611791633015855e-08
core O 0 5.388214958657045e-07
motif O 0 2.528628151310386e-08
, O 0 7.28688706597147e-11
the O 0 3.6570760308940464e-10
majority O 0 4.461808006395174e-11
( O 0 1.417151257454563e-10
five O 0 1.2946302363481266e-10
of O 0 2.0538972744787998e-09
seven O 0 3.2349216638749567e-09
) O 0 1.6350215625848818e-10
of O 0 1.0278280448972055e-09
which O 0 3.1186500604185596e-10
were O 0 2.081012517862746e-08
missense O 0 1.7867962469608756e-06
mutations O 0 9.895999575348924e-09
, O 0 1.5492663818506003e-09
possibly O 0 2.4211669824580895e-07
pointing O 0 1.3425443512460333e-06
to O 0 5.786273682417686e-09
the O 0 1.7401477592215997e-08
functional O 0 2.155173660867149e-06
significance O 0 9.548003276904637e-08
of O 0 2.1665577776275313e-08
this O 0 1.9976167386914767e-09
region O 0 2.298436996284181e-08
. O 0 2.6391445473450403e-08

Germline O 1 0.9999997615814209
PTEN O 0 0.12436872720718384
mutations O 0 5.8987129847309916e-08
were O 0 1.1551316347890861e-08
identified O 0 3.1652389598235686e-09
in O 0 2.208555116567368e-09
four O 0 3.0110027804397532e-09
of O 0 3.880538557154978e-08
seven O 0 5.137672687283157e-08
( O 0 1.8882928998209536e-08
57 O 0 1.816667776211034e-07
% O 0 3.85953811132822e-08
) O 0 4.1379163207011516e-08
BZS B-Disease 0 0.00789453461766243
families O 0 9.986772653292064e-08
studied O 0 3.8095711261121323e-06
. O 0 4.927769623463973e-07

Interestingly O 0 8.037892257561907e-06
, O 0 4.841146150624809e-09
none O 0 1.7585422895649572e-08
of O 0 6.299921917474194e-09
these O 0 6.405013741606069e-10
mutations O 0 3.6594502983433586e-09
was O 0 1.0918230231027337e-07
observed O 0 2.143012345356965e-08
in O 0 1.9081443980439872e-08
the O 0 4.669524855671625e-07
PTPase O 0 0.31926998496055603
core O 0 0.0001720407308312133
motif O 0 4.701900707004825e-06
. O 0 1.1053337800603913e-07

It O 0 3.214301003140463e-08
is O 0 3.976282858531022e-09
also O 0 3.4876632137859076e-10
worthy O 0 1.7819782982542165e-08
of O 0 1.7281939435065397e-08
note O 0 9.180980953260587e-08
that O 0 5.205252895379431e-10
a O 0 1.272298888466139e-08
single O 0 4.985628621057003e-08
nonsense O 0 3.0571467846129963e-07
point O 0 1.3153268696441955e-07
mutation O 0 2.80220763260175e-10
, O 0 5.580979428598809e-11
R233X O 0 1.6090391241618818e-08
, O 0 2.350563077513357e-10
was O 0 1.3644255503209024e-08
observed O 0 4.12467660027005e-09
in O 0 1.3113414798482381e-09
the O 0 7.3327788285837414e-09
germline O 0 7.829068522369198e-07
DNA O 0 6.622883130802393e-09
from O 0 5.186502893828049e-10
two O 0 1.1626325596703069e-10
unrelated O 0 1.5359386651425666e-08
CD B-Disease 0 1.8255181544191146e-07
families O 0 8.636660830951826e-10
and O 0 1.95999216856535e-09
one O 0 1.0227230262671583e-07
BZS B-Disease 1 0.8458502888679504
family O 0 3.261108986407635e-06
. O 0 3.4434862072885153e-07

Genotype O 0 5.715449879062362e-05
- O 0 3.400031346245669e-06
phenotype O 0 2.3214582256514404e-07
studies O 0 5.275664705095551e-08
were O 0 3.3283469313971636e-09
not O 0 1.1026579649353607e-10
performed O 0 4.467575198674467e-10
on O 0 2.921766828478667e-09
this O 0 8.555306463264856e-10
small O 0 3.6760017252390753e-09
group O 0 2.664371612226546e-09
of O 0 2.491972281859489e-07
BZS B-Disease 1 0.9777862429618835
families O 0 1.7523490214443882e-07
. O 0 7.32914671175422e-08

However O 0 6.104325933620203e-08
, O 0 7.831945647573946e-10
genotype O 0 3.985039143117319e-08
- O 0 2.3833774065451507e-08
phenotype O 0 5.387173018789326e-08
analysis O 0 1.3059382908409134e-08
inthe O 0 8.483579563289823e-07
group O 0 5.945518743999401e-09
of O 0 6.461672796831408e-08
CD B-Disease 0 6.780835519748507e-06
families O 0 2.981212832153801e-09
revealed O 0 2.4252729602380896e-08
two O 0 4.930190145024937e-10
possible O 0 2.297563472808406e-09
associations O 0 3.467818476821094e-09
worthy O 0 6.497612048406154e-08
of O 0 1.146979329291753e-07
follow O 0 1.6791494417134345e-08
- O 0 2.313699809519676e-08
up O 0 8.839336373966944e-09
in O 0 4.15352374716349e-09
independent O 0 2.8413866814958055e-08
analyses O 0 2.784132391298044e-07
. O 0 4.7654754808945654e-08

The O 0 3.528264642227441e-06
first O 0 1.85099381155851e-07
was O 0 9.494952450950223e-07
an O 0 1.9151011443341304e-08
association O 0 1.9574040166503437e-08
noted O 0 7.245994471105632e-09
in O 0 7.0332069057599256e-09
the O 0 1.8533883761051584e-08
group O 0 1.1006036082505943e-09
of O 0 1.2722114917096405e-08
CD B-Disease 0 8.947423339122906e-06
families O 0 2.6665476493548113e-09
with O 0 3.660909131397716e-09
breast B-Disease 1 0.9999855756759644
disease I-Disease 1 0.9992468357086182
. O 0 3.4449774943823286e-07

A O 0 4.540035206446191e-06
correlation O 0 2.9081229513394646e-07
was O 0 9.663883027144493e-09
observed O 0 1.5980521350655863e-09
between O 0 5.691664917151229e-10
the O 0 1.452184483774488e-09
presence O 0 9.81672254596333e-09
/ O 0 2.963701888347714e-07
absence O 0 1.382451557674358e-07
of O 0 1.8980122717948689e-07
a O 0 1.8661660305951955e-07
PTEN O 0 8.274009815067984e-06
mutation O 0 3.3040567504194485e-10
and O 0 9.430521467901354e-12
the O 0 8.806595730437294e-11
type O 0 3.58271989853165e-09
of O 0 7.268532442594733e-08
breast O 0 6.29267015028745e-05
involvement O 0 0.012674319557845592
( O 0 3.6060865227227623e-07
unaffected O 0 7.323875252041034e-06
versus O 0 3.402585571166128e-05
benign O 0 0.0013123881071805954
versus O 0 1.8943621398648247e-05
malignant O 0 0.000794636900536716
) O 0 7.692459114139183e-09
. O 0 1.119252512893354e-08

Specifically O 0 2.3830963868931576e-07
and O 0 1.768545088154383e-09
more O 0 2.293512463280578e-10
directly O 0 2.383776287473438e-09
, O 0 1.0527985150332597e-09
an O 0 9.981741655451515e-09
association O 0 7.852744943193102e-08
was O 0 5.774347187070816e-07
also O 0 1.3429511946938533e-09
observed O 0 3.3297120616282427e-09
between O 0 2.4779314156120336e-09
the O 0 6.027616183956752e-09
presence O 0 5.743216124898254e-09
of O 0 8.070446000374432e-08
a O 0 5.23019366482913e-07
PTEN O 1 0.8918002247810364
mutation O 0 7.025178092590068e-07
and O 0 1.2647987546188233e-07
malignant B-Disease 1 1.0
breast I-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 5.318908620211005e-07

Secondly O 0 0.0005139989079907537
, O 0 4.663143116090396e-08
there O 0 2.680066124582936e-08
appeared O 0 4.0501571874074216e-08
to O 0 2.8303455135159084e-09
be O 0 8.983416677210698e-09
an O 0 6.771204041911005e-09
interdependent O 0 9.327069392384146e-07
association O 0 2.708064439360669e-09
between O 0 1.1677720124225743e-08
mutations O 0 2.9063279782803875e-08
upstream O 0 3.137022588362015e-07
and O 0 3.918997071306052e-10
within O 0 2.79855711937671e-08
the O 0 1.387909946970467e-07
PTPase O 0 0.04283340647816658
core O 0 4.413339411257766e-05
motif O 0 4.437161180703697e-07
, O 0 3.5146555110721067e-10
the O 0 1.8588324213197893e-09
core O 0 8.687472785595673e-08
motif O 0 1.2455314113424265e-08
containing O 0 1.5850951107232447e-10
the O 0 3.1844937797842476e-10
majority O 0 6.164727756052812e-11
of O 0 7.668798929216791e-09
missense O 0 5.367172661863151e-07
mutations O 0 3.6765765987212262e-09
, O 0 2.6620436410773607e-10
and O 0 2.2812877975564305e-10
the O 0 1.1035301561435062e-08
involvement O 0 1.7351982251057052e-06
of O 0 3.7412925735225144e-07
all O 0 4.388568619617672e-09
major O 0 2.038047455243941e-07
organ O 1 0.9613238573074341
systems O 1 0.9915584325790405
( O 0 2.8138867492089048e-05
central O 1 0.9998972415924072
nervous O 1 0.9999997615814209
system O 1 0.921288788318634
, O 0 7.570434377157653e-07
thyroid O 1 1.0
, O 0 8.994246854854282e-06
breast O 1 1.0
, O 0 2.9626229661516845e-05
skin O 1 1.0
and O 1 0.9954742789268494
gastrointestinal O 1 1.0
tract O 1 1.0
) O 0 1.147106468124548e-05
. O 0 5.601798989118834e-07

However O 0 5.820746196150139e-07
, O 0 1.9913168891605437e-09
these O 0 2.915463703789811e-10
observations O 0 4.7277410430979216e-08
would O 0 1.0532945626806622e-09
need O 0 2.3159281159479406e-09
to O 0 1.5008788656345473e-09
be O 0 3.647367297077153e-09
confirmed O 0 3.6606997433352717e-09
by O 0 6.875719438248495e-10
studying O 0 5.034689110061663e-08
a O 0 2.9715390148510323e-09
larger O 0 4.1066036682302354e-10
number O 0 3.173700746650354e-10
of O 0 3.421003258452515e-09
CD B-Disease 0 8.939286999520846e-07
families O 0 9.042346427179382e-09
. O 0 1.7462054913153224e-08

Molecular O 1 0.9999986886978149
defects O 1 0.9999998807907104
leading O 0 8.119101835291076e-07
to O 0 5.215551546200459e-09
human O 0 1.5699111344247285e-08
complement B-Disease 0 8.14189752418315e-06
component I-Disease 1 1.0
C6 I-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 1.0064197653036899e-07
an O 0 1.929292281488415e-09
African O 0 4.22514112585759e-09
- O 0 4.369602280007712e-08
American O 0 6.443507061248965e-08
family O 0 9.366435449464916e-08
. O 0 2.33389307879861e-08

Complement B-Disease 0 0.0001627458696020767
component I-Disease 1 0.9999996423721313
C6 I-Disease 1 1.0
deficiency I-Disease 1 1.0
( O 0 3.936967004847247e-06
C6D B-Disease 0 0.00025249971076846123
) O 0 5.644241074520551e-09
was O 0 1.290455884372932e-07
diagnosed O 0 1.780806968554316e-07
in O 0 2.550210709273415e-08
a O 0 1.0632243174768519e-07
16 O 0 1.1575438918498548e-07
- O 0 4.494868921511852e-09
year O 0 1.4811010196069674e-08
- O 0 2.1424892082677616e-08
old O 0 1.7666430949248024e-06
African O 0 4.277690550225088e-06
- O 0 1.0149088893740554e-06
American O 0 4.284792609610122e-08
male O 0 4.9972026516798e-09
with O 0 4.455534274860895e-10
meningococcal B-Disease 1 1.0
meningitis I-Disease 1 1.0
. O 0 5.541364771488588e-07

The O 0 1.4345272347782156e-06
patients O 0 7.511973620921708e-08
father O 0 1.7055961620826565e-07
and O 0 2.3186297326560634e-08
two O 0 3.995412356516681e-08
brothers O 0 3.1387960916617885e-05
also O 0 2.924228112988203e-07
had O 0 3.2910988920775708e-06
C6D B-Disease 1 0.7355561256408691
, O 0 9.008056522930019e-09
but O 0 1.3707792678729902e-09
gave O 0 6.897251214610378e-09
no O 0 4.115984442165654e-09
history O 0 1.748658817746218e-08
of O 0 1.2340264277099777e-07
meningitis B-Disease 1 1.0
or O 0 3.2492439459019806e-06
other O 0 1.664389159827806e-08
neisserial B-Disease 0 0.44486573338508606
infection I-Disease 1 0.9998581409454346
. O 0 7.765950158500345e-07

By O 0 4.543173659499189e-08
using O 0 1.8081287578297633e-08
exon O 0 2.832917722628281e-08
- O 0 1.954097994527615e-09
specific O 0 4.676311560203317e-10
polymerase O 0 8.117869043644532e-09
chain O 0 1.7571902821700291e-09
reaction O 0 3.206080678719303e-10
( O 0 9.594363081788515e-10
PCR O 0 6.45308195768024e-10
) O 0 1.993732956506733e-10
/ O 0 1.3426003642180717e-09
single O 0 9.304782500052511e-10
- O 0 4.102824302520958e-09
strand O 0 7.885957664655052e-09
conformation O 0 1.7175592059714972e-09
polymorphism O 0 1.6534564828418752e-09
as O 0 9.938526564223782e-12
a O 0 2.2980917516179922e-11
screening O 0 7.202963919761274e-12
step O 0 3.499282461016939e-11
and O 0 8.521976527231523e-12
nucleotide O 0 3.3558720247128804e-09
sequencing O 0 6.59168830630108e-10
of O 0 5.8449409756633486e-09
target O 0 1.5753943927165892e-08
exons O 0 2.6840398792415954e-09
, O 0 1.3240605833964025e-10
we O 0 9.527946209786364e-10
determined O 0 1.421172335369647e-08
that O 0 1.2278659200504194e-09
the O 0 3.770117729118283e-08
proband O 0 2.528122649891884e-06
was O 0 6.784210881960462e-07
a O 0 6.686692444191067e-08
compound O 0 3.5376712048673653e-07
heterozygote O 0 2.627117225983966e-07
for O 0 3.749548227460764e-09
two O 0 4.931624530968293e-08
C6 O 0 0.001897210837341845
gene O 0 2.9068002049825736e-07
mutations O 0 7.630007559100704e-08
. O 0 3.927966218952861e-08

The O 0 4.54869706345562e-07
first O 0 3.0536760675659025e-08
, O 0 2.5188644503515434e-09
1195delC O 0 3.021342820375139e-07
located O 0 3.556549543759502e-08
in O 0 1.2210260358358482e-08
exon O 0 1.4697465644530894e-07
7 O 0 1.8500584531011555e-07
, O 0 5.777591738365118e-10
is O 0 3.9776765214938337e-10
a O 0 1.6351158205196725e-09
novel O 0 4.8096508997730325e-09
mutation O 0 4.3516160119771996e-10
, O 0 8.947207558174242e-11
while O 0 6.659500173533672e-10
the O 0 2.5756339283589114e-09
second O 0 4.393998409568667e-08
, O 0 1.3191809866697213e-09
1936delG O 0 6.761088400253357e-08
in O 0 1.1618689121917214e-08
exon O 0 4.8815756770181906e-08
12 O 0 2.690027045559873e-08
, O 0 3.208980581259624e-10
has O 0 2.644145180585866e-10
been O 0 4.129609987302274e-10
described O 0 3.4200182685850677e-09
before O 0 1.1756969620080326e-08
to O 0 1.4763203992629315e-08
cause O 0 1.536145873615169e-06
C6D B-Disease 0 0.0006225496181286871
in O 0 7.344340691162188e-09
an O 0 3.2476632494393698e-09
unrelated O 0 1.2638653856811288e-07
African O 0 1.3576014623595256e-07
- O 0 6.989679235402946e-08
American O 0 6.827139031884144e-08
individual O 0 1.2345405586700053e-08
. O 0 3.507413026682116e-08

Both O 0 2.8329338874755194e-08
mutations O 0 6.887824977042101e-09
result O 0 4.981329571052129e-09
in O 0 6.350495684870339e-09
premature O 0 3.0121907457214547e-07
termination O 0 4.6855348045937717e-07
codons O 0 3.2681651873645023e-07
and O 0 3.3686994527215575e-08
C6 O 0 0.00023454402980860323
null O 0 4.968658686266281e-06
alleles O 0 1.3442375745853496e-07
. O 0 1.0320820820197696e-07

Allele O 0 4.4463786252890714e-07
- O 0 1.1272904032466613e-07
specific O 0 1.5230559924361842e-08
PCR O 0 6.08113097655405e-08
indicated O 0 7.200338103530157e-09
that O 0 1.4989670615861428e-10
the O 0 9.416947222007366e-09
probands O 0 2.5775623271329096e-06
two O 0 2.4651953367538226e-08
brothers O 0 7.979836595950474e-07
also O 0 9.302852710391107e-09
inherited O 0 1.6955411297203682e-07
the O 0 9.683242296887329e-08
1195delC O 0 1.8585041061669472e-07
mutation O 0 7.80817077661311e-10
from O 0 9.25317378275281e-10
their O 0 6.612743685963096e-10
heterozygous O 0 1.4017327742976704e-08
mother O 0 1.0126387728348618e-08
and O 0 3.8814967906475317e-10
the O 0 6.030836274817375e-09
1936delG O 0 1.7702713250855595e-07
mutation O 0 1.6253709489433277e-09
from O 0 2.039916680018905e-09
their O 0 8.892888092582041e-10
homozygous O 0 1.8723406824960875e-08
father O 0 1.3260034847917268e-07
. O 0 1.170983754406052e-08
. O 0 5.211586895370601e-08

PAX6 O 0 0.018035106360912323
mutations O 0 5.970970960333943e-06
reviewed O 0 6.728939752065344e-06
. O 0 2.8128113171987934e-07

Mutations O 0 2.005131818805239e-06
in O 0 6.856409129341046e-08
PAX6 O 0 0.0005173616809770465
are O 0 6.192179657915631e-09
responsible O 0 3.621277144816304e-08
for O 0 2.381982078247802e-08
human O 0 0.0006942776381038129
aniridia B-Disease 1 1.0
and O 0 2.6261173502462043e-07
have O 0 1.6935259861128316e-09
also O 0 1.3400566767352018e-10
been O 0 1.660801079994556e-10
found O 0 4.976632994591057e-11
in O 0 8.22407003608916e-11
patients O 0 1.0688835927474827e-10
with O 0 2.2522299303329163e-10
Peters B-Disease 1 1.0
anomaly I-Disease 1 1.0
, O 0 6.606471174563922e-07
with O 0 0.00020197338017169386
congenital B-Disease 1 1.0
cataracts I-Disease 1 1.0
, O 0 1.0648778925315128e-06
with O 0 3.864754205551435e-07
autosomal B-Disease 1 1.0
dominant I-Disease 1 1.0
keratitis I-Disease 1 1.0
, O 0 3.098813650126431e-08
and O 0 1.2851276487424457e-08
with O 0 1.3291803497850196e-06
isolated B-Disease 1 1.0
foveal I-Disease 1 1.0
hypoplasia I-Disease 1 1.0
. O 0 0.0006653940072283149

No O 0 3.883896170009393e-06
locus O 0 6.347821681629284e-07
other O 0 2.871150817096435e-10
than O 0 3.1644042941536554e-10
chromosome O 0 1.7827670006909102e-08
11p13 O 0 2.0410429613093584e-07
has O 0 3.616422938890196e-09
been O 0 1.6111673772911672e-08
implicated O 0 1.6450620421437634e-07
in O 0 2.85212763628806e-07
aniridia B-Disease 1 1.0
, O 0 5.0949111596310104e-08
and O 0 2.2814466760223695e-08
PAX6 O 0 0.014996958896517754
is O 0 3.7178313760932724e-08
clearly O 0 1.092320456308471e-08
the O 0 1.4022942806946048e-08
major O 0 6.547187325622872e-08
, O 0 8.479472679567834e-10
if O 0 6.37718378104779e-10
not O 0 2.2424952172972468e-10
only O 0 3.6881919740494595e-10
, O 0 3.0458607858108167e-10
gene O 0 2.2301096525012554e-09
responsible O 0 1.0184520959910515e-07
. O 0 1.7031776167186763e-07

Twenty O 0 1.083286952052731e-05
- O 0 8.241890014915043e-08
eight O 0 1.3933920683939505e-08
percent O 0 2.3032367124642406e-09
of O 0 3.119204894375116e-09
identified O 0 3.83883467236501e-08
PAX6 O 0 1.1278284546278883e-05
mutations O 0 7.651880018499924e-09
are O 0 1.570778951354157e-09
C O 0 5.499130111275008e-06
- O 0 8.54163499752758e-06
T O 0 8.699923341737303e-07
changes O 0 3.4058857956154043e-09
at O 0 3.2595838206361805e-07
CpG O 0 5.037368737248471e-06
dinucleotides O 0 1.3923431652074214e-07
, O 0 1.4276477222630035e-10
20 O 0 6.810784158872707e-10
% O 0 1.703314711498649e-10
are O 0 8.679158086666305e-12
splicing O 0 6.457231416234777e-10
errors O 0 4.809259124272103e-08
, O 0 5.549400522442127e-11
and O 0 2.3794764769657917e-11
more O 0 9.147315717383808e-12
than O 0 1.970369006842887e-11
30 O 0 1.4473289233762898e-09
% O 0 5.167041239317882e-10
are O 0 9.23729912005733e-11
deletion O 0 3.830640693536225e-09
or O 0 5.540300218598304e-09
insertion O 0 8.585720223663884e-08
events O 0 1.263986035837661e-07
. O 0 2.0105495934785722e-07

There O 0 1.8126958138964255e-06
is O 0 3.3462224990898903e-08
a O 0 5.924692558778588e-08
noticeably O 0 1.6045821382704162e-07
elevated O 0 4.9208946251155794e-08
level O 0 1.4011143889547384e-07
of O 0 1.4358144895254554e-08
mutation O 0 1.9677797169492806e-09
in O 0 3.634616607683938e-09
the O 0 4.88971751977374e-09
paired O 0 2.731107073827843e-08
domain O 0 7.51399440446221e-08
compared O 0 9.07347474932152e-10
with O 0 1.609696577420383e-11
the O 0 1.7829939746860646e-09
rest O 0 2.478140714856636e-08
of O 0 5.48512240072796e-08
the O 0 6.153329223934634e-08
gene O 0 5.090617349878812e-08
. O 0 5.8197478836063965e-08

Increased O 0 2.864410078018409e-07
mutation O 0 7.637896537460165e-09
in O 0 2.371215002128224e-09
the O 0 1.0323867982720003e-08
homeodomain O 0 2.6731338493846124e-06
is O 0 9.860291472207905e-10
accounted O 0 4.318116531010219e-09
for O 0 2.7377489164592816e-10
by O 0 1.0189330490462112e-09
the O 0 4.661906771730173e-08
hypermutable O 0 1.4229824046196882e-05
CpG O 0 3.0127963327686302e-05
dinucleotide O 0 4.002543391834479e-06
in O 0 3.3218288564285103e-08
codon O 0 3.5491234484652523e-07
240 O 0 3.1463738991988066e-07
. O 0 1.6082688958363178e-08

Very O 0 1.684499153498109e-07
nearly O 0 1.7987176192946208e-08
all O 0 6.192932833215536e-10
mutations O 0 4.149024179778138e-10
appear O 0 2.2428383594785828e-09
to O 0 8.209186108665278e-10
cause O 0 2.0120555177527422e-07
loss O 0 5.982023481010401e-07
of O 0 5.304993351273879e-07
function O 0 6.63537718992302e-07
of O 0 2.8214211411636825e-08
the O 0 3.9125387374383536e-09
mutant O 0 5.367569944070283e-09
allele O 0 1.1631227231356789e-10
, O 0 6.815676061727727e-12
and O 0 2.2102332984663686e-12
more O 0 9.36973697414356e-13
than O 0 4.026540819518365e-12
80 O 0 1.1895817664253627e-10
% O 0 4.1972730846495665e-11
of O 0 2.8530924844893946e-10
exonic O 0 7.543201974158364e-08
substitutions O 0 8.201364920523702e-09
result O 0 1.5156691901552222e-08
in O 0 2.7481576125865104e-08
nonsense O 0 3.685998763103271e-06
codons O 0 1.1370958645784413e-06
. O 0 1.1075179884301178e-07

In O 0 1.2116403240725049e-06
a O 0 6.546275699292892e-08
gene O 0 7.511793964631863e-10
with O 0 3.2739744942889004e-11
such O 0 1.6451191797717257e-10
extraordinarily O 0 5.2635634517628205e-08
high O 0 1.3636633156011158e-08
sequence O 0 3.1365479102873906e-09
conservation O 0 1.008977124072885e-09
throughout O 0 5.413006848309365e-11
evolution O 0 4.9201570595514e-10
, O 0 5.714055530819939e-12
there O 0 4.172448844763643e-11
are O 0 3.617433436131634e-11
presumed O 0 3.2073415923150606e-07
undiscovered O 0 8.239196904469281e-05
missense O 0 3.5950201890955213e-06
mutations O 0 3.276670490492961e-09
, O 0 9.314135573923465e-11
these O 0 1.280455602659103e-10
are O 0 1.800892213132954e-10
hypothesized O 0 1.3967393464042743e-08
to O 0 9.362516317779068e-10
exist O 0 5.771309119495527e-08
in O 0 1.552624695477789e-08
as O 0 4.563391442502507e-08
- O 0 4.467971947974547e-08
yet O 0 1.7618964065491127e-08
unidentified O 0 6.133595888968557e-06
phenotypes O 0 1.3014815181122685e-07
. O 0 4.3074801503451e-09
. O 0 2.2310297609351437e-08

Genetic O 0 1.091811282094568e-05
heterogeneity O 0 5.901458735024789e-07
and O 0 3.585249208626351e-09
penetrance O 0 4.200653165753465e-06
analysis O 0 3.012526761381196e-08
of O 0 1.5245092299664975e-08
the O 0 2.894467421299396e-08
BRCA1 O 0 1.4391956426607067e-07
and O 0 6.258447093898667e-09
BRCA2 O 0 2.179820484116135e-07
genes O 0 1.3619970040679164e-08
in O 0 5.379574474773108e-08
breast B-Disease 1 0.9995943903923035
cancer I-Disease 1 0.9998639822006226
families O 0 9.769149755811668e-07
. O 0 1.693001081548573e-07

The O 0 0.001245274324901402
Breast B-Disease 1 1.0
Cancer I-Disease 1 1.0
Linkage O 1 0.9999995231628418
Consortium O 0 1.3868655514670536e-05
. O 0 2.2991560655327703e-08

The O 0 7.170955740321006e-08
contribution O 0 9.656388755274747e-08
of O 0 1.0049772924958233e-07
BRCA1 O 0 3.310943270662392e-07
and O 0 8.136672668968004e-09
BRCA2 O 0 6.756718903488945e-06
to O 0 5.816784209855541e-07
inherited B-Disease 1 1.0
breast I-Disease 1 1.0
cancer I-Disease 1 1.0
was O 0 0.37663358449935913
assessed O 0 3.449198686666932e-07
by O 0 1.6314087858404491e-09
linkage O 0 3.928363412342151e-08
and O 0 2.5622204011255256e-11
mutation O 0 4.751635890309913e-11
analysis O 0 2.637989549025832e-10
in O 0 9.284886054450325e-11
237 O 0 1.429948603970388e-09
families O 0 7.864064954787864e-11
, O 0 1.683472979074896e-11
each O 0 3.811476481652143e-11
with O 0 2.3588122774476084e-11
at O 0 3.3769598672961365e-08
least O 0 8.265653717032251e-10
four O 0 1.7298476540084096e-10
cases O 0 3.2906982694314024e-10
of O 0 4.6999947045378576e-08
breast B-Disease 0 0.061764877289533615
cancer I-Disease 0 1.868575236585457e-05
, O 0 2.195588433284712e-10
collected O 0 2.2770634267033074e-09
by O 0 1.0721797893964435e-09
the O 0 4.1304775777462055e-07
Breast B-Disease 1 1.0
Cancer I-Disease 1 1.0
Linkage O 0 0.2717795670032501
Consortium O 0 2.7386977308196947e-07
. O 0 3.4479201715953423e-09

Families O 0 6.82040251831495e-07
were O 0 3.047363250630042e-08
included O 0 7.769044962913085e-09
without O 0 1.593101295327415e-08
regard O 0 5.866131047582712e-08
to O 0 1.4318891627951302e-09
the O 0 4.553382115801696e-09
occurrence O 0 4.410432211443549e-06
of O 0 0.00030073587549850345
ovarian B-Disease 1 1.0
or I-Disease 0 0.006342388689517975
other I-Disease 0 1.3901977524710674e-07
cancers I-Disease 1 0.9007549285888672
. O 0 2.4301448320329655e-07

Overall O 0 0.00012719018559437245
, O 0 1.4997728214893868e-07
disease O 0 2.3313707060879096e-05
was O 0 4.82332825413323e-06
linked O 0 1.1203203939658124e-05
to O 0 3.188447550428464e-08
BRCA1 O 0 4.1129101902015464e-08
in O 0 5.614582132551504e-10
an O 0 7.259904483136737e-11
estimated O 0 7.321088180134439e-11
52 O 0 4.114726337434149e-10
% O 0 1.5268938891033201e-10
of O 0 8.913469407012542e-10
families O 0 5.348783083114483e-10
, O 0 5.986602880092562e-11
to O 0 5.586882623198619e-10
BRCA2 O 0 4.83302686760112e-09
in O 0 1.601561216979519e-09
32 O 0 6.617781433959635e-09
% O 0 2.2892381046357713e-10
of O 0 5.26787669041795e-10
families O 0 2.0583711124455562e-10
, O 0 3.2455545195819724e-11
and O 0 5.065350222599463e-11
to O 0 8.438749143913071e-10
neither O 0 6.5402456783658636e-09
gene O 0 1.4331480446827527e-10
in O 0 2.94635538189425e-10
16 O 0 2.9161992820547766e-09
% O 0 1.387312487111103e-10
( O 0 4.0051194999390916e-11
95 O 0 7.100855459185595e-10
% O 0 8.260542944116267e-11
confidence O 0 9.854975502321395e-09
interval O 0 4.702066007666872e-07
[ O 0 2.513829713279847e-06
CI O 0 0.0001722730085020885
] O 0 5.109703238304064e-08
6 O 0 7.561146375678618e-09
% O 0 8.572715454180369e-11
- O 0 3.402921347483989e-11
28 O 0 6.339551661405096e-10
% O 0 7.759203696222627e-11
) O 0 7.926692288662274e-12
, O 0 6.078312766305549e-12
suggesting O 0 1.7288788178859704e-09
other O 0 2.609768512407129e-10
predisposition O 0 8.0453463624508e-07
genes O 0 1.1281131406803979e-07
. O 0 6.745875680280733e-08

The O 0 4.4825341660725826e-07
majority O 0 2.3546387062367558e-09
( O 0 2.259231246526383e-09
81 O 0 2.755122352482431e-08
% O 0 1.0552229090521337e-09
) O 0 1.2668709137297895e-10
of O 0 2.8291957665516065e-09
the O 0 9.981057473851251e-07
breast B-Disease 1 1.0
- I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 3.6212679788150126e-06
were O 0 7.697463111355773e-09
due O 0 9.507600928770898e-09
to O 0 2.5709512296856474e-09
BRCA1 O 0 2.8679283392563093e-09
, O 0 2.5387775215435227e-11
with O 0 7.316282996105983e-12
most O 0 1.8820095482041665e-10
others O 0 1.0705893810358802e-10
( O 0 2.0893027585788815e-10
14 O 0 3.5988694246924524e-09
% O 0 5.700758753945934e-10
) O 0 8.014276742240867e-11
due O 0 6.170663091609185e-09
to O 0 4.556833488322809e-08
BRCA2 O 0 2.9139102935005212e-06
. O 0 2.966863519304752e-07

Conversely O 0 1.3381930330069736e-05
, O 0 1.6628368681992356e-09
the O 0 8.817760965840193e-10
majority O 0 9.467400474694188e-11
of O 0 4.60170745952837e-09
families O 0 6.21883156082248e-10
with O 0 2.4322796554621107e-10
male B-Disease 0 2.1516918025099585e-07
and I-Disease 0 3.348169741457241e-08
female I-Disease 0 1.9789516954915598e-05
breast I-Disease 0 0.32590389251708984
cancer I-Disease 1 0.7846681475639343
were O 0 6.484228833869565e-07
due O 0 8.051609938775073e-07
to O 0 1.2181322617266233e-08
BRCA2 O 0 1.6909993405533896e-08
( O 0 6.911022309985526e-10
76 O 0 6.0982490168726144e-09
% O 0 5.231929334215124e-10
) O 0 4.3196135557366233e-10
. O 0 2.907113882955059e-09

The O 0 1.185147311844048e-06
largest O 0 1.4172735518513946e-07
proportion O 0 1.3968833201261077e-08
( O 0 1.2557330730800231e-09
67 O 0 4.834889377747231e-09
% O 0 3.7616812442742287e-10
) O 0 2.2777821295782985e-11
of O 0 2.9543012480814923e-10
families O 0 2.778794416791186e-10
due O 0 1.3676512367055693e-08
to O 0 1.3468991477694203e-09
other O 0 1.832741042262498e-10
genes O 0 7.029783422041191e-10
was O 0 1.3065760029462581e-08
found O 0 8.568011300447154e-10
in O 0 6.76775302466126e-10
families O 0 6.043508055109115e-11
with O 0 2.596302513258042e-11
four O 0 9.629678388023422e-09
or O 0 5.273347980505605e-09
five O 0 2.0189754312838204e-09
cases O 0 2.1411277195682032e-09
of O 0 7.787371032463852e-06
female O 1 0.9137823581695557
breast B-Disease 1 0.9999997615814209
cancer I-Disease 1 0.9999977350234985
only O 0 2.2023741621524096e-06
. O 0 6.238748539999506e-08

These O 0 1.3078900629182044e-08
estimates O 0 1.4356446698116088e-08
were O 0 1.01478248026865e-09
not O 0 1.2282541650421308e-10
substantially O 0 3.3725682246910083e-09
affected O 0 6.176040789895865e-10
either O 0 6.340797331638726e-10
by O 0 6.193286994360392e-10
changing O 0 1.806646388047284e-08
the O 0 8.189547706649591e-09
assumed O 0 5.558211668699187e-08
penetrance O 0 3.002179198574595e-07
model O 0 1.3734964277034578e-08
for O 0 1.905099633603413e-09
BRCA1 O 0 4.433631239919578e-09
or O 0 5.492948318419622e-10
by O 0 1.8484441755006742e-10
including O 0 1.7699725018971435e-09
or O 0 3.695645744983267e-08
excluding O 0 1.299811060562206e-06
BRCA1 O 0 6.788417294956162e-07
mutation O 0 3.5075469639878065e-08
data O 0 1.6297713045787532e-07
. O 0 1.8110901223167275e-08

Among O 0 6.5326903886386845e-09
those O 0 4.636178385641898e-10
families O 0 5.551224480093708e-10
with O 0 4.4122347442332455e-10
disease O 0 4.034828634758014e-06
due O 0 6.268592551350594e-05
to O 0 1.9895152547633188e-07
BRCA1 O 0 1.4291265415522503e-07
that O 0 3.3377028918479823e-10
were O 0 1.5082195492510664e-09
tested O 0 1.4339462950374582e-10
by O 0 8.115863536772849e-11
one O 0 2.3270986526657822e-10
of O 0 2.628436635010445e-10
the O 0 1.6410264813693232e-10
standard O 0 8.238043580632848e-11
screening O 0 7.65968104915471e-12
methods O 0 1.0137973099899611e-10
, O 0 1.6093220506219197e-11
mutations O 0 2.8992974687724882e-11
were O 0 2.809426857819375e-10
detected O 0 2.2934918408878957e-09
in O 0 7.671107082884987e-10
the O 0 4.26391144614513e-09
coding O 0 1.2764083123784076e-07
sequence O 0 1.2289893902561744e-07
or O 0 3.4980597973799377e-08
splice O 0 1.1539649591441048e-07
sites O 0 6.836162746992613e-10
in O 0 2.8290000897435164e-10
an O 0 3.571882789543679e-10
estimated O 0 7.568429216675554e-10
63 O 0 1.0070396072592303e-08
% O 0 7.775267096832295e-10
( O 0 6.456381540509426e-10
95 O 0 1.6930487234390057e-08
% O 0 3.3089271322950253e-09
CI O 0 4.007879397249781e-06
51 O 0 3.075924226436655e-08
% O 0 9.7224306383481e-10
- O 0 1.6350846232526806e-09
77 O 0 4.830714050996221e-09
% O 0 4.517238250123512e-10
) O 0 3.2044422670907124e-10
. O 0 2.3071853316736224e-09

The O 0 3.411986995160987e-07
estimated O 0 1.6659868151691626e-08
sensitivity O 0 2.5929610458774732e-08
was O 0 1.1775170172256821e-08
identical O 0 3.325756059435747e-10
for O 0 6.465965957103137e-11
direct O 0 3.2486466294834315e-10
sequencing O 0 2.450023794953182e-10
and O 0 4.9589901629509825e-11
other O 0 5.146698345281919e-11
techniques O 0 2.2686289469220355e-07
. O 0 4.175798906658201e-08

The O 0 2.423438672849443e-06
penetrance O 0 9.151449194177985e-05
of O 0 8.049275379562459e-07
BRCA2 O 0 2.9717455163336126e-07
was O 0 8.953433905389829e-08
estimated O 0 1.0799832139696264e-09
by O 0 3.1763833230336047e-10
maximizing O 0 2.2212347516870068e-07
the O 0 6.332500390726636e-08
LOD O 0 0.00011696730507537723
score O 0 1.6959704751684512e-08
in O 0 5.82488635103573e-09
BRCA2 O 0 1.9960065600344024e-08
- O 0 7.032951998553472e-09
mutation O 0 6.636245442059874e-10
families O 0 1.4236750667251385e-10
, O 0 2.547742052050328e-11
over O 0 2.2251968323505622e-10
all O 0 4.988876534106623e-10
possible O 0 5.18785370218211e-08
penetrance O 0 4.4563963456312194e-05
functions O 0 1.7406842971467995e-06
. O 0 6.693213094877137e-08

The O 0 1.0396967553560899e-07
estimated O 0 9.003247036787343e-09
cumulative O 0 3.908363765958711e-08
risk O 0 5.891472198982228e-08
of O 0 1.0196513500204674e-07
breast B-Disease 0 3.0415263609029353e-05
cancer I-Disease 0 2.9715641858274466e-07
reached O 0 3.3835496537903964e-07
28 O 0 5.8191258034412385e-08
% O 0 3.4736885590191946e-10
( O 0 7.244149724527915e-11
95 O 0 1.9957657748648217e-09
% O 0 7.027383119861952e-10
CI O 0 6.538851380355482e-07
9 O 0 2.7865938889704012e-08
% O 0 3.267214276903019e-10
- O 0 1.9913463933374231e-10
44 O 0 2.6793531282542915e-10
% O 0 3.353008842799099e-11
) O 0 1.2957431351837134e-12
by O 0 2.5853605280928837e-12
age O 0 2.6384272544532905e-10
50 O 0 2.909419927199508e-10
years O 0 8.613591784278896e-11
and O 0 6.080832365418232e-11
84 O 0 2.563591783300012e-09
% O 0 1.1005715089273949e-10
( O 0 8.592489914027723e-11
95 O 0 1.9699688547092364e-09
% O 0 6.970754529156409e-10
CI O 0 1.0474769851498422e-06
43 O 0 2.526246589695802e-08
% O 0 5.813850512126351e-10
- O 0 1.1687162349005575e-09
95 O 0 4.109473650260043e-09
% O 0 7.90403506534254e-11
) O 0 4.4617378368305705e-12
by O 0 1.328499463215671e-11
age O 0 2.570446300254048e-09
70 O 0 1.2482949784953234e-08
years O 0 6.4849690062374066e-09
. O 0 2.4798145759064028e-08

The O 0 1.6723723774703103e-06
corresponding O 1 0.9999572038650513
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
risks O 0 0.014503415673971176
were O 0 7.627505027585357e-08
0 O 0 1.6383415513132604e-08
. O 0 2.6712920764282444e-09

4 O 0 3.3632543363637524e-06
% O 0 1.8996868078602347e-08
( O 0 2.960812262031709e-09
95 O 0 1.613353717289101e-08
% O 0 1.994989284881399e-09
CI O 0 1.3987008742333273e-06
0 O 0 3.343273435874039e-09
% O 0 1.441218117070875e-10
- O 0 1.4875629894550713e-10
1 O 0 2.2488697570821614e-09
% O 0 5.974386263485343e-11
) O 0 2.6850340527351246e-12
by O 0 7.813585715943372e-12
age O 0 3.7568625987915993e-10
50 O 0 4.681979248744028e-10
years O 0 2.300443446845435e-10
and O 0 3.165374559688239e-11
27 O 0 1.8398764733973394e-09
% O 0 2.3981264196670793e-10
( O 0 9.743886947299885e-11
95 O 0 1.9902459680309903e-09
% O 0 5.465597974207981e-10
CI O 0 2.744920948316576e-07
0 O 0 1.1075951267258688e-09
% O 0 4.390322480563036e-11
- O 0 4.1148657398126787e-11
47 O 0 7.5159795054347e-10
% O 0 2.110255720166876e-11
) O 0 1.3058658971873416e-12
by O 0 8.549637560417711e-12
age O 0 1.326988963157305e-09
70 O 0 2.0329492755877254e-08
years O 0 1.3065760029462581e-08
. O 0 1.6182509554596436e-08

The O 0 4.12141986316783e-07
lifetime O 0 5.950188551651081e-06
risk O 0 6.737189778505126e-06
of O 0 7.830733920854982e-06
breast B-Disease 1 1.0
cancer I-Disease 1 0.987456738948822
appears O 0 3.962956043324084e-07
similar O 0 9.317142612985663e-10
to O 0 6.371651539716083e-10
the O 0 7.117482603291592e-09
risk O 0 7.946371738398739e-08
in O 0 7.018064351882458e-09
BRCA1 O 0 3.928549041631868e-09
carriers O 0 1.6610006425832324e-10
, O 0 7.717993605327322e-11
but O 0 1.0727355809203587e-10
there O 0 1.504943614172305e-09
was O 0 2.8635080084882247e-08
some O 0 9.780400100911635e-11
suggestion O 0 2.965808709731732e-09
of O 0 5.19579312907581e-09
a O 0 4.81901718529798e-09
lower O 0 1.920540526612058e-08
risk O 0 3.9504765680931087e-08
in O 0 1.2481758737692417e-08
BRCA2 O 0 6.528794216364986e-08
carriers O 0 1.6353653986556083e-09
< O 0 1.0043851261798409e-07
50 O 0 2.3120840797474784e-09
years O 0 1.3199863424517844e-09
of O 0 5.788713508536603e-09
age O 0 9.591462912794668e-08
. O 0 9.720584159822465e-08

Eye B-Disease 1 0.999901533126831
movement I-Disease 0 6.167468654894037e-06
abnormalities I-Disease 0 0.0006529169622808695
correlate O 0 1.4623910260525008e-07
with O 0 1.5062495695161715e-10
genotype O 0 1.9089348768375203e-07
in O 0 3.063833275973593e-08
autosomal O 0 0.051129862666130066
dominant O 0 0.02229847013950348
cerebellar B-Disease 1 1.0
ataxia I-Disease 1 1.0
type I-Disease 1 1.0
I I-Disease 1 0.9999998807907104
. O 0 6.503968506876845e-06

We O 0 6.882495426907553e-07
compared O 0 3.2400305371993454e-07
horizontal O 0 5.002945727028418e-06
eye O 0 2.093592229357455e-05
movements O 0 2.70062827212314e-07
( O 0 1.0824006579923662e-08
visually O 0 4.2938985700402554e-08
guided O 0 1.5348909698786883e-07
saccades O 0 2.711058414206491e-06
, O 0 2.193781156734076e-09
antisaccades O 0 6.891677912790328e-07
, O 0 7.59538487660194e-10
and O 0 1.0791101345830612e-09
smooth O 0 6.607907465649987e-08
pursuit O 0 9.744120461618877e-07
) O 0 1.7384385042618078e-09
in O 0 5.531016755710993e-10
control O 0 3.80228071250599e-09
subjects O 0 1.4496336575575697e-08
( O 0 1.584397613108024e-09
n O 0 1.4858546393270444e-08
= O 0 2.0767419783851437e-08
14 O 0 1.9693791042385556e-09
) O 0 2.2366676219465198e-11
and O 0 4.1485608351377046e-12
patients O 0 3.87349093772249e-12
with O 0 2.6443379278796864e-13
three O 0 2.720351548191058e-11
forms O 0 7.712935290449252e-10
of O 0 5.618762315862114e-06
autosomal O 1 0.9649690389633179
dominant O 0 0.21819236874580383
cerebellar B-Disease 1 0.9999998807907104
ataxias I-Disease 1 0.9999997615814209
type I-Disease 1 1.0
I I-Disease 1 0.999951958656311
spinocerebellar B-Disease 1 0.9924818873405457
ataxias I-Disease 0 0.00014091534831095487
1 I-Disease 0 1.4790340401305002e-06
and I-Disease 0 3.781061685970144e-09
2 I-Disease 0 1.2079502198503178e-07
( O 0 7.293680326370122e-09
SCA1 B-Disease 0 6.606243800888478e-07
, O 0 1.2093760437537071e-09
n O 0 3.4808280702236516e-08
= O 0 4.398509645398008e-08
11 O 0 5.2453805743368775e-09
; O 0 1.3192104353354495e-10
SCA2 B-Disease 0 2.5508902012916224e-07
, O 0 8.830653430713653e-10
n O 0 3.198211118160543e-08
= O 0 3.468283082952439e-08
10 O 0 1.8282589886453593e-09
) O 0 3.7391623131100005e-10
and O 0 2.706953994291439e-09
SCA3 B-Disease 1 1.0
/ O 0 0.00013092115113977343
Machado B-Disease 0 3.3827475363068515e-06
- I-Disease 0 1.5769959418321378e-06
Joseph I-Disease 0 9.465648327022791e-05
disease I-Disease 1 0.927800178527832
( O 0 2.578467217517755e-07
MJD B-Disease 1 1.0
) O 0 7.0507351068727075e-09
( O 0 1.1578972225478878e-09
n O 0 7.992287720526292e-09
= O 0 1.8275070345907807e-08
16 O 0 9.88854687022922e-09
) O 0 1.1435475899546077e-09
. O 0 4.8594630541742845e-09

In O 0 4.41316706201178e-06
SCA1 B-Disease 0 0.000643556471914053
, O 0 3.4867486675693726e-08
saccade O 0 1.2163931387476623e-05
amplitude O 0 2.1213571699263412e-07
was O 0 2.296692791503574e-08
significantly O 0 8.607897172829837e-10
increased O 0 1.2693772699634565e-09
, O 0 1.3986441171898178e-10
resulting O 0 5.220667453897931e-09
in O 0 1.6150872639286717e-08
hypermetria B-Disease 0 1.3095922440697905e-05
. O 0 1.7868921986519126e-07

The O 0 8.069081559369806e-06
smooth O 0 5.203301043366082e-06
pursuit O 0 3.940468741348013e-05
gain O 0 4.9426365876570344e-05
was O 0 3.5593197935668286e-06
decreased O 0 8.048162271734327e-06
. O 0 8.95466385486543e-08

In O 0 1.2156427146692295e-05
SCA2 B-Disease 0 0.0007220198167487979
, O 0 9.788867316729011e-08
saccade O 0 1.9580111256800592e-05
velocity O 0 3.3598753361729905e-06
was O 0 9.981027915273444e-07
markedly O 0 2.9913810521975392e-06
decreased O 0 2.1519103938771877e-06
. O 0 5.007968439940669e-08

The O 0 7.841786668905115e-07
percentage O 0 5.842591690452537e-07
of O 0 6.459750068188441e-08
errors O 0 4.83484982396476e-05
in O 0 2.4806053033898934e-07
antisaccades O 0 0.0003092064580414444
was O 0 3.153428906443878e-06
greatly O 0 6.355539028390922e-08
increased O 0 1.2818203387610083e-08
and O 0 5.228278365798644e-10
was O 0 8.187673650184024e-09
significantly O 0 8.64470328654221e-10
correlated O 0 3.67129326939164e-09
with O 0 8.840300887158481e-12
age O 0 1.858457387982071e-08
at O 0 3.224390070499794e-07
disease O 0 6.632213853663416e-07
onset O 0 8.3248551163706e-06
. O 0 3.47832624925104e-08

In O 0 3.507995813833986e-07
addition O 0 1.7627938220243777e-08
, O 0 6.277560693490614e-10
a O 0 3.5534561959593702e-09
correlation O 0 1.1232859975507381e-08
between O 0 6.542915542695482e-09
smooth O 0 1.54253925188641e-07
pursuit O 0 5.945571956544882e-06
gain O 0 9.178404525300721e-07
and O 0 1.7916486350078031e-10
the O 0 9.970890779698038e-10
number O 0 2.294340495367919e-09
of O 0 1.6158574922542357e-08
trinucleotide O 0 3.409382316021947e-06
repeats O 0 1.0123920191063007e-07
was O 0 4.103378898889787e-07
found O 0 2.4364004147514606e-08
. O 0 3.504403878196172e-08

In O 0 0.00013545075489673764
SCA3 B-Disease 1 1.0
, O 0 8.778608275861188e-07
gaze B-Disease 0 0.00016038210014812648
- I-Disease 0 1.0860963811865076e-05
evoked I-Disease 0 3.893144821631722e-06
nystagmus I-Disease 0 7.721860310994089e-05
was O 0 6.790871225348383e-07
often O 0 1.4756440513963298e-09
present O 0 1.2643126545697214e-09
as O 0 3.643313428725037e-09
was O 0 4.1450661569797376e-07
saccade O 0 1.118202544603264e-05
hypometria O 0 4.810686277778586e-06
and O 0 2.7385612000330184e-08
smooth O 0 2.011818651226349e-06
pursuit O 0 5.0676600949373096e-05
gain O 0 6.650791328866035e-05
was O 0 2.5965250642911997e-06
markedly O 0 1.4192891057973611e-06
decreased O 0 1.4844122233625967e-06
. O 0 2.5912209267175967e-08

Three O 0 2.4300589984704857e-07
major O 0 3.6719672635854295e-08
criteria O 0 1.0272366068875272e-08
, O 0 1.067374522101261e-09
saccade O 0 2.7129465252073715e-06
amplitude O 0 1.3608757853944553e-07
, O 0 1.6990099327429675e-09
saccade O 0 1.940590436788625e-06
velocity O 0 2.251062483082933e-07
, O 0 7.190342765639457e-10
and O 0 2.6296101407474737e-10
presence O 0 1.119290971018927e-08
of O 0 6.410030550796364e-07
gaze B-Disease 0 0.0001603660493856296
- I-Disease 0 1.1065440958191175e-05
evoked I-Disease 0 1.635415173950605e-06
nystagmus I-Disease 0 3.2025961900217226e-06
, O 0 5.273396164184874e-10
permitted O 0 1.3107038787651959e-09
the O 0 1.4507227641402665e-09
correct O 0 1.3825696143499044e-08
assignment O 0 5.691290994036535e-08
of O 0 2.3048595920727166e-08
90 O 0 3.358486111437742e-08
% O 0 1.4812359117044593e-09
of O 0 7.197467954966896e-09
the O 0 1.8202779727971574e-08
SCA1 B-Disease 0 1.2830949344788678e-05
, O 0 1.3234628948310956e-09
90 O 0 9.197295369745007e-09
% O 0 6.045067224569323e-10
of O 0 2.543777410934922e-09
the O 0 7.603099483333153e-09
SCA2 B-Disease 0 4.75601382277091e-06
, O 0 3.379327651042985e-10
and O 0 8.378810145703852e-11
93 O 0 2.748854832645975e-08
% O 0 2.516500896554419e-10
of O 0 2.622377592853553e-10
the O 0 1.9254471350649283e-09
patients O 0 6.727444157306195e-10
with O 0 9.122549382567513e-10
SCA3 B-Disease 1 1.0
to O 0 2.6042123124625505e-08
their O 0 1.2363400303527783e-09
genetically O 0 6.038760463900061e-11
confirmed O 0 9.322190797078633e-10
patient O 0 2.1520236259675585e-08
group O 0 1.7912386851559603e-10
and O 0 1.6028775529086658e-10
, O 0 1.255473780492622e-10
therefore O 0 3.3799418819313587e-09
, O 0 2.2342212802062278e-10
may O 0 1.7363936954950532e-09
help O 0 1.2802590099170175e-08
orient O 0 0.0003267097345087677
diagnoses O 0 8.320214419654803e-07
of O 0 3.7797664731442637e-07
SCA1 B-Disease 0 0.0014758389443159103
, O 0 1.7544886432574458e-08
SCA2 B-Disease 0 0.00013291386130731553
, O 0 5.5961533185211465e-09
and O 0 1.2853115016753236e-08
SCA3 B-Disease 1 1.0
at O 0 9.727982615004294e-07
early O 0 3.657554259461904e-08
clinical O 0 3.523935632188113e-08
stages O 0 1.4635803680107529e-08
of O 0 2.867082216084782e-08
the O 0 6.668224727945926e-08
diseases O 0 5.610829248325899e-05
. O 0 7.22364035254941e-09
. O 0 5.279198234120486e-08

Genetic O 0 4.2248450426995987e-07
basis O 0 2.5189235586253744e-08
and O 0 6.439529465218641e-11
molecular O 0 7.163106552354748e-09
mechanism O 0 2.1116746040661383e-07
for O 0 1.1551754823813098e-06
idiopathic B-Disease 1 1.0
ventricular I-Disease 1 1.0
fibrillation I-Disease 1 1.0
. O 0 2.639367039591889e-06

Ventricular B-Disease 1 1.0
fibrillation I-Disease 1 0.9999988079071045
causes O 0 6.547574571413861e-07
more O 0 2.9818708613404965e-10
than O 0 2.864040393735223e-10
300 O 0 2.3390034353809597e-09
, O 0 1.1200009669698474e-10
000 O 0 2.6370615913151596e-08
sudden O 0 1.898737700400943e-08
deaths O 0 1.4469589970644847e-09
each O 0 1.1154217133269029e-10
year O 0 7.002483592977171e-10
in O 0 2.3762496415002943e-09
the O 0 4.188641966607065e-08
USA O 0 3.408565589779755e-07
alone O 0 5.1846487991724644e-08
. O 0 2.7321334528096486e-08

In O 0 2.650182580055116e-07
approximately O 0 1.7507845839759284e-08
5 O 0 2.1859632326481915e-08
- O 0 1.9055574895787686e-09
12 O 0 2.4487825101005e-09
% O 0 7.06480846046631e-11
of O 0 7.048733992320866e-12
these O 0 1.5914613377132625e-12
cases O 0 1.1495165930242024e-11
, O 0 5.417373147298399e-12
there O 0 9.809076467748312e-11
are O 0 4.6579004542302016e-11
no O 0 2.6315081225192216e-09
demonstrable O 0 1.1105455996585079e-05
cardiac O 0 0.44657430052757263
or O 0 2.459963468481874e-07
non O 0 0.045977573841810226
- O 1 0.5294357538223267
cardiac O 1 1.0
causes O 0 1.047179353008687e-06
to O 0 3.0124560623789876e-09
account O 0 2.2814292677253434e-08
for O 0 5.207279052399372e-10
the O 0 4.938870645787574e-09
episode O 0 1.0984737741637218e-07
, O 0 1.7501543617126636e-11
which O 0 5.381490066937167e-13
is O 0 3.1739438551350863e-13
therefore O 0 7.527577519650386e-12
classified O 0 4.784194707063705e-10
as O 0 6.137550023765925e-09
idiopathic B-Disease 1 1.0
ventricular I-Disease 1 1.0
fibrillation I-Disease 1 1.0
( O 1 0.9925177097320557
IVF B-Disease 1 1.0
) O 0 1.0333584299360155e-07
. O 0 4.682456733462459e-08

A O 0 1.5856975323913503e-06
distinct O 0 2.7348759701339986e-08
group O 0 9.86262893576395e-09
of O 0 1.760952545737382e-05
IVF B-Disease 1 1.0
patients O 0 2.9821806037944043e-06
has O 0 3.811492788052817e-10
been O 0 6.171260169551829e-10
found O 0 2.0317456050911176e-10
to O 0 9.52341747129104e-11
present O 0 2.4071220017241046e-10
with O 0 1.6240654654442466e-10
a O 0 5.903744337842909e-08
characteristic O 0 3.0929621175346256e-07
electrocardiographic O 0 7.214968354674056e-05
pattern O 0 1.0610111530695576e-05
. O 0 1.5589148461003788e-07

Because O 0 5.623493279927061e-07
of O 0 1.7610622649044672e-07
the O 0 2.040941105008187e-08
small O 0 3.6940301928467534e-09
size O 0 9.494154795675058e-09
of O 0 2.28460805828945e-08
most O 0 8.319763766806432e-10
pedigrees O 0 2.8259881545977805e-08
and O 0 8.203047269228492e-11
the O 0 6.798194229773458e-10
high O 0 8.04939670473459e-09
incidence O 0 2.58492775628838e-07
of O 0 1.0128879068815877e-08
sudden B-Disease 0 6.748437186843148e-08
death I-Disease 0 4.553998955714178e-09
, O 0 1.108697335328035e-11
however O 0 1.6222101786866894e-11
, O 0 1.0757449618592485e-11
molecular O 0 1.3437275736549736e-09
genetic O 0 9.508848153316762e-10
studies O 0 4.698522015900153e-09
of O 0 3.847822256375366e-07
IVF B-Disease 1 1.0
have O 0 1.2743620048105697e-10
not O 0 4.382274057523894e-11
yet O 0 5.205094133486909e-10
been O 0 1.9186101596346816e-09
done O 0 3.947283033767235e-08
. O 0 3.1898224506221595e-08

Because O 0 9.732466423884034e-06
IVF B-Disease 1 1.0
causes O 0 0.0002723900252021849
cardiac O 1 1.0
rhythm O 1 0.9999527931213379
disturbance O 1 0.6649563312530518
, O 0 9.288114721783813e-10
we O 0 2.043764268933046e-09
investigated O 0 1.5101927886007616e-07
whether O 0 2.0274816492360515e-08
malfunction O 0 0.003524061059579253
of O 0 1.3671824206085148e-07
ion O 0 1.2826428701373516e-06
channels O 0 1.665339368628338e-06
could O 0 3.2826319440459883e-09
cause O 0 7.689234848839988e-08
the O 0 3.721774666232136e-09
disorder O 0 9.808263534694106e-09
by O 0 1.091956872145694e-10
studying O 0 3.960025640736831e-09
mutations O 0 3.138808657432435e-10
in O 0 1.658458509412597e-10
the O 0 6.905873206619617e-09
cardiac O 0 1.4844084034848493e-05
sodium O 0 1.392449462400691e-07
channel O 0 2.8199876851431327e-06
gene O 0 7.983256722354781e-08
SCN5A O 0 5.698383029084653e-05
. O 0 9.212994456220258e-08

We O 0 6.167459787320695e-07
have O 0 3.19346127319875e-09
now O 0 1.8776038501755465e-09
identified O 0 7.645009070245123e-09
a O 0 2.43916229436536e-08
missense O 0 2.5797166358643153e-07
mutation O 0 3.329343689628672e-09
, O 0 4.5901690781668947e-10
a O 0 1.108373393066131e-08
splice O 0 1.5952822707276937e-07
- O 0 1.4241708257145547e-08
donor O 0 4.021006194676602e-09
mutation O 0 4.8555143239426e-10
, O 0 5.7678663928362184e-11
and O 0 8.211437085847706e-11
a O 0 1.0935670147205201e-08
frameshift O 0 5.107121978653595e-07
mutation O 0 1.1977695502096708e-09
in O 0 8.481591540210331e-10
the O 0 4.917514395685885e-09
coding O 0 8.12171379038773e-08
region O 0 1.5977756007146127e-08
of O 0 2.7703779892362945e-07
SCN5A O 0 0.0007281947182491422
in O 0 5.092773491810476e-08
three O 0 2.5221021360266604e-07
IVF B-Disease 1 1.0
families O 0 6.945475750086416e-09
. O 0 7.14512182753424e-09

We O 0 2.85813683831293e-07
show O 0 1.3765124151632335e-08
that O 0 6.182119399733566e-11
sodium O 0 7.561489212548622e-10
channels O 0 1.6855405959859127e-09
with O 0 1.2372494521961652e-11
the O 0 1.5183418966557838e-09
missense O 0 6.677948931610445e-07
mutation O 0 1.0946745732098861e-09
recover O 0 2.4389578356931452e-08
from O 0 7.985381800246216e-10
inactivation O 0 1.1039091418751923e-08
more O 0 7.6646354194021e-12
rapidly O 0 2.8277269414900275e-10
than O 0 5.038889444586303e-11
normal O 0 1.5195268376899662e-09
and O 0 2.1569721703196265e-11
that O 0 2.319572832421013e-11
the O 0 1.1207003103308466e-09
frameshift O 0 3.972138813423953e-07
mutation O 0 4.0365491504879003e-10
causes O 0 2.2017991596623432e-10
the O 0 3.419370897539409e-10
sodium O 0 1.5579842971291669e-09
channel O 0 1.2540366967073169e-08
to O 0 2.0719367888055729e-10
be O 0 1.8015355873757244e-09
non O 0 2.841273669673683e-07
- O 0 1.128934854932595e-06
functional O 0 1.3307416338648181e-05
. O 0 1.1381771969354304e-07

Our O 0 3.649658992799232e-07
results O 0 6.213404013521995e-09
indicate O 0 2.6062876301580218e-09
that O 0 3.2460128335243255e-11
mutations O 0 1.920553160950078e-10
in O 0 4.3561587670382096e-10
cardiac O 0 1.48464408766813e-07
ion O 0 1.9472795997899084e-07
- O 0 1.8578321032691747e-05
channel O 0 6.5528718096175e-07
genes O 0 7.419664882490906e-10
contribute O 0 1.1683233547277183e-10
to O 0 1.4158543781839228e-10
the O 0 6.503098615162628e-10
risk O 0 6.7490133481840076e-09
of O 0 2.164971490969947e-08
developing O 0 2.896864543799893e-06
IVF B-Disease 1 1.0
. O 0 6.2707665726691175e-09
. O 0 7.1922396926993315e-09

Molecular O 0 9.509891242487356e-06
heterogeneity O 0 1.5688597159169149e-06
in O 0 4.475042203466728e-08
mucopolysaccharidosis B-Disease 0 8.173146852641366e-06
IVA I-Disease 0 0.00044689621427096426
in O 0 2.5709724127409572e-08
Australia O 0 3.354847954994966e-09
and O 0 7.668791990322887e-11
Northern O 0 2.1671353600538623e-09
Ireland O 0 9.453294813610569e-10
: O 0 2.1527399307608164e-10
nine O 0 1.3367489337667848e-09
novel O 0 1.6995381768580842e-09
mutations O 0 3.662143643889948e-10
including O 0 1.832290152936622e-10
T312S O 0 1.4162236539050355e-07
, O 0 9.180255444718455e-10
a O 0 4.4421972766883755e-09
common O 0 1.2188869913387634e-09
allele O 0 2.977428081862854e-09
that O 0 2.1775591052541898e-10
confers O 0 2.6681259868155394e-08
a O 0 1.4716760254884775e-08
mild O 0 9.735651218534258e-08
phenotype O 0 3.86826826570541e-07
. O 0 1.6824964532702325e-08

Mucopolysaccharidosis B-Disease 1 0.6683886647224426
IVA I-Disease 1 0.9999990463256836
( O 0 0.00010891685087699443
MPS B-Disease 1 1.0
IVA I-Disease 1 1.0
) O 0 4.089138982976692e-08
is O 0 8.270669149545995e-10
an O 0 6.367925298178534e-09
autosomal B-Disease 1 0.999998927116394
recessive I-Disease 1 1.0
lysosomal I-Disease 1 1.0
storage I-Disease 1 1.0
disorder I-Disease 1 1.0
caused O 1 0.999896764755249
by O 0 6.235620020333954e-08
a O 0 6.449692591559142e-05
genetic B-Disease 1 1.0
defect I-Disease 1 1.0
in O 0 5.213008762439131e-07
N O 0 7.186536095105112e-06
- O 0 1.5725311186542967e-07
acetylgalactosamine O 0 3.717445679285447e-06
- O 0 1.6445269466203172e-06
6 O 0 1.0410583854536526e-05
- O 0 9.400562817063474e-07
sulfate O 0 1.4144816304906271e-05
sulfatase O 1 0.9554089307785034
( O 0 8.074416655290406e-07
GALNS O 0 0.00015635433373972774
) O 0 2.7027404314594605e-08
. O 0 2.0670363198860287e-08

Previous O 0 2.4576986561442027e-06
studies O 0 7.527176393296031e-08
of O 0 1.8732551509970108e-08
patients O 0 1.0438407915813741e-09
from O 0 2.0144903523089397e-09
a O 0 9.26363252773399e-09
British O 0 1.9203231715891889e-07
- O 0 1.2174487551419588e-07
Irish O 0 1.2739590715682425e-07
population O 0 3.2364444457755326e-10
showed O 0 6.206412606069023e-10
that O 0 2.6749397835645894e-11
the O 0 1.0338602196569013e-09
I113F O 0 8.74277645834809e-08
mutation O 0 1.9540523366057272e-10
is O 0 2.5637160797065128e-11
the O 0 5.097119601393807e-11
most O 0 8.112486377109818e-12
common O 0 1.0705541488020831e-11
single O 0 6.86848078412794e-11
mutation O 0 2.583365292518902e-11
among O 0 1.8539983437371177e-10
MPS B-Disease 1 1.0
IVA I-Disease 1 1.0
patients O 0 1.6390769815188833e-05
and O 0 1.9629053937819663e-10
produces O 0 1.2183727637893327e-10
a O 0 1.6312657891148774e-09
severe O 0 5.8325046126128655e-08
clinical O 0 4.3368638102947443e-07
phenotype O 0 6.258736107156437e-08
. O 0 8.514060567677006e-09

We O 0 9.302252124143706e-08
studied O 0 2.3119534375837247e-07
mutations O 0 1.0661197258343691e-08
in O 0 6.827630461003764e-09
the O 0 4.367685946249367e-08
GALNS O 0 2.59467851719819e-05
gene O 0 2.0340267248286636e-09
from O 0 1.3639460672010273e-09
23 O 0 1.979234731663837e-08
additional O 0 1.6818097137161203e-08
MPS B-Disease 1 1.0
IVA I-Disease 1 1.0
patients O 0 2.9546531550295185e-06
( O 0 8.185920830072746e-10
15 O 0 4.956364207941988e-10
from O 0 3.489938893430633e-10
Australia O 0 1.0630529789779075e-09
, O 0 4.7835176791855005e-11
8 O 0 1.6568406646655376e-09
from O 0 4.94694785135863e-10
Northern O 0 3.522529379296202e-09
Ireland O 0 2.562066558908782e-09
) O 0 1.1101050634287901e-10
, O 0 1.830325387780496e-12
with O 0 7.359498752600169e-13
various O 0 1.2108158919943435e-10
clinical O 0 3.402348738745786e-05
phenotypes O 0 1.7756221950548934e-06
( O 0 3.860308961378678e-09
severe O 0 6.639771044092413e-08
, O 0 4.111813667329045e-11
16 O 0 9.091958852458504e-10
cases O 0 1.0892754753744072e-10
; O 0 1.0561340864356783e-11
intermediate O 0 2.6222939375486476e-09
, O 0 5.757600646250083e-11
4 O 0 1.9388097793893166e-09
cases O 0 1.0942773770450387e-10
; O 0 1.1457188496544202e-11
mild O 0 7.024020254320362e-10
, O 0 5.999017255176042e-11
3 O 0 4.0928198608014554e-09
cases O 0 4.617302096221465e-10
) O 0 2.31128907679512e-10
. O 0 1.689003270577416e-09

We O 0 3.159459538437659e-07
found O 0 4.234911088474291e-09
two O 0 4.566878819556308e-10
common O 0 2.5748514431711556e-10
mutations O 0 4.639017781027377e-10
that O 0 2.4733487827277578e-11
together O 0 1.4273973669709505e-10
accounted O 0 1.2246132108373331e-08
for O 0 8.001054263573337e-10
32 O 0 2.9247178900959625e-08
% O 0 1.4753765986696976e-09
of O 0 9.846909954092098e-10
the O 0 1.0448945042540458e-09
44 O 0 2.2969632862412936e-09
unrelated O 0 3.967986828001813e-09
alleles O 0 3.060639242047358e-11
in O 0 8.19155507314484e-11
these O 0 1.711968761197724e-10
patients O 0 1.6506205291477727e-09
. O 0 7.3695702873521896e-09

One O 0 1.01108048511378e-06
is O 0 9.872678674582858e-09
the O 0 1.2299714136077e-08
T312S O 0 5.485069891619787e-07
mutation O 0 5.221643117891972e-09
, O 0 2.2855821402156806e-10
a O 0 4.181517632151355e-10
novel O 0 2.6124342689115565e-09
mutation O 0 1.6638924960066248e-10
found O 0 3.61637803036885e-11
exclusively O 0 2.887230177162081e-10
in O 0 5.621954568546528e-10
milder O 0 6.980004574330678e-09
patients O 0 1.776636437966772e-08
. O 0 9.721990323896534e-09

The O 0 2.096723619615659e-06
other O 0 9.026975611448051e-09
is O 0 3.1082416640515476e-09
the O 0 4.516680807142848e-09
previously O 0 1.462286434161797e-07
described O 0 1.7745595926044189e-07
I113F O 0 1.0493106401554542e-06
that O 0 8.385001026844918e-10
produces O 0 1.89416460294467e-09
a O 0 1.3700139689376556e-08
severe O 0 5.001425051887054e-07
phenotype O 0 1.218585225615243e-06
. O 0 1.1769740382305827e-07

The O 0 4.611353688233066e-06
I113F O 0 9.35038406169042e-06
and O 0 2.2983229541750916e-08
T312S O 0 3.005464577654493e-06
mutations O 0 1.6985344686304416e-08
accounted O 0 8.580628474419427e-08
for O 0 3.6074738751779023e-09
8 O 0 6.681440112288328e-08
( O 0 1.3017893429889682e-09
18 O 0 5.690311333239606e-09
% O 0 1.9056510536241689e-10
) O 0 9.405947375140666e-12
and O 0 2.154743571070039e-11
6 O 0 4.0479388729863786e-09
( O 0 2.3419977068783737e-10
14 O 0 8.921157146346559e-10
% O 0 6.168596883293631e-11
) O 0 2.7809761871805394e-12
of O 0 7.099362070439597e-11
44 O 0 4.671836806302565e-10
unrelated O 0 4.166798905913538e-09
alleles O 0 2.937276533110378e-10
, O 0 3.099224210600937e-10
respectively O 0 5.801394564741713e-08
. O 0 6.119049089647888e-08

The O 0 7.354379931712174e-07
relatively O 0 9.669529532629895e-08
high O 0 4.950152288074605e-07
residual O 0 5.245411739451811e-05
GALNS O 0 0.005030534695833921
activity O 0 5.738916115660686e-06
seen O 0 1.3116948416325158e-08
when O 0 2.2519119902142393e-10
the O 0 5.689179682910606e-10
T312S O 0 2.5030328032471516e-08
mutant O 0 1.8782996491495396e-08
cDNA O 0 1.108084219936245e-07
is O 0 1.3108331087252623e-10
overexpressed O 0 3.508510459937497e-08
in O 0 2.505824714393867e-10
mutant O 0 4.120610963553872e-09
cells O 0 6.433075738776495e-10
provides O 0 6.002816993477822e-11
an O 0 1.4868672265633265e-11
explanation O 0 2.804399767963872e-10
for O 0 2.4380469865192822e-11
the O 0 5.273416148199317e-10
mild O 0 1.0887032608764002e-08
phenotype O 0 6.95695723251788e-09
in O 0 6.354660131435708e-10
patients O 0 1.423990092508376e-10
with O 0 1.3171129985278807e-11
this O 0 1.6291855642336373e-09
mutation O 0 7.3915029652482644e-09
. O 0 9.486425867066828e-09

The O 0 1.9718457977546677e-08
distribution O 0 9.143801271704888e-10
and O 0 5.2940832273584704e-11
relative O 0 9.201910344813768e-09
frequencies O 0 1.8340603480382356e-09
of O 0 4.920676310860017e-09
the O 0 4.345704684993734e-09
I113F O 0 1.2520510495050985e-07
and O 0 1.347415623520476e-09
T312S O 0 1.8598109363665571e-07
mutations O 0 2.3488970768426043e-09
in O 0 8.14654566028139e-10
Australia O 0 1.894038037519863e-09
corresponded O 0 2.4492401440312506e-09
to O 0 3.705841744583438e-10
those O 0 2.5345114895714005e-10
observed O 0 2.315384994844294e-09
in O 0 2.620539119035925e-09
Northern O 0 1.3894350558985025e-08
Ireland O 0 1.0418839124781698e-08
and O 0 9.68158997416424e-10
are O 0 1.4668878611789893e-10
unique O 0 3.6136910130935007e-10
to O 0 4.655964155886316e-11
these O 0 1.4525875294268964e-11
two O 0 3.4369711937598524e-11
populations O 0 3.335900305989625e-11
, O 0 1.5612044643176226e-11
suggesting O 0 1.0600847977215722e-09
that O 0 7.147895469961085e-11
both O 0 2.9200106221871636e-10
mutations O 0 6.202649505127056e-10
were O 0 3.586795083165839e-09
probably O 0 2.4038062651499104e-09
introduced O 0 1.5674740672100285e-10
to O 0 1.0593888266630103e-10
Australia O 0 4.447018309150508e-10
by O 0 2.949234190197103e-10
Irish O 0 3.135688331212805e-08
migrants O 0 3.049175356650835e-09
during O 0 3.4018865502360995e-09
the O 0 3.459824204909978e-09
19th O 0 1.9713480980954046e-07
century O 0 2.4295200091728475e-06
. O 0 9.595579086862926e-08

Haplotype O 0 6.000334178679623e-05
analysis O 0 3.591527786284132e-07
using O 0 1.9105989679246704e-08
6 O 0 1.788236829725065e-07
RFLPs O 0 2.9344516860874137e-06
provides O 0 7.92181764630584e-10
additional O 0 3.227118017257169e-10
data O 0 7.95228061178932e-09
that O 0 6.276420355666446e-11
the O 0 3.0357472091679938e-09
I113F O 0 4.3900195123569574e-07
mutation O 0 2.133407006610355e-09
originated O 0 8.02081423501022e-09
from O 0 1.04911013210085e-09
a O 0 5.655362400602826e-09
common O 0 3.3865821258416418e-09
ancestor O 0 2.905674989506224e-07
. O 0 3.418226413032244e-08

The O 0 2.3452592756711965e-07
other O 0 6.367933957918126e-10
9 O 0 2.6065228198035584e-08
novel O 0 8.854877719954857e-09
mutations O 0 8.023136044421619e-10
identified O 0 1.1007630362769305e-09
in O 0 4.533569353259992e-10
these O 0 2.3188354014713752e-10
23 O 0 8.866255996053951e-08
patients O 0 1.7074986979892515e-09
were O 0 2.5897763933357965e-09
each O 0 6.506274963236081e-10
limited O 0 3.402548465203381e-09
to O 0 2.6564557220609686e-09
a O 0 6.77367353318914e-08
single O 0 6.168770738668172e-08
family O 0 5.136496739055474e-08
. O 0 1.7080534320257357e-08

These O 0 2.889811412387644e-08
data O 0 1.3849634328266802e-08
provide O 0 3.594161634978832e-10
further O 0 1.973198271443266e-10
evidence O 0 1.8894807940483815e-09
for O 0 1.5326535873771974e-10
extensive O 0 1.7121763562499837e-08
allelic O 0 1.8821411629232898e-07
heterogeneity O 0 1.4869284541418892e-06
in O 0 1.9700870268479775e-07
MPS B-Disease 1 0.9999970197677612
IVA I-Disease 1 1.0
in O 0 6.644965111490819e-08
British O 0 1.9367267611869465e-07
- O 0 2.193309533993215e-08
Irish O 0 5.034917371915526e-09
patients O 0 1.8308858595883493e-10
and O 0 9.90004432599445e-12
provide O 0 1.447664904619117e-10
evidence O 0 3.2935127958211297e-09
for O 0 2.516351849113363e-10
their O 0 3.640262258297611e-10
transmission O 0 3.761682965119917e-09
to O 0 1.6089148069386994e-10
Australia O 0 6.089574955403521e-10
by O 0 1.4257157954222777e-10
British O 0 1.245020708751099e-08
- O 0 1.5537830577727618e-08
Irish O 0 2.3081899058752242e-08
migrants O 0 3.2681695127934063e-09
. O 0 1.279120281916235e-10
. O 0 3.035920848049045e-09

Identification O 0 3.137507462724898e-07
of O 0 5.7155386201657166e-08
constitutional O 0 2.054004681895094e-07
WT1 O 0 0.0015522970352321863
mutations O 0 1.2422668227429767e-08
, O 0 4.3282131351185527e-11
in O 0 6.92417373437948e-11
patients O 0 3.624139530145065e-11
with O 0 7.797986562030346e-11
isolated O 0 0.0001473377487855032
diffuse B-Disease 1 1.0
mesangial I-Disease 1 1.0
sclerosis I-Disease 1 1.0
, O 0 4.0835522463478213e-11
and O 0 3.23362734158672e-12
analysis O 0 3.1525362875761687e-10
of O 0 2.236994145476956e-09
genotype O 0 3.8459145912383974e-07
/ O 0 3.551642464572069e-07
phenotype O 0 5.512756473535774e-09
correlations O 0 1.3328085302077852e-08
by O 0 1.2172253482933826e-10
use O 0 7.806200824633791e-11
of O 0 1.4146485094457262e-09
a O 0 3.4673817150832065e-09
computerized O 0 6.11908390624194e-08
mutation O 0 5.252869694771789e-09
database O 0 9.926060329235042e-08
. O 0 7.3196160244037856e-09

Constitutional O 0 4.606931156558858e-07
mutations O 0 3.4598524933926456e-08
of O 0 4.873304959573943e-08
the O 0 5.837691219312546e-08
WT1 O 0 8.148747838276904e-06
gene O 0 1.9444315046968086e-09
, O 0 9.754188429189625e-11
encoding O 0 6.433173438402662e-10
a O 0 1.2789801218104913e-08
zinc O 0 3.524834255586029e-06
- O 0 9.460539331485052e-06
finger O 0 0.11260252445936203
transcription O 0 0.007862011902034283
factor O 0 4.534153106305894e-07
involved O 0 4.4600447779430397e-08
in O 0 9.445012238984418e-08
renal O 1 1.0
and O 0 4.780186486641469e-07
gonadal O 1 1.0
development O 1 0.9999977350234985
, O 0 8.798541895060907e-10
are O 0 2.2320607168113682e-11
found O 0 3.6076079623637014e-11
in O 0 6.230011645458333e-11
most O 0 2.7804682167786865e-11
patients O 0 5.2390161653370626e-11
with O 0 1.6093504306979867e-10
Denys B-Disease 1 1.0
- I-Disease 1 1.0
Drash I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.09984086453914642
DDS B-Disease 1 1.0
) O 0 7.431778303867986e-09
, O 0 3.1792987686962704e-10
or O 0 1.4924633262580755e-07
diffuse B-Disease 1 0.999997615814209
mesangial I-Disease 1 1.0
sclerosis I-Disease 1 1.0
( O 0 0.4442838430404663
DMS B-Disease 1 0.9999191761016846
) O 0 6.183277778681884e-10
associated O 0 2.7190989460024184e-09
with O 0 1.9786376981301146e-09
pseudohermaphroditism B-Disease 1 1.0
and O 0 0.0008245704229921103
/ O 1 0.9999997615814209
or O 0 0.4118494689464569
Wilms B-Disease 1 1.0
tumor I-Disease 1 1.0
( O 0 1.3562515960074961e-05
WT B-Disease 1 1.0
) O 0 2.4618215022087497e-08
. O 0 9.574734782802352e-09

Most O 0 3.136214488108635e-08
mutations O 0 5.99978022819414e-08
in O 0 9.248594778910046e-08
DDS B-Disease 1 1.0
patients O 0 1.7664880260781501e-06
lie O 0 1.3679084986506496e-05
in O 0 4.182861701451657e-08
exon O 0 1.4531819658714085e-07
8 O 0 2.0981747184123378e-07
or O 0 3.251625813049941e-08
exon O 0 4.0503888243392794e-08
9 O 0 9.472724116221798e-08
, O 0 2.6370501338135455e-09
encoding O 0 1.04491732599854e-07
zinc O 0 0.0004072484152857214
finger O 1 0.998598039150238
2 O 1 0.9989124536514282
or O 0 0.00024522680905647576
zinc O 0 0.16401782631874084
finger O 0 0.06982491165399551
3 O 0 1.54916870087618e-05
, O 0 2.7646804845460338e-09
respectively O 0 1.4513933166426796e-08
, O 0 2.2045011649485247e-10
with O 0 6.522698353661482e-11
a O 0 6.639125160745607e-08
hot O 0 7.023610351097886e-07
spot O 0 6.196891035870067e-07
( O 0 9.431812664217887e-09
R394W O 0 1.0014048257289687e-07
) O 0 1.3553699274027053e-09
in O 0 7.581046013172e-09
exon O 0 3.159676396080613e-07
9 O 0 9.56739654611738e-07
. O 0 1.0533055672112823e-07

We O 0 1.9260234296325507e-07
analyzed O 0 1.3606266691112978e-07
a O 0 1.2654497005826215e-08
series O 0 1.8138929247513147e-09
of O 0 6.64948895945372e-09
24 O 0 3.635159373516217e-08
patients O 0 6.369489380375626e-10
, O 0 4.57124234298778e-11
10 O 0 1.8719077399254047e-09
with O 0 7.522519274161255e-10
isolated B-Disease 1 0.9803624749183655
DMS I-Disease 1 1.0
( O 0 7.267122782650404e-06
IDMS B-Disease 0 0.20201492309570312
) O 0 1.937759952497231e-09
, O 0 1.5038525980060058e-10
10 O 0 2.6061584001979554e-09
with O 0 1.4064589493045787e-09
DDS B-Disease 1 1.0
, O 0 5.160297522621704e-09
and O 0 1.1725208581836455e-09
4 O 0 7.217060016273535e-08
with O 0 3.466654296957472e-09
urogenital B-Disease 0 0.03900233283638954
abnormalities I-Disease 1 0.9999995231628418
and O 0 1.2908233657071833e-05
/ O 1 0.9999960660934448
or O 1 0.9746399521827698
WT B-Disease 1 1.0
. O 0 1.4282478559835e-06

We O 0 1.760531063155213e-06
report O 0 4.981218353350414e-07
WT1 O 0 0.00019495267770253122
heterozygous O 0 1.7321283962701273e-07
mutations O 0 1.8776362686878656e-09
in O 0 7.616187680525854e-10
16 O 0 2.1493203661293592e-08
patients O 0 1.6154960702507992e-09
, O 0 4.0147657420774863e-10
4 O 0 1.057984917451904e-07
of O 0 1.5178582657426887e-07
whom O 0 7.163929183207074e-08
presented O 0 4.3525798787413805e-07
with O 0 7.802615300533944e-07
IDMS B-Disease 1 0.9999996423721313
. O 0 1.7549791664350778e-06

One O 0 1.622487047825416e-06
male O 0 7.247518141184628e-08
and O 0 1.8487905650843572e-09
two O 0 1.865500109943241e-08
female O 0 1.3344488252187148e-06
IDMS B-Disease 1 0.9999946355819702
patients O 0 2.7002241154150397e-07
with O 0 1.83835489053763e-08
WT1 O 1 1.0
mutations O 0 0.00014201889280229807
underwent O 0 3.6742618249263614e-05
normal O 0 0.00013841567852068692
puberty O 0 6.363144348142669e-05
. O 0 2.5260971980856084e-08

Two O 0 3.8556908066311735e-07
mutations O 0 1.3127289832937095e-07
associated O 0 1.931479118866264e-07
with O 0 9.791291333272056e-09
IDMS B-Disease 1 1.0
are O 0 1.7464379942211394e-09
different O 0 1.0457412713549274e-10
from O 0 1.7476542435446163e-09
those O 0 5.314279571955183e-10
described O 0 3.985434204878402e-08
in O 0 4.310762165005144e-07
DDS B-Disease 1 1.0
patients O 0 3.876026823945722e-07
. O 0 2.1893596269251248e-08

No O 0 1.926750883285422e-05
WT1 O 0 0.0010772808454930782
mutations O 0 1.764071129173317e-07
were O 0 2.2854274916994655e-08
detected O 0 1.527961757119556e-08
in O 0 1.5356215188333522e-09
the O 0 4.493325711507623e-09
six O 0 2.3496555812130282e-08
other O 0 2.661522113811543e-09
IDMS B-Disease 1 1.0
patients O 0 5.976492190029603e-08
, O 0 8.757417013782742e-11
suggesting O 0 9.389202304532773e-09
genetic O 0 1.862350700321258e-07
heterogeneity O 0 2.933655309789174e-07
of O 0 2.2831313728488567e-08
this O 0 4.273543297017568e-09
disease O 0 3.3091796467488166e-06
. O 0 1.733343779619645e-08

We O 0 1.6372145239529345e-07
analyzed O 0 4.5112631141819293e-07
genotype O 0 4.122471182199661e-06
/ O 0 1.6071595609901124e-06
phenotype O 0 7.725279971282362e-08
correlations O 0 2.9934992085145495e-07
, O 0 4.0004258239356716e-10
on O 0 1.0037541908758385e-09
the O 0 6.356587478606457e-10
basis O 0 1.4168932693792158e-08
of O 0 9.471342599098875e-10
the O 0 6.538595775928968e-10
constitution O 0 3.367360279504794e-10
of O 0 2.8542259666863856e-09
a O 0 7.130772416985565e-09
WT1 O 0 3.0431515369855333e-06
mutation O 0 2.013906152953382e-09
database O 0 2.2363638052524948e-08
of O 0 4.997955826979705e-09
84 O 0 1.6669666536017758e-07
germ O 0 0.0010547689162194729
- O 0 0.0008235316490754485
line O 0 1.1933209407288814e-06
mutations O 0 7.789774159050467e-09
, O 0 9.220241931062745e-11
to O 0 1.808427019245329e-10
compare O 0 3.3480913597117024e-09
the O 0 1.218645184764e-09
distribution O 0 1.0968460584237505e-09
and O 0 1.9945850526781328e-10
type O 0 1.0205775424765307e-07
of O 0 9.426295832781761e-08
mutations O 0 2.6208839543073736e-09
, O 0 8.012855656769347e-11
according O 0 1.5509744877295617e-10
to O 0 8.761025932502164e-11
the O 0 3.5354577598845083e-10
different O 0 2.564509715696772e-10
symptoms O 0 2.2895555673585477e-07
. O 0 4.401757536243167e-08

This O 0 1.1966002944063803e-07
demonstrated O 0 3.951787519440586e-08
( O 0 6.040806077578509e-09
1 O 0 3.3460498372051006e-08
) O 0 1.802163696051906e-10
the O 0 1.5159104527207035e-10
association O 0 3.8251482536999504e-10
between O 0 1.155296414090401e-09
mutations O 0 1.7298849019908857e-09
in O 0 9.092016028944272e-09
exons O 0 1.0588949272971604e-08
8 O 0 8.124158235034429e-09
and O 0 3.2178310016561795e-10
9 O 0 3.421958183480456e-08
and O 0 4.4637533669344975e-09
DMS B-Disease 0 9.47004446061328e-06
; O 0 3.561433925547419e-10
( O 0 3.117151536891072e-10
2 O 0 1.5146944809529828e-09
) O 0 9.909262646545791e-12
among O 0 2.043620914854438e-12
patients O 0 2.5555581956160367e-11
with O 0 2.951539707085615e-11
DMS B-Disease 0 0.035904768854379654
, O 0 1.5981091450179008e-10
a O 0 6.908478233924598e-10
higher O 0 1.2328432719144189e-09
frequency O 0 8.635277493063143e-10
of O 0 1.5511704143378324e-09
exon O 0 7.855407879731047e-09
8 O 0 1.9914270232845865e-09
mutations O 0 6.705534738582486e-11
among O 0 5.008349637791731e-12
46 O 0 1.917808800655507e-09
, O 0 6.763907212103959e-10
XY O 1 0.8146225214004517
patients O 0 6.0996914186262075e-09
with O 0 1.1194286470006531e-10
female O 0 7.396156576078283e-09
phenotype O 0 1.7030266086237589e-09
than O 0 4.613177895240739e-12
among O 0 3.031715286802572e-12
46 O 0 1.4751374566301934e-09
, O 0 3.0336849698997526e-10
XY O 1 0.8534063696861267
patients O 0 1.5286081289644926e-09
with O 0 3.253252181534272e-11
sexual O 0 9.772190168177985e-08
ambiguity O 0 5.226812618275289e-07
or O 0 4.11964649060792e-08
male O 0 7.560768122694128e-10
phenotype O 0 2.2288754175647796e-10
; O 0 8.149676246349546e-12
and O 0 5.689003088060751e-11
( O 0 2.5273189097063664e-10
3 O 0 3.139325244205793e-09
) O 0 2.447570618402395e-11
statistically O 0 2.5529384162226165e-10
significant O 0 6.792320178528044e-11
evidence O 0 1.047426700928611e-09
that O 0 1.2544175767570387e-11
mutations O 0 5.675347344857862e-11
in O 0 5.914975731435845e-10
exons O 0 2.2457922188579005e-09
8 O 0 5.915599565753382e-09
and O 0 1.535245958139697e-10
9 O 0 7.338193164230233e-09
preferentially O 0 4.703292422192362e-09
affect O 0 4.265440445294644e-09
amino O 0 1.4786192270577203e-09
acids O 0 5.002747868743107e-11
with O 0 2.4584756973256017e-12
different O 0 3.528295017263261e-11
functions O 0 1.7247296923983413e-08
. O 0 1.1815299849615712e-09
. O 0 1.579094721648744e-08

The O 0 6.0448123804235365e-06
185delAG O 0 2.753395528998226e-05
BRCA1 O 0 3.3510195862618275e-07
mutation O 0 1.2927727777167775e-09
originated O 0 1.0204539435676452e-09
before O 0 3.185162134045072e-10
the O 0 7.397084611504567e-10
dispersion O 0 1.8167643389688237e-08
of O 0 2.53327208099563e-08
Jews O 0 4.1368355852000605e-08
in O 0 3.134789761105594e-09
the O 0 1.0618782297910911e-08
diaspora O 0 1.2394338000376592e-08
and O 0 4.961774324740986e-10
is O 0 6.34515273656433e-10
not O 0 1.7277142216887142e-10
limited O 0 1.998500920308288e-09
to O 0 1.8820795588680994e-08
Ashkenazim O 0 1.423712819814682e-05
. O 0 9.832410796661861e-08

The O 0 6.324973469418183e-07
185delAG O 0 1.32801221752743e-06
mutation O 0 7.828709236434861e-09
in O 0 1.896673484935718e-09
BRCA1 O 0 9.13348685571691e-09
is O 0 1.2416828676364844e-10
detected O 0 2.9661650913226367e-09
in O 0 8.795756345492123e-10
Ashkenazi O 0 5.4113325376192734e-08
Jews O 0 7.071961238835911e-09
both O 0 2.5305746387260797e-10
in O 0 1.343969202594053e-08
familial B-Disease 1 0.9999997615814209
breast I-Disease 1 1.0
and I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 2.8323944434305304e-07
in O 0 9.277743018287765e-09
the O 0 3.2703644237130902e-09
general O 0 5.3827533541550565e-09
population O 0 3.9785413852300167e-10
. O 0 2.67511102158835e-09

All O 0 1.2667180726566585e-07
tested O 0 9.514443632951952e-08
Ashkenazi O 0 2.5201063635904575e-07
mutation O 0 4.772067185854212e-09
carriers O 0 1.1399458044181188e-09
share O 0 6.2179927873273755e-09
the O 0 9.146021717754138e-09
same O 0 1.0980669706839308e-08
allelic O 0 6.755680033165845e-07
pattern O 0 7.070534024933295e-07
at O 0 1.0101368843606906e-06
the O 0 3.192385236161499e-07
BRCA1 O 0 1.2081603699698462e-06
locus O 0 1.8283072904523578e-06
. O 0 2.694191536534163e-08

Our O 0 3.6882352105749305e-06
previous O 0 3.569908528788801e-07
study O 0 8.291205944033209e-09
showed O 0 3.612190324631115e-09
that O 0 3.438643467190694e-11
this O 0 3.912947188489113e-10
Ashkenazi O 0 3.462242048613007e-08
mutation O 0 6.984742229043661e-10
also O 0 5.413802045550753e-11
occurs O 0 5.757295751251945e-10
in O 0 1.2601741872231287e-09
Iraqi O 0 2.8275849217607174e-07
Jews O 0 3.051725272484873e-08
with O 0 9.381566357102855e-11
a O 0 2.685053512863078e-09
similar O 0 5.96863780621959e-10
allelic O 0 1.630302932653649e-07
pattern O 0 8.775151059126074e-07
. O 0 8.570439291588627e-08

We O 0 7.884605111030396e-07
extended O 0 1.682827672766507e-07
our O 0 2.6225754012898506e-08
analysis O 0 3.59135410299416e-09
to O 0 1.0007948914037001e-09
other O 0 8.057257638860449e-10
non O 0 6.620725656603099e-08
- O 0 3.500128542555103e-08
Ashkenazi O 0 1.8103655463619361e-07
subsets O 0 7.782796274113934e-08
354 O 0 4.1003545447892975e-08
of O 0 2.1405970329624324e-09
Moroccan O 0 1.0532291838671881e-07
origin O 0 1.0754342971708297e-09
, O 0 6.996035972761661e-10
200 O 0 4.802390929370404e-09
Yemenites O 0 2.0779769727141684e-07
and O 0 1.3759027250870304e-09
150 O 0 2.0729270744368478e-08
Iranian O 0 8.793212487034907e-07
Jews O 0 1.0910569159250372e-07
. O 0 3.165131801097232e-08

Heteroduplex O 0 0.00012015320680802688
analysis O 0 5.932822588761155e-08
complemented O 0 1.6195386365325248e-08
by O 0 4.2813325107360356e-10
direct O 0 2.764400930388433e-09
DNA O 0 3.0280560281426006e-09
sequencing O 0 1.8730255124665973e-09
of O 0 2.7175590666672633e-09
abnormally O 0 4.396991570843056e-08
migrating O 0 9.120183497302037e-10
bands O 0 1.0850713216825625e-08
were O 0 3.7516105777513076e-08
employed O 0 7.141513833630597e-07
. O 0 7.660966616640508e-08

Four O 0 9.44714429351734e-07
of O 0 3.540638147114805e-07
Moroccan O 0 1.2226220860611647e-05
origin O 0 2.5837488593083435e-08
( O 0 1.3067747994810475e-09
1 O 0 3.9792720230025225e-09
. O 0 3.3310489783167085e-11
1 O 0 2.451226333022305e-09
% O 0 4.941711276296168e-11
) O 0 4.123836255115476e-12
and O 0 4.807919687377371e-12
none O 0 7.266626744772964e-10
of O 0 8.531422679425305e-09
the O 0 4.804720177276067e-08
Yemenites O 0 7.963168172864243e-05
or O 0 1.4790170155265514e-07
Iranians O 0 2.8719131250909413e-07
was O 0 1.0873942812850146e-07
a O 0 1.0122024107772631e-08
carrier O 0 3.2346194611676538e-09
of O 0 2.040594715424504e-08
the O 0 6.252567175124568e-08
185delAG O 0 3.613340368247009e-06
mutation O 0 7.715458849588686e-08
. O 0 8.093275738474404e-08

BRCA1 O 0 1.3642451449413784e-05
allelic O 0 1.4873311329210992e-06
patterns O 0 2.0428306868325308e-07
were O 0 2.597623982580899e-08
determined O 0 1.3638999263321239e-08
for O 0 1.2020492379249959e-09
four O 0 1.4768886114069346e-09
of O 0 2.6848743228669036e-09
these O 0 4.980099319040754e-11
individuals O 0 5.538128636239925e-11
and O 0 4.4894411105333987e-11
for O 0 1.7272168417736822e-10
12 O 0 5.9569722488106436e-09
additional O 0 4.23556567596961e-09
non O 0 6.466721629294625e-07
- O 0 3.153793954879802e-07
Ashkenazi O 0 1.8307659388483444e-07
185delAG O 0 9.698768366206423e-08
mutation O 0 1.1769124563798528e-09
carriers O 0 2.622432826449028e-10
who O 0 2.7316267026122887e-09
had O 0 0.00016989491996355355
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.00014578178524971008

Six O 0 2.497832610970363e-05
non O 0 0.00025953855947591364
- O 0 1.2163686733401846e-05
Ashkenazi O 0 4.436705694388365e-06
individuals O 0 7.787025246841495e-09
shared O 0 6.861314716388733e-08
the O 0 2.5668759562336163e-08
common O 0 1.76782766203587e-08
Ashkenazi O 0 1.93393179870327e-06
haplotype O 0 3.7617462567141047e-07
, O 0 1.9693415787003232e-09
four O 0 2.614748773055453e-08
had O 0 2.5772617817665378e-08
a O 0 3.856271035829195e-08
closely O 0 2.705443158390608e-08
related O 0 3.76484365460783e-07
pattern O 0 1.312998506364238e-06
, O 0 6.985621525679164e-10
and O 0 3.277600135742631e-10
the O 0 8.347982749512539e-09
rest O 0 2.0227151509288888e-08
( O 0 3.8458827233966986e-09
n O 0 1.96329690282937e-08
= O 0 3.457873276602186e-08
6 O 0 4.271220710450052e-09
) O 0 3.020415861865189e-11
displayed O 0 6.863062895767769e-10
a O 0 4.663327946019535e-09
distinct O 0 4.0049097371763764e-09
BRCA1 O 0 6.438015276444276e-08
allelic O 0 8.829093189888226e-07
pattern O 0 1.383075527883193e-06
. O 0 1.482517575368547e-07

We O 0 4.124698875784816e-07
conclude O 0 7.871532261560787e-07
that O 0 2.5835451555877853e-09
the O 0 4.021897836992139e-08
185delAG O 0 9.288580145039305e-07
BRCA1 O 0 2.008038890721764e-08
mutation O 0 1.3206204185767234e-10
occurs O 0 1.7901662097141724e-10
in O 0 1.7756388026590741e-10
some O 0 1.7978754596192914e-10
non O 0 3.2087243084788497e-07
- O 0 1.1213278128252568e-07
Ashkenazi O 0 9.062292605221955e-08
populations O 0 1.1961411028327262e-10
at O 0 1.1754833773025553e-09
rates O 0 5.216723164558346e-10
comparable O 0 1.8184829198020225e-09
with O 0 1.1226245627549147e-11
that O 0 1.68335498318406e-10
of O 0 5.8978130823561514e-08
Ashkenazim O 0 7.280233603523811e-06
. O 0 9.107310461331508e-08

The O 0 5.637724243001685e-08
majority O 0 1.8958308256600276e-09
of O 0 5.077584930290868e-08
Jewish O 0 2.169206027247128e-06
185delAG O 0 8.555949193578272e-07
mutation O 0 2.1332360322645627e-09
carriers O 0 2.6777385864207304e-10
have O 0 8.18276349456859e-11
a O 0 6.930465645815787e-10
common O 0 1.364916096813218e-10
allelic O 0 3.532306891429471e-08
pattern O 0 6.360104407576728e-07
, O 0 1.4792058689039322e-09
supporting O 0 2.1048482068408703e-08
the O 0 6.577502631444077e-08
founder O 0 2.5701617687445832e-06
effect O 0 4.7165542582661146e-08
notion O 0 3.012808136304557e-08
, O 0 8.364071935051953e-11
but O 0 5.888833864986509e-11
dating O 0 1.7051302592108186e-08
the O 0 1.3010694743798012e-09
mutations O 0 4.6013715060411187e-10
origin O 0 1.1357137452705501e-09
to O 0 5.084654364218011e-10
an O 0 3.031417616927712e-10
earlier O 0 9.55947432323967e-10
date O 0 1.1521215981247224e-08
than O 0 5.511628931031964e-10
currently O 0 7.425270398542239e-10
estimated O 0 6.0554565806114624e-09
. O 0 1.4849932838956192e-08

However O 0 1.0018978002790391e-07
, O 0 3.5437214274125495e-10
the O 0 2.484437378047488e-10
different O 0 7.08899675072594e-11
allelic O 0 9.153896485258883e-08
pattern O 0 2.605519568987802e-07
at O 0 4.5120850700186566e-07
the O 0 1.0395361726978081e-07
BRCA1 O 0 1.9143604390592373e-07
locus O 0 1.0596995281275667e-07
even O 0 2.048258923581514e-10
in O 0 1.612558281349763e-10
some O 0 7.626330122967317e-11
Jewish O 0 1.6438944427932256e-08
mutation O 0 3.3082944717044427e-10
carriers O 0 1.406747912602313e-10
, O 0 1.3194269288252514e-10
might O 0 3.1428237790009916e-09
suggest O 0 1.3700532264238063e-08
that O 0 7.851924666013588e-11
the O 0 8.858437872127922e-10
mutation O 0 2.3617846567347556e-10
arose O 0 2.3967925422141434e-09
independently O 0 1.0534860095390286e-08
. O 0 1.3970370416060973e-09
. O 0 1.1198482141594468e-08

Crystal O 0 0.0019888433162122965
structure O 0 5.346296893549152e-05
of O 0 0.0007789366063661873
the O 0 0.008870734833180904
hemochromatosis B-Disease 1 1.0
protein O 1 0.9999998807907104
HFE O 1 0.9999998807907104
and O 0 8.220848890516663e-09
characterization O 0 3.689519019189902e-07
of O 0 1.1766890395392693e-07
its O 0 4.681508070092377e-09
interaction O 0 4.014831134213637e-08
with O 0 8.827554243140412e-10
transferrin O 0 3.2599109545117244e-05
receptor O 0 8.870567398844287e-06
. O 0 2.2532763210847406e-08

HFE O 1 0.9993334412574768
is O 0 2.2058121373902395e-07
an O 0 2.826780587383837e-08
MHC O 0 2.008937144637457e-06
- O 0 7.280072168214247e-05
related O 0 8.817005436867476e-05
protein O 0 8.07414653536398e-06
that O 0 5.359945265404065e-10
is O 0 2.347059768759152e-10
mutated O 0 5.954969295451917e-10
in O 0 1.1549835532420616e-09
the O 0 1.0919688264721117e-07
iron B-Disease 1 1.0
- I-Disease 1 1.0
overload I-Disease 1 1.0
disease I-Disease 1 1.0
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
. O 0 0.0469779297709465

HFE O 0 0.008543013595044613
binds O 0 1.8918206023954554e-06
to O 0 4.389625729572799e-08
transferrin O 0 7.615106824232498e-06
receptor O 0 3.0227427032514242e-06
( O 0 1.383595815696026e-08
TfR O 0 4.783588792633964e-06
) O 0 2.3147080085994531e-10
and O 0 4.8298708782423816e-11
reduces O 0 1.4807755022161473e-09
its O 0 1.0259380012200836e-09
affinity O 0 1.714470343472385e-08
for O 0 1.4512077761708042e-08
iron O 0 3.0380620955838822e-05
- O 0 3.33863476953411e-06
loaded O 0 9.377640708407853e-07
transferrin O 0 1.9904175132978708e-05
, O 0 1.562836438040449e-08
implicating O 0 0.00023129947658162564
HFE O 1 0.9993546605110168
in O 0 3.067753368668491e-06
iron O 1 0.9979641437530518
metabolism O 1 0.9999992847442627
. O 0 1.5332539078372065e-06

The O 0 9.654409041104373e-06
2 O 0 1.0946335351036396e-05
. O 0 2.501615767869225e-07

6 O 0 0.0002554171660449356
A O 0 1.5101831195352133e-05
crystal O 0 6.278451473917812e-05
structure O 0 0.00021143328922335058
of O 0 0.0005978505359962583
HFE O 1 0.9999940395355225
reveals O 0 2.773518644971773e-06
the O 0 3.0856785571131695e-08
locations O 0 1.9703368536738708e-07
of O 0 6.030532404111e-06
hemochromatosis B-Disease 1 1.0
mutations O 0 6.355788354994729e-05
and O 0 5.8451782081192505e-08
a O 0 3.0876446999172913e-06
patch O 0 4.671834904002026e-05
of O 0 0.0008620686712674797
histidines O 0 0.21323908865451813
that O 0 1.306810304413375e-08
could O 0 5.8625935217548886e-09
be O 0 4.332380232341393e-09
involved O 0 2.3563741180510078e-08
in O 0 2.5336875708603657e-08
pH O 0 4.704389994003577e-06
- O 0 1.916075007102336e-06
dependent O 0 1.633842089177051e-06
interactions O 0 1.586122522212463e-07
. O 0 2.1269965344572483e-08

We O 0 9.087214607461647e-07
also O 0 6.637261407149708e-09
demonstrate O 0 3.9633672344052684e-08
that O 0 7.681433267237026e-09
soluble O 0 3.618939081206918e-05
TfR O 0 0.06100008636713028
and O 0 8.948637031380713e-08
HFE O 0 0.0008146727923303843
bind O 0 2.8902147164444614e-07
tightly O 0 4.7496229171883897e-07
at O 0 6.718678946526779e-08
the O 0 9.92906734609278e-09
basic O 0 2.2144284628211608e-07
pH O 0 5.642102252068071e-08
of O 0 2.0379188114816316e-08
the O 0 1.763284807054788e-08
cell O 0 1.8992652428551082e-07
surface O 0 1.234490270007882e-07
, O 0 1.6698927796099383e-09
but O 0 5.511303080574237e-10
not O 0 1.123120485502227e-09
at O 0 2.2463760629420904e-08
the O 0 1.2699083562495161e-08
acidic O 0 9.57124711931101e-07
pH O 0 2.617054633446969e-06
of O 0 1.0006848469856777e-06
intracellular O 0 8.39990025269799e-05
vesicles O 0 0.00027665597735904157
. O 0 1.0401762438050355e-06

TfR O 1 0.9989356398582458
HFE O 0 0.01401854120194912
stoichiometry O 0 9.111686267715413e-06
( O 0 3.885537580572418e-08
2 O 0 4.9871594853811985e-08
1 O 0 2.441508328843156e-08
) O 0 2.1865947941179797e-10
differs O 0 1.3456459280192234e-09
from O 0 7.567768633975902e-09
TfR O 0 3.7387642805697396e-05
transferrin O 0 1.2331353218542063e-06
stoichiometry O 0 1.3497729867140151e-07
( O 0 1.2740757338036701e-09
2 O 0 3.2457128096297083e-09
2 O 0 3.3562943535514478e-09
) O 0 1.1733995719520607e-10
, O 0 1.2706430525810664e-11
implying O 0 1.1244365438756176e-09
a O 0 1.2198818344355544e-10
different O 0 2.0018178087388705e-11
mode O 0 1.0220127855120609e-08
of O 0 2.691590950121281e-09
binding O 0 2.0909063369600744e-09
for O 0 1.7595723988961254e-08
HFE O 0 0.0002665799984242767
and O 0 1.9513764826228908e-08
transferrin O 0 9.255525583284907e-06
to O 0 6.714311240330062e-08
TfR O 0 0.003950397949665785
, O 0 2.4516846330868702e-09
consistent O 0 4.163408462432017e-08
with O 0 9.96615082127228e-11
our O 0 1.5631972161145313e-08
demonstration O 0 3.388948854876617e-08
that O 0 1.83314396995371e-09
HFE O 0 1.2807990060537122e-05
, O 0 2.8796420803445244e-09
transferrin O 0 4.0091879327519564e-07
, O 0 5.435532579589619e-10
and O 0 8.66527238851944e-10
TfR O 0 3.724178532138467e-05
form O 0 1.0082831458646524e-08
a O 0 1.1891921047890719e-07
ternary O 0 2.419906377326697e-05
complex O 0 5.8579371398082e-05
. O 0 1.0438019160119438e-07

Identification O 0 5.568100505115581e-07
of O 0 3.652896651828996e-08
three O 0 3.0470823642048117e-09
novel O 0 2.1676326511510524e-08
mutations O 0 1.922782821850433e-09
and O 0 3.4229077905401084e-10
a O 0 2.2251129827566274e-09
high O 0 5.00516783574767e-09
frequency O 0 4.709396428381751e-09
of O 0 6.8269017106104e-09
the O 0 1.1187893278474803e-08
Arg778Leu O 0 2.905200199165847e-05
mutation O 0 2.9514188870649605e-09
in O 0 2.099514562203808e-09
Korean O 0 2.961892732855631e-06
patients O 0 4.512175078019709e-10
with O 0 1.7906784388621588e-10
Wilson B-Disease 0 4.685264502768405e-05
disease I-Disease 0 0.00048682952183298767
. O 0 5.793963353539766e-08

Four O 0 4.989381636733015e-07
mutations O 0 1.0698454566693272e-08
- O 0 1.4383064694811765e-07
- O 0 2.4024996037042e-07
R778L O 0 5.655375616697711e-07
, O 0 2.7147148973227786e-09
A874V O 0 3.532566950070759e-07
, O 0 1.13966092119e-09
L1083F O 0 1.230673518648473e-07
, O 0 7.185791406350006e-10
and O 0 6.623094295221676e-10
2304delC O 0 5.874853314935535e-08
- O 0 5.0133778017880104e-08
- O 0 5.087569476813769e-08
in O 0 1.2170175089920576e-08
the O 0 2.8509736793580487e-08
copper O 0 1.6792636188256438e-06
- O 0 1.0322906973669888e-07
transporting O 0 3.1538812095277535e-07
enzyme O 0 9.867788008932621e-08
, O 0 4.141357035081228e-09
P O 0 3.724114503711462e-05
- O 0 1.216474288412428e-06
type O 0 6.946716166567057e-05
ATPase O 1 0.9999896287918091
( O 0 5.8893039778240563e-08
ATP7B O 0 6.3923298512236215e-06
) O 0 1.3507858720451793e-10
, O 0 3.705859404068423e-12
were O 0 6.165186416939861e-11
identified O 0 4.1717351795256263e-10
in O 0 3.5627740757604442e-09
Korean O 0 0.0006846804171800613
Patients O 0 3.127874848019019e-08
with O 0 6.018376907945822e-10
Wilson B-Disease 0 0.0006609868141822517
disease I-Disease 0 0.301835834980011
. O 0 1.1498082130856346e-07

Arg778Leu O 0 0.001944343326613307
, O 0 1.636882807076745e-08
the O 0 8.962554254310362e-09
most O 0 5.075023179479388e-10
frequently O 0 7.926351797138409e-10
reported O 0 1.8358417008812467e-09
mutation O 0 4.1290035279750725e-10
of O 0 6.602059787752523e-09
this O 0 2.3394630677131545e-09
enzyme O 0 1.1251236387010977e-08
, O 0 3.492915678915409e-10
was O 0 2.1619921852789048e-08
found O 0 8.68049077062949e-10
in O 0 9.920658738948873e-10
six O 0 2.3738579990606468e-09
of O 0 4.843408785148995e-09
eight O 0 9.114831556189529e-09
unrelated O 0 2.9780096610920737e-07
patients O 0 2.0404302691900966e-09
studied O 0 4.476040871281839e-08
, O 0 1.7682912079042268e-10
an O 0 1.4819302729396355e-10
allele O 0 2.767501505740455e-10
frequency O 0 1.1138198807714161e-08
of O 0 5.148581294633914e-08
37 O 0 6.592335921595804e-07
. O 0 5.957690873970023e-08

5 O 0 4.801656814379385e-06
% O 0 1.510788472103286e-08
, O 0 1.2751205646921449e-10
which O 0 3.2863808896443913e-11
is O 0 5.95225257971066e-11
considerably O 0 4.158151045707825e-10
higher O 0 1.921488523848325e-09
than O 0 1.768317263450836e-11
those O 0 9.411690177207888e-12
in O 0 4.184292148878832e-11
other O 0 2.2750379705116508e-11
Asian O 0 7.88164200571373e-09
populations O 0 2.8943539231995885e-10
. O 0 8.793206163204559e-10

The O 0 1.589697973258808e-07
novel O 0 1.418056427837655e-07
single O 0 5.130543812015276e-08
nucleotide O 0 9.293400466958701e-07
deletion O 0 9.840591275178667e-08
, O 0 9.010474588677653e-10
2304delC O 0 6.984162581602504e-08
, O 0 2.083819561349287e-09
was O 0 7.758578846051023e-08
found O 0 8.256455963362441e-09
in O 0 1.6125138557754326e-08
one O 0 5.2902557001743844e-08
patient O 0 1.1098669574494124e-06
. O 0 1.305077148572309e-07

Since O 0 2.0014549306779372e-07
a O 0 1.412292949254379e-08
mutation O 0 1.43619161008246e-09
at O 0 2.992374348309568e-08
cDNA O 0 6.353805588332762e-07
nucleotide O 0 5.639229243570298e-07
2302 O 0 8.526611964043695e-06
( O 0 3.5120304442415318e-09
2302insC O 0 1.787349823700879e-08
) O 0 8.733467837807041e-10
had O 0 6.282354636510945e-09
been O 0 6.982908029584678e-09
previously O 0 2.2716420744472998e-08
described O 0 1.2568910356947072e-08
, O 0 1.9252846539252744e-10
this O 0 4.28360319437715e-10
region O 0 4.2357193308362184e-09
of O 0 1.4224082178770914e-07
the O 0 9.917239367496222e-07
ATP7B O 1 0.9999408721923828
gene O 0 1.5155881882833455e-08
may O 0 2.0818966550706364e-09
be O 0 1.3664094300480656e-09
susceptible O 0 2.0076022622106393e-08
to O 0 5.9696314558266295e-09
gene O 0 1.6503969391123974e-07
rearrangements O 0 6.037930506863631e-05
causing O 0 0.0027941972948610783
Wilson B-Disease 1 0.8499411344528198
disease I-Disease 1 0.9974328875541687
. O 0 3.428550598982838e-07

Disruption O 0 0.0020302189514040947
of O 0 4.435639311850537e-06
splicing O 0 1.750335741235176e-06
regulated O 0 3.5578125334723154e-07
by O 0 1.476179622983409e-08
a O 0 1.8322542416626675e-07
CUG O 0 6.82578538544476e-05
- O 0 1.0710197528851495e-07
binding O 0 2.04921430935201e-08
protein O 0 5.061982619736227e-07
in O 0 4.4959605816075054e-07
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 1.0610905292196549e-06

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9995391368865967
DM B-Disease 1 1.0
) O 0 1.8088242370595253e-07
is O 0 9.734942629791021e-09
caused O 0 3.793271119434394e-08
by O 0 9.397389533205569e-09
a O 0 2.475120481904014e-07
CTG O 0 9.852670336840674e-05
expansion O 0 6.849311517953538e-08
in O 0 3.1925599941473592e-09
the O 0 5.050623919089503e-09
3 O 0 4.3956578821280345e-08
untranslated O 0 5.269181656331057e-06
region O 0 1.807418570365371e-08
of O 0 9.532607947448923e-08
the O 0 1.868796175585885e-06
DM B-Disease 1 1.0
gene O 0 2.4558642053307267e-06
. O 0 8.01057495891655e-08

One O 0 1.280122745583867e-07
model O 0 1.6083065190741763e-07
of O 0 2.124561433447525e-06
DM B-Disease 1 1.0
pathogenesis O 1 0.9999994039535522
suggests O 0 7.785482125655108e-07
that O 0 1.7902559434901377e-09
RNAs O 0 2.663677605596604e-06
from O 0 2.907884599778754e-09
the O 0 4.5335174503335907e-10
expanded O 0 7.988976702399953e-10
allele O 0 2.1727424026618536e-10
create O 0 4.5432296813530115e-10
a O 0 5.3474087380323e-09
gain O 0 2.074331746371172e-07
- O 0 7.877974717018787e-09
of O 0 9.207899864804858e-08
- O 0 5.607706299315396e-08
function O 0 1.3470899062895114e-08
mutation O 0 1.0696116908848197e-10
by O 0 4.1481831858369844e-11
the O 0 8.539394746875928e-10
inappropriate O 0 9.78040937127389e-09
binding O 0 7.288975534258668e-10
of O 0 3.750320942685903e-09
proteins O 0 2.951794642047645e-10
to O 0 3.013248983663175e-09
the O 0 7.193985140929726e-08
CUG O 0 0.0006883921450935304
repeats O 0 2.775857865344733e-06
. O 0 1.6035679095693922e-07

Data O 0 2.5732690573931905e-06
presented O 0 4.05522015967108e-08
here O 0 4.153177002308439e-08
indicate O 0 2.608656579639046e-08
that O 0 6.262321911032487e-11
the O 0 9.90107329457146e-10
conserved O 0 1.3548425670251163e-07
heterogeneous O 0 2.63006000977839e-07
nuclear O 0 2.694325849006418e-05
ribonucleoprotein O 0 0.0029862793162465096
, O 0 7.893213904708318e-08
CUG O 0 2.903804306697566e-05
- O 0 1.8762378317660477e-07
binding O 0 2.53240735048621e-08
protein O 0 9.536191214465362e-08
( O 0 7.257087375478477e-09
CUG O 0 2.0649656562454766e-06
- O 0 4.133251536586613e-07
BP O 0 6.1944074332132e-06
) O 0 6.316598355482483e-09
, O 0 8.28712265477094e-10
may O 0 7.802338330975545e-09
mediate O 0 3.0264988026829087e-07
the O 0 2.6362599214735383e-07
trans O 0 7.277063218680269e-07
- O 0 1.9588196664699353e-06
dominant O 0 2.700484174056328e-07
effect O 0 3.181182250955317e-08
of O 0 6.343597647173738e-08
the O 0 4.5248917501794494e-08
RNA O 0 8.847940193845716e-07
. O 0 1.49571270924298e-08

CUG O 1 0.8210134506225586
- O 0 0.0028674283530563116
BP O 0 0.0005393020110204816
was O 0 2.05928608920658e-06
found O 0 1.6166959326824326e-08
to O 0 1.9784602844907795e-09
bind O 0 4.729614477838595e-09
to O 0 2.17898943333239e-09
the O 0 2.0506845999079815e-08
human O 0 2.1315925380349654e-07
cardiac O 0 0.0006739358068443835
troponin O 0 5.7803586969384924e-05
T O 0 8.880352652340662e-06
( O 0 4.688924803986083e-09
cTNT O 0 6.731403345838771e-08
) O 0 8.205022217211422e-10
pre O 0 2.5103430445483355e-08
- O 0 1.7556835985033103e-08
messenger O 0 4.809965403751448e-08
RNA O 0 3.37153451823724e-08
and O 0 1.683624767379044e-10
regulate O 0 1.4359285982479264e-09
its O 0 4.87319795627883e-10
alternative O 0 1.0310349018993747e-08
splicing O 0 1.7159695175905654e-07
. O 0 2.4849091673218027e-08

Splicing O 0 5.720889021176845e-06
of O 0 6.204891747074726e-07
cTNT O 0 1.6750022041378543e-05
was O 0 2.8124702566856286e-06
disrupted O 0 3.4872708056354895e-05
in O 0 2.052149739029119e-06
DM B-Disease 1 1.0
striated O 0 0.08478996157646179
muscle O 0 1.3331155969353858e-05
and O 0 1.4917839408212785e-08
in O 0 2.027574375063068e-08
normal O 0 2.633071744639892e-06
cells O 0 2.361314344057064e-08
expressing O 0 7.982811744966511e-09
transcripts O 0 1.1914067954421625e-07
that O 0 4.536778452912671e-10
contain O 0 1.2350516165327008e-08
CUG O 0 2.7340336600900628e-05
repeats O 0 1.6379186718040728e-06
. O 0 8.285359598403375e-08

Altered O 0 2.556560275479569e-06
expression O 0 1.5064097169670276e-07
of O 0 4.1107146131480476e-08
genes O 0 4.059213409846052e-08
regulated O 0 1.9138401796681137e-07
posttranscriptionally O 0 9.957336715160636e-07
by O 0 2.842579149842095e-08
CUG O 0 0.1019836813211441
- O 0 2.5848145014606416e-05
BP O 0 8.859053195919842e-06
therefore O 0 1.075941469252939e-08
may O 0 4.6212429438696745e-09
contribute O 0 2.0373006393015203e-08
to O 0 3.703001993926591e-07
DM B-Disease 1 1.0
pathogenesis O 1 0.9999227523803711
. O 0 4.7846288708797147e-08
. O 0 4.749912108081844e-08

Identification O 0 4.615801003637898e-07
of O 0 2.777732177605685e-08
a O 0 2.3134791860002224e-08
novel O 0 4.351180749040395e-08
nonsense O 0 7.570730531369918e-07
mutation O 0 2.1308610431702846e-09
and O 0 3.323587516312898e-10
a O 0 3.8159684301319885e-09
missense O 0 4.20324788308335e-08
substitution O 0 1.116426950886762e-09
in O 0 1.1041233483055635e-09
the O 0 7.475123631195402e-09
vasopressin O 0 2.671579295565607e-07
- O 0 6.224450288527805e-08
neurophysin O 0 1.31958893234696e-06
II O 0 3.4896613669843646e-06
gene O 0 9.716091264877491e-10
in O 0 5.548366210916811e-10
two O 0 7.179132843759817e-10
Spanish O 0 1.0902580527272221e-07
kindreds O 0 2.230125119240256e-06
with O 0 1.6684035486491666e-08
familial B-Disease 1 1.0
neurohypophyseal I-Disease 1 1.0
diabetes I-Disease 1 1.0
insipidus I-Disease 1 1.0
. O 0 1.5508836668232107e-06

Familial B-Disease 1 1.0
neurohypophyseal I-Disease 1 1.0
diabetes I-Disease 1 1.0
insipidus I-Disease 1 1.0
( O 0 0.0024610012769699097
FNDI B-Disease 1 1.0
) O 0 4.399013064926294e-08
is O 0 1.7764052451241241e-09
an O 0 2.0098589459394134e-08
autosomal B-Disease 1 1.0
dominant I-Disease 1 1.0
disease I-Disease 1 1.0
caused O 0 0.03512868285179138
by O 0 3.904839473989341e-08
deficiency O 1 1.0
in O 0 1.0903949032581295e-06
the O 0 1.1399090453778626e-06
antidiuretic O 0 3.546968582668342e-05
hormone O 0 5.075396458664727e-08
arginine O 0 1.5903424355201423e-07
vasopressin O 0 4.213618467474589e-07
( O 0 3.4456915098957097e-09
AVP O 0 1.801153928226995e-07
) O 0 4.3245740322106485e-11
encoded O 0 3.7396830077085497e-10
by O 0 6.307926403437136e-10
the O 0 4.271597831007057e-08
AVP O 0 2.2077401808928698e-05
- O 0 4.4119576614320977e-07
neurophysin O 0 1.6837228031363338e-05
II O 0 0.08521898090839386
( O 0 4.101643753529061e-06
AVP O 0 0.0003519593155942857
- O 0 1.1830684343294706e-06
NPII O 0 4.330433512222953e-05
) O 0 1.065749710704722e-08
gene O 0 1.875141597551533e-09
on O 0 1.5510115858319296e-08
chromosome O 0 3.7570177369161684e-07
20p13 O 0 4.318297669669846e-06
. O 0 1.3123884912147332e-07

In O 0 2.2809534527823416e-07
this O 0 1.97716998329156e-09
study O 0 1.8786858735353462e-09
, O 0 4.31382325694063e-11
we O 0 7.529362550107166e-11
analyzed O 0 1.0524631166575205e-09
two O 0 1.2774087343458973e-10
families O 0 6.442551353513792e-11
with O 0 8.103922394253615e-11
FNDI B-Disease 1 1.0
using O 0 1.3339504612019937e-08
direct O 0 1.663808468777006e-08
automated O 0 2.2261160026459947e-08
fluorescent O 0 1.6292996118938419e-10
, O 0 1.0652725229709503e-11
solid O 0 2.7315953943229943e-09
phase O 0 7.023353898460982e-09
, O 0 9.817405915990562e-11
single O 0 3.0832811304115637e-10
- O 0 5.972430328071709e-10
stranded O 0 2.4134585441260015e-09
DNA O 0 4.2742320099931064e-11
sequencing O 0 4.9228680160107174e-11
of O 0 1.849227881933757e-09
PCR O 0 1.0019662433080612e-08
- O 0 6.24794154191477e-08
amplified O 0 1.734561237753951e-06
AVP O 0 3.1738502002554014e-05
- O 0 5.313777933224628e-07
NPII O 0 2.524789670133032e-05
DNA O 0 4.62981176951871e-07
. O 0 1.419739081853777e-08

In O 0 4.028262878819078e-07
one O 0 2.7312829775638647e-09
of O 0 2.041356639281844e-09
the O 0 1.2851539832325898e-09
families O 0 2.2166231350428944e-10
, O 0 3.324130901094513e-11
affected O 0 1.2494227874526587e-10
individuals O 0 3.994232722348556e-11
presented O 0 2.7571340766030517e-09
a O 0 9.717282090093704e-09
novel O 0 1.5661665742072728e-08
nonsense O 0 9.610672435655943e-08
mutation O 0 5.114788037552387e-10
in O 0 1.0077924050833076e-09
exon O 0 8.737621293164466e-09
3 O 0 1.1147379908038602e-08
of O 0 2.952060595973194e-09
the O 0 3.6144094384127357e-09
gene O 0 2.3242065216866337e-10
, O 0 5.877175829338555e-11
consisting O 0 1.1501515295719855e-09
in O 0 9.57077261887207e-09
a O 0 9.154036462177828e-08
G O 0 7.45527643175592e-07
to O 0 4.918510754237104e-08
T O 0 6.598109507649497e-07
transition O 0 4.714364365554502e-07
at O 0 1.426478320354363e-06
nucleotide O 0 4.269132205081405e-06
2101 O 0 3.993480277131312e-06
, O 0 1.533203425330143e-10
which O 0 1.494330353901674e-11
produces O 0 4.0820805069508026e-11
a O 0 1.4888495991627337e-09
stop O 0 2.3164758999882906e-09
signal O 0 3.027352946105566e-08
in O 0 5.041211004197521e-09
codon O 0 2.1707113262436906e-07
82 O 0 8.231927495216951e-07
( O 0 1.0146324314064259e-07
Glu O 0 2.79632458841661e-05
) O 0 1.0998318700217169e-08
of O 0 1.7416759590105357e-07
NPII O 0 0.001015537534840405
. O 0 8.463611607112398e-07

The O 0 2.6522250209382037e-06
premature O 0 6.4735859268694185e-06
termination O 0 1.8830941144187818e-06
eliminates O 0 2.3709726804099773e-07
part O 0 4.991279922705871e-08
of O 0 3.4428131812092033e-07
the O 0 1.81503480689571e-07
C O 0 0.002986753825098276
- O 0 1.3384240446612239e-05
terminal O 0 4.069861006428255e-06
domain O 0 4.615651960193645e-06
of O 0 5.52470623915724e-07
NPII O 0 0.0021445283200591803
, O 0 5.949806869409713e-09
including O 0 1.4699835793052785e-09
a O 0 1.8867378770437426e-08
cysteine O 0 2.224986772603188e-08
residue O 0 3.3417072131669556e-07
in O 0 4.803242692474896e-09
position O 0 3.3267362198330375e-08
85 O 0 5.607845565691605e-08
, O 0 1.3098759577001573e-10
which O 0 8.345937135834092e-11
could O 0 2.0184506843712313e-10
be O 0 1.6472614383644668e-09
involved O 0 2.6494387128650487e-08
in O 0 1.0494348501310924e-08
the O 0 3.551499361265087e-08
correct O 0 2.1560065306402976e-06
folding O 0 1.5547396969850524e-06
of O 0 8.828823752082826e-07
the O 0 1.6088571328509715e-06
prohormone O 0 0.012139430269598961
. O 0 5.820169235448702e-07

In O 0 1.3019312063988764e-06
the O 0 1.7638456029089866e-07
second O 0 3.8176708017090277e-07
family O 0 3.089943163558928e-07
, O 0 2.2436685842563975e-09
a O 0 1.2262726833967008e-08
G279A O 0 1.100755753213889e-07
substitution O 0 1.7038688682191605e-08
at O 0 2.264716414401846e-07
position O 0 2.6455612101017323e-07
- O 0 7.488541342581811e-08
1 O 0 2.716164715366176e-07
of O 0 2.8325988665756086e-08
the O 0 2.2480648453893082e-08
signal O 0 3.7353743209678214e-07
peptide O 0 1.5494149963046766e-08
was O 0 1.0875244704777742e-08
observed O 0 1.2299661289461028e-09
in O 0 2.77950468197119e-10
all O 0 1.6750022202582926e-10
affected O 0 4.829513455817391e-10
individuals O 0 1.4425224348357801e-09
. O 0 1.8249432187644743e-08

This O 0 7.666461669941782e-07
missense O 0 3.2783642382128164e-05
mutation O 0 3.3607676641622675e-08
, O 0 1.5161338851044093e-09
which O 0 1.9066628276220854e-09
replaces O 0 1.1963475117227063e-06
Ala O 0 0.00030595011776313186
with O 0 2.4662769604333334e-08
Thr O 0 0.201527401804924
, O 0 3.87842780114056e-09
is O 0 1.0361363989019878e-09
frequent O 0 1.0224592728036441e-08
among O 0 2.425641909553633e-09
FNDI B-Disease 1 1.0
patients O 0 0.00011302746861474589
and O 0 1.932680682159571e-09
is O 0 4.270243270099172e-09
thought O 0 4.47408377013403e-09
to O 0 3.986410923584316e-10
reduce O 0 1.978150976356119e-09
the O 0 1.191858611804264e-08
efficiency O 0 3.631908995771482e-08
of O 0 2.5619993238024108e-08
cleavage O 0 1.4817754845353193e-07
by O 0 4.631778960373367e-09
signal O 0 6.70592100959766e-07
peptidases O 0 5.694429091818165e-06
. O 0 7.192733519900685e-09
. O 0 3.11871275471276e-08

Genetic O 0 1.8950287994812243e-05
heterogeneity O 0 5.279296601656824e-06
of O 0 2.5851251848507673e-05
Saethre B-Disease 1 1.0
- I-Disease 1 1.0
Chotzen I-Disease 1 1.0
syndrome I-Disease 1 1.0
, O 0 5.345613729446086e-09
due O 0 1.864237447080086e-06
to O 0 1.0561340246795226e-07
TWIST O 0 7.169517630245537e-05
and O 0 1.0623060120451555e-07
FGFR O 0 0.10728142410516739
mutations O 0 3.8120245449135837e-07
. O 0 4.7401016445292043e-08

Thirty O 0 0.00020346615929156542
- O 0 6.140503501228523e-07
two O 0 2.5795225955249634e-09
unrelated O 0 7.935678070225549e-08
patients O 0 4.847278689545931e-10
with O 0 2.42088779578431e-11
features O 0 2.0969061154119117e-08
of O 0 0.016043202951550484
Saethre B-Disease 1 1.0
- I-Disease 1 1.0
Chotzen I-Disease 1 1.0
syndrome I-Disease 1 1.0
, O 0 6.210983949372917e-10
a O 0 6.891346604476212e-09
common O 0 2.9084464614470562e-08
autosomal B-Disease 0 0.003102261573076248
dominant I-Disease 0 0.0001217187600559555
condition I-Disease 1 0.9972503781318665
of O 1 0.9876207709312439
craniosynostosis B-Disease 1 1.0
and O 0 0.0001248848857358098
limb B-Disease 1 1.0
anomalies I-Disease 1 1.0
, O 0 2.2461275506202583e-08
were O 0 3.016747029960243e-08
screened O 0 1.716164987897173e-08
for O 0 3.36686101221062e-09
mutations O 0 7.358474718444086e-09
in O 0 4.834652500562697e-08
TWIST O 0 4.2416879296069965e-05
, O 0 5.227684951591982e-08
FGFR2 O 0 0.0019287063041701913
, O 0 1.857189069198739e-08
and O 0 6.617897696514774e-08
FGFR3 O 1 0.9360945224761963
. O 0 1.7918712273967685e-06

Nine O 0 1.53793416757253e-06
novel O 0 1.4394976233234047e-07
and O 0 3.758584554702793e-09
three O 0 1.015875294996249e-08
recurrent O 0 1.8612212443258613e-05
TWIST O 0 8.309481927426532e-06
mutations O 0 1.9284287944287826e-08
were O 0 1.1797718357797748e-08
found O 0 1.2903339507985834e-09
in O 0 1.3757190941987574e-09
12 O 0 6.963477972021792e-08
families O 0 1.3832976542005326e-08
. O 0 5.52625607497248e-08

Seven O 0 4.104449999431381e-06
families O 0 2.6521840723603418e-08
were O 0 2.3202710863756693e-08
found O 0 3.306952267578822e-09
to O 0 2.783389296823202e-09
have O 0 9.565858105631264e-10
the O 0 4.210115989167207e-08
FGFR3 O 0 0.0003483027685433626
P250R O 0 9.441190513825859e-07
mutation O 0 5.731988217405615e-09
, O 0 1.6986169415478258e-10
and O 0 1.2118762937607386e-10
one O 0 4.610394011006491e-10
individual O 0 1.7717086686630523e-09
was O 0 1.4051221342015197e-07
found O 0 2.7717661499337964e-09
to O 0 1.5167962441609006e-09
have O 0 2.2744590655321417e-09
an O 0 1.0139781458917696e-08
FGFR2 O 0 2.1261514120851643e-05
VV269 O 0 4.046180492878193e-06
- O 0 2.6590785182634136e-06
270 O 0 1.971373421838507e-06
deletion O 0 8.910620294955152e-07
. O 0 5.020908488972964e-08

To O 0 7.679004454530514e-08
date O 0 1.4161899741793604e-07
, O 0 4.817103382848131e-10
our O 0 7.602515839089108e-10
detection O 0 3.6244540702057293e-09
rate O 0 2.467800186423119e-09
for O 0 4.008637033425799e-10
TWIST O 0 9.569668009135057e-07
or O 0 5.705268080191672e-08
FGFR O 0 8.643185537948739e-06
mutations O 0 1.0392596783148633e-09
is O 0 1.9749490931531e-10
68 O 0 7.354629794065204e-09
% O 0 6.801800789268952e-10
in O 0 6.392674722910385e-10
our O 0 1.601538315298967e-07
Saethre B-Disease 1 0.9999970197677612
- I-Disease 1 0.9999986886978149
Chotzen I-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 0 3.400512937901112e-08
, O 0 4.98366244106041e-11
including O 0 1.261996895873807e-10
our O 0 6.529750518069477e-09
five O 0 5.528076663097181e-09
patients O 0 2.620142991460739e-10
elsewhere O 0 4.3418249551230303e-10
reported O 0 8.843851206918885e-10
with O 0 1.9193741040979262e-10
TWIST O 0 1.2747038454108406e-05
mutations O 0 1.7716951106194756e-07
. O 0 3.117951763442761e-08

More O 0 1.7682483255399006e-09
than O 0 9.76822581155723e-11
35 O 0 5.124259905286976e-10
different O 0 1.5384490556491492e-11
TWIST O 0 6.093298310361206e-08
mutations O 0 1.1053328252685901e-09
are O 0 9.248617149903993e-11
now O 0 3.526292036148959e-10
known O 0 7.351232400587548e-10
in O 0 7.770551979646712e-10
the O 0 1.027583529378262e-08
literature O 0 2.81781325384145e-07
. O 0 5.297323824038358e-08

The O 0 9.81043726255848e-08
most O 0 3.903688761131008e-10
common O 0 1.7793953810407714e-10
phenotypic O 0 1.0063906152879554e-08
features O 0 1.0723317345195937e-08
, O 0 2.3310345320659565e-10
present O 0 6.316522860316809e-10
in O 0 1.0894359858681923e-09
more O 0 6.629233273436341e-11
than O 0 6.011421915808057e-11
a O 0 4.235717054879018e-10
third O 0 1.1177672121220894e-09
of O 0 7.284403080731749e-10
our O 0 1.638693958305737e-09
patients O 0 1.0493137608813541e-10
with O 0 1.6306482206185358e-11
TWIST O 0 6.694374405924464e-07
mutations O 0 7.991342698687731e-09
, O 0 3.227370315439515e-10
are O 0 4.568333211718567e-10
coronal B-Disease 0 4.576305855152896e-06
synostosis I-Disease 0 0.0001007605969789438
, O 0 3.909907064780782e-08
brachycephaly B-Disease 0 0.0007864123326726258
, O 0 1.6567648231102794e-07
low B-Disease 1 0.9997683167457581
frontal I-Disease 1 1.0
hairline I-Disease 1 1.0
, O 0 2.69339307124028e-06
facial B-Disease 1 0.9999949932098389
asymmetry I-Disease 1 1.0
, O 0 1.3989849776407937e-06
ptosis B-Disease 1 0.9999884366989136
, O 0 1.3488168804087763e-07
hypertelorism B-Disease 0 0.0450604073703289
, O 0 3.814769655718919e-08
broad B-Disease 0 1.1448681107140146e-05
great I-Disease 1 0.9989936947822571
toes I-Disease 1 0.9999995231628418
, O 0 8.68222116423567e-08
and O 0 7.406563895528961e-08
clinodactyly B-Disease 0 0.005031184293329716
. O 0 2.3186337330116658e-06

Significant O 0 1.7467040379415266e-05
intra O 0 0.0008761114440858364
- O 0 3.3709031868056627e-06
and O 0 4.239404827188764e-09
interfamilial O 0 3.2081109111459227e-06
phenotypic O 0 2.7949621994594054e-07
variability O 0 2.5138560886261985e-06
is O 0 6.728906876141139e-10
present O 0 2.661597053865705e-10
for O 0 5.020223681206915e-10
either O 0 3.545063265164572e-08
TWIST O 0 5.736306320613949e-06
mutations O 0 9.29120602677358e-08
or O 0 7.736088036836009e-08
FGFR O 0 0.00012149473332101479
mutations O 0 3.731931030870328e-07
. O 0 5.201854236247527e-08

The O 0 5.856638836121419e-07
overlap O 0 1.2830059858970344e-07
in O 0 6.077070402454865e-09
clinical O 0 1.5936947761474585e-07
features O 0 9.137529843883385e-09
and O 0 4.096707417744483e-10
the O 0 4.610668735693935e-09
presence O 0 2.114972197375664e-09
, O 0 1.4120302149756014e-10
in O 0 2.439843882484638e-10
the O 0 3.5548372578908527e-10
same O 0 3.2778940672884005e-10
genes O 0 6.600995444694391e-11
, O 0 3.842906895479281e-12
of O 0 6.091686183262723e-11
mutations O 0 1.3131472471894501e-11
for O 0 1.349158423868957e-10
more O 0 5.250640547349583e-11
than O 0 1.3770679041513745e-10
one O 0 9.890956942371076e-10
craniosynostotic B-Disease 0 2.6732612923296983e-07
condition I-Disease 0 2.4962400857475586e-06
- O 0 5.8157080928822324e-08
such O 0 4.373193362994243e-09
as O 0 4.253370633477971e-08
Saethre B-Disease 0 0.0004975088522769511
- I-Disease 0 3.1594731808581855e-06
Chotzen I-Disease 0 0.00022130513389129192
, I-Disease 0 8.05031863393424e-09
Crouzon I-Disease 0 0.00010204439604422078
, I-Disease 0 6.8728120972139095e-09
and I-Disease 0 1.6950457037978595e-08
Pfeiffer I-Disease 1 0.9986575841903687
syndromes I-Disease 1 0.867418646812439
- O 0 1.6679377949913032e-05
support O 0 9.59460990657135e-08
the O 0 1.3855624558800628e-07
hypothesis O 0 2.274987878081447e-07
that O 0 5.026957322629144e-11
TWIST O 0 2.8809180818711866e-08
and O 0 5.639740341401023e-10
FGFRs O 0 1.7838201529229991e-06
are O 0 1.6473612751699562e-10
components O 0 4.399573150237757e-09
of O 0 4.906225203882286e-09
the O 0 4.486800264658086e-09
same O 0 4.605535952606488e-09
molecular O 0 5.318584328506404e-08
pathway O 0 1.566438534439385e-08
involved O 0 9.66116964207231e-10
in O 0 1.6412329828519034e-10
the O 0 1.0521842286337346e-09
modulation O 0 7.460968021177905e-08
of O 0 2.0432554492799682e-07
craniofacial O 1 1.0
and O 0 1.8694556729315082e-06
limb O 1 1.0
development O 0 0.21646854281425476
in O 0 8.553617902862243e-08
humans O 0 1.2985686304034516e-08
. O 0 8.767917503149647e-10
. O 0 6.007713437838902e-09

Mutation O 0 1.2988886055609328e-07
analysis O 0 2.981646574085062e-08
of O 0 4.0779930543521914e-08
UBE3A O 1 0.999990701675415
in O 0 0.011286445893347263
Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 0 0.10073386877775192
. O 0 3.831475581250743e-08

Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 1 0.9999513626098633
AS B-Disease 1 1.0
) O 0 1.0866727251368502e-07
is O 0 4.964096245174687e-09
caused O 0 5.378128165034468e-08
by O 0 8.840753018546366e-09
chromosome O 0 1.6737540136091411e-06
15q11 O 0 1.1515477126522455e-05
- O 0 2.447796987326001e-06
q13 O 0 5.753454843215877e-06
deletions O 0 2.457163930102979e-07
of O 0 3.4948850924365615e-08
maternal O 0 6.284322466854064e-07
origin O 0 4.525564989421582e-08
, O 0 1.3691016098604791e-09
by O 0 1.72890946004145e-08
paternal O 0 0.05437770113348961
uniparental B-Disease 1 0.9999998807907104
disomy I-Disease 1 0.9999456405639648
( O 0 6.886247865622863e-05
UPD B-Disease 1 1.0
) O 0 1.8354540998188895e-08
15 O 0 1.7365369586741508e-08
, O 0 4.082549853734463e-10
by O 0 4.469657088890244e-09
imprinting O 1 0.9935111403465271
defects O 1 0.9999948740005493
, O 0 2.806033405633457e-09
and O 0 4.944692988395616e-10
by O 0 2.132491516704249e-09
mutations O 0 5.590264695598535e-09
in O 0 2.4872326420677382e-08
the O 0 1.6763258372520795e-06
UBE3A O 1 0.6450281739234924
gene O 0 1.15093314434489e-06
. O 0 9.73204947740669e-08

UBE3A O 1 0.9528639316558838
encodes O 0 5.402344686444849e-05
a O 0 7.039234333205968e-07
ubiquitin O 0 2.0989123186154757e-06
- O 0 1.8297865835847915e-06
protein O 0 2.6837884092856257e-07
ligase O 0 2.0779492615474737e-07
and O 0 1.5978174339181805e-09
shows O 0 1.0531769589761097e-07
brain O 0 0.0003425873874220997
- O 0 4.122783536786301e-07
specific O 0 1.2756136413827335e-07
imprinting O 0 0.00018732046009972692
. O 0 1.3099489137857745e-07

Here O 0 7.301449613805744e-07
we O 0 2.467279180962123e-08
describe O 0 5.928908421992674e-07
UBE3A O 0 0.0009101566392928362
coding O 0 4.53756183560472e-05
- O 0 5.536198841582518e-07
region O 0 2.0626176322480205e-08
mutations O 0 1.1464353910639602e-08
detected O 0 2.0677736856100637e-08
by O 0 1.4738326115093514e-09
SSCP O 0 9.22281396924518e-05
analysis O 0 4.0453475236290615e-08
in O 0 2.113399677483585e-09
13 O 0 5.852027840091978e-08
AS B-Disease 1 0.9999885559082031
individuals O 0 4.3876227096006915e-09
or O 0 1.6889558196453436e-08
families O 0 6.493360515946733e-09
. O 0 1.0813399953235603e-08

Two O 0 3.670353692086792e-07
identical O 0 1.9712183529918548e-07
de O 0 7.487507446057862e-06
novo O 0 3.4193985811725724e-06
5 O 0 3.4394370231893845e-06
- O 0 1.1003354529748322e-06
bp O 0 3.2309203561453614e-06
duplications O 0 1.5874102246016264e-06
in O 0 1.3561442813170288e-07
exon O 0 4.893293521490705e-07
16 O 0 2.976255188968935e-07
were O 0 1.0207585887656023e-07
found O 0 3.5399825293325193e-08
. O 0 7.394157108819854e-08

Among O 0 5.6898365130564343e-08
the O 0 7.018988057438946e-09
other O 0 7.769926368972335e-11
11 O 0 4.012869148084519e-09
unique O 0 2.0293598745890762e-10
mutations O 0 2.518767416859191e-10
, O 0 8.359032216409545e-11
8 O 0 1.8578479199504727e-08
were O 0 6.877848068853609e-09
small O 0 5.403099745393547e-09
deletions O 0 4.6858520619252886e-08
or O 0 1.2310925967540243e-07
insertions O 0 8.031356060200778e-07
predicted O 0 3.041176626084052e-07
to O 0 2.6405947650687267e-08
cause O 0 1.8233309901916073e-06
frameshifts O 0 0.0001135304119088687
, O 0 1.3238397045256534e-08
1 O 0 4.296069562315097e-07
was O 0 5.487979493068451e-08
a O 0 2.0979811221621958e-09
mutation O 0 5.365916044830499e-11
to O 0 1.3548316635247915e-10
a O 0 3.9150918063057816e-09
stop O 0 3.288760819231129e-09
codon O 0 2.023093159664313e-08
, O 0 3.482332200377414e-10
1 O 0 2.679411892358985e-08
was O 0 6.68539144044189e-08
a O 0 1.1837072655396241e-08
missense O 0 7.529042989062873e-08
mutation O 0 4.659795327377481e-10
, O 0 1.1909984110047844e-10
and O 0 2.782788166566519e-10
1 O 0 1.4173829754327016e-07
was O 0 4.307408687509451e-07
predicted O 0 5.7291600796816056e-08
to O 0 2.1198025557112032e-09
cause O 0 3.8714674133188964e-08
insertion O 0 1.0095477875893266e-07
of O 0 2.4250098817901744e-07
an O 0 6.551609743610243e-08
isoleucine O 0 6.994906470936257e-06
in O 0 4.1157353081189285e-08
the O 0 2.0984710147331498e-07
hect O 0 3.7072793929837644e-05
domain O 0 1.5947422298268066e-06
of O 0 5.075222020423098e-08
the O 0 8.12042841857874e-08
UBE3A O 0 0.0002528047189116478
protein O 0 1.3349715288768493e-07
, O 0 1.8766219134214168e-10
which O 0 9.043235604799804e-11
functions O 0 4.7596047103581895e-09
in O 0 5.4402131688391364e-09
E2 O 0 4.528966996986128e-07
binding O 0 3.860912922704074e-09
and O 0 3.0022975217036674e-09
ubiquitin O 0 1.8931331169369514e-07
transfer O 0 7.72086707456765e-07
. O 0 3.00263451435967e-07

Eight O 0 8.430711204709951e-07
of O 0 6.340138725136057e-08
the O 0 1.6428694848968917e-08
cases O 0 9.114240917540428e-09
were O 0 9.220905639040211e-08
familial O 0 3.1964418667485006e-06
, O 0 5.4325508536123834e-09
and O 0 2.9312337002096456e-09
five O 0 8.192113654104105e-08
were O 0 1.5945629172620102e-07
sporadic O 0 2.5268814169976395e-06
. O 0 4.608169774655835e-07

In O 0 4.072941237609484e-07
two O 0 1.5940496922439706e-08
familial O 0 1.922081764860195e-06
cases O 0 1.1637363961369829e-08
and O 0 6.940201746630237e-10
one O 0 2.6583109047351172e-09
sporadic O 0 8.244122540190801e-08
case O 0 2.1810071970662648e-08
, O 0 2.506179486161386e-09
mosaicism O 0 0.00045816306374035776
for O 0 6.880527081420951e-08
UBE3A O 1 0.9990062117576599
mutations O 0 1.9612483015407634e-07
was O 0 1.0239136116751979e-07
detected O 0 2.1265583072249683e-08
in O 0 8.603284751274032e-10
the O 0 3.6860841046149062e-09
mother O 0 7.96424615145952e-08
of O 0 4.331130583068443e-07
three O 0 2.589057714885712e-07
AS B-Disease 1 1.0
sons O 0 6.87256979290396e-05
, O 0 7.631081544445806e-09
in O 0 1.704388985501737e-08
the O 0 2.608716727081628e-07
maternal O 0 6.283614493440837e-05
grandfather O 0 0.0009392022038809955
of O 0 0.1324179321527481
two O 0 2.8975885015825043e-06
AS B-Disease 1 1.0
first O 0 1.4932847989257425e-06
cousins O 0 7.018441579020873e-07
, O 0 4.3867607324443725e-09
and O 0 2.9080509111878428e-09
in O 0 5.103061084810179e-08
the O 0 2.807068085530773e-06
mother O 0 2.0253602997399867e-05
of O 0 0.0021924106404185295
an O 0 3.556829324224964e-05
AS B-Disease 1 1.0
daughter O 1 0.9998212456703186
. O 0 1.2344635251793079e-05

The O 0 2.380965469228613e-07
frequencies O 0 1.3324222614130576e-08
with O 0 8.353565061902657e-11
which O 0 1.2934331383718245e-10
we O 0 8.870932322047054e-10
detected O 0 5.8033835514947896e-09
mutations O 0 2.7930616153248877e-10
were O 0 6.604050195591071e-09
5 O 0 1.04462598571331e-08
( O 0 2.409097088484913e-10
14 O 0 1.8920125466337367e-09
% O 0 1.719866193905517e-10
) O 0 2.629292963907126e-11
of O 0 6.479080050247887e-10
35 O 0 1.9648394022908633e-09
in O 0 7.582039440734434e-10
sporadic O 0 2.4404560150514953e-08
cases O 0 1.2287022510548695e-09
and O 0 2.902939832960527e-10
8 O 0 1.3756095817996083e-08
( O 0 2.5667706848864213e-10
80 O 0 5.109747069909076e-10
% O 0 1.3062799973651007e-11
) O 0 2.237208248517808e-12
of O 0 5.5866773013280024e-11
10 O 0 2.2627316687007237e-10
in O 0 4.2149003731672963e-10
familial O 0 7.3852206128322e-08
cases O 0 1.8969086301723337e-09
. O 0 6.671985186557094e-10
. O 0 6.243769945513122e-09

The O 0 6.108285015216097e-05
hemochromatosis B-Disease 1 1.0
845 O 0 2.4504279281245545e-05
G O 0 3.862001449306263e-06
- O 0 1.4828809469236148e-07
- O 0 2.340676417134091e-07
> O 0 9.625495067666634e-08
A O 0 1.1249262854562403e-08
and O 0 3.005010129619734e-11
187 O 0 4.3338904687217905e-10
C O 0 3.314833518786031e-09
- O 0 3.896460043506522e-09
- O 0 2.8858677225684914e-08
> O 0 1.1067514549267798e-07
G O 0 8.243226545801008e-08
mutations O 0 1.395508375523491e-09
: O 0 4.5780306628939726e-11
prevalence O 0 2.768791196317011e-09
in O 0 2.6565202815298505e-10
non O 0 1.3813762222980586e-07
- O 0 2.1119022619586758e-07
Caucasian O 0 1.8960216721097822e-06
populations O 0 1.3079324290288241e-08
. O 0 7.717058991829617e-09

Hemochromatosis B-Disease 1 1.0
, O 0 2.2399716215204535e-07
the O 0 1.3096671864332166e-05
inherited B-Disease 1 1.0
disorder I-Disease 1 1.0
of I-Disease 1 1.0
iron I-Disease 1 1.0
metabolism I-Disease 1 1.0
, O 0 1.300341381238468e-07
leads O 0 1.018408852360153e-06
, O 0 6.6134533405204365e-09
if O 0 1.6824473902943282e-07
untreated O 1 0.9999865293502808
, O 0 1.0371433489808624e-08
to O 0 4.5058456521474e-07
progressive O 1 1.0
iron B-Disease 1 1.0
overload I-Disease 1 1.0
and O 0 4.400829993755906e-07
premature B-Disease 0 0.00017619054415263236
death I-Disease 0 4.0312665987585206e-06
. O 0 1.942131291343685e-07

The O 0 0.0004705442115664482
hemochromatosis B-Disease 1 1.0
gene O 0 1.8866512618842535e-05
, O 0 8.708011023372819e-08
HFE O 1 0.9018297791481018
, O 0 6.910840788521e-09
recently O 0 1.959159590114723e-08
has O 0 3.3729849469033013e-10
been O 0 3.106171708733285e-10
identified O 0 2.1774770875282456e-09
, O 0 1.2554306205725396e-10
and O 0 2.42060760324847e-10
characterization O 0 8.745811896915257e-08
of O 0 1.9553448282749741e-07
this O 0 1.1756341677937598e-08
gene O 0 3.5101417328320395e-09
has O 0 5.7985203444355093e-11
shown O 0 9.579948639926172e-11
that O 0 2.110568664281942e-12
it O 0 7.710540105704267e-13
contains O 0 2.078830380405905e-12
two O 0 4.4793799745812546e-12
mutations O 0 1.5345308357339604e-11
that O 0 3.7633637525735786e-12
result O 0 2.6314514456338145e-10
in O 0 5.150029291911551e-10
amino O 0 4.4654564490542725e-09
acid O 0 1.3311616253730563e-09
substitutions O 0 3.7026288701724752e-09
- O 0 4.3871899890746135e-08
cDNA O 0 1.2030400853291212e-07
nucleotides O 0 3.7508933736774e-09
845 O 0 3.978621165856566e-08
G O 0 3.822103522566067e-08
- O 0 2.9746255236773322e-08
- O 0 1.7122162887517334e-07
> O 0 2.0751667761942372e-07
A O 0 1.587711722095264e-07
( O 0 8.504156823185838e-10
C282Y O 0 5.192285712496414e-09
) O 0 3.6529331642887186e-11
and O 0 2.6102750169676447e-11
187 O 0 7.443549110419667e-10
C O 0 7.08538117066837e-09
- O 0 5.475785158637336e-09
- O 0 4.4096648110780734e-08
> O 0 1.799617166398093e-07
G O 0 7.487811330975092e-07
( O 0 1.6027202676127672e-08
H63D O 0 1.1658651601464953e-05
) O 0 8.280980345887201e-09
. O 0 8.370336423979552e-09

Although O 0 0.0003609957348089665
hemochromatosis B-Disease 1 1.0
is O 0 6.794947182697797e-08
common O 0 6.814750541650483e-09
in O 0 5.569032790475603e-09
Caucasians O 0 2.513634633771744e-08
, O 0 3.3102637297943716e-10
affecting O 0 3.799076164767712e-09
> O 0 6.572534072546432e-09
= O 0 1.1267578869933459e-08
1 O 0 6.848865030661955e-09
/ O 0 2.7287105908158082e-09
300 O 0 6.302106059230539e-10
individuals O 0 2.8704264659618062e-11
of O 0 6.98053392866882e-10
northern O 0 1.5650661322474946e-10
European O 0 6.916389128086564e-10
origin O 0 2.1131578709088217e-09
, O 0 8.836798653932831e-11
it O 0 2.30644375126543e-11
has O 0 1.7550884356953844e-11
not O 0 1.476419507484561e-11
been O 0 9.075027534999336e-11
recognized O 0 6.561530485615918e-11
in O 0 1.5119341889580085e-10
other O 0 1.0428551772134753e-10
populations O 0 3.4088215583594206e-10
. O 0 3.41651706925461e-09

The O 0 4.906237194290952e-08
present O 0 2.383649055914816e-09
study O 0 1.0820491169738489e-09
used O 0 9.152661267775031e-11
PCR O 0 3.5747729776325343e-10
and O 0 3.981788856965984e-11
restriction O 0 2.27153251763923e-09
- O 0 8.800605799663686e-10
enzyme O 0 9.096001174491164e-10
digestion O 0 2.237681151484594e-09
to O 0 9.306658915742005e-11
analyze O 0 2.445799784922542e-09
the O 0 1.6502111899185934e-09
frequency O 0 5.736953578860948e-09
of O 0 4.65694549589557e-09
the O 0 6.3562275443018734e-09
845 O 0 6.837198895937036e-08
G O 0 5.979661921173829e-08
- O 0 2.2217131245838573e-08
- O 0 3.005519033649762e-08
> O 0 1.4804147241420651e-08
A O 0 2.701213475120312e-09
and O 0 1.6474200476013223e-11
187 O 0 2.395616760519914e-10
C O 0 1.2032376206505546e-09
- O 0 5.648913004030476e-10
- O 0 3.4920184521780584e-09
> O 0 2.8519851369424032e-08
G O 0 5.21798213526381e-08
mutations O 0 2.236917318043652e-09
in O 0 6.765020543753053e-09
HLA O 0 7.866071882745018e-08
- O 0 2.5589310670426357e-09
typed O 0 4.230328087828639e-08
samples O 0 7.558374481853036e-10
from O 0 2.129776133230621e-09
non O 0 1.91398257243236e-07
- O 0 8.118972516513168e-08
Caucasian O 0 9.026359037989096e-08
populations O 0 4.4529602227783016e-10
, O 0 1.736603916224766e-11
comprising O 0 1.0242056092124585e-09
Australian O 0 6.057388191038626e-07
Aboriginal O 0 1.536312879579782e-06
, O 0 6.87238876917462e-10
Chinese O 0 2.9022841019354928e-08
, O 0 8.915012478238893e-11
and O 0 2.9372318466336367e-10
Pacific O 0 2.869315096631908e-07
Islanders O 0 1.10889357074484e-06
. O 0 1.0776013681379482e-07

Results O 0 1.6195868965951377e-06
showed O 0 1.0622919432989875e-07
that O 0 5.346283971086052e-10
the O 0 6.067503388607065e-09
845 O 0 2.608719285035477e-07
G O 0 5.496443122865458e-07
- O 0 5.086444616608787e-07
- O 0 1.3144970125722466e-06
> O 0 3.719697474480199e-07
A O 0 1.9176086496486278e-08
mutation O 0 2.888899397479605e-10
was O 0 4.5740877752109554e-10
present O 0 3.639246889952652e-11
in O 0 1.6325277935047566e-11
these O 0 9.402251546775098e-12
populations O 0 5.709687063426561e-12
( O 0 4.608375746978366e-12
allele O 0 3.446626014105836e-12
frequency O 0 1.4750804744334545e-10
0 O 0 3.410796992064924e-11
. O 0 1.883505070660041e-12
32 O 0 1.059574789019635e-10
% O 0 2.238067196846938e-11
) O 0 3.879250219662733e-12
, O 0 6.149094254614962e-12
and O 0 3.078061763805984e-11
, O 0 6.987936618241264e-11
furthermore O 0 2.126078868514014e-09
, O 0 9.52815951138497e-11
it O 0 4.340473119812671e-11
was O 0 1.0284208151745133e-08
always O 0 4.29107149813035e-09
seen O 0 3.1359499441663274e-09
in O 0 5.747026743385675e-10
conjunction O 0 8.007561724809875e-09
with O 0 3.975107354392549e-09
HLA O 0 2.3412565496983007e-05
haplotypes O 0 1.7625525572384504e-07
common O 0 1.2391471182482405e-09
in O 0 2.007057631203679e-09
Caucasians O 0 6.105572225578726e-08
, O 0 2.2183740955306064e-10
suggesting O 0 2.0814956425141418e-09
that O 0 1.2042586372551511e-10
845 O 0 3.286210770170328e-08
G O 0 1.2496485624069464e-07
- O 0 2.1007255668337166e-07
- O 0 1.7916918295668438e-06
> O 0 1.5615797792634112e-06
A O 0 4.3101081814711506e-07
may O 0 5.9671609875522336e-09
have O 0 2.6770288763522387e-10
been O 0 1.950038602815951e-10
introduced O 0 3.1421254487185024e-11
into O 0 1.6890048387674383e-11
these O 0 6.065180042230667e-12
populations O 0 1.3703019621780221e-11
by O 0 2.9739588569555053e-10
Caucasian O 0 4.2017168766506074e-07
admixture O 0 7.645499522368482e-07
. O 0 6.142646924445216e-08

187 O 0 5.583739834946755e-07
C O 0 2.979469968522608e-07
- O 0 3.517401836461431e-08
- O 0 1.2744669675157638e-07
> O 0 3.8632654764114704e-07
G O 0 2.284497639948313e-07
was O 0 2.5276108317484614e-08
present O 0 1.5903106609371775e-09
at O 0 8.211070046115765e-09
an O 0 1.6228918209293397e-10
allele O 0 1.7468167190504147e-10
frequency O 0 3.403872739227154e-09
of O 0 2.685269784308275e-08
2 O 0 7.574904543616867e-07
. O 0 7.254931944089549e-08

68 O 0 1.946596057678107e-06
% O 0 5.975988592865633e-09
in O 0 1.5951369392031012e-10
the O 0 1.6786994017081724e-10
two O 0 3.243209173442452e-11
populations O 0 1.0851855004878619e-11
analyzed O 0 1.0748375522950937e-09
( O 0 7.440170701755733e-10
Australian O 0 1.5696797106556915e-07
Aboriginal O 0 7.654780347365886e-07
and O 0 1.3705544477105036e-09
Chinese O 0 3.0064825295994524e-07
) O 0 1.3783403307598974e-09
. O 0 3.4977911678168994e-09

In O 0 1.3427013811906363e-07
the O 0 1.834557927793412e-08
Australian O 0 8.218531633019666e-08
Aboriginal O 0 2.3652674485674652e-08
samples O 0 1.1927625553909138e-10
, O 0 3.567374173840676e-11
187 O 0 2.710636437530667e-10
C O 0 2.2613866335063904e-09
- O 0 1.8379052724171174e-09
- O 0 2.565197299020383e-08
> O 0 1.1945240885324893e-07
G O 0 1.7410100383585814e-07
was O 0 2.604957316520995e-08
found O 0 6.430855292727244e-10
to O 0 1.8136223078890623e-10
be O 0 7.294163051341229e-10
associated O 0 9.272259404724537e-09
with O 0 1.5140365405841294e-08
HLA O 1 0.9337754249572754
haplotypes O 0 4.641094164981041e-06
common O 0 2.7253831191842437e-08
in O 0 2.232719786832149e-08
Caucasians O 0 5.484055236593122e-07
, O 0 1.352911116470068e-09
suggesting O 0 1.6245721212726494e-08
that O 0 8.495722181312004e-11
it O 0 4.655928420582711e-11
was O 0 1.9353183500214755e-09
introduced O 0 2.2954510514594517e-10
by O 0 2.3278444449825741e-10
recent O 0 2.4315849334044515e-09
admixture O 0 1.0032479025312568e-07
. O 0 2.363017337358997e-08

In O 0 2.4527531650164747e-07
the O 0 1.3544790178343646e-08
Chinese O 0 1.1712987912915196e-08
samples O 0 4.138794515440303e-11
analyzed O 0 3.070241560987341e-10
, O 0 3.928095348992855e-11
187 O 0 4.2093969976342294e-10
C O 0 2.515326391616668e-09
- O 0 1.457962750528452e-09
- O 0 2.097210050067133e-08
> O 0 9.20837379680961e-08
G O 0 6.039425670678611e-08
was O 0 2.176074787030302e-08
present O 0 1.3126026932042123e-09
in O 0 2.2835222601713667e-09
association O 0 8.890005398498602e-10
with O 0 1.780344968671521e-11
a O 0 1.562358797890795e-09
wide O 0 7.349129083067396e-10
variety O 0 1.4256349434305093e-09
of O 0 6.074592988625227e-07
HLA O 0 5.0612317863851786e-05
haplotypes O 0 1.7785733064101805e-07
, O 0 2.0600519901048386e-10
showing O 0 1.8692389858188108e-09
this O 0 8.868119433236288e-11
mutation O 0 3.0224326513783595e-11
to O 0 4.5269052395546794e-11
be O 0 2.879377014597395e-10
widespread O 0 2.555263556303089e-09
and O 0 1.5647975970534134e-10
likely O 0 1.7431431853509594e-09
to O 0 1.8162887860384558e-09
predate O 0 4.923288443592355e-08
the O 0 9.475823459226262e-10
more O 0 8.457480375756443e-12
genetically O 0 1.3369974398436124e-11
restricted O 0 1.467173327274196e-10
845 O 0 5.3093383023394836e-09
G O 0 1.4240702839174446e-08
- O 0 2.3848143015925416e-08
- O 0 1.5609855097409309e-07
> O 0 1.9062824208049278e-07
A O 0 9.05671129203256e-08
mutation O 0 6.705618282865089e-09
. O 0 3.319806651802537e-09

Genotype O 0 2.9351147531997412e-05
- O 0 1.0179574019275606e-06
phenotype O 0 2.406028443147079e-07
correlations O 0 1.1783256468334002e-06
in O 0 3.7219899695628555e-07
attenuated B-Disease 1 0.9998192191123962
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
coli I-Disease 1 1.0
. O 0 1.2542659533210099e-06

Germ O 0 0.17105866968631744
- O 0 7.729212666163221e-05
line O 0 4.6100203121568484e-07
mutations O 0 2.495734108265424e-08
of O 0 1.4371296153115054e-08
the O 0 6.508403060934143e-08
tumor B-Disease 0 1.669205812504515e-05
suppressor O 0 1.4060758985579014e-05
APC O 0 3.3090927331613784e-08
are O 0 7.486902070530377e-11
implicated O 0 3.93651653496363e-08
in O 0 1.34034351617629e-07
attenuated B-Disease 1 0.9999054670333862
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
coli I-Disease 1 1.0
( O 1 0.7308464646339417
AAPC B-Disease 1 1.0
) O 0 5.494931620830812e-09
, O 0 6.260172241701056e-11
a O 0 2.545107236073818e-09
variant O 0 4.525849703895801e-07
of O 1 0.9357760548591614
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 1 0.9932123422622681
FAP B-Disease 0 0.00011489776079542935
) O 0 5.27876515832304e-08
. O 0 5.460977092752728e-08

AAPC B-Disease 1 1.0
is O 0 2.3189267039924744e-07
recognized O 0 8.431754849880235e-09
by O 0 3.275025528548525e-10
the O 0 1.957343398473199e-09
occurrence O 0 9.051598937048766e-08
of O 0 1.514015650627698e-07
< O 0 3.811894930549897e-05
100 O 0 1.245899397872563e-06
colonic B-Disease 0 0.0017531865742057562
adenomas I-Disease 0 0.00015914952382445335
and O 0 1.2044683028733516e-09
a O 0 2.883582927992734e-09
later O 0 2.7075440556245667e-08
onset O 0 0.12178535014390945
of O 1 0.999894380569458
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 1.5812562992323365e-07
age O 0 5.789632950836676e-08
> O 0 2.027968903917099e-08
40 O 0 2.297900980607892e-09
years O 0 1.0147805928895082e-09
) O 0 8.033564369291923e-10
. O 0 3.5706517742539745e-09

The O 0 8.287239552373649e-07
aim O 0 4.2144827716583677e-07
of O 0 1.2158992035438132e-08
this O 0 5.8230725796804e-10
study O 0 7.499911802710812e-10
was O 0 2.332966042573048e-09
to O 0 1.0816152834491888e-10
assess O 0 2.5842563644573602e-08
genotype O 0 2.6121225005226734e-07
- O 0 1.1623482265576968e-07
phenotype O 0 8.903248982505829e-08
correlations O 0 1.216379132529255e-06
in O 0 7.166641466938017e-07
AAPC B-Disease 1 1.0
families O 0 2.7317071271681925e-07
. O 0 8.303522491814874e-08

By O 0 2.871258573122759e-07
protein O 0 1.467108319275212e-07
- O 0 4.687103327682962e-08
truncation O 0 9.466326673646108e-07
test O 0 3.1141716760885174e-08
( O 0 1.1446233827427932e-07
PTT O 0 2.6820387574844062e-05
) O 0 5.37099809072572e-10
assay O 0 2.2787665088230824e-09
, O 0 2.1731599159080517e-11
the O 0 1.5977251466292586e-10
entire O 0 3.3589667935984835e-08
coding O 0 6.971119859144892e-08
region O 0 1.515302017196518e-08
of O 0 6.840121358209217e-08
the O 0 4.6399426878451777e-07
APC B-Disease 0 7.615075219291612e-07
gene O 0 1.0850872422807356e-09
was O 0 4.229704586578009e-09
screened O 0 9.710736659229724e-10
in O 0 2.1340894329480165e-10
affected O 0 1.9215352919932371e-10
individuals O 0 1.8363696674406071e-10
from O 0 1.5170806832998096e-08
11 O 0 4.9866619519889355e-05
AAPC B-Disease 1 1.0
kindreds O 0 0.016666587442159653
, O 0 1.394789950204256e-09
and O 0 6.468531960068802e-11
their O 0 2.2007411171198754e-10
phenotypic O 0 1.3667853515642037e-08
differences O 0 2.3864433984499556e-08
were O 0 1.445742299210906e-07
examined O 0 1.3185008356231265e-06
. O 0 1.2367492274734104e-07

Five O 0 2.4183500499930233e-06
novel O 0 2.2535271000379e-06
germ O 0 0.0005757942562922835
- O 0 0.00037231101305224
line O 0 3.5575653782871086e-06
APC B-Disease 0 3.6967708183510695e-07
mutations O 0 2.3077662003601063e-09
were O 0 4.720809076985688e-09
identified O 0 1.1516777753683982e-08
in O 0 2.1141747907904573e-08
seven O 0 9.189440106638358e-07
kindreds O 0 7.860277401050553e-05
. O 0 9.807281458051875e-07

Mutations O 0 2.4329577286152926e-07
were O 0 3.138051596351943e-08
located O 0 3.711580376375423e-09
in O 0 9.824111663059298e-11
three O 0 5.0221080766243986e-11
different O 0 1.7458767070932524e-11
regions O 0 1.3136570720106988e-09
of O 0 2.454447098898527e-07
the O 0 1.6050551039370475e-06
APC B-Disease 0 9.15776126930723e-07
gene O 0 3.382186086753336e-09
( O 0 6.325794332795454e-10
1 O 0 8.452010646919916e-09
) O 0 2.4665472442286784e-10
at O 0 4.0763192821202665e-09
the O 0 1.8350330144301097e-09
5 O 0 2.5331752695478826e-08
end O 0 4.740327597119176e-08
spanning O 0 1.8467056861481979e-07
exons O 0 1.3330780035403222e-08
4 O 0 3.074356547116963e-09
and O 0 6.991029977143626e-11
5 O 0 1.5763313987449123e-09
, O 0 1.0790622562151242e-10
( O 0 1.7510834449119272e-10
2 O 0 1.2138524629889957e-09
) O 0 4.259761293701203e-11
within O 0 7.460562723160535e-10
exon O 0 1.6462123886284985e-09
9 O 0 3.5145364396527157e-09
, O 0 2.5977687015399376e-11
and O 0 1.1964856883039943e-10
( O 0 7.184064454435202e-10
3 O 0 7.83756881617137e-09
) O 0 2.1517546078264616e-10
at O 0 2.6226740779122792e-09
the O 0 4.9074415642280655e-09
3 O 0 8.7551256910956e-08
distal O 0 4.779338880211981e-08
end O 0 2.2428269019769687e-08
of O 0 3.839859630261344e-08
the O 0 7.705987314921003e-08
gene O 0 4.603483105825035e-08
. O 0 2.816173783060094e-08

Variability O 0 6.409311754396185e-05
in O 0 1.3283520061690979e-08
the O 0 4.596172775706009e-09
number O 0 3.869540421419515e-08
of O 0 0.00015746193821541965
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
was O 0 2.9800385163980536e-05
most O 0 5.645185985336809e-10
apparent O 0 5.4879873978563865e-09
in O 0 9.669368083997654e-11
individuals O 0 2.4420774430433667e-11
with O 0 1.9491155217599143e-11
mutations O 0 4.4509476659904124e-10
in O 0 1.0658939508800813e-08
region O 0 1.1372657127139973e-07
1 O 0 3.296855356893502e-05
, O 0 1.7017343090230952e-09
and O 0 4.765599914691165e-09
upper O 1 0.9999946355819702
- O 1 0.9975818395614624
gastrointestinal O 1 0.5625478625297546
manifestations O 1 0.9996238946914673
were O 0 1.9119009664336772e-07
more O 0 8.431440962075598e-11
severe O 0 6.228069615588083e-09
in O 0 5.569656957860047e-10
them O 0 3.3606246674366957e-09
. O 0 3.304248963331702e-08

In O 0 4.299225153658881e-08
individuals O 0 3.0994132260708795e-10
with O 0 5.803599267828474e-11
mutations O 0 9.422188584906621e-10
in O 0 3.695354910959736e-09
either O 0 1.1315239412112987e-08
region O 0 7.697657622429688e-08
2 O 0 8.373235687031411e-07
or O 0 1.3493477446502311e-08
region O 0 6.6219478789264485e-09
3 O 0 2.9229555664755935e-08
, O 0 5.799881408474761e-11
the O 0 4.0151870717153315e-10
average O 0 5.874884134726699e-09
number O 0 5.256204360648553e-10
of O 0 1.7829847820394207e-08
adenomas B-Disease 0 1.1024195373465773e-05
tended O 0 1.0257545923764155e-08
to O 0 2.982888935854078e-10
be O 0 1.954570533202471e-10
lower O 0 7.445948857487394e-10
than O 0 1.9760068581398116e-11
those O 0 2.3759969686176774e-12
in O 0 1.4091103284208373e-11
individuals O 0 9.522250175864055e-12
with O 0 2.002725676270023e-12
mutations O 0 7.73734618042532e-11
in O 0 3.6375763512452863e-10
region O 0 1.5257302088400593e-09
1 O 0 2.215509375957936e-08
, O 0 6.66979318997285e-11
although O 0 1.1209456279859253e-10
age O 0 5.549543935501333e-09
at O 0 6.576424027571193e-08
diagnosis O 0 1.7130297180756315e-07
was O 0 2.1788451931570307e-08
similar O 0 2.1905866010030195e-09
. O 0 2.018090938804562e-08

In O 0 6.122859758761479e-06
all O 0 2.995295062646619e-06
AAPC B-Disease 1 1.0
kindreds O 0 0.0010223326971754432
, O 0 9.595411576412971e-09
a O 0 2.7497568666490224e-08
predominance O 0 1.6379764247176354e-06
of O 0 6.387680059560807e-06
right O 1 0.9999727010726929
- O 1 1.0
sided O 1 1.0
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and O 0 0.31968003511428833
rectal B-Disease 1 1.0
polyp I-Disease 0 0.25760728120803833
sparing O 0 1.7865627341961954e-06
was O 0 2.7871473662344215e-07
observed O 0 1.4695308436785126e-07
. O 0 4.1735379596730127e-08

No O 0 0.003004619851708412
desmoid B-Disease 1 0.999998927116394
tumors I-Disease 1 1.0
were O 0 9.4296370889424e-07
found O 0 2.2669805588293457e-08
in O 0 5.372506883816186e-09
these O 0 1.0016872664664334e-08
kindreds O 0 1.597402115294244e-05
. O 0 4.137317830554821e-07

Our O 0 1.4262592458180734e-06
data O 0 2.1987717957472341e-07
suggest O 0 6.328561674706634e-09
that O 0 1.3368094131660513e-10
, O 0 4.829467936673382e-10
in O 0 5.132941893748466e-08
AAPC B-Disease 1 1.0
families O 0 2.807078658406681e-08
, O 0 1.9682065699466733e-10
the O 0 2.176779645424176e-09
location O 0 1.27250316950267e-07
of O 0 5.892483301295215e-08
the O 0 2.3720515684999555e-07
APC B-Disease 0 1.9838912521663588e-06
mutation O 0 1.902644930495967e-09
may O 0 2.5448838592012635e-09
partially O 0 6.456781420638436e-08
predict O 0 1.1618069173380263e-08
specific O 0 1.081723155493819e-09
phenotypic O 0 2.198631392502648e-07
expression O 0 2.8018797593176714e-07
. O 0 5.300436711763723e-08

This O 0 2.827148080086772e-07
should O 0 1.336298272036629e-08
help O 0 6.9992824869302694e-09
in O 0 1.6228864918588215e-09
the O 0 1.315537567769809e-09
design O 0 7.09035674617553e-09
of O 0 4.9763722032025726e-09
tailored O 0 3.657621761021801e-09
clinical O 0 3.824371560767759e-06
- O 0 2.323154575378794e-07
management O 0 5.3503395491816264e-08
protocols O 0 1.5006850873078292e-08
in O 0 4.769762917966602e-10
this O 0 6.832577836846099e-10
subset O 0 1.121462531727957e-07
of O 0 1.274443395260505e-08
FAP B-Disease 0 6.900713742652442e-07
patients O 0 1.2886565148306772e-09
. O 0 2.809491250754803e-10
. O 0 8.05638578071921e-09

Wilms B-Disease 1 0.9999998807907104
' I-Disease 0 4.406021616887301e-05
tumor I-Disease 0 2.3329398572968785e-06
1 O 0 1.6511825151610537e-07
and O 0 6.302518062994977e-09
Dax O 0 8.022259862627834e-05
- O 0 1.1257787946306053e-07
1 O 0 1.1109602127135076e-07
modulate O 0 8.955910857366689e-08
the O 0 2.9733873141424283e-09
orphan O 0 4.4340815463783656e-08
nuclear O 0 1.6483944875744783e-07
receptor O 0 1.5646760402887594e-06
SF O 0 7.232649295474403e-06
- O 0 3.272960125144664e-09
1 O 0 1.0815168760558436e-09
in O 0 8.513061783288478e-11
sex O 0 2.325323961160919e-10
- O 0 2.392146480900692e-10
specific O 0 2.896192730084124e-10
gene O 0 2.6767799088389665e-09
expression O 0 2.0624524310619563e-08
. O 0 1.6368298716429308e-08

Products O 0 7.865066464773918e-08
of O 0 3.6446743933993275e-07
steroidogenic O 0 0.00011992964573437348
factor O 0 2.6054897261929e-06
1 O 0 4.4256663045416644e-07
( O 0 1.433037422060579e-08
SF O 0 6.3580523601558525e-06
- O 0 4.6638188422321036e-08
1 O 0 7.1916936406069e-08
) O 0 6.098164750945045e-10
and O 0 3.9646785854330346e-10
Wilms B-Disease 0 0.0005004944396205246
tumor I-Disease 0 1.4343356724566547e-06
1 O 0 1.8357067688157258e-07
( O 0 1.3941569010356147e-09
WT1 O 0 1.5955164656134002e-07
) O 0 4.1391813587754456e-11
genes O 0 9.011101760603157e-12
are O 0 1.4556375852944892e-12
essential O 0 6.963070398047222e-11
for O 0 2.065032450593307e-10
mammalian O 0 1.235613922290213e-07
gonadogenesis O 0 4.063490166572592e-07
prior O 0 5.32764126148777e-08
to O 0 2.803219434355242e-09
sexual O 0 1.1448504722011421e-07
differentiation O 0 2.9792937539241393e-07
. O 0 2.7549015513272934e-08

In O 0 1.7227972648470313e-07
males O 0 1.0273660144832775e-08
, O 0 1.2363219781263979e-08
SF O 0 0.0008034525089897215
- O 0 2.2706744573497417e-07
1 O 0 7.220585018785641e-08
participates O 0 3.3874476557116395e-09
in O 0 1.6618086073894034e-10
sexual O 0 1.7731758283900945e-09
development O 0 1.820221418036283e-09
by O 0 1.894756296305644e-10
regulating O 0 1.5137883835336652e-08
expression O 0 2.0596326866240133e-09
of O 0 4.999004321604161e-09
the O 0 3.5572554679674795e-08
polypeptide O 0 3.970699253841303e-05
hormone O 0 6.894031230331166e-07
Mullerian O 0 9.001098806038499e-05
inhibiting O 0 5.444959469969035e-07
substance O 0 4.284094075046596e-07
( O 0 1.0547148576733889e-07
MIS O 0 3.5721968743018806e-05
) O 0 6.4746119576852834e-09
. O 0 1.177487884973516e-08

Here O 0 2.014420033447095e-06
, O 0 6.146031239495642e-09
we O 0 1.0332042776894923e-08
show O 0 2.5432161265825926e-08
that O 0 6.168603849943111e-09
WT1 O 0 4.383449777378701e-05
- O 0 2.502467941667419e-05
KTS O 0 0.05863521620631218
isoforms O 0 6.192436785568134e-07
associate O 0 2.2733915727712883e-07
and O 0 5.724009599639146e-10
synergize O 0 3.175490519424784e-07
with O 0 2.515130859137571e-08
SF O 1 0.999872088432312
- O 0 5.063569915364496e-06
1 O 0 1.2593815199579694e-06
to O 0 1.514331238183786e-08
promote O 0 3.962835251059005e-07
MIS O 0 0.008127436973154545
expression O 0 3.4601202969497535e-07
. O 0 2.4349230187681314e-08

In O 0 1.6943594971507991e-07
contrast O 0 1.0142802864265832e-07
, O 0 2.1646743064707152e-08
WT1 O 0 0.0014971067430451512
missense O 0 5.823986793984659e-05
mutations O 0 1.2624170153685554e-08
, O 0 3.5862116054552473e-10
associated O 0 7.387007006087742e-09
with O 0 7.604492147095243e-09
male B-Disease 0 8.135236566886306e-05
pseudohermaphroditism I-Disease 1 1.0
in O 0 5.477350714500062e-05
Denys B-Disease 1 1.0
- I-Disease 1 1.0
Drash I-Disease 1 1.0
syndrome I-Disease 1 1.0
, O 0 1.5609795411819505e-07
fail O 0 1.7240906799997902e-06
to O 0 9.035626646891615e-08
synergize O 0 4.1068684367928654e-05
with O 0 1.6666627971062553e-06
SF O 1 1.0
- O 0 0.0008595314575359225
1 O 0 3.9687987737124786e-05
. O 0 8.005763163509982e-08

Additionally O 0 1.118633463192964e-06
, O 0 2.1829829055519667e-09
the O 0 9.121405852852149e-09
X O 0 1.2995064025744796e-05
- O 0 4.232273340676329e-07
linked O 0 1.0930539247056004e-06
, O 0 2.6879523606915257e-10
candidate O 0 5.757405663331383e-10
dosage O 0 3.777617862965599e-08
- O 0 2.1431596053389512e-08
sensitive O 0 8.326010458858946e-08
sex O 0 8.917486304937938e-09
- O 0 8.641641180417992e-09
reversal O 0 9.582264937080254e-08
gene O 0 1.973948338118703e-09
, O 0 6.841967548076866e-10
Dax O 0 4.392019400256686e-05
- O 0 1.2534214022252854e-07
1 O 0 2.0170466541458154e-07
, O 0 1.0437849473632355e-09
antagonizes O 0 2.296562229275878e-07
synergy O 0 1.6721955375942343e-07
between O 0 3.023069155005942e-07
SF O 0 0.00020706807845272124
- O 0 1.218862450969027e-07
1 O 0 4.430505384789285e-08
and O 0 4.977091516700227e-10
WT1 O 0 2.955932814074913e-06
, O 0 2.3027438289524582e-10
most O 0 4.9635132809422444e-11
likely O 0 6.521976708695476e-11
through O 0 3.307366602811612e-10
a O 0 1.507152735946704e-09
direct O 0 1.993140985590003e-09
interaction O 0 1.001308991277483e-08
with O 0 3.067304632509149e-09
SF O 1 0.9876093864440918
- O 0 1.3802090506942477e-05
1 O 0 2.676271606105729e-06
. O 0 4.942095799265189e-08

We O 0 1.0393215461590444e-06
propose O 0 2.0362990937883296e-07
that O 0 4.508248352408373e-08
WT1 O 0 2.2119906134321354e-05
and O 0 1.7776982019768184e-07
Dax O 0 0.18439161777496338
- O 0 1.2457473985705292e-06
1 O 0 3.48738126376702e-07
functionally O 0 7.874207597069471e-08
oppose O 0 2.3735396981194867e-10
each O 0 3.17545503780714e-11
other O 0 1.4643572812667038e-11
in O 0 1.078657385633619e-09
testis O 0 5.159276952326763e-07
development O 0 1.0548049544922833e-08
by O 0 2.842859725404878e-09
modulating O 0 4.950147740601096e-07
SF O 0 0.00035994878271594644
- O 0 7.254959086822055e-07
1 O 0 1.1373779216228286e-06
- O 0 1.191559064750436e-07
mediated O 0 3.659780531961587e-07
transactivation O 0 9.621081517252605e-06
. O 0 1.9707919740596935e-09
. O 0 6.440297628529379e-09

A O 0 4.553698090603575e-06
mouse O 0 7.76525581613896e-08
model O 0 1.4181801510915193e-08
for O 0 2.3882646971173926e-08
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
imprinting O 1 0.9999979734420776
- O 0 0.0002886659058276564
centre O 0 2.5555436877766624e-06
mutations O 0 2.5726899366418365e-07
. O 0 7.27613453932463e-08

Imprinting O 0 0.00040450808592140675
in O 0 3.1516293574895826e-07
the O 0 1.5269151276697812e-07
15q11 O 0 2.361711722187465e-06
- O 0 5.595215952780563e-07
q13 O 0 8.974581078291521e-07
region O 0 1.3821582989237413e-08
involves O 0 3.047479069095971e-08
an O 0 5.977584205396624e-09
imprinting O 0 1.0795388334372547e-06
centre O 0 1.7572299384482903e-06
( O 0 2.0820328572312974e-08
IC O 0 9.597900998414843e-07
) O 0 3.9080691460746664e-10
, O 0 4.0829523789698285e-11
mapping O 0 6.334756275094833e-09
in O 0 1.4550013416325669e-09
part O 0 3.3399334409267567e-09
to O 0 8.023722131156319e-09
the O 0 3.658488978430796e-08
promoter O 0 4.865354981120618e-07
and O 0 6.399961449687908e-09
first O 0 1.7398764384779497e-07
exon O 0 6.3350370282933e-07
of O 0 6.205933118508256e-07
SNRPN O 0 0.0007335154223255813
. O 0 1.0662599834176945e-06

Deletion O 0 1.1590396752581e-05
of O 0 1.9785335325650522e-07
this O 0 1.3661442643808641e-08
IC O 0 7.152649232011754e-06
abolishes O 0 9.450796767396241e-08
local O 0 1.113698733234969e-08
paternally O 0 2.79592200058687e-07
derived O 0 1.4744237830655038e-08
gene O 0 1.0999802180222673e-09
expression O 0 9.126169264739303e-10
and O 0 6.366886184938636e-11
results O 0 2.8287747699806687e-09
in O 0 9.252900667888753e-08
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 1 0.7610297799110413
PWS B-Disease 1 1.0
) O 0 2.5512866841381765e-07
. O 0 3.195229680841294e-08

We O 0 3.2846946851350367e-07
have O 0 1.0356463464589183e-09
created O 0 2.909643415094365e-09
two O 0 1.7847530120462807e-09
deletion O 0 1.7571709420849402e-08
mutations O 0 3.430916439839393e-09
in O 0 1.0095435598600488e-08
mice O 0 7.221755993214174e-08
to O 0 2.0830180247344288e-08
understand O 0 9.155429870588705e-05
PWS B-Disease 1 1.0
and O 0 4.081510596165572e-08
the O 0 3.323070529859251e-08
mechanism O 0 1.3089710648728214e-07
of O 0 5.542448633377717e-08
this O 0 2.060619941346431e-08
IC O 0 9.93705543805845e-06
. O 0 4.48078161241483e-08

Mice O 0 0.2144104689359665
harbouring O 0 0.0049570584669709206
an O 0 1.0660530591621864e-07
intragenic O 0 1.4549873412761372e-05
deletion O 0 5.229061343925423e-07
in O 0 3.789315883295785e-08
Snrpn O 0 0.0010790727101266384
are O 0 1.2383255310055574e-08
phenotypically O 0 2.2054382498026825e-05
normal O 0 2.9494308364519384e-06
, O 0 1.0639983338833758e-09
suggesting O 0 1.1997959958875981e-08
that O 0 1.2993130182881174e-10
mutations O 0 1.033215624168804e-09
of O 0 5.220032761599214e-08
SNRPN O 0 0.0010910221608355641
are O 0 7.566509641065977e-10
not O 0 3.6111827417251163e-10
sufficient O 0 2.872167215173249e-08
to O 0 9.205704998294095e-08
induce O 0 0.00013422264601103961
PWS B-Disease 1 1.0
. O 0 1.8357677618041635e-06

Mice O 0 6.958804533496732e-06
with O 0 4.875801429271576e-10
a O 0 6.019286846736804e-09
larger O 0 2.4494972716837538e-09
deletion O 0 2.9641137544444973e-08
involving O 0 3.8909586663748996e-08
both O 0 1.3819026811745516e-08
Snrpn O 0 0.00018332530453335494
and O 0 9.267768774634533e-09
the O 0 2.901371942698461e-07
putative O 0 0.0005002295365557075
PWS O 1 1.0
- O 0 0.0007213348872028291
IC O 0 0.00024889627820812166
lack O 0 8.51342917940201e-07
expression O 0 3.03107938748326e-08
of O 0 1.4149568627885856e-08
the O 0 2.187235104145202e-08
imprinted O 0 4.775434376824705e-07
genes O 0 9.056123673190086e-08
Zfp127 O 0 2.8852220566477627e-05
( O 0 7.474998398038224e-08
mouse O 0 8.433640630300943e-08
homologue O 0 7.59014824325277e-07
of O 0 1.4437458162319672e-07
ZNF127 O 0 6.109687819844112e-05
) O 0 3.34655432254749e-08
, O 0 8.993429112535978e-09
Ndn O 0 3.55817646777723e-05
and O 0 1.726628973131028e-08
Ipw O 0 0.00034844077890738845
, O 0 3.6654577151296053e-09
and O 0 5.859638885219454e-10
manifest O 0 2.6241897899126343e-07
several O 0 4.594217895004249e-09
phenotypes O 0 1.065768856278737e-06
common O 0 7.549981262400252e-08
to O 0 1.6646470157866133e-06
PWS B-Disease 1 1.0
infants O 1 0.9998581409454346
. O 0 4.1180211951541423e-07

These O 0 5.262148405904554e-08
data O 0 5.381350121069772e-08
demonstrate O 0 1.4593545039076616e-08
that O 0 3.048475916145321e-10
both O 0 3.690000249800818e-10
the O 0 2.1836741304070983e-09
position O 0 7.234618948359639e-08
of O 0 3.1763200070145103e-08
the O 0 1.6671567237835916e-08
IC O 0 9.119997343987052e-07
and O 0 1.8057283446282213e-10
its O 0 1.7203451163627648e-10
role O 0 1.875864352740564e-09
in O 0 4.831678945826923e-10
the O 0 8.662644490620153e-10
coordinate O 0 2.442196223029214e-09
expression O 0 5.345083931018735e-09
of O 0 2.611831417809185e-09
genes O 0 8.756786962216268e-10
is O 0 7.284927522333007e-11
conserved O 0 4.257036501087441e-09
between O 0 6.641655669881175e-09
mouse O 0 3.1731655525391034e-08
and O 0 2.2898495599665836e-10
human O 0 5.134368930015398e-09
, O 0 1.1398799265593951e-10
and O 0 1.850843089901133e-10
indicate O 0 4.089628191650263e-09
that O 0 9.034167164356788e-11
the O 0 2.465259774098172e-09
mouse O 0 1.1462145010909808e-08
is O 0 5.32060541458268e-11
a O 0 1.1455205534138813e-10
suitable O 0 1.988440079259135e-09
model O 0 2.4829935885151144e-09
system O 0 1.6840945304963384e-09
in O 0 1.789783737882189e-10
which O 0 4.09104417009587e-11
to O 0 7.131131796178636e-11
investigate O 0 2.7195345975172813e-09
the O 0 2.746840754852542e-09
molecular O 0 9.002494749665857e-08
mechanisms O 0 1.5957326127136184e-07
of O 0 9.153808377959649e-08
imprinting O 0 4.0980017956826487e-07
in O 0 2.7239679400992145e-09
this O 0 3.320444474930184e-10
region O 0 2.206976157381746e-09
of O 0 3.55772167281998e-09
the O 0 8.226949788081583e-09
genome O 0 5.804535074815931e-09
. O 0 5.962504934231561e-10
. O 0 8.956112296232277e-09

Mutations O 0 9.345642979496915e-07
of O 0 3.139204522994987e-07
the O 0 1.542790641906322e-07
ATM O 0 9.292627510149032e-06
gene O 0 4.007148390883231e-09
detected O 0 1.6132153390913118e-08
in O 0 2.182197356148663e-08
Japanese O 1 0.9999992847442627
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
patients O 0 0.00829810556024313
: O 0 2.5458293806401855e-10
possible O 0 2.8577014088426722e-09
preponderance O 0 4.964263098372612e-06
of O 0 9.383708743371244e-08
the O 0 2.0016834412217577e-08
two O 0 7.705895477272406e-09
founder O 0 1.7130049627667177e-06
mutations O 0 2.6504496375423514e-08
4612del165 O 0 5.984717290630215e-07
and O 0 2.584754454915128e-08
7883del5 O 0 1.86227225640323e-05
. O 0 5.140927328284306e-07

The O 0 5.720648914575577e-06
ATM O 0 0.00014109066978562623
( O 0 3.2545162866881583e-06
A O 1 1.0
- O 1 0.9985985159873962
T O 1 0.9999998807907104
, O 0 1.0861743726664486e-09
mutated O 0 1.9334698286854746e-09
) O 0 6.694777510141137e-10
gene O 0 2.5631796685132713e-10
on O 0 2.6929158902788686e-09
human O 0 3.921691416053363e-09
chromosome O 0 2.132773744278893e-07
11q22 O 0 1.5491452813876094e-06
. O 0 5.3074575845357685e-08

3 O 0 3.911454768967815e-06
has O 0 2.3438220253524378e-09
recently O 0 2.6416413501095803e-09
been O 0 1.3196893577926971e-09
identified O 0 1.5470871250755636e-09
as O 0 4.0745062879210536e-10
the O 0 1.064916044235531e-09
gene O 0 2.3699162077228664e-10
responsible O 0 1.1576323233342123e-09
for O 0 1.8289521286352084e-10
the O 0 5.2706159436866074e-08
human O 0 1.700514621916227e-05
recessive B-Disease 1 0.9999992847442627
disease I-Disease 1 1.0
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 1.0
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 8.685368158012352e-08
. O 0 2.605175986047925e-08

In O 0 2.898092077430192e-07
order O 0 1.3790615760456149e-08
to O 0 1.1632719232324007e-09
define O 0 4.478925674789025e-09
the O 0 8.837966469776859e-10
types O 0 2.6171373956884736e-09
of O 0 1.6419335224782117e-07
disease O 0 0.002880204003304243
- O 0 1.273123757528083e-06
causing O 0 1.0504561487323372e-06
ATM O 0 1.0279931302648038e-05
mutations O 0 1.9619930125003293e-09
in O 0 2.3147932459721687e-09
Japanese O 0 0.00019478212925605476
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 1.2226596624032027e-08
as O 0 4.0904377107686685e-10
well O 0 1.228879775716507e-10
as O 0 9.67914776106582e-11
to O 0 8.883169200224472e-11
look O 0 2.2122935428026125e-10
for O 0 1.0532518607275776e-10
possible O 0 1.2413997829696655e-08
mutational O 0 2.1115408799232682e-06
hotspots O 0 5.2278647189041294e-08
, O 0 2.409621113752536e-10
reverse O 0 4.995392099971241e-09
- O 0 9.961257596557971e-09
transcribed O 0 9.147211699200852e-08
RNA O 0 1.428114959622917e-08
derived O 0 3.171619078479182e-10
from O 0 1.6677274838894363e-10
ten O 0 6.542765884631763e-09
patients O 0 2.9592298056435595e-10
belonging O 0 1.2948143002233792e-08
to O 0 7.383749167644282e-10
eight O 0 1.628524515240315e-08
unrelated O 0 1.1936168675674708e-06
Japanese O 1 0.9922031164169312
A B-Disease 1 1.0
- I-Disease 1 0.9999992847442627
T I-Disease 1 1.0
families O 0 1.1626132279118906e-09
was O 0 2.7501119159722975e-09
analyzed O 0 9.748687412880486e-10
for O 0 5.568570604630452e-11
mutations O 0 6.377350730835118e-11
by O 0 9.239872061916898e-11
the O 0 2.2585933123764335e-09
restriction O 0 5.252869694771789e-09
endonuclease O 0 2.9134600509905795e-08
fingerprinting O 0 5.342861708612645e-09
method O 0 8.047831734359079e-09
. O 0 4.984047397016411e-09

As O 0 1.0115386430697981e-06
has O 0 4.5201020704155326e-09
been O 0 1.6589086770935069e-09
reported O 0 6.846875844068734e-10
by O 0 2.9951349733714494e-10
others O 0 9.255892718940117e-10
, O 0 4.5500547773968947e-10
mutations O 0 7.562743764566449e-10
that O 0 3.9666905871094116e-10
lead O 0 2.0709430614829216e-08
to O 0 5.898184340935586e-08
exon O 0 1.5208127024379792e-06
skipping O 0 1.575662508912501e-06
or O 0 1.5883476578437694e-07
premature O 0 1.8400569956611434e-07
protein O 0 6.220960813152487e-08
truncation O 0 9.099754606722854e-06
were O 0 1.4570022699444962e-07
also O 0 4.003901210580807e-09
predominant O 0 8.482198410320052e-08
in O 0 4.388311580783011e-08
our O 0 5.428725557976577e-07
mutants O 0 4.024747795483563e-06
. O 0 8.883910851409382e-08

Six O 0 1.2877389110599324e-07
different O 0 2.6524496488100624e-10
mutations O 0 2.562887679857795e-09
were O 0 9.360824115844935e-09
identified O 0 9.965096303687915e-09
on O 0 2.1472551736678724e-08
12 O 0 3.537592974112158e-08
of O 0 1.8309364691049268e-08
the O 0 1.6354597676127014e-08
16 O 0 9.795852662364268e-08
alleles O 0 6.606909686013296e-09
examined O 0 7.512280717492104e-07
. O 0 1.1609943584289795e-07

Four O 0 1.3069918622932164e-06
were O 0 1.4127030567578913e-07
deletions O 0 7.217115438606925e-08
involving O 0 2.70853661277215e-07
a O 0 4.992670596948301e-07
loss O 0 1.948814133356791e-05
of O 0 5.496800076798536e-05
a O 0 2.233624172731652e-06
single O 0 7.418496466016222e-07
exon O 0 6.556109610755811e-07
exon O 0 3.0669906436742167e-07
7 O 0 4.762567584748467e-07
, O 0 4.711714574057169e-09
exon O 0 1.1031180946474706e-07
16 O 0 1.3519604635803262e-07
, O 0 9.50489997819659e-09
exon O 0 5.480086997522449e-07
33 O 0 8.845797196954663e-07
or O 0 3.978318545705406e-07
exon O 0 1.913292180688586e-06
35 O 0 5.379182312026387e-06
. O 0 4.5712758378613216e-07

The O 0 1.0315109193470562e-06
others O 0 2.025066159205835e-08
were O 0 1.6385040879640655e-08
minute O 0 1.8575821769672984e-08
deletions O 0 5.73662859437718e-08
, O 0 1.77268555390242e-09
4649delA O 0 1.5184721746663854e-07
in O 0 4.467401026886364e-08
exon O 0 1.6450464102035767e-07
33 O 0 1.9028477993288107e-07
and O 0 5.984189144214724e-09
7883del5 O 0 1.730656663312402e-06
in O 0 3.3019753686858166e-07
exon O 0 4.316996182751609e-06
55 O 0 1.6478740008096793e-06
. O 0 2.8085199232918967e-07

The O 0 2.0621375824703136e-06
mutations O 0 1.1285811751804431e-07
4612del165 O 0 7.872883998061297e-07
and O 0 3.8620546760625984e-09
7883del5 O 0 6.183814775795327e-07
were O 0 4.6288491262203024e-08
found O 0 3.1531994792999285e-09
in O 0 1.1729748283784147e-09
more O 0 4.668956540831992e-11
than O 0 3.35855163124954e-11
two O 0 4.999066091637694e-11
unrelated O 0 2.1301824748576337e-09
families O 0 3.409170862278543e-11
; O 0 1.0997315905147964e-11
44 O 0 1.3713911117818611e-09
% O 0 9.14830267095823e-10
( O 0 3.785079194518204e-10
7 O 0 7.020929615464411e-09
of O 0 9.769875575216247e-09
16 O 0 2.5534427905427037e-08
) O 0 4.958538579735716e-10
of O 0 1.0579375153696446e-09
the O 0 1.234895408153136e-09
mutant O 0 8.041203258812857e-09
alleles O 0 2.82069201329449e-10
had O 0 1.3488427041963291e-09
one O 0 2.8629151826997656e-10
of O 0 1.4067271791873281e-09
the O 0 3.1026856639471134e-09
two O 0 1.951204087191627e-09
mutations O 0 9.476479156944606e-09
. O 0 4.3488494583243664e-08

The O 0 1.0823985121533042e-06
4612del165 O 0 6.69801465846831e-07
mutations O 0 1.0008980311226878e-09
in O 0 2.2872871652257487e-10
three O 0 6.430226490161672e-11
different O 0 2.9619220270893365e-11
families O 0 5.106765565976445e-10
were O 0 2.4527138098306978e-09
all O 0 9.371217135623056e-10
ascribed O 0 1.0162322183759898e-07
to O 0 5.292786209309952e-09
the O 0 1.2098359647438883e-08
same O 0 1.3311825419748402e-08
T O 0 6.237939942366211e-08
- O 0 4.04135249709725e-08
- O 0 1.980829154035746e-07
> O 0 1.113682230879931e-07
A O 0 1.2596557574795497e-08
substitution O 0 1.0806013861497377e-09
at O 0 8.079345192868459e-09
the O 0 1.1918017683854032e-08
splice O 0 5.125585289533774e-07
donor O 0 8.872121703973335e-09
site O 0 5.4958565698370876e-08
in O 0 2.0584359106123884e-08
intron O 0 1.0219103387498762e-05
33 O 0 2.2928534235688858e-06
. O 0 1.697398488431645e-07

Microsatellite O 0 0.0019983600359410048
genotyping O 0 2.6593230359139852e-05
around O 0 3.474382026524836e-07
the O 0 2.3317534214584157e-07
ATM O 0 0.00029834534507244825
locus O 0 1.1867805369547568e-06
also O 0 1.326885268326805e-09
indicated O 0 3.4049114638889932e-09
that O 0 1.0963938090746694e-10
a O 0 5.827008653369603e-09
common O 0 2.024242773401852e-09
haplotype O 0 6.268508911944082e-08
was O 0 7.318837447201076e-08
shared O 0 6.3405707351194e-09
by O 0 5.609123721050935e-10
the O 0 1.329705012764748e-09
mutant O 0 5.169715322494994e-09
alleles O 0 1.7758082504482076e-10
in O 0 3.4679489835376387e-10
both O 0 8.977863452663826e-10
mutations O 0 4.3667863991458944e-08
. O 0 5.7416205123672626e-08

This O 0 9.911966003528505e-08
suggests O 0 1.7307801414290225e-08
that O 0 3.01522383450159e-11
these O 0 1.0926964194579725e-10
two O 0 1.198420807035916e-09
founder O 0 5.631065960187698e-07
mutations O 0 4.535024356044914e-09
may O 0 4.246056839463108e-09
be O 0 2.4736341863729194e-09
predominant O 0 6.86894878754174e-08
among O 0 3.4504334944784887e-09
Japanese O 0 9.103357001549739e-07
ATM O 0 4.266368250682717e-06
mutant O 0 2.3508576418862503e-07
alleles O 0 1.0686360241152215e-08
. O 0 1.3271997723052209e-08

W474C O 0 2.9664170142496005e-05
amino O 0 2.600400819119386e-07
acid O 0 6.3441758513249624e-09
substitution O 0 3.417396809979323e-09
affects O 0 8.899149195329414e-10
early O 0 2.4946003041037557e-09
processing O 0 9.59262980160247e-09
of O 0 2.9731847206448947e-08
the O 0 1.2953107919599915e-08
alpha O 0 1.030771841215028e-07
- O 0 2.515110342216076e-09
subunit O 0 4.0825536729016676e-08
of O 0 8.512648363989683e-09
beta O 0 7.98942565438665e-08
- O 0 7.49479678319176e-09
hexosaminidase O 0 1.5499712446853664e-07
A O 0 2.3379385538646602e-08
and O 0 1.0979905179508975e-10
is O 0 2.2863450022114762e-10
associated O 0 3.09955661137451e-09
with O 0 1.3366622253485616e-09
subacute O 0 0.293417364358902
G B-Disease 1 0.9999803304672241
( I-Disease 0 2.574639620434027e-05
M2 I-Disease 0 0.0009293131879530847
) I-Disease 0 1.363385564445707e-07
gangliosidosis I-Disease 0 1.1443485163908917e-05
. O 0 1.85728694646059e-07

Mutations O 0 3.1390578669743263e-07
in O 0 1.9666211770186237e-08
the O 0 7.637885346412077e-08
HEXA O 0 2.4310067601618357e-05
gene O 0 1.841617858211464e-09
, O 0 5.5869971843369726e-11
encoding O 0 1.4907526602048193e-10
the O 0 1.2890990497282928e-09
alpha O 0 1.172733909982071e-08
- O 0 7.008309488298892e-10
subunit O 0 3.00035267741805e-08
of O 0 1.5189741020549263e-08
beta O 0 8.300291653995373e-08
- O 0 2.7057682316922183e-08
hexosaminidase O 0 1.0284128393323044e-06
A O 0 2.16356147575425e-06
( O 0 2.4472056381341645e-08
Hex O 0 2.844005621227552e-06
A O 0 3.5451049029688875e-07
) O 0 6.829581344902635e-10
, O 0 3.926447361690677e-11
that O 0 1.256065251808991e-10
abolish O 0 4.5430954997982553e-08
Hex O 0 7.0439150476886425e-06
A O 0 1.2768295221121662e-07
enzyme O 0 5.4261327875337884e-08
activity O 0 7.346710617639474e-07
cause O 0 0.0017762063071131706
Tay B-Disease 1 1.0
- I-Disease 1 1.0
Sachs I-Disease 1 1.0
disease I-Disease 1 1.0
( O 0 1.285227767766628e-06
TSD B-Disease 1 0.9943721294403076
) O 0 1.6138268499332753e-09
, O 0 7.808047264301621e-11
the O 0 3.2120623938425297e-09
fatal O 0 2.95942481898237e-06
infantile B-Disease 0 1.181514193149269e-07
form I-Disease 0 5.0605653001412065e-09
of I-Disease 0 5.442755536932964e-06
G I-Disease 0 6.966100772842765e-05
( I-Disease 0 1.3613470173368114e-07
M2 I-Disease 0 7.47362491893e-06
) I-Disease 0 4.4276902144702035e-09
gangliosidosis I-Disease 0 1.2306219332458568e-07
, I-Disease 0 6.822121201288667e-10
Type I-Disease 0 2.7278332481728285e-07
1 I-Disease 0 1.6874445236680913e-06
. O 0 7.531600232368874e-08

Less O 0 8.468875876133097e-07
severe O 0 5.6108319768100046e-06
, O 0 1.2857749531747231e-08
subacute O 0 0.2393951416015625
( O 0 1.742667564030853e-06
juvenile O 0 0.001156236743554473
- O 0 4.372288913145894e-06
onset O 1 0.9999961853027344
) O 0 6.120248752239377e-09
and O 0 2.0566139902200575e-09
chronic O 1 1.0
( O 0 2.798867342335143e-07
adult O 0 3.7176516798353987e-06
- O 0 4.867086431659118e-07
onset O 1 0.6789208054542542
) O 0 4.4608233773502093e-10
variants O 0 3.1291308433267773e-10
are O 0 8.775704989083533e-12
characterized O 0 3.748171911732712e-11
by O 0 5.283723458759937e-11
a O 0 5.38503075464547e-10
broad O 0 2.4696447664673826e-10
spectrum O 0 4.557906829738556e-10
of O 0 1.915878344860289e-09
clinical O 0 9.235761666559483e-08
manifestations O 0 7.04980962495938e-08
and O 0 9.385217603075091e-11
are O 0 2.3233278148571124e-11
associated O 0 6.978057576212393e-10
with O 0 8.332798340227043e-11
residual O 0 0.00015751027967780828
levels O 0 1.4450077287619933e-05
of O 0 1.9491949387884233e-06
Hex O 0 8.350025746040046e-05
A O 0 5.010261361348967e-07
enzyme O 0 7.389137834934445e-08
activity O 0 1.36894755087269e-07
. O 0 5.303042893700649e-09

We O 0 6.672028689536091e-07
identified O 0 1.7299409194038162e-07
a O 0 7.509595434385119e-08
1422 O 0 2.411339892205433e-06
G O 0 7.293327826118912e-07
- O 0 1.2289072515159205e-07
- O 0 2.0763150132552255e-07
> O 0 3.296129591490171e-07
C O 0 6.159471581668186e-07
( O 0 2.2244934783088866e-09
amino O 0 2.947154964516585e-09
acid O 0 1.437490682043574e-09
W474C O 0 1.87496382864083e-08
) O 0 1.3289259970239442e-10
substitution O 0 6.232843685616274e-10
in O 0 6.134937002855168e-10
the O 0 3.6956298021806333e-09
first O 0 2.444192048756122e-08
position O 0 1.2408818861331383e-07
of O 0 2.465694137754326e-07
exon O 0 3.269212811574107e-07
13 O 0 3.450981864716596e-07
of O 0 6.425931928788486e-07
HEXA O 0 0.003206711495295167
of O 0 4.899068699160125e-06
a O 0 6.360147040140873e-07
non O 0 5.510800292540807e-06
- O 0 1.119472244681674e-06
Jewish O 0 3.0983699161879485e-06
proband O 0 6.318615487543866e-05
who O 0 1.3547374777544974e-08
manifested O 0 4.181777342182613e-07
a O 0 1.1677747835392438e-07
subacute O 0 7.961562914715614e-06
variant O 0 7.917701339010819e-08
of O 0 1.2256422451173421e-05
G B-Disease 0 0.006046086549758911
( I-Disease 0 2.159403720725095e-06
M2 I-Disease 0 0.000163051241543144
) I-Disease 0 1.0060742994255634e-07
gangliosidosis I-Disease 0 1.3764536561211571e-05
. O 0 1.7351190706449415e-07

On O 0 3.0129920105537167e-06
the O 0 4.686057764047291e-08
second O 0 6.842443411869681e-08
maternally O 0 3.562413439794909e-06
inherited O 0 4.408517213505547e-07
allele O 0 1.0119650006856773e-08
, O 0 4.819915577769507e-10
we O 0 6.748919756383032e-10
identified O 0 3.6205640707720477e-09
the O 0 1.573070385063602e-08
common O 0 3.994872201928956e-07
infantile O 1 0.8949467539787292
disease O 0 0.05978434905409813
- O 0 5.634799435938476e-07
causing O 0 5.013979262002977e-06
4 O 0 0.00013349202345125377
- O 0 1.103678528124874e-06
bp O 0 9.165030974145338e-07
insertion O 0 5.7176979595396915e-08
, O 0 6.641009964170053e-09
+ O 0 4.7355746346511296e-07
TATC O 0 3.6398094380274415e-05
1278 O 0 1.4100332009547856e-05
, O 0 2.6444137990466743e-09
in O 0 8.515555371957362e-09
exon O 0 3.7951136278024933e-07
11 O 0 2.5835623773673433e-07
. O 0 5.8003653435889646e-08

Pulse O 0 0.00036362805985845625
- O 0 6.472999302786775e-06
chase O 0 6.694668286399974e-07
analysis O 0 2.242882501946042e-08
using O 0 2.0853315518820636e-08
proband O 0 1.0443198334542103e-05
fibroblasts O 0 2.448135546728736e-06
revealed O 0 4.1794368144110194e-07
that O 0 4.015079935193455e-10
the O 0 3.557090622052783e-09
W474C O 0 2.986233837987129e-08
- O 0 1.953084582950737e-09
containing O 0 1.6453899354118562e-09
alpha O 0 6.696801335692726e-08
- O 0 3.85532761271179e-09
subunit O 0 2.9346924890205628e-08
precursor O 0 1.1782089082146285e-08
was O 0 5.011529857767982e-09
normally O 0 4.3749351363864264e-10
synthesized O 0 6.6556182787280704e-09
, O 0 1.724856230067573e-10
but O 0 1.5686016374694134e-10
not O 0 5.33891653109464e-10
phosphorylated O 0 8.349610425284482e-08
or O 0 7.483911268479915e-09
secreted O 0 1.2069064858621914e-08
, O 0 1.4096755707182496e-10
and O 0 9.697700281696697e-11
the O 0 9.393554378789304e-09
mature O 0 2.922318458331574e-07
lysosomal O 0 0.0002644392370712012
alpha O 0 1.8857682562156697e-06
- O 0 4.207603154782191e-08
subunit O 0 2.620425902932766e-07
was O 0 5.525444279896874e-08
not O 0 2.875075955088846e-09
detected O 0 9.240977050239962e-08
. O 0 1.910289171291879e-08

When O 0 4.2479950934648514e-07
the O 0 6.151147147193115e-08
W474C O 0 1.7764136828191113e-07
- O 0 1.2513486247200944e-08
containing O 0 4.068202663631837e-09
alpha O 0 1.501587405527971e-07
- O 0 1.6231412658385125e-08
subunit O 0 2.1547492679019342e-07
was O 0 8.901483283807465e-08
transiently O 0 4.292670041650126e-07
co O 0 3.361575977578468e-07
- O 0 3.0597334443882573e-08
expressed O 0 2.4196347148119912e-09
with O 0 5.010160619711712e-10
the O 0 2.844444857430517e-08
beta O 0 6.771064420263428e-08
- O 0 1.6990002738026533e-09
subunit O 0 9.702613823492356e-09
to O 0 1.963029044871334e-10
produce O 0 9.046206561613701e-10
Hex O 0 3.9194305827550124e-06
A O 0 1.1962927146669244e-06
( O 0 6.615080927474537e-09
alphabeta O 0 1.904561628407464e-07
) O 0 1.273162353321311e-09
in O 0 3.729875963642826e-09
COS O 0 5.37463893124368e-06
- O 0 9.455303739969168e-08
7 O 0 8.117532956930518e-08
cells O 0 1.1181019443640139e-09
, O 0 3.195657280463671e-11
the O 0 6.38966324295609e-10
mature O 0 4.2064294270005576e-09
alpha O 0 9.028425296264686e-08
- O 0 2.470564641754436e-09
subunit O 0 2.7214975162337396e-08
was O 0 4.247854956673791e-09
present O 0 3.5966582490054577e-10
, O 0 6.614581798958241e-11
but O 0 3.888378855010366e-11
its O 0 1.2479199618109504e-10
level O 0 2.6442236844559375e-08
was O 0 1.1851305714571936e-08
much O 0 5.112388845596172e-10
lower O 0 1.091742918291061e-09
than O 0 4.6418743848697375e-11
that O 0 3.5903144606636017e-12
from O 0 1.525531506674227e-10
normal O 0 5.177540618461762e-09
alpha O 0 1.7537825414137842e-08
- O 0 1.1718925829740101e-09
subunit O 0 1.8032382698152105e-08
transfections O 0 1.948070327273399e-08
, O 0 1.0271254333171775e-11
although O 0 1.0406650367833503e-11
higher O 0 2.686219857661598e-10
than O 0 8.882606455928865e-12
in O 0 4.895666858018011e-11
those O 0 8.163775905289938e-11
cells O 0 3.4024816297772986e-10
transfected O 0 7.552238834307445e-09
with O 0 3.543935631067363e-11
an O 0 1.130718740860459e-09
alpha O 0 5.412127279669221e-08
- O 0 5.895088861507247e-09
subunit O 0 8.83231194848122e-08
associated O 0 3.0605622924895215e-08
with O 0 2.0047400184353137e-08
infantile O 0 0.007897526025772095
TSD B-Disease 0 0.08383090794086456
. O 0 4.5233903733787884e-07

Furthermore O 0 1.0618882697599474e-06
, O 0 9.28478460782145e-10
the O 0 1.8586019390198771e-09
precursor O 0 9.32803274622529e-08
level O 0 2.777213694571401e-07
of O 0 2.757719563817318e-08
the O 0 6.44725384191247e-09
W474C O 0 6.151639553308996e-08
alpha O 0 5.4032049945362814e-08
- O 0 2.2346144934459744e-09
subunit O 0 2.1114948012268542e-08
was O 0 3.850910701430621e-09
found O 0 9.943536272150055e-11
to O 0 8.951065583184814e-11
accumulate O 0 1.5101481176671427e-09
in O 0 1.3114139774117461e-09
comparison O 0 4.220541693911173e-09
to O 0 1.3628175254964958e-09
the O 0 1.2537735294415597e-08
normal O 0 1.3797409792459803e-07
alpha O 0 2.951142903384607e-07
- O 0 9.08594799398088e-09
subunit O 0 6.722601142428175e-08
precursor O 0 5.0474387336407744e-08
levels O 0 1.4447424590002811e-08
. O 0 5.021145721428866e-09

We O 0 6.607762657040439e-07
conclude O 0 6.512203754027723e-07
that O 0 3.69325503513096e-09
the O 0 9.050628690943086e-09
1422 O 0 2.0510697140707634e-06
G O 0 4.4544685806613415e-07
- O 0 1.4191873276558908e-07
- O 0 1.647592995368541e-07
> O 0 1.4865695163734927e-07
C O 0 1.0108175274581299e-07
mutation O 0 4.5133372039707353e-10
is O 0 5.623453439018711e-11
the O 0 5.976509287464182e-10
cause O 0 4.648889984082416e-08
of O 0 1.1481233741506003e-06
Hex B-Disease 1 0.9970665574073792
A I-Disease 1 0.829097330570221
enzyme I-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 2.1249127257760847e-07
the O 0 1.9553654340143112e-07
proband O 0 2.632347786857281e-05
. O 0 1.1098207863824427e-07

The O 0 3.23108508837322e-07
resulting O 0 1.0194938937502229e-07
W474C O 0 4.954922587785404e-07
substitution O 0 2.7114355205526408e-08
clearly O 0 3.68673980233325e-08
interferes O 0 1.7351034387047548e-08
with O 0 3.3239805352636154e-10
alpha O 0 4.13607814664374e-08
- O 0 2.533396159520862e-09
subunit O 0 4.9157911519159825e-08
processing O 0 4.6789750740572345e-08
, O 0 1.2198585197520373e-10
but O 0 5.962581123286625e-11
because O 0 1.3010613419961459e-10
the O 0 6.989540057844579e-10
base O 0 6.533849017387183e-09
substitution O 0 3.3330604942705122e-09
falls O 0 4.640022268631583e-07
at O 0 6.35450874142407e-08
the O 0 3.018455041470247e-09
first O 0 2.342941396449305e-09
position O 0 6.213217318418174e-08
of O 0 1.2891962342109764e-07
exon O 0 1.4204871945366904e-07
13 O 0 6.240867378437542e-08
, O 0 2.0060855199233174e-09
aberrant O 0 1.166266656582593e-07
splicing O 0 6.522010664866684e-08
may O 0 1.2364681722942805e-08
also O 0 9.030587388991762e-10
contribute O 0 1.0697230656830925e-08
to O 0 1.498163157975796e-07
Hex B-Disease 1 0.9997848868370056
A I-Disease 0 0.030343269929289818
deficiency I-Disease 1 0.9990587830543518
in O 0 6.140643193930373e-08
this O 0 2.960667089269009e-08
proband O 0 2.3345533008978236e-06
. O 0 1.1015597323194015e-08
. O 0 6.250015616160454e-08

Two O 0 1.2224619183598406e-07
frequent O 0 1.5084812332588626e-07
missense O 0 1.8871765860239975e-05
mutations O 0 1.1816116511909058e-06
in O 0 1.929722748172935e-05
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 1.4911068319634069e-05

Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
is O 0 2.982607156809536e-06
an O 0 0.012030418962240219
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
characterized O 1 0.709884524345398
by O 0 1.4747998378084048e-09
early O 0 4.57449204986915e-05
childhood O 1 1.0
deafness B-Disease 1 1.0
and O 1 0.9999995231628418
goiter B-Disease 1 1.0
. O 0 0.00017813568410929292

A O 0 8.217180038627703e-06
century O 0 2.430281540455326e-07
after O 0 8.641690918409495e-09
its O 0 5.448528295204369e-10
recognition O 0 1.7063853663401574e-09
as O 0 1.1744614170083878e-09
a O 0 2.046468594585349e-08
syndrome O 0 1.1744646855049723e-07
by O 0 1.0477543277431778e-09
Vaughan O 0 6.1108153204259e-07
Pendred O 0 0.00015020174032542855
, O 0 1.881479194665303e-09
the O 0 1.6983207729026617e-08
disease O 0 1.5818429801583989e-06
gene O 0 2.8856254274955973e-08
( O 0 6.150684157546493e-07
PDS O 0 6.79392360325437e-06
) O 0 4.70955552334118e-10
was O 0 3.976616369527619e-09
mapped O 0 1.6056636908956534e-08
to O 0 3.520447044991215e-09
chromosome O 0 8.875849744072184e-08
7q22 O 0 2.063896772597218e-06
- O 0 2.787965968309436e-06
q31 O 0 3.9150025259004906e-05
. O 0 3.0585437116315006e-07

1 O 0 1.336654804617865e-06
and O 0 5.386142643004632e-09
, O 0 1.5062819880284906e-09
recently O 0 5.835149696764574e-09
, O 0 4.443347634275341e-10
found O 0 2.0108663623119583e-09
to O 0 1.7950632091867647e-09
encode O 0 6.294135346252006e-08
a O 0 1.3523447250918252e-07
putative O 0 5.684049938281532e-06
sulfate O 0 1.679585147940088e-05
transporter O 0 0.0012216647155582905
. O 0 4.3768847035607905e-07

We O 0 8.243147675557339e-08
performed O 0 4.572729750407234e-09
mutation O 0 1.3505701002003434e-09
analysis O 0 1.6006755920727755e-09
of O 0 9.379518495222783e-09
the O 0 1.4457243935339648e-07
PDS B-Disease 0 1.8442064174450934e-05
gene O 0 1.0627753121994488e-09
in O 0 6.316570599906868e-10
patients O 0 6.337931846012168e-10
from O 0 1.929564730218658e-09
14 O 0 8.838649279141464e-08
Pendred B-Disease 0 0.00010211701010121033
families O 0 1.5895614824401605e-09
originating O 0 5.913162848258935e-09
from O 0 2.6960444987622623e-10
seven O 0 2.6232133132353397e-10
countries O 0 9.563617259233936e-13
and O 0 4.536533995680436e-11
identified O 0 2.0585093629676976e-09
all O 0 2.457476000472525e-09
mutations O 0 1.5106328632441546e-08
. O 0 1.4186563923601625e-08

The O 0 4.205793970868399e-07
mutations O 0 1.1218921791567027e-08
include O 0 1.2958784045835614e-09
three O 0 1.866634624647645e-09
single O 0 4.444095313971275e-09
base O 0 3.119611236002129e-08
deletions O 0 5.656875856629995e-08
, O 0 4.239922635207449e-09
one O 0 1.309055530640535e-08
splice O 0 1.3834317087457748e-06
site O 0 2.591270131802048e-08
mutation O 0 6.70579369810298e-10
and O 0 6.113035633248387e-10
10 O 0 9.62694528539032e-08
missense O 0 2.1208132238825783e-05
mutations O 0 4.4601728177440236e-07
. O 0 2.993998862166336e-07

One O 0 3.5796629163087346e-06
missense O 0 9.917401257553138e-06
mutation O 0 7.172269533839426e-08
( O 0 1.9071400458869903e-08
L236P O 0 4.3984721287415596e-07
) O 0 3.93828702982546e-09
was O 0 7.08627609924406e-08
found O 0 5.854157159035367e-09
in O 0 3.6437026729174704e-09
a O 0 1.8841770810240632e-08
homozygous O 0 4.400882325228395e-09
state O 0 6.169871280548023e-10
in O 0 1.1561560597783682e-09
two O 0 1.4606570397646124e-09
consanguineous O 0 4.0771996282273903e-05
families O 0 1.7293207976720737e-09
and O 0 2.810423838095488e-10
in O 0 3.812738125219539e-09
a O 0 9.542610257540218e-09
heterozygous O 0 8.718921695738402e-10
state O 0 1.898004392542063e-10
in O 0 1.619141487552156e-10
five O 0 9.114270449472883e-10
additional O 0 4.4265586751635055e-09
non O 0 1.6908597899600863e-06
- O 0 3.951987309847027e-06
consanguineous O 0 0.006061183288693428
families O 0 2.0960648328127718e-07
. O 0 4.954015508928933e-08

Another O 0 9.224006134900264e-06
missense O 0 2.9395430829026736e-05
mutation O 0 5.7442711920430156e-08
( O 0 1.384665004877661e-08
T416P O 0 8.497289627484861e-08
) O 0 2.0211872175934786e-09
was O 0 4.368868999904407e-08
found O 0 1.907739299866762e-09
in O 0 2.3887007927214654e-09
a O 0 8.183411281947883e-09
homozygous O 0 1.1528925591974826e-09
state O 0 2.5420593408043146e-10
in O 0 4.310817036667913e-09
one O 0 9.277567158960665e-09
family O 0 1.3278707911013043e-08
and O 0 6.657340789750776e-10
in O 0 5.168847572178947e-09
a O 0 1.3583235869418786e-08
heterozygous O 0 1.2854285413865796e-09
state O 0 7.568613097364008e-11
in O 0 6.532188678853856e-10
four O 0 3.874752962929051e-09
families O 0 3.3460230142168257e-09
. O 0 1.7129405449622936e-08

Pendred B-Disease 0 0.030122309923171997
patients O 0 2.498139792805887e-07
in O 0 1.0989847254450069e-08
three O 0 7.899310539016824e-09
non O 0 1.823084062380076e-06
- O 0 1.0641550716172787e-06
consanguineous O 1 0.885966956615448
families O 0 6.565041399397842e-09
were O 0 4.855914337298373e-09
shown O 0 9.76089209459019e-10
to O 0 1.4106608103858775e-09
be O 0 4.692656041527243e-09
compound O 0 2.921616157891549e-07
heterozygotes O 0 2.2679190081476008e-08
for O 0 2.2456381199020825e-09
L236P O 0 7.737149871900328e-07
and O 0 3.8508172650608685e-08
T416P O 0 3.841205398202874e-05
. O 0 5.215792953094933e-07

In O 0 6.352333343784267e-07
total O 0 2.857300103187299e-07
, O 0 1.3077346983081384e-09
one O 0 3.2862026433377878e-09
or O 0 1.875706923115672e-09
both O 0 1.3775405816041086e-10
of O 0 4.889437743571534e-09
these O 0 3.9737937940209633e-10
mutations O 0 7.791493561448704e-10
were O 0 5.39669331445225e-09
found O 0 2.0003578793392762e-09
in O 0 1.3984500224495378e-09
nine O 0 3.0767282055421674e-08
of O 0 2.7347038411562608e-08
the O 0 1.925477377540119e-08
14 O 0 8.473352863802575e-08
families O 0 2.6953981269173255e-09
analyzed O 0 9.694219471612087e-08
. O 0 3.329846975930195e-08

The O 0 1.3624418215840706e-07
identification O 0 2.6985166101667346e-08
of O 0 2.2144448053040833e-08
two O 0 1.369802404838083e-08
frequent O 0 1.1064770433222293e-07
PDS B-Disease 0 1.7976907429329003e-06
mutations O 0 4.935553632456902e-10
will O 0 2.8834918827658207e-11
facilitate O 0 1.2995565734641445e-09
the O 0 5.717018858319989e-09
molecular O 0 6.340697837003972e-06
diagnosis O 1 0.6027987599372864
of O 0 0.009112116880714893
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 1.7420061340089887e-06

Insertional O 0 0.00017426229896955192
mutation O 0 2.2824739431825947e-08
by O 0 3.926938330067742e-09
transposable O 0 3.7854908896406414e-06
element O 0 1.4624846471633646e-06
, O 0 1.5926516994113626e-08
L1 O 0 2.0509880414465442e-05
, O 0 1.4738212872345002e-09
in O 0 8.593088907105084e-09
the O 0 1.3862933201380656e-07
DMD B-Disease 1 1.0
gene O 0 5.162404281833233e-09
results O 0 2.260765574746415e-09
in O 0 7.2629862124529154e-09
X B-Disease 1 0.9997754693031311
- I-Disease 1 0.8130466341972351
linked I-Disease 1 0.9999939203262329
dilated I-Disease 1 0.9999996423721313
cardiomyopathy I-Disease 1 1.0
. O 0 4.5869398945797e-07

X B-Disease 1 0.9999997615814209
- I-Disease 1 0.9999991655349731
linked I-Disease 1 0.9999996423721313
dilated I-Disease 1 1.0
cardiomyopathy I-Disease 1 1.0
( O 0 4.9126047088066116e-05
XLDCM B-Disease 1 0.964365541934967
) O 0 2.737724269508135e-09
is O 0 2.5834998029772294e-10
a O 0 2.8953162090061824e-09
clinical O 0 1.483609395336316e-07
phenotype O 0 1.8119857259080163e-07
of O 0 6.144247208794695e-07
dystrophinopathy B-Disease 0 0.00020725117065012455
which O 0 4.0222927766286887e-10
is O 0 6.876751945661397e-11
characterized O 0 1.2913378699686007e-10
by O 0 1.4641457490860432e-10
preferential O 0 9.365255948523554e-08
myocardial B-Disease 1 1.0
involvement I-Disease 0 2.587088090422185e-07
without O 0 2.9713520532936855e-09
any O 0 1.053212184132235e-09
overt O 0 7.3912067577452945e-09
clinical O 0 6.380766848224084e-08
signs O 0 1.9953214192014457e-08
of O 0 4.955762960889842e-06
skeletal B-Disease 1 1.0
myopathy I-Disease 1 1.0
. O 0 5.476133446791209e-05

To O 0 4.2334114880304696e-08
date O 0 6.396754059778686e-08
, O 0 2.0762054575573785e-10
several O 0 1.3238787843761202e-10
mutations O 0 4.1689190988236646e-10
in O 0 1.1572282021532487e-09
the O 0 9.26849395455065e-07
Duchenne B-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 0.9999996423721313
gene O 0 4.294553548334079e-07
, O 0 2.6841638245400645e-08
DMD O 1 1.0
, O 0 1.1163374669109771e-09
have O 0 7.986626637812577e-11
been O 0 2.3310881003268946e-10
identified O 0 5.511776035582727e-10
in O 0 8.683869179293424e-10
patients O 0 4.732030323140179e-10
with O 0 2.516985508904668e-10
XLDCM B-Disease 1 0.9999130964279175
, O 0 1.3535073062342917e-09
but O 0 1.4621003019410495e-10
a O 0 7.495135623258875e-10
pathogenic O 0 7.627803388920995e-10
correlation O 0 7.524790568425033e-09
of O 0 4.0546285773324087e-10
these O 0 1.1992387638493085e-10
cardiospecific O 0 2.872551192467654e-07
mutations O 0 5.7013163079489004e-09
in O 0 2.6258989649363684e-08
DMD O 1 1.0
with O 0 2.4064901182896392e-09
the O 0 1.8763076070626994e-07
XLDCM B-Disease 0 0.033393844962120056
phenotype O 0 8.192635050363606e-07
has O 0 1.3587789782221193e-09
remained O 0 5.926161250613404e-08
to O 0 1.005164285139415e-09
be O 0 1.0787855053706608e-08
elucidated O 0 5.2959247113903984e-05
. O 0 1.85896851689904e-07

We O 0 6.626726190006593e-07
report O 0 5.4724466735933674e-08
here O 0 4.917402041115793e-09
the O 0 2.4548758581488528e-09
identification O 0 2.7481090736358738e-09
of O 0 7.571811622142377e-09
a O 0 8.154555253270246e-09
unique O 0 1.2510909641605394e-08
de O 0 3.403489472475485e-06
novo O 0 5.089063051855192e-06
L1 O 0 3.656658373074606e-05
insertion O 0 1.421576882876252e-07
in O 0 1.0567260844140947e-08
the O 0 2.6430033273072695e-08
muscle O 0 7.230783438672006e-08
exon O 0 1.8591883588214841e-07
1 O 0 2.2531844479090068e-07
in O 0 4.4413948074861764e-08
DMD O 1 1.0
in O 0 2.4277582610920945e-08
three O 0 6.185062240149364e-09
XLDCM B-Disease 0 0.00010790376109071076
patients O 0 2.965356182826895e-09
from O 0 8.734318268643904e-10
two O 0 1.6958016102464057e-09
unrelated O 0 5.011694952372636e-07
Japanese O 0 1.7574615412740968e-05
families O 0 1.0261732796834622e-08
. O 0 2.447308133923798e-08

The O 0 4.319319032219937e-06
insertion O 0 1.609502987776068e-06
was O 0 7.847591518839181e-07
a O 0 9.612762141841813e-08
5 O 0 1.5313658252580353e-07
- O 0 1.1741215999450105e-08
truncated O 0 3.3189788695153766e-08
form O 0 1.5120418250802459e-09
of O 0 5.499495259186915e-08
human O 0 2.7425022253169118e-08
L1 O 0 5.9166623032069765e-06
inversely O 0 1.8412013957913587e-07
integrated O 0 1.118004746558654e-07
in O 0 6.124662998985286e-09
the O 0 7.262723311640684e-09
5 O 0 5.3327038784800607e-08
- O 0 1.2380231950714915e-08
untranslated O 0 4.1272701309935655e-06
region O 0 1.1475686179096556e-08
in O 0 7.015374503538396e-09
the O 0 2.5101467571175817e-08
muscle O 0 3.246921664867841e-08
exon O 0 1.58472790445785e-08
1 O 0 5.219054521887756e-09
, O 0 2.0853284377064796e-11
which O 0 1.0791234225648871e-11
affected O 0 7.644548882801416e-11
the O 0 1.6472677666357072e-09
transcription O 0 6.045603129223309e-08
or O 0 8.375122262371804e-10
the O 0 2.7705819860557312e-09
stability O 0 1.5221041849144967e-07
of O 0 6.25850944402373e-08
the O 0 2.4645981255844163e-08
muscle O 0 9.605537698575972e-09
form O 0 3.754278665724087e-09
of O 0 4.6113396479086077e-07
dystrophin O 0 2.4407622731814627e-06
transcripts O 0 9.530123747936159e-07
but O 0 2.1437911168487034e-10
not O 0 8.592505873483702e-11
that O 0 4.109030476984188e-11
of O 0 2.869312565323412e-09
the O 0 9.411348145249576e-08
brain O 0 0.012376600876450539
or O 0 6.760295150343154e-07
Purkinje O 0 0.08163145929574966
cell O 0 9.765733921085484e-06
form O 0 6.374596850378111e-09
, O 0 1.5993877333642104e-09
probably O 0 4.2369009634057875e-08
due O 0 2.12725666415281e-07
to O 0 1.8743049334801754e-09
its O 0 7.21137094483737e-10
unique O 0 1.8261713252698542e-09
site O 0 6.055987711306443e-09
of O 0 2.504894069943475e-09
integration O 0 6.1901723746871085e-09
. O 0 5.275071046639823e-08

We O 0 8.62261003931053e-07
speculate O 0 4.3591225562522595e-07
that O 0 2.6732122071493336e-10
this O 0 5.260697433229211e-10
insertion O 0 1.5182180845840776e-08
of O 0 1.2305510388443963e-08
an O 0 1.0209022960339098e-08
L1 O 0 2.019075327552855e-05
sequence O 0 2.2107104769020225e-07
in O 0 2.5302909989477484e-07
DMD O 1 1.0
is O 0 7.524317169327333e-09
responsible O 0 4.049861779265029e-09
for O 0 2.56607540771725e-10
some O 0 3.426485484236963e-11
of O 0 2.633851747813054e-10
the O 0 3.7556377452396816e-10
population O 0 1.7677441108143732e-11
of O 0 3.8125907986241714e-10
Japanese O 0 7.270918445101415e-08
patients O 0 2.2145101030712766e-10
with O 0 8.454565519899759e-11
XLDCM B-Disease 0 7.070525316521525e-05
. O 0 1.1687480316879828e-08
. O 0 2.4582835322917163e-08

Severe O 1 0.9713029265403748
early O 0 0.0003425172180868685
- O 1 0.682964563369751
onset O 1 1.0
obesity B-Disease 1 1.0
, O 0 4.098620775039308e-05
adrenal B-Disease 1 1.0
insufficiency I-Disease 1 1.0
and O 0 1.3274588127387688e-05
red O 0 6.323010165942833e-05
hair O 1 0.9475288987159729
pigmentation O 1 0.9998016953468323
caused O 0 5.371660154196434e-05
by O 0 1.7894328152578964e-07
POMC O 1 0.9999767541885376
mutations O 0 6.222016679657827e-08
in O 0 1.1309198022502187e-08
humans O 0 5.4840239016584746e-08
. O 0 1.3965583356423394e-08

Sequential O 0 5.4596774134552106e-05
cleavage O 0 5.262758349999785e-06
of O 0 2.5046307428056025e-07
the O 0 3.307748741576688e-08
precursor O 0 1.2233950030804408e-07
protein O 0 3.9848110588991403e-08
pre O 0 6.656209734501317e-07
- O 0 6.381631010299316e-07
pro O 0 2.023566139541799e-06
- O 0 1.2103226936233114e-06
opiomelanocortin O 0 4.2903640860458836e-05
( O 0 1.1728776172503785e-07
POMC O 0 1.3597276847576723e-05
) O 0 6.02295879836845e-10
generates O 0 1.4458167996167504e-09
the O 0 3.212999866164523e-09
melanocortin O 0 4.446558705240022e-06
peptides O 0 6.944207342485242e-08
adrenocorticotrophin O 0 2.79060486718663e-06
( O 0 3.534854542408539e-08
ACTH O 0 9.97008896774787e-07
) O 0 1.6073451458709087e-09
, O 0 1.5862421376411362e-09
melanocyte O 0 2.6903560410573846e-06
- O 0 4.6392624426516704e-06
stimulating O 0 1.4205566003511194e-06
hormones O 0 3.016689475998646e-08
( O 0 1.5227153982166897e-09
MSH O 0 1.6523104306997993e-07
) O 0 4.6169474493540363e-11
alpha O 0 8.271189289033032e-10
, O 0 6.264516249493424e-12
beta O 0 3.4045979924179903e-10
and O 0 5.1544857791741006e-12
gamma O 0 1.2844114660737205e-09
as O 0 4.147740484405915e-11
well O 0 3.53965953769908e-11
as O 0 5.779517489590269e-11
the O 0 6.461802204427158e-10
opioid O 0 3.824042948963324e-08
- O 0 6.92182977601874e-09
receptor O 0 3.05679357381905e-08
ligand O 0 1.7821864162215206e-07
beta O 0 6.763893338757043e-07
- O 0 1.93961767536166e-07
endorphin O 0 3.549042594386265e-05
. O 0 3.1639185493759214e-08

While O 0 3.374105119746673e-07
a O 0 1.2004689686762049e-08
few O 0 4.860128410832942e-10
cases O 0 2.958067402136777e-10
of O 0 2.9789008593184008e-08
isolated O 1 0.9528623223304749
ACTH B-Disease 1 1.0
deficiency I-Disease 1 1.0
have O 0 1.555428852384466e-08
been O 0 1.0045438258998729e-08
reported O 0 3.2737485611278316e-08
( O 0 2.0125364486034414e-08
OMIM O 0 6.757838855264708e-05
201400 O 0 2.0580962427629856e-06
) O 0 3.1517863874341856e-09
, O 0 4.4824527423159566e-10
an O 0 1.642524871670048e-08
inherited O 1 0.9999998807907104
POMC O 1 1.0
defect O 1 1.0
has O 0 4.195014113861362e-08
not O 0 3.205287368857057e-09
been O 0 7.053478690011161e-09
described O 0 1.1360437035534687e-08
so O 0 2.9712725613251223e-09
far O 0 2.2719280678984433e-08
. O 0 1.77911871901415e-08

Recent O 0 1.207524036317409e-07
studies O 0 7.650275080095525e-09
in O 0 2.2203296146106055e-10
animal O 0 4.668255781936637e-10
models O 0 2.885105487848705e-10
elucidated O 0 4.2361821783742926e-07
a O 0 5.101170597043847e-09
central O 0 7.909201293898604e-09
role O 0 1.5084792082120657e-08
of O 0 1.4486144550573954e-07
alpha O 0 7.388407993857982e-06
- O 0 1.0468459095136495e-06
MSH O 0 3.746177753782831e-05
in O 0 5.058307550598329e-09
the O 0 4.808348386120542e-09
regulation O 0 7.432217508096528e-09
of O 0 2.668348653145358e-09
food O 0 1.6354246845651232e-09
intake O 0 2.2125774545855847e-09
by O 0 1.2781642411141547e-10
activation O 0 5.947628167746188e-09
of O 0 2.5656278879182537e-08
the O 0 5.371956390831656e-08
brain O 0 2.681442538232659e-06
melanocortin O 0 4.485220870265039e-06
- O 0 8.424781583471486e-08
4 O 0 3.1076598361323704e-07
- O 0 2.6278630826936933e-08
receptor O 0 1.0350549217719163e-07
( O 0 1.40229361456079e-09
MC4 O 0 7.101849632817903e-07
- O 0 2.028448697899421e-08
R O 0 1.361592438797743e-07
; O 0 8.262249218127238e-10
refs O 0 3.279010130086135e-08
3 O 0 1.864031062837057e-08
- O 0 2.091361084310961e-09
5 O 0 3.447953034196871e-09
) O 0 7.654572808935001e-11
and O 0 1.99028224456832e-11
the O 0 7.566047788287733e-10
linkage O 0 2.3457603504084545e-07
of O 0 5.0562171338697226e-08
human O 0 2.7636070853986894e-07
obesity B-Disease 1 1.0
to O 0 4.175128243133486e-09
chromosome O 0 8.015676122852256e-09
2 O 0 1.4367238954093864e-08
in O 0 2.8287694409101505e-09
close O 0 1.1763658847030456e-07
proximity O 0 1.304288304027068e-07
to O 0 6.111453121349086e-09
the O 0 2.6321703217035974e-07
POMC O 0 0.0052974349819123745
locus O 0 2.564041096775327e-06
, O 0 8.622784708478548e-10
led O 0 2.430384116181017e-09
to O 0 5.1066778583575e-10
the O 0 1.400227600534265e-09
proposal O 0 2.308928603866889e-09
of O 0 6.022904397440243e-09
an O 0 2.4600459447299272e-09
association O 0 1.1439147407088512e-08
of O 0 2.8486181236075936e-07
POMC O 1 0.824938952922821
with O 0 2.4189992231526958e-08
human O 0 0.006483654025942087
obesity B-Disease 1 1.0
. O 0 1.2070657362528436e-07

The O 0 1.5998849676179816e-06
dual O 0 1.6850034398885327e-06
role O 0 6.56793702091818e-07
of O 0 3.094620115007274e-05
alpha O 0 0.014979070983827114
- O 0 0.00027189034153707325
MSH O 0 0.033374663442373276
in O 0 1.2755231537653344e-08
regulating O 0 7.952132818900282e-08
food O 0 1.7853190925620765e-08
intake O 0 9.886684182447425e-08
and O 0 2.1519281911963617e-09
influencing O 0 7.886388630140573e-06
hair O 0 0.0004491764702834189
pigmentation O 0 0.014162215404212475
predicts O 0 2.48788808221434e-07
that O 0 7.491016140726003e-11
the O 0 1.1294900570391064e-09
phenotype O 0 2.009824484616729e-08
associated O 0 4.4280872302238095e-09
with O 0 3.6423736249346916e-10
a O 0 3.5228072192694526e-07
defect O 0 9.140527254203334e-06
in O 0 4.857065860619514e-08
POMC O 0 0.009646672755479813
function O 0 2.459098027429718e-07
would O 0 3.6680017356793826e-10
include O 0 2.5155435068313636e-08
obesity B-Disease 1 1.0
, O 0 5.498265398529156e-09
alteration O 0 3.0018496545380913e-05
in O 0 1.4713089058204787e-07
pigmentation O 1 0.5032229423522949
and O 0 6.60076193526038e-06
ACTH B-Disease 1 1.0
deficiency I-Disease 1 1.0
. O 0 7.71918848840869e-07

The O 0 3.941430577469873e-07
observation O 0 1.512424205429852e-05
of O 0 3.7375833983332996e-08
these O 0 2.0169932390956546e-09
symptoms O 0 3.265081147674209e-07
in O 0 5.1565319125757014e-08
two O 0 2.9463921080719047e-08
probands O 0 1.1664623343676794e-05
prompted O 0 5.760498211770937e-08
us O 0 6.5294765150269996e-09
to O 0 1.4982753926418013e-10
search O 0 5.614499531958472e-09
for O 0 1.365715596168826e-10
mutations O 0 9.871017336848809e-10
within O 0 1.4219640576129677e-08
their O 0 4.6922199459231706e-08
POMC O 0 0.0019442266784608364
genes O 0 1.231490642794597e-07
. O 0 1.9437836229485583e-08

Patient O 0 0.0012213686713948846
1 O 0 2.5611798264435492e-06
was O 0 3.3546072586432274e-07
found O 0 2.4997488523581524e-09
to O 0 5.920901546829782e-10
be O 0 1.955048789525904e-09
a O 0 1.4292540484461824e-08
compound O 0 1.369832887121447e-07
heterozygote O 0 5.737000918770718e-08
for O 0 2.0882708062774924e-10
two O 0 4.591140800869198e-10
mutations O 0 6.677179364977803e-10
in O 0 2.0289052216071468e-08
exon O 0 8.453481115111572e-08
3 O 0 1.9699028541708685e-07
( O 0 2.9720887972928267e-09
G7013T O 0 5.3873886685096295e-08
, O 0 1.2735242860273388e-09
C7133delta O 0 1.2442394563549897e-06
) O 0 6.909545713362775e-10
which O 0 2.494079075210376e-11
interfere O 0 1.720555087292297e-10
with O 0 7.078873077992487e-12
appropriate O 0 3.523584313214201e-09
synthesis O 0 5.399805402817037e-08
of O 0 7.653430600385036e-08
ACTH O 0 2.5519732389511773e-06
and O 0 2.207722182845373e-08
alpha O 0 2.102231519529596e-05
- O 0 9.553970812703483e-06
MSH O 0 0.00039251652196981013
. O 0 7.070817531484863e-08

Patient O 0 0.00018910318613052368
2 O 0 1.1899277296834043e-06
was O 0 1.7576277855368971e-07
homozygous O 0 1.1258234344779794e-08
for O 0 7.12024939009126e-10
a O 0 4.056873947888562e-09
mutation O 0 7.413539226952537e-10
in O 0 6.844829592012047e-09
exon O 0 5.939469005511455e-08
2 O 0 1.3870008785943355e-07
( O 0 1.0246379744671685e-08
C3804A O 0 1.978107064815049e-07
) O 0 1.140978977964835e-09
which O 0 5.145041614973422e-10
abolishes O 0 8.829817375044513e-07
POMC O 0 0.00041969507583417
translation O 0 6.686579126835568e-06
. O 0 1.006260390568059e-07

These O 0 6.283076459112635e-08
findings O 0 2.963661493993186e-08
represent O 0 5.118343082699539e-09
the O 0 3.006922266735046e-09
first O 0 1.5254566498867916e-09
examples O 0 5.418022031022929e-09
of O 0 9.637487252689425e-09
a O 0 1.3177537994124577e-07
genetic B-Disease 1 1.0
defect I-Disease 1 1.0
within O 0 7.118843114994888e-08
the O 0 3.229504130786154e-08
POMC O 0 2.7350375603418797e-05
gene O 0 8.083749225562542e-10
and O 0 3.3928436449226496e-11
define O 0 3.4644531687888502e-09
a O 0 7.49654027742963e-09
new O 0 3.7064040725454106e-08
monogenic B-Disease 1 1.0
endocrine I-Disease 1 1.0
disorder I-Disease 1 0.9999903440475464
resulting O 0 1.8415808256122546e-07
in O 0 1.7066140500787697e-08
early O 0 5.9991900343447924e-05
- O 0 0.02369891293346882
onset O 1 1.0
obesity B-Disease 1 1.0
, O 0 0.001015802612528205
adrenal B-Disease 1 1.0
insufficiency I-Disease 1 1.0
and O 0 6.90224123900407e-06
red O 0 1.110334869736107e-05
hair O 0 0.0001625941804377362
pigmentation O 0 0.2579670250415802
. O 0 5.465103569690655e-08
. O 0 8.279435803615343e-08

A O 0 3.3905378131748876e-06
European O 0 6.533515062301376e-08
multicenter O 0 0.00012125087960157543
study O 0 3.853992041058518e-07
of O 0 1.9070919734076597e-05
phenylalanine B-Disease 1 1.0
hydroxylase I-Disease 1 1.0
deficiency I-Disease 1 1.0
: O 0 1.7172062882764294e-08
classification O 0 1.6492052168359805e-08
of O 0 1.0103911485259687e-08
105 O 0 1.3804331899791578e-07
mutations O 0 6.073532787809199e-10
and O 0 1.5272724751547173e-10
a O 0 3.754715649506579e-09
general O 0 2.5241306822465504e-09
system O 0 1.1771525976200792e-09
for O 0 1.541054922560292e-10
genotype O 0 1.6733146424030565e-08
- O 0 1.5980345935417972e-08
based O 0 1.3704374524081686e-08
prediction O 0 8.364815471395559e-07
of O 0 5.644847078656312e-08
metabolic O 0 0.0006510659004561603
phenotype O 0 1.9827846244879765e-06
. O 0 4.5559556127727774e-08

Phenylketonuria B-Disease 1 0.9987314343452454
( O 0 1.4115329349806416e-06
PKU B-Disease 0 2.680923898878973e-05
) O 0 3.240485879629773e-09
and O 0 1.538447702564838e-09
mild B-Disease 0 7.129808363970369e-05
hyperphenylalaninemia I-Disease 1 1.0
( O 1 0.9999996423721313
MHP B-Disease 1 1.0
) O 0 2.4603005854828552e-08
are O 0 6.029085009018331e-10
allelic B-Disease 0 1.894141678349115e-05
disorders I-Disease 1 0.9999270439147949
caused O 0 1.2751856104387116e-07
by O 0 7.598833229316426e-10
mutations O 0 6.856481493677791e-10
in O 0 7.479968866519471e-10
the O 0 8.223514313954183e-09
gene O 0 4.540009701514691e-09
encoding O 0 1.0432644614866149e-07
phenylalanine O 0 4.034599623992108e-05
hydroxylase O 0 0.0012827671598643064
( O 0 4.0509306131752965e-07
PAH O 0 0.00016721322026569396
) O 0 4.361550409726078e-08
. O 0 5.370777955704398e-08

Previous O 0 2.161322299798485e-05
studies O 0 3.2585396070317074e-07
have O 0 2.022790407396613e-10
suggested O 0 2.4498930661920326e-10
that O 0 6.4181533351859166e-12
the O 0 1.3077540439443425e-10
highly O 0 1.9577504062340267e-09
variable O 0 1.0245597650282434e-06
metabolic O 0 0.0011697843438014388
phenotypes O 0 2.7807494916487485e-05
of O 0 0.0005738706095144153
PAH B-Disease 1 1.0
deficiency I-Disease 1 1.0
correlate O 0 0.0009173995349556208
with O 0 2.321400671689844e-07
PAH O 1 0.9999998807907104
genotypes O 0 0.00015641219215467572
. O 0 3.155415697619901e-07

We O 0 1.1352707929290773e-07
identified O 0 5.6939946091461024e-08
both O 0 6.653079420715358e-09
causative O 0 6.47973729428486e-06
mutations O 0 1.942241745211959e-08
in O 0 1.7096112969738897e-08
686 O 0 8.291761446344026e-07
patients O 0 1.0033158748257165e-09
from O 0 1.205010646820881e-09
seven O 0 9.980884563276504e-09
European O 0 4.759952076938134e-08
centers O 0 3.3907141983036126e-07
. O 0 7.991254591388497e-08

On O 0 2.699268861761084e-07
the O 0 5.087955390337129e-09
basis O 0 3.8075512520663324e-08
of O 0 1.7604813162819255e-09
the O 0 6.120887685590048e-10
phenotypic O 0 9.612484141996447e-09
characteristics O 0 5.3809880995459025e-09
of O 0 1.5549096232803095e-08
297 O 0 1.442815431573763e-07
functionally O 0 1.9015597274574247e-07
hemizygous O 0 2.5997783836828603e-07
patients O 0 1.6507653022301838e-09
, O 0 1.353687301142159e-10
105 O 0 3.394104197695924e-08
of O 0 9.526570643458854e-09
the O 0 1.4216223753749091e-08
mutations O 0 6.415727948905214e-09
were O 0 7.739228813363752e-09
assigned O 0 1.8832142956171083e-08
to O 0 2.830005341181163e-09
one O 0 1.3160872391893008e-09
of O 0 8.823653807610299e-09
four O 0 3.73557895727572e-09
arbitrary O 0 2.033593204942008e-08
phenotype O 0 4.084890292688215e-08
categories O 0 9.714950266470623e-08
. O 0 8.360957082231835e-08

We O 0 3.7937527963549655e-07
proposed O 0 1.4669510051135148e-08
and O 0 8.381802474310973e-10
tested O 0 2.119980413439748e-09
a O 0 1.949518990684851e-09
simple O 0 6.432915866660949e-10
model O 0 9.63343502191627e-11
for O 0 1.7702136631547738e-11
correlation O 0 2.369551221903521e-09
between O 0 7.416636749191241e-10
genotype O 0 1.7132542495801317e-08
and O 0 3.238519175052801e-10
phenotypic O 0 4.82542148461107e-08
outcome O 0 2.461495682837267e-07
. O 0 1.1650605102886402e-07

The O 0 3.394979160020739e-07
observed O 0 2.3524363257365621e-07
phenotype O 0 8.840806486887232e-08
matched O 0 5.237136235791695e-08
the O 0 2.0685350321514306e-08
predicted O 0 6.459947599068983e-08
phenotype O 0 5.523871138279901e-09
in O 0 4.1456385546645436e-10
79 O 0 1.021432005643419e-08
% O 0 5.347814413525498e-10
of O 0 5.967659144623383e-10
the O 0 1.074573097170628e-09
cases O 0 7.572659721510888e-10
, O 0 3.493520403519135e-11
and O 0 6.046459860575837e-11
in O 0 5.284260251592343e-10
only O 0 4.892606875195327e-10
5 O 0 1.0315280851713737e-09
of O 0 2.912657059983559e-10
184 O 0 4.238305262305175e-09
patients O 0 6.791801843153422e-11
was O 0 1.1707107505642966e-09
the O 0 4.098051620271548e-10
observed O 0 1.2943714988722377e-09
phenotype O 0 6.810277342061966e-10
more O 0 4.055482945991562e-12
than O 0 1.1418704523591394e-11
one O 0 1.1352496720462568e-10
category O 0 4.2417021006713185e-09
away O 0 5.318419038502498e-09
from O 0 2.684254818419163e-09
that O 0 2.2117536968568885e-10
expected O 0 1.3017156241801331e-08
. O 0 5.703831718051333e-08

Among O 0 3.4046792052322417e-08
the O 0 2.915999219865739e-09
seven O 0 4.029881761624665e-09
contributing O 0 2.767979445650326e-08
centers O 0 4.237763917558368e-09
, O 0 2.333026133394256e-11
the O 0 1.2172345076333357e-10
proportion O 0 1.5550571941247426e-09
of O 0 1.6593769691652938e-09
patients O 0 1.9624338265522567e-10
for O 0 8.26905557915758e-11
whom O 0 1.2179620645369482e-09
the O 0 2.7424644777340745e-09
observed O 0 1.561978280051335e-08
phenotype O 0 3.48135098526825e-09
did O 0 4.974395895196437e-10
not O 0 1.0630403501910024e-10
match O 0 3.852438812401715e-09
the O 0 1.2386043302115013e-08
predicted O 0 3.357019551231133e-08
phenotype O 0 4.345787285586766e-09
was O 0 1.3492421402361288e-08
4 O 0 7.243493360675757e-09
% O 0 1.177639374905226e-10
- O 0 7.123777262529885e-11
23 O 0 1.5929547680926248e-09
% O 0 4.374526296757608e-10
( O 0 2.861075543147962e-10
P O 0 4.1708807430040906e-07
< O 0 2.4656701569369943e-08
. O 0 7.596830109424246e-11
0001 O 0 1.1184307595613063e-06
) O 0 1.0992289023459278e-10
, O 0 7.507719272659141e-12
suggesting O 0 1.1261530596939906e-10
that O 0 2.0852319437131284e-12
differences O 0 6.522698353661482e-11
in O 0 1.006274438775101e-10
methods O 0 3.3739885885175624e-10
used O 0 5.578318709731356e-11
for O 0 6.339089669848974e-11
mutation O 0 1.6902731436729823e-09
detection O 0 4.942991438383615e-08
or O 0 5.401481928402063e-09
phenotype O 0 3.757145705662879e-08
classification O 0 2.6491607130196826e-08
may O 0 2.4093833594918124e-09
account O 0 1.6266115121510438e-09
for O 0 8.648805283062444e-11
a O 0 2.7828944704211267e-10
considerable O 0 2.6723112611648503e-09
proportion O 0 2.5589310670426357e-09
of O 0 1.3166954637711115e-08
genotype O 0 2.267640439868046e-07
- O 0 5.505308990905178e-07
phenotype O 0 4.24387309294616e-07
inconsistencies O 0 2.0273676000215346e-06
. O 0 7.919710043324812e-08

Our O 0 3.171270236634882e-06
data O 0 2.665293550307979e-07
indicate O 0 2.6410129194687215e-08
that O 0 2.472185234303481e-10
the O 0 2.399826648513681e-08
PAH O 0 6.055798621673603e-06
- O 0 2.2953615896881274e-08
mutation O 0 6.495611271084556e-10
genotype O 0 2.346264293962008e-09
is O 0 3.824197902790871e-11
the O 0 2.136345683689811e-10
main O 0 1.2601988785831963e-08
determinant O 0 2.90807577130181e-07
of O 0 4.412071064052725e-08
metabolic O 0 9.536188008496538e-05
phenotype O 0 1.9270572693130816e-08
in O 0 6.457711587692927e-10
most O 0 3.156386818581325e-10
patients O 0 6.105068894868282e-09
with O 0 1.1100875951797207e-07
PAH B-Disease 1 1.0
deficiency I-Disease 1 1.0
. O 0 3.26183253491763e-05

In O 0 2.536251031415304e-07
the O 0 1.7050457046252632e-08
present O 0 5.970531180565786e-09
study O 0 3.249745361699752e-09
, O 0 8.736195794556423e-11
the O 0 3.352128019606937e-10
classification O 0 1.1640426400560955e-08
of O 0 1.027121498964334e-07
105 O 0 7.188665767898783e-05
PAH O 1 0.9738085865974426
mutations O 0 3.010717009033215e-08
may O 0 2.0029962133349954e-09
allow O 0 2.852961755728245e-10
the O 0 3.2017617446200575e-09
prediction O 0 1.440016603737604e-07
of O 0 3.910882284685613e-09
the O 0 4.131581743394008e-09
biochemical O 0 1.1911477315607044e-07
phenotype O 0 2.6179076684229585e-08
in O 0 3.2886293688250134e-09
> O 0 4.598110336928585e-09
10 O 0 5.198099728431771e-10
, O 0 3.5756914790185945e-11
000 O 0 7.78573383541925e-09
genotypes O 0 1.3423807843082614e-08
, O 0 6.835155358375644e-11
which O 0 1.615947479993718e-11
may O 0 7.638063098669434e-11
be O 0 5.888047688307196e-11
useful O 0 2.019264311314828e-09
for O 0 1.608420618914863e-10
the O 0 6.290844289935649e-09
management O 0 5.205333195590356e-07
of O 0 8.514444402862864e-07
hyperphenylalaninemia B-Disease 1 1.0
in O 0 9.090474009099125e-07
newborns O 0 6.871942446196044e-07
. O 0 3.331079412305371e-08

Somatic O 0 0.00013252762437332422
instability O 0 1.5682802768424153e-05
of O 0 2.777706185952411e-06
the O 0 1.8127027487935266e-06
CTG O 1 0.9958171248435974
repeat O 0 4.685334261012031e-06
in O 0 9.318074489783612e-08
mice O 0 6.43750013296085e-08
transgenic O 0 1.3670175214031133e-08
for O 0 5.818354686937255e-10
the O 0 3.357881723786704e-07
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
region O 0 2.6479742132323736e-07
is O 0 5.738165498314629e-10
age O 0 1.6616733544694284e-09
dependent O 0 1.0265060801373238e-08
but O 0 1.9656394567579838e-11
not O 0 1.6036718827883156e-11
correlated O 0 1.3010869048812879e-09
to O 0 8.161580439258742e-11
the O 0 7.082378572498271e-10
relative O 0 5.102672275825171e-07
intertissue O 0 4.173874913249165e-06
transcription O 0 2.0685712343038176e-07
levels O 0 2.984797076166501e-09
and O 0 8.922774186181925e-10
proliferative O 0 4.062892548972741e-05
capacities O 0 4.655700649891514e-06
. O 0 1.6748160192037176e-07

A O 0 0.000776636297814548
( O 0 3.5731720799958566e-06
CTG O 0 0.0006112284609116614
) O 0 6.240938432711118e-08
nexpansion O 0 1.6226881598413456e-06
in O 0 1.3578624447063703e-08
the O 0 3.923847913256395e-08
3 O 0 4.0477178231412836e-07
- O 0 7.07146483591714e-08
untranslated O 0 2.1541591195273213e-05
region O 0 7.773124366394768e-08
( O 0 2.8960300824110163e-08
UTR O 0 1.055936809279956e-05
) O 0 1.6324110951870807e-09
of O 0 6.051773304704966e-09
the O 0 1.9054681388297467e-07
DM O 1 1.0
protein O 0 7.703569281147793e-06
kinase O 0 7.48231013858458e-06
gene O 0 1.6755621334851867e-09
( O 0 4.258016994551639e-10
DMPK O 0 2.045731548605545e-07
) O 0 9.029687414452425e-11
is O 0 4.095400754633438e-11
responsible O 0 1.0521078452896404e-09
for O 0 1.1704478275476049e-08
causing O 1 0.999916672706604
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9980098605155945
DM B-Disease 1 1.0
) O 0 3.3223226836298636e-08
. O 0 1.2866286702717389e-08

Major O 0 0.0007344104815274477
instability O 0 0.008108251728117466
, O 0 5.033918615282573e-09
with O 0 2.455319558780644e-10
very O 0 4.407266551709199e-09
large O 0 5.023042426444135e-09
expansions O 0 3.4617929856040064e-08
between O 0 3.6597083141742814e-09
generations O 0 1.6161340044007488e-09
and O 0 4.0556474845132584e-11
high O 0 9.624936403440643e-10
levels O 0 2.9553790525937984e-09
of O 0 4.443688528255052e-09
somatic O 0 1.0662299132491171e-07
mosaicism O 0 2.231801545349299e-06
, O 0 3.3983420244521056e-11
is O 0 1.9779299725852795e-11
observed O 0 4.045405399555335e-10
in O 0 1.0763433477833928e-09
patients O 0 2.717429392617987e-09
. O 0 8.098785642118855e-09

There O 0 1.968816604858148e-06
is O 0 2.8740194224496918e-08
a O 0 3.006854853992991e-08
good O 0 2.4531967568464097e-08
correlation O 0 6.402137131544805e-08
between O 0 2.0321071492190868e-09
repeat O 0 7.83075471133543e-09
size O 0 8.72348326907968e-09
( O 0 6.061172674876047e-10
at O 0 1.8555345038251403e-09
least O 0 2.548039834682214e-10
in O 0 2.4494631323257465e-10
leucocytes O 0 4.30764650616311e-08
) O 0 6.615944597720969e-11
, O 0 8.353927792581484e-12
clinical O 0 8.142971852365122e-10
severity O 0 1.3860575798219088e-08
and O 0 1.812208022533568e-10
age O 0 6.731865198617015e-08
of O 0 3.503435550555878e-07
onset O 0 0.0001848104438977316
. O 0 7.921432398916295e-08

The O 0 9.70260862231953e-06
trinucleotide O 0 0.0009827122557908297
repeat O 0 5.876444447494578e-06
instability O 0 1.5288664144463837e-05
mechanisms O 0 8.0933432400343e-06
involved O 0 1.617325551706017e-06
in O 0 1.681183334767411e-06
DM B-Disease 1 1.0
and O 0 3.0106581672129096e-09
other O 0 8.470097401236387e-10
human O 0 1.8522312075219816e-06
genetic B-Disease 1 1.0
diseases I-Disease 1 1.0
are O 0 2.1345669676264833e-09
unknown O 0 1.2816426533390768e-06
. O 0 1.6322312390570914e-08

We O 0 2.385219772804703e-07
studied O 0 7.486676167900441e-07
somatic O 0 4.121291567571461e-06
instability O 0 7.102148060766922e-07
by O 0 7.371749877194134e-09
measuring O 0 7.85150859883288e-06
the O 0 1.2656748538120155e-07
CTG O 0 0.00020497621153481305
repeat O 0 4.583087687137777e-08
length O 0 2.039247437579661e-09
at O 0 6.326120183253181e-10
several O 0 6.767410416774755e-12
ages O 0 8.334483103666912e-11
in O 0 2.4591849390187548e-11
various O 0 1.6020615389855664e-10
tissues O 0 1.9665564732207486e-09
of O 0 3.915750923511041e-08
transgenic O 0 5.42706430906037e-08
mice O 0 2.2412904865376504e-09
carrying O 0 9.78159775399945e-10
a O 0 3.636025880382476e-08
( O 0 1.7244206063082856e-08
CTG O 0 3.358141839271411e-05
) O 0 7.953707026331358e-09
55expansion O 0 4.7654208401581855e-07
surrounded O 0 5.873845054793492e-08
by O 0 4.5878691956602324e-09
45 O 0 9.302926429199943e-08
kb O 0 9.116483852267265e-06
of O 0 2.1000545302740647e-07
the O 0 1.6567314276016987e-07
human O 0 2.549329110479448e-06
DM B-Disease 1 1.0
region O 0 2.6296682165138918e-08
, O 0 1.7152797238129125e-10
using O 0 6.189602164141661e-10
small O 0 5.82778669766526e-09
- O 0 3.982144036740465e-08
pool O 0 1.3972170336273848e-06
PCR O 0 5.146426360624901e-07
. O 0 1.7184710543460824e-08

These O 0 4.3007096905967046e-07
mice O 0 3.0456433819381346e-07
have O 0 1.3025884537665178e-10
been O 0 1.1850795345047516e-10
shown O 0 4.912943663004654e-11
to O 0 2.2205234179173416e-11
reproduce O 0 4.152674037971593e-10
the O 0 6.237267924369405e-10
intergenerational O 0 1.0505123881898726e-08
and O 0 2.576423518974025e-10
somatic O 0 5.521936330410426e-08
instability O 0 2.015506623820329e-07
of O 0 4.526082975075951e-08
the O 0 4.244342477477403e-08
55 O 0 6.768506750631786e-07
CTG O 0 0.0003529567620716989
repeat O 0 1.66838205473141e-07
suggesting O 0 1.7535150220737705e-08
that O 0 3.911311205473389e-11
surrounding O 0 6.041044331439593e-10
sequences O 0 1.3621366257154932e-09
and O 0 9.17013548429324e-11
the O 0 1.3026237866142765e-09
chromatin O 0 9.945044787684765e-09
environment O 0 2.2635875396304073e-09
are O 0 3.9760209014083614e-11
involved O 0 2.292175338425295e-09
in O 0 8.67031868523327e-09
instability O 0 2.92389245259983e-06
mechanisms O 0 1.4726757399330381e-05
. O 0 3.1550393941870425e-07

As O 0 2.67414890231521e-07
observed O 0 3.689419969532537e-08
in O 0 4.69189531671077e-09
some O 0 1.44419282088748e-10
of O 0 1.7849572930828117e-09
the O 0 2.583481206741567e-09
tissues O 0 9.695638958362451e-09
of O 0 7.497868409700459e-06
DM B-Disease 1 1.0
patients O 0 4.1835201614048856e-07
, O 0 8.494150521842769e-11
there O 0 2.5841107031965294e-10
is O 0 1.9061961731292598e-10
a O 0 9.153748314894017e-10
tendency O 0 7.329559181812328e-10
for O 0 9.225537001000816e-11
repeat O 0 3.971250439605001e-09
length O 0 8.331070833200727e-10
and O 0 4.936306363667597e-10
somatic O 0 3.1887279305919947e-07
mosaicism O 0 2.4949022190412506e-06
to O 0 9.132420375479455e-10
increase O 0 7.389215350706024e-10
with O 0 4.190585378704981e-11
the O 0 1.5176557788265654e-09
age O 0 3.6492199484428056e-08
of O 0 4.8049589196352827e-08
the O 0 6.398853003020122e-08
mouse O 0 1.7384319050961494e-07
. O 0 7.928306899884774e-09

Furthermore O 0 1.277172032132512e-06
, O 0 1.5111567552850147e-09
we O 0 1.2913016211868467e-09
observed O 0 4.208692949703163e-09
no O 0 1.7891294001870506e-09
correlation O 0 2.900589324283942e-09
between O 0 2.739948268271064e-10
the O 0 2.6581117862356507e-10
somatic O 0 4.602910053108644e-09
mutation O 0 1.626275503152641e-10
rate O 0 8.991298261484815e-10
and O 0 1.0840234265785398e-10
tissue O 0 3.3772561636169485e-08
proliferation O 0 5.036864422436338e-06
capacity O 0 1.663566195020394e-06
. O 0 1.1861113335953632e-07

The O 0 3.675390587432048e-07
somatic O 0 3.488758579806017e-07
mutation O 0 1.8420395209162166e-09
rates O 0 5.607369013560515e-10
in O 0 3.017352340206614e-11
different O 0 2.2094881479972628e-11
tissues O 0 2.8222000292288385e-09
were O 0 2.7910143529652487e-08
also O 0 2.3133089888105474e-10
not O 0 2.1246021608689603e-10
correlated O 0 7.645359012542485e-09
to O 0 4.6130066433391903e-10
the O 0 3.983319452061096e-09
relative O 0 1.198673771796166e-06
inter O 0 1.171901385532692e-05
- O 0 1.6267835007965914e-06
tissue O 0 2.1102391656313557e-07
difference O 0 1.3791436970223003e-07
in O 0 8.654309269218174e-09
transcriptional O 0 5.7657967289515e-08
levels O 0 1.8263872636481437e-09
of O 0 1.8368889742603756e-09
the O 0 1.2237159063843706e-09
three O 0 6.61592280959411e-10
genes O 0 8.530197659339933e-10
( O 0 5.262253410798223e-10
DMAHP O 0 6.226611048987252e-07
, O 0 1.5769509031926532e-09
DMPK O 0 3.71126816389733e-06
and O 0 1.2750342115452895e-08
59 O 0 2.2414333500364592e-07
) O 0 2.8975259969143963e-09
surrounding O 0 2.259969278384233e-08
the O 0 1.3670513610009039e-08
repeat O 0 1.8303994409052393e-07
. O 0 6.0083782393860474e-09
. O 0 4.0891702468570656e-08

A O 0 2.027653636105242e-06
novel O 0 4.2328139215896954e-07
missense O 0 8.529295882908627e-06
mutation O 0 8.109063642791625e-09
in O 0 2.1053450094399295e-09
patients O 0 5.859571716726464e-10
from O 0 4.333198244665937e-09
a O 0 5.115535017807815e-08
retinoblastoma B-Disease 1 0.8103429675102234
pedigree O 0 3.662438030005433e-05
showing O 0 1.0753634427373981e-07
only O 0 9.878853290956613e-10
mild O 0 5.393040236612023e-09
expression O 0 4.672676467976089e-09
of O 0 1.8732686513089902e-09
the O 0 4.634297390282427e-09
tumor B-Disease 0 5.468637596095505e-07
phenotype O 0 5.50388179476613e-08
. O 0 4.249054441629596e-09

We O 0 3.4478108545954456e-07
have O 0 1.0271636874392698e-09
used O 0 1.5325317681558204e-09
single O 0 6.225575610585565e-09
strand O 0 4.006859910532512e-08
conformation O 0 1.1411688483065063e-08
polymorphism O 0 1.5303767142427205e-08
analysis O 0 1.1558584089854662e-09
to O 0 1.1070602767837556e-10
study O 0 4.975240774918177e-10
the O 0 1.9290384845049857e-09
27 O 0 1.267764559997886e-07
exons O 0 3.4079018718102816e-08
of O 0 2.345634442235678e-08
the O 0 4.4959602263361376e-08
RB1 O 0 9.799824329093099e-05
gene O 0 1.844542740769839e-09
in O 0 5.014739734576779e-10
individuals O 0 2.664903853144551e-10
from O 0 1.289726325737206e-09
a O 0 1.5919653151286184e-08
family O 0 1.6096008081945e-08
showing O 0 1.6692597526457575e-08
mild O 0 3.205924770099955e-08
expression O 0 1.186358655758113e-08
of O 0 9.676905499134136e-09
the O 0 1.3562059919536296e-08
retinoblastoma B-Disease 0 1.4570786333933938e-05
phenotype O 0 1.3381369399212417e-06
. O 0 2.910244489839897e-08

In O 0 1.6072823427748517e-07
this O 0 4.555701593744743e-09
family O 0 9.402158163140939e-09
affected O 0 1.713599928621079e-09
individuals O 0 1.0139138417741833e-09
developed O 0 1.7990471334883296e-08
unilateral B-Disease 0 5.069264807389118e-05
tumors I-Disease 1 1.0
and O 0 8.738058454582642e-08
, O 0 3.169937645708387e-10
as O 0 1.1533120292117616e-10
a O 0 1.5758526428211184e-10
result O 0 1.297099372354893e-10
of O 0 9.973039061250688e-10
linkage O 0 2.8135216822988696e-08
analysis O 0 2.6763153915254634e-09
, O 0 7.266595658528274e-11
unaffected O 0 7.344144847820644e-09
mutation O 0 1.3607129312198651e-10
carriers O 0 8.334721801617206e-11
were O 0 1.3936783949120013e-09
also O 0 2.386340847149171e-10
identified O 0 4.359078431548369e-09
within O 0 4.717706048040782e-08
the O 0 1.1512697284388196e-07
pedigree O 0 2.397547177679371e-06
. O 0 5.983540773968343e-08

A O 0 6.38547544440371e-06
single O 0 1.187305258554261e-07
band O 0 1.812251753108285e-07
shift O 0 9.265880862585618e-08
using O 0 3.441627427491767e-08
SSCP O 0 1.6843972844071686e-05
was O 0 3.085046671458258e-07
identified O 0 4.846969403615731e-08
in O 0 8.290130359966952e-09
exon O 0 5.2034323516636505e-08
21 O 0 8.131273432354647e-09
which O 0 3.013745850100058e-11
resulted O 0 1.354147793897198e-09
in O 0 1.0618533829998e-09
a O 0 8.204838586323149e-09
missense O 0 1.1554957524140264e-07
mutation O 0 7.832483550629377e-10
converting O 0 3.016643290720822e-08
a O 0 5.914395373451953e-08
cys O 0 4.517037723417161e-06
- O 0 2.9666080081369728e-06
- O 0 5.196407983021345e-06
> O 0 3.5093585211143363e-06
arg O 0 3.7070162761665415e-07
at O 0 1.1613572326041322e-08
nucleotide O 0 5.0172520360547423e-08
position O 0 2.95820594686802e-08
28 O 0 5.741050657093183e-08
in O 0 1.133001159558944e-08
the O 0 1.226238026674764e-07
exon O 0 1.0728614370236755e-06
. O 0 7.268117485637049e-08

The O 0 1.0245950079479371e-06
mutation O 0 8.029160625255827e-08
destroyed O 0 5.042775683250511e-06
an O 0 1.4730856534583836e-08
NdeI O 0 2.662391125340946e-05
restriction O 0 2.2508542940613552e-07
enzyme O 0 1.043865580641068e-07
site O 0 1.3138085819264234e-07
. O 0 2.850614677640806e-08

Analysis O 0 3.2036898574006045e-06
of O 0 9.077654539169089e-08
all O 0 9.437841619330811e-09
family O 0 5.183818174714361e-08
members O 0 1.0101305347731682e-09
demonstrated O 0 2.185286840372669e-09
that O 0 1.5906889694328186e-10
the O 0 8.095680570363584e-09
missense O 0 8.01430132923997e-07
mutation O 0 1.3730459436089859e-08
co O 0 4.056093985127518e-06
- O 0 3.4014776701951632e-06
segregated O 0 1.0999141863976547e-07
with O 0 9.950409385339753e-10
patients O 0 1.197430208321748e-07
with O 0 1.0332712463423377e-06
tumors B-Disease 1 1.0
or O 1 1.0
who O 0 1.7429168792659766e-06
, O 0 1.3195886605643636e-09
as O 0 1.0231727687326497e-09
a O 0 1.900983592761918e-09
result O 0 3.500620904262064e-09
of O 0 4.117070062648054e-08
linkage O 0 7.210640546873037e-07
analysis O 0 3.288511862820087e-08
had O 0 1.0295041263930216e-08
been O 0 5.217541954039007e-09
predicted O 0 2.7920243894641317e-09
to O 0 1.5426546151608989e-10
carry O 0 6.975768851447128e-10
the O 0 1.717678088652974e-08
predisposing O 0 4.244749106874224e-06
mutation O 0 2.153239009317076e-08
. O 0 2.35040857887725e-08

These O 0 6.917846917531278e-08
observations O 0 1.1715712844306836e-06
point O 0 1.3394898701335478e-07
to O 0 1.9901730263782724e-10
another O 0 3.1720848170380123e-10
region O 0 1.124046300482462e-09
of O 0 6.743840597067674e-09
the O 0 1.018996158563823e-07
RB1 O 0 0.0001333063410129398
gene O 0 1.5471992576010507e-09
where O 0 3.343054999493944e-10
mutations O 0 3.9246654537361536e-11
only O 0 2.9746323459978186e-11
modify O 0 5.433933511489464e-11
the O 0 4.0759676189772165e-10
function O 0 7.45217576536561e-09
of O 0 6.651328376960919e-09
the O 0 1.0027195074258088e-08
gene O 0 1.0515421866585939e-09
and O 0 1.3285736399915038e-10
raise O 0 6.874041336146774e-10
important O 0 2.5953877935691594e-10
questions O 0 1.1140784961227723e-09
for O 0 6.761866067073186e-11
genetic O 0 4.428180044868668e-09
counseling O 0 3.715362906220321e-09
in O 0 4.703161818331303e-11
families O 0 9.572236232824327e-12
with O 0 1.657950903302674e-12
these O 0 3.6042516193823815e-11
distinctive O 0 1.782052172494275e-09
phenotypes O 0 3.0936991635144295e-08
. O 0 3.487159450088484e-09
. O 0 2.4039175983148198e-08

Maternal B-Disease 0 0.01492475438863039
disomy I-Disease 0 0.1448076367378235
and O 0 2.091852184094023e-05
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
consistent O 0 0.00044747901847586036
with O 0 2.6152711107840787e-09
gamete O 0 3.557551826816052e-05
complementation O 0 1.693571721261833e-05
in O 0 3.2886919854036023e-09
a O 0 5.3309925363009825e-09
case O 0 5.451421092317332e-09
of O 0 1.4916793134034378e-07
familial O 0 1.4380927495949436e-05
translocation O 0 3.3417200029361993e-07
( O 0 4.1217034230101035e-09
3 O 0 1.0055963173272175e-08
; O 0 5.4318195774616385e-11
15 O 0 5.3269673117029015e-09
) O 0 1.2671156346399925e-09
( O 0 1.0487900548028506e-09
p25 O 0 6.417933207103488e-08
; O 0 2.620997585633944e-10
q11 O 0 4.994346625153412e-08
. O 0 1.1380426601093063e-09
2 O 0 5.143124326423276e-08
) O 0 2.8761180104197592e-09
. O 0 1.025572604618219e-08

Maternal B-Disease 1 0.9999915361404419
uniparental I-Disease 1 1.0
disomy I-Disease 1 0.999992847442627
( I-Disease 0 0.00021721073426306248
UPD I-Disease 1 1.0
) I-Disease 0 1.801278948221352e-08
for I-Disease 0 1.170505359304741e-09
chromosome I-Disease 0 4.9559716330804804e-08
15 I-Disease 0 6.381642947417276e-08
is O 0 1.7272472341289813e-09
responsible O 0 4.320579893857257e-09
for O 0 8.563991737986498e-10
an O 0 3.2711005015784167e-09
estimated O 0 1.9021551000975023e-09
30 O 0 2.4090571759671775e-09
% O 0 1.7042441069481384e-10
of O 0 2.8009250474525516e-10
cases O 0 6.46794284797636e-10
of O 0 2.147750592484954e-06
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.00022188258299138397
PWS B-Disease 1 1.0
) O 0 3.5887129712364185e-08
. O 0 1.0788164139796663e-08

We O 0 1.298196707466559e-06
report O 0 1.5870364222791977e-07
on O 0 2.0305002124132443e-08
an O 0 4.673422759893242e-10
unusual O 0 3.2423095319700224e-09
case O 0 7.922970723939216e-09
of O 0 1.3641802354413812e-07
maternal B-Disease 0 6.79790946378489e-06
disomy I-Disease 0 7.125989213818684e-05
15 I-Disease 0 1.97142617253121e-06
in O 0 3.499241358895233e-07
PWS B-Disease 1 1.0
that O 0 7.008509883554837e-10
is O 0 3.9834924248083325e-10
most O 0 3.919174706989992e-11
consistent O 0 1.9278099117059355e-09
with O 0 5.543381031980488e-11
adjacent O 0 4.03800086701267e-08
- O 0 5.420474380457563e-08
1 O 0 1.0655788855729043e-06
segregation O 0 3.520139912893683e-08
of O 0 1.1071225713976673e-08
a O 0 3.3961313761210477e-08
paternal O 0 8.355967651141327e-08
t O 0 2.8903393012313927e-09
( O 0 1.2784567848811434e-10
3 O 0 1.0347539491917246e-09
; O 0 1.0125966905250028e-11
15 O 0 8.698656239758407e-10
) O 0 1.5678687514952827e-10
( O 0 2.1987733855866054e-10
p25 O 0 4.763891947590082e-09
; O 0 2.4873046330919912e-11
q11 O 0 4.788816898582127e-09
. O 0 7.915515465306555e-11
2 O 0 2.466802540013191e-09
) O 0 2.736056346763771e-11
with O 0 8.691813761785294e-12
simultaneous O 0 1.6412409209465295e-08
maternal O 0 4.2618080442480277e-07
meiotic O 0 1.2076928214810323e-05
nondisjunction O 0 1.0978787031490356e-05
for O 0 9.911961917907774e-09
chromosome O 0 1.4560689010068018e-07
15 O 0 2.28066411978034e-07
. O 0 4.645415430104549e-08

The O 0 1.7632094113650965e-06
patient O 0 1.003140368993627e-06
( O 0 1.9902662629078804e-08
J O 0 2.0838432135406038e-07
. O 0 8.155655595309952e-10
B O 0 9.453663096792297e-08
. O 0 4.1707481912567346e-10
) O 0 4.5610548671248807e-10
, O 0 1.4034755302372304e-10
a O 0 7.347479069608198e-09
17 O 0 3.195320985582839e-08
- O 0 7.137766377951493e-09
year O 0 2.7239227762265728e-08
- O 0 2.5786491164581093e-07
old O 0 3.982539055868983e-06
white O 0 2.830131791142776e-07
male O 0 4.588738278243909e-08
with O 0 1.214341693867027e-08
PWS B-Disease 1 1.0
, O 0 7.758238496080594e-08
was O 0 7.363783538494317e-07
found O 0 8.811847251877225e-09
to O 0 1.7716815792212515e-09
have O 0 1.993981202375039e-09
47 O 0 2.985208524819427e-08
chromosomes O 0 1.1197457183698134e-08
with O 0 6.399896723685572e-10
a O 0 8.564030622437713e-07
supernumerary O 0 0.0034251364413648844
, O 0 1.0347702250612656e-08
paternal O 0 7.193517603809596e-07
der O 0 0.00011679298768285662
( O 0 2.628935824589007e-08
15 O 0 1.2618392553065405e-08
) O 0 1.1233149133094145e-10
consisting O 0 7.526365641830068e-10
of O 0 2.4790296038190718e-08
the O 0 8.439095466883373e-08
short O 0 3.611572481077019e-07
arm O 0 2.443980974931037e-06
and O 0 1.3411063370938336e-08
the O 0 1.1298395747871837e-06
proximal O 0 0.19912660121917725
long O 0 1.6738114254621905e-06
arm O 0 4.997309133614181e-06
of O 0 1.1561994597286684e-06
chromosome O 0 6.028320171935775e-07
15 O 0 1.632158728170907e-07
, O 0 8.206071377969693e-10
and O 0 2.805867316268973e-09
distal O 0 6.504801422124729e-05
chromosome O 1 0.7176140546798706
arm O 1 0.9999889135360718
3p O 1 1.0
. O 0 1.1175724466738757e-05

The O 0 1.930742473632563e-05
t O 0 3.2083173095998063e-07
( O 0 8.043013366432206e-09
3 O 0 1.924067660752371e-08
; O 0 1.323146731069258e-10
15 O 0 5.992515816899413e-09
) O 0 3.7428157795282857e-10
was O 0 7.609948227127461e-09
present O 0 8.067191914484795e-10
in O 0 7.156657488849305e-10
the O 0 2.8833022636121086e-09
balanced O 0 1.0737767119906039e-08
state O 0 6.558755760721624e-10
in O 0 4.576898027242038e-10
the O 0 3.802679504616435e-09
patients O 0 1.2672508598043919e-09
father O 0 2.059861614611691e-08
and O 0 1.0859512400429594e-08
a O 0 1.289704414375592e-06
sister O 0 1.4506548723147716e-05
. O 0 3.886842705469462e-07

Fluorescent O 0 5.951092134637292e-07
in O 0 4.6514596618862925e-09
situ O 0 1.3524741007131524e-06
hybridization O 0 2.723907144286386e-08
analysis O 0 2.734806825444025e-09
demonstrated O 0 9.90929227562276e-10
that O 0 7.051023653836808e-11
the O 0 7.460424278349365e-09
PWS B-Disease 1 1.0
critical O 0 3.4330398079873703e-07
region O 0 7.075549923740709e-09
resided O 0 4.929292458655254e-07
on O 0 8.190609968039553e-09
the O 0 6.0601359486156525e-09
derivative O 0 1.1378071462786465e-07
chromosome O 0 6.061350088515383e-09
3 O 0 3.7938701069606395e-09
and O 0 3.63094068700498e-11
that O 0 3.49742734773173e-11
there O 0 6.401068564088064e-10
was O 0 7.387912148715259e-08
no O 0 9.703001957461765e-09
deletion O 0 9.746758955486712e-09
of O 0 7.07768563756872e-08
the O 0 8.921018661567359e-07
PWS B-Disease 1 1.0
region O 0 3.649669451988302e-06
on O 0 2.0324924321357685e-07
the O 0 6.872448210515358e-08
normal O 0 3.0303053222269227e-07
pair O 0 1.4025858696697924e-08
of O 0 3.060819153688499e-08
15s O 0 3.804851189670444e-07
present O 0 8.203966217479319e-08
in O 0 2.824582736593584e-07
J O 0 4.887115574092604e-05
. O 0 2.0823593160912424e-07

B O 0 0.0006290051387622952
. O 0 2.0988804863009136e-06

Methylation O 0 7.994096449692734e-06
analysis O 0 3.4512189017732453e-07
at O 0 1.3286020816849486e-07
exon O 0 1.2367043211725104e-07
alpha O 0 9.572327996920649e-08
of O 0 4.195276126495173e-09
the O 0 2.7327939911003796e-09
small O 0 5.91628790402865e-09
nuclear O 0 5.475379794006585e-07
ribonucleoprotein O 0 0.00027729131397791207
- O 0 1.02485682873521e-06
associated O 0 5.100210387354309e-07
polypeptide O 0 0.0001336074055870995
N O 0 0.00013492829748429358
( O 0 4.3141422878534286e-08
SNRPN O 0 3.700170054798946e-05
) O 0 3.974160112107938e-09
gene O 0 5.617334930541062e-10
showed O 0 9.625596986140295e-10
a O 0 1.032636420816857e-09
pattern O 0 7.595476247956867e-09
characteristic O 0 3.2760392176811592e-09
of O 0 1.2806594895664603e-08
only O 0 1.3325918146733784e-09
the O 0 2.8356139658569646e-09
maternal O 0 1.9960941344265848e-08
chromosome O 0 1.096641710773838e-08
15 O 0 1.5171991663009976e-08
in O 0 3.494525202540899e-08
J O 0 1.916373730637133e-05
. O 0 2.1052703402801853e-07

B O 0 0.0004976459313184023
. O 0 1.92417974176351e-06

Maternal B-Disease 0 0.0016146025154739618
disomy I-Disease 0 9.569182293489575e-05
was O 0 4.0959972125165223e-07
confirmed O 0 6.520018303035613e-09
by O 0 1.2660671400155366e-09
polymerase O 0 2.2194090121274712e-08
chain O 0 3.80370224206672e-09
reaction O 0 2.6488344850861267e-10
analysis O 0 4.611046655611517e-09
of O 0 1.4821777583051698e-08
microsatellite O 0 3.698484647429723e-07
repeats O 0 5.47188321320391e-08
at O 0 4.9516913236402615e-08
the O 0 8.35298408219387e-09
gamma O 0 4.967745326212025e-07
- O 0 1.2449309849671408e-07
aminobutyric O 0 1.0755824177977047e-06
acid O 0 6.926111240090904e-08
receptor O 0 2.0113877496896748e-07
beta3 O 0 4.5126702730158286e-07
subunit O 0 1.8638324661424122e-07
( O 0 9.43751743420762e-09
GABRB3 O 0 2.2677863853459712e-06
) O 0 1.809643279671036e-08
locus O 0 3.2388564363827754e-07
. O 0 1.4953505100834263e-08

A O 0 5.4008301958674565e-05
niece O 0 2.069434594886843e-05
( O 0 4.312052936938926e-08
B O 0 1.6907777933283796e-07
. O 0 3.9591926959126056e-10
B O 0 3.405842008419313e-08
. O 0 7.321786232861172e-11
) O 0 2.0501418271368088e-11
with O 0 2.0299424034059266e-12
45 O 0 8.18251799650227e-10
chromosomes O 0 6.321174694789988e-10
and O 0 8.675057894258487e-11
the O 0 1.1725834747622343e-09
derivative O 0 7.060803852709796e-08
3 O 0 9.904648656799964e-09
but O 0 5.6807190895735715e-11
without O 0 3.0999924849339777e-10
the O 0 4.625317018280839e-09
der O 0 2.435333044559229e-06
( O 0 2.66914268465257e-09
15 O 0 4.609947978906348e-09
) O 0 1.3212149430064102e-10
demonstrated O 0 7.423542891515922e-10
a O 0 2.8167095322828573e-09
phenotype O 0 9.389435007278735e-09
consistent O 0 4.727602753717974e-09
with O 0 1.224985043957183e-11
that O 0 5.4452633374557635e-11
reported O 0 1.470479848997286e-09
for O 0 4.6112205720483246e-10
haploinsufficiency O 0 1.3514593319996493e-06
of O 0 9.164463108390919e-07
distal O 0 3.683197974169161e-06
3 O 0 4.346689092926681e-05
p O 0 0.00013245700392872095
. O 0 1.0333505429116485e-07

Uniparental B-Disease 1 1.0
disomy I-Disease 1 1.0
associated O 0 1.8483529856894165e-05
with O 0 2.332353332690218e-08
unbalanced O 0 0.0005313614965416491
segregation O 0 2.19105527321517e-06
of O 0 1.0637288596626604e-06
non O 0 0.00033665899536572397
- O 0 0.00011372890730854124
Robertsonian O 1 0.9995213747024536
translocations O 0 5.9882160712732e-05
has O 0 6.1725229372200374e-09
been O 0 5.7784430573804e-09
reported O 0 1.8022307202159027e-08
previously O 0 3.551668825707566e-08
but O 0 1.222890011476352e-09
has O 0 4.6476972270781403e-10
not O 0 6.05161976086066e-10
, O 0 2.8814536867649565e-10
to O 0 2.43329223437172e-09
our O 0 3.8537049107389976e-08
knowledge O 0 2.2534345589519944e-06
, O 0 1.397388871282601e-09
been O 0 1.8043107008480774e-09
observed O 0 2.0465416028514483e-09
in O 0 2.3687649619574813e-09
a O 0 1.8498038656389326e-08
case O 0 7.638497123707566e-08
of O 0 5.813528787257383e-06
PWS B-Disease 1 1.0
. O 0 1.7290102505285176e-06

Furthermore O 0 3.149386611767113e-05
, O 0 6.790578321869134e-09
our O 0 8.496200187835257e-09
findings O 0 5.052733786925501e-09
are O 0 1.5637950656621769e-10
best O 0 1.1498817453770016e-09
interpreted O 0 6.693836152038557e-09
as O 0 5.765846133876096e-10
true O 0 1.4003992632183326e-08
gamete O 0 2.5326980903628282e-06
complementation O 0 1.7256533055842738e-06
resulting O 0 4.902214811863814e-08
in O 0 6.076330549831255e-08
maternal B-Disease 0 0.0007097481866367161
UPD I-Disease 1 1.0
15 I-Disease 0 9.412722283741459e-05
and O 0 2.5505134999548318e-06
PWS B-Disease 1 1.0

Schwartz B-Disease 1 0.9999992847442627
- I-Disease 1 1.0
Jampel I-Disease 1 1.0
syndrome I-Disease 1 1.0
type I-Disease 0 0.00034595676697790623
2 I-Disease 0 0.00011253813136136159
and O 0 6.355683979109017e-08
Stuve B-Disease 1 1.0
- I-Disease 1 1.0
Wiedemann I-Disease 1 1.0
syndrome I-Disease 1 1.0
: O 0 3.329572395571745e-09
a O 0 8.726928513169696e-09
case O 0 6.5108469726737894e-09
for O 0 2.0644388420976156e-09
" O 0 1.0387968529812497e-07
lumping O 0 6.260299869609298e-07
" O 0 3.1892662377686065e-07
. O 0 4.153398691641996e-08

Recent O 0 6.276446242736711e-07
studies O 0 7.206647012480971e-08
demonstrated O 0 6.4755623085943625e-09
the O 0 4.438318601529545e-09
existence O 0 2.5912166279340454e-07
of O 0 1.3709158253050191e-08
a O 0 2.4025641476299597e-09
genetically O 0 3.493520403519135e-11
distinct O 0 6.67522773167839e-11
, O 0 6.637352559929477e-12
usually O 0 6.1004968437972096e-12
lethal O 0 1.8418057010083366e-11
form O 0 1.0169599190534839e-10
of O 0 9.095936448488828e-09
the O 0 3.966255945897501e-08
Schwartz B-Disease 1 0.9944822788238525
- I-Disease 1 0.9999982118606567
Jampel I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 1.3584423186330241e-06
SJS B-Disease 1 0.9950504899024963
) O 0 8.03838151597347e-09
of O 0 4.4380541908140003e-07
myotonia B-Disease 1 0.9999997615814209
and O 0 0.0006363143329508603
skeletal B-Disease 1 1.0
dysplasia I-Disease 1 1.0
, O 0 2.6599149549610956e-08
which O 0 2.3282407113356385e-09
we O 0 2.1908675762460916e-08
called O 0 6.66232608637074e-07
SJS B-Disease 1 0.6903992891311646
type I-Disease 0 2.6418389097671025e-05
2 I-Disease 0 2.021682303166017e-05
. O 0 1.1114519082866536e-07

This O 0 1.5542742630714201e-06
disorder O 0 0.2815949320793152
is O 0 9.751127905133217e-09
reminiscent O 0 1.3158185652173415e-07
of O 0 3.7308954148329576e-08
another O 0 2.31901911007526e-08
rare O 0 2.580006253083411e-08
condition O 0 2.088099108732422e-06
, O 0 1.2585792408259522e-09
the O 0 2.3424205153332878e-07
Stuve B-Disease 1 1.0
- I-Disease 1 1.0
Wiedemann I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 1 0.9616504907608032
SWS B-Disease 1 0.9999985694885254
) O 0 1.7761410120442633e-09
, O 0 1.0187460597332887e-10
which O 0 1.0876229777911917e-10
comprises O 0 1.9197750944499603e-08
campomelia B-Disease 0 3.5019449569517747e-05
at O 0 8.08288314146921e-06
birth O 0 4.489808361540781e-06
with O 0 5.642909428615894e-08
skeletal B-Disease 1 1.0
dysplasia I-Disease 1 1.0
, O 0 2.5202243136845937e-07
contractures B-Disease 1 0.9993399977684021
, O 0 1.9020072627995432e-08
and O 0 5.778112655008272e-09
early B-Disease 0 9.769223652256187e-07
death I-Disease 0 3.587773107938119e-06
. O 0 2.4166200773834134e-07

To O 0 3.4342505728091055e-08
test O 0 3.346871890741454e-09
for O 0 9.281774793201691e-10
possible O 0 2.3349972622099813e-08
nosologic O 0 6.35635806247592e-05
identity O 0 1.0660835414455505e-07
between O 0 1.1722486092935469e-08
these O 0 6.397886664899488e-09
disorders O 0 0.0003632263105828315
, O 0 4.424521860002528e-10
we O 0 1.1112262221502078e-09
reviewed O 0 2.354702743900816e-08
the O 0 5.663598923177915e-09
literature O 0 1.8744847452012436e-08
and O 0 3.0133109896191e-10
obtained O 0 2.519552921853574e-08
a O 0 7.601664187006918e-09
follow O 0 2.159147749480894e-09
- O 0 2.018852196528087e-09
up O 0 5.219253473853769e-09
of O 0 8.16739653686227e-09
the O 0 4.699176603395472e-09
only O 0 5.912787481854309e-10
two O 0 4.6217779603452414e-10
surviving O 0 8.129491675390454e-07
patients O 0 1.7052009804174872e-09
, O 0 3.202077492048261e-10
one O 0 4.534488340368625e-09
with O 0 8.337766921329148e-09
SJS B-Disease 1 0.9999945163726807
type I-Disease 0 0.009756813757121563
2 I-Disease 0 1.7525942894280888e-05
at O 0 1.6657810419928865e-07
age O 0 1.882460232138783e-08
10 O 0 3.678596982581439e-09
years O 0 8.510079307910701e-10
and O 0 1.261862003776315e-10
another O 0 2.423292677633526e-09
with O 0 2.0259112165632587e-09
SWS B-Disease 0 0.0001812229020288214
at O 0 4.449950097296096e-08
age O 0 3.3907976870750645e-08
7 O 0 2.6575369815873273e-07
years O 0 6.49024229915085e-08
. O 0 3.978719931296837e-08

Patients O 0 2.3847724150982685e-06
reported O 0 6.414848741087553e-08
as O 0 2.3315516184396756e-09
having O 0 1.0435869057801028e-07
either O 0 6.80396260577254e-05
neonatal O 1 1.0
SJS B-Disease 1 1.0
or O 1 0.9999996423721313
SWS B-Disease 1 0.999972939491272
presented O 0 2.8636064186571275e-08
a O 0 3.6984220130875656e-09
combination O 0 2.4439297252598635e-09
of O 0 7.615930108784141e-09
a O 0 2.0992830584987132e-08
severe O 0 1.1206323051737854e-06
, O 0 1.0344150425112275e-08
prenatal O 1 0.9999353885650635
- O 1 0.9992610812187195
onset O 1 1.0
neuromuscular B-Disease 1 1.0
disorder I-Disease 1 1.0
( O 0 0.002222767099738121
with O 0 7.2743132477626204e-06
congenital B-Disease 1 1.0
joint I-Disease 1 1.0
contractures I-Disease 1 1.0
, O 1 0.999994158744812
respiratory O 1 1.0
and O 0 3.3232063287869096e-05
feeding O 1 0.999998927116394
difficulties O 1 1.0
, O 0 5.275030900975253e-08
tendency O 0 4.627719647487538e-07
to O 0 2.2991473613842572e-08
hyperthermia B-Disease 1 0.9999997615814209
, O 0 1.3821996880380993e-09
and O 0 5.552611148651465e-10
frequent O 0 1.7094450299737218e-08
death O 0 8.808825668893405e-08
in O 0 4.654505758594496e-08
infancy O 0 0.004697781056165695
) O 0 3.907681678239072e-10
with O 0 1.4387372369861762e-11
a O 0 8.49485548570783e-09
distinct O 0 8.271843654483746e-08
campomelic B-Disease 1 0.9999816417694092
- I-Disease 1 1.0
metaphyseal I-Disease 1 1.0
skeletal I-Disease 1 1.0
dysplasia I-Disease 1 1.0
. O 0 2.540402647355222e-06

The O 0 7.346142751885054e-07
similarity O 0 4.3798743831757747e-07
of O 0 1.3253534802970535e-07
the O 0 3.6302882477912135e-08
clinical O 0 1.8151280301026418e-06
and O 0 2.013361033448291e-09
radiographic O 0 1.9163353499607183e-05
findings O 0 2.3259656245500082e-07
is O 0 1.5400712927160498e-09
so O 0 2.3287102801639037e-10
extensive O 0 4.543673881585164e-09
that O 0 1.0056411953174305e-10
these O 0 1.0258126570406034e-09
disorders O 0 1.5006288776930887e-05
appear O 0 4.247241491839304e-08
to O 0 4.147823418065855e-09
be O 0 2.8548248209858684e-09
a O 0 9.130004308133266e-09
single O 0 6.78339340254297e-09
entity O 0 5.171888233235222e-07
. O 0 2.1150000861780427e-07

The O 0 4.116091076866724e-06
follow O 0 2.1288153106979735e-07
- O 0 2.635342752910219e-07
up O 0 7.429301263073285e-08
observation O 0 1.0443985956953838e-05
of O 0 2.9382769994867886e-08
an O 0 1.4812499005145696e-09
identical O 0 1.7433759991192233e-09
and O 0 1.3863946102254943e-10
unique O 0 2.1199237920654923e-09
pattern O 0 1.523432899830368e-07
of O 0 7.389308302663267e-05
progressive O 1 1.0
bone B-Disease 1 1.0
dysplasia I-Disease 1 0.9999998807907104
in O 0 9.310364390557879e-08
the O 0 1.5273965203732587e-08
two O 0 1.779168812277021e-09
patients O 0 6.118891504591772e-10
( O 0 2.8297231224883035e-10
one O 0 4.816497201076686e-10
with O 0 5.821606530176382e-10
SJS B-Disease 0 0.3354227542877197
type I-Disease 0 1.692086698312778e-05
2 I-Disease 0 1.1225684829696547e-05
, O 0 3.206166165892199e-10
one O 0 2.026931511522889e-09
with O 0 6.290720722113008e-10
SWS B-Disease 0 0.3546273708343506
) O 0 1.6310852668510734e-09
surviving O 0 2.3250430558618973e-07
beyond O 0 3.166847193369904e-07
infancy O 0 2.6482266548555344e-06
adds O 0 3.168585172019789e-09
to O 0 2.8433352894374764e-10
the O 0 5.128855673497412e-10
evidence O 0 2.4425315103826506e-09
in O 0 7.097957777091324e-10
favor O 0 2.1086321577712397e-09
of O 0 1.507127578292966e-08
identity O 0 1.0055754984250598e-07
. O 0 3.311270901917851e-08

The O 0 7.413651701426716e-07
hypothesis O 0 3.7891172723902855e-06
that O 0 1.6885243425690533e-08
SWS B-Disease 0 0.00016034585132729262
and O 0 1.9909800030859515e-08
SJS B-Disease 0 0.00259584398008883
type I-Disease 0 1.9351662103872513e-06
2 I-Disease 0 2.55214126809733e-06
are O 0 4.749473037080065e-10
the O 0 1.7508605676397337e-09
same O 0 4.310885159952704e-08
disorder O 0 1.391033265463193e-06
should O 0 9.099124231859435e-10
be O 0 7.082391895174567e-10
testable O 0 4.569053047021043e-08
by O 0 2.2226559481808295e-10
molecular O 0 3.8579166528052156e-09
methods O 0 7.7055570812945e-09
. O 0 5.752323617436161e-10
. O 0 1.1048506998179164e-08

A O 0 5.9085314205731265e-06
mouse O 0 1.0147001461291438e-07
model O 0 5.2789737026159855e-09
of O 0 1.2500247059676894e-08
severe O 0 0.0007741145673207939
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
: O 0 0.07571979612112045
defects O 1 0.9999997615814209
in O 0 6.179063234412752e-07
hemostasis O 1 0.9999986886978149
and O 0 6.500637255157926e-07
thrombosis B-Disease 1 0.9999998807907104
. O 0 6.617312010348542e-06

von B-Disease 1 0.9999773502349854
Willebrand I-Disease 1 1.0
factor I-Disease 1 0.9710242748260498
( I-Disease 0 1.0632325029291678e-05
vWf I-Disease 1 0.99996018409729
) I-Disease 0 7.037515842966968e-06
deficiency I-Disease 1 1.0
causes O 1 0.9997822642326355
severe O 1 1.0
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
in O 0 0.007297853473573923
humans O 0 2.7772928206104552e-06
. O 0 1.8889412700673347e-08

We O 0 3.7800981544933165e-07
generated O 0 1.4971547557252052e-07
a O 0 2.609681715171064e-08
mouse O 0 6.733943180847746e-09
model O 0 4.2898989915940433e-10
for O 0 4.022958008387256e-11
this O 0 1.6798716584442985e-10
disease O 0 4.5233769507824206e-10
by O 0 8.071435186884912e-11
using O 0 1.770357416219781e-09
gene O 0 2.8231206261608577e-09
targeting O 0 4.044035861738848e-08
. O 0 1.0644758852151881e-08

vWf B-Disease 1 0.9999914169311523
- I-Disease 1 1.0
deficient I-Disease 1 0.9999642372131348
mice O 0 8.346257800440071e-07
appeared O 0 3.129772707666234e-08
normal O 0 3.5989401681035815e-08
at O 0 3.428822781259555e-09
birth O 0 1.30511579321535e-09
; O 0 2.5019692914685088e-11
they O 0 5.218989476696301e-11
were O 0 3.5166285439203193e-09
viable O 0 1.4179670415614964e-07
and O 0 4.5297166018087864e-09
fertile O 0 8.366216206923127e-06
. O 0 2.2603082072691905e-07

Neither O 0 0.0002044408320216462
vWf O 0 0.0020569420885294676
nor O 0 5.818031058879569e-05
vWf O 0 0.0005098495748825371
propolypeptide O 0 0.00035518131335265934
( O 0 5.363500008570554e-07
von B-Disease 0 0.001369021600112319
Willebrand I-Disease 0 0.014827209524810314
antigen O 0 7.671201274206396e-07
II O 1 0.9890628457069397
) O 0 3.273099125067347e-08
were O 0 6.694946819152392e-09
detectable O 0 5.554110771299747e-08
in O 0 1.04985087290288e-09
plasma O 0 2.45324365266697e-08
, O 0 1.9566703812756714e-10
platelets O 0 1.5351449889067226e-08
, O 0 6.706893929120383e-10
or O 0 5.42708233908229e-09
endothelial O 0 9.961542701830695e-09
cells O 0 1.2915503111443627e-09
of O 0 6.343159331123616e-09
the O 0 3.4410891913694286e-08
homozygous O 0 4.958822614753444e-07
mutant O 0 1.8293869743502e-06
mice O 0 4.3384025616433064e-07
. O 0 3.5322846869689783e-09

The O 0 1.1910130979231326e-06
mutant O 0 1.6387159121222794e-05
mice O 0 3.3629528388701146e-06
exhibited O 0 2.115666802637861e-06
defects O 1 0.8462084531784058
in O 0 4.86426934287465e-08
hemostasis O 0 0.0003207847767043859
with O 0 1.103123481449586e-09
a O 0 1.3935839149326057e-07
highly O 0 3.0460635116469348e-06
prolonged O 1 0.9999998807907104
bleeding O 1 0.9999613761901855
time O 0 1.6165130318768206e-06
and O 0 2.00040854991812e-08
spontaneous O 0 1.3326593034435064e-05
bleeding O 0 5.658770533045754e-05
events O 0 4.85701701080643e-09
in O 0 3.727740338632657e-10
approximately O 0 6.940691354984097e-10
10 O 0 9.217416274687196e-10
% O 0 4.246038520783202e-10
of O 0 1.1959393475535762e-08
neonates O 0 1.8234665049021714e-06
. O 0 1.045300095370294e-07

As O 0 1.9262475348114094e-07
in O 0 8.172102994308261e-09
the O 0 9.845336990110809e-09
human O 0 4.567380074149696e-08
disease O 0 1.3270737042603287e-07
, O 0 1.0556130275451991e-10
the O 0 3.89999188499246e-09
factor O 0 4.438582834609406e-08
VIII O 0 7.765149803162785e-07
level O 0 2.4634036890347488e-05
in O 0 1.5815383447304043e-09
these O 0 3.473403509257622e-10
mice O 0 2.306507651539391e-09
was O 0 2.2017583312106126e-09
reduced O 0 7.421957493036757e-10
strongly O 0 4.2924935828025923e-10
as O 0 1.785862291381335e-10
a O 0 8.800505324479957e-10
result O 0 9.980518633767588e-10
of O 0 3.412323090756786e-09
the O 0 6.041428246561509e-09
lack O 0 6.67603856641108e-08
of O 0 1.750771261299633e-08
protection O 0 1.3803036047477235e-08
provided O 0 7.91774379393928e-09
by O 0 1.3587795777425526e-08
vWf O 0 1.9510844140313566e-05
. O 0 2.468197521920956e-07

Defective O 1 0.993563175201416
thrombosis B-Disease 1 0.9630830883979797
in O 0 8.352922122867312e-07
mutant O 0 9.603187208995223e-05
mice O 0 2.4057696919044247e-06
was O 0 1.2933288928707043e-07
also O 0 1.7766922655315653e-10
evident O 0 2.8183593236974502e-09
in O 0 4.882520499016607e-10
an O 0 1.732727156200653e-10
in O 0 7.285667624756798e-10
vivo O 0 1.0456390242552516e-07
model O 0 6.3557057394803e-09
of O 0 5.751122102992667e-07
vascular B-Disease 1 0.9999998807907104
injury I-Disease 1 0.9999997615814209
. O 0 5.739929292758461e-06

In O 0 1.3874468152152986e-07
this O 0 2.932710074787792e-09
model O 0 1.7889631109824222e-08
, O 0 7.226806375548733e-10
the O 0 1.9931190919919572e-08
exteriorized O 0 1.7596314137335867e-05
mesentery O 0 4.053071097587235e-05
was O 0 4.553407507046359e-06
superfused O 0 4.615898433257826e-06
with O 0 6.229008420177706e-09
ferric O 0 6.0599661082960665e-05
chloride O 0 6.695219326502411e-06
and O 0 6.162020582678451e-08
the O 0 5.207552362662682e-07
accumulation O 0 0.001605242840014398
of O 0 0.00022854565759189427
fluorescently O 0 0.003575552487745881
labeled O 0 7.79563379182946e-06
platelets O 0 4.665644155465998e-06
was O 0 4.831093747270643e-07
observed O 0 2.7124286816615495e-08
by O 0 6.788273498870012e-09
intravital O 0 3.6552323763316963e-06
microscopy O 0 1.5502846508752555e-06
. O 0 2.892823545153078e-07

We O 0 1.01155501397443e-06
conclude O 0 2.24426003114786e-06
that O 0 1.66648173038908e-09
these O 0 1.6261958446506242e-09
mice O 0 3.00841520584072e-08
very O 0 1.2826829598466816e-09
closely O 0 2.866480741658961e-08
mimic O 0 2.418117446723045e-06
severe O 0 9.990783291868865e-05
human O 0 0.00013403347111307085
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
and O 0 4.3795903792442914e-08
will O 0 5.346376119597096e-10
be O 0 1.8992754591273808e-10
very O 0 1.0637036390592769e-10
useful O 0 1.63558999677349e-09
for O 0 8.416610464134777e-11
investigating O 0 1.2956370198935474e-08
the O 0 6.571569066693428e-09
role O 0 1.6003863123614792e-08
of O 0 5.404823255616975e-08
vWf O 0 1.6992008795568836e-06
in O 0 1.0800207839167797e-08
normal O 0 1.5557839105895255e-06
physiology O 0 3.9033648135955445e-06
and O 0 2.5649402046745706e-10
in O 0 1.2041742047941284e-09
disease O 0 2.4379437135735316e-08
models O 0 7.348484043490089e-10
. O 0 4.5376871704583266e-10
. O 0 4.854210811089388e-09

Oral O 0 0.0009548040688969195
contraceptives O 0 5.100909220345784e-06
and O 0 7.101315646629303e-10
the O 0 5.330789143442871e-09
risk O 0 1.1352788533258718e-05
of O 1 0.9998723268508911
hereditary B-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.0004693123628385365

Hereditary B-Disease 1 1.0
Ovarian I-Disease 1 1.0
Cancer I-Disease 1 1.0
Clinical O 1 1.0
Study O 0 0.00010997131903422996
Group O 0 9.161809089164308e-08
. O 0 9.439822257206743e-09

BACKGROUND O 0 2.8802680390072055e-05
Women O 0 6.912119321356158e-09
with O 0 3.2378134895427735e-11
mutations O 0 5.963710636436304e-10
in O 0 1.3707243118332713e-09
either O 0 1.1085531603782783e-08
the O 0 1.1421536072475647e-07
BRCA1 O 0 1.2161025608747877e-07
or O 0 5.991500984237064e-08
the O 0 3.494205103038439e-08
BRCA2 O 0 1.36429207486799e-07
gene O 0 1.5060089841867352e-09
have O 0 7.312980082607723e-11
a O 0 7.347307762195499e-10
high O 0 1.2113714475958659e-08
lifetime O 0 1.6434405836207588e-07
risk O 0 5.363885065889917e-05
of O 1 0.9999995231628418
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 1.782523759175092e-05

Oral O 0 0.31362995505332947
contraceptives O 0 0.0388757660984993
protect O 0 6.515360837511253e-06
against O 1 0.9980369210243225
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 0.0003957209410145879
general O 0 3.6398705560714006e-07
, O 0 5.038892081365987e-10
but O 0 7.9075329617595e-11
it O 0 4.3742905131427534e-11
is O 0 3.517309360434595e-11
not O 0 3.037736728828122e-11
known O 0 1.0462001404087928e-10
whether O 0 1.462278770292258e-10
they O 0 5.429999228034887e-10
also O 0 5.474779518621631e-10
protect O 0 1.4828669403499362e-09
against O 0 3.4333056397883865e-09
hereditary B-Disease 0 0.11757240444421768
forms I-Disease 0 2.1009207557654008e-05
of I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 2.9083660137985134e-06

METHODS O 0 1.3771054909739178e-06
We O 0 1.3428341105736763e-08
enrolled O 0 3.179144414389157e-08
207 O 0 1.8448288230388243e-08
women O 0 3.2661112703280537e-10
with O 0 3.658110259152636e-09
hereditary B-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 1.302462692365225e-06
161 O 0 4.5830441308680747e-07
of O 0 1.1753543560644175e-07
their O 0 3.396008096956393e-08
sisters O 0 5.011220764572499e-06
as O 0 2.9610058405182826e-08
controls O 0 7.622328013212609e-08
in O 0 4.394264063733999e-09
a O 0 9.315800042486444e-08
case O 0 4.158306126100797e-07
- O 0 5.702503926841018e-07
control O 0 3.88395619665971e-07
study O 0 1.710248085373678e-07
. O 0 2.102962071148795e-08

All O 0 5.0582521282649395e-08
the O 0 9.104684117744455e-09
patients O 0 3.490684408191669e-10
carried O 0 3.875024190413967e-10
a O 0 5.989130302808121e-10
pathogenic O 0 4.817765075770808e-10
mutation O 0 3.753725386079765e-10
in O 0 1.4221424038396435e-09
either O 0 9.392927324824996e-09
BRCA1 O 0 1.8082667807561847e-08
( O 0 7.944151447780712e-10
179 O 0 3.4295617457047456e-09
women O 0 2.238047108749086e-10
) O 0 1.6898467347647994e-10
or O 0 3.3875964255969393e-09
BRCA2 O 0 8.450946609173116e-09
( O 0 3.310921981025672e-09
28 O 0 1.2480062139275105e-07
women O 0 7.944398028314481e-09
) O 0 6.518401818311759e-09
. O 0 2.4016168609364286e-08

The O 0 2.732235770963598e-06
control O 0 8.128359922920936e-07
women O 0 5.658534529828785e-09
were O 0 2.742872373673322e-09
enrolled O 0 1.9411936946767128e-08
regardless O 0 6.369176741571891e-09
of O 0 3.022886829739946e-08
whether O 0 3.990368480089046e-09
or O 0 5.0109875360249134e-08
not O 0 1.251111769740021e-09
they O 0 4.4469253279721954e-10
had O 0 7.039743010750499e-09
either O 0 4.6968287037429945e-09
mutation O 0 5.909070122100957e-09
. O 0 3.44382726780168e-08

Lifetime O 0 1.5648562111891806e-05
histories O 0 4.088241894351086e-06
of O 0 1.022500100589241e-06
oral O 0 1.4559339433617424e-05
- O 0 8.551261089451145e-06
contraceptive O 0 4.289478283681092e-07
use O 0 2.028780254903495e-09
were O 0 8.968847886592357e-09
obtained O 0 2.8730875456517424e-08
by O 0 1.1475949079908787e-08
interview O 0 7.757068942737533e-08
or O 0 3.79985154452811e-09
by O 0 9.355959756929266e-11
written O 0 5.978516015581192e-10
questionnaire O 0 1.2084624967378943e-10
and O 0 3.906658677110819e-11
were O 0 8.613234570020722e-10
compared O 0 5.458680729653054e-10
between O 0 1.4102518042236056e-09
patients O 0 1.1285532508509277e-09
and O 0 6.049127310170377e-10
control O 0 9.572069075147738e-07
women O 0 4.608644299519682e-10
, O 0 2.4845923929373015e-11
after O 0 6.906581417887026e-10
adjustment O 0 3.246104185450349e-08
for O 0 2.1609222744523038e-10
year O 0 5.166055916383527e-10
of O 0 4.362829653103972e-09
birth O 0 8.420086849980635e-09
and O 0 2.4864204029029224e-09
parity O 0 1.0169492270506453e-06
. O 0 2.607989912917219e-08

RESULTS O 0 4.773904493049486e-06
The O 0 8.001671858437476e-08
adjusted O 0 8.829185844660969e-07
odds O 0 1.3029795127295074e-06
ratio O 0 5.233082447375637e-07
for O 0 3.2417290185549064e-06
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
associated O 0 2.186369101764285e-06
with O 0 1.5131228214837478e-10
any O 0 3.3609837135628595e-09
past O 0 3.5309579704545513e-09
use O 0 6.061354890229964e-11
of O 0 8.342917467984989e-10
oral O 0 2.592001813184197e-08
contraceptives O 0 4.711618117880789e-08
was O 0 1.1068147642845361e-07
0 O 0 3.586831098800758e-08
. O 0 3.1550824175496928e-09

5 O 0 1.9079716366832145e-06
( O 0 1.4267238057641407e-08
95 O 0 8.003488716212814e-08
percent O 0 6.327185442245309e-09
confidence O 0 2.3836365770080192e-08
interval O 0 6.27081675474983e-08
, O 0 6.452232637066402e-10
0 O 0 5.779134948369347e-10
. O 0 2.2967201057655373e-11
3 O 0 2.8336227808622994e-10
to O 0 1.198829507886856e-10
0 O 0 5.042449235936886e-10
. O 0 3.2367514918307805e-11
8 O 0 4.692324750976695e-09
) O 0 1.3564277479005682e-09
. O 0 5.107829714745549e-09

The O 0 9.809537004912272e-07
risk O 0 9.262608386961801e-07
decreased O 0 2.6011076670329203e-07
with O 0 4.037640360943229e-11
increasing O 0 3.399752479538165e-09
duration O 0 2.18308855437499e-07
of O 0 1.6798093582792717e-08
use O 0 5.031458583104609e-10
( O 0 3.607031617836043e-10
P O 0 4.1438873665811116e-08
for O 0 9.49802111960274e-11
trend O 0 5.0087303193890875e-09
, O 0 4.535919556625245e-11
< O 0 4.233069894610253e-09
0 O 0 1.4682820237421623e-10
. O 0 4.491417220781058e-12
001 O 0 6.24034113272387e-09
) O 0 2.4385526150444425e-12
; O 0 4.369716394281298e-13
use O 0 9.688063719315299e-12
for O 0 7.974357979501079e-11
six O 0 5.934075897329194e-09
or O 0 9.435051850914533e-09
more O 0 1.936860949403041e-10
years O 0 2.613665506245866e-09
was O 0 2.59447485717601e-08
associated O 0 2.064372006671533e-09
with O 0 4.814051587920254e-11
a O 0 1.174300834350106e-08
60 O 0 8.141640250869386e-09
percent O 0 2.419296707412144e-10
reduction O 0 1.4516693402910619e-09
in O 0 6.578428468628772e-09
risk O 0 9.486959697824204e-07
. O 0 8.708077103847245e-08

Oral O 0 0.0011240077437832952
- O 0 7.1959452725423034e-06
contraceptive O 0 1.428328033625803e-07
use O 0 1.7755753534132168e-09
protected O 0 1.7582659666004474e-06
against O 0 0.03404955938458443
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
both O 0 1.386528136748666e-08
for O 0 1.4171701312459817e-10
carriers O 0 3.6504396727643496e-11
of O 0 1.8347950936359325e-09
the O 0 1.4120128177808056e-08
BRCA1 O 0 3.8071952701557166e-08
mutation O 0 3.9935493800768995e-10
( O 0 8.779978827311297e-11
odds O 0 6.139037278529713e-09
ratio O 0 8.847984567239564e-10
, O 0 1.4542035978171164e-11
0 O 0 4.3285930395597916e-11
. O 0 1.0351530830426947e-12
5 O 0 3.564218017948484e-11
; O 0 2.143069359125671e-12
95 O 0 1.1771617014488811e-09
percent O 0 2.8957730657808156e-10
confidence O 0 1.8227054310315793e-09
interval O 0 7.278102120977792e-09
, O 0 1.6105204669880635e-10
0 O 0 1.85798779139823e-10
. O 0 8.392384877320413e-12
3 O 0 8.573107501685939e-11
to O 0 3.857302324772327e-11
0 O 0 7.47280640145398e-11
. O 0 3.217250684611761e-12
9 O 0 1.786148451365932e-10
) O 0 4.00434590000498e-12
and O 0 1.653031335945021e-12
for O 0 1.7219397782652912e-11
carriers O 0 1.818242639783918e-10
of O 0 3.3564993007217936e-09
the O 0 2.783194297251157e-08
BRCA2 O 0 1.1738421079598993e-07
mutation O 0 4.189734781334664e-09
( O 0 4.738894832101437e-10
odds O 0 4.220568072810238e-08
ratio O 0 4.627955352276558e-09
, O 0 6.239739280822221e-11
0 O 0 1.3364780115932007e-10
. O 0 5.39119139955635e-12
4 O 0 1.5694844035518685e-10
; O 0 9.665435118932919e-12
95 O 0 1.9313761701056364e-09
percent O 0 8.214950386609132e-10
confidence O 0 5.0247863647712165e-09
interval O 0 2.2398216614760713e-08
, O 0 3.653694291561038e-10
0 O 0 5.241917455656164e-10
. O 0 1.70408080008011e-11
2 O 0 1.6814168113388206e-10
to O 0 5.804429506484077e-11
1 O 0 1.2353266187759004e-09
. O 0 8.945245932867607e-11
1 O 0 6.998454704643109e-09
) O 0 5.821118032045547e-10
. O 0 4.286515142837288e-09

CONCLUSIONS O 0 9.737505024531856e-05
Oral O 0 0.004460940603166819
- O 0 1.2039417924825102e-05
contraceptive O 0 9.775284581792221e-08
use O 0 2.02472802413034e-10
may O 0 5.606222430731833e-11
reduce O 0 6.065796476217855e-11
the O 0 1.6883752174123856e-09
risk O 0 2.5632965844124556e-05
of O 1 0.9999397993087769
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 3.320606367651635e-08
women O 0 1.3002098529779627e-11
with O 0 2.178698166972401e-13
pathogenic O 0 4.775503950615878e-11
mutations O 0 1.6025168692035408e-10
in O 0 5.665454216874366e-10
the O 0 1.513430269994842e-08
BRCA1 O 0 1.4145850002478255e-07
or O 0 8.422789221640414e-08
BRCA2 O 0 3.6993808407714823e-06
gene O 0 1.227818302140804e-06

A O 0 0.00016290236089844257
Japanese O 0 0.00020510933245532215
family O 0 4.5794703851242957e-07
with O 0 7.854898953496559e-09
adrenoleukodystrophy B-Disease 1 1.0
with O 0 6.87971102308893e-09
a O 0 3.27772227137757e-08
codon O 0 8.227361547596956e-08
291 O 0 1.5545776221870256e-08
deletion O 0 8.371006998686426e-09
: O 0 1.3214643268533166e-10
a O 0 8.76393846382939e-10
clinical O 0 3.0418579655133726e-08
, O 0 3.2266378457990186e-10
biochemical O 0 2.7721118840418058e-06
, O 0 1.3049024083500171e-08
pathological O 1 0.9999206066131592
, O 0 9.215394558559353e-10
and O 0 2.6603854674789318e-09
genetic O 0 8.666708026794367e-07
report O 0 1.6624436227630213e-07
. O 0 6.208940561691634e-08

We O 0 1.129219072026899e-06
report O 0 9.030802061715804e-08
a O 0 4.544499887515485e-08
Japanese O 0 1.1195641036465531e-06
family O 0 3.7320127432849404e-08
with O 0 2.343282545780312e-08
adrenoleukodystrophy B-Disease 1 1.0
( O 1 0.9999992847442627
ALD B-Disease 1 1.0
) O 0 4.017786103815979e-09
with O 0 8.864128875352151e-11
a O 0 1.1316707571040752e-08
three O 0 1.8337455998107544e-09
base O 0 3.800614933879842e-08
pair O 0 9.045558613252069e-08
deletion O 0 3.3539672017468547e-07
( O 0 2.376522800773273e-08
delGAG O 0 2.929911602223001e-07
291 O 0 6.413797137838628e-08
) O 0 9.439025117075062e-10
in O 0 6.40821840036665e-09
the O 0 1.5737657577119535e-06
ALD B-Disease 1 1.0
gene O 0 2.2706860818288988e-06
. O 0 1.4899319467076566e-07

A O 0 1.5510906905547017e-06
variety O 0 9.706092818362322e-09
of O 0 7.207732721781213e-08
phenotypes O 0 4.175162473529781e-07
were O 0 1.4094269751296906e-08
observed O 0 1.0190871257975687e-08
within O 0 6.908310368203274e-09
this O 0 1.1760536544613842e-08
family O 0 1.3909576068726892e-07
. O 0 3.6312510331981684e-08

While O 0 7.543661126874213e-07
the O 0 1.7866501877961127e-07
proband O 0 2.1708863641833887e-05
( O 0 9.350120677709128e-08
patient O 0 2.503465452718956e-07
1 O 0 6.546113695549138e-07
) O 0 5.913737943785691e-09
was O 0 1.1384996412289183e-07
classified O 0 6.12648776154856e-08
as O 0 9.6881480615707e-10
having O 0 2.565499368500923e-09
a O 0 1.6155669024797703e-09
rare O 0 3.426199601808122e-10
intermediate O 0 3.0194049482901164e-09
type O 0 7.4308568187575474e-09
of O 0 4.985961510328707e-08
adult O 0 8.665162454235542e-07
cerebral O 0 0.007869159802794456
and O 0 9.732643491133786e-08
cerebello O 1 1.0
- O 1 0.999998927116394
brain O 1 0.9999997615814209
stem O 0 5.462911303766305e-06
forms O 0 3.1187112892183677e-09
, O 0 1.3522991060277434e-10
his O 0 3.1941556066783505e-09
younger O 0 3.216519273152585e-09
brother O 0 8.841363552392068e-08
( O 0 8.078004931633131e-09
patient O 0 1.862982479394759e-08
2 O 0 1.0171742559350605e-08
) O 0 1.1422042478503869e-10
and O 0 1.0933989824657431e-10
nephew O 0 4.8004799282352906e-06
( O 0 2.1398597027655342e-07
patient O 0 1.9185069959348766e-06
3 O 0 8.067258363553265e-07
) O 0 4.387631147295679e-09
had O 0 1.8470785789759248e-08
a O 0 3.410685565086169e-07
childhood O 1 0.9996336698532104
ALD B-Disease 1 1.0
type O 0 0.20503640174865723
. O 0 6.182204970173188e-07

Another O 0 7.977707355166785e-06
nephew O 0 0.00011161093425471336
( O 0 5.517124463949585e-07
patient O 0 7.525553655796102e-07
4 O 0 3.6338531117507955e-07
) O 0 3.361906975030138e-09
of O 0 4.3024076745723505e-08
patient O 0 3.3218652788491454e-06
1 O 0 1.467301080992911e-05
was O 0 7.495708814531099e-06
classified O 0 3.618616233325156e-07
as O 0 3.610089560623919e-09
having O 0 2.1994342347397833e-08
an O 0 8.033691045739033e-09
adolescent O 0 6.08775792443339e-07
form O 0 3.739608445130216e-08
. O 0 2.465226316417102e-07

The O 0 2.2807389541412704e-06
tau O 0 4.314152192819165e-06
level O 0 2.847936286798358e-07
in O 0 3.277689231140357e-09
the O 0 8.60829629800719e-09
cerebrospinal O 0 1.8965516801472404e-06
fluid O 0 8.54992413223954e-06
( O 0 1.8138439372705761e-06
CSF O 0 0.0008591182413510978
) O 0 3.5443061818796195e-08
in O 0 3.9128316586811707e-08
patient O 0 6.20062473899452e-06
1 O 0 3.8031928397685988e-06
was O 0 1.294959474762436e-06
as O 0 1.9750516777605753e-09
high O 0 2.1305686104255983e-09
as O 0 7.352266018223474e-11
that O 0 4.177798731963556e-12
of O 0 4.428304389847426e-10
patients O 0 4.930453822993286e-10
with O 0 1.692796125496443e-09
Alzheimers B-Disease 1 1.0
disease I-Disease 1 0.9999996423721313
( O 0 4.621042393182506e-08
AD B-Disease 0 5.638492552861862e-07
) O 0 1.3447992719406443e-09
. O 0 3.4917517766075434e-09

His O 0 3.9492297219112515e-06
brain O 0 5.689310455636587e-06
magnetic O 0 1.8505785419620224e-06
resonance O 0 1.2547517371785943e-06
image O 0 1.9705002785030956e-07
( O 0 5.601642261154893e-09
MRI O 0 7.750457484689832e-07
) O 0 7.328412876539403e-10
showed O 0 6.5831478046618486e-09
abnormalities B-Disease 0 8.336631367455993e-07
in I-Disease 0 1.2902036106154924e-09
the I-Disease 0 9.569621539640139e-09
bilateral I-Disease 0 8.824169526633341e-06
cerebellar I-Disease 1 0.9998924732208252
hemispheres I-Disease 0 5.1435399655019864e-05
and O 0 4.195406333451501e-08
brain O 1 0.9393523335456848
stem O 0 1.3049642575424514e-06
, O 0 1.295877849472049e-10
but O 0 7.508266924860507e-11
not O 0 1.7047091516175783e-10
in O 0 4.6051557012205535e-10
the O 0 8.99433860723775e-09
cerebral O 0 4.2351498450443614e-06
white O 0 3.687328442580906e-09
matter O 0 1.5314453705173037e-08
, O 0 1.8648471655779986e-10
where O 0 1.1671628941112289e-10
marked O 0 5.356807775136474e-10
reductions O 0 1.662795678925022e-09
of O 0 8.391997319279199e-09
the O 0 7.481056663038999e-09
cerebral O 0 3.6909827372255677e-07
blood O 0 1.0933563387993672e-08
flow O 0 1.1414501699391622e-07
and O 0 1.1465222105044859e-09
oxygen O 0 7.66662992646161e-07
metabolism O 0 4.3791169446194544e-05
were O 0 2.5370773926169932e-08
clearly O 0 9.096768671668087e-09
demonstrated O 0 5.40848166252772e-09
by O 0 6.371651539716083e-10
positron O 0 1.748979769899961e-07
emission O 0 1.2333307708445318e-08
tomography O 0 2.6209258408016467e-07
( O 0 3.755295630014643e-09
PET O 0 6.246118999797545e-08
) O 0 1.006823957538927e-09
. O 0 6.932743268350805e-09

In O 0 5.473030455505068e-07
patients O 0 1.0564398245094253e-08
2 O 0 1.3843903801102897e-08
and O 0 1.0436556063808666e-09
3 O 0 4.742878090269187e-08
, O 0 2.5589785845880897e-10
the O 0 1.60315050123927e-09
autopsy O 0 2.3157090822678583e-07
findings O 0 1.3507613694230258e-08
showed O 0 6.947055197770169e-08
massive O 0 6.581681191164535e-07
demyelination B-Disease 1 1.0
of I-Disease 0 4.8727310058893636e-05
the I-Disease 0 1.954315393959405e-06
cerebral I-Disease 0 0.02000720053911209
white I-Disease 0 6.640680449976344e-09
matter I-Disease 0 9.251749588656821e-09
with O 0 5.056443042050773e-10
sparing O 0 5.695157057061806e-08
of O 0 4.2425781998645107e-07
the O 0 1.6253023886747542e-06
U O 1 0.9999990463256836
- O 0 6.981609476497397e-05
fibers O 0 1.2467457963794004e-06
, O 0 2.6557667176518862e-09
compatible O 0 7.96083998721997e-09
with O 0 3.096817594028245e-11
the O 0 3.155786743036515e-09
findings O 0 1.6871204877588752e-08
of O 0 4.487273201903008e-07
childhood O 1 0.9999074935913086
ALD B-Disease 1 1.0
. O 0 1.261015995623893e-06

Oleic O 0 0.0019091861322522163
and O 0 4.964960567122034e-07
erucic O 0 0.0058834608644247055
acids O 0 3.715276761795394e-06
( O 0 1.227270018944182e-07
Lorenzos O 0 2.8731106795021333e-05
Oil O 0 1.0338891115679871e-05
) O 0 1.204856547865063e-09
were O 0 5.118233059597799e-10
administered O 0 4.016052490563027e-10
to O 0 3.970975215317196e-10
patients O 0 1.1895454066213063e-10
1 O 0 4.379796525455504e-09
and O 0 3.0282448770790893e-10
4 O 0 2.0190610072745585e-08
, O 0 4.135038492170118e-11
but O 0 1.5114838200491754e-11
sufficient O 0 2.022398026824135e-09
effectiveness O 0 7.0066552559922e-09
was O 0 2.581679936497494e-08
not O 0 2.8471125457230073e-10
obtained O 0 8.188520439489366e-08
. O 0 4.1243005455271486e-08

The O 0 3.1676930234425527e-07
findings O 0 1.5053039703616378e-07
in O 0 9.889603802548663e-09
this O 0 2.4263451248174306e-09
family O 0 1.93716207519401e-08
suggest O 0 4.563842193050505e-09
that O 0 3.2492911139492264e-10
delGAG291 O 0 3.548046478840661e-08
is O 0 7.616420272249513e-10
part O 0 1.532213134147753e-09
of O 0 2.2440035607473874e-08
the O 0 3.359293643256933e-08
cause O 0 6.889981705171522e-07
of O 0 2.1123946680745576e-06
Japanese O 1 0.9732499718666077
ALD B-Disease 1 1.0
with O 0 1.0429133112666022e-09
phenotypic O 0 1.704482315290079e-07
variations O 0 1.8049695427180268e-07
. O 0 9.047025173458678e-08

Moreover O 0 2.9288847144925967e-05
, O 0 5.338990582970382e-09
although O 0 9.787533006289095e-10
the O 0 2.307233737397496e-09
scale O 0 6.355478632258382e-08
of O 0 1.8114358013576748e-08
the O 0 2.8635120941089554e-09
study O 0 1.2505583235622453e-09
is O 0 5.507369907342685e-11
limited O 0 1.248643688445128e-10
, O 0 4.512009516011162e-11
there O 0 3.290974437408778e-10
is O 0 1.2073887722952037e-10
a O 0 1.6696124482962205e-09
possibility O 0 1.3241554519538568e-08
that O 0 2.4312092339329183e-09
PET O 0 3.5267265729999053e-07
can O 0 1.9677233176196296e-09
detect O 0 1.4353385324739065e-07
an O 0 1.8536995938234213e-08
insidious B-Disease 0 6.378804300766205e-06
lesion I-Disease 0 9.494268306298181e-05
which O 0 5.918429080153942e-10
is O 0 1.456544468370069e-10
undetectable O 0 1.746855282647175e-08
by O 0 6.402363084134777e-10
computed O 0 8.470637880009235e-08
tomogram O 0 1.4168128927849466e-06
( O 0 1.7366861726486604e-08
CT O 0 1.0355756785429548e-06
) O 0 4.273027487400327e-10
or O 0 7.315076322456093e-10
MRI O 0 5.941123149000305e-08
analysis O 0 4.770392969533077e-09
, O 0 3.7923827272967614e-11
and O 0 1.3043653830646651e-11
that O 0 1.0060129812528018e-11
the O 0 6.682275843772345e-10
higher O 0 1.0796933125334363e-08
level O 0 6.466210322741972e-08
of O 0 4.4853627478858016e-09
tau O 0 3.8306499305917896e-08
reflects O 0 5.648599921137532e-10
the O 0 1.462010928987567e-10
process O 0 2.060084325350431e-09
of O 0 3.848107965609415e-08
neuronal B-Disease 0 0.050796084105968475
degeneration I-Disease 1 0.9999932050704956
in O 0 6.277302873058943e-07
ALD B-Disease 1 1.0
. O 0 2.710448541165533e-07

Lorenzos O 0 0.0008445337880402803
Oil O 0 1.7635793483350426e-05
should O 0 8.501517712034001e-09
be O 0 1.297379537135157e-09
given O 0 1.421949780144871e-09
in O 0 1.7570964683244483e-09
the O 0 1.2509400182381114e-09
early O 0 1.878976974012403e-08
stage O 0 1.9889455415977864e-08
. O 0 5.340111020046834e-09
. O 0 1.7907007432427235e-08

Nonsense O 0 8.16694155219011e-05
mutation O 0 1.274528926842322e-07
in O 0 2.0544820955592513e-08
exon O 0 1.1611970052172182e-07
4 O 0 4.5630088152393e-08
of O 0 8.486628289006148e-09
human O 0 7.10039849138866e-09
complement O 0 1.930494022417406e-07
C9 O 0 0.04006769135594368
gene O 0 1.6318516316005116e-08
is O 0 2.6521460028128274e-10
the O 0 8.979918475482407e-10
major O 0 1.2082400857593711e-08
cause O 0 7.09893868133804e-08
of O 0 2.3759569955927873e-07
Japanese O 0 0.0001015460366033949
complement B-Disease 0 5.663283445755951e-06
C9 I-Disease 1 0.9999997615814209
deficiency I-Disease 1 0.9999994039535522
. O 0 2.5859583274723263e-07

Deficiency B-Disease 1 1.0
of I-Disease 0 0.0007256571552716196
the I-Disease 0 3.4338786463194992e-06
ninth I-Disease 0 2.7938780476688407e-05
component I-Disease 0 1.1961264135607053e-05
of I-Disease 0 7.136536623875145e-07
human I-Disease 0 1.089004868504162e-07
complement I-Disease 0 4.0012702129388344e-07
( O 0 1.6616129983049177e-07
C9 O 0 0.0004703688609879464
) O 0 2.2568191759830825e-09
is O 0 1.0173926284773316e-10
the O 0 1.168321134281669e-10
most O 0 2.225587214521596e-10
common O 0 5.881173770205805e-09
complement B-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 6.55399298921111e-06
Japan O 0 1.8671964880923042e-06
but O 0 9.534067979544147e-11
is O 0 5.75358233279033e-11
rare O 0 1.5458061219941754e-10
in O 0 2.2630468332618392e-10
other O 0 6.13787146108713e-11
countries O 0 1.7051805800694098e-10
. O 0 1.3728049808037213e-08

We O 0 4.3522433657017245e-08
studied O 0 2.9578334448387977e-08
the O 0 1.7361122539583107e-09
molecular O 0 2.962858758337461e-08
basis O 0 2.5011721049850166e-07
of O 0 4.610222674727993e-07
C9 B-Disease 1 0.9999656677246094
deficiency I-Disease 1 0.9961431622505188
in O 0 2.2498150897831692e-08
four O 0 3.729073583258469e-08
Japanese O 0 7.646814992767759e-06
C9 B-Disease 1 0.9992438554763794
- I-Disease 1 0.9672446250915527
deficient I-Disease 1 0.971024751663208
patients O 0 6.54439062941492e-08
who O 0 2.8785436256839603e-09
had O 0 5.3331515204035895e-08
suffered O 0 0.0002459740499034524
from O 0 2.2389945115719456e-06
meningococcal B-Disease 1 1.0
meningitis I-Disease 1 1.0
. O 0 1.2965190308023011e-06

Direct O 0 3.7271436781338707e-07
sequencing O 0 2.178874147773513e-08
of O 0 4.2851279857814006e-08
amplified O 0 3.412917806144833e-07
C9 O 0 2.581584885774646e-05
cDNA O 0 9.282469477511768e-07
and O 0 8.753397451322087e-10
DNA O 0 9.86902648492105e-09
revealed O 0 4.4118774411572304e-08
a O 0 1.3252443586964091e-08
nonsense O 0 4.2055170013099996e-08
substitution O 0 2.202027005182572e-09
( O 0 3.02514080452454e-09
CGA O 0 1.0201629407902146e-07
- O 0 2.478537730610242e-08
- O 0 8.169269705149418e-08
> O 0 2.083912704620161e-07
TGA O 0 2.1163842234273034e-07
) O 0 9.036579123877786e-11
at O 0 1.6040222483582056e-09
codon O 0 9.02244856604284e-09
95 O 0 2.1206689737596207e-08
in O 0 2.5611088805277404e-09
exon O 0 1.7707973753999795e-08
4 O 0 2.743585447717578e-08
in O 0 2.514132235731381e-09
the O 0 1.1400702604191792e-08
four O 0 1.2914578917389008e-07
C9 B-Disease 0 0.004426765721291304
- I-Disease 0 0.0023109910544008017
deficient I-Disease 0 2.8963042495888658e-05
individuals O 0 1.4493765299050665e-08
. O 0 3.257777336784784e-08

An O 0 6.699420396216738e-08
allele O 0 5.0428656805934224e-09
- O 0 3.12644345967783e-08
specific O 0 1.2067131294202227e-08
polymerase O 0 5.443453687803412e-07
chain O 0 4.089708127708036e-08
reaction O 0 9.821438107238123e-10
system O 0 2.5308799500578516e-09
designed O 0 1.1624291529344077e-09
to O 0 8.571018894620863e-10
detect O 0 9.19675091637373e-09
exclusively O 0 2.2186048553862747e-08
only O 0 2.415337263528272e-09
one O 0 4.986289159347734e-10
of O 0 5.797074487112752e-10
the O 0 5.495977006830799e-10
normal O 0 6.633135374300991e-09
and O 0 1.1021406703948244e-10
mutant O 0 4.380364959644112e-09
alleles O 0 1.1700361512989588e-10
indicated O 0 1.1828506230049385e-10
that O 0 3.271020607154007e-12
all O 0 7.654773516441171e-12
the O 0 2.8121598799613068e-11
four O 0 7.872980045675604e-11
patients O 0 9.345199961097173e-12
were O 0 3.7381906597966363e-11
homozygous O 0 1.943959437866738e-10
for O 0 5.7098315658921095e-11
the O 0 8.20937373635644e-10
mutation O 0 1.26660515409327e-10
in O 0 3.35818350905015e-09
exon O 0 1.9368000536701402e-08
4 O 0 3.861099173718685e-08
and O 0 1.6318561779637974e-10
that O 0 3.5293386269064086e-11
the O 0 6.852337031126865e-10
parents O 0 9.974923109723477e-10
of O 0 8.379856808460318e-09
patient O 0 3.9485932745719765e-08
2 O 0 1.0025878793840093e-07
were O 0 3.859037533970877e-08
heterozygous O 0 5.371648725827072e-08
. O 0 1.7529430351714836e-08

The O 0 1.179132311790454e-07
common O 0 4.379403950593996e-09
mutation O 0 4.414998144852689e-09
at O 0 1.8224699971369773e-08
codon O 0 1.0109389592116713e-07
95 O 0 8.272948548437853e-08
in O 0 2.9299926929127196e-09
exon O 0 3.611909349388043e-08
4 O 0 3.823474514774716e-08
might O 0 4.208112747150494e-10
be O 0 3.1662031330093043e-10
responsible O 0 1.0795054850021302e-09
for O 0 2.9900848463881857e-09
most O 0 1.7225172399548683e-08
Japanese O 0 0.0003064144984818995
C9 B-Disease 1 0.9999994039535522
deficiency I-Disease 1 0.999990701675415
. O 0 3.117196456514648e-08
. O 0 4.2730889049380494e-08

BRCA1 O 0 3.810479825006041e-07
required O 0 4.756682603357376e-09
for O 0 4.293912336805761e-09
transcription O 0 4.199815975880483e-06
- O 0 1.1489328244351782e-06
coupled O 0 3.877693598042242e-05
repair O 0 8.533916843589395e-05
of O 0 2.7074358968093293e-06
oxidative O 0 0.00047856339369900525
DNA O 0 0.00026014004833996296
damage O 0 0.0165261160582304
. O 0 1.6798918522908934e-07

The O 0 2.5478766474407166e-05
breast B-Disease 1 1.0
and I-Disease 1 0.9999979734420776
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
susceptibility O 1 1.0
gene O 0 1.3086257695249515e-06
BRCA1 O 0 4.16704011740876e-07
encodes O 0 3.513009971811698e-08
a O 0 6.307472322220065e-09
zinc O 0 9.384994541505876e-07
finger O 0 1.604765770935046e-06
protein O 0 1.601125916295132e-07
of O 0 1.32682814069085e-07
unknown O 0 2.5542971343384124e-05
function O 0 9.202349815495836e-07
. O 0 2.8377741045915172e-08

Association O 0 8.671315299579874e-06
of O 0 1.2274751952645602e-06
the O 0 2.812899708715122e-07
BRCA1 O 0 5.8021910831485e-08
protein O 0 2.3908977020425937e-09
with O 0 5.404042144330212e-11
the O 0 1.3824773326120976e-08
DNA O 0 7.867239446568419e-07
repair O 0 2.2058629838284105e-05
protein O 0 7.677407438677619e-07
Rad51 O 0 2.43617996602552e-05
and O 0 3.5509473139683223e-10
changes O 0 4.601187486574787e-10
in O 0 1.150015527251469e-09
the O 0 3.394652781096852e-09
phosphorylation O 0 4.949519905039779e-08
and O 0 2.0831043556768236e-09
cellular O 0 1.4396925962500973e-07
localization O 0 8.426579825027147e-07
of O 0 2.9340263552057877e-08
the O 0 2.9399025436305237e-08
protein O 0 3.215343369333823e-08
after O 0 1.8267401813432116e-08
exposure O 0 2.495558817372512e-07
to O 0 6.6954961575049765e-09
DNA O 0 3.4881895771832205e-07
- O 0 3.835731661183672e-07
damaging O 0 6.928673883521697e-07
agents O 0 1.7018908948784883e-08
are O 0 1.8621210129410315e-10
consistent O 0 4.2743502071118655e-09
with O 0 2.1072390360421522e-11
a O 0 3.782425039844384e-09
role O 0 4.502136441431048e-09
for O 0 2.128854204030972e-09
BRCA1 O 0 1.3514416252746742e-08
in O 0 9.196172712222506e-09
DNA O 0 1.0965328556267195e-06
repair O 0 6.036468766978942e-05
. O 0 1.7738167912284553e-07

Here O 0 2.056738594546914e-06
, O 0 1.8944537050202825e-09
it O 0 3.830461642317928e-11
is O 0 3.473149892685434e-11
shown O 0 1.2307023455893074e-10
that O 0 3.4373122403952294e-11
mouse O 0 6.231194671357798e-09
embryonic O 0 5.303487871088919e-09
stem O 0 2.460568104822869e-08
cells O 0 6.975612532045261e-09
deficient B-Disease 0 4.544595100242077e-08
in I-Disease 0 8.56092197132341e-10
BRCA1 I-Disease 0 5.364336086444155e-09
are O 0 1.5734379077425587e-10
defective O 0 3.3273248600806937e-09
in O 0 1.3238390383918386e-09
the O 0 3.457792496774914e-09
ability O 0 1.0359585411734429e-09
to O 0 7.231425458442686e-10
carry O 0 1.4952841187465538e-09
out O 0 8.413327812206717e-09
transcription O 0 6.26413395821146e-07
- O 0 7.148778280452461e-08
coupled O 0 2.344414724575472e-06
repair O 0 4.478505616134498e-06
of O 0 2.468913180564414e-07
oxidative O 0 3.5824359656544402e-06
DNA O 0 2.316487552889157e-06
damage O 0 0.00010194558126386255
, O 0 6.859516288315604e-10
and O 0 2.4696742428886864e-09
are O 0 3.387718994218858e-09
hypersensitive O 0 2.4709040644665947e-06
to O 0 4.2439051384235427e-08
ionizing O 0 0.0009043036843650043
radiation O 0 0.0005015530623495579
and O 0 5.295825999951376e-09
hydrogen O 0 6.60358665527383e-08
peroxide O 0 2.3740051346976543e-06
. O 0 2.851695057870529e-07

These O 0 1.224353241013887e-07
results O 0 6.813830566443357e-08
suggest O 0 5.0739735968363675e-08
that O 0 1.8053091244141228e-09
BRCA1 O 0 9.887697771659987e-09
participates O 0 3.952230986925542e-09
, O 0 2.5306470807784365e-10
directly O 0 1.7788737149970757e-09
or O 0 5.154641158355844e-09
indirectly O 0 1.8007119351182155e-08
, O 0 6.008054609374369e-10
in O 0 1.6065460073377835e-08
transcription O 0 6.656490768364165e-06
- O 0 3.003327435635583e-07
coupled O 0 7.406779332086444e-06
repair O 0 2.500387745385524e-05
of O 0 9.433738910047396e-07
oxidative O 0 7.047886902000755e-05
DNA O 0 1.477045861975057e-05
damage O 0 9.148605022346601e-05
. O 0 2.9136528745254964e-09
. O 0 2.3205721788599476e-08

Truncation O 0 0.0002227300137747079
mutations O 0 2.4344132043552236e-07
in O 0 1.5123598373634195e-08
the O 0 1.7327224099972227e-08
transactivation O 0 5.545030035136733e-06
region O 0 2.319700520558854e-08
of O 0 4.4175530433676613e-07
PAX6 O 0 0.0007072968292050064
result O 0 1.517233272352314e-07
in O 0 8.009639174133554e-09
dominant O 0 1.1278270051207073e-07
- O 0 3.016758398644015e-08
negative O 0 4.7342016529228204e-08
mutants O 0 2.2053934856103297e-07
. O 0 6.206688496490642e-09

PAX6 O 0 0.007104015909135342
is O 0 2.661549558524712e-07
a O 0 1.9640839354906348e-07
transcription O 0 4.463415166355844e-07
factor O 0 9.292637770386136e-09
with O 0 1.4560576702682404e-11
two O 0 1.1880607608816263e-09
DNA O 0 3.2012078321486115e-08
- O 0 5.698340288518011e-08
binding O 0 2.1602446054203028e-08
domains O 0 5.054298526374623e-07
( O 0 3.322372155167841e-09
paired O 0 4.216856197558627e-09
box O 0 8.337357115806299e-08
and O 0 4.77989248182098e-09
homeobox O 0 3.6142675980954664e-06
) O 0 4.248349227964354e-09
and O 0 7.480696617712113e-10
a O 0 3.207686560813272e-08
proline O 0 2.781407033580763e-07
- O 0 3.6349484844322433e-07
serine O 0 2.1699445369449677e-06
- O 0 9.833627245825483e-07
threonine O 0 2.962028247566195e-06
( O 0 4.4404202981240815e-08
PST O 0 7.5699458648159634e-06
) O 0 1.1736178251453566e-08
- O 0 8.848837040886792e-08
rich O 0 2.0263706801415537e-07
transactivation O 0 0.003529381938278675
domain O 0 4.382195766083896e-05
. O 0 2.0536013778382767e-07

PAX6 O 1 0.9999986886978149
regulates O 0 0.0004026586830150336
eye O 0 0.0006069453665986657
development O 0 1.0011299167445031e-07
in O 0 2.493044659601651e-09
animals O 0 7.580969740850207e-10
ranging O 0 1.296888019197695e-08
from O 0 3.3904599128220525e-09
jellyfish O 0 3.659987424242672e-09
to O 0 4.5754056099411855e-10
Drosophila O 0 6.605463198638972e-08
to O 0 6.50065556939694e-10
humans O 0 1.2308491115220477e-08
. O 0 1.2281475392228458e-08

Heterozygous O 0 3.765482460948988e-06
mutations O 0 3.563985373489231e-08
in O 0 2.28924368350647e-09
the O 0 6.619536474516963e-09
human O 0 4.158313160473881e-08
PAX6 O 0 0.000333152012899518
gene O 0 4.401713216140024e-09
result O 0 1.2596648168994307e-09
in O 0 1.126771870252341e-10
various O 0 6.146251285699122e-10
phenotypes O 0 2.386957653754962e-08
, O 0 9.966227149105222e-11
including O 0 1.1105355524065885e-09
aniridia B-Disease 1 1.0
, O 0 1.1672970146037187e-07
Peters B-Disease 1 1.0
anomaly I-Disease 1 1.0
, O 0 2.890054062731906e-08
autosomal B-Disease 0 0.0008057995000854135
dominant I-Disease 0 0.0007727613556198776
keratitis I-Disease 1 1.0
, O 0 7.407411573012723e-08
and O 0 2.2243136754696025e-06
familial B-Disease 1 1.0
foveal I-Disease 1 1.0
dysplasia I-Disease 1 1.0
. O 0 0.00013203795242588967

It O 0 2.8535742657709307e-08
is O 0 1.719132391997391e-09
believed O 0 3.2138456340646826e-09
that O 0 5.341735734298858e-11
the O 0 3.542139914713971e-10
mutated O 0 1.3590277792019378e-09
allele O 0 2.697321477285186e-09
of O 0 2.7069038566196468e-08
PAX6 O 0 8.840342343319207e-05
produces O 0 6.9492127607873044e-09
an O 0 2.2598904969584055e-09
inactive O 0 2.495368107702234e-07
protein O 0 1.3031717571720947e-07
and O 0 1.4090399069743853e-08
aniridia B-Disease 1 1.0
is O 0 4.72293670839008e-08
caused O 0 5.313788165040023e-08
due O 0 1.8012003977219138e-07
to O 0 3.880990107063553e-08
genetic O 0 3.7074687497806735e-06
haploinsufficiency O 0 4.1841853089863434e-05
. O 0 1.2840108354339463e-07

However O 0 1.828834257366907e-07
, O 0 1.7850935174479332e-09
several O 0 1.471144761566734e-09
truncation O 0 1.533572685730178e-06
mutations O 0 1.0540004424797189e-08
have O 0 6.908201788391466e-10
been O 0 2.024423961799471e-09
found O 0 1.601911658877242e-10
to O 0 9.101062958816186e-11
occur O 0 8.464267065022568e-10
in O 0 1.3771629392422824e-09
the O 0 1.566420593235307e-08
C O 0 0.00013842966291122139
- O 0 6.021867875460885e-07
terminal O 0 1.4823621086179628e-07
half O 0 3.2088351975545493e-09
of O 0 1.2577663355273216e-08
PAX6 O 0 1.9239860193920322e-05
in O 0 4.161325950491346e-09
patients O 0 7.769455634409894e-10
with O 0 2.239682744820115e-10
Aniridia B-Disease 1 1.0
resulting O 0 2.5210223952853994e-07
in O 0 2.8247473249365385e-09
mutant O 0 1.0411450368508213e-08
proteins O 0 2.2628267315472073e-10
that O 0 3.0816450086179614e-11
retain O 0 3.2959371343288524e-10
the O 0 4.305098499912674e-09
DNA O 0 2.8907926719057286e-08
- O 0 5.342464248769829e-09
binding O 0 3.2064737531811716e-09
domains O 0 2.6203004210856307e-08
but O 0 4.329337999209315e-10
have O 0 6.102178207179065e-10
lost O 0 2.1525002580347063e-07
most O 0 5.049513585042575e-10
of O 0 8.994819111762808e-09
the O 0 5.6579224860797694e-08
transactivation O 0 0.00010521072545088828
domain O 0 8.870551027939655e-06
. O 0 6.66433450646764e-08

It O 0 5.6407465365282405e-08
is O 0 1.9319621458180336e-09
not O 0 1.884153805198352e-10
clear O 0 1.7205691316135585e-09
whether O 0 1.2594053577785758e-09
such O 0 2.303377488743763e-09
mutants O 0 1.0980365914292634e-06
really O 0 2.014438109654293e-07
behave O 0 1.5086575544387415e-08
as O 0 7.937521750989163e-09
loss O 0 3.325689874600357e-07
- O 0 6.122679963027622e-08
of O 0 3.645286824394134e-06
- O 0 3.7905699628026923e-06
function O 0 2.9012271625106223e-06
mutants O 0 1.575829315925148e-07
as O 0 3.1425722024636116e-09
predicted O 0 2.4897101269516497e-08
by O 0 8.289165798203157e-09
haploinsufficiency O 0 1.4952706806070637e-05
. O 0 2.7720906814465707e-07

Contrary O 0 2.246301301056519e-05
to O 0 7.405402957516571e-09
this O 0 1.1688701118117706e-09
theory O 0 1.0012482931642808e-07
, O 0 2.475889493425143e-10
our O 0 2.381794761419087e-09
data O 0 1.0385546644897659e-08
showed O 0 4.149973975575705e-10
that O 0 3.9406329761793035e-12
these O 0 1.766992281659885e-11
mutants O 0 3.0896525338164338e-09
are O 0 3.4265573017888684e-11
dominant O 0 9.759775210227417e-10
- O 0 9.386601496075286e-10
negative O 0 4.389983487840254e-09
in O 0 2.1216832735149183e-09
transient O 0 8.09545099400566e-07
transfection O 0 3.2204874855779053e-07
assays O 0 1.4743844367615111e-08
when O 0 1.858017184552807e-09
they O 0 2.259252562808456e-09
are O 0 1.176896691212903e-09
coexpressed O 0 2.043688027697499e-07
with O 0 4.3869117227757215e-09
wild O 0 5.683262997990823e-07
- O 0 5.795295237476239e-06
type O 0 3.4566150134196505e-05
PAX6 O 1 0.7501494884490967
. O 0 7.162425390561111e-07

We O 0 3.5169867373952e-07
found O 0 2.333327664416629e-08
that O 0 7.576199112513393e-10
the O 0 1.3863510339717777e-08
dominant O 0 1.4505165779610252e-07
- O 0 1.7793698958712412e-08
negative O 0 9.306597270608563e-09
effects O 0 3.0187496946609826e-08
result O 0 1.1081360273834662e-09
from O 0 1.9243667770396655e-10
the O 0 5.256074464554672e-10
enhanced O 0 2.905772289452102e-09
DNA O 0 1.0203838884947913e-09
binding O 0 1.1392539689403236e-10
ability O 0 4.5282197436158356e-10
of O 0 1.3676453303190783e-09
these O 0 2.910263419142467e-10
mutants O 0 2.570158983417059e-07
. O 0 1.5022916244333828e-08

Kinetic O 0 1.3372132343647536e-05
studies O 0 2.9745584129159397e-07
of O 0 1.848594166631301e-08
binding O 0 4.818511811777171e-09
and O 0 6.24436224949676e-10
dissociation O 0 2.0088936025786097e-07
revealed O 0 2.5141957848973107e-08
that O 0 1.9887651248051696e-10
various O 0 1.527494686293096e-09
truncation O 0 1.30121748043166e-06
mutants O 0 9.262895162009954e-08
have O 0 3.539236126393064e-10
3 O 0 3.8709191407804155e-09
- O 0 1.0000774652851874e-09
5 O 0 1.6366705324344366e-08
- O 0 2.591871828272474e-09
fold O 0 6.4020855283786204e-09
higher O 0 1.0093009983336287e-08
affinity O 0 2.381967290077114e-09
to O 0 1.821846007388217e-10
various O 0 4.1138634165882593e-10
DNA O 0 7.2947514695442806e-09
- O 0 6.702303156913558e-10
binding O 0 3.1712985015808215e-10
sites O 0 6.943273733739375e-10
when O 0 1.1780167119557206e-10
compared O 0 5.2465493061149e-10
with O 0 9.452563731748853e-12
the O 0 3.4437992457725386e-09
wild O 0 4.359421623689741e-08
- O 0 5.842380232934374e-07
type O 0 3.8066548313508974e-06
PAX6 O 0 0.0019263277063146234
. O 0 3.7538228525590966e-07

These O 0 5.990003870692817e-08
results O 0 2.404435583969189e-08
provide O 0 4.034757861148819e-09
a O 0 3.902224321450376e-09
new O 0 7.354991060637417e-10
insight O 0 6.536281915714426e-08
into O 0 2.610596183671987e-09
the O 0 5.938084246537301e-09
role O 0 3.2933765936604686e-08
of O 0 1.813552046314726e-07
mutant O 0 1.7858320688901586e-06
PAX6 O 0 0.00046552999992854893
in O 0 1.6500523258855537e-07
causing O 0 5.641430561809102e-06
aniridia B-Disease 1 1.0
. O 0 8.145092067479709e-08
. O 0 7.176730321134528e-08

Reversal O 0 0.00010143745748791844
of O 0 2.1098660454299534e-06
severe O 1 0.9999910593032837
hypertrophic B-Disease 1 1.0
cardiomyopathy I-Disease 1 1.0
and O 0 1.3838550216860313e-07
excellent O 0 9.897312338580377e-07
neuropsychologic O 0 4.732094112114282e-06
outcome O 0 2.856373839676962e-07
in O 0 4.3785796322026727e-08
very B-Disease 0 3.3213598982229087e-08
- I-Disease 0 1.795848874053263e-07
long I-Disease 0 1.8959805458962364e-07
- I-Disease 0 2.8050348532815406e-07
chain I-Disease 0 3.301653919152159e-07
acyl I-Disease 0 2.00158851271226e-07
- I-Disease 0 4.13619318351266e-07
coenzyme I-Disease 0 3.01427371596219e-06
A I-Disease 0 0.000713000597897917
dehydrogenase I-Disease 0 0.017109718173742294
deficiency I-Disease 1 0.9004822373390198
. O 0 7.659096468159987e-08

Very B-Disease 0 3.3772159895306686e-06
- I-Disease 0 1.639800416342041e-06
long I-Disease 0 2.0708985459805263e-07
- I-Disease 0 1.3302172874318785e-07
chain I-Disease 0 6.746364533682936e-08
acyl I-Disease 0 4.1074539325336445e-08
- I-Disease 0 1.657321924142252e-08
coenzyme I-Disease 0 7.400619495001592e-08
A I-Disease 0 1.1690287919918774e-06
dehydrogenase I-Disease 0 4.4207016003383615e-07
( I-Disease 0 3.845626039833405e-09
VLCAD I-Disease 0 0.00010894645674852654
) I-Disease 0 1.7221196912942105e-08
deficiency I-Disease 0 6.0987153119640425e-05
is O 0 5.0568216281021705e-09
a O 0 2.2322838333366235e-07
disorder O 1 0.9999988079071045
of O 1 0.9992387294769287
fatty O 1 0.993953287601471
acid O 0 0.27009284496307373
beta O 0 0.00011949847976211458
oxidation O 0 2.1016107965010633e-08
that O 0 1.3283760202931205e-10
reportedly O 0 2.4284934063700803e-09
has O 0 1.9892346450611775e-11
high O 0 2.3492097156463387e-10
rates O 0 4.4396705756177823e-10
of O 0 7.352788933268073e-10
morbidity O 0 3.380846749223565e-07
and O 0 7.617234065726564e-10
mortality O 0 1.1571988807190792e-06
. O 0 1.8956292535676766e-08

We O 0 2.6210659598291386e-07
describe O 0 1.393610489230923e-07
the O 0 2.6424489263376927e-08
outcome O 0 9.500751474433855e-08
of O 0 3.224906777177239e-07
a O 0 6.850265776847664e-08
5 O 0 5.438286265757597e-08
- O 0 2.7833255700215886e-09
year O 0 9.8848129681528e-09
- O 0 4.798639352543432e-08
old O 0 4.914609803563508e-07
girl O 0 1.4881576134939678e-05
with O 0 4.5817856175744964e-07
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
who O 0 4.497171539696865e-05
was O 0 5.730039902118733e-06
first O 0 1.0712669507029204e-07
seen O 0 6.267241303703486e-08
at O 0 3.8595455720269456e-08
5 O 0 1.9634729397921546e-08
months O 0 2.020262179769361e-09
of O 0 1.4798916536662432e-09
age O 0 1.367207858038455e-08
with O 0 2.0488459817613602e-09
severe O 1 0.9999980926513672
hypertrophic B-Disease 1 1.0
cardiomyopathy I-Disease 1 1.0
, O 0 4.123987673665397e-05
hepatomegaly B-Disease 1 1.0
, O 0 0.03497587889432907
encephalopathy B-Disease 1 0.999996542930603
, O 0 9.934375100328907e-08
and O 0 3.7562037960015005e-06
hypotonia B-Disease 1 0.9999980926513672
. O 0 2.030746873060707e-05

Biochemical O 0 0.03961104154586792
studies O 0 0.0005355303292162716
indicated O 1 0.8718824982643127
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
caused O 0 0.0003006644838023931
by O 0 9.428084979390405e-10
a O 0 2.593246506421565e-09
stable O 0 4.874048897818284e-08
yet O 0 2.2242008235195954e-09
inactive O 0 3.564095152341906e-07
enzyme O 0 1.7561013976319373e-07
. O 0 2.62823398600176e-08

Molecular O 0 3.5239310818724334e-05
genetic O 0 1.5971622815413866e-06
analysis O 0 7.353258268949503e-08
of O 0 1.2587855735546327e-07
her O 0 1.2687337402894627e-06
VLCAD O 1 0.8313267230987549
gene O 0 1.734935466402021e-07
revealed O 0 5.833528007315181e-07
a O 0 1.3090934203319193e-07
T1372C O 0 7.49668629396183e-07
( O 0 2.046577840530972e-08
F458L O 0 8.925682664084889e-07
) O 0 2.7162494475874155e-08
missense O 0 3.4676893392315833e-06
mutation O 0 5.486179333047403e-08
and O 0 2.6387168006181128e-08
a O 0 3.1243921512214e-06
1668 O 1 0.9457067251205444
ACAG O 1 0.9999569654464722
1669 O 0 0.41108542680740356
splice O 0 0.000456616107840091
site O 0 1.6834775351526332e-06
mutation O 0 7.235639998270926e-08
. O 0 3.89402536882244e-08

After O 0 9.648876897472292e-08
initial O 0 3.965900674529621e-08
treatment O 0 3.6959399984937136e-09
with O 0 2.630628492816811e-10
intravenous O 0 3.1768109920449206e-08
glucose O 0 4.18280887970468e-06
and O 0 5.340274000786849e-09
carnitine O 0 1.0177459444093984e-05
, O 0 1.4014619464930433e-09
the O 0 1.690876949567155e-08
patient O 0 5.613652319880202e-06
has O 0 7.736390972290508e-10
thrived O 0 4.5416314264912216e-08
on O 0 6.0294098602753365e-09
a O 0 1.7377530525664042e-08
low O 0 4.791290848515928e-07
- O 0 7.206138263882167e-08
fat O 0 3.505466850128869e-08
diet O 0 3.779633939160476e-09
supplemented O 0 2.4533077791488722e-09
with O 0 5.09130931858337e-11
medium O 0 3.010556781646301e-07
- O 0 3.540395255186013e-06
chain O 0 7.498165928154776e-07
triglyceride O 0 1.403305077474215e-06
oil O 0 5.666145739269268e-07
and O 0 1.069929034258621e-08
carnitine O 0 7.793396434863098e-06
and O 0 1.0054658439173636e-08
avoidance O 0 7.457495030394057e-07
of O 0 3.4521931979725196e-07
fasting O 0 1.0126454981218558e-05
. O 0 1.24766344811178e-07

Her O 0 0.0013850168325006962
ventricular O 1 0.9999179840087891
hypertrophy O 0 0.0083036283031106
resolved O 0 7.605968676216435e-06
significantly O 0 3.540671045243471e-08
over O 0 3.5049902979977787e-09
1 O 0 8.905096215983122e-09
year O 0 6.806225583133596e-10
, O 0 5.1293816416553284e-11
and O 0 3.647128710149161e-10
cognitively O 0 2.695867351576453e-06
, O 0 7.727896100817588e-10
she O 0 1.902985991009132e-09
is O 0 2.0184968974046313e-10
in O 0 9.65550903120338e-11
the O 0 4.923856322669451e-10
superior O 0 7.674256785605849e-09
range O 0 6.346075664964701e-09
for O 0 3.3808251753697505e-09
age O 0 1.8417318869978772e-07
. O 0 4.9850768846226856e-08

Clinical O 0 0.001899643917568028
recognition O 0 7.537745659647044e-06
of O 1 0.999869704246521
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
is O 0 2.385775587754324e-05
important O 0 4.4173003033165514e-08
because O 0 1.0593004251546745e-09
it O 0 8.777634175061166e-11
is O 0 1.0871750028007554e-10
one O 0 1.725774384508938e-10
of O 0 9.906155895578195e-10
the O 0 2.6428104149545106e-09
few O 0 2.8488955639005553e-09
directly O 0 1.736388099971009e-08
treatable O 0 2.1876245227758773e-05
causes O 0 6.879634497636289e-07
of O 0 0.00045489397598430514
cardiomyopathy B-Disease 1 1.0
in O 0 9.82958567874448e-07
children O 0 1.9755839630875016e-08
. O 0 3.507103718547455e-09
. O 0 2.378767760546907e-08

Cloning O 0 2.2480220650322735e-05
of O 0 3.0208644830054254e-07
a O 0 6.241783268023937e-08
novel O 0 1.8778614219172596e-07
member O 0 5.691486748560237e-08
of O 0 1.0499918801087915e-07
the O 0 5.589926033167103e-08
low O 0 3.251516091040685e-06
- O 0 5.131131501912023e-07
density O 0 3.320071471080155e-07
lipoprotein O 0 0.00014346258831210434
receptor O 0 2.69332140305778e-05
family O 0 1.9374250825876516e-07
. O 0 2.458855696829687e-08

A O 0 2.6946750040224288e-06
gene O 0 8.522346384154389e-09
encoding O 0 1.0173528686152622e-08
a O 0 9.939374656653399e-09
novel O 0 5.8382035206250293e-08
transmembrane O 0 5.533865419238282e-07
protein O 0 9.371578180150664e-09
was O 0 8.953925600962975e-09
identified O 0 2.0864115990448795e-10
by O 0 5.23777722583052e-11
DNA O 0 1.6947755698826228e-10
sequence O 0 4.0684644542210435e-10
analysis O 0 2.2600617211043783e-10
within O 0 1.4513973356500287e-10
the O 0 1.0220005952632505e-09
insulin B-Disease 0 8.165731628650974e-07
- I-Disease 0 0.00010883483628276736
dependent I-Disease 1 0.9999858140945435
diabetes I-Disease 1 1.0
mellitus I-Disease 1 1.0
( O 0 1.2988481330467039e-06
IDDM B-Disease 0 0.0002809040597639978
) O 0 5.8821387760588095e-09
locus O 0 1.333617660748132e-07
IDDM4 O 0 3.0477460768452147e-06
on O 0 5.9596231949399225e-08
chromosome O 0 5.22212417308765e-07
11q13 O 0 3.1189858873403864e-06
. O 0 1.4465533126895025e-07

Based O 0 8.092470693554787e-07
on O 0 6.615222503114637e-08
its O 0 3.7028407007255737e-09
chromosomal O 0 1.5690976340465568e-07
position O 0 2.5744472509359184e-07
, O 0 1.6674611691414043e-09
this O 0 1.547051708961078e-09
gene O 0 5.440739525575111e-10
is O 0 1.771248286930316e-10
a O 0 1.0795507821015349e-09
candidate O 0 5.728597041176897e-10
for O 0 1.615190203807515e-10
conferring O 0 8.656525096739642e-08
susceptibility O 0 2.8522510547190905e-05
to O 0 3.117794449281064e-07
diabetes B-Disease 1 1.0
. O 0 3.34379222977077e-07

The O 0 9.965706340153702e-07
gene O 0 5.022220861405913e-08
, O 0 2.34736985404993e-09
termed O 0 1.4314002783066826e-07
low O 0 3.1565464269078802e-06
- O 0 8.304795642288809e-07
density O 0 2.5832616756815696e-07
lipoprotein O 0 1.7572201613802463e-05
receptor O 0 2.49211495884083e-07
related O 0 6.072365721365713e-09
protein O 0 8.421821462434309e-09
5 O 0 9.51852374697637e-09
( O 0 7.530788215248663e-10
LRP5 O 0 3.5102311812806875e-07
) O 0 2.1729869292830273e-10
, O 0 1.1021554502388398e-10
encodes O 0 3.877961507470218e-09
a O 0 9.089584085408831e-10
protein O 0 2.557633216326849e-09
of O 0 1.4152483629459311e-08
1615 O 0 4.381075996207073e-05
amino O 0 2.9736253281953395e-07
acids O 0 1.4906262890690414e-08
that O 0 9.331205946816468e-11
contains O 0 3.705092621597572e-10
conserved O 0 5.584118412116368e-08
modules O 0 5.8757944287890496e-08
which O 0 9.19858425540987e-11
are O 0 3.594818540064715e-11
characteristic O 0 2.121242292929537e-09
of O 0 2.9380695210079466e-08
the O 0 4.914460305371904e-08
low O 0 5.4229226407187525e-06
- O 0 1.0839128208317561e-06
density O 0 3.686160141569417e-07
lipoprotein O 0 3.883262616000138e-05
( O 0 2.1805647065775702e-07
LDL O 0 1.954483195731882e-05
) O 0 7.126367052023852e-09
receptor O 0 1.514285656867287e-07
family O 0 1.937461391321449e-08
. O 0 7.620754693959952e-09

These O 0 6.378916594940165e-08
modules O 0 6.442874678214139e-07
include O 0 1.1832445245829604e-08
a O 0 8.940379814248445e-08
putative O 0 5.644685074912559e-07
signal O 0 9.37787589805339e-08
peptide O 0 3.582159457948819e-09
for O 0 3.9001610274702614e-10
protein O 0 1.90039983749557e-09
export O 0 6.4533813848299815e-09
, O 0 1.2183959396949717e-10
four O 0 3.5286888966368224e-09
epidermal O 0 1.6673321567850508e-07
growth O 0 1.2201763155417211e-08
factor O 0 3.066229936621312e-08
( O 0 3.916891699873304e-09
EGF O 0 3.728064541519416e-07
) O 0 1.591684423152273e-10
repeats O 0 1.2425409590122172e-09
with O 0 1.1095736829336289e-10
associated O 0 2.0037218462221063e-07
spacer O 0 1.265392256755149e-05
domains O 0 2.4261235012090765e-06
, O 0 9.29230115076507e-09
three O 0 4.5509878532357106e-08
LDL O 0 8.070558578765485e-06
- O 0 1.3934231901657768e-06
receptor O 0 2.2691274352837354e-06
( O 0 1.567783591838179e-08
LDLR O 0 3.4488575693103485e-06
) O 0 1.035822205786019e-09
repeats O 0 4.354914651116815e-09
, O 0 2.432061774193528e-10
a O 0 1.4058857189525042e-08
single O 0 6.972436494834255e-08
transmembrane O 0 1.2651822544285096e-05
spanning O 0 2.7362608307157643e-05
domain O 0 2.203959957114421e-05
, O 0 2.180244873528636e-09
and O 0 3.858034336445826e-09
a O 0 7.026759476502775e-07
cytoplasmic O 0 0.00015651901776436716
domain O 0 0.0001167190566775389
. O 0 1.7898834414609155e-07

The O 0 8.502119612785464e-07
encoded O 0 4.7203792519212584e-07
protein O 0 5.1760920882770733e-08
has O 0 1.9721672905870236e-10
a O 0 4.926270502636498e-10
unique O 0 2.4414650301451957e-09
organization O 0 2.353746353378483e-08
of O 0 6.467618277383735e-06
EGF O 0 0.004374568350613117
and O 0 8.798310524582575e-09
LDLR O 0 0.00011171592632308602
repeats O 0 6.469355895433182e-08
; O 0 2.802817145042269e-10
therefore O 0 9.076924101236727e-09
, O 0 2.1795214522057904e-09
LRP5 O 0 1.8562577679404058e-05
likely O 0 1.5965204269718924e-08
represents O 0 3.1213416296083096e-09
a O 0 1.4743583021115114e-09
new O 0 6.465340485206639e-10
category O 0 5.18521261483329e-08
of O 0 6.212482617229398e-08
the O 0 2.087295740693662e-07
LDLR O 0 0.03464769572019577
family O 0 2.924927230196772e-06
. O 0 1.2394283999128675e-07

Both O 0 8.045231538744702e-07
human O 0 4.6872108327988826e-07
and O 0 5.8989943596543526e-08
mouse O 0 2.604237579362234e-06
LRP5 O 0 0.047479987144470215
cDNAs O 0 3.845595711027272e-05
have O 0 1.8073348373448539e-09
been O 0 2.9285289748770538e-09
isolated O 0 4.208275061756694e-09
and O 0 4.460242591930452e-11
the O 0 1.0794436455796586e-09
encoded O 0 5.983721518276752e-09
mature O 0 1.0014651330436664e-09
proteins O 0 7.252472233876261e-11
are O 0 2.5657120525379717e-11
95 O 0 1.6282690751268092e-09
% O 0 5.872156233488468e-11
identical O 0 2.0704120362591283e-10
, O 0 7.310065053278691e-11
indicating O 0 6.318526590831652e-09
a O 0 8.956312913532827e-10
high O 0 4.634836514583185e-09
degree O 0 5.1328640893189e-07
of O 0 5.853475926187457e-09
evolutionary O 0 2.3520366099205603e-08
conservation O 0 7.539641688758536e-10
. O 0 3.0704213477283915e-11
. O 0 8.864031730837496e-10

The O 0 6.4895953073573764e-06
APC B-Disease 0 2.356496679567499e-06
variants O 0 2.8040442856536174e-08
I1307K O 0 2.1549034556755942e-07
and O 0 1.7394632401135368e-09
E1317Q O 0 6.678961312900356e-07
are O 0 4.3471550803531045e-09
associated O 0 1.0488402040209621e-05
with O 1 0.9999994039535522
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 0.0005454117199406028
but O 0 2.011491639919427e-09
not O 0 5.515593537452901e-10
always O 0 2.2686965639451273e-09
with O 0 7.167978710587164e-11
a O 0 5.159020943779069e-08
family O 0 1.45025936149068e-07
history O 0 1.1921675877601956e-06
. O 0 8.148013819209154e-08

Classical O 1 0.9999994039535522
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 0 0.1024472787976265
FAP B-Disease 0 1.9056740711675957e-05
) O 0 3.130320447297663e-09
is O 0 4.680559273495533e-10
a O 0 1.5439072242884322e-08
high O 0 0.11320892721414566
- O 1 1.0
penetrance O 1 1.0
autosomal B-Disease 1 1.0
dominant I-Disease 1 1.0
disease I-Disease 1 0.9999949932098389
that O 0 2.9744123830610647e-10
predisposes O 0 3.645685708875135e-08
to O 0 2.410089905424684e-10
hundreds O 0 1.7117958439616388e-10
or O 0 1.1938374733233559e-09
thousands O 0 1.0190573940249692e-09
of O 0 4.5569460780825466e-05
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 1.0
carcinoma I-Disease 1 1.0
and O 0 1.448295372519226e-09
that O 0 8.004652496396147e-11
results O 0 4.888167093319851e-10
from O 0 9.871168327180158e-10
truncating O 0 3.127547358872107e-07
mutations O 0 2.567232204597758e-09
in O 0 2.5576576412333907e-09
the O 0 4.555738541967003e-08
APC B-Disease 0 8.747152264731994e-07
gene O 0 3.939100068350854e-08
. O 0 3.311075502665517e-08

A O 0 2.737783688644413e-06
variant O 0 1.6483048170812253e-07
of O 0 2.1359288382427621e-07
FAP B-Disease 0 2.063683859887533e-05
is O 0 8.226984959947004e-08
attenuated B-Disease 0 0.31935104727745056
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
coli I-Disease 1 1.0
, O 0 3.832204775733317e-09
which O 0 1.8970923443273335e-10
results O 0 1.0055900556693587e-09
from O 0 1.41524560959283e-08
germ O 0 6.773407221771777e-05
- O 0 2.864051566575654e-06
line O 0 6.076863456883075e-08
mutations O 0 6.743155478439178e-10
in O 0 1.1385377085559867e-09
the O 0 1.4721187602262376e-09
5 O 0 4.568545097782817e-09
and O 0 9.093047148578393e-11
3 O 0 4.245594986684864e-09
regions O 0 8.790289052207356e-10
of O 0 4.520389040862938e-08
the O 0 2.480907994595327e-07
APC B-Disease 0 1.5927572576401872e-06
gene O 0 5.48360574725848e-08
. O 0 2.3042881380774816e-08

Attenuated B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
coli I-Disease 1 1.0
patients O 0 8.816365880193189e-05
have O 0 5.483380971504914e-10
" O 0 4.481770954356534e-09
multiple O 0 1.919825081131421e-07
" O 1 0.9999973773956299
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
( O 0 2.5571453843298286e-09
typically O 0 1.782502617730941e-11
fewer O 0 7.964533546567232e-12
than O 0 4.172558566023499e-12
100 O 0 2.507082041969255e-10
) O 0 6.212458499021967e-12
without O 0 1.091255211194131e-10
the O 0 3.588462582637675e-10
florid O 0 1.2438320595720143e-07
phenotype O 0 1.970503582526817e-08
of O 0 2.9653577371391293e-08
classical O 0 3.047766313102329e-06
FAP B-Disease 0 6.824763204349438e-06
. O 0 4.0490142794169515e-08

Another O 0 1.0494428579477244e-06
group O 0 6.520764816997371e-09
of O 0 8.509937643452758e-09
patients O 0 1.0848038023425488e-09
with O 0 1.5191609081810498e-10
multiple O 0 2.8620613647944992e-06
adenomas B-Disease 1 0.9999591112136841
has O 0 1.0671893369007535e-09
no O 0 4.708226586380704e-10
mutations O 0 8.579454507939843e-11
in O 0 6.219649795191629e-10
the O 0 8.018352204430812e-09
APC B-Disease 0 3.601116560503215e-08
gene O 0 3.84695941768598e-10
, O 0 2.0582757720433165e-11
and O 0 6.163481530707671e-11
their O 0 2.7150967585320984e-10
phenotype O 0 2.6697790644902852e-09
probably O 0 1.6383437939637702e-09
results O 0 5.615578557716105e-10
from O 0 1.7651918815531076e-09
variation O 0 1.1966238666616391e-08
at O 0 4.7453937668251456e-08
a O 0 1.9237962334273107e-08
locus O 0 2.7051179074533138e-08
, O 0 5.428815730290637e-11
or O 0 1.6152609805253348e-10
loci O 0 2.8126492801483494e-10
, O 0 2.7093842794312373e-11
elsewhere O 0 9.254745303444167e-10
in O 0 1.034055507886933e-09
the O 0 2.6296781641121925e-08
genome O 0 7.607919627616866e-08
. O 0 4.2965609736711485e-08

Recently O 0 3.702472440636484e-06
, O 0 2.7953814818459932e-09
however O 0 3.938196879715861e-09
, O 0 8.419600572295849e-10
a O 0 2.055638503861701e-08
missense O 0 7.112890898497426e-07
variant O 0 1.8330790396703378e-07
of O 0 9.082164069695864e-06
APC B-Disease 0 6.19852653471753e-06
( O 0 1.5585237633786164e-07
I1307K O 0 1.3505548395187361e-06
) O 0 1.3941948928675174e-08
was O 0 9.256606858798477e-08
described O 0 2.9453920191713223e-08
that O 0 3.8356320897214857e-10
confers O 0 3.2378786318787434e-09
an O 0 1.1960019086210139e-10
increased O 0 3.523207947608853e-09
risk O 0 1.8213762814411893e-05
of O 1 0.9999998807907104
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 1.659102366602383e-08
including O 0 2.562808298911534e-10
multiple O 0 7.205901653151159e-09
adenomas B-Disease 0 1.2395030353218317e-05
, O 0 9.987106697195713e-10
in O 0 6.728797075084003e-08
Ashkenazim O 0 0.00022499417536891997
. O 0 4.671025806146645e-07

We O 0 9.188108265334449e-07
have O 0 2.7587752082780526e-09
studied O 0 2.7678263236907696e-08
a O 0 2.1563575369754062e-09
set O 0 5.111209233632508e-10
of O 0 3.612677657027774e-10
164 O 0 5.331216357262747e-09
patients O 0 1.5438850198279397e-10
with O 0 4.525221516948896e-11
multiple O 1 0.9822324514389038
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 0.9986283779144287
/ I-Disease 1 1.0
or I-Disease 1 0.9843409657478333
carcinoma I-Disease 1 1.0
and O 0 8.059720890685185e-09
analyzed O 0 5.502998874362675e-07
codons O 0 3.162700465964008e-07
1263 O 0 9.003067134472076e-06
- O 0 8.033633491777437e-08
1377 O 0 1.9142594283039216e-06
( O 0 9.711333959216972e-09
exon O 0 2.606885729505848e-08
15G O 0 1.2158800188899477e-07
) O 0 6.688115616881873e-10
of O 0 5.796060520424362e-09
the O 0 8.077607560608158e-08
APC B-Disease 0 6.631018436564773e-07
gene O 0 7.1488841513200896e-09
for O 0 1.726309584171304e-08
germ O 0 0.008514586836099625
- O 0 0.001446508220396936
line O 0 2.7399673854233697e-06
variants O 0 5.140859116181673e-07
. O 0 1.2276164795821387e-07

Three O 0 2.0397509103986522e-07
patients O 0 3.348187060936425e-09
with O 0 5.949301468133328e-11
the O 0 1.779556590975062e-08
I1307K O 0 4.0018309732658963e-07
allele O 0 4.628440741782924e-09
were O 0 3.338105569739014e-09
detected O 0 3.392801817270197e-09
, O 0 3.980847249063224e-11
each O 0 2.034184765076219e-10
of O 0 3.245299495802101e-08
Ashkenazi O 0 8.209723091567867e-06
descent O 0 1.8026583347818814e-05
. O 0 4.854759367844963e-07

Four O 0 9.384168151882477e-06
patients O 0 1.8462530704255187e-07
had O 0 8.89535556325427e-08
a O 0 3.4490344091864245e-07
germ O 0 0.0007540922379121184
- O 0 0.00035528262378647923
line O 0 7.549997008027276e-06
E1317Q O 0 2.3713175323791802e-05
missense O 0 2.6290286768926308e-05
variant O 0 3.682123121961922e-07
of O 0 4.0159907257475425e-06
APC O 0 6.024590106790129e-07
that O 0 1.2398516657796677e-09
was O 0 7.610314156636377e-08
not O 0 1.0549311424412622e-09
present O 0 2.177244606826889e-09
in O 0 5.315802908967271e-09
controls O 0 4.300455103134482e-08
; O 0 2.2943218158655299e-10
one O 0 5.915404832634863e-10
of O 0 2.6406639097587004e-09
these O 0 4.091897098934538e-10
individuals O 0 1.1062186722199385e-09
had O 0 5.959517324072294e-09
an O 0 7.023886472445895e-10
unusually O 0 1.4516418067600512e-09
large O 0 4.092997329951942e-10
number O 0 1.7388729345313436e-09
of O 0 5.901256372453645e-08
metaplastic B-Disease 0 6.897354614920914e-05
polyps I-Disease 0 1.0845818678717478e-06
of I-Disease 0 2.57770750522468e-07
the I-Disease 0 2.581414833002782e-07
colorectum I-Disease 0 9.4062794232741e-05
. O 0 4.021963491140923e-07

There O 0 2.6052734369841346e-07
is O 0 6.558830145664274e-10
increasing O 0 6.289917475754692e-10
evidence O 0 5.030530658700627e-09
that O 0 6.721130596520908e-11
there O 0 1.8225097819790648e-10
exist O 0 1.684942740887152e-09
germ O 0 2.037208020055914e-07
- O 0 1.6054492846251378e-08
line O 0 8.066857404287475e-09
variants O 0 1.0498748537202118e-09
of O 0 3.2189131360382817e-09
the O 0 1.1374355679549808e-08
APC B-Disease 0 1.572909127389721e-07
gene O 0 5.049051177152819e-10
that O 0 2.541122520738348e-11
predispose O 0 7.436627758039549e-09
to O 0 9.320071103768868e-11
the O 0 3.645077017999654e-10
development O 0 3.902871803518337e-09
of O 0 5.875099873264844e-08
multiple O 1 0.9999951124191284
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 1.0
carcinoma I-Disease 1 1.0
, O 0 7.64736773906094e-10
but O 0 8.993283201474966e-11
without O 0 4.114177054592716e-10
the O 0 1.0380729609238415e-09
florid O 0 1.0696519581188113e-07
phenotype O 0 2.0679866707951078e-08
of O 0 2.448059888138232e-08
classical O 0 5.9335970945539884e-06
FAP B-Disease 0 7.71287488987582e-07
, O 0 1.0291084651115057e-10
and O 0 3.600287082350384e-11
possibly O 0 1.5781935758241161e-09
with O 0 9.683173013419477e-11
importance O 0 4.5291676542547066e-06
for O 1 0.9999949932098389
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
risk O 1 0.9999988079071045
in O 0 1.2423562179009195e-09
the O 0 4.374442752475005e-10
general O 0 5.862702545655907e-10
population O 0 1.890957182504316e-11
. O 0 1.3202300364056896e-10
. O 0 3.1371643061106624e-09

Genomic O 0 6.505686997115845e-06
structure O 0 1.2433328322458692e-07
of O 0 1.0892291868458415e-07
the O 0 1.3707128800888313e-06
human O 1 0.9999604225158691
congenital B-Disease 1 1.0
chloride I-Disease 1 1.0
diarrhea I-Disease 1 1.0
( O 1 0.9999994039535522
CLD B-Disease 1 1.0
) O 0 1.9333091927364876e-07
gene O 0 5.026475946579012e-08
. O 0 4.188482094491519e-08

Congenital B-Disease 1 1.0
chloride I-Disease 1 1.0
diarrhea I-Disease 1 1.0
( O 1 0.9999997615814209
CLD B-Disease 1 1.0
) O 0 1.7231555204944016e-07
is O 0 8.289209318945723e-10
caused O 0 6.234939675664464e-09
by O 0 7.596471229831536e-10
mutations O 0 1.2567321627798833e-09
in O 0 3.7232372740447772e-09
a O 0 2.1046997034090964e-08
gene O 0 4.520108454197924e-10
which O 0 1.323752496507069e-10
encodes O 0 5.174193962176332e-09
an O 0 8.435321885436053e-10
intestinal O 0 9.215101499648881e-07
anion O 0 9.703273826744407e-05
transporter O 0 0.0037346412427723408
. O 0 3.161837867082795e-07

We O 0 3.166753685945878e-07
report O 0 5.3077002348800306e-08
here O 0 1.7463587909105627e-08
the O 0 5.411721737402786e-09
complete O 0 9.488021390779977e-08
genomic O 0 1.2844505192788347e-07
organization O 0 1.337728949835082e-08
of O 0 5.7502454353652865e-08
the O 0 1.9852622301641532e-07
human O 0 2.2361093670042465e-06
CLD B-Disease 1 0.9999512434005737
gene O 0 7.044658634214329e-09
which O 0 1.965123064273655e-10
spans O 0 6.604100377671784e-09
approximately O 0 1.8112343846965473e-09
39kb O 0 1.6257041579592624e-07
, O 0 5.660388269213001e-10
and O 0 6.170894906176727e-10
comprises O 0 2.8075337610289353e-08
21 O 0 3.1903945796329936e-07
exons O 0 6.590525458705088e-07
. O 0 5.2868259103888704e-08

All O 0 2.8775875762221403e-06
exon O 0 1.6262472854577936e-05
/ O 0 2.8402055249898694e-06
intron O 0 2.114882363457582e-06
boundaries O 0 3.5808017884164656e-08
conform O 0 2.823676936714037e-08
to O 0 7.917019040348805e-09
the O 0 2.708469537537894e-07
GT O 0 3.524173007463105e-05
/ O 0 2.7492236768011935e-05
AG O 0 0.0001518455392215401
rule O 0 1.5410188325404306e-06
. O 0 1.319285303225115e-07

An O 0 5.013970394429634e-08
analysis O 0 3.615066290763025e-08
of O 0 1.6837869765140567e-08
the O 0 3.451652830221974e-08
putative O 0 4.606540642271284e-06
promoter O 0 7.571640026071691e-07
region O 0 5.231834521168821e-08
sequence O 0 3.500520051602507e-07
shows O 0 2.8028847509631305e-07
a O 0 4.267933206847374e-07
putative O 0 1.6929565390455537e-05
TATA O 0 1.4892649232933763e-05
box O 0 1.4196855602222058e-07
and O 0 1.0708084419164265e-09
predicts O 0 2.435824342228443e-08
multiple O 0 1.8294356252113175e-08
transcription O 0 2.8571823804668384e-06
factor O 0 8.131370776709446e-08
binding O 0 1.5920564422344796e-08
sites O 0 1.4291782690634136e-07
. O 0 4.5859909647560926e-08

The O 0 7.100468337739585e-07
genomic O 0 9.312093425251078e-07
structure O 0 1.9690745034495194e-07
was O 0 1.2039743069180986e-07
determined O 0 9.721637717063913e-09
using O 0 1.2290211071075419e-09
DNA O 0 1.7871819579795556e-09
from O 0 2.4666507725257247e-10
several O 0 7.366583731904797e-11
sources O 0 4.935590824928227e-10
including O 0 1.970504315274013e-11
multiple O 0 4.826281596592708e-10
large O 0 1.3898299400239011e-08
- O 0 1.6782216505362157e-07
insert O 0 3.132257688776008e-07
libaries O 0 8.600026148997131e-07
and O 0 6.766719962136847e-10
genomic O 0 1.741811495037382e-08
DNA O 0 2.1663471017063785e-08
from O 0 2.275032784382347e-08
Finnish O 0 0.04752316325902939
CLD B-Disease 1 1.0
patients O 0 1.5880129922152264e-06
and O 0 7.381105504578045e-09
controls O 0 6.453309993048606e-07
. O 0 4.0627302411166966e-08

Exon O 0 1.1009947229467798e-05
- O 0 4.0333283379823115e-08
specific O 0 6.784464101627918e-10
primers O 0 1.22751293574197e-08
developed O 0 4.897247052326748e-10
in O 0 8.623356195780474e-11
this O 0 3.501044940068532e-11
study O 0 7.084981906713139e-11
will O 0 9.444670739933159e-12
facilitate O 0 5.136844838382615e-10
mutation O 0 1.6123091750586127e-10
screening O 0 1.9111437432606238e-10
studies O 0 4.663610053690093e-10
of O 0 3.71910446883561e-10
patients O 0 8.905987752827471e-11
with O 0 1.7590496767527775e-11
the O 0 3.2985761322379403e-07
disease O 0 0.003527143271639943
. O 0 5.882018072611572e-08

Genomic O 0 1.7225129340658896e-06
sequencing O 0 8.390288286364012e-08
of O 0 1.8597523876451305e-07
a O 0 1.5185532902250998e-06
BAC O 1 0.9491977095603943
clone O 0 0.0017217645654454827
H O 1 1.0
_ O 0 3.240042190100212e-08
RG364P16 O 0 3.1338680628323345e-07
revealed O 0 1.0733654676187143e-07
the O 0 4.842346079669824e-09
presence O 0 1.4577401508120147e-09
of O 0 8.611793056445549e-09
another O 0 4.761329996938457e-09
, O 0 1.68697417146646e-10
highly O 0 3.2851310560744196e-09
homologous O 0 1.0179913800811846e-08
gene O 0 7.419466152569498e-10
3 O 0 2.061351267457212e-08
of O 0 4.058779978777238e-08
the O 0 5.440121526589792e-07
CLD B-Disease 1 0.9998825788497925
gene O 0 2.0270098488595067e-08
, O 0 1.1123114235234155e-10
with O 0 2.096423035169437e-11
a O 0 6.648508965589883e-10
similar O 0 1.1331275501236249e-10
genomic O 0 7.093846399186532e-09
structure O 0 1.9004477991302338e-08
, O 0 1.8657615730166555e-10
recently O 0 9.097632092114338e-10
identified O 0 4.212893145449925e-09
as O 0 3.3162310675294293e-09
the O 0 6.976226814003894e-07
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
gene O 0 1.9824460650852416e-06
( O 0 1.6139267700054916e-07
PDS B-Disease 0 9.193560686071578e-07
) O 0 2.495879058983519e-10
. O 0 2.1727133980853353e-10
. O 0 8.877148793828837e-09

The O 0 2.4619728264951846e-06
APCI1307K O 0 0.00015314565098378807
allele O 0 7.38710923542385e-08
and O 0 5.320814011611219e-09
cancer B-Disease 0 6.162671525089536e-06
risk O 0 3.2981590720737586e-06
in O 0 3.6886248722112214e-08
a O 0 9.921480170760333e-08
community O 0 1.344306888029223e-09
- O 0 7.60112417452774e-10
based O 0 5.449151685432696e-10
study O 0 3.334790221742878e-09
of O 0 9.208020124162886e-09
Ashkenazi O 0 7.244946687023912e-07
Jews O 0 1.355739698283287e-07
. O 0 1.879453748188098e-08

Mutations O 0 9.57225211095647e-07
in O 0 5.39272448918382e-08
APC O 0 1.6148922554748424e-07
are O 0 2.966565326723014e-10
classically O 0 6.963052783248713e-07
associated O 0 2.618497489947913e-07
with O 0 2.513319259378477e-06
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 1 0.9962965846061707
FAP B-Disease 0 1.0925382412096951e-05
) O 0 2.459387971054383e-10
, O 0 1.3746475312215178e-11
a O 0 2.738941295987729e-09
highly O 0 4.49577382823918e-05
penetrant O 1 1.0
autosomal B-Disease 1 1.0
dominant I-Disease 1 1.0
disorder I-Disease 1 1.0
characterized O 1 0.9998502731323242
by O 0 7.627243547858598e-08
multiple O 0 8.168476051650941e-05
intestinal O 1 0.9999783039093018
polyps B-Disease 0 3.8259622670011595e-06
and O 0 3.5886562610443207e-09
, O 0 1.1228099561222393e-09
without O 0 4.0417070579223946e-08
surgical O 0 0.008217500522732735
intervention O 0 0.0001213466384797357
, O 0 1.3032301904303267e-09
the O 0 1.1863518167842813e-08
development O 0 0.00012888798664789647
of O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
( O 1 0.9999953508377075
CRC B-Disease 0 0.39823514223098755
) O 0 1.0213112133783397e-08
. O 0 8.712442323144387e-09

APC B-Disease 0 3.0024422812857665e-05
is O 0 6.905731453343833e-08
a O 0 3.5266930353827775e-07
tumour O 1 1.0
- O 0 7.0325240812962875e-06
suppressor O 0 2.215407448602491e-06
gene O 0 8.920987282223791e-10
, O 0 1.7442524855026953e-11
and O 0 8.07947528325137e-11
somatic O 0 3.702299693486566e-07
loss O 0 2.5407418888789834e-06
occurs O 0 4.876745833826135e-07
in O 0 3.6432049910217756e-06
tumours B-Disease 1 1.0
. O 0 1.1393678960303077e-06

The O 0 1.0187432053498924e-05
germline O 0 5.803817111882381e-05
T O 0 2.3675163447478553e-06
- O 0 5.5846403057557836e-08
to O 0 1.9635365333670052e-08
- O 0 8.074249535638955e-08
A O 0 5.93946253957256e-07
transversion O 0 1.2383985676933662e-06
responsible O 0 4.869793102102449e-08
for O 0 3.282268679072331e-09
the O 0 8.39701215227251e-08
APC O 0 2.9295148351593525e-07
I1307K O 0 1.3587593628017203e-07
allele O 0 2.4316684221759033e-09
converts O 0 1.6663102009317754e-09
the O 0 1.716465303225334e-09
wild O 0 3.52545304060925e-09
- O 0 5.159097149487479e-09
type O 0 1.2945846172840447e-08
sequence O 0 1.7309186972624957e-08
to O 0 5.566707539372828e-09
a O 0 1.8851302741040854e-07
homopolymer O 0 0.00020148961630184203
tract O 0 0.00033504015300422907
( O 0 5.201090971240774e-07
A8 O 0 8.370837349502835e-06
) O 0 2.5258009572759477e-10
that O 0 4.314119547710327e-11
is O 0 2.1546048278864305e-10
genetically O 0 8.920510996546227e-10
unstable O 0 5.42316229257267e-07
and O 0 7.892594133807052e-09
prone O 0 5.438140533442493e-07
to O 0 2.923262343301758e-08
somatic O 0 9.654059795138892e-06
mutation O 0 3.230336460546823e-07
. O 0 3.635908285559708e-08

The O 0 5.224169399298262e-06
I1307K O 0 1.584832170919981e-05
allele O 0 1.7419966980014578e-07
was O 0 4.281851602172537e-07
found O 0 1.899599944010788e-08
in O 0 3.711299001452062e-08
6 O 0 2.79208484244009e-06
. O 0 2.8738858759425057e-07

1 O 0 2.633126996443025e-06
% O 0 2.046933111898852e-08
of O 0 3.086685040898374e-08
unselected O 0 0.43903622031211853
Ashkenazi O 0 7.91286802268587e-05
Jews O 0 1.1697854773728977e-07
and O 0 7.977480898091471e-10
higher O 0 1.447263286991074e-08
proportions O 0 3.748799315417273e-08
of O 0 1.2849027086758724e-07
Ashkenazim O 0 2.4456201117573073e-06
with O 0 3.64436991695527e-09
family O 0 1.457598614251765e-06
or O 0 3.0259619165917684e-07
personal O 0 1.4255740097723901e-05
histories O 0 1.350469665339915e-05
of O 0 0.001721687731333077
CRC B-Disease 1 0.9944754242897034
( O 0 3.50406116922386e-06
ref O 0 5.12364795213216e-06
. O 0 2.619274797055482e-09
2 O 0 1.417926540625558e-07
) O 0 1.7807076702069935e-08
. O 0 2.4302368117901096e-08

To O 0 2.580641762506275e-07
evaluate O 0 5.236007609710214e-07
the O 0 3.706814055703944e-08
role O 0 1.3867958159607952e-07
of O 0 2.9088465680615627e-07
I1307K O 0 3.204291942893178e-06
in O 0 6.995361445660819e-08
cancer B-Disease 0 7.448994665537612e-07
, O 0 3.5449398971820756e-09
we O 0 1.7777484373482366e-08
genotyped O 0 4.877978426520713e-06
5 O 0 2.2940230337553658e-07
, O 0 7.725689421533843e-09
081 O 0 4.3078867747681215e-05
Ashkenazi O 0 4.850516006627004e-07
volunteers O 0 2.0408165823937452e-08
in O 0 3.0144620133398803e-09
a O 0 1.610860067557951e-08
community O 0 5.108521605734495e-09
survey O 0 4.460351021862152e-08
. O 0 7.326557582842952e-09

Risk O 0 3.1156243494478986e-05
of O 0 4.362881895758619e-07
developing O 1 0.9967817068099976
colorectal B-Disease 1 1.0
, I-Disease 0 2.5338469640701078e-05
breast I-Disease 1 0.9993997812271118
and I-Disease 0 5.4974083951719876e-08
other I-Disease 0 4.434738798408944e-09
cancers I-Disease 0 0.00036905601155012846
were O 0 3.551099680976222e-08
compared O 0 7.680627689410358e-09
between O 0 1.0336793643261899e-08
genotyped O 0 1.2527035551102017e-06
I1307K O 0 1.0759789148551135e-07
carriers O 0 3.821633287603987e-10
and O 0 7.329055695670661e-10
non O 0 4.260158164015593e-07
- O 0 5.9489018156000384e-08
carriers O 0 2.159362022524647e-09
and O 0 5.28666943555578e-10
their O 0 1.3536570753203137e-09
first O 0 1.9964824460316777e-08
- O 0 2.80621659243252e-08
degree O 0 1.5943247490213253e-05
relatives O 0 2.1655027637734747e-07
. O 0 1.406588356900329e-08

Sperm O 0 8.117932566165109e-07
DNA O 0 5.691985549560741e-08
analysis O 0 1.2900664536630302e-08
in O 0 2.1559418694749866e-09
a O 0 1.4439977746860677e-07
Friedreich B-Disease 1 0.9995604157447815
ataxia I-Disease 1 0.9994701743125916
premutation O 0 0.018360991030931473
carrier O 0 1.4836957973329845e-07
suggests O 0 8.596797584914384e-08
both O 0 4.969078482019995e-09
meiotic O 0 2.29370448323607e-06
and O 0 1.1666076993321894e-08
mitotic O 0 8.491423386658425e-07
expansion O 0 4.7191999641427174e-08
in O 0 1.0554408902407886e-08
the O 0 9.558298330603066e-08
FRDA B-Disease 0 0.000360261183232069
gene O 0 4.08260518725001e-07
. O 0 1.0765003111146143e-07

Friedreich B-Disease 1 1.0
ataxia I-Disease 1 1.0
is O 0 1.794709351088386e-05
usually O 0 4.592836262418132e-07
caused O 0 3.1204032779896806e-07
by O 0 3.0600122435942012e-09
an O 0 5.732272434499919e-09
expansion O 0 1.6877909558843385e-07
of O 0 7.457253445863898e-07
a O 0 1.9461560896161245e-06
GAA O 0 8.832313324091956e-05
trinucleotide O 0 9.970601240638644e-06
repeat O 0 4.251878067407233e-07
in O 0 4.968863009935376e-08
intron O 0 1.1403885764593724e-06
1 O 0 9.664901057249153e-08
of O 0 6.887066206218151e-08
the O 0 2.107705086018541e-07
FRDA B-Disease 0 0.0019963604863733053
gene O 0 7.032718940536142e-07
. O 0 1.1255576737312367e-07

Occasionally O 0 1.6377736756112427e-05
, O 0 2.0145257906278857e-08
a O 0 2.9773726595294647e-08
fully O 0 5.067677477654797e-08
expanded O 0 1.427540397003213e-08
allele O 0 6.173099809103633e-09
has O 0 6.012204067928906e-10
been O 0 4.1294526131885334e-10
found O 0 2.1602135358289587e-10
to O 0 4.428523936450546e-10
arise O 0 3.854219343679688e-08
from O 0 3.5030335965302584e-08
a O 0 7.64584342505259e-08
premutation O 0 5.444637736218283e-07
of O 0 3.826984311672277e-07
100 O 0 1.8985137728577683e-07
or O 0 1.4438499285063244e-08
less O 0 1.6097267518944136e-08
triplet O 0 2.3201243948278716e-06
repeats O 0 1.1593562021516846e-06
. O 0 1.352075287286425e-07

We O 0 4.79001187159156e-07
have O 0 2.2806145860698734e-09
examined O 0 9.920133159369016e-09
the O 0 5.861956253738754e-09
sperm O 0 1.3526022080156963e-08
DNA O 0 2.2089858831009224e-08
of O 0 2.355565165146345e-08
a O 0 1.253766868103412e-07
premutation O 0 5.096289896755479e-06
carrier O 0 7.031169957372185e-07
. O 0 2.2232077867556654e-07

This O 0 5.74889554627589e-07
mans O 0 6.468265837611398e-06
leucocyte O 0 1.1946361837544828e-06
DNA O 0 4.1391871263840585e-08
showed O 0 3.3766167639726063e-09
one O 0 2.3975729734893036e-10
normal O 0 1.0341659750778831e-09
allele O 0 1.1652299958253565e-10
and O 0 6.876699903957117e-11
one O 0 1.5877123227259204e-10
allele O 0 1.3572060142408304e-10
of O 0 4.038391843153022e-09
approximately O 0 1.3963664891036842e-08
100 O 0 1.5795683339092648e-07
repeats O 0 1.3360261164052645e-07
. O 0 4.881370685438924e-08

His O 0 4.906587491859682e-06
sperm O 0 8.357463912034291e-07
showed O 0 1.5652378948516343e-08
an O 0 3.7647174266908223e-10
expanded O 0 2.3943067528620077e-09
allele O 0 2.0703576630864973e-09
in O 0 5.951146242466621e-09
a O 0 3.850934859883637e-08
tight O 0 6.724179257844298e-08
range O 0 2.6524016760731683e-08
centering O 0 2.3549010563783668e-07
on O 0 5.984063466968337e-09
a O 0 1.371814994932663e-09
size O 0 4.370473427606214e-10
of O 0 1.265282545404034e-09
approximately O 0 7.482156227922587e-09
320 O 0 1.6153819615283282e-07
trinucleotide O 0 7.012499736447353e-06
repeats O 0 1.1213817288080463e-06
. O 0 2.15417614413127e-07

His O 0 2.1891082724323496e-05
affected O 0 1.7724095187077182e-06
son O 0 2.1667538021574728e-05
has O 0 1.7063829460539637e-08
repeat O 0 2.1001081762506146e-08
sizes O 0 3.2443526976067005e-08
of O 0 3.4977534824065515e-07
1040 O 0 1.0946480415441329e-06
and O 0 8.127152995029974e-08
540 O 0 4.947725756210275e-06
. O 0 1.958601529850057e-07

These O 0 4.889570703880963e-08
data O 0 9.682096901997284e-08
suggest O 0 4.393191588292211e-09
that O 0 3.779428506267557e-11
expansion O 0 1.243038783016459e-09
occurs O 0 2.2151480649768018e-10
in O 0 1.7741932922810122e-10
two O 0 6.416871894954213e-11
stages O 0 2.0826393942741106e-09
, O 0 2.5927704427886056e-10
the O 0 1.6644107203589442e-09
first O 0 5.322925211714846e-09
during O 0 1.2825514872361055e-08
meiosis O 0 1.8483085284515255e-08
followed O 0 7.023059023225642e-09
by O 0 1.1704026636749632e-09
a O 0 7.639892274369231e-09
second O 0 4.330382807893329e-08
mitotic O 0 3.5721768654184416e-07
expansion O 0 3.001136974489782e-07
. O 0 1.0418943929835223e-07

We O 0 1.408393131896446e-06
also O 0 6.7899694755624296e-09
show O 0 1.0285992502190311e-08
that O 0 1.5738491065953042e-10
in O 0 8.147508778755252e-10
all O 0 1.0448566456489061e-09
informative O 0 6.61780958921554e-08
carrier O 0 2.65893951301166e-09
father O 0 1.5071504932961943e-08
to O 0 4.577930479143788e-09
affected O 0 1.8370617027585467e-08
child O 0 1.5059988811572111e-07
transmissions O 0 1.3141695376361895e-07
, O 0 1.376364022753762e-10
with O 0 4.618250920573885e-11
the O 0 1.0630171409786726e-08
notable O 0 4.458326685607972e-08
exception O 0 7.849839533946579e-08
of O 0 4.864195091158763e-08
the O 0 3.308922202904796e-08
premutation O 0 1.919817350426456e-06
carrier O 0 3.0962258534827924e-08
, O 0 9.529146360875984e-10
the O 0 4.5751895605405934e-09
expansion O 0 3.0852373100742625e-08
size O 0 1.6574578154404662e-08
decreases O 0 1.0861318600063896e-07
. O 0 2.4368778106520494e-09
. O 0 1.1767490981640094e-08

The O 0 2.2455487851402722e-06
R496H O 0 1.1116973837488331e-05
mutation O 0 4.9695838555408045e-08
of O 0 2.1144333572920004e-07
arylsulfatase O 0 0.00021957956778351218
A O 0 3.1544324883725494e-05
does O 0 1.775837077389042e-08
not O 0 6.0643003507721e-08
cause O 0 7.535218173870817e-05
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
. O 0 2.193229420299758e-06

Deficiency B-Disease 1 1.0
of I-Disease 0 0.013884875923395157
arylsulfatase I-Disease 1 0.9993116855621338
A I-Disease 1 0.9891237020492554
( O 0 1.1414188520575408e-05
ARSA O 1 0.9502217769622803
) O 0 2.6931228802595797e-08
enzyme O 0 1.8920971456282132e-07
activity O 0 1.4688822602693108e-06
causes O 0 1.6498257537023164e-05
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
( O 0 0.00020494747150223702
MLD B-Disease 1 1.0
) O 0 1.2042993091654353e-07
. O 0 2.2592365311879803e-08

A O 0 9.361235129290435e-07
number O 0 1.3382393859728836e-08
of O 0 2.0228856101311976e-07
ARSA O 0 0.004213663283735514
gene O 0 8.336880341630604e-08
mutations O 0 1.4897309164041417e-08
responsible O 0 4.6147533794282936e-08
for O 0 3.64892457582755e-07
MLD B-Disease 1 1.0
have O 0 3.715953482696932e-07
been O 0 5.789014423385197e-08
identified O 0 1.1665614607636599e-07
. O 0 7.009759173115526e-08

Recently O 0 1.9704789337993134e-06
, O 0 2.6578037548574684e-09
the O 0 1.1685094669644513e-08
R496H O 0 2.4392800241912482e-06
mutation O 0 6.150947484684366e-08
of O 0 1.6245895722022397e-06
ARSA O 1 0.9683188199996948
was O 0 2.8725808078888804e-06
proposed O 0 1.5046344614688678e-08
to O 0 2.58816656995009e-09
be O 0 2.500283091677602e-09
a O 0 1.4415935112310763e-08
cause O 0 1.9662242323192913e-07
of O 0 3.101821130258031e-05
MLD B-Disease 1 1.0
( O 0 1.0756792107713409e-05
Draghia O 0 0.0002722023637033999
et O 0 1.0046080205938779e-05
al O 0 1.3409115808826755e-06
. O 0 7.272810687020126e-10
, O 0 4.5931117242936637e-10
1997 O 0 3.380239732564405e-08
) O 0 9.835839698268956e-09
. O 0 2.570075174901376e-08

We O 0 4.5013405269855866e-07
have O 0 2.120514208669988e-09
investigated O 0 1.1185657200485366e-07
the O 0 5.8451306017559546e-09
R496H O 0 1.4208612242327945e-07
mutation O 0 3.292958405953783e-10
and O 0 3.40334947723786e-11
found O 0 1.2000418714297467e-10
this O 0 1.179700920284077e-10
mutation O 0 1.8145357438825727e-10
at O 0 1.411333494516498e-09
a O 0 2.868884296791663e-10
relatively O 0 8.352052383031605e-11
high O 0 1.3122740394333476e-10
frequency O 0 1.0466832262023829e-10
in O 0 3.652835672829369e-11
an O 0 7.182553163342931e-11
African O 0 5.168460659454865e-10
American O 0 2.7380361866669034e-10
population O 0 2.7392504497320003e-12
( O 0 5.145419246926908e-12
f O 0 4.620605564831237e-10
= O 0 9.174653259336196e-10
0 O 0 7.816451652598033e-11
. O 0 7.155735205766067e-12
09 O 0 2.9161881798245304e-09
, O 0 9.292540348315725e-11
n O 0 7.477076735540322e-09
= O 0 3.32600684771478e-08
61 O 0 6.139915242897587e-09
subjects O 0 1.300475247489885e-07
) O 0 8.364366976820747e-09
. O 0 1.7225074699922516e-08

The O 0 4.2956821744155604e-06
ARSA O 0 0.03393480181694031
enzyme O 0 3.809011843713961e-07
activity O 0 1.9476398449569388e-07
in O 0 6.416960296462548e-10
subjects O 0 1.126665516437697e-08
with O 0 1.8819699965089143e-10
and O 0 1.1606456906676499e-09
without O 0 1.3022471101464816e-08
the O 0 2.4154124034225788e-08
R496H O 0 2.5396224145879387e-07
mutation O 0 4.3133646654425206e-10
was O 0 7.771979504411775e-09
determined O 0 2.782571950632473e-09
and O 0 6.707022159879727e-10
found O 0 4.002061348984398e-09
to O 0 3.532978798403974e-09
be O 0 1.8709306104369716e-08
normal O 0 1.0832535508598085e-06
. O 0 8.587849720242957e-08

It O 0 5.0247120242374876e-08
is O 0 1.8477893659607503e-09
therefore O 0 2.265099219300737e-09
concluded O 0 7.749391350841961e-09
that O 0 8.62858812178402e-11
the O 0 1.6927670376531978e-09
R496H O 0 2.2054922510506003e-07
mutation O 0 5.089236587707546e-09
of O 0 8.680864027610369e-08
ARSA O 0 0.005148432217538357
does O 0 6.663048335298072e-09
not O 0 6.178727529615458e-10
negatively O 0 8.970713061273727e-09
influence O 0 5.998668228812676e-09
the O 0 7.143976965551246e-09
activity O 0 5.36859033672954e-07
of O 0 2.885323624468583e-07
ARSA O 0 0.0005370621220208704
and O 0 3.433999973267987e-09
is O 0 6.102329752621927e-10
not O 0 7.009993696627248e-10
a O 0 2.4058026681927913e-08
cause O 0 5.559282385547704e-07
of O 0 2.6036615963676013e-05
MLD B-Disease 1 1.0

Down O 0 0.0006204465171322227
- O 0 1.942977405633428e-06
regulation O 0 1.982896975505355e-07
of O 0 3.90370011871255e-08
transmembrane O 0 2.628866695886245e-06
carbonic O 0 0.00013953344023320824
anhydrases O 0 0.11345866322517395
in O 0 2.4694818421266973e-05
renal B-Disease 1 1.0
cell I-Disease 1 1.0
carcinoma I-Disease 1 1.0
cell O 1 1.0
lines O 0 8.616198101663031e-07
by O 0 1.846719221987314e-08
wild O 0 3.876851337736298e-07
- O 0 4.066873316332931e-06
type O 0 0.0001280693686567247
von B-Disease 1 1.0
Hippel I-Disease 1 1.0
- I-Disease 1 0.9999915361404419
Lindau I-Disease 1 0.9999892711639404
transgenes O 0 0.0019558577332645655
. O 0 9.666556479714927e-07

To O 0 1.5897221317118237e-07
discover O 0 5.645045462188136e-07
genes O 0 1.0374025194437309e-08
involved O 0 3.170654494510927e-08
in O 0 8.551024421876718e-08
von B-Disease 1 0.9999994039535522
Hippel I-Disease 1 1.0
- I-Disease 1 0.9999997615814209
Lindau I-Disease 1 1.0
( O 0 8.426471140410285e-06
VHL B-Disease 0 0.002721835393458605
) O 0 1.0194919042305628e-07
- O 0 1.4416642102332844e-07
mediated O 0 7.600245908179204e-07
carcinogenesis O 1 0.8987706899642944
, O 0 2.8026634346645096e-09
we O 0 8.030688114502027e-09
used O 0 7.010400508988823e-07
renal B-Disease 1 1.0
cell I-Disease 1 1.0
carcinoma I-Disease 1 1.0
cell O 1 1.0
lines O 0 4.236631139065139e-05
stably O 0 0.0010226969607174397
transfected O 0 5.44926842849236e-06
with O 0 1.0566428843006292e-09
wild O 0 1.0635103109279953e-07
- O 0 1.1818437997135334e-06
type O 0 2.4406561351497658e-05
VHL O 1 0.989083468914032
- O 0 1.839100877987221e-05
expressing O 0 3.7801410712745565e-07
transgenes O 0 1.4324506992124952e-05
. O 0 6.93682054020428e-08

Large O 0 1.1101579957539798e-06
- O 0 4.167020222212159e-07
scale O 0 2.0485324512264924e-06
RNA O 0 8.636329198452586e-07
differential O 0 1.6848349559950293e-07
display O 0 8.294827935628746e-09
technology O 0 3.1627539698320106e-08
applied O 0 5.811458425597493e-09
to O 0 7.049373307310702e-10
these O 0 7.517858002792366e-10
cell O 0 3.860907682451398e-08
lines O 0 7.026391690700962e-10
identified O 0 3.689993310906914e-10
several O 0 9.611923756924767e-11
differentially O 0 2.685157340920341e-08
expressed O 0 3.994768404957938e-10
genes O 0 1.3830853129448428e-10
, O 0 1.014220391698517e-11
including O 0 2.682276449561538e-11
an O 0 1.2755929645891229e-09
alpha O 0 3.4319268138460757e-07
carbonic O 0 9.143108400166966e-06
anhydrase O 0 3.0130349841783755e-05
gene O 0 3.950129823238058e-08
, O 0 4.373093442922027e-09
termed O 0 1.3425341194306384e-06
CA12 O 0 0.0007581067038699985
. O 0 6.860143457743106e-07

The O 0 1.8575310605228879e-06
deduced O 0 8.968712791102007e-06
protein O 0 1.4623392985413375e-07
sequence O 0 1.4675575243927597e-07
was O 0 3.8801985624559165e-07
classified O 0 9.443570547773561e-08
as O 0 3.0304132536684847e-09
a O 0 3.9132494578097976e-08
one O 0 4.3369130509063325e-08
- O 0 1.8411910218674166e-07
pass O 0 2.7376376010579406e-07
transmembrane O 0 0.0007174179772846401
CA O 0 0.00013310258509591222
possessing O 0 1.916107976285275e-06
an O 0 3.960896890475851e-07
apparently O 0 8.509708095516544e-06
intact O 0 4.47700840595644e-05
catalytic O 0 1.1462492466307594e-06
domain O 0 1.5643954611732624e-06
in O 0 1.4478541920937005e-08
the O 0 2.0269254719096352e-07
extracellular O 0 0.0016954746097326279
CA O 0 0.09428708255290985
module O 0 0.0010681633139029145
. O 0 7.705750135755807e-07

Reintroduced O 0 3.751965323317563e-06
wild O 0 1.054354243024136e-06
- O 0 1.241148652297852e-06
type O 0 8.787930596554361e-07
VHL B-Disease 0 0.0022718971595168114
strongly O 0 7.690657355396979e-08
inhibited O 0 8.899633030523546e-08
the O 0 1.1897888230194553e-09
overexpression O 0 1.1421009027401396e-08
of O 0 1.0522163140791463e-09
the O 0 4.182979740363635e-09
CA12 O 0 1.5072560017870273e-06
gene O 0 4.3697565010880624e-10
in O 0 4.61202964707752e-10
the O 0 7.663637724419914e-09
parental O 0 6.171542190713808e-05
renal B-Disease 1 1.0
cell I-Disease 1 1.0
carcinoma I-Disease 1 1.0
cell O 1 1.0
lines O 0 5.566674371948466e-05
. O 0 2.799961862365308e-07

Similar O 0 3.464078446313579e-08
results O 0 1.1836847946256057e-08
were O 0 3.430085326883159e-09
obtained O 0 1.500312940549975e-08
with O 0 1.3686995981032624e-09
CA9 O 0 0.003438100451603532
, O 0 3.0008375784262853e-09
encoding O 0 8.54562376417789e-09
another O 0 7.370417165475374e-08
transmembrane O 0 3.855672184727155e-05
CA O 0 5.442350357043324e-06
with O 0 1.214864764342849e-09
an O 0 5.321222573684281e-08
intact O 0 6.786615995224565e-05
catalytic O 0 2.5805925361055415e-06
domain O 0 1.322960997640621e-05
. O 0 1.2521644521257258e-07

Although O 0 8.509827154057348e-08
both O 0 7.931770795721604e-09
domains O 0 2.3802434157005337e-07
of O 0 1.0664739846788507e-07
the O 0 2.7310454697726527e-07
VHL B-Disease 0 0.00020205545297358185
protein O 0 1.6630635002456984e-07
contribute O 0 1.6775800748547454e-09
to O 0 2.51603160528191e-09
regulation O 0 2.4470281800859084e-08
of O 0 5.366876365542339e-08
CA12 O 0 0.0019555999897420406
expression O 0 2.3652815173136332e-07
, O 0 5.344408249285948e-10
the O 0 5.030472483014137e-09
elongin O 0 9.498955364506401e-07
binding O 0 1.5732084079900233e-08
domain O 0 1.7784732619929855e-07
alone O 0 4.30958380093216e-09
could O 0 1.2184476760879193e-09
effectively O 0 2.3029084417203194e-08
regulate O 0 5.395835955823713e-07
CA9 O 1 0.9998019337654114
expression O 0 3.707977839439991e-06
. O 0 7.704267090957728e-08

We O 0 1.0806007821884123e-06
mapped O 0 9.871994734567124e-06
CA12 O 0 0.0004999611992388964
and O 0 1.6907792144138512e-07
CA9 O 0 0.11575640738010406
loci O 0 1.293501554755494e-07
to O 0 6.05353944749254e-09
chromosome O 0 9.179072435472335e-08
bands O 0 1.3504759976967762e-07
15q22 O 0 2.4002513328014174e-06
and O 0 4.52677362261511e-08
17q21 O 0 2.356436561967712e-05
. O 0 4.1932744920814e-07

2 O 0 4.950643415213563e-07
respectively O 0 6.811985286958588e-08
, O 0 8.60531979007817e-10
regions O 0 4.781241624840504e-09
prone O 0 1.939872902312345e-07
to O 0 4.393535313340635e-09
amplification O 0 1.2676801475208777e-07
in O 0 8.032036369343132e-09
some O 0 4.265180209017672e-09
human O 0 1.0259271476797949e-07
cancers B-Disease 0 2.1072091840323992e-05
. O 0 2.5877534781670875e-08

Additional O 0 3.713947549499608e-08
experiments O 0 1.4433025796734e-07
are O 0 4.093731464926975e-10
needed O 0 2.1622510448793264e-09
to O 0 1.6285734982801614e-09
define O 0 2.166938095626847e-08
the O 0 2.4607230031392646e-08
role O 0 3.6048245988240524e-07
of O 0 9.665399375080597e-06
CA O 0 5.5121541663538665e-05
IX O 0 5.826905635331059e-06
and O 0 5.129076185994563e-08
CA O 0 7.0178243731788825e-06
XII O 0 8.037171937758103e-06
enzymes O 0 4.505254391773406e-09
in O 0 2.4090984762636936e-09
the O 0 2.0946824275114295e-09
regulation O 0 8.498047598948233e-09
of O 0 9.055083793896301e-09
pH O 0 5.957975091064327e-08
in O 0 4.529483454973615e-09
the O 0 1.3293456113672164e-08
extracellular O 0 2.9752495720458683e-06
microenvironment O 0 3.4652262002055068e-06
and O 0 5.143158121612146e-10
its O 0 1.7438074595421682e-10
potential O 0 7.123155953969729e-10
impact O 0 1.0020274388011785e-08
on O 0 7.488883824180448e-08
cancer B-Disease 0 2.050364128081128e-05
cell O 0 1.21155962915509e-05
growth O 0 1.4669571157810424e-07
. O 0 1.0428124141981243e-08

A O 0 3.745848289327114e-06
gene O 0 3.8074350783290356e-08
encoding O 0 3.436478479557081e-08
a O 0 3.205888177149063e-08
transmembrane O 0 5.383802772485069e-07
protein O 0 7.183245998021448e-09
is O 0 1.3580779729960302e-11
mutated O 0 2.5896259095437024e-11
in O 0 4.8183415590763445e-11
patients O 0 9.269797152100523e-10
with O 0 1.0701641883770208e-07
diabetes B-Disease 1 1.0
mellitus I-Disease 1 1.0
and O 1 1.0
optic B-Disease 1 1.0
atrophy I-Disease 1 1.0
( O 1 1.0
Wolfram B-Disease 1 1.0
syndrome I-Disease 1 1.0
) O 0 2.370999219181158e-08
. O 0 8.680678398320651e-09

Wolfram B-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.0001783552870620042
WFS B-Disease 1 0.9999803304672241
; O 0 6.94606114848284e-08
OMIM O 0 0.033114202320575714
222300 O 0 2.7784424219134962e-06
) O 0 8.128214767921804e-10
is O 0 2.4745533400150066e-10
an O 0 1.1481159134518748e-08
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
neurodegenerative I-Disease 1 1.0
disorder I-Disease 1 1.0
defined O 0 1.8116468254447682e-06
by O 0 4.302126654920357e-09
young O 0 2.7947146463702666e-07
- O 0 2.6022664314950816e-05
onset O 1 1.0
non O 1 1.0
- O 1 0.9997228980064392
immune O 0 0.002210490172728896
insulin B-Disease 1 0.9999905824661255
- I-Disease 1 0.9999921321868896
dependent I-Disease 1 1.0
diabetes I-Disease 1 1.0
mellitus I-Disease 1 1.0
and O 0 0.14309881627559662
progressive O 1 1.0
optic B-Disease 1 1.0
atrophy I-Disease 1 0.9999957084655762
. O 0 2.715999016800197e-07

Linkage O 0 0.0006029288051649928
to O 0 1.286140900447208e-07
markers O 0 1.0017561180575285e-06
on O 0 1.8010817370850418e-07
chromosome O 0 1.3202876516515971e-06
4p O 0 0.015930097550153732
was O 0 7.564086899947142e-06
confirmed O 0 5.149878035126676e-08
in O 0 1.4992203034580598e-08
five O 0 3.072857523989114e-08
families O 0 1.5366770966807053e-08
. O 0 3.7280283748941656e-08

On O 0 3.418697076540411e-07
the O 0 5.985011153342157e-09
basis O 0 6.783564998613656e-08
of O 0 3.633606482367213e-08
meiotic O 0 3.0260333005571738e-05
recombinants O 0 0.00027999948360957205
and O 0 2.286927625050339e-08
disease O 0 2.3062217223923653e-05
- O 0 1.297641887276768e-07
associated O 0 1.4590603996111895e-06
haplotypes O 0 6.394097454176517e-06
, O 0 3.976737605881908e-09
the O 0 1.9905210990600608e-07
WFS B-Disease 1 0.8499066233634949
gene O 0 5.012679693550126e-08
was O 0 1.453576885523944e-07
localized O 0 4.947226273088745e-08
to O 0 1.2024580442471233e-08
a O 0 4.7595165142411133e-07
BAC O 0 0.002916462253779173
/ O 0 1.1748711585823912e-05
P1 O 0 5.7305453083245084e-05
contig O 0 8.010832743821084e-07
of O 0 1.228609125547564e-08
less O 0 1.2999333831587023e-09
than O 0 5.391268542709327e-10
250 O 0 3.6228659183734635e-08
kb O 0 6.908813702466432e-06
. O 0 7.519800249156106e-08

Mutations O 0 3.315783771995484e-07
in O 0 7.398075485554045e-09
a O 0 3.112651469905359e-08
novel O 0 7.454808326201601e-08
gene O 0 2.511564289875423e-08
( O 0 1.3628961959000208e-08
WFS1 O 0 1.1284953870926984e-05
) O 0 6.968511545579759e-09
encoding O 0 1.752257894338527e-08
a O 0 1.2707144492196676e-07
putative O 0 2.4502985525032273e-06
transmembrane O 0 1.9067092580371536e-06
protein O 0 1.5044077983361603e-08
were O 0 1.1577868663792401e-09
found O 0 3.648408797296554e-10
in O 0 1.89432622366148e-10
all O 0 1.923229214773059e-10
affected O 0 3.3493161022413176e-10
individuals O 0 1.1804954236360743e-10
in O 0 2.853839387029211e-09
six O 0 9.547326271786005e-07
WFS B-Disease 1 0.9999984502792358
families O 0 4.850425394664626e-09
, O 0 6.411035591291636e-11
and O 0 3.012694260728921e-11
these O 0 4.091207927992002e-11
mutations O 0 4.675937415044018e-10
were O 0 2.5516984081264127e-09
associated O 0 1.9803403361606797e-09
with O 0 3.72416569804912e-10
the O 0 2.371403070355882e-06
disease O 0 0.007316497154533863
phenotype O 0 1.0026124073192477e-06
. O 0 3.621505229034483e-08

WFS1 O 0 0.0011913320049643517
appears O 0 1.758732679491004e-07
to O 0 8.774475590556108e-10
function O 0 8.169437570870741e-09
in O 0 1.4243248802614517e-09
survival O 0 1.9393564798519947e-06
of O 0 3.9782958083378617e-07
islet O 0 5.951602588538663e-07
beta O 0 1.0449587080074707e-06
- O 0 6.450441958349984e-08
cells O 0 2.128452303296058e-09
and O 0 2.889367634040241e-10
neurons O 0 1.0501982217192563e-07
. O 0 1.9576569254553533e-09
. O 0 2.3570123630634043e-08

Stable O 0 0.0004515053587965667
interaction O 0 6.148273996586795e-07
between O 0 1.4317123486762284e-08
the O 0 3.495343348092206e-09
products O 0 3.34690192227427e-10
of O 0 1.0895051083537055e-08
the O 0 1.0266529848479422e-08
BRCA1 O 0 1.4901145206636102e-08
and O 0 8.738233470140244e-10
BRCA2 O 0 7.771493670816199e-08
tumor B-Disease 0 1.639451880919296e-07
suppressor O 0 9.503833808821582e-08
genes O 0 3.98495125786269e-10
in O 0 3.7174024969388597e-10
mitotic O 0 5.219415655233206e-08
and O 0 2.4618014293764645e-09
meiotic O 0 1.668282857281156e-05
cells O 0 4.1033226807485335e-06
. O 0 2.1047844711574726e-07

BRCA1 O 0 1.4139299310045317e-05
and O 0 1.3667594167543484e-08
BRCA2 O 0 6.395973173312086e-08
account O 0 2.031851353834213e-09
for O 0 3.407896881357786e-11
most O 0 7.72567773643651e-12
cases O 0 7.984189004384135e-11
of O 0 1.056085352502123e-08
familial O 0 1.3683390534424689e-05
, O 0 1.1841222447017685e-09
early O 0 2.9683408797609445e-07
onset O 1 0.9963364601135254
breast B-Disease 1 0.9935327768325806
and I-Disease 1 0.8999082446098328
/ I-Disease 1 1.0
or I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 1.2723761528832256e-06
encode O 0 8.058675504685198e-09
products O 0 9.617370788639334e-11
that O 0 1.182065296340129e-11
each O 0 4.5600086207020496e-11
interact O 0 3.9884645586241163e-10
with O 0 3.6718728058104944e-10
hRAD51 O 0 1.3914565215600305e-06
. O 0 5.7530535002570105e-08

Results O 0 6.746403187207761e-07
presented O 0 2.3247814340265904e-07
here O 0 1.0684489382128959e-07
show O 0 5.0753186542351614e-08
that O 0 1.0679406248215173e-09
BRCA1 O 0 1.9806018158874394e-08
and O 0 7.84677878229445e-10
BRCA2 O 0 4.512721929472718e-08
coexist O 0 2.923351338779412e-08
in O 0 2.3606780974461117e-09
a O 0 9.99378091393055e-09
biochemical O 0 1.8747729768620047e-07
complex O 0 2.5606132112443447e-06
and O 0 3.5840186374258565e-09
colocalize O 0 6.474375823017908e-06
in O 0 6.897898430224814e-08
subnuclear O 0 2.290283373440616e-05
foci O 0 2.014273195527494e-05
in O 0 1.0152379381622723e-08
somatic O 0 7.062016038617003e-08
cells O 0 2.6205639880316767e-09
and O 0 6.942634661610825e-11
on O 0 1.4111908308578336e-09
the O 0 9.87591453061043e-10
axial O 0 3.6882992215936383e-09
elements O 0 4.175876533452083e-09
of O 0 1.7797093576632506e-08
developing O 0 6.872251390177553e-08
synaptonemal O 0 0.00010097440826939419
complexes O 0 2.370982429056312e-06
. O 0 7.401607859947035e-08

Like O 0 1.1559664926608093e-05
BRCA1 O 0 6.213831511558965e-06
and O 0 3.418308835989592e-07
RAD51 O 0 0.0022880733013153076
, O 0 4.960653043895036e-08
BRCA2 O 0 3.21546053783095e-07
relocates O 0 5.20193395914248e-07
to O 0 1.0621253210274517e-08
PCNA O 0 1.4023408766661305e-05
+ O 0 3.633752498899412e-07
replication O 0 1.009451100486558e-08
sites O 0 4.5805487181027615e-10
following O 0 3.6474348541482016e-10
exposure O 0 4.962820199239104e-08
of O 0 1.1980688441326492e-07
S O 0 4.520549737208057e-06
phase O 0 9.576534694133443e-07
cells O 0 6.860111767537092e-08
to O 0 1.2516303549148233e-08
hydroxyurea O 0 2.8500846838142024e-06
or O 0 9.291985492154708e-08
UV O 0 2.721593773458153e-05
irradiation O 0 3.6965559502277756e-06
. O 0 4.373170980898067e-08

Thus O 0 1.943514917002176e-06
, O 0 1.2159363294017567e-08
BRCA1 O 0 3.73677053744359e-08
and O 0 3.057240904880132e-09
BRCA2 O 0 1.7707703747760206e-08
participate O 0 4.099398154266964e-09
, O 0 4.5308459761805864e-10
together O 0 1.2657436210261608e-09
, O 0 3.3753791428559055e-10
in O 0 2.6423669918784753e-09
a O 0 2.7750100883849882e-08
pathway O 0 1.5978182332787583e-08
( O 0 1.4078007648521407e-09
s O 0 9.814439039246281e-09
) O 0 9.36706615051186e-11
associated O 0 3.198586118191571e-10
with O 0 5.411262063437228e-11
the O 0 4.067553049935668e-08
activation O 0 1.1109051456514862e-07
of O 0 3.198894944489439e-07
double O 0 4.8209592762304965e-08
- O 0 1.1022053314491131e-07
strand O 0 2.054874812529306e-07
break O 0 4.926801580040774e-07
repair O 0 4.896518476016354e-06
and O 0 2.9437856596814527e-08
/ O 0 2.99772705147916e-06
or O 0 1.4391845581940288e-07
homologous O 0 8.936038966567139e-07
recombination O 0 7.348560302489204e-07
. O 0 8.978658883052049e-08

Dysfunction O 1 0.9999997615814209
of O 0 1.4403243767446838e-05
this O 0 3.503903087676008e-07
pathway O 0 5.889904514333466e-06
may O 0 1.2453318376515199e-08
be O 0 1.2005003657833413e-09
a O 0 3.941623472059064e-09
general O 0 2.444535684986704e-09
phenomenon O 0 7.624610987022606e-08
in O 0 2.798164477901821e-10
the O 0 4.139238674039092e-10
majority O 0 1.261712175709695e-11
of O 0 4.4230788476262717e-10
cases O 0 3.8168690430495644e-10
of O 0 2.3517451097632147e-08
hereditary B-Disease 1 0.9999991655349731
breast I-Disease 1 0.9999996423721313
and I-Disease 1 0.9997501969337463
/ I-Disease 1 1.0
or I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 2.6638856525096344e-06
. O 0 7.236426569079413e-08

A O 0 6.442551239160821e-06
novel O 0 9.64176251727622e-07
Arg362Ser O 0 9.959577255358454e-06
mutation O 0 3.2943046068822923e-09
in O 0 2.8910449589858445e-09
the O 0 9.336039497043203e-09
sterol O 0 2.2955001099944639e-07
27 O 0 8.390589982809615e-07
- O 0 5.822656135023863e-07
hydroxylase O 0 1.0178399861615617e-05
gene O 0 5.236866584823474e-08
( O 0 6.39272679237024e-09
CYP27 O 0 2.710851731535513e-06
) O 0 7.79464437439259e-10
: O 0 3.428145961548168e-11
its O 0 4.017038784942528e-11
effects O 0 2.789586339702055e-09
on O 0 5.781144452043918e-09
pre O 0 8.406050255871378e-08
- O 0 1.162474116966905e-08
mRNA O 0 3.234115197869869e-08
splicing O 0 1.6835750571431163e-08
and O 0 3.6993305640997676e-10
enzyme O 0 9.922593413591585e-09
activity O 0 1.640611060338415e-07
. O 0 1.6839475591723385e-08

A O 0 5.668686753779184e-06
novel O 0 1.3461968819683534e-06
C O 0 3.5277498682262376e-06
to O 0 7.37350713819751e-09
A O 0 6.105455696570061e-08
mutation O 0 6.595360368955028e-10
in O 0 8.456150224489534e-10
the O 0 6.1589635613756855e-09
sterol O 0 9.440761061796366e-08
27 O 0 5.099539066577563e-07
- O 0 5.528194719772728e-07
hydroxylase O 0 9.624596714274958e-06
gene O 0 2.8844040045328256e-08
( O 0 7.522494627210108e-09
CYP27 O 0 1.9326080291648395e-06
) O 0 5.101012390262838e-10
was O 0 2.727721826190077e-09
identified O 0 4.697444655477057e-10
by O 0 2.0506825404442708e-10
sequencing O 0 1.7686776487835232e-08
amplified O 0 3.460559128143359e-07
CYP27 O 0 1.099538440030301e-05
gene O 0 6.521249762414527e-09
products O 0 4.5872633469556945e-10
from O 0 4.436304212873665e-09
a O 0 3.219319921754504e-08
patient O 0 9.06379682419356e-08
with O 0 4.033580580653506e-09
cerebrotendinous B-Disease 1 1.0
xanthomatosis I-Disease 1 1.0
( O 0 2.2828126020613126e-05
CTX B-Disease 0 0.0023840046487748623
) O 0 1.2331261345366329e-08
. O 0 9.441659010178682e-09

The O 0 3.66625016567923e-07
mutation O 0 3.51141586918402e-08
changed O 0 4.063714342805724e-08
the O 0 3.3122375953098526e-08
adrenodoxin O 0 5.048925231676549e-06
cofactor O 0 1.1179380408066208e-06
binding O 0 1.406220917488099e-08
residue O 0 6.456756977968325e-07
362Arg O 0 2.713065612169885e-07
to O 0 2.499249696086281e-08
362Ser O 0 1.6436990790680284e-06
( O 0 2.0780068155090703e-07
CGT O 0 1.0958514394587837e-05
362Arg O 0 8.717073001207609e-07
to O 0 1.2823564077280025e-07
AGT O 0 3.022301461896859e-05
362Ser O 0 1.5273826647899114e-07
) O 0 5.779499101521424e-10
, O 0 5.320240081818639e-11
and O 0 1.070750640930207e-10
was O 0 1.2231919299665606e-07
responsible O 0 1.234394915172743e-07
for O 0 8.981159282939188e-08
deficiency O 1 0.9999940395355225
in O 0 7.203704626590479e-06
the O 0 4.971374437445775e-06
sterol O 0 4.32487104262691e-06
27 O 0 5.087898443889571e-06
- O 0 1.1181919035152532e-06
hydroxylase O 0 4.0811635699355975e-05
activity O 0 2.182646312576253e-06
, O 0 7.737715329581007e-11
as O 0 4.749298176953687e-11
confirmed O 0 1.5965796740236016e-10
by O 0 1.0105154213402301e-10
expression O 0 1.012783190645905e-09
of O 0 2.3273749594210358e-09
mutant O 0 2.1821890072715178e-08
cDNA O 0 5.227735044854853e-08
into O 0 6.001140029354701e-09
COS O 0 2.058445716102142e-06
- O 0 8.945223584078121e-08
1 O 0 1.4296008998826437e-07
cells O 0 2.4048301128232197e-08
. O 0 5.673686409579659e-09

Quantitative O 0 2.201714778493624e-06
analysis O 0 6.633353422103028e-08
showed O 0 2.962218914603909e-09
that O 0 1.1780656311577431e-11
the O 0 3.415824845198756e-10
expression O 0 2.1890202983598783e-09
of O 0 9.188247496183521e-09
CYP27 O 0 2.6653851818991825e-06
gene O 0 1.7987785705386727e-09
mRNA O 0 3.0765623382222884e-09
in O 0 3.653910507495084e-10
the O 0 5.710804051872742e-10
patient O 0 2.2623227735607543e-09
represented O 0 1.1707800284810332e-09
52 O 0 3.008478870469844e-07
. O 0 6.818706310696143e-08

5 O 0 1.3693136224901536e-06
% O 0 1.24559784708822e-08
of O 0 1.1882223205361697e-08
the O 0 1.90191649096505e-08
normal O 0 1.358044642074674e-06
level O 0 8.386178706132341e-06
. O 0 1.4444688645198767e-07

As O 0 4.0779156051939935e-08
the O 0 4.5351455923992035e-09
mutation O 0 2.0328863037377687e-09
occurred O 0 5.222064203280752e-08
at O 0 9.902343833800842e-09
the O 0 4.886528515157806e-09
penultimate O 0 2.3305706520204694e-07
nucleotide O 0 8.986042843162068e-08
of O 0 8.389680061782201e-08
exon O 0 2.4741027004893112e-08
6 O 0 9.135843015428691e-08
( O 0 2.6575603939704706e-09
- O 0 1.6243296707685317e-09
2 O 0 1.9976138077026917e-08
position O 0 3.574844598119853e-08
of O 0 1.8395726897324494e-07
exon O 0 1.629906591915642e-07
6 O 0 2.4687606128281914e-06
- O 0 9.271464023186127e-07
intron O 0 5.439361757453298e-06
6 O 0 2.379826355536352e-06
splice O 0 1.0244200439046836e-06
site O 0 3.787884850225964e-08
) O 0 2.6220725590775373e-10
of O 0 1.0847127640545295e-09
the O 0 5.767773370024543e-09
gene O 0 5.737019304064006e-09
, O 0 1.194138010696122e-09
we O 0 6.868356550171484e-09
hypothesized O 0 5.230617361462464e-08
that O 0 9.651440063818129e-11
the O 0 6.302887656239875e-10
mutation O 0 1.4430666384068758e-10
may O 0 2.4105495377568786e-10
partially O 0 1.2756667722158e-08
affect O 0 8.238911775038105e-10
the O 0 1.636142332728241e-09
normal O 0 2.1747554868056795e-08
splicing O 0 1.8850030425454634e-09
efficiency O 0 2.1480814904606405e-09
in O 0 7.099920651398861e-10
exon O 0 8.363872261440974e-09
6 O 0 5.243500300622372e-09
and O 0 9.169803111275243e-11
cause O 0 3.1088760454878184e-09
alternative O 0 1.7328007917427612e-09
splicing O 0 4.463540648202979e-09
elsewhere O 0 1.242645319976532e-09
, O 0 2.1920555648424767e-11
which O 0 4.986369823989367e-12
resulted O 0 2.9305166626691914e-10
in O 0 9.846421455961263e-10
decreased O 0 7.993265285222151e-07
transcript O 0 1.7001104879454942e-07
in O 0 2.327264159163178e-09
the O 0 2.4422629252285333e-08
patient O 0 4.3562300788835273e-07
. O 0 2.555011313631894e-08

Transfection O 0 0.003119342727586627
of O 0 2.379774059591e-06
constructed O 0 1.0865958756767213e-05
minigenes O 0 2.2509608243126422e-05
, O 0 3.4048335262326646e-09
with O 0 4.814503795635972e-10
or O 0 2.1847043285561085e-08
without O 0 7.442942262514407e-09
the O 0 2.6517492202060566e-08
mutation O 0 1.215455736058857e-09
, O 0 4.1759462554580296e-10
into O 0 1.426000117987769e-08
COS O 0 0.0002726735547184944
- O 0 9.293134439758433e-07
1 O 0 8.729693945497274e-07
cells O 0 3.4055023245826987e-09
confirmed O 0 6.012663145149588e-10
that O 0 1.665739768341723e-11
the O 0 1.5157782806696218e-09
mutant O 0 7.857614292561266e-08
minigene O 0 3.923863403088035e-07
was O 0 2.800666365487814e-08
responsible O 0 2.846147317825398e-09
for O 0 3.6423736249346916e-10
a O 0 5.805421032789582e-09
mRNA O 0 1.6784513334755502e-08
species O 0 3.9107366650581454e-11
alternatively O 0 2.7936544189088863e-09
spliced O 0 4.09098781517514e-08
at O 0 9.849548376905659e-08
an O 0 1.383207948180143e-08
activated O 0 8.36398612591438e-07
cryptic O 0 5.332390173862223e-06
5 O 0 2.4156533982022665e-06
splice O 0 1.013691053231014e-05
site O 0 1.169751385532436e-06
88 O 0 1.015513021229708e-06
bp O 0 1.830561473070702e-06
upstream O 0 7.806530106790888e-07
from O 0 1.3276832966369057e-08
the O 0 3.9116827110774466e-08
3 O 0 3.0899315106580616e-07
end O 0 1.890109615487745e-07
of O 0 1.0012719258156721e-06
exon O 0 1.5938574051688192e-06
6 O 0 2.2399876797862817e-06
. O 0 1.1439358615916717e-07

Our O 0 2.4481262244080426e-06
data O 0 2.3021341633011616e-07
suggest O 0 9.28436350022821e-09
that O 0 1.5939081998705973e-10
the O 0 2.498414364282553e-09
C O 0 1.1261181498412043e-07
to O 0 1.6962447002555336e-09
A O 0 2.718934410950169e-08
mutation O 0 5.19315479508009e-10
at O 0 2.3136323967776207e-09
the O 0 9.664745670434627e-10
penultimate O 0 1.490312655505477e-07
nucleotide O 0 1.1657495946337804e-07
of O 0 1.9384335914196527e-08
exon O 0 1.7260790130535497e-08
6 O 0 2.987817637745138e-08
of O 0 7.311076632987579e-09
the O 0 2.245545083212619e-08
CYP27 O 0 0.0001611811458133161
gene O 0 4.73522865362952e-09
not O 0 3.5247454954756563e-10
only O 0 6.139841413066449e-10
causes O 0 3.845105123190251e-09
the O 0 9.841507164765062e-09
deficiency B-Disease 0 3.1523431971436366e-05
in I-Disease 0 4.1181458243499947e-08
the I-Disease 0 1.484008578245266e-07
sterol I-Disease 0 4.7637988132009923e-07
27 I-Disease 0 1.2387977221806068e-06
- I-Disease 0 5.24570396009949e-07
hydroxylase I-Disease 0 1.5798221284057945e-05
activity I-Disease 0 2.546391669966397e-06
, O 0 1.1900355700866783e-10
but O 0 6.582111938824298e-11
also O 0 7.610810592861839e-11
partially O 0 1.232761626113188e-08
leads O 0 2.4472682214060626e-10
to O 0 6.363972543388385e-11
alternative O 0 3.6968972327855454e-10
pre O 0 2.4834875489432306e-08
- O 0 7.110101840623884e-09
mRNA O 0 1.922145820287824e-08
splicing O 0 7.73345831817096e-09
of O 0 4.905298389701329e-09
the O 0 7.942307256314507e-09
gene O 0 1.5666865138541652e-08
. O 0 2.6150978271743952e-08

To O 0 5.228702093518223e-07
our O 0 1.5231395877890463e-07
knowledge O 0 1.6452329418825684e-06
, O 0 9.84189618691289e-10
this O 0 3.3895206086320684e-10
is O 0 2.322823738909463e-10
the O 0 1.0837753611214751e-10
first O 0 2.958891187621049e-10
report O 0 4.409727860643642e-10
regarding O 0 6.919239625702289e-10
effects O 0 5.296432181722821e-09
on O 0 5.275631931311864e-09
pre O 0 7.077793640064556e-08
- O 0 1.0210424505885385e-08
mRNA O 0 2.8657812123356052e-08
splicing O 0 6.5416676520158035e-09
of O 0 3.4657552383521306e-09
a O 0 1.5104708595004013e-09
mutation O 0 2.1863780230724217e-10
at O 0 8.8369764839058e-09
the O 0 6.3320144683132185e-09
- O 0 1.9045119259430976e-08
2 O 0 2.8425691311895207e-07
position O 0 7.531168932928267e-08
of O 0 1.1327379922931868e-07
a O 0 2.53288163776233e-07
5 O 0 6.922835495970503e-07
splice O 0 4.167566657997668e-06
site O 0 6.977184625611699e-07
. O 0 2.6966745281242765e-08

ATM O 0 0.0005282986094243824
germline O 0 0.0001219853074871935
mutations O 0 1.0152712803801478e-07
in O 0 4.001498155048466e-08
classical O 1 0.9999982118606567
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
patients O 0 0.34773173928260803
in O 0 2.250766462097431e-09
the O 0 6.557182352651125e-09
Dutch O 0 4.198018359602429e-06
population O 0 1.5041946577198928e-09
. O 0 4.577791035131895e-09

Germline O 0 0.0010055912425741553
mutations O 0 4.699958822129702e-08
in O 0 3.282813354488212e-09
the O 0 6.6976166834820106e-09
ATM O 0 4.980012136002188e-07
gene O 0 1.6286347270799695e-10
are O 0 8.144424371026027e-12
responsible O 0 1.3157577805067433e-10
for O 0 8.914761706613206e-10
the O 1 0.8999255895614624
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 0.9999998807907104
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 1.5163579973886954e-06
. O 0 1.0751295320687859e-07

In O 0 3.9273226093428093e-07
our O 0 3.636768042269978e-08
study O 0 5.997295549065029e-09
, O 0 1.604339439076341e-10
we O 0 2.1312340781065586e-10
have O 0 2.958257944163378e-11
determined O 0 9.864354888478033e-10
the O 0 3.2154459095323773e-09
ATM O 0 2.2823329004495463e-07
mutation O 0 5.650655637845503e-11
spectrum O 0 9.491519376014779e-11
in O 0 6.812706510039845e-10
19 O 0 8.55126884857782e-08
classical O 0 7.384054333670065e-05
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 3.671489334777789e-09
, O 0 5.399619553564383e-12
including O 0 2.74286821554115e-12
some O 0 4.548687815297825e-12
immigrant O 0 1.0313033066422506e-10
populations O 0 1.2752828307260877e-11
, O 0 6.04833674464067e-12
as O 0 4.813087428612306e-11
well O 0 1.0608892236918521e-10
as O 0 1.8522380851315745e-10
12 O 0 1.2782330749416815e-09
of O 0 1.0379125336967832e-09
Dutch O 0 4.159947764037497e-08
ethnic O 0 2.8546287555997196e-09
origin O 0 2.6961037846717772e-08
. O 0 3.127636460931171e-08

Both O 0 1.8492610820430855e-07
the O 0 4.4529475218269e-08
protein O 0 2.7251905621028527e-08
truncation O 0 2.2457832926647825e-07
test O 0 3.393864744793973e-08
( O 0 5.617941312152652e-08
PTT O 0 1.400101427861955e-05
) O 0 2.792736875090185e-10
and O 0 3.995878974927258e-11
the O 0 9.603223771748048e-10
restriction O 0 8.507664794876746e-09
endonuclease O 0 1.7644362060309504e-07
fingerprinting O 0 7.991647343885688e-09
( O 0 3.5214209326284163e-09
REF O 0 2.3638766322164884e-07
) O 0 5.14690408348617e-11
method O 0 4.969445965841146e-10
were O 0 8.10142286589155e-10
used O 0 2.653876562952462e-10
and O 0 1.2073173016879934e-10
compared O 0 1.6019614523798964e-09
for O 0 1.3565874812382361e-10
their O 0 3.3962571643897377e-10
detection O 0 2.8580173783154805e-09
efficiency O 0 9.413063661867227e-10
, O 0 2.473122401314143e-11
identifying O 0 7.273380231431759e-10
76 O 0 1.1872505645271758e-08
% O 0 1.2805702331863955e-10
and O 0 2.0274011636178813e-11
60 O 0 1.7507403304861668e-09
% O 0 1.1256290344263675e-10
of O 0 1.0799455774090916e-10
the O 0 3.509296464532241e-10
mutations O 0 2.166150731008898e-10
, O 0 1.2305591268191307e-10
respectively O 0 3.0694597086267095e-08
. O 0 2.3452185970995743e-08

Most O 0 4.898798238173185e-07
patients O 0 2.6095820615523735e-08
were O 0 9.179314197638178e-09
found O 0 5.485590648390826e-09
to O 0 2.3673691895709226e-09
be O 0 4.422046018248693e-08
compound O 0 1.1264525710430462e-05
heterozygote O 0 2.7740243240259588e-05
. O 0 1.9238957804645906e-07

Seventeen O 0 4.520067250268767e-06
mutations O 0 2.795094999896719e-08
were O 0 8.910294724273626e-09
distinct O 0 1.177271613528319e-09
, O 0 3.889211452889896e-10
of O 0 3.2716197750914944e-08
which O 0 6.632815963136807e-10
10 O 0 1.8840045967749575e-08
were O 0 1.6665843816099368e-08
not O 0 4.322013413826653e-09
reported O 0 6.065283741918392e-08
previously O 0 2.6433974653627956e-07
. O 0 1.1091097462667676e-07

Mutations O 0 5.445096576295327e-06
are O 0 2.367337881281628e-09
small O 0 7.3344015305565335e-09
deletions O 0 1.8344728403008048e-07
or O 0 1.8418619163185213e-07
point O 0 1.942988546943525e-06
mutations O 0 5.064681829480833e-08
frequently O 0 5.012804038528884e-08
affecting O 0 1.8720322714216309e-07
splice O 0 5.549934485316044e-06
sites O 0 5.290831381898897e-07
. O 0 1.398561977339341e-07

Moreover O 0 3.5042630770476535e-05
, O 0 2.925169617640222e-08
a O 0 1.3687112243587762e-07
16 O 0 1.0235772833766532e-06
. O 0 1.0873154110413452e-07

7 O 0 2.3491380488849245e-05
- O 0 1.0009806601374294e-06
kb O 0 2.2615771740674973e-05
genomic O 0 2.3452638231447054e-07
deletion O 0 5.2395339622535175e-08
of O 0 2.7259028811954522e-08
the O 0 1.1625716389573881e-08
3 O 0 1.0345338097295098e-07
end O 0 1.971883456519663e-08
of O 0 1.4746150966971072e-08
the O 0 1.3545435884054768e-08
gene O 0 1.0291540952778178e-09
, O 0 1.6731566132577314e-10
most O 0 7.805039253794277e-11
likely O 0 4.0128519951387887e-10
a O 0 1.636370150492894e-09
result O 0 1.957836115451528e-09
of O 0 7.663286893944132e-09
recombination O 0 1.0909310121931526e-09
between O 0 2.725740300135726e-09
two O 0 2.1823793883157805e-09
LINE O 0 7.117431266578933e-08
elements O 0 4.138121667551786e-08
, O 0 3.188938668685637e-09
was O 0 2.675620578429516e-07
identified O 0 1.5937828834466927e-07
. O 0 8.889742275641765e-08

The O 0 5.135728429195296e-07
most O 0 2.7737176999664825e-09
frequently O 0 2.3348314392990233e-09
found O 0 7.558763615023167e-10
mutation O 0 3.459492414759069e-10
, O 0 9.898727670876184e-11
identified O 0 3.304505780121758e-09
in O 0 4.639568285114137e-09
three O 0 1.506932001404948e-08
unrelated O 0 1.1077330555053777e-06
Turkish O 0 0.00017787211982067674
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
individuals O 0 1.2673416449615615e-07
, O 0 1.2088872125559647e-09
was O 0 1.0520165716343399e-07
previously O 0 1.6614615461207904e-08
described O 0 4.593052604917602e-09
to O 0 7.88082599179063e-10
be O 0 1.819988826312624e-09
a O 0 2.5193465091888356e-08
Turkish O 0 3.184897195751546e-06
A B-Disease 1 1.0
- I-Disease 1 0.9999997615814209
T I-Disease 1 1.0
founder O 0 0.00040990140405483544
mutation O 0 2.3951011485223717e-07
. O 0 2.6121169227621976e-08

The O 0 8.12355551715882e-07
presence O 0 1.1381077769101466e-07
of O 0 7.385783646896016e-07
a O 0 9.834699454813745e-08
founder O 0 2.86188168274748e-07
mutation O 0 1.8678873725530565e-10
among O 0 3.185681319434197e-12
relatively O 0 3.194639691672663e-11
small O 0 1.1642475178375022e-11
ethnic O 0 3.548427177091362e-11
population O 0 5.013013875537764e-12
groups O 0 2.433956898875711e-12
in O 0 1.1528149962414247e-10
Western O 0 8.188969502498367e-09
Europe O 0 5.439217076741443e-09
could O 0 6.05799521657957e-10
indicate O 0 3.0770317405171e-09
a O 0 3.0383873195205524e-10
high O 0 1.8440177163014937e-10
carrier O 0 7.257634077051378e-11
frequency O 0 4.7444476125591e-10
in O 0 7.575992611030813e-11
such O 0 3.378489987770905e-10
communities O 0 5.718698403711642e-09
. O 0 3.199340170567666e-08

In O 0 1.1184398829300335e-07
patients O 0 5.81164671942247e-09
of O 0 5.825175009022132e-09
Dutch O 0 9.06503828446148e-07
ethnic O 0 1.0084099777429856e-08
origin O 0 1.7663076334883954e-08
, O 0 4.087544192010739e-10
however O 0 1.0966160202130482e-09
, O 0 2.92310869953738e-10
no O 0 9.300417103119685e-10
significant O 0 2.918976171883969e-09
founder O 0 9.233753672788225e-08
effect O 0 6.794841134194485e-09
could O 0 1.543950634008695e-09
be O 0 4.615085646975103e-09
identified O 0 1.0520065529817657e-07
. O 0 4.5070787990653116e-08

The O 0 9.950456814067365e-08
observed O 0 9.346376828034408e-08
genetic O 0 9.795553523872513e-08
heterogeneity O 0 2.6951173026645847e-07
including O 0 1.0216341106428217e-09
the O 0 8.062181144907754e-09
relative O 0 1.0718980547608226e-06
high O 0 4.4824230371887097e-07
percentage O 0 3.8761743326176656e-07
of O 0 1.8274621993441542e-07
splice O 0 3.3342944334435742e-06
- O 0 4.391710888285161e-07
site O 0 8.729279699082326e-08
mutations O 0 8.473042711898415e-09
had O 0 1.4800053627084253e-08
no O 0 8.828872744004457e-09
reflection O 0 6.25426110900662e-08
on O 0 3.5423934008349534e-08
the O 0 4.16323366891902e-08
phenotype O 0 3.810610564869421e-07
. O 0 4.50800747842095e-08

All O 0 2.335264426278627e-08
patients O 0 3.741133625112525e-09
manifested O 0 4.526557617623439e-08
classical O 0 0.0001604472636245191
A B-Disease 1 1.0
- I-Disease 0 0.11436881870031357
T I-Disease 1 0.9999892711639404
and O 0 4.4679931976432385e-10
increased O 0 1.9822685715098487e-08
cellular O 0 6.179840283948579e-08
radioresistant O 0 9.33425951643585e-07
DNA O 0 1.8906089849224372e-07
synthesis O 0 1.9242757787196751e-07
. O 0 5.644435141505255e-09

Determination O 0 2.812185812217649e-06
of O 0 1.3537525944684603e-07
the O 0 2.3031546447782603e-08
genomic O 0 6.204737701409613e-08
structure O 0 3.555328831339466e-08
of O 0 3.5964969669066704e-08
the O 0 2.737908211258855e-08
COL4A4 O 0 1.502254144725157e-05
gene O 0 3.790215363785876e-10
and O 0 9.354348892709474e-12
of O 0 1.1842802294381727e-09
novel O 0 3.8966820170571737e-07
mutations O 0 9.356913324154448e-06
causing O 0 0.0002760486677289009
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 1.201235136250034e-05

Autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
is O 0 5.525480446522124e-07
a O 0 6.5926396928261966e-06
progressive O 1 0.9999974966049194
hematuric B-Disease 1 1.0
glomerulonephritis I-Disease 1 1.0
characterized O 0 0.0013665765291079879
by O 0 7.647067263860663e-07
glomerular B-Disease 1 1.0
basement I-Disease 1 1.0
membrane I-Disease 1 0.9267829656600952
abnormalities I-Disease 1 0.9999992847442627
and O 0 2.5510851209276098e-09
associated O 0 2.895445447848033e-07
with O 0 8.321593192306409e-09
mutations O 0 1.3012927979616506e-07
in O 0 2.9707368298659276e-07
either O 0 6.062179522814404e-07
the O 0 5.50824688616558e-06
COL4A3 O 1 0.9931021928787231
or O 0 7.142344315980154e-07
the O 0 2.3104854562916444e-07
COL4A4 O 0 0.0002720863849390298
gene O 0 1.3571400891976282e-08
, O 0 3.0368921266621385e-10
which O 0 1.0200098404800073e-10
encode O 0 2.7369253530196147e-09
the O 0 1.5096103922473958e-08
alpha3 O 0 3.329709215904586e-06
and O 0 1.8437065207876913e-08
alpha4 O 0 0.0001809885579859838
type O 0 0.00033596871071495116
IV O 1 0.9999916553497314
collagen O 0 0.11221656203269958
chains O 0 5.985772077110596e-05
, O 0 9.81983117043228e-09
respectively O 0 4.869472718382895e-07
. O 0 1.847508883656701e-07

To O 0 2.7621201326155642e-08
date O 0 8.610056312363668e-08
, O 0 4.363110150951144e-10
mutation O 0 1.100330174197417e-10
screening O 0 3.265314130196373e-10
in O 0 3.593730035778009e-10
the O 0 1.2420340311791733e-09
two O 0 8.938666473667922e-10
genes O 0 2.3061601517326835e-09
has O 0 5.364261812523807e-10
been O 0 3.4971507911762956e-09
hampered O 0 1.0139746819959328e-07
by O 0 4.690855481825906e-10
the O 0 6.495020077323943e-09
lack O 0 1.0688994223073678e-07
of O 0 1.6727689455819927e-08
genomic O 0 3.861702779772713e-08
structure O 0 9.217019680818339e-08
information O 0 1.9542579821063555e-07
. O 0 9.0789363582644e-08

We O 0 1.2269158560229698e-06
report O 0 2.3597434051225719e-07
here O 0 1.957669226726466e-08
the O 0 5.5096558426726006e-09
complete O 0 9.783006760244461e-08
characterization O 0 1.5395323771372205e-07
of O 0 4.640535777866717e-08
the O 0 3.150928407080755e-08
48 O 0 2.828156766554457e-07
exons O 0 5.0543754070986324e-08
of O 0 2.3224538736599243e-08
the O 0 7.65880443509559e-08
COL4A4 O 0 0.00011035452916985378
gene O 0 5.725847351811808e-09
, O 0 1.6622399290344703e-10
a O 0 1.2543972527367941e-09
comprehensive O 0 5.788879153811877e-09
gene O 0 5.648675971414718e-10
screen O 0 5.417029935728124e-09
, O 0 1.2655064496325252e-10
and O 0 1.1119168780160393e-10
the O 0 9.891391039573705e-10
subsequent O 0 5.7466023051233606e-09
detection O 0 4.688156085563833e-09
of O 0 2.8251931349920767e-10
10 O 0 2.2176759040259952e-10
novel O 0 2.3163555795679969e-10
mutations O 0 3.5147672966528987e-11
in O 0 3.548169744127527e-11
eight O 0 1.8891999076231514e-09
patients O 0 1.1771779107050406e-08
diagnosed O 0 4.039565624225361e-07
with O 0 3.7841225264401146e-08
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 8.580973371863365e-06

Furthermore O 0 2.1756552541774e-06
, O 0 3.1164695268870446e-09
we O 0 4.2922665421940565e-09
identified O 0 8.349256397366389e-09
a O 0 1.2318073672190621e-08
glycine O 0 5.865884844524771e-08
to O 0 6.742914226975927e-09
alanine O 0 4.200202283755061e-07
substitution O 0 5.110717182787994e-08
in O 0 3.13705825760735e-08
the O 0 1.1211674433297958e-07
collagenous O 0 0.0006804758450016379
domain O 0 1.0516349675526726e-06
that O 0 2.278500305097353e-10
is O 0 7.586928862934883e-10
apparently O 0 1.2971947072060175e-08
silent O 0 5.5875169380215084e-08
in O 0 1.158825257974172e-09
the O 0 2.9899707154612543e-09
heterozygous O 0 3.169177587025729e-09
carriers O 0 1.4130971393022662e-10
, O 0 2.9777502685846e-10
in O 0 1.2369988589000513e-08
11 O 0 1.432203362128348e-06
. O 0 3.6288005844653526e-07

5 O 0 4.141857630202139e-07
% O 0 2.902138751537109e-09
of O 0 1.257206894145213e-09
all O 0 3.1950009304893e-10
control O 0 2.7283151293744368e-09
individuals O 0 2.7679766811949946e-10
, O 0 8.660080291766903e-11
and O 0 8.560983172367642e-11
in O 0 9.595277905560806e-10
one O 0 3.485189636887043e-10
control O 0 2.446376989873045e-10
individual O 0 4.0993548833245796e-11
homozygous O 0 2.5238650058767576e-10
for O 0 1.3237978768732006e-10
this O 0 8.699519438160053e-10
glycine O 0 9.865153316468422e-08
substitution O 0 5.906684208412116e-08
. O 0 4.889794524842728e-08

There O 0 1.1587394510570448e-06
has O 0 1.9766421832656533e-09
been O 0 1.7392742801547456e-09
no O 0 8.595969491764777e-10
previous O 0 4.6397898856298525e-09
finding O 0 6.521037931861429e-09
of O 0 1.301976393364157e-08
a O 0 7.402084278851362e-09
glycine O 0 9.782330501195702e-09
substitution O 0 4.9559596426718144e-09
that O 0 1.3629779249679785e-10
is O 0 1.6366158428482436e-10
not O 0 5.35219889241656e-11
associated O 0 4.783446416745107e-10
with O 0 3.3559967305141214e-11
any O 0 1.4330511000082424e-08
obvious O 0 5.6853341590112905e-08
phenotype O 0 1.3600604198416022e-08
in O 0 3.945008320016541e-09
homozygous O 0 2.41808599810156e-08
individuals O 0 2.242825702936102e-09
. O 0 1.621439338350683e-08

Founder O 0 0.05008275806903839
BRCA1 O 0 9.501124623056967e-06
and O 0 1.1762891105604467e-08
BRCA2 O 0 6.841921873501633e-08
mutations O 0 8.466834455767014e-10
in O 0 7.31227189909589e-10
French O 0 1.4343548855322297e-06
Canadian O 1 0.9999730587005615
breast B-Disease 1 1.0
and I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 6.903171743033454e-05
. O 0 4.31946958201479e-08

We O 0 9.932764299946939e-08
have O 0 3.0397726002995284e-10
identified O 0 8.906264059582725e-10
four O 0 2.145419120136438e-10
mutations O 0 5.005296524474012e-11
in O 0 1.9689912200693271e-10
each O 0 1.8916111732547591e-10
of O 0 3.2720191001089916e-08
the O 0 1.6514076150997425e-06
breast B-Disease 1 0.9995809197425842
cancer I-Disease 1 0.9892295002937317
- O 0 8.46198236104101e-05
susceptibility O 0 0.00017652584938332438
genes O 0 6.003683949984406e-08
, O 0 4.862056868226716e-10
BRCA1 O 0 3.727294473065967e-09
and O 0 2.2665846977076853e-10
BRCA2 O 0 4.85195217336809e-09
, O 0 5.4390353332323116e-11
in O 0 4.036403156160162e-10
French O 0 7.179317549343978e-07
Canadian O 0 0.02962532266974449
breast B-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
and O 1 0.9221470952033997
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 9.550886943543446e-07
from O 0 9.337001394271738e-09
Quebec O 0 3.040889566818805e-07
. O 0 4.767848338360636e-08

To O 0 2.1073775258173555e-07
identify O 0 3.191289579262957e-07
founder O 0 4.294236350688152e-05
effects O 0 6.587450479855761e-05
, O 0 2.110648100739354e-09
we O 0 8.726341316211972e-10
examined O 0 8.706113163725604e-09
independently O 0 1.4188321628694212e-08
ascertained O 0 1.547094399256821e-07
French O 0 3.71927129094729e-08
Canadian O 0 3.02933443663278e-07
cancer B-Disease 0 3.621982500590093e-07
families O 0 7.165722876179004e-11
for O 0 8.859222383472698e-12
the O 0 1.1448018921722536e-10
distribution O 0 1.6315510054099036e-10
of O 0 1.0015129836560277e-09
these O 0 2.9706309634391914e-10
eight O 0 1.1999744309321159e-08
mutations O 0 3.814389248901762e-09
. O 0 9.328349648285439e-09

Mutations O 0 2.557669859015732e-06
were O 0 8.192989042754562e-08
found O 0 4.4493027040459765e-09
in O 0 3.1701326008715114e-09
41 O 0 5.4917698832923634e-08
of O 0 1.438531427311318e-07
97 O 0 1.2097505532437935e-05
families O 0 3.556400329784992e-08
. O 0 1.1441181868576678e-07

Six O 0 1.984339633054333e-06
of O 0 2.2563992274626798e-07
eight O 0 3.660289493723212e-08
mutations O 0 4.849796120254268e-09
were O 0 7.209874919311687e-09
observed O 0 7.077695762802705e-09
at O 0 5.984009021631209e-08
least O 0 9.212464568975065e-09
twice O 0 4.4802007437283464e-08
. O 0 3.7296786103979684e-08

The O 0 7.150862984417472e-06
BRCA1 O 0 4.239506324665854e-06
C4446T O 0 3.1413626402354566e-06
mutation O 0 8.126870731928193e-09
was O 0 2.0758786689611952e-08
the O 0 9.347367324608058e-10
most O 0 8.290786807085837e-11
common O 0 4.9944819113800776e-11
mutation O 0 9.171989556744364e-11
found O 0 5.842653028054201e-10
, O 0 8.676828699982764e-11
followed O 0 8.619578384383431e-10
by O 0 8.01137656214479e-10
the O 0 4.681929866023893e-08
BRCA2 O 0 4.33733106319778e-07
8765delAG O 0 1.573722215653106e-06
mutation O 0 1.2077451572167774e-07
. O 0 3.222760369681055e-08

Together O 0 8.208818513821825e-08
, O 0 1.148170114539937e-09
these O 0 2.353200967419866e-10
mutations O 0 8.688392227895747e-10
were O 0 3.398728187775646e-09
found O 0 5.228028565618104e-10
in O 0 8.074257373813509e-10
28 O 0 2.2915646269439094e-08
of O 0 5.535813940582557e-08
41 O 0 1.4423778793570818e-07
families O 0 1.4849387275361892e-09
identified O 0 5.93432503137592e-09
to O 0 7.627384945863014e-09
have O 0 6.232383054083357e-09
a O 0 3.45358905917692e-08
mutation O 0 3.077784782590243e-08
. O 0 4.047192092571095e-08

The O 0 1.2370151125651319e-06
odds O 0 4.34642197433277e-06
of O 0 4.518871676850722e-08
detection O 0 9.224952179920365e-08
of O 0 1.534457005902823e-08
any O 0 1.7490723536184305e-08
of O 0 1.151639850149877e-07
the O 0 3.152455363419904e-08
four O 0 2.0120452859373472e-08
BRCA1 O 0 1.979427466380912e-08
mutations O 0 9.757691321610196e-10
was O 0 6.787654172057955e-08
18 O 0 1.7463629831127037e-07
. O 0 7.855846462234695e-08

7x O 0 0.013819077052175999
greater O 0 1.0467670108482707e-06
if O 0 1.5375272610640422e-08
one O 0 2.8658342365872613e-09
or O 0 1.721467690618539e-10
more O 0 2.511971316718209e-12
cases O 0 1.75223932585844e-10
of O 0 0.00024613310233689845
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
were O 0 0.01807682029902935
also O 0 5.066338459869257e-10
present O 0 5.847146100634859e-10
in O 0 2.499377149689508e-09
the O 0 2.5356165167522704e-08
family O 0 2.274642980637509e-07
. O 0 5.5495782191883336e-08

The O 0 1.2915136267110938e-06
odds O 0 7.258402092702454e-06
of O 0 9.124610755861795e-08
detection O 0 2.3330835574597586e-07
of O 0 2.4492882388926773e-08
any O 0 1.5897381189233784e-08
of O 0 6.856866718862875e-08
the O 0 1.922684766952898e-08
four O 0 2.5372516532229383e-08
BRCA2 O 0 3.872922249570365e-08
mutations O 0 1.0623395496622834e-09
was O 0 1.1574963565408325e-07
5 O 0 1.9299233144920436e-07
. O 0 2.982744362611811e-08

3x O 0 0.0004077583143953234
greater O 0 6.645927896897774e-08
if O 0 6.564740751002773e-09
there O 0 3.13638648385961e-09
were O 0 2.2046411363163543e-09
at O 0 1.5012510123924017e-09
least O 0 6.980597350159101e-11
five O 0 3.191369390975751e-11
cases O 0 3.043605992236742e-11
of O 0 6.599680357766147e-09
breast B-Disease 0 7.623997225891799e-05
cancer I-Disease 0 0.00023285616771318018
in O 0 1.0126283314093598e-06
the O 0 1.1734010513464455e-05
family O 0 4.060258106619585e-06
. O 0 3.970509609985129e-08

Interestingly O 0 7.474352059944067e-06
, O 0 2.455428527170511e-09
the O 0 1.936448112971334e-09
presence O 0 4.143925202981791e-09
of O 0 1.1300610225362107e-07
a O 0 1.2798594752894132e-06
breast B-Disease 0 0.00013815826969221234
cancer I-Disease 0 9.898492407955928e-07
case O 0 3.8011592096154345e-07
< O 0 1.022587866827962e-06
36 O 0 2.6842137401672517e-09
years O 0 5.758624688212421e-10
of O 0 9.453186011754156e-10
age O 0 2.881334282278658e-09
was O 0 1.6025705207312058e-08
strongly O 0 1.6174940276059147e-09
predictive O 0 6.5081899869312565e-09
of O 0 6.200662205912977e-10
the O 0 8.6369572604994e-10
presence O 0 5.335353825408617e-10
of O 0 7.012150859964095e-09
any O 0 7.060855011786771e-09
of O 0 1.0227479307900467e-08
the O 0 5.765936617052603e-09
eight O 0 7.476948837847885e-09
mutations O 0 2.4702018208699883e-09
screened O 0 3.720796826200967e-08
. O 0 4.7168601469138594e-08

Carriers O 0 7.076969268382527e-07
of O 0 8.594141576168113e-08
the O 0 1.3354906513995957e-08
same O 0 1.899363555324385e-09
mutation O 0 1.226098389484065e-10
, O 0 5.067086507326568e-12
from O 0 6.155066473861881e-12
different O 0 1.0510378158079536e-11
families O 0 3.806354537116974e-11
, O 0 2.778480223675217e-11
shared O 0 7.181804040357065e-10
similar O 0 6.312295686150549e-10
haplotypes O 0 5.588913509768645e-08
, O 0 2.851656133451286e-10
indicating O 0 9.373920306643413e-09
that O 0 3.3808861960027414e-11
the O 0 1.1008597367023754e-09
mutant O 0 1.0306770548140776e-08
alleles O 0 2.1786973614101868e-10
were O 0 1.1223239004820584e-09
likely O 0 2.7381977241169864e-10
to O 0 1.257381282426806e-10
be O 0 1.7867071711030746e-10
identical O 0 5.381211032329247e-10
by O 0 2.5607363451918275e-10
descent O 0 1.9687417918134997e-08
for O 0 9.892259233978962e-10
a O 0 1.2818228256605835e-08
mutation O 0 1.0569110031610762e-09
in O 0 2.5095039379863238e-09
the O 0 2.6095024807659684e-08
founder O 0 7.191561508079758e-06
population O 0 1.6442541772576647e-09
. O 0 3.895078037885469e-09

The O 0 2.6432754651750656e-08
identification O 0 2.504951357451546e-09
of O 0 8.973776388643273e-09
common O 0 1.5437040090660048e-08
BRCA1 O 0 1.1374751096582258e-07
and O 0 6.5845546792786536e-09
BRCA2 O 0 1.0880062717433248e-07
mutations O 0 5.813284853495304e-10
will O 0 6.772630373186317e-11
facilitate O 0 6.773461236342371e-10
carrier O 0 2.6984019463327513e-09
detection O 0 3.741926946077001e-08
in O 0 1.720109832348271e-09
French O 0 5.792532192572253e-06
Canadian O 1 0.9826233983039856
breast B-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
and O 0 0.017652349546551704
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 7.141009632505302e-07
. O 0 3.003116422206631e-09

Are O 0 5.712116148970381e-07
Dp71 O 0 0.00019759625138249248
and O 0 5.8833418137282933e-08
Dp140 O 0 0.00011269965762039647
brain O 0 0.0005906099686399102
dystrophin O 0 5.237199275143212e-06
isoforms O 0 4.139053189078368e-08
related O 0 1.2067500776424822e-08
to O 0 1.8281927083307892e-09
cognitive B-Disease 1 0.9645376205444336
impairment I-Disease 1 0.9999997615814209
in O 0 8.74019242473878e-05
Duchenne B-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
? O 0 9.524476809019689e-06

Molecular O 0 1.3857707926945295e-05
study O 0 1.2867268139871157e-08
and O 0 2.59430893434498e-10
neuropsychological O 0 1.716443343013907e-08
analysis O 0 6.811008201879076e-09
were O 0 1.8143877511533901e-09
performed O 0 6.192991675035842e-10
concurrently O 0 2.482378302914867e-09
on O 0 3.2613944878079337e-09
49 O 0 2.3142424865341127e-08
patients O 0 1.5157811672494859e-09
with O 0 4.4858929904023626e-09
Duchenne B-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 8.371272997464985e-05
DMD B-Disease 1 1.0
) O 0 1.0209990630727361e-09
in O 0 1.524664700047751e-10
order O 0 4.54155740792217e-10
to O 0 4.179827040040607e-10
find O 0 2.540810006834704e-09
a O 0 1.2740903887475952e-09
molecular O 0 5.371123545927503e-09
explanation O 0 9.400252798386077e-10
for O 0 1.8141438004604105e-11
the O 0 7.437361282391919e-10
cognitive B-Disease 0 8.286019692604896e-06
impairment I-Disease 0 1.2124900194976362e-06
observed O 0 2.7164657190326125e-09
in O 0 1.0345091450147947e-09
most O 0 4.558100563656353e-09
DMD B-Disease 1 1.0
patients O 0 1.7162199128506472e-07
. O 0 1.465055099458823e-08

Complete O 0 3.2259756608254975e-06
analysis O 0 2.961187419714406e-07
of O 0 5.860427165771398e-08
the O 0 3.830394135206916e-08
dystrophin O 0 3.308188752271235e-06
gene O 0 2.345580796259128e-08
was O 0 1.6040206674006185e-07
performed O 0 7.505439825195026e-09
to O 0 2.9692048819640604e-09
define O 0 2.7665596036285933e-08
the O 0 1.5434448386031363e-08
localization O 0 1.801878852347727e-06
of O 0 3.2897727209046934e-08
deletions O 0 4.9345040054049605e-08
and O 0 4.912452222782804e-09
duplications O 0 3.86534026119989e-07
in O 0 2.9438924187275006e-08
relation O 0 6.551509841301595e-07
to O 0 1.144584693690831e-08
the O 0 1.0347647361186318e-07
different O 0 5.950240620222758e-07
DMD B-Disease 1 1.0
promoters O 0 0.00010977905913023278
. O 0 2.7172399086339283e-07

Qualitative O 0 7.986019227246288e-06
analysis O 0 8.783509741761009e-08
of O 0 2.6112999762517575e-08
the O 0 5.931680036042053e-08
Dp71 O 0 2.0732411940116435e-05
transcript O 0 6.337864988381625e-07
and O 0 2.5766591638110015e-10
testing O 0 4.732689240505294e-10
for O 0 1.698798463012352e-10
the O 0 1.7764120174845743e-09
specific O 0 9.045999505019608e-10
first O 0 1.7046620115479527e-08
exon O 0 6.282872533347472e-08
of O 0 7.532432988455184e-08
Dp140 O 0 1.0359984798924415e-06
were O 0 9.663389732850192e-08
also O 0 2.926652920010042e-09
carried O 0 2.5481442733621407e-08
out O 0 5.3845841563315844e-08
. O 0 1.3206964410983346e-07

Neuropsychological O 0 2.1283462046994828e-05
analysis O 0 3.3204102578565653e-07
assessed O 0 5.800619646834093e-07
verbal O 0 1.7432492995794746e-06
and O 0 5.360155341804784e-08
visuospatial O 1 0.9876514673233032
intelligence O 0 1.4267313417803962e-05
, O 0 1.1859355275589678e-08
verbal O 0 3.47506193065783e-06
memory O 1 0.926491916179657
, O 0 3.973462447959264e-09
and O 0 2.1569868113857638e-09
reading O 0 6.922314241819549e-06
skills O 0 0.00022237777011469007
. O 0 4.87330510168249e-07

Comparison O 0 3.9457813727494795e-06
of O 0 1.0289921448247696e-07
molecular O 0 6.273556323321827e-07
and O 0 3.4436744567045707e-09
psychometric O 0 6.886848950671265e-06
findings O 0 6.303385902128866e-08
demonstrated O 0 1.0185682519647798e-08
that O 0 1.9475408785663006e-10
deletions O 0 8.417549324235551e-09
and O 0 8.498351466990073e-10
duplications O 0 7.304988258738376e-08
that O 0 4.755392191135854e-10
were O 0 5.272865255534498e-09
localized O 0 7.607803098608201e-08
in O 0 8.883771052126122e-09
the O 0 5.880156095372513e-08
distal O 0 1.1800260608652025e-06
part O 0 7.065923313120948e-08
of O 0 3.7741076539532514e-06
the O 0 1.0694740240069223e-06
gene O 0 2.3576959051752056e-08
seemed O 0 5.3887038831135214e-08
to O 0 5.921105272754801e-10
be O 0 5.23859899903556e-10
preferentially O 0 8.909020188241357e-09
associated O 0 8.851332111703414e-09
with O 0 9.714464788146415e-09
cognitive B-Disease 1 1.0
impairment I-Disease 1 0.9999997615814209
. O 0 6.718800591443141e-07

Two O 0 4.946683702655719e-07
altered O 0 5.73340116716281e-07
Dp71 O 0 4.842140697292052e-05
transcripts O 0 2.0793358999071643e-06
and O 0 3.6016645221792487e-09
two O 0 4.690812627217156e-09
deleted O 0 1.613894511365288e-07
Dp140 O 0 7.383728473087103e-08
DNA O 0 3.4103124768591897e-09
sequences O 0 1.2072374211413717e-09
were O 0 1.7283182662808372e-09
found O 0 2.052917141837085e-10
in O 0 2.0236509690185756e-10
four O 0 7.995500928004162e-10
patients O 0 4.1060477240506543e-10
with O 0 6.674785169025199e-10
severe O 1 1.0
cerebral B-Disease 1 1.0
dysfunction I-Disease 1 1.0
. O 0 1.3471238162310328e-05

These O 0 2.7750736819598387e-08
findings O 0 2.178346392156527e-08
suggest O 0 2.816585853437914e-09
that O 0 1.4444977332328524e-11
some O 0 2.0549180412832158e-11
sequences O 0 7.265961721181213e-10
located O 0 3.208100896046062e-09
in O 0 5.706383143788685e-10
the O 0 5.448167250676761e-09
distal O 0 8.155181063784767e-08
part O 0 6.38330810431853e-09
of O 0 6.115840278653195e-08
the O 0 1.3869328796545233e-08
gene O 0 3.3396069243352144e-10
and O 0 7.841657878593367e-11
, O 0 1.8670742035764576e-11
in O 0 8.615876068152062e-11
particular O 0 1.6666471536197491e-09
, O 0 2.2496496332458094e-10
some O 0 1.7389525375222092e-09
DMD B-Disease 1 1.0
isoforms O 0 5.244623224598399e-08
expressed O 0 1.5589624036138616e-09
in O 0 1.793191484189549e-09
the O 0 1.2990368780663175e-08
brain O 0 1.160253941634437e-05
may O 0 9.975531511940972e-10
be O 0 1.8377853405748823e-10
related O 0 1.291853291007783e-09
to O 0 3.8699277116194253e-10
the O 0 6.533986240953027e-09
cognitive B-Disease 1 0.6789953708648682
impairment I-Disease 0 0.0005865073180757463
associated O 0 1.0501356655368e-06
with O 0 1.877664601579454e-07
DMD B-Disease 1 1.0
. O 0 4.3704108776410067e-08
. O 0 1.717894271280329e-08

I1307K O 0 9.233700257027522e-05
APC O 0 2.066604793071747e-06
and O 0 1.5093707395053002e-09
hMLH1 O 0 2.2216880779524217e-07
mutations O 0 4.128084540866439e-09
in O 0 9.458348770863267e-09
a O 0 5.592603002924079e-08
non O 0 5.808009063912323e-06
- O 0 7.591914936710964e-07
Jewish O 0 1.0199240932706743e-05
family O 0 1.2535564053450798e-07
with O 0 2.141152144474745e-09
hereditary B-Disease 1 1.0
non I-Disease 1 1.0
- I-Disease 1 1.0
polyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.00037565393722616136

We O 0 3.2897358437367075e-07
describe O 0 1.466050889575854e-07
a O 0 4.526186714315372e-08
French O 0 4.851126504945569e-07
Canadian O 0 2.5554081730660982e-05
hereditary B-Disease 1 1.0
non I-Disease 1 1.0
- I-Disease 1 1.0
polyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
( O 1 1.0
HNPCC B-Disease 1 1.0
) O 0 4.383894491866158e-08
kindred O 0 9.941879852704005e-07
which O 0 4.4270206944752033e-10
carries O 0 1.0624733315367507e-09
a O 0 1.1933046772938383e-09
novel O 0 6.967049159811722e-09
truncating O 0 5.701590453099925e-07
mutation O 0 7.091478959608821e-09
in O 0 8.956556385442127e-09
hMLH1 O 0 1.1024004606952076e-06
. O 0 9.31720336438957e-08

Interestingly O 0 1.031530587169982e-06
, O 0 2.3014274930233114e-09
the O 0 9.052407712317745e-09
I1307K O 0 8.139980991472839e-07
APC O 0 2.47704974754015e-07
polymorphism O 0 6.587471546026791e-08
, O 0 1.24430007963916e-10
associated O 0 5.785564249904951e-10
with O 0 3.107355345255414e-11
an O 0 4.38423269910615e-10
increased O 0 4.692864408184505e-08
risk O 0 0.0004326423513703048
of O 1 0.9999998807907104
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, O 0 1.393181179309977e-07
is O 0 3.428677342043329e-10
also O 0 2.246925388804666e-11
present O 0 2.456851666554627e-10
in O 0 1.0430226682345278e-09
this O 0 3.4992657660382065e-09
family O 0 6.085353732032672e-08
. O 0 2.1844250852609548e-08

The O 0 2.4222324555012165e-06
I1307K O 0 5.409807272371836e-06
polymorphism O 0 1.1613834658419364e-06
has O 0 2.3832624762576415e-09
previously O 0 7.744588970126642e-09
only O 0 9.8767427569868e-10
been O 0 1.3580533364532243e-09
identified O 0 1.5323037283465624e-09
in O 0 1.0980476528033023e-09
individuals O 0 1.6182655215857267e-09
of O 0 3.9919700611790176e-07
self O 0 2.046923509624321e-05
- O 0 3.0214341677492484e-06
reported O 0 6.930048357389751e-07
Ashkenazi O 0 1.025867959469906e-06
Jewish O 0 1.3765552466793451e-06
origins O 0 1.3038907127338462e-06
. O 0 5.9240370831048494e-08

In O 0 5.542289045479265e-07
addition O 0 2.152335554228557e-08
, O 0 1.9158674646746476e-09
in O 0 5.437764905025233e-09
this O 0 6.91024792942585e-09
family O 0 1.133266351871498e-07
, O 0 5.565249927563798e-10
there O 0 2.8666105045260792e-09
appears O 0 8.959221808879647e-09
to O 0 1.3858295622171113e-09
be O 0 2.736998405694635e-09
no O 0 6.456434054058491e-09
relationship O 0 8.250316874125474e-09
between O 0 4.89107954138035e-09
the O 0 4.647681350888888e-09
I1307K O 0 8.142870910887723e-08
polymorphism O 0 1.306262120692736e-08
and O 0 2.994853670612585e-11
the O 0 3.763690470393044e-10
presence O 0 1.0008196493771493e-09
or O 0 3.5516671825774893e-09
absence O 0 7.68641896797817e-08
of O 0 1.9247583793458034e-07
cancer B-Disease 0 7.717797529949166e-07
. O 0 4.630021255280781e-09
. O 0 2.7621464226967873e-08

Identification O 0 3.468541649453982e-07
of O 0 3.3343720673428834e-08
a O 0 9.332301154074685e-09
novel O 0 2.7192559315381004e-08
mutation O 0 5.818434622995028e-09
of O 0 5.470004893481928e-08
the O 0 3.366513396940718e-07
CPO O 0 6.39442223473452e-05
gene O 0 2.2311020586585073e-08
in O 0 4.8358604232134894e-08
a O 0 9.385790917804115e-07
Japanese O 0 0.001198083395138383
hereditary B-Disease 1 0.9999995231628418
coproporphyria I-Disease 1 0.9996770620346069
family O 0 2.8064927391824313e-05
. O 0 3.0024051511645666e-07

Hereditary B-Disease 1 1.0
coproporphyria I-Disease 1 0.9999998807907104
( O 0 0.0005067902966402471
HCP B-Disease 1 1.0
) O 0 4.9452641093239436e-08
is O 0 1.5017751486823272e-09
an O 0 3.010097060496264e-08
autosomal B-Disease 1 1.0
dominant I-Disease 1 1.0
disease I-Disease 1 1.0
characterized O 0 1.0173275768465828e-05
by O 0 1.5673231601454063e-08
a O 0 5.403065301834431e-07
deficiency B-Disease 1 0.9422990679740906
of I-Disease 0 0.0043769474141299725
coproporphyrinogen I-Disease 0 0.06448240578174591
oxidase I-Disease 0 1.8970310975419125e-06
( O 0 4.237523398842313e-08
CPO O 0 2.856558467101422e-06
) O 0 3.8881156072534395e-09
caused O 0 1.2274731453487675e-08
by O 0 7.729518136656566e-10
a O 0 6.2842726578082875e-09
mutation O 0 7.802319901273336e-10
in O 0 1.7516589290167417e-09
the O 0 8.252823135990184e-08
CPO O 0 3.677045242511667e-05
gene O 0 1.7696180520943017e-07
. O 0 5.419141047013909e-08

Only O 0 1.3155275269127742e-07
11 O 0 8.76127259630266e-08
mutations O 0 7.693852666079692e-09
of O 0 3.560106165423349e-08
the O 0 1.2728030185371608e-07
gene O 0 2.6542286590824915e-08
have O 0 2.322603220861197e-09
been O 0 7.554616487936983e-09
reported O 0 5.610991138382815e-08
in O 0 4.61301112864021e-08
HCP B-Disease 1 0.9999958276748657
patients O 0 4.116593572689453e-06
. O 0 1.3260427067507408e-07

We O 0 7.117919835764042e-07
report O 0 4.6080863569386565e-08
another O 0 8.792304662108563e-09
mutation O 0 2.227924511544188e-09
in O 0 4.252232344015283e-09
a O 0 2.1812780914842733e-07
Japanese O 0 3.496421777526848e-05
family O 0 3.331851985421963e-07
. O 0 6.137622676760657e-08

Polymerase O 0 1.7971946363104507e-05
chain O 0 9.55995673734833e-08
reaction O 0 4.317301183220934e-09
- O 0 9.205209927642954e-09
single O 0 3.432729434038606e-09
strand O 0 1.0653595339249478e-08
conformational O 0 1.963767815027495e-09
polymorphism O 0 1.6479591025131413e-09
and O 0 4.3759763174167077e-11
direct O 0 9.463017036637211e-10
sequence O 0 2.401363774495735e-09
analyses O 0 1.2133091864541257e-08
demonstrated O 0 1.0409702433378243e-08
a O 0 8.100345283423849e-09
C O 0 6.243164563102255e-08
to O 0 2.411452149075899e-09
T O 0 9.591276217690847e-09
substitution O 0 1.385279779775317e-09
in O 0 4.122442831544504e-09
exon O 0 1.303688446085971e-08
1 O 0 9.891734542577524e-09
of O 0 1.4445247664696126e-08
the O 0 1.7297669074878286e-08
CPO O 0 1.1875707741637598e-06
gene O 0 3.66631769388448e-09
at O 0 2.9000817747260044e-08
nucleotide O 0 3.945822868445248e-08
position O 0 1.946168914912505e-08
85 O 0 1.72526615216384e-08
, O 0 4.346280280120851e-11
which O 0 2.360743198148718e-11
lies O 0 4.475261938807762e-09
in O 0 7.396548373783673e-10
the O 0 1.1474001304634385e-08
putative O 0 2.57241282497489e-07
presequence O 0 3.1996913207876787e-07
for O 0 3.3866918158764747e-09
targeting O 0 1.823853956750554e-08
to O 0 9.319653493378155e-09
mitochondria O 0 8.637086352791812e-07
. O 0 7.333704843404121e-08

This O 0 1.3193930392674247e-08
mutation O 0 1.092030244009834e-09
changes O 0 2.591499792536922e-10
the O 0 1.9918069416036133e-09
codon O 0 2.4707780710286897e-08
for O 0 1.10186804125334e-09
glutamine O 0 4.121753249819449e-08
to O 0 3.492937494797843e-09
a O 0 3.5679235566021816e-08
termination O 0 4.800635338142456e-07
codon O 0 6.406265811165213e-07
at O 0 2.068305064995002e-07
amino O 0 1.6756659704242338e-07
acid O 0 5.4410982386343676e-08
position O 0 1.3069308124613599e-06
29 O 0 4.128782165935263e-06
. O 0 2.5511408807687985e-07

MaeI O 0 0.0006965561769902706
restriction O 0 3.585032573028002e-07
analysis O 0 4.925871621708211e-08
showed O 0 4.015839660809206e-09
two O 0 1.6913009881491803e-10
other O 0 2.716695965410132e-11
carriers O 0 1.0524185689586574e-10
in O 0 3.3559361956037037e-09
the O 0 2.3231412171753618e-07
family O 0 1.8288060346094426e-06
. O 0 2.1619700873998227e-07

The O 0 5.003623300581239e-06
C O 0 0.03994649276137352
- O 0 0.0009421225404366851
T O 0 1.2956727005075663e-05
mutation O 0 4.698343047948583e-09
is O 0 9.285882618392804e-10
located O 0 3.036824347546485e-09
within O 0 1.932924043046569e-09
a O 0 4.868239589228551e-09
recently O 0 7.645996613625528e-10
proposed O 0 4.5334480613945516e-10
putative O 0 7.621542863489594e-08
alternative O 0 5.010230452739961e-09
translation O 0 1.9518044069855023e-08
initiation O 0 7.2313595111950235e-09
codon O 0 1.6428163718273936e-08
( O 0 1.223545598172393e-09
TIC O 0 3.4576753904502766e-08
- O 0 4.986596024991741e-09
1 O 0 2.3730351017547946e-08
) O 0 5.370557887296457e-10
, O 0 1.1184831533173067e-10
supporting O 0 3.73051634028343e-09
that O 0 1.2770779989068615e-09
TIC O 0 5.062248078502307e-07
- O 0 1.729452776544349e-07
1 O 0 3.740636032034672e-07
is O 0 2.415480038209239e-09
the O 0 1.6320507612022084e-08
real O 0 3.451539214438526e-06
TIC O 0 6.021808530931594e-06
rather O 0 4.446564716431567e-08
than O 0 6.501006399872722e-09
TIC O 0 6.774402550036029e-07
- O 0 5.822101201147234e-08
2 O 0 1.0494693469809135e-07
. O 0 3.1037687975299377e-09
. O 0 1.9152400554389715e-08

Human B-Disease 0 6.365013405229547e-07
complement I-Disease 0 3.0913158752809977e-06
factor I-Disease 0 0.007167998701334
H I-Disease 1 1.0
deficiency I-Disease 1 1.0
associated O 0 0.10222083330154419
with O 0 4.56344241683837e-05
hemolytic B-Disease 1 1.0
uremic I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 0.010892413556575775

This O 0 1.2769683621627337e-07
study O 0 3.157763117656032e-08
reports O 0 1.115884629143693e-08
on O 0 1.7356355241915367e-09
six O 0 1.445364716801123e-09
cases O 0 3.675123538826597e-10
of O 0 1.553362416473192e-08
deficiency B-Disease 0 0.2186051905155182
in I-Disease 0 2.1743820965980376e-08
the I-Disease 0 1.5310540391055838e-08
human I-Disease 0 8.505454118790112e-10
complement I-Disease 0 1.2704455265577508e-09
regulatory I-Disease 0 6.757231219012283e-09
protein I-Disease 0 1.1116974008018587e-08
Factor I-Disease 0 3.06715463693763e-07
H I-Disease 1 0.9999964237213135
( O 0 5.620928611449472e-09
FH O 0 4.0535741163694183e-07
) O 0 1.5877297740440888e-11
in O 0 8.61927369755211e-12
the O 0 1.7105546146201078e-11
context O 0 5.513931533585037e-10
of O 0 6.526982287979877e-10
an O 0 1.4631226896710814e-08
acute B-Disease 1 1.0
renal I-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 4.884848749497905e-06

Five O 0 5.001858767172962e-07
of O 0 2.4572990753313206e-08
the O 0 1.329730436872012e-09
cases O 0 2.6170560163407686e-10
were O 0 3.1767893871048614e-10
observed O 0 3.168390272367816e-10
in O 0 1.4889056654254773e-10
children O 0 1.6591800156007253e-10
presenting O 0 5.559661175880137e-09
with O 0 1.8503848764339637e-07
idiopathic O 1 1.0
hemolytic B-Disease 1 1.0
uremic I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 1 1.0
HUS B-Disease 1 1.0
) O 0 4.2896812374237925e-05
. O 0 1.4701533928018762e-06

Two O 0 8.887673885737968e-08
of O 0 4.0696171765830513e-08
the O 0 4.883985216252995e-09
children O 0 6.144202924218689e-09
exhibited O 0 7.465387170668691e-07
a O 0 3.0265789519035025e-06
homozygous O 0 5.268085078569129e-05
deficiency O 1 0.999966025352478
characterized O 0 1.1977088831827132e-07
by O 0 4.244081086568485e-09
the O 0 4.8168601551878965e-08
absence O 0 2.568062029695284e-07
of O 0 1.3861082948096737e-07
the O 0 2.1548165918261475e-08
150 O 0 1.7110924233065816e-08
- O 0 3.2300941921192816e-09
kD O 0 1.0193543857894838e-06
form O 0 4.084880433907756e-09
of O 0 7.552039278380107e-07
Factor O 0 0.00021486374316737056
H O 1 1.0
and O 0 2.1335004873890284e-09
the O 0 2.4841402268549473e-09
presence O 0 6.20425877340125e-10
, O 0 5.6316756813501456e-11
upon O 0 2.1033703667683312e-09
immunoblotting O 0 1.2271271998542943e-07
, O 0 3.422777061778959e-10
of O 0 3.452579555585089e-09
the O 0 3.4779266133710962e-09
42 O 0 3.383278013302515e-08
- O 0 2.120313169484689e-08
kD O 0 5.941861672908999e-05
Factor O 0 4.929766873829067e-05
H O 1 1.0
- O 0 5.913256018175161e-07
like O 0 7.505769339388735e-09
protein O 0 1.87454904931883e-08
1 O 0 1.232428274988706e-07
( O 0 2.8288935638443036e-09
FHL O 0 4.2286904999855324e-07
- O 0 1.2611631738934648e-08
1 O 0 1.9410826723742503e-08
) O 0 1.3654108399485665e-10
and O 0 5.3615785422511664e-11
other O 0 2.7362140331277374e-10
FH O 0 2.3771610813128063e-06
- O 0 8.086856695399547e-08
related O 0 2.1631477409300714e-07
protein O 0 1.5756940285882592e-07
( O 0 6.175231437310913e-09
FHR O 0 3.349873850311269e-06
) O 0 1.6627417220860252e-09
bands O 0 4.639889539248543e-08
. O 0 5.593723173547005e-08

Southern O 0 1.191615297102544e-06
blot O 0 1.1907859516213648e-06
and O 0 1.9397641271012844e-09
PCR O 0 1.4162258032968111e-08
analysis O 0 1.909453928305993e-09
of O 0 8.444803745177865e-10
DNA O 0 1.7324173207100557e-09
of O 0 3.6069374154124034e-09
one O 0 1.532198479203828e-09
patient O 0 1.2146521122247123e-08
with O 0 6.851017531062098e-10
homozygous O 0 6.805888915550895e-06
deficiency O 1 0.9998328685760498
ruled O 0 1.4221382116375025e-07
out O 0 8.903393577952556e-10
the O 0 4.084045046592877e-10
presence O 0 2.0864154848254657e-10
of O 0 1.3878159732527706e-09
a O 0 6.896720972093817e-10
large O 0 2.719906799786287e-10
deletion O 0 4.329050895535147e-09
of O 0 1.5297638711331274e-08
the O 0 1.445266661903588e-07
FH O 0 0.0006389432237483561
gene O 0 2.1293660168453243e-09
as O 0 4.3305603547594274e-10
the O 0 5.284061188604028e-09
underlying O 0 0.00011474742495920509
defect O 0 2.609428520372603e-06
for O 0 7.4085391155165325e-09
the O 0 1.021160187519854e-06
deficiency O 1 0.9999990463256836
. O 0 1.1465991747172666e-06

The O 0 2.8920621275574376e-07
other O 0 1.0374415770897372e-09
four O 0 1.0869681821290555e-09
children O 0 1.6803844427037973e-10
presented O 0 3.6929312940969794e-09
with O 0 4.212893145449925e-09
heterozygous O 0 0.00016191824397537857
deficiency O 1 0.9999606609344482
and O 0 1.3994353231794321e-08
exhibited O 0 4.591085144056706e-06
a O 0 1.767497565197118e-06
normal O 0 2.7282956580165774e-05
immunoblotting O 0 1.3829324416292366e-05
pattern O 0 5.780099172625341e-07
of O 0 9.426295832781761e-08
proteins O 0 1.4136512405116264e-08
of O 0 1.8105914705301984e-06
the O 0 7.309110515052453e-06
FH O 1 0.9999902248382568
family O 0 1.1969466413574992e-06
. O 0 5.091724730732494e-08

Factor B-Disease 1 1.0
H I-Disease 1 1.0
deficiency I-Disease 1 1.0
is O 0 2.917380292899452e-08
the O 0 9.756839780550308e-09
only O 0 4.021437760570734e-08
complement B-Disease 1 1.0
deficiency I-Disease 1 1.0
associated O 0 0.0003313079650979489
with O 0 1.342253312941466e-07
HUS B-Disease 1 1.0
. O 0 1.9322708340041572e-06

These O 0 3.782924551387623e-08
observations O 0 5.289161322252767e-07
suggest O 0 3.099410506024469e-08
a O 0 5.380721201930783e-09
role O 0 5.920125722980174e-09
for O 0 5.618549181463095e-09
FH O 0 1.0660876796464436e-05
and O 0 2.187919534435423e-08
/ O 0 4.3412023842392955e-06
or O 0 1.0918354576006095e-07
FH O 0 1.666517709963955e-05
receptors O 0 1.1091875862234701e-08
in O 0 6.793683948735918e-10
the O 0 4.1707899356424605e-09
pathogenesis O 0 9.281476377509534e-05
of O 0 1.1694330169120803e-05
idiopathic O 1 0.9999998807907104
HUS B-Disease 1 1.0
. O 0 1.5441833056684118e-07
. O 0 1.5162163435888942e-07

Further O 0 1.2550350447781966e-07
evidence O 0 7.999535256431045e-08
for O 0 5.024822224974912e-10
a O 0 3.2265228266936674e-09
major O 0 4.668373687621852e-09
ancient O 0 4.846987735618313e-07
mutation O 0 1.3470406656779232e-06
underlying O 1 0.9393799901008606
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
from O 0 1.7852892142400378e-07
linkage O 0 2.4861119527486153e-06
disequilibrium O 0 2.34891513173352e-06
studies O 0 6.6436700585370545e-09
in O 0 5.855315676761563e-10
the O 0 4.011537768633389e-09
Japanese O 0 7.37469861178397e-07
population O 0 2.196966497614028e-10
. O 0 2.2488784168217535e-09

The O 0 5.6571574532426894e-05
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.14343935251235962
DM B-Disease 1 1.0
) O 0 8.663822548271582e-09
mutation O 0 6.071633196214066e-10
is O 0 3.4137015436641605e-10
an O 0 1.2442675778601142e-09
unstable O 0 5.502450676431181e-06
( O 0 8.787847036728635e-07
CTG O 0 0.0006796931847929955
) O 0 1.0098771241473514e-07
n O 0 1.017657496049651e-06
repeat O 0 2.434928489947197e-07
, O 0 3.1666640420979775e-09
present O 0 2.2048986636491463e-08
at O 0 2.1388721904713748e-07
a O 0 1.0073488709849698e-08
copy O 0 2.1119298310168233e-08
number O 0 2.9875537599366453e-09
of O 0 1.0183740073443914e-08
5 O 0 1.5916192808163032e-08
- O 0 7.379501010262857e-09
37 O 0 2.4496900508097497e-08
repeats O 0 7.097026966107478e-09
on O 0 4.738047731933648e-09
normal O 0 1.662476023511772e-08
chromosomes O 0 2.2778887664998138e-09
but O 0 1.0140874251440835e-10
amplified O 0 6.221254622573724e-09
to O 0 9.399536704535194e-10
50 O 0 4.384586027583737e-09
- O 0 4.292766142555138e-09
3000 O 0 2.269026566636967e-08
copies O 0 1.668600901894024e-08
on O 0 7.473102670019216e-08
DM B-Disease 1 0.9999912977218628
chromosomes O 0 3.8143045344440907e-07
. O 0 2.292194167807793e-08

Previous O 0 2.2740189251635456e-06
findings O 0 4.848032375548428e-08
in O 0 2.6671072017592223e-09
Caucasian O 0 5.040252517574118e-07
populations O 0 1.1376216635383685e-09
of O 0 7.651605926639604e-08
a O 0 2.6723218979896046e-05
DM B-Disease 1 1.0
founder O 1 0.7155209183692932
chromosome O 0 3.475479388725944e-06
raise O 0 1.2583974751123606e-08
a O 0 6.8990537727131596e-09
question O 0 5.593336016573858e-09
about O 0 8.724311273411445e-10
the O 0 9.768826858547186e-10
molecular O 0 8.132484019540698e-09
events O 0 1.116231107545218e-09
involved O 0 3.0256890326540997e-09
in O 0 1.2689053141556883e-09
the O 0 5.105492473234108e-09
expansion O 0 9.064280703796612e-08
mutation O 0 4.740472547837271e-08
. O 0 1.9950816110281266e-08

To O 0 1.5027049471427745e-07
investigate O 0 3.514874151733238e-07
whether O 0 3.794964698045078e-08
a O 0 7.590048767269764e-08
founder O 0 1.1363522389729042e-06
chromosome O 0 5.119742141346251e-08
for O 0 2.9547477797819965e-09
the O 0 4.038787153604062e-07
DM B-Disease 1 1.0
mutation O 0 3.776045254255678e-09
exists O 0 1.1293112001098393e-09
in O 0 3.7725142454370086e-11
the O 0 1.2639071733655527e-10
Japanese O 0 9.700947600776999e-09
population O 0 1.7891435945618928e-12
, O 0 2.4117335732654066e-12
we O 0 1.308724656423621e-10
genotyped O 0 2.0511697229608217e-08
families O 0 8.288541381018533e-11
using O 0 1.4286012650632784e-10
polymorphic O 0 2.1224078050607886e-09
markers O 0 3.035903528569861e-09
near O 0 5.515946099876601e-08
the O 0 2.9471001639080896e-08
( O 0 1.1096769014784513e-07
CTG O 0 2.8932949135196395e-05
) O 0 7.31447968860266e-09
n O 0 9.254859634211243e-08
repeat O 0 3.8057141438230246e-08
region O 0 6.594898849243691e-09
and O 0 4.835350342347056e-09
constructed O 0 7.7017775765853e-06
haplotypes O 0 5.51714720131713e-06
. O 0 1.6128683455463033e-07

Six O 0 3.001360369125905e-07
different O 0 1.6253399737209406e-09
haplotypes O 0 1.9974353904217423e-07
were O 0 1.2690269279858057e-08
found O 0 9.537297174233572e-09
and O 0 2.111942087879015e-08
DM B-Disease 1 1.0
alleles O 0 8.129199358108963e-08
were O 0 1.7001526941839984e-07
always O 0 1.4684212601423496e-07
haplotype O 0 5.110327379043156e-07
A O 0 4.327557235228596e-06
. O 0 1.761426773327912e-07

To O 0 1.0475934431042333e-07
find O 0 1.662336579499879e-08
an O 0 6.692211784731228e-10
origin O 0 2.2634061291881835e-09
of O 0 4.4459799397600364e-08
the O 0 1.2952236261298822e-07
( O 0 1.0160751884313868e-07
CTG O 0 3.3955937396967784e-05
) O 0 1.1403987087987844e-08
n O 0 4.2797612564982046e-08
repeat O 0 1.2005559213434935e-08
mutation O 0 1.147909434173755e-09
and O 0 1.4093502753720344e-10
to O 0 9.741587536638008e-10
investigate O 0 4.5951665583743306e-08
the O 0 9.780017684590803e-09
mechanism O 0 1.1139987776687121e-07
of O 0 9.378981147278864e-09
the O 0 3.119258629169508e-09
expansion O 0 6.923559503491106e-09
mutation O 0 1.359140994194874e-10
in O 0 8.77986156000432e-11
the O 0 3.9779723959298963e-10
Japanese O 0 3.867562980985895e-08
population O 0 5.166149192464831e-12
we O 0 2.024981918258284e-11
have O 0 1.110894622818881e-11
studied O 0 2.512722696579317e-09
90 O 0 1.4869263154082546e-08
Japanese O 0 2.6584953047859017e-06
DM B-Disease 1 1.0
families O 0 1.7213003244975766e-10
comprising O 0 2.8501334625730124e-10
190 O 0 2.1392705384926103e-09
affected O 0 1.4182192920042525e-10
and O 0 5.81683139155853e-11
130 O 0 1.7648964956151758e-08
unaffected O 0 1.3409905363914731e-07
members O 0 6.648905870321187e-09
. O 0 5.7696688315900246e-08

The O 0 3.675103471323382e-06
results O 0 1.6408847614002298e-07
suggest O 0 8.18653731471386e-08
that O 0 2.965009626709758e-10
a O 0 2.4424851030602213e-09
few O 0 9.552183488636956e-10
common O 0 9.265537226355036e-10
ancestral O 0 9.861804528554785e-08
mutations O 0 5.301098449095321e-10
in O 0 1.326988963157305e-09
both O 0 1.2599098431209654e-09
Caucasian O 0 9.844136457104469e-07
and O 0 5.708813421989589e-09
Japanese O 0 9.10842754819896e-06
populations O 0 2.534603360526688e-10
have O 0 1.5699747057951186e-11
originated O 0 1.3830905865042098e-10
by O 0 3.612593557633659e-11
expansion O 0 3.3114588848803805e-09
of O 0 3.0229201364306846e-09
an O 0 1.0436694841686744e-09
ancestral O 0 6.274142805295924e-08
n O 0 2.6538439001910774e-08
= O 0 1.0625913482442684e-08
5 O 0 2.5807036507785597e-09
repeat O 0 1.370295543701161e-09
to O 0 1.0796474825269797e-09
n O 0 4.6586890789512836e-08
= O 0 1.0690420992887084e-07
19 O 0 3.3200361571061876e-08
- O 0 1.3979174262601646e-08
37 O 0 5.179430218049674e-08
copies O 0 7.055419359858206e-08
. O 0 3.925442371155441e-08

These O 0 1.505871871643194e-08
data O 0 3.868131059903135e-08
support O 0 1.2433897245145431e-09
multistep O 0 1.5476537384984113e-07
models O 0 2.1236724379036787e-08
of O 0 1.6295801685828337e-07
triplet O 0 1.3276931895234156e-05
repeat O 0 5.767197990280692e-07
expansion O 0 3.3901196161423286e-07
that O 0 1.1587987236438835e-09
have O 0 2.186728298436691e-10
been O 0 1.5228134031541884e-10
proposed O 0 1.1095271923444727e-10
for O 0 6.437359534317011e-10
both O 0 3.543724957921768e-08
DM B-Disease 1 1.0
and O 0 4.182120107998344e-07
Friedreichs B-Disease 1 0.9999867677688599
ataxia I-Disease 0 0.03692043200135231
. O 0 1.512642455736568e-08
. O 0 4.3298790330936754e-08

The O 0 2.717037830279878e-07
molecular O 0 6.69095356897742e-07
basis O 0 2.259426037198864e-05
of O 0 0.32920023798942566
C6 B-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 2.391878126672964e-07
the O 0 7.222152209607202e-09
western O 0 7.225775533470369e-09
Cape O 0 1.0814064665964906e-07
, O 0 2.4962601430367215e-10
South O 0 6.5281318128995736e-09
Africa O 0 2.253929487494588e-08
. O 0 3.586017172096945e-08

Deficiency B-Disease 1 1.0
of I-Disease 0 0.0003838085976894945
the I-Disease 0 1.4222374602468335e-06
sixth I-Disease 0 1.8074919353239238e-05
component I-Disease 0 1.375196734443307e-05
of I-Disease 0 2.017935003095772e-06
human I-Disease 0 2.1261614335799095e-07
complement I-Disease 0 6.002779855407425e-07
( O 0 7.825067882549774e-07
C6 O 0 0.00032621395075693727
) O 0 1.1933547483522489e-09
has O 0 6.517698186714327e-11
been O 0 1.8180797145550542e-10
reported O 0 6.558130150047248e-10
in O 0 7.487987313536948e-11
a O 0 2.7602900520840024e-10
number O 0 1.6347409537154078e-10
of O 0 2.5090063360266868e-09
families O 0 2.933424891882197e-10
from O 0 1.0447849252415153e-09
the O 0 2.4633513007188412e-09
western O 0 5.947049963594964e-09
Cape O 0 2.1564453334121936e-07
, O 0 7.03245239819239e-10
South O 0 2.8512237904010362e-08
Africa O 0 1.8392388057009157e-08
. O 0 1.5296063082814726e-08

Meningococcal B-Disease 1 0.9999998807907104
disease I-Disease 1 0.9999995231628418
is O 0 4.420924426540296e-08
endemic O 0 5.6919638780073e-08
in O 0 9.720242388766565e-10
the O 0 8.161634923453676e-09
Cape O 0 2.649368582297029e-07
and O 0 1.157132722973131e-10
almost O 0 1.1926789555971595e-09
all O 0 7.49184464465813e-11
pedigrees O 0 1.721558184897276e-08
of O 0 2.411839794547177e-08
total O 0 0.0001176115038106218
C6 B-Disease 1 1.0
deficiency I-Disease 1 1.0
( O 0 3.10305676975986e-06
C6Q0 O 0 0.0009680810035206378
) O 0 1.2039630403748447e-09
have O 0 4.1763741770450835e-11
been O 0 2.368411577968743e-10
ascertained O 0 5.81422199275039e-08
because O 0 2.4955282285077374e-09
of O 0 1.0383946857928095e-07
recurrent O 1 0.9999986886978149
disease O 1 0.9992485642433167
. O 0 3.8743118579986913e-07

We O 0 2.1210902900747897e-07
have O 0 1.5464970415379753e-09
sequenced O 0 9.68560254221984e-09
the O 0 4.499578043493102e-09
expressed O 0 1.1866007731953232e-08
exons O 0 1.8748821162262175e-07
of O 0 1.9021510411221243e-07
the O 0 3.189689152804931e-07
C6 O 0 3.69828958355356e-05
gene O 0 7.821913672323433e-10
from O 0 6.73244723858879e-11
selected O 0 2.9009142310520986e-10
cases O 0 1.8104080734548944e-10
and O 0 8.811636836858483e-11
have O 0 9.92841364677588e-11
found O 0 5.076853382135482e-10
three O 0 3.285920646689533e-09
molecular O 0 0.00019297383551020175
defects O 1 0.9902848601341248
leading O 0 3.996733994426904e-06
to O 0 6.279074682424834e-08
total O 0 0.003756395075470209
deficiency O 1 1.0
879delG O 0 0.0005488604074344039
, O 0 4.276389020674287e-09
which O 0 9.427941760620229e-10
is O 0 7.768478083036712e-10
the O 0 4.504506989633228e-09
common O 0 2.8296613052702924e-08
defect O 0 5.418602881945844e-07
in O 0 1.1007636580018243e-08
the O 0 4.0605918627534265e-08
Cape O 0 4.61671703533284e-07
and O 0 9.60767687629982e-10
hitherto O 0 1.5681267768741236e-06
unreported O 0 1.8197175677414634e-06
, O 0 1.0091614349727607e-10
and O 0 1.1139334593623929e-10
1195delC O 0 2.520764397218045e-08
and O 0 1.3344053639841036e-09
1936delG O 0 1.8381942368250748e-07
, O 0 1.0478983236694717e-09
which O 0 3.278957105834479e-10
have O 0 2.2535018295855025e-10
been O 0 2.490449846348497e-09
previously O 0 8.270751195027515e-09
reported O 0 3.776758905615907e-09
in O 0 3.62975338674687e-09
African O 0 8.92678286845694e-08
- O 0 4.931465014124115e-07
Americans O 0 1.6372426614452706e-07
. O 0 4.8310202060974916e-08

We O 0 1.0833589385583764e-06
also O 0 4.609736592442459e-09
show O 0 5.177757778085379e-09
that O 0 5.797326160794647e-11
the O 0 1.7522704398587052e-09
879delG O 0 6.206892066984437e-08
and O 0 2.4090662797959794e-09
1195delC O 0 5.250521098787431e-06
defects O 0 3.581991040846333e-05
are O 0 9.403476608493833e-11
associated O 0 1.5135364073159963e-09
with O 0 1.9222143876618247e-09
characteristic O 1 0.9903855323791504
C6 O 1 1.0
/ O 1 0.9999881982803345
C7 O 0 0.37330198287963867
region O 0 4.465279701548752e-08
DNA O 0 3.85743391007054e-07
marker O 0 5.82863428633118e-08
haplotypes O 0 2.5533939407296202e-08
, O 0 1.8201292903419208e-11
although O 0 2.6581762832544875e-11
small O 0 1.207351996157513e-10
variations O 0 8.513666993614777e-10
were O 0 8.995076683504521e-09
observed O 0 3.70930344217868e-08
. O 0 3.561777006666489e-08

The O 0 5.8372847888676915e-06
1936delG O 0 4.2781441152328625e-05
defect O 0 3.3740379876689985e-05
was O 0 2.52233519404399e-07
observed O 0 1.0199602940019759e-08
only O 0 1.5337539016613277e-09
once O 0 3.009963389644099e-09
in O 0 1.5250027907143249e-09
the O 0 2.998119974506608e-09
Cape O 0 1.2291462780922302e-07
, O 0 1.4078806176431868e-10
but O 0 4.1107239140414364e-11
its O 0 1.5688080001741156e-10
associated O 0 1.1619775364124507e-08
haplotype O 0 1.0161353714011057e-07
could O 0 5.624692711592161e-09
be O 0 2.6588192980625536e-08
deduced O 0 4.2136930460401345e-06
. O 0 1.4207716958480887e-07

The O 0 4.906896720058285e-07
data O 0 8.145014618321511e-08
from O 0 2.8384168349049332e-09
the O 0 4.722619184605037e-09
haplotypes O 0 1.3330925696664053e-07
indicate O 0 4.492811456202617e-09
that O 0 2.6288417623310245e-11
these O 0 1.0425111468537196e-10
three O 0 1.4252380386992058e-09
molecular O 0 7.932663947940455e-07
defects O 0 3.2597438348602736e-06
account O 0 1.102061997215742e-08
for O 0 3.700426187691619e-09
the O 0 3.823679151082615e-07
defects O 0 0.0012500355951488018
in O 0 1.812693817271338e-08
all O 0 4.208098314251174e-09
the O 0 2.3698328632804078e-08
38 O 0 2.097978608617268e-07
unrelated O 0 4.607348387253296e-07
C6Q0 O 0 0.00026889119180850685
individuals O 0 7.712968042028479e-09
we O 0 6.013698428120051e-09
have O 0 3.6259181768194537e-10
studied O 0 1.9103767456840615e-08
from O 0 8.758394898222832e-09
the O 0 1.610436051180386e-08
Cape O 0 6.956587981221674e-07
. O 0 6.29807459517906e-08

We O 0 1.6398505522374762e-06
have O 0 6.137901298330917e-09
also O 0 3.1580429937783094e-10
observed O 0 4.254585128649069e-09
the O 0 8.130250250815152e-09
879delG O 0 1.010470327855728e-06
defect O 0 5.865224466106156e-07
in O 0 6.061257273870524e-09
two O 0 9.908919018641882e-09
Dutch O 1 0.9999434947967529
C6 B-Disease 1 1.0
- I-Disease 1 1.0
deficient I-Disease 1 1.0
kindreds O 0 3.375093365320936e-05
, O 0 4.3297346263848624e-10
but O 0 1.8626147846312335e-10
the O 0 1.14158469344261e-08
879delG O 0 1.31972615236009e-06
defect O 0 8.720157893549185e-07
in O 0 1.3715147240134229e-08
the O 0 9.936800893228792e-08
Cape O 0 7.059887138893828e-06
probably O 0 8.243745241998113e-08
did O 0 6.342240066459226e-09
not O 0 6.33625207857591e-10
come O 0 1.2852569009069725e-09
from O 0 8.194293577012957e-10
The O 0 5.926655610721809e-09
Netherlands O 0 3.9445588129183307e-08
. O 0 4.141230469656421e-09
. O 0 2.287546863044554e-08

Complement B-Disease 1 0.9999988079071045
C7 I-Disease 1 1.0
deficiency I-Disease 1 1.0
: O 0 4.917807316928702e-08
seven O 0 9.805345868585391e-09
further O 0 9.027801617378373e-09
molecular O 0 4.804130730917677e-05
defects O 0 0.0017432293388992548
and O 0 1.1934412347258672e-09
their O 0 5.056773666467507e-09
associated O 0 5.785597636531747e-07
marker O 0 3.91644880437525e-06
haplotypes O 0 4.104246272618184e-06
. O 0 9.185271920841842e-08

Seven O 0 4.037431722281326e-07
further O 0 1.2288060347032115e-08
molecular O 0 3.0877103540660755e-07
bases O 0 2.8742803692693997e-07
of O 1 0.5678535103797913
C7 B-Disease 1 1.0
deficiency I-Disease 1 1.0
are O 0 5.524611310647742e-07
described O 0 3.396640408936946e-07
. O 0 5.400742608685505e-08

All O 0 4.032082401295156e-08
these O 0 1.0014651330436664e-09
new O 0 3.6104406131443056e-09
molecular O 0 2.6180532586295158e-06
defects O 0 4.015822014480364e-06
involve O 0 7.175074046017471e-08
single O 0 1.2844101604514435e-07
- O 0 2.1110906800458906e-07
nucleotide O 0 6.658133315795567e-07
events O 0 3.358467282055244e-08
, O 0 2.5693569494222857e-10
deletions O 0 1.508935976168857e-09
and O 0 2.8008451113947785e-10
substitutions O 0 3.3883007510837615e-09
, O 0 6.520934903164743e-10
some O 0 1.2860195131025876e-09
of O 0 2.9136545620644938e-08
which O 0 8.257983630244325e-09
alter O 0 4.927798045173404e-07
splice O 0 1.482001835029223e-06
sites O 0 2.477138849599214e-08
, O 0 4.1387335225628874e-10
and O 0 1.9564623254808566e-09
others O 0 4.103788953102594e-08
codons O 0 1.468000050408591e-06
. O 0 4.150161032612232e-07

They O 0 3.5215300897561974e-08
are O 0 1.784132841464725e-10
distributed O 0 3.201326426172102e-10
along O 0 7.2552883700893744e-09
the O 0 8.533395146059775e-08
C7 O 0 7.43223208701238e-05
gene O 0 1.1894394358336058e-09
, O 0 3.5827504157870393e-11
but O 0 8.87474815858269e-12
predominantly O 0 7.082415209858084e-11
towards O 0 1.9537997886232006e-09
the O 0 4.3997658849548316e-09
3 O 0 5.441461681243709e-08
end O 0 9.136034861967346e-08
. O 0 5.070074848845252e-08

All O 0 1.3616599403576402e-07
were O 0 2.866409687385385e-08
found O 0 3.0065263612044646e-09
in O 0 4.794940888785959e-09
compound O 0 4.5435288598127954e-07
heterozygous O 0 1.5539075803872038e-08
individuals O 0 2.928149278602632e-09
. O 0 3.272175419510859e-08

The O 0 0.0001786301436368376
C6 O 1 0.9999982118606567
/ O 0 0.005171455908566713
C7 O 0 0.0018540879245847464
marker O 0 1.4345970384965767e-06
haplotypes O 0 3.514465447551629e-07
associated O 0 8.565924858316976e-09
with O 0 3.4593490294554385e-09
most O 0 7.992700830072863e-07
C7 B-Disease 1 1.0
defects I-Disease 1 0.9999979734420776
are O 0 1.1955926915163673e-08
tabulated O 0 1.79662993105012e-06
. O 0 3.8850856753924745e-08
. O 0 5.343934716961485e-08

A O 0 6.033230420143809e-06
genome O 0 3.8598031437686586e-08
- O 0 2.2953045686335827e-08
wide O 0 6.155310927624669e-09
search O 0 3.0454568644699975e-08
for O 0 1.463161036774352e-09
chromosomal O 0 2.1201803974690847e-05
loci O 0 4.2488460394451977e-07
linked O 0 5.335437435860513e-06
to O 0 1.3120751596318314e-08
mental O 1 1.0
health O 0 8.604439472037484e-07
wellness O 0 2.6606410301610595e-06
in O 0 6.647368211432081e-10
relatives O 0 1.9211514601380486e-09
at O 0 2.042408242530769e-09
high O 0 9.518469568092769e-09
risk O 0 9.95539949144586e-07
for O 0 5.414034148998326e-06
bipolar B-Disease 1 1.0
affective I-Disease 1 1.0
disorder I-Disease 1 1.0
among O 0 7.543241586915883e-09
the O 0 3.5954542454419425e-08
Old O 0 3.2394791560363956e-06
Order O 0 3.480795953691995e-07
Amish O 0 9.749606761033647e-06
. O 0 6.169064903360777e-08

Bipolar B-Disease 1 1.0
affective I-Disease 1 1.0
disorder I-Disease 1 1.0
( O 1 0.9999330043792725
BPAD B-Disease 1 1.0
; O 1 0.9995751976966858
manic B-Disease 1 1.0
- I-Disease 1 1.0
depressive I-Disease 1 1.0
illness I-Disease 1 1.0
) O 0 3.0988931030151434e-06
is O 0 6.86487311440942e-09
characterized O 0 7.838734994436436e-09
by O 0 1.8566780335405042e-09
episodes O 0 1.7130506648754817e-06
of O 0 1.853109642979689e-05
mania B-Disease 0 0.0002843945985659957
and O 0 8.71304473548662e-06
/ O 1 1.0
or O 1 0.9999736547470093
hypomania B-Disease 1 1.0
interspersed O 0 3.2812600693432614e-05
with O 0 6.914836259142021e-09
periods O 0 0.3823980987071991
of O 0 0.11799824982881546
depression B-Disease 1 1.0
. O 0 1.525507514088531e-06

Compelling O 0 2.2829781300970353e-06
evidence O 0 9.132079981100105e-08
supports O 0 7.974118032549882e-10
a O 0 4.620376581332408e-10
significant O 0 1.1616334560926589e-09
genetic O 0 1.1105657726773188e-08
component O 0 3.339107124133989e-08
in O 0 1.6131621594084322e-09
the O 0 1.1972539404325744e-08
susceptibility O 0 2.353437338342701e-07
to O 0 2.0314415039024425e-08
develop O 0 6.0700222093146294e-06
BPAD B-Disease 1 1.0
. O 0 2.584111825854052e-06

To O 0 2.21334683914165e-08
date O 0 5.8266337532586476e-08
, O 0 3.1052005411424943e-10
however O 0 5.000126979126662e-10
, O 0 4.289571753357535e-10
linkage O 0 1.0291530827544193e-07
studies O 0 4.289475885599359e-09
have O 0 8.708280624381004e-11
attempted O 0 9.527043154378134e-09
only O 0 3.314054031200442e-10
to O 0 4.1201611566954455e-10
identify O 0 2.6800917041214234e-08
chromosomal O 0 1.165290450444445e-05
loci O 0 4.1357870372848993e-07
that O 0 2.350313277332816e-09
cause O 0 1.208610456160386e-07
or O 0 5.0502286796927365e-09
increase O 0 7.661442036344113e-10
the O 0 4.680865028916514e-09
risk O 0 1.12936398011243e-07
of O 0 2.634430416037503e-07
developing O 0 9.36480410018703e-06
BPAD B-Disease 1 1.0
. O 0 1.2400282685121056e-06

To O 0 5.961407367749416e-08
determine O 0 4.472380155107203e-08
whether O 0 1.4424378136368432e-08
there O 0 1.2872251708984095e-08
could O 0 3.6412641790661837e-09
be O 0 5.694132720890366e-09
protective O 0 1.8940570001291235e-08
alleles O 0 5.727733842775251e-10
that O 0 1.6315448991832682e-10
prevent O 0 1.613337574646323e-09
or O 0 2.6809594544374704e-09
reduce O 0 1.1406133815228259e-09
the O 0 6.280713282791339e-09
risk O 0 3.8044012740101607e-07
of O 0 4.909269932795723e-07
developing O 0 0.0003623999946285039
BPAD B-Disease 1 1.0
, O 0 1.2491445655626876e-09
similar O 0 4.0793098066149724e-11
to O 0 5.236868230729108e-11
what O 0 1.6498066801595712e-11
is O 0 1.400381199889722e-11
observed O 0 1.3202425264147166e-10
in O 0 1.3217896221995318e-10
other O 0 1.3976606538790293e-09
genetic B-Disease 1 1.0
disorders I-Disease 1 1.0
, O 0 7.323340267539891e-10
we O 0 6.02311978070702e-10
used O 0 1.234443924857942e-08
mental O 1 0.8527392148971558
health O 0 1.014895687490025e-07
wellness O 0 1.2113249567846651e-06
( O 0 3.2799077342993144e-10
absence O 0 2.1168933272974755e-09
of O 0 2.272455557061903e-09
any O 0 2.6955433440889465e-08
psychiatric B-Disease 1 0.9999998807907104
disorder I-Disease 0 0.008977517485618591
) O 0 3.997123465548924e-10
as O 0 1.3752776695241664e-10
the O 0 8.297498799159087e-10
phenotype O 0 5.50361622941864e-09
in O 0 1.742717747887923e-09
our O 0 2.234091489583534e-08
genome O 0 8.376437321544472e-09
- O 0 3.7520901940979456e-08
wide O 0 6.733419155580123e-08
linkage O 0 8.937010989029659e-07
scan O 0 2.968892829358083e-07
of O 0 2.875828819526305e-08
several O 0 4.002397080427045e-09
large O 0 3.4369371348930144e-08
multigeneration O 0 3.9158832805696875e-05
Old O 0 1.1190368240932003e-05
Order O 0 1.3816567445701367e-07
Amish O 0 3.4237252748425817e-06
pedigrees O 0 1.1165727187290031e-07
exhibiting O 0 6.568699362219377e-09
an O 0 2.5953136861822657e-10
extremely O 0 6.470167512873104e-09
high O 0 7.395849621616435e-08
incidence O 0 0.00019399067969061434
of O 0 0.0005343326483853161
BPAD B-Disease 1 1.0
. O 0 2.308451030330616e-06

We O 0 2.8971194865334837e-07
have O 0 2.313080837978987e-09
found O 0 1.6057086771326112e-09
strong O 0 1.3021991263073573e-09
evidence O 0 1.6321068940783334e-08
for O 0 3.0949429685733776e-09
a O 0 6.674765273828598e-08
locus O 0 2.4863274461495166e-07
on O 0 3.79421187801654e-08
chromosome O 0 1.7826437215262558e-07
4p O 0 0.00016821302415337414
at O 0 1.9634001091617392e-06
D4S2949 O 0 8.61118735429045e-07
( O 0 9.652572074969612e-09
maximum O 0 5.423204640919721e-08
GENEHUNTER O 0 1.5855977153478307e-06
- O 0 8.18713061789822e-08
PLUS O 0 2.5346574261675414e-07
nonparametric O 0 1.0904240070885862e-06
linkage O 0 6.114942152635194e-08
score O 0 7.168423188375073e-09
= O 0 1.1057867510544384e-08
4 O 0 1.0343301326543042e-08
. O 0 3.917353108562338e-10
05 O 0 1.5884477022609644e-07
, O 0 1.3560784717370211e-09
P O 0 8.794638119979936e-07
= O 0 3.759117106483245e-08
5 O 0 1.7464313328829917e-09
. O 0 3.612166121769178e-11
22 O 0 5.835781302643284e-10
x O 0 1.2598594389956475e-09
10 O 0 4.938368602935839e-10
( O 0 1.2325322706896458e-10
- O 0 4.0738842854715074e-10
4 O 0 3.371642076643866e-09
) O 0 1.267175392394293e-10
; O 0 7.869647294933557e-11
SIBPAL O 0 8.440703140877304e-07
Pempirical O 0 1.3151478697182029e-06
value O 0 8.747730362301809e-08
< O 0 4.615537108065837e-08
3 O 0 2.1423942619946956e-09
x O 0 3.1903075736749997e-09
10 O 0 8.192325151590296e-10
( O 0 1.0323818189217349e-10
- O 0 9.902730718769348e-11
5 O 0 8.61517357453323e-10
) O 0 4.488610177988406e-11
) O 0 5.515019864399395e-12
and O 0 4.2105008715709324e-12
suggestive O 0 2.1431829644313893e-09
evidence O 0 3.5483491700460945e-09
for O 0 8.362225356606245e-10
a O 0 2.6404942232716166e-08
locus O 0 1.7003910102175723e-07
on O 0 2.7253415524342017e-08
chromosome O 0 6.798719027756306e-07
4q O 0 9.481826964474749e-06
at O 0 2.824550335844833e-07
D4S397 O 0 4.507835740241717e-07
( O 0 5.912519807083072e-09
maximum O 0 5.8596672403155026e-08
GENEHUNTER O 0 3.4620090900716605e-06
- O 0 1.2715109676264547e-07
PLUS O 0 2.8237261062713515e-07
nonparametric O 0 5.331951342668617e-07
linkage O 0 5.23359098281162e-08
score O 0 2.6037734190964557e-09
= O 0 3.6626761623637094e-09
3 O 0 4.883199955507678e-10
. O 0 1.2127381564253081e-11
29 O 0 1.5245346096648404e-09
, O 0 3.015121763372264e-10
P O 0 3.2899836810429406e-07
= O 0 2.0391397015373514e-08
2 O 0 1.881382383217556e-09
. O 0 2.718474056973008e-11
57 O 0 6.301865695945708e-10
x O 0 3.019071215248914e-09
10 O 0 1.8557151371112468e-09
( O 0 3.4744040977585655e-10
- O 0 7.722503192475472e-10
3 O 0 4.779372453356245e-09
) O 0 2.868205950523617e-10
; O 0 1.8332479978511174e-10
SIBPAL O 0 6.805959174016607e-07
Pempirical O 0 1.0975027180393226e-06
value O 0 1.074022790703566e-07
< O 0 4.221332972065284e-08
1 O 0 3.924886193829025e-09
x O 0 2.9043814020468517e-09
10 O 0 9.977092485513595e-10
( O 0 1.6976679784175275e-10
- O 0 3.1859459515004573e-10
3 O 0 2.453775849176054e-09
) O 0 8.541280877016888e-11
) O 0 1.1579225425717432e-11
that O 0 8.264475258659698e-13
are O 0 1.3384262448346007e-11
linked O 0 3.718077845604739e-09
to O 0 3.837002271467327e-09
mental O 1 0.9999935626983643
health O 0 5.7186634876416065e-06
wellness O 0 7.344152982113883e-05
. O 0 3.203583887056993e-08

These O 0 1.4768583689317438e-08
findings O 0 1.7304996546840812e-08
are O 0 4.1180553411734877e-10
consistent O 0 3.073723275903717e-09
with O 0 1.3209345076092838e-11
the O 0 1.4264291969823262e-09
hypothesis O 0 6.603885882583427e-09
that O 0 6.0717082403516365e-12
certain O 0 5.785495346688485e-11
alleles O 0 2.109371427527762e-10
could O 0 1.0791081361816168e-09
prevent O 0 1.1961675205895972e-08
or O 0 1.018659645524167e-08
modify O 0 2.372219531920905e-09
the O 0 4.921924645628906e-09
clinical O 0 1.689296254880901e-06
manifestations O 0 1.8771072063827887e-05
of O 0 0.00025730289053171873
BPAD B-Disease 1 1.0
and O 0 3.3185025838378124e-09
perhaps O 0 1.7065187041254148e-09
other O 0 1.2991246967075654e-10
related O 0 3.424764872761443e-05
affective B-Disease 1 0.9999998807907104
disorders I-Disease 1 1.0
. O 0 8.268245892395498e-07

Segregation O 0 0.0009078480070456862
distortion O 0 0.001017842791043222
in O 0 7.849509529478382e-06
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 4.508146503212629e-06

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9987163543701172
DM B-Disease 1 1.0
) O 0 7.415314229319847e-08
is O 0 2.3785351466187876e-09
an O 0 6.9644188194217804e-09
autosomal B-Disease 1 0.9999954700469971
dominant I-Disease 1 0.999996542930603
disease I-Disease 1 0.9999978542327881
which O 0 3.9735081891478785e-09
, O 0 1.3420083100346147e-10
in O 0 1.346292965997975e-09
the O 0 1.7993970757856914e-08
typical O 0 8.988680519905756e-07
pedigree O 0 9.42420967930957e-08
, O 0 7.398265333691256e-11
shows O 0 6.484024983599568e-10
a O 0 1.41509637341386e-09
three O 0 1.010005412638293e-09
generation O 0 2.0349162355159933e-08
anticipation O 0 4.2797776700354007e-07
cascade O 0 1.8340129827265628e-05
. O 0 3.6098060718359193e-07

This O 0 8.932893535984476e-09
results O 0 1.3957406785891635e-08
in O 0 5.8888208087637395e-08
infertility B-Disease 1 0.9999996423721313
and O 0 1.4503822967526503e-05
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.0007250591879710555
CDM B-Disease 0 0.00010552552703302354
) O 0 9.735341005567832e-11
with O 0 7.573085387957423e-12
the O 0 4.785182916577924e-09
disappearance O 0 0.00013573365868069232
of O 0 0.0002664471394382417
DM B-Disease 1 1.0
in O 0 7.591074790980201e-07
that O 0 2.3310990471259174e-08
pedigree O 0 2.29534111895191e-06
. O 0 1.1318309134367155e-07

The O 0 1.648790686203938e-07
concept O 0 1.8096508824783086e-07
of O 0 1.3044487445768027e-07
segregation O 0 3.0310221177387575e-07
distortion O 0 2.917946062552801e-07
, O 0 1.4432757766691395e-10
where O 0 1.5670674480272595e-10
there O 0 1.2847635455504047e-10
is O 0 6.457179235752619e-11
preferential O 0 3.433814899089782e-10
transmission O 0 3.0272129247777002e-09
of O 0 1.3836874979133995e-09
the O 0 2.315305280831126e-09
larger O 0 2.2547197442435163e-09
allele O 0 2.765956796935143e-09
at O 0 7.599638252031582e-08
the O 0 4.4261093989916844e-07
DM B-Disease 1 1.0
locus O 0 2.5324493435618933e-06
, O 0 8.78955075389598e-10
has O 0 1.7314190359218884e-10
been O 0 3.896413469650639e-10
put O 0 8.107327587048019e-10
forward O 0 6.0678040370021336e-09
to O 0 7.326683704178549e-09
explain O 0 2.7978347816315363e-07
partially O 0 1.28740771287994e-06
the O 0 9.696068303810534e-08
maintenance O 0 6.49163339403458e-05
of O 0 1.977942156372592e-05
DM B-Disease 1 1.0
in O 0 1.1733183669093705e-07
the O 0 3.0371040793397697e-08
population O 0 1.042945174667409e-09
. O 0 5.188226737118384e-09

In O 0 5.115564363222802e-07
a O 0 1.1363821528220797e-07
survey O 0 1.278439185625757e-07
of O 0 3.9293831832765136e-07
DM B-Disease 1 1.0
in O 0 1.1800604227119038e-07
Northern O 0 9.317452054347086e-08
Ireland O 0 3.261171954704878e-08
, O 0 2.0626087504638235e-09
59 O 0 9.582118565276687e-08
pedigrees O 0 5.510330538527342e-07
were O 0 6.190776957737398e-08
ascertained O 0 2.740288664426771e-06
. O 0 1.2944296656769438e-07

Sibships O 0 0.001017126371152699
where O 0 2.0550726276269415e-07
the O 0 1.8022067393985708e-08
status O 0 8.096333203866379e-08
of O 0 4.25355679567474e-08
all O 0 2.467098969560766e-09
the O 0 1.1518249465325425e-08
members O 0 2.345512450929732e-09
had O 0 8.322228239876495e-09
been O 0 1.8793273603989746e-09
identified O 0 1.1585776782396806e-09
were O 0 2.0704762349055272e-09
examined O 0 6.959054221766792e-09
to O 0 5.940324343534087e-10
determine O 0 1.5595013280744752e-08
the O 0 3.887850752448685e-08
transmission O 0 4.250264566962869e-07
of O 0 6.43289752133569e-07
the O 0 6.523704996652668e-06
DM B-Disease 1 1.0
expansion O 0 5.907939794269623e-06
from O 0 1.0197194200145532e-07
affected O 0 1.6032736027682404e-08
parents O 0 9.35310939809142e-10
to O 0 9.165873060545948e-10
their O 0 2.048213154637324e-09
offspring O 0 3.802304249234112e-08
. O 0 8.336208168202575e-09

Where O 0 7.504403924940561e-07
the O 0 2.4885810034902534e-07
transmitting O 0 0.002184435026720166
parent O 0 1.977742249437142e-05
was O 0 3.538887176546268e-05
male O 0 1.7225310955382156e-07
, O 0 2.495428308435521e-09
58 O 0 2.5352883881168964e-07
. O 0 4.322469493445169e-08

3 O 0 1.9142521523463074e-06
% O 0 5.562472260578488e-09
of O 0 4.18216572484198e-09
the O 0 2.8348567937541702e-09
offspring O 0 5.995087981602865e-09
were O 0 5.997592644746419e-09
affected O 0 1.3568339785052785e-09
, O 0 6.617584952239852e-11
and O 0 1.0318561977085139e-10
in O 0 3.1473827988293124e-09
the O 0 1.3842609725145394e-08
case O 0 6.32596908189953e-08
of O 0 1.0631067226540836e-07
a O 0 1.1863250648502799e-07
female O 0 3.536864312536636e-08
transmitting O 0 9.54500478655973e-07
parent O 0 1.7010511044190935e-07
, O 0 7.009836711091566e-09
68 O 0 1.703594875834824e-06
. O 0 1.6437807914826408e-07

7 O 0 3.484865601421916e-06
% O 0 1.3346095784072531e-08
were O 0 1.9559523778411858e-08
affected O 0 1.3475627724801598e-08
. O 0 3.879569021592033e-08

Studies O 0 2.5941515104932478e-06
on O 0 6.343755387661076e-08
meiotic O 0 2.0517838947853306e-06
drive O 0 7.554921666041992e-08
in O 0 6.172019340056067e-08
DM B-Disease 1 1.0
have O 0 4.738415215754799e-10
shown O 0 4.6090928296216305e-10
increased O 0 1.3381366015252638e-09
transmission O 0 2.0552217705471776e-09
of O 0 7.563580317615504e-10
the O 0 4.173533463269763e-10
larger O 0 1.1262690086111249e-10
allele O 0 2.1914714487536457e-10
at O 0 9.335184181225031e-09
the O 0 7.538728397094019e-08
DM B-Disease 1 1.0
locus O 0 2.3458611053683853e-07
in O 0 6.525068929619238e-09
non O 0 7.188298809523985e-07
- O 0 8.891588549886364e-06
DM O 1 1.0
heterozygotes O 0 2.827287744366913e-06
for O 0 1.847423902745504e-08
CTGn O 0 0.00017004302935674787
. O 0 3.051571582091128e-07

This O 0 4.269097075848549e-08
study O 0 7.490437603507871e-09
provides O 0 4.492681227041828e-10
further O 0 1.5565519706495223e-10
evidence O 0 3.4885565547426722e-09
that O 0 3.658373604054077e-10
the O 0 4.771223416355497e-08
DM B-Disease 1 1.0
expansion O 0 8.20523212041735e-07
tends O 0 3.8721687189990917e-08
to O 0 3.8570027727224954e-10
be O 0 7.21263604397393e-10
transmitted O 0 1.4474454523849545e-08
preferentially O 0 4.221993066266805e-08
. O 0 2.8643492910873647e-08

Diagnosis O 1 1.0
of O 1 0.7557197213172913
hemochromatosis B-Disease 1 1.0
. O 0 9.478555148234591e-05

If O 0 0.0003717984654940665
untreated O 1 1.0
, O 0 8.163199709088076e-06
hemochromatosis B-Disease 1 1.0
can O 0 2.2514373995363712e-05
cause O 1 0.9996682405471802
serious O 1 0.9999998807907104
illness O 1 1.0
and O 0 8.320482081103364e-09
early B-Disease 0 1.1450000414470196e-07
death I-Disease 0 2.704359580718574e-08
, O 0 5.3438958119711444e-11
but O 0 5.323173499216516e-11
the O 0 1.5628982552584603e-09
disease O 0 6.028872121532913e-07
is O 0 6.083735182293992e-10
still O 0 1.1195551152809458e-09
substantially O 0 6.236724026109641e-09
under O 0 4.3860271148332686e-07
- O 0 0.00011108556645922363
diagnosed O 0 1.4499411008728202e-05
. O 0 9.634715780748593e-08

The O 0 1.3880743381378124e-06
cornerstone O 0 3.79023026653158e-06
of O 0 4.270359710289995e-08
screening O 0 2.7022133419762895e-09
and O 0 1.4079960808377479e-10
case O 0 3.060350639572107e-09
detection O 0 3.4117523028953656e-08
is O 0 2.1053037091434135e-10
the O 0 1.742525013170848e-09
measurement O 0 3.5085511740362563e-07
of O 0 5.460071150764634e-08
serum O 0 3.248407438150025e-06
transferrin O 0 4.551230085780844e-05
saturation O 0 1.2881286011179327e-06
and O 0 7.702820603583405e-10
the O 0 3.944135240629976e-09
serum O 0 6.677541364297213e-07
ferritin O 0 1.2959273590240628e-05
level O 0 2.4165012746379944e-06
. O 0 5.844977479796398e-08

Once O 0 2.369000185353798e-06
the O 0 5.1861917427231674e-08
diagnosis O 0 9.77335457719164e-06
is O 0 7.277741076450184e-09
suspected O 0 4.125074610783486e-06
, O 0 4.528463826147799e-09
physicians O 0 2.2743821048720747e-08
must O 0 1.8825534908728514e-08
use O 0 4.0556304981009816e-08
serum O 0 2.5278301109210588e-05
ferritin O 1 0.6352205276489258
levels O 0 9.58885793806985e-05
and O 0 7.7879199977815e-08
hepatic O 1 0.9955785870552063
iron O 0 0.039978545159101486
stores O 0 6.517577730846824e-07
on O 0 4.150215104914423e-08
liver O 0 1.7445286459860654e-07
biopsy O 0 9.047939641959601e-08
specimens O 0 1.3689632760716108e-09
to O 0 2.0345727880233255e-10
assess O 0 4.504827444407056e-08
patients O 0 3.0544606843818656e-09
for O 0 2.4266355591606725e-10
the O 0 7.596750783989137e-09
presence O 0 3.810232129808355e-08
of O 0 5.2726550165971275e-06
iron B-Disease 1 0.9997872710227966
overload I-Disease 1 0.9996687173843384
. O 0 8.481088116241153e-07

Liver O 1 0.9999969005584717
biopsy O 1 0.9999911785125732
is O 0 1.193777023900111e-07
also O 0 1.1881537975710899e-09
used O 0 6.604147229083424e-10
to O 0 6.955321874002607e-10
establish O 0 2.7715612915812926e-08
the O 0 1.2686784067739154e-08
presence O 0 1.5918379503432334e-08
or O 0 8.294119169249825e-08
absence O 0 3.790393350300292e-07
of O 0 4.370338047010591e-06
cirrhosis B-Disease 1 0.9999998807907104
, O 0 7.29213245342919e-10
which O 0 9.133913070336064e-11
can O 0 1.8410270530289097e-10
affect O 0 4.003811326924733e-08
prognosis O 0 0.00019273000361863524
and O 0 3.7717718726071325e-08
management O 0 2.630904782563448e-05
. O 0 3.3058191206691845e-07

A O 0 3.289840606157668e-06
DNA O 0 4.080420623608916e-08
- O 0 3.5238194584508165e-09
based O 0 4.015171806148743e-10
test O 0 2.8240618177299837e-10
for O 0 3.543288717988702e-10
the O 0 1.9899131231682077e-08
HFE O 0 0.00012718570360448211
gene O 0 1.099353164057959e-09
is O 0 3.3249042408201035e-11
commercially O 0 3.667497971981959e-10
available O 0 2.7611957165163403e-10
, O 0 2.8516435740533197e-11
but O 0 3.362570638598683e-11
its O 0 3.051441391233034e-11
place O 0 3.902616840800732e-10
in O 0 1.3692837141920933e-10
the O 0 2.6367783512171172e-09
diagnosis O 0 3.4639178920770064e-06
of O 0 1.3061869594821474e-06
hemochromatosis B-Disease 1 1.0
is O 0 2.87809854171428e-07
still O 0 1.7443847255549372e-08
being O 0 1.2538740712386698e-08
evaluated O 0 1.4900554390351317e-07
. O 0 8.118910699295157e-08

Currently O 0 5.276822321320651e-07
, O 0 7.154296044475927e-10
the O 0 1.7544274921732494e-09
most O 0 2.3562188311565535e-10
useful O 0 9.654469224074091e-09
role O 0 3.5188292279997313e-09
for O 0 7.14466874551789e-10
this O 0 2.484157879401039e-10
test O 0 3.062112508001036e-10
is O 0 7.077783498177226e-11
in O 0 6.784991318786737e-11
the O 0 1.0573525388579696e-09
detection O 0 2.3250031233601476e-07
of O 0 1.0302259170202888e-06
hemochromatosis B-Disease 1 1.0
in O 0 2.2886872557137394e-06
the O 0 5.716617579309968e-07
family O 0 5.5798274445351126e-08
members O 0 2.741343818613018e-10
of O 0 4.295739319815084e-09
patients O 0 1.675123650901611e-10
with O 0 1.808019012283779e-11
a O 0 8.053697264642778e-09
proven O 0 2.3494230561027507e-07
case O 0 1.0208457190685749e-08
of O 0 2.662188691715528e-08
the O 0 1.0343819667468779e-07
disease O 0 6.917080554558197e-06
. O 0 3.849186924753667e-08

It O 0 7.420489112064388e-09
is O 0 1.5544224796215644e-09
crucial O 0 6.957345277669447e-08
to O 0 1.0622088097989035e-07
diagnose O 1 1.0
hemochromatosis B-Disease 1 1.0
before O 1 1.0
hepatic B-Disease 1 1.0
cirrhosis I-Disease 1 1.0
develops O 1 0.8699787855148315
because O 0 1.2688047945630387e-07
phlebotomy O 1 0.9999998807907104
therapy O 0 0.08380913734436035
can O 0 8.755217106859448e-10
avert O 0 2.9143270694476087e-06
serious O 1 1.0
chronic O 1 1.0
disease O 1 1.0
and O 0 3.718099383931417e-09
can O 0 2.5422837168775914e-09
even O 0 1.1200058658289436e-09
lead O 0 2.7371604982562303e-09
to O 0 1.0732927879786303e-09
normal O 0 7.062003248847759e-08
life O 0 1.4647812740520294e-08
expectancy O 0 1.347490830028164e-08
. O 0 1.0360608204695865e-10
. O 0 1.4308899620729676e-09

Prevalence O 0 0.0005309901316650212
of O 0 2.7714509087672923e-07
the O 0 1.6276619874133758e-07
I1307K O 0 1.7926005966728553e-05
APC B-Disease 0 1.3022963685216382e-06
gene O 0 5.3606639127679045e-09
variant O 0 5.425591975694033e-09
in O 0 1.2265012339085501e-09
Israeli O 0 4.5310407870147174e-08
Jews O 0 9.913224685575983e-10
of O 0 7.285247405341977e-11
differing O 0 1.1412411814182288e-11
ethnic O 0 8.375944902938581e-12
origin O 0 7.791296080528198e-11
and O 0 1.0674004735644615e-10
risk O 0 1.723152251997817e-07
for O 0 1.343386793450918e-05
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 8.15692783362465e-06

BACKGROUND O 0 0.001031218678690493
& O 0 5.8758170780492947e-05
AIMS O 0 9.292069080402143e-06
Israeli O 0 6.274181941989809e-06
Jews O 0 4.792328311964411e-08
of O 0 1.6798477275870027e-08
European O 0 3.2808042949028504e-09
birth O 0 8.002248641503229e-09
, O 0 3.1356134355675636e-10
i O 0 2.150221556362908e-09
. O 0 1.513838776556753e-10
e O 0 2.600363924187832e-09
. O 0 6.330511115315574e-11
, O 0 2.3493529344165154e-10
Ashkenazim O 0 1.874646073929398e-07
, O 0 2.645931251876732e-10
have O 0 1.0838663300205553e-10
the O 0 3.030702355744097e-09
highest O 1 0.9999654293060303
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
incidence O 1 1.0
of O 0 4.562390643059189e-08
any O 0 2.350541761231284e-09
Israeli O 0 1.0544714257321175e-07
ethnic O 0 1.0597228650155444e-09
group O 0 6.0287081993237734e-09
. O 0 1.6900933985652955e-08

The O 0 8.992402399599086e-06
I1307K O 0 0.0001289752690354362
APC B-Disease 0 6.7082892201142386e-06
gene O 0 1.9941456486094467e-08
variant O 0 1.0887282186899938e-08
was O 0 1.0615687529025308e-07
found O 0 4.419901777907853e-09
in O 0 5.667370128747962e-09
6 O 0 8.221069833780348e-07
. O 0 1.1644562647461498e-07

1 O 0 1.0546781368248048e-06
% O 0 1.0436740360830754e-08
of O 0 5.686904280821636e-09
American O 0 8.708621379582837e-09
Jews O 0 3.656324576439829e-09
, O 0 4.7253354007459336e-11
28 O 0 2.3945032623373663e-09
% O 0 1.7554273312736512e-10
of O 0 4.505922579500776e-10
their O 0 1.6929882917793293e-07
familial O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
cases O 0 0.023288507014513016
, O 0 6.436962768363585e-11
but O 0 2.971003304486075e-11
not O 0 4.444099255263012e-11
in O 0 7.767381182688382e-10
non O 0 1.7276063601912028e-07
- O 0 5.8430604354953175e-08
Jews O 0 1.4066654330235906e-07
. O 0 2.2256065435044547e-08

We O 0 2.275128991868769e-07
assessed O 0 2.504628469068848e-07
the O 0 1.970041374477205e-08
I1307K O 0 9.268723601962847e-07
prevalence O 0 1.802908542458681e-07
in O 0 4.6282527810248553e-10
Israeli O 0 2.48489957499487e-08
Jews O 0 2.7753302433985994e-10
of O 0 1.5375015496865707e-11
differing O 0 2.1120345056191425e-12
ethnic O 0 3.893527427550891e-12
origin O 0 2.9933003992121954e-11
and O 0 2.0937498262929566e-11
risk O 0 2.8845194677273867e-08
for O 0 2.2088695459387964e-06
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 4.627067028195597e-06

METHODS O 0 1.9958752091042697e-06
DNA O 0 4.445352175252992e-08
samples O 0 2.728960390996349e-09
from O 0 3.1742288797431684e-09
500 O 0 1.068554489336293e-08
unrelated O 0 1.7649570693833994e-08
Jews O 0 1.7986558020766097e-08
of O 0 2.834306656041008e-08
European O 0 1.504456648149244e-08
or O 0 3.741962828485157e-08
non O 0 7.417223457650834e-08
- O 0 3.450045138464475e-09
European O 0 1.4747267851333845e-09
origin O 0 3.402859993784091e-09
, O 0 5.899266491971034e-11
with O 0 2.2779037336939645e-11
or O 0 2.335539539544129e-09
without O 0 2.249560537848083e-09
a O 0 1.5473830217160867e-08
personal O 0 1.9632412318060233e-07
and O 0 4.677152887211378e-09
/ O 0 2.383696937613422e-06
or O 0 3.835120878648013e-07
family O 0 2.052555601039785e-07
history O 0 1.1049476142943604e-06
of O 0 1.6504598079336574e-06
neoplasia B-Disease 0 0.00020671673701144755
, O 0 2.9728541850460033e-09
were O 0 1.791845249954349e-08
examined O 0 5.8580472028779695e-08
for O 0 3.5724845304230257e-09
the O 0 2.742486593376725e-08
I1307K O 0 2.9842183835171454e-07
variant O 0 1.2346387245898427e-09
by O 0 1.9982977772503574e-10
the O 0 6.980507283316228e-10
allele O 0 1.1569915164821865e-10
- O 0 9.531508915472386e-10
specific O 0 6.184067702363905e-10
oligonucleotide O 0 1.9889347413482028e-07
( O 0 4.122193075772884e-08
ASO O 0 1.0499734344193712e-06
) O 0 5.089078602971142e-10
method O 0 9.060992844922566e-09
. O 0 7.420914105438214e-09

RESULTS O 0 8.966522386799625e-07
In O 0 1.0926663129851022e-08
persons O 0 9.4935570515986e-09
at O 0 4.438284406660387e-09
average O 0 1.0403569561390213e-08
risk O 0 3.520844771287557e-08
for O 0 4.259457455191296e-06
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, O 0 7.297182378351863e-07
I1307K O 0 1.1866887916767155e-06
was O 0 5.70646498943006e-08
found O 0 1.068468424847424e-09
in O 0 1.1827182566648275e-09
5 O 0 8.18933258983634e-08
. O 0 2.0789613586202904e-08

0 O 0 3.1462326433029375e-07
% O 0 2.7832780524761347e-09
of O 0 3.3463292137270173e-09
120 O 0 1.0401068450960338e-08
European O 0 4.661015573503846e-09
and O 0 5.086344678773003e-09
1 O 0 7.581322734040441e-07
. O 0 5.99281548829822e-08

6 O 0 2.6414470539748436e-06
% O 0 9.468348771690671e-09
of O 0 7.0520798090001335e-09
188 O 0 1.8025504644469947e-08
non O 0 3.1398716515695924e-08
- O 0 6.568773969206632e-09
European O 0 8.022880138014443e-09
Jews O 0 2.660062037307398e-08
( O 0 1.1131227051208725e-09
P O 0 1.1671077970731858e-07
= O 0 8.958367381239896e-09
0 O 0 3.6624089871928334e-10
. O 0 3.816124499733675e-11
08 O 0 1.81757524586601e-08
) O 0 1.1604176508583919e-09
. O 0 2.032793267048305e-09

It O 0 7.5844184266316e-08
occurred O 0 4.534222455276904e-07
in O 0 1.048310505069594e-08
15 O 0 1.4293105721208121e-07
. O 0 4.9944514302069365e-08

4 O 0 9.7021700184996e-07
% O 0 2.7386903855841638e-09
of O 0 2.448903968499394e-09
52 O 0 2.984468494560133e-08
Ashkenazi O 0 2.2027742829777708e-07
Israelis O 0 7.975342697363885e-08
with O 0 2.424809242285164e-09
familial O 0 0.00011219226144021377
cancer B-Disease 0 1.1793007615779061e-05
( O 0 2.3338357379998342e-07
P O 0 0.00021227724209893495
= O 0 2.7137204483551614e-07
0 O 0 6.671059704643767e-09
. O 0 1.8106877108792219e-10
02 O 0 6.108320604880646e-08
) O 0 9.556552771350368e-11
and O 0 5.7672946279785364e-11
was O 0 9.019196944848318e-09
not O 0 4.3215994671719216e-10
detected O 0 3.5386167329676255e-09
in O 0 8.378350235815901e-10
51 O 0 7.000847546123623e-08
non O 0 3.4573768061818555e-06
- O 0 8.082847102741653e-08
European O 0 1.0385150517322472e-08
Jews O 0 2.0536750966471118e-08
at O 0 8.77732553306032e-09
increased O 0 6.925527262779951e-09
cancer B-Disease 0 4.392531991470605e-07
risk O 0 1.3128291698194516e-07
. O 0 1.9101216608419236e-08

Colorectal B-Disease 1 0.9999998807907104
neoplasia I-Disease 1 0.9999996423721313
occurred O 1 0.8605436682701111
personally O 0 4.837382221012376e-06
or O 0 1.1145279898983063e-07
in O 0 9.651339283323068e-09
the O 0 1.9469819534378985e-08
families O 0 2.351353334262285e-09
of O 0 5.32782387097086e-08
13 O 0 1.8455946815265634e-07
of O 0 7.667616728213034e-07
20 O 0 8.973108833743026e-07
Ashkenazi O 0 8.051163717937015e-07
I1307K O 0 3.507340124997427e-07
carriers O 0 3.4193856635056363e-09
, O 0 1.2480705358086652e-09
8 O 0 7.347566821636065e-08
of O 0 5.103149192109413e-07
whom O 0 5.860292731085792e-07
also O 0 4.9932989298895336e-08
had O 0 3.0227434422158694e-07
a O 0 5.849009312441922e-07
personal O 0 6.228205893421546e-05
or O 0 1.8603981288833893e-07
family O 0 8.477086765878994e-08
history O 0 8.14383156466647e-07
of O 0 1.8068043573293835e-05
noncolonic O 0 0.1439560502767563
neoplasia B-Disease 1 0.999805748462677
. O 0 5.098015662952093e-06

CONCLUSIONS O 0 6.10143797530327e-05
The O 0 2.54227143159369e-06
I1307K O 0 3.452262899372727e-05
APC O 0 1.2531086213130038e-06
variant O 0 5.050999618561036e-09
may O 0 1.6778006761697384e-09
represent O 0 1.854922326849362e-09
a O 0 3.375942370098528e-08
susceptibility O 0 4.6395976482926926e-07
gene O 0 6.54677290157224e-09
for O 0 1.8522682054822326e-08
colorectal B-Disease 1 1.0
, I-Disease 0 1.567879905906011e-07
or I-Disease 0 1.1682536182888725e-07
other I-Disease 0 2.765976336860376e-10
, I-Disease 0 8.994591738087365e-10
cancers I-Disease 0 8.431270543951541e-06
in O 0 1.0661729987759827e-07
Ashkenazi O 0 0.0002660891623236239
Jews O 0 1.0059608257506625e-06
, O 0 7.402094492903188e-10
and O 0 9.684840707180342e-10
partially O 0 1.3404513765635784e-06
explains O 0 2.3618277111836505e-08
the O 0 1.4742260745492786e-09
higher O 0 7.306410054752632e-08
incidence O 0 0.0002710731641855091
of O 0 0.03314045071601868
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 2.429107780699269e-06
European O 0 8.173773835551401e-08
Israelis O 0 6.043707685421396e-07
. O 0 8.322196265453385e-09

Systematic O 0 2.285766640852671e-06
analysis O 0 5.0348237579100896e-08
of O 0 3.719001995250437e-08
coproporphyrinogen O 0 0.00014284424833022058
oxidase O 0 1.4445667147811037e-05
gene O 0 3.063341637243866e-06
defects O 0 0.04929209500551224
in O 0 2.316906346777614e-07
hereditary B-Disease 1 1.0
coproporphyria I-Disease 1 0.9999610185623169
and O 0 8.622875924402251e-08
mutation O 0 9.17700688773948e-08
update O 0 8.414277203883103e-07
. O 0 6.472762237308416e-08

Hereditary B-Disease 1 1.0
coproporphyria I-Disease 1 0.9999961853027344
( O 0 2.2131322111818008e-05
HC B-Disease 1 1.0
) O 0 3.219836344214855e-07
is O 0 3.3555966894027733e-09
an O 0 4.095117489555378e-08
acute O 1 1.0
hepatic B-Disease 1 1.0
porphyria I-Disease 1 1.0
with O 0 0.0070343310944736
autosomal O 1 1.0
dominant O 1 0.9999982118606567
inheritance O 0 0.36447182297706604
caused O 0 5.544791747524869e-06
by O 0 4.997355418367988e-09
deficient B-Disease 0 1.2682905435212888e-05
activity I-Disease 0 1.3994895198266022e-06
of I-Disease 0 1.0984985010509263e-06
coproporphyrinogen I-Disease 0 2.119401870004367e-05
III I-Disease 0 0.047349315136671066
oxidase I-Disease 0 5.576875992119312e-06
( O 0 9.763788000327622e-08
CPO O 0 6.238295100047253e-06
) O 0 2.1532757799036517e-08
. O 0 2.856514491611506e-08

Clinical O 1 0.6801032423973083
manifestations O 0 0.004428939428180456
of O 0 1.617521547814249e-06
the O 0 5.193071501707891e-07
disease O 1 0.5938976407051086
are O 0 8.034020670955044e-11
characterized O 0 4.908394246605496e-10
by O 0 1.7955487097154332e-10
acute O 0 0.0022281650453805923
attacks O 0 6.234918004111023e-08
of O 0 0.0006582142086699605
neurological B-Disease 1 1.0
dysfunction I-Disease 1 1.0
often O 0 1.4647924651001176e-08
precipitated O 0 9.685384583235646e-08
by O 0 4.849756707336894e-10
drugs O 0 9.394267586060323e-10
, O 0 3.629980205310801e-10
fasting O 0 1.2039276953146327e-06
, O 0 2.128789367006334e-09
cyclical O 0 0.004158043768256903
hormonal O 0 9.819403203437105e-06
changes O 0 2.863998371793741e-09
, O 0 1.7174411892639796e-09
or O 0 2.6463334279469564e-07
infectious B-Disease 1 0.9394076466560364
diseases I-Disease 1 0.9999994039535522
. O 0 3.718754214787623e-06

Skin O 1 1.0
photosensitivity O 1 1.0
may O 0 0.0001476133766118437
also O 0 1.9663024986016353e-08
be O 0 8.569699616600701e-09
present O 0 6.013677733562872e-08
. O 0 2.2517752995554474e-07

The O 0 3.237846613046713e-07
seven O 0 1.3904549689414125e-07
exons O 0 7.138014268548432e-08
, O 0 1.0771812331000774e-09
the O 0 3.028253559023142e-08
exon O 0 5.610498305941292e-07
/ O 0 4.2596707316988613e-07
intron O 0 2.6652276119421003e-07
boundaries O 0 3.113017843503485e-09
and O 0 5.273566583419154e-10
part O 0 5.501370470284428e-09
of O 0 1.1905310515203382e-07
3 O 0 5.146941930433968e-07
noncoding O 0 3.1072420370037435e-07
sequence O 0 1.7968110554988925e-08
of O 0 5.6969383877003565e-08
the O 0 7.409390434531815e-08
CPO O 0 7.902011020632926e-06
gene O 0 6.307641076119808e-09
were O 0 1.4441556395183852e-08
systematically O 0 3.5642777618249966e-08
analyzed O 0 5.053813367794646e-09
by O 0 1.0115823734224705e-09
an O 0 2.757639006034651e-09
exon O 0 8.151273434009454e-09
- O 0 7.277269009620113e-09
by O 0 1.5434979516726344e-08
- O 0 7.137877560126071e-07
exon O 0 1.01249509043555e-06
denaturing O 0 4.6212499000830576e-05
gradient O 0 3.1287693218473578e-06
gel O 0 5.771423730038805e-07
electrophoresis O 0 1.7198225350512075e-06
( O 0 6.538551389212444e-08
DGGE O 0 1.999269261432346e-05
) O 0 1.94842608713941e-09
strategy O 0 2.6028796895616324e-09
followed O 0 7.426743664495916e-10
by O 0 9.164645431436469e-11
direct O 0 7.208331154195946e-10
sequencing O 0 3.739761555987542e-10
in O 0 2.9576779914108897e-10
seven O 0 3.9313374777805166e-09
unrelated O 0 1.0386066406908867e-07
heterozygous O 0 9.847575910271189e-08
HC B-Disease 0 0.03283553197979927
patients O 0 9.219006358307524e-08
from O 0 9.887848761991336e-09
France O 0 2.884261007807254e-08
, O 0 1.0764500402160593e-09
Holland O 0 8.248920124742654e-08
, O 0 1.1301861668755464e-09
and O 0 6.777221561726776e-10
Czech O 0 1.7921582866620156e-06
Republic O 0 9.041056910064071e-05
. O 0 2.4868706987035694e-06

Seven O 0 5.511749918696296e-07
novel O 0 9.922180055355057e-08
mutations O 0 6.5612866251285595e-09
and O 0 2.690891676149221e-10
two O 0 7.61659457726438e-10
new O 0 5.277252412838607e-09
polymorphisms O 0 7.443689469255332e-07
were O 0 5.041608233113948e-07
detected O 0 1.5220242630675784e-06
. O 0 1.3451546010401216e-07

Among O 0 4.830944089206923e-09
these O 0 9.952871860008372e-11
mutations O 0 2.795252085352473e-10
two O 0 3.478707599757769e-10
are O 0 4.983988222129199e-10
missense O 0 2.792612576740794e-07
( O 0 1.74186460810688e-08
G197W O 0 1.0418705187476007e-07
, O 0 1.4711083462515262e-09
W427R O 0 7.169123961148216e-08
) O 0 1.6393534307823643e-09
, O 0 4.0410405577340214e-10
two O 0 1.4504544232352146e-09
are O 0 4.680445364613206e-09
nonsense O 0 2.96768894259003e-06
( O 0 1.0153254947908863e-07
Q306X O 0 8.582721306993335e-07
, O 0 5.787642809451654e-09
Q385X O 0 3.964116217503033e-07
) O 0 2.636758367202674e-09
, O 0 1.1809998812228883e-10
two O 0 1.533542737242044e-10
are O 0 1.0258141558416867e-10
small O 0 1.637672109033872e-09
deletions O 0 3.35428005371341e-08
( O 0 1.9759495373250502e-08
662de14bp O 0 2.18412793628886e-07
; O 0 4.3706838148693805e-09
1168del3bp O 0 2.974446715597878e-06
removing O 0 8.269050226772379e-07
a O 0 6.727039476572827e-07
glycine O 0 6.25654593022773e-07
at O 0 4.437135885382304e-07
position O 0 1.1298411806137665e-07
390 O 0 5.5275840793456155e-08
) O 0 1.1445595166081901e-10
, O 0 9.895852366714752e-12
and O 0 4.098033717925276e-11
one O 0 1.5718188972613234e-09
is O 0 9.864185024355265e-10
a O 0 1.2366260904173032e-08
splicing O 0 2.338812699065329e-08
mutation O 0 2.547720256984576e-09
( O 0 4.014752530423493e-09
IVS1 O 0 6.890139729875955e-07
- O 0 2.5101851264253128e-08
15c O 0 1.1626646028162213e-06
- O 0 5.7129884822870736e-08
- O 0 1.2338841770542786e-07
> O 0 1.8895238440563844e-07
g O 0 2.4813143539859084e-08
) O 0 2.397367304673992e-10
which O 0 1.7288507431212352e-11
creates O 0 1.228826485011325e-09
a O 0 3.446434249099184e-09
new O 0 3.0055575805931767e-09
acceptor O 0 1.6582538364673383e-07
splice O 0 1.1392265150789171e-05
site O 0 1.1439668696766603e-06
. O 0 7.328657147809281e-08

The O 0 1.1146995575472829e-06
pathological O 0 0.00012028698256472126
significance O 0 4.3984675812680507e-07
of O 0 2.1111409864715824e-07
the O 0 4.876698866951301e-08
point O 0 2.0666547584369255e-07
mutations O 0 1.0023556429317182e-09
G197W O 0 2.4458335801114117e-08
, O 0 4.705156264606103e-10
W427R O 0 8.136831297633762e-08
, O 0 1.3911446439252018e-09
and O 0 5.484531162558426e-10
the O 0 3.096521083989501e-08
in O 0 8.126455242063457e-08
- O 0 2.428296284051612e-07
frame O 0 3.832356924249325e-06
deletion O 0 1.7004137475851167e-07
390delGly O 0 7.242847743782477e-08
were O 0 2.335339255310487e-09
assessed O 0 1.1075851347186472e-08
by O 0 1.0400483252404058e-10
their O 0 1.8513125754626714e-10
respective O 0 3.714512697428063e-09
expression O 0 3.81708931129765e-09
in O 0 1.5280308129916875e-09
a O 0 1.975828167743998e-09
prokaryotic O 0 2.1377408732092817e-09
system O 0 7.974940152699617e-10
using O 0 6.220041703919321e-10
site O 0 1.7843182931187584e-08
- O 0 9.983303073113348e-09
directed O 0 5.562496596667188e-08
mutagenesis O 0 8.667544534546323e-06
. O 0 2.1102472658185434e-07

These O 0 6.038999345037155e-08
mutations O 0 2.763954221052245e-08
resulted O 0 5.258586455170189e-08
in O 0 6.818677178443977e-09
the O 0 1.5356457438997495e-08
absence O 0 3.2970507390928105e-07
or O 0 2.1349221057676004e-08
a O 0 7.717294359110838e-09
dramatic O 0 5.996908924998934e-08
decrease O 0 5.461965884023812e-07
of O 0 1.999532969421125e-06
CPO O 0 0.00028278608806431293
activity O 0 4.754451947519556e-05
. O 0 1.1871615868130903e-07

The O 0 2.5990223662120115e-07
two O 0 6.2255041122227794e-09
polymorphisms O 0 7.924802503112005e-08
were O 0 4.898473626724353e-09
localized O 0 3.307666673890708e-08
in O 0 5.646028533590197e-09
noncoding O 0 2.918305312960001e-07
part O 0 1.5744751280521996e-08
of O 0 6.329565849227947e-08
the O 0 2.5411214465975718e-08
gene O 0 4.885556958988957e-10
1 O 0 6.897869830879699e-09
) O 0 5.4132649751625905e-11
a O 0 4.077234938559826e-10
C O 0 3.201537523978004e-08
/ O 0 1.6191894047778987e-08
G O 0 1.0686853357810833e-07
polymorphism O 0 4.5835946593797416e-08
in O 0 1.6820528303540527e-09
the O 0 1.0458061971974075e-08
promotor O 0 1.061066723195836e-05
region O 0 3.0737780321032915e-08
, O 0 4.065301872913096e-09
142 O 0 9.057833949555061e-08
bp O 0 6.005081445437099e-07
upstream O 0 3.6024155747327313e-07
from O 0 1.4078713306275858e-08
the O 0 2.298182621984779e-08
transcriptional O 0 2.2493651385957492e-07
initiation O 0 8.315008237502752e-09
site O 0 3.6538287950804715e-09
( O 0 2.86317192177421e-10
- O 0 5.615717335594184e-10
142C O 0 4.42164100888931e-08
/ O 0 2.8376170746469143e-08
G O 0 1.3681605537385622e-07
) O 0 8.103493986943988e-10
, O 0 1.202216104445597e-10
and O 0 3.5649272422944023e-10
2 O 0 4.394601660351327e-08
) O 0 9.448030136027796e-10
a O 0 5.992275564636884e-09
6 O 0 4.256137486891021e-08
bp O 0 7.606743679389183e-08
deletion O 0 2.6272553022010925e-09
polymorphism O 0 5.823431070695051e-09
in O 0 2.928047249106669e-10
the O 0 2.0797019661955574e-09
3 O 0 3.94677108772612e-08
noncoding O 0 1.2966114582013688e-07
part O 0 5.993795682002201e-09
of O 0 5.3812371447747864e-08
the O 0 2.4519249564036727e-07
CPO O 0 8.208532563003246e-06
gene O 0 1.376037239708694e-08
, O 0 1.5669456843170337e-09
574 O 0 5.718263764720177e-07
bp O 0 6.616540417780925e-07
downstream O 0 4.107721167656564e-07
of O 0 7.234342547235428e-08
the O 0 2.425004907991024e-08
last O 0 1.663729065626285e-08
base O 0 3.1819350709838545e-08
of O 0 1.7921459871672596e-08
the O 0 8.394286155066766e-09
normal O 0 1.6614924902569328e-07
termination O 0 8.426742681422184e-08
codon O 0 8.747780810836048e-08
( O 0 9.914666421195761e-09
+ O 0 3.479932075833858e-08
574 O 0 2.281825857153308e-07
delATTCTT O 0 1.3781682355329394e-06
) O 0 1.3736169535150111e-08
. O 0 1.385372971896004e-08

Five O 0 1.3006805602344684e-05
intragenic O 0 0.00011330436245771125
dimorphisms O 0 0.00030056247487664223
are O 0 2.740170401693831e-08
now O 0 1.4758080091326065e-08
well O 0 4.622168425783002e-09
characterized O 0 7.27117788201781e-09
and O 0 3.924824354406553e-10
the O 0 3.231449774432349e-09
high O 0 2.396843967744644e-08
degree O 0 8.422578616773535e-07
of O 0 1.0394266780622274e-08
allelic O 0 1.6465830299239315e-07
heterogeneity O 0 1.0370730478825863e-06
in O 0 6.137564412256324e-08
HC B-Disease 1 0.9999988079071045
is O 0 8.308243337751264e-08
demonstrated O 0 6.278030539874635e-09
with O 0 2.805254466220486e-11
seven O 0 2.1908654057600785e-10
new O 0 8.225697900599016e-12
different O 0 2.923875334556736e-12
mutations O 0 2.092252586460841e-11
making O 0 1.5663621788508664e-10
a O 0 3.53903351069107e-10
total O 0 2.250994279862084e-09
of O 0 1.2507234359304675e-08
nineteen O 0 3.4677520943660056e-06
CPO O 0 0.0015078209107741714
gene B-Disease 0 9.043166755873244e-06
defects I-Disease 0 0.0003455721016507596
reported O 0 3.229553513506289e-08
so O 0 1.4524892399947475e-09
far O 0 3.899449207978023e-09
. O 0 8.393897799052752e-10
. O 0 2.276908084297702e-08

Coincidence O 0 0.0001862376375356689
of O 0 2.573703454800125e-07
two O 0 8.2888025332295e-09
novel O 0 2.3197561915822007e-07
arylsulfatase O 0 4.694069048127858e-06
A O 0 1.236773954360615e-07
alleles O 0 5.393459567848424e-10
and O 0 2.2215072836839767e-10
mutation O 0 3.5082543536901767e-09
459 O 0 6.843447977189498e-07
+ O 0 1.5733877489765291e-06
1G O 0 8.976944627647754e-06
> O 0 7.229211718140505e-08
A O 0 1.465111054699264e-08
within O 0 3.253162628169548e-09
a O 0 8.574326137988919e-09
family O 0 4.068862136108464e-09
with O 0 2.2843280600426397e-09
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
: O 0 4.445282364429204e-09
molecular O 0 1.3056568270997104e-08
basis O 0 1.3929082776087398e-08
of O 0 5.827720084283783e-09
phenotypic O 0 2.7389538104216626e-07
heterogeneity O 0 1.0487211511645e-05
. O 0 2.339431262043945e-07

In O 0 4.152545898250537e-06
a O 0 3.764649818549515e-07
family O 0 2.1609780631592912e-08
with O 0 6.449780987072273e-11
three O 0 8.191203271223912e-09
siblings O 0 1.9178177979028987e-07
, O 0 4.1948419737813936e-10
one O 0 7.05487446239772e-10
developed O 0 1.0138292871886279e-08
classical O 0 1.1700030881911516e-05
late O 0 0.009506518952548504
infantile O 1 0.9999997615814209
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
( O 0 4.099277430213988e-05
MLD B-Disease 1 1.0
) O 0 3.6825792193440066e-08
, O 0 1.516599512640937e-09
fatal O 0 1.0379852710684645e-06
at O 0 5.572541681431176e-07
age O 0 6.221393391570018e-07
5 O 0 1.0914956192209502e-06
years O 0 1.4345086896128123e-08
, O 0 5.508413170041138e-10
with O 0 9.160000535857193e-10
deficient O 0 0.00010418202873552218
arylsulfatase O 0 0.00011730506230378523
A O 0 0.0003902015450876206
( O 0 2.608896068068134e-07
ARSA O 0 4.280050052329898e-05
) O 0 6.755913606326658e-10
activity O 0 4.062379321823073e-09
and O 0 1.050723674733689e-10
increased O 0 1.2416129457903935e-08
galactosylsulfatide O 0 1.6258378309430555e-05
( O 0 6.80873085912026e-07
GS O 1 0.9999988079071045
) O 0 4.810623455142604e-09
excretion O 0 6.097530302895393e-08
. O 0 8.813930918449842e-09

The O 0 1.782315280252078e-06
two O 0 1.0525861959820304e-08
other O 0 1.112746894627037e-09
siblings O 0 1.0750886048072061e-07
, O 0 3.752002264434395e-09
apparently O 0 6.121180149420979e-07
healthy O 0 1.64815389780415e-07
at O 0 5.550053856495651e-07
12 O 0 1.785554957223212e-07
( O 0 3.8052405670896405e-09
1 O 0 1.0902747504815125e-07
/ O 0 1.317333531147824e-08
2 O 0 1.4107395251983235e-08
) O 0 6.482278602781832e-11
and O 0 1.918498346298314e-11
15 O 0 6.049807876884472e-10
years O 0 9.472786999253913e-10
, O 0 5.181299833623143e-11
respectively O 0 3.1413016632342305e-09
, O 0 1.3182697988778358e-10
and O 0 7.462992723805684e-11
their O 0 7.447507194280334e-11
father O 0 1.334515431494765e-08
, O 0 6.085012493883823e-10
apparently O 0 2.3470578369710893e-08
healthy O 0 5.041393968951979e-09
as O 0 3.304409523785523e-10
well O 0 5.185612494962299e-10
, O 0 3.608180976222286e-10
presented O 0 1.9173056386989629e-07
ARSA O 0 0.14377497136592865
and O 0 6.149400064714428e-07
GS O 1 1.0
values O 0 1.832277973790042e-08
within O 0 1.2214259603737787e-09
the O 0 4.315010015965015e-10
range O 0 3.0412121709844087e-09
of O 0 8.632996184587682e-08
MLD B-Disease 1 1.0
patients O 0 8.184240414266242e-07
. O 0 3.017961347495657e-08

Mutation O 0 4.641598039256678e-08
screening O 0 1.7206872593433786e-09
and O 0 5.804285871380266e-11
sequence O 0 8.648764371343987e-09
analysis O 0 1.6338136177296292e-08
disclosed O 0 6.0556430980796e-08
the O 0 8.75884520468162e-09
involvement O 0 2.1480975931353896e-07
of O 0 2.4210118354517363e-08
three O 0 1.3279587429693152e-09
different O 0 3.408504811730495e-09
ARSA O 0 0.0002921113045886159
mutations O 0 8.026033171404379e-09
being O 0 3.0598485967203715e-09
the O 0 7.901838072754686e-10
molecular O 0 5.412950532246441e-09
basis O 0 2.8867155776879372e-08
of O 0 3.3742555416438336e-08
intrafamilial O 0 9.68309450399829e-06
phenotypic O 0 2.5276597170886816e-06
heterogeneity O 0 2.44833772740094e-05
. O 0 2.3664570392156747e-07

The O 0 3.049220140383113e-06
late O 0 3.630622450145893e-05
infantile O 0 0.007396478671580553
patient O 0 4.196193003735971e-06
inherited O 0 3.957701665058266e-06
from O 0 1.60061904352915e-06
his O 0 1.0365678235757514e-06
mother O 0 8.429826721112477e-07
the O 0 5.595878604935933e-08
frequent O 0 4.558467736615057e-08
0 O 0 1.3192722470023455e-08
- O 0 1.867407339872784e-09
type O 0 1.2505112501060012e-08
mutation O 0 4.92028195964167e-09
459 O 0 4.165089251273457e-07
+ O 0 1.1038547143016331e-07
1G O 0 4.884709596808534e-07
> O 0 1.524102266614591e-08
A O 0 1.8308456972704334e-08
, O 0 7.653813693941913e-11
and O 0 8.029316794777586e-11
from O 0 3.970538120512401e-09
his O 0 2.30120065225492e-08
father O 0 1.719265299016115e-07
a O 0 2.0788702315144292e-08
novel O 0 9.22512466416947e-09
, O 0 2.2512033903687723e-10
single O 0 3.1744891160201405e-09
basepair O 0 3.953115310650901e-07
microdeletion O 0 4.249117466770258e-07
of O 0 1.2769915258559195e-07
guanine O 0 4.1524648963786603e-07
at O 0 2.6089779225912935e-07
nucleotide O 0 2.5282719207098125e-07
7 O 0 6.497042193132074e-08
in O 0 2.304731072655386e-09
exon O 0 1.4028347372629923e-08
1 O 0 2.4236360474105823e-08
( O 0 2.220279959885829e-09
7delG O 0 7.367704313310242e-08
) O 0 2.448450775460742e-09
. O 0 4.32788738180534e-09

The O 0 1.800764124482157e-07
two O 0 1.2897933387989724e-08
clinically O 0 7.293998351087794e-05
unaffected O 0 5.899685788790521e-07
siblings O 0 4.241412909777864e-08
carried O 0 1.4457534058820443e-09
the O 0 2.1280259776546018e-09
maternal O 0 6.663749729796109e-08
mutation O 0 2.7635047583629557e-09
459 O 0 1.0792984284080376e-07
+ O 0 1.1380349462797312e-07
1G O 0 9.351696803605591e-07
> O 0 4.538358311378943e-08
A O 0 2.7394230883714954e-08
and O 0 2.655137221196924e-10
, O 0 1.8041997063011905e-10
on O 0 2.6989990242753947e-09
their O 0 7.629448184331977e-10
paternal O 0 1.8946858304502712e-08
allele O 0 3.373467338807501e-10
, O 0 3.4590816322399576e-11
a O 0 3.965540951167412e-10
novel O 0 2.139425525626848e-09
cytosine O 0 9.140842749388867e-09
to O 0 9.347367324608058e-10
thymidine O 0 1.6567520333410357e-07
transition O 0 6.569278099277653e-08
at O 0 8.420877151138484e-08
nucleotide O 0 5.453981088976434e-07
2435 O 0 1.1461791473266203e-05
in O 0 6.138908048569647e-09
exon O 0 1.2547065608714547e-08
8 O 0 3.2971836372297503e-09
, O 0 1.0981470940918392e-11
resulting O 0 1.1447844755485548e-10
in O 0 1.8818265001829815e-10
substitution O 0 2.381122632399979e-09
of O 0 2.2904808716361913e-08
alanine O 0 6.189242753862345e-07
464 O 0 3.4826419437195e-07
by O 0 4.9175355343322735e-08
valine O 0 2.019682142417878e-05
( O 0 7.603726714933146e-08
A464V O 0 1.3608437257062178e-06
) O 0 3.027670558708451e-08
. O 0 3.424543493224519e-08

The O 0 2.1585985905403504e-06
fathers O 0 2.361500264669303e-06
genotype O 0 1.4558563066202623e-07
thus O 0 8.12431650842882e-08
was O 0 1.2140102398916497e-06
7delG O 0 7.755827027722262e-06
/ O 0 1.1813156561402138e-05
A464V O 0 3.411413126741536e-05
. O 0 6.635693239331886e-07

Mutation O 0 4.2562533053569496e-06
A464V O 0 5.794162461825181e-06
was O 0 2.487202550582879e-07
not O 0 9.56669743423788e-10
found O 0 8.064053313994179e-10
in O 0 1.1138894251416787e-09
18 O 0 1.1993422788236785e-07
unrelated O 0 0.00012918622815050185
MLD B-Disease 1 1.0
patients O 0 3.499103695503436e-05
and O 0 3.972189688283834e-09
50 O 0 1.8314260330498655e-07
controls O 0 1.7167846522170294e-07
. O 0 2.5707812767450378e-08

A464V O 0 2.2194624762050807e-05
, O 0 1.2847256591896894e-08
although O 0 4.403972297950531e-09
clearly O 0 7.124874912278756e-08
modifying O 0 8.972040177468443e-07
ARSA O 1 0.7847465872764587
and O 0 2.1280186501826392e-06
GS O 1 1.0
levels O 0 1.690408225840656e-06
, O 0 1.6774648337047893e-09
apparently O 0 9.167052184011482e-08
bears O 0 1.596246335111573e-08
little O 0 4.346218496209531e-09
significance O 0 1.120271342358592e-08
for O 0 1.2384713254931512e-09
clinical O 0 2.86753163436515e-07
manifestation O 0 7.106888915586751e-06
of O 0 4.043364697281504e-06
MLD B-Disease 1 1.0
, O 0 6.645802130833545e-08
mimicking O 0 1.3755999361819704e-06
the O 0 1.7898406667882227e-07
frequent O 0 2.528349341446301e-06
ARSA O 0 0.00420455913990736
pseudodeficiency O 0 7.325295155169442e-05
allele O 0 1.5137312630031374e-06
. O 0 3.558962760052964e-07

Our O 0 1.00153249604773e-06
results O 0 7.918498745596025e-09
demonstrate O 0 7.3622370422299355e-09
that O 0 9.5953418821626e-12
in O 0 3.9339961843687377e-11
certain O 0 2.137478805064319e-10
genetic O 0 6.681182718182299e-09
conditions O 0 7.481986585844425e-07
MLD B-Disease 1 1.0
- O 0 0.0008696673321537673
like O 0 1.8980630045462021e-07
ARSA O 1 0.9754865765571594
and O 0 1.161336484756248e-07
GS O 1 1.0
values O 0 1.3561282763419058e-08
need O 0 5.31779786872022e-10
not O 0 5.5789466796296594e-11
be O 0 1.610618860503621e-10
paralleled O 0 9.725811267458084e-09
by O 0 2.5458829489011237e-10
clinical O 0 1.8192231436842121e-06
disease O 0 2.2002359401085414e-07
, O 0 3.239345250372061e-11
a O 0 2.8138674723621193e-10
finding O 0 1.26330268468422e-09
with O 0 2.4165284356891803e-11
serious O 0 8.162588471805066e-08
diagnostic O 0 1.7030752985647268e-07
and O 0 1.8198430540294908e-09
prognostic O 0 0.0003309708263259381
implications O 0 6.019059810569161e-07
. O 0 6.372763294848482e-08

Moreover O 0 5.5348073146888055e-06
, O 0 8.398706619061613e-09
further O 0 1.3453032465804426e-07
ARSA O 0 0.0014755537267774343
alleles O 0 2.3996708620188656e-08
functionally O 0 1.2002759319784673e-07
similar O 0 4.1758427271609833e-10
to O 0 6.246101413864835e-10
A464V O 0 1.6543127401291713e-07
might O 0 9.046107862786812e-09
exist O 0 1.696184170896231e-08
which O 0 3.928479208603619e-10
, O 0 6.411549763329916e-11
together O 0 1.9862141098503372e-10
with O 0 5.23430465637631e-10
0 O 0 1.3916555019477528e-07
- O 0 1.3103069740338924e-08
type O 0 2.027953449612596e-08
mutations O 0 3.256011682495341e-09
, O 0 1.0028982505572159e-10
may O 0 8.391596750811914e-09
cause O 0 1.3967539416626096e-05
pathological O 1 1.0
ARSA O 1 0.9999954700469971
and O 0 1.0512177368582343e-06
GS O 1 1.0
levels O 0 1.4089759758917353e-07
, O 0 5.5677743665549784e-11
but O 0 1.6655204992943595e-11
not O 0 5.1285403007694796e-11
clinical O 0 3.5262062159091556e-09
outbreak O 0 1.0249091575431635e-09
of O 0 4.143585030647046e-09
the O 0 4.287498711619264e-08
disease O 0 1.0674095847207354e-06
. O 0 9.255963773213693e-10
. O 0 8.746424917660534e-09

Human O 1 0.9998412132263184
MLH1 O 1 1.0
deficiency O 1 1.0
predisposes O 0 0.012325936928391457
to O 0 2.0543770062886324e-07
hematological B-Disease 1 1.0
malignancy I-Disease 1 1.0
and O 0 4.1158892827297677e-07
neurofibromatosis B-Disease 1 0.9999431371688843
type I-Disease 1 0.5670433640480042
1 I-Disease 0 0.01228400319814682
. O 0 2.863533268282481e-07

Heterozygous O 0 1.0911658137047198e-05
germ O 0 2.2266664018388838e-05
- O 0 7.690318852837663e-07
line O 0 3.071216880812244e-08
mutations O 0 7.093924336842861e-10
in O 0 4.739780790075088e-10
the O 0 5.830076865720457e-09
DNA O 0 5.292400260259456e-07
mismatch O 1 0.9893306493759155
repair O 0 0.007831811904907227
genes O 0 6.842664674877597e-07
lead O 0 1.4627565860791947e-06
to O 0 1.31056538066332e-06
hereditary B-Disease 1 1.0
nonpolyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 1.6497564502060413e-05

The O 0 6.108018624217948e-07
disease O 0 3.7953664104861673e-06
susceptibility O 0 3.399499519218807e-06
of O 0 7.05397212641401e-07
individuals O 0 1.0995407961900128e-07
who O 0 2.685720801309799e-08
constitutionally O 0 6.195963351274258e-07
lack O 0 1.096158896984889e-07
both O 0 1.098818591671602e-09
wild O 0 3.5607836679218963e-09
- O 0 8.166446185953191e-09
type O 0 1.3358319783662864e-08
alleles O 0 1.8779264809865026e-09
is O 0 8.88478401961379e-10
unknown O 0 5.00450198614999e-07
. O 0 2.5535205949722695e-08

We O 0 3.066446936372813e-07
have O 0 1.2712599861686158e-09
identified O 0 5.4323434639513835e-09
three O 0 1.0537185568537666e-09
offspring O 0 3.463231035283343e-09
in O 0 2.2344184280598256e-09
a O 0 4.7680120474069554e-07
hereditary B-Disease 1 1.0
nonpolyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
family O 1 1.0
who O 0 4.9203315199974895e-08
developed O 0 1.391591922583757e-06
hematological B-Disease 1 1.0
malignancy I-Disease 1 1.0
at O 0 1.8388780517852865e-05
a O 0 5.600491448376488e-08
very O 0 1.0497066549319811e-09
early O 0 8.865625567011648e-09
age O 0 3.630087519468361e-08
, O 0 3.127084702292393e-10
and O 0 2.4714968960282135e-10
at O 0 4.662787489451148e-08
least O 0 2.595671233507346e-09
two O 0 2.126978038141658e-10
of O 0 1.6775318911754766e-09
them O 0 4.520237795180293e-10
displayed O 0 8.89959892447223e-08
signs O 0 7.842865556995093e-08
of O 0 4.272364151347574e-07
neurofibromatosis B-Disease 0 0.06015627458691597
type I-Disease 0 0.0006660342332907021
1 I-Disease 0 0.01589573547244072
( O 0 3.4713548302534036e-07
NF1 B-Disease 0 7.450846896972507e-05
) O 0 2.218207129089933e-08
. O 0 1.2632841439597087e-08

DNA O 0 3.458480080098525e-08
sequence O 0 5.753215237547238e-09
analysis O 0 1.0050050791576837e-09
and O 0 1.2406428315236973e-11
allele O 0 6.382315509423364e-11
- O 0 3.323130937094021e-10
specific O 0 1.7748905123404768e-10
amplification O 0 1.8441557170234546e-09
in O 0 7.420343783870464e-10
two O 0 2.100788210057658e-09
siblings O 0 7.53593951685616e-08
revealed O 0 1.992218869872886e-07
a O 0 1.1160915391883464e-07
homozygous O 0 1.0929355909183869e-07
MLH1 O 0 5.522606443264522e-06
mutation O 0 3.4369485035767866e-09
( O 0 2.4711255264264764e-09
C676T O 0 4.479653625821811e-08
- O 0 3.986320393778442e-07
- O 0 5.9339877225284e-06
> O 0 5.987090844428167e-06
Arg226Stop O 0 0.00010158904478885233
) O 0 2.5645418233466444e-08
. O 0 4.052529334330757e-08

Thus O 0 1.7458347656429396e-06
, O 0 1.0618377288551528e-08
a O 0 5.393917490437161e-08
homozygous O 0 1.574552470628987e-07
germ O 0 0.00017551345808897167
- O 0 0.00010934934834949672
line O 0 2.1978632958052913e-06
MLH1 O 0 0.00811445526778698
mutation O 0 3.640203516397378e-08
and O 0 1.3111989272118763e-09
consequent O 0 0.0006937597645446658
mismatch O 1 1.0
repair O 1 1.0
deficiency O 1 1.0
results O 0 4.516253284236882e-06
in O 0 7.545129676600482e-08
a O 0 1.350219633877714e-07
mutator O 0 0.0011839382350444794
phenotype O 0 2.92045996275192e-07
characterized O 0 1.030287943848407e-08
by O 0 1.6684569281721906e-09
leukemia B-Disease 1 0.9998015761375427
and O 0 0.0004265830502845347
/ O 1 1.0
or O 1 1.0
lymphoma B-Disease 1 1.0
associated O 1 0.9999997615814209
with O 0 1.3637968550028745e-06
neurofibromatosis B-Disease 1 1.0
type I-Disease 1 0.9999991655349731
1 I-Disease 0 0.23658683896064758
. O 0 9.90066251205235e-09
. O 0 1.3144773269857524e-08

Missense O 0 0.008451475761830807
mutations O 0 2.511303875962767e-07
in O 0 1.6964753157822088e-08
the O 0 6.476884362172086e-09
most O 0 3.0556479568843997e-10
ancient O 0 1.04510469611796e-07
residues O 0 1.8689124203774554e-07
of O 0 1.2014567118967534e-07
the O 0 2.0003939482649002e-07
PAX6 O 0 0.04318354278802872
paired O 0 1.7213682212968706e-06
domain O 0 3.445717766226153e-06
underlie O 0 7.706044584665506e-07
a O 0 8.308081334007511e-09
spectrum O 0 2.104093432819809e-08
of O 0 3.4848058021452744e-06
human O 1 1.0
congenital B-Disease 1 1.0
eye I-Disease 1 1.0
malformations I-Disease 1 1.0
. O 0 5.8922803873429075e-05

Mutations O 0 5.164928325029905e-07
of O 0 4.5858858044312e-08
the O 0 1.8241044230649095e-08
human O 0 1.7687861486592737e-07
PAX6 O 1 0.850297749042511
gene O 0 1.642132156121079e-05
underlie O 1 0.9998823404312134
aniridia B-Disease 1 1.0
( O 1 0.9999500513076782
congenital B-Disease 1 1.0
absence I-Disease 0 0.00036539731081575155
of I-Disease 0 0.015092164278030396
the I-Disease 0 3.637737609096803e-05
iris I-Disease 0 0.00019772272207774222
) O 0 9.080373075676107e-08
, O 0 2.32979124881183e-09
a O 0 1.5924945273582125e-07
rare O 0 0.0004350794479250908
dominant O 1 1.0
malformation B-Disease 1 1.0
of I-Disease 1 1.0
the I-Disease 1 0.9999970197677612
eye I-Disease 1 1.0
. O 0 5.251127277006162e-06

The O 0 4.228230920944043e-07
spectrum O 0 3.362329152878374e-07
of O 0 7.561494612673414e-07
PAX6 O 0 0.20585758984088898
mutations O 0 4.4720474079440464e-07
in O 0 9.066286565939663e-08
aniridia B-Disease 1 1.0
patients O 0 6.815078279487352e-08
is O 0 2.542485944001527e-10
highly O 0 1.1421656953558568e-09
biased O 0 1.0786765258785636e-08
, O 0 2.237952011208133e-11
with O 0 9.580017334975821e-12
92 O 0 4.2811329592495895e-08
% O 0 3.3230801443906444e-10
of O 0 6.463429236269747e-10
all O 0 7.885788133599192e-10
reported O 0 1.795992154995929e-08
mutations O 0 1.6693831872416354e-09
leading O 0 1.1156313206583945e-08
to O 0 2.5694022465216904e-09
premature O 0 1.511341167770297e-07
truncation O 0 1.8097905467584496e-06
of O 0 3.9030047105370613e-07
the O 0 4.8889177151068e-08
protein O 0 1.9629267455911759e-07
( O 0 1.1897008711514445e-08
nonsense O 0 8.528855488521003e-08
, O 0 7.3745165529715e-10
splicing O 0 6.022272902583836e-09
, O 0 5.92631388407483e-10
insertions O 0 4.283444354769017e-08
and O 0 1.0951005657844348e-09
deletions O 0 1.1495709273390275e-08
) O 0 2.399285214949032e-09
and O 0 7.250802180891469e-10
just O 0 6.589469592199748e-08
2 O 0 4.372754460746364e-07
% O 0 5.690658166912499e-09
leading O 0 1.9400490103294032e-09
to O 0 7.171013782780733e-11
substitution O 0 1.5033284617160803e-09
of O 0 2.052359349136168e-08
one O 0 3.935343162453364e-09
amino O 0 3.2403992822338523e-09
acid O 0 6.848809297466119e-10
by O 0 6.495450288745985e-10
another O 0 1.7630291893055983e-08
( O 0 1.9214125401845195e-08
missense O 0 1.3727835721510928e-06
) O 0 2.1884536849370306e-08
. O 0 2.6192161328708607e-08

The O 0 5.264066089694097e-07
extraordinary O 0 1.9327574136696057e-06
conservation O 0 6.148948159534484e-07
of O 0 6.693915111100068e-08
the O 0 9.402808132108476e-08
PAX6 O 0 8.734459697734565e-05
protein O 0 3.364411043094151e-07
at O 0 4.403587894330485e-08
the O 0 4.372276318775903e-09
amino O 0 4.2580133197134273e-08
acid O 0 1.4141257942412722e-08
level O 0 3.3713806146806746e-07
amongst O 0 6.234799343474151e-08
vertebrates O 0 1.301304655498825e-05
predicts O 0 1.0532834693322002e-07
that O 0 1.696846552157183e-09
pathological O 0 0.00014929873577784747
missense O 0 1.7210684745805338e-05
mutations O 0 1.4401588366297347e-08
should O 0 1.1182383907737403e-09
in O 0 1.9936960971023154e-09
fact O 0 1.066599697452375e-08
be O 0 3.0544142770594362e-09
common O 0 1.054186959947856e-09
even O 0 4.289964494752496e-10
though O 0 1.1687023571127497e-10
they O 0 2.0638984965515306e-10
are O 0 1.6713704031889876e-10
hardly O 0 2.358298623050814e-08
ever O 0 1.5692824817392648e-08
seen O 0 3.833259043517501e-08
in O 0 6.042548506002277e-08
aniridia B-Disease 1 1.0
patients O 0 1.2122031876060646e-06
. O 0 5.698307958823534e-08

This O 0 1.1678983469209925e-07
indicates O 0 3.822665632924327e-07
that O 0 4.3756528955718466e-10
there O 0 1.2893155432180947e-09
is O 0 7.016615621857625e-10
a O 0 5.667413205401317e-09
heavy O 0 2.8413143127181684e-07
ascertainment O 0 3.2026797271100804e-05
bias O 0 1.7560931553362025e-07
in O 0 3.4662955838982157e-10
the O 0 1.1221307216757737e-10
selection O 0 1.946501015925861e-10
of O 0 9.605478634711062e-10
patients O 0 3.168136308850933e-10
for O 0 4.5723258512708753e-10
PAX6 O 0 2.468332604621537e-05
mutation O 0 3.842935303310924e-09
analysis O 0 1.6493364451974912e-09
and O 0 3.078196725292415e-11
that O 0 2.4653090333059957e-11
the O 0 3.4838885110133333e-09
missing O 0 1.3443889656628016e-05
PAX6 O 1 0.9450420141220093
missense O 0 0.00043214322067797184
mutations O 0 1.1685830081376025e-08
frequently O 0 4.4457804104780507e-10
may O 0 1.1045319103786255e-09
underlie O 0 2.1251295834190387e-07
phenotypes O 0 5.322369389659798e-08
distinct O 0 7.230021914494955e-09
from O 0 7.739748753010645e-08
textbook O 0 0.0005584056489169598
aniridia B-Disease 1 1.0
. O 0 1.368074890706339e-06

Here O 0 1.3781196912532323e-06
we O 0 9.076369877902835e-09
present O 0 5.793717505753193e-09
four O 0 2.248210506650139e-08
novel O 0 8.708847190064262e-07
PAX6 O 0 0.0014372426085174084
missense O 0 4.997258656658232e-05
mutations O 0 2.8931149032018766e-08
, O 0 3.7042802158993027e-10
two O 0 1.505554431124878e-10
in O 0 2.1067549926812035e-09
association O 0 1.763825419054399e-09
with O 0 4.868924152745535e-10
atypical O 0 8.987035471363924e-06
phenotypes O 0 1.660958514548838e-05
ectopia B-Disease 0 0.0009461025474593043
pupillae I-Disease 0 0.0003530858375597745
( O 0 4.7019582893881307e-08
displaced B-Disease 0 5.131875013830722e-08
pupils I-Disease 0 4.480405735307613e-08
) O 0 5.3748362205396916e-08
and O 0 5.29736439602857e-07
congenital B-Disease 1 1.0
nystagmus I-Disease 1 0.9999908208847046
( O 0 6.362552994687576e-06
searching B-Disease 0 9.754475468071178e-05
gaze I-Disease 0 1.612155210750643e-05
) O 0 1.7110988181912035e-08
, O 0 1.3596318515496364e-09
and O 0 1.971062646433097e-09
two O 0 1.956970940852898e-08
in O 0 1.1521868259478651e-07
association O 0 2.775428420420667e-08
with O 0 9.972792591739221e-10
more O 0 6.178495048914101e-09
recognizable O 0 6.028290044923779e-06
aniridia B-Disease 1 1.0
phenotypes O 0 3.463884422671981e-05
. O 0 1.5525483831879683e-07

Strikingly O 0 1.4976709280745126e-05
, O 0 3.4732199338805003e-09
all O 0 4.2853193216174645e-10
four O 0 6.863534185441722e-10
mutations O 0 2.646148300478046e-10
are O 0 7.597467793774015e-11
located O 0 2.27015517495488e-09
within O 0 6.185345124976038e-09
the O 0 1.0732937738566761e-07
PAX6 O 0 0.0012361140688881278
paired O 0 5.322166316545918e-07
domain O 0 5.292001787893241e-07
and O 0 2.7102539656986835e-10
affect O 0 6.097864879706094e-09
amino O 0 1.196185728247201e-08
acids O 0 1.19439536039323e-09
which O 0 8.991773992050867e-11
are O 0 2.3376318242229743e-11
highly O 0 1.1439316160988255e-09
conserved O 0 4.0073945939411715e-08
in O 0 3.4658478309523844e-09
all O 0 5.850629758441528e-09
known O 0 4.486922122737269e-08
paired O 0 1.3287149158713873e-07
domain O 0 1.1716807648554095e-06
proteins O 0 4.459993974137433e-08
. O 0 7.22219581916761e-08

Our O 0 1.7915465377882356e-06
results O 0 3.875707932365913e-08
support O 0 1.9359052139122923e-09
the O 0 3.6982952256181534e-09
hypothesis O 0 1.896634849174461e-08
that O 0 1.2343902809630602e-11
the O 0 9.102104486791163e-11
under O 0 1.1117434750573807e-09
- O 0 2.2326889226320645e-09
representation O 0 4.777413131762387e-09
of O 0 1.966489904248192e-08
missense O 0 3.651654697023332e-05
mutations O 0 3.817448046561367e-08
is O 0 1.2352158185180429e-09
caused O 0 6.76274947153388e-09
by O 0 2.329960002711573e-09
ascertainment O 1 0.9291506409645081
bias O 0 1.943353890965227e-05
and O 0 3.306920515200318e-09
suggest O 0 1.0346458800825076e-08
that O 0 5.491280000158305e-11
a O 0 5.990524187815538e-10
substantial O 0 5.158860894027839e-09
burden O 0 1.1328795324061502e-07
of O 0 7.485440960408596e-07
PAX6 B-Disease 1 0.9999668598175049
- I-Disease 0 0.0026904393453150988
related I-Disease 0 0.3673238754272461
disease I-Disease 1 0.9999970197677612
remains O 0 1.7335177062705043e-06
to O 0 9.350683560782613e-10
be O 0 2.195958082040761e-09
uncovered O 0 3.0928019896236947e-06
. O 0 4.129375508199473e-09
. O 0 1.6366580979365608e-08

The O 0 7.102879067133472e-07
chromosomal O 0 3.0869850888848305e-06
order O 0 2.1806119576694982e-08
of O 0 3.3603132010284753e-07
genes O 0 9.932841038562401e-08
controlling O 0 8.95937773748301e-06
the O 0 1.544527890473546e-06
major O 0 1.3045415471424349e-05
histocompatibility O 0 0.03555344045162201
complex O 0 0.006148957647383213
, O 0 2.5139739179280696e-09
properdin O 0 7.80903235408914e-07
factor O 0 1.0649657156136527e-07
B O 0 7.289649488484429e-07
, O 0 5.710847350570702e-10
and O 0 2.701687540351827e-09
deficiency B-Disease 1 0.9999995231628418
of I-Disease 1 0.9999748468399048
the I-Disease 0 5.3179242968326434e-05
second I-Disease 0 6.0374263739504386e-06
component I-Disease 0 1.0850467333511915e-05
of I-Disease 0 1.0280804190188064e-06
complement I-Disease 0 1.9702722511283355e-06
. O 0 3.9748294966557296e-07

The O 0 4.986646331417433e-07
relationship O 0 1.6936793656441296e-07
of O 0 1.0464131605658622e-07
the O 0 1.5134650865888943e-08
genes O 0 6.151378961760656e-09
coding O 0 3.630745482041675e-08
for O 0 2.293159218069718e-09
HLA O 0 5.708947270477438e-08
to O 0 3.836854167715842e-10
those O 0 2.601270587820892e-10
coding O 0 9.939186362828423e-09
for O 0 9.808838186131652e-10
properdin O 0 1.2940657825311064e-06
Factor O 0 1.0700248367356835e-06
B O 0 2.621515875489422e-07
allotypes O 0 2.98229508643999e-07
and O 0 7.493420328685829e-10
for O 0 2.8676603314181648e-09
deficiency B-Disease 1 0.9813841581344604
of I-Disease 0 0.0016003516502678394
the I-Disease 0 4.0583239524494275e-07
second I-Disease 0 8.907223048026935e-08
component I-Disease 0 7.272360136312273e-08
of I-Disease 0 8.221353198223369e-08
complement I-Disease 0 1.4593635455639742e-07
( O 0 1.2976160235211864e-07
C2 O 0 1.5961024928401457e-06
) O 0 4.5547610127982807e-10
was O 0 1.7366554860842598e-09
studied O 0 1.1797263166357652e-09
in O 0 3.401235959543669e-10
families O 0 1.4037138118538905e-10
of O 0 1.5301628852881777e-09
patients O 0 1.1968703361731059e-08
with O 0 4.773717421358015e-08
connective O 1 1.0
tissue O 1 1.0
disorders O 1 1.0
. O 0 0.006147999316453934

Patients O 0 8.48973911615758e-07
were O 0 4.580795742725741e-09
selected O 0 7.653029321375016e-10
because O 0 4.0532061040821077e-10
they O 0 3.384623692426203e-10
were O 0 3.715107776969262e-09
heterozygous O 0 6.5130207893560055e-09
or O 0 8.780205007496988e-09
homozygous O 0 1.591559168900858e-07
for O 0 4.678243840317009e-06
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
. O 0 4.479673589230515e-05

12 O 0 2.3989559849724174e-06
families O 0 5.7813536180617575e-09
with O 0 1.2756580514139415e-10
15 O 0 4.314792079185281e-08
matings O 0 2.7530320494406624e-06
informative O 0 5.758598490501754e-06
for O 0 3.165402631566394e-06
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
were O 0 2.2944964257476386e-06
found O 0 5.271902736581069e-08
. O 0 3.6423426053033836e-08

Of O 0 7.787519280100241e-06
57 O 0 2.7629557735053822e-06
informative O 0 2.496973365850863e-06
meioses O 0 3.122810539935017e-06
, O 0 1.454346532092643e-09
two O 0 1.7677660446580035e-09
crossovers O 0 1.432859786376639e-08
were O 0 6.501862159780103e-09
noted O 0 5.585276685593499e-09
between O 0 3.880730758965001e-08
the O 0 3.0090004656813107e-06
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
gene O 0 1.661800830277116e-08
and O 0 9.55732382124097e-10
the O 0 3.6196613706351854e-08
HLA O 0 3.370525689661008e-07
- O 0 4.158108026786067e-07
B O 0 4.596215148922056e-06
gene O 0 4.612322523911416e-09
, O 0 1.1665865495835703e-10
with O 0 4.2532016103491443e-11
a O 0 3.4663900638776113e-09
recombinant O 0 4.853218382727675e-10
fraction O 0 4.32753211043746e-09
of O 0 4.369227468714598e-08
0 O 0 5.5696837364394014e-08
. O 0 7.59718599141479e-09

035 O 0 0.02298443205654621
. O 0 5.348102149582701e-06

A O 0 4.1109986341325566e-05
lod O 0 0.00016359661822207272
score O 0 1.6032804239785037e-07
of O 0 5.229560073871653e-08
13 O 0 5.000027414325814e-08
was O 0 1.811079819447059e-08
calculated O 0 5.524274726553813e-08
for O 0 1.5485631665868027e-09
linkage O 0 4.422999779762904e-07
between O 0 3.502490926621249e-06
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
and O 0 2.360423252412147e-07
HLA O 0 4.96384757298074e-07
- O 0 1.7194219381622133e-08
B O 0 1.0893870694417274e-07
at O 0 4.274774756396482e-09
a O 0 1.370506624853718e-10
maximum O 0 3.506794021834736e-10
likelihood O 0 9.46888567554538e-10
value O 0 3.3629443674243475e-10
of O 0 3.9901232318229063e-10
the O 0 1.9643547899406144e-10
recombinant O 0 1.7991894085689353e-10
fraction O 0 1.4028821437861438e-09
of O 0 4.119660168555583e-09
0 O 0 1.1609939676304748e-08
. O 0 2.054195258338609e-09

04 O 0 0.004569548182189465
. O 0 5.4635884225717746e-06

18 O 0 1.7438096620026045e-06
families O 0 7.762645637399146e-09
with O 0 3.895388178687398e-10
21 O 0 7.490212539096319e-08
informative O 0 1.8097733800459537e-07
matings O 0 1.821198765128429e-07
for O 0 2.8714697286602586e-09
both O 0 1.116459369399081e-08
properdin O 0 4.084402917214902e-06
Factor O 0 1.96437008526118e-06
B O 0 3.1328670502261957e-07
allotype O 0 2.925851561030868e-07
and O 0 4.0382301946806365e-09
HLA O 0 1.2590869857831422e-07
- O 0 4.652295970686282e-08
B O 0 7.281826128746616e-07
were O 0 2.2197941262902532e-08
found O 0 2.1463257837694982e-08
. O 0 1.4543417137247161e-08

Of O 0 3.287019717390649e-05
72 O 0 1.1014789379260037e-05
informative O 0 2.7981866423942847e-06
meioses O 0 7.4788008532777894e-06
, O 0 7.133928558999969e-09
three O 0 7.76254260870246e-09
recombinants O 0 1.760616783030855e-06
were O 0 2.790865138990739e-08
found O 0 8.712475185745916e-09
, O 0 2.6513721773646637e-10
giving O 0 8.164542930622076e-10
a O 0 2.8037328014818286e-09
recombinant O 0 5.038007788726873e-10
fraction O 0 7.225307463443187e-09
of O 0 1.1768494800890039e-07
0 O 0 2.271393526598331e-07
. O 0 1.791472747925127e-08

042 O 0 0.002758238697424531
. O 0 2.886360562115442e-06

A O 0 2.866720205929596e-05
lod O 0 8.118310506688431e-05
score O 0 1.154994393459674e-07
of O 0 4.27502939714941e-08
16 O 0 5.712084316655819e-08
between O 0 2.2260906007431913e-08
HLA O 0 6.76735893989644e-08
- O 0 1.5729563429545124e-08
B O 0 9.300886461005575e-08
and O 0 6.467585356162431e-10
Factor O 0 2.518780206628435e-07
B O 0 1.9889688473995193e-07
allotypes O 0 6.275387249843334e-07
was O 0 4.3871313692989133e-08
calculated O 0 3.553383010057587e-08
at O 0 6.808358765653111e-09
a O 0 2.4609317361701244e-10
maximum O 0 7.117343936435816e-10
likelihood O 0 1.1741164707146368e-09
value O 0 1.7914376648775487e-09
of O 0 9.326032168743836e-10
the O 0 4.603021852567224e-10
recombinant O 0 1.5221281179922386e-10
fraction O 0 1.7287700160295572e-09
of O 0 5.792899493428649e-09
0 O 0 1.153680617704822e-08
. O 0 7.132594959102789e-09

04 O 0 0.0038237443659454584
. O 0 3.939558155252598e-06

A O 0 1.339617847406771e-05
crossover O 0 4.4101196294832334e-07
was O 0 7.850798056097119e-08
shown O 0 2.0798844868608057e-09
to O 0 4.743923032179964e-10
have O 0 4.7053333451785306e-11
occurred O 0 2.726140646558406e-09
between O 0 9.961988872708716e-11
genes O 0 1.509628186346923e-11
for O 0 2.971774215598799e-11
Factor O 0 9.662537436838647e-09
B O 0 6.879946834459361e-09
and O 0 1.8838196280679398e-10
HLA O 0 1.7041678290752316e-08
- O 0 4.737731096327025e-09
D O 0 2.756289063654549e-08
, O 0 2.7468133323438337e-10
in O 0 7.456650297221756e-10
which O 0 4.101601835948543e-10
HLA O 0 9.570936043701295e-09
- O 0 5.628395527423891e-09
D O 0 9.858757721303846e-08
segregared O 0 4.545934473298985e-07
with O 0 4.058158697972658e-09
HLA O 0 6.427415542020753e-07
- O 0 5.876097475265851e-08
A O 0 1.8942780855013552e-07
and O 0 1.6411961789586371e-09
B O 0 1.3869125723431353e-06
. O 0 5.71206228983101e-08

These O 0 2.7301071625629447e-08
studies O 0 2.4174035218038625e-08
suggest O 0 1.8993560058078174e-09
that O 0 8.358900377425371e-12
the O 0 3.596367995073457e-11
genes O 0 4.2235975133975145e-11
for O 0 6.508282107686725e-11
Factor O 0 3.077955454955372e-07
B O 0 2.390624285908416e-05
and O 0 7.224386422421958e-07
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
are O 0 2.6476236758554705e-09
located O 0 2.8216617931065002e-09
outside O 0 4.190653601909844e-09
those O 0 4.4684192457289384e-10
for O 0 9.849544291284928e-09
HLA O 0 2.082078253806685e-06
, O 0 9.539238288169827e-10
that O 0 3.8803918411822735e-11
the O 0 7.561820614121473e-10
order O 0 2.486154615510827e-09
of O 0 3.6398841274376537e-08
genese O 0 7.00780049101013e-07
is O 0 1.648315084423757e-08
HLA O 0 3.366875489518861e-08
- O 0 5.001092873158086e-09
A O 0 7.39805088301182e-08
, O 0 9.417979590642389e-11
- O 0 3.913797896881732e-10
B O 0 1.3028731871145283e-08
, O 0 6.982607547723063e-11
- O 0 9.367981945729298e-10
D O 0 3.187936670201452e-08
, O 0 1.032839258563456e-09
Factor O 0 6.30700583315047e-07
B O 0 6.921601197973359e-06
allotype O 0 0.04895348474383354
, O 0 3.474803406788851e-06
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
, O 0 4.860545299578689e-10
that O 0 1.3761165817971488e-11
the O 0 3.106746526704285e-10
genes O 0 3.934892855994576e-09
coding O 0 1.8513522093144275e-07
for O 0 8.242204785346985e-08
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
and O 0 5.4233598945074846e-08
Factor O 0 6.24866106591071e-06
B O 0 4.2998811977668083e-07
allotypes O 0 3.963220649438881e-07
are O 0 1.570376745307911e-10
approximately O 0 1.0053349264182998e-09
3 O 0 7.59709894992966e-09
- O 0 1.9656452021621362e-09
- O 0 9.255861854740033e-09
5 O 0 2.668462073529554e-08
centimorgans O 0 2.7350489517630194e-07
from O 0 1.0915726988969254e-08
the O 0 1.665748605716999e-08
HLA O 0 3.505847701035236e-08
- O 0 3.53062112878888e-09
A O 0 5.427726890161466e-08
and O 0 5.311746043012988e-10
HLA O 0 2.4722440983282468e-08
- O 0 7.954981562363628e-09
B O 0 9.275907331129929e-08
loci O 0 3.4355327471757846e-09
, O 0 1.1173082598014972e-10
and O 0 2.8358435391617753e-11
that O 0 4.495189984132786e-11
the O 0 1.2803974547281882e-09
apparent O 0 1.7956622855308524e-07
lack O 0 1.5923639296033798e-07
of O 0 1.4650384017045326e-08
recombinants O 0 6.741181124425566e-08
between O 0 2.2739732319365658e-09
the O 0 3.1688147661412813e-09
Factor O 0 2.676154338132619e-07
B O 0 6.09442531640525e-06
gene O 0 7.924460874164652e-07
and O 0 2.197120920754969e-05
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
gene O 0 9.389058845954423e-07
suggests O 0 7.348263775242003e-09
that O 0 9.594463244722018e-12
these O 0 2.3143936420111366e-11
two O 0 2.671474153004283e-10
genes O 0 2.2210340233641546e-09
lie O 0 1.467476522520883e-06
in O 0 3.541488169389595e-08
close O 0 3.835069492197363e-06
proximity O 0 8.985483646029024e-07
to O 0 5.7169424749758946e-09
one O 0 8.289593012023033e-09
another O 0 3.2127442040064125e-08
. O 0 3.1234872466257e-08

Distribution O 0 5.098352744425938e-07
of O 0 1.1620394388955901e-06
emerin O 0 5.789946953882463e-05
and O 0 3.512929680482557e-08
lamins O 0 0.0021851654164493084
in O 0 5.881670261942418e-08
the O 0 1.803121705279409e-07
heart O 0 2.7210985535930376e-06
and O 0 1.1639554875486624e-09
implications O 0 1.1101531782742313e-07
for O 0 5.777862455147442e-08
Emery B-Disease 1 0.9999794960021973
- I-Disease 1 1.0
Dreifuss I-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 4.5143491433918825e-07

Emerin O 0 0.03570152446627617
is O 0 2.2418652179112541e-07
a O 0 9.785619425883851e-08
nuclear O 0 1.8485958435121574e-06
membrane O 0 2.1789628590340726e-06
protein O 0 1.3994372238812502e-07
which O 0 2.706931900853249e-10
is O 0 8.311135668570557e-10
missing O 0 3.184783281540149e-07
or O 0 3.593151021163976e-08
defective O 0 4.6624853666799027e-07
in O 0 1.323087985838356e-07
Emery B-Disease 1 0.9999996423721313
- I-Disease 1 1.0
Dreifuss I-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 4.481707946979441e-05
EDMD B-Disease 1 1.0
) O 0 1.3626224415475008e-07
. O 0 2.3844913599191386e-08

It O 0 1.0090896296333085e-07
is O 0 7.368811782981766e-09
one O 0 3.022539774022448e-09
member O 0 1.093594104162321e-08
of O 0 3.603274478791718e-07
a O 0 6.489698307632352e-07
family O 0 6.530935934279114e-07
of O 0 4.23295341533958e-06
lamina O 1 0.9994522929191589
- O 0 0.017008351162075996
associated O 0 2.5292995360359782e-06
proteins O 0 1.3090454942243923e-08
which O 0 6.598657176226652e-10
includes O 0 3.115256941299549e-09
LAP1 O 0 4.337931386544369e-05
, O 0 1.0231907765501091e-08
LAP2 O 0 6.865619798190892e-05
and O 0 4.6789928376256285e-08
lamin O 0 4.0541613998357207e-05
B O 0 4.5512431825045496e-05
receptor O 0 3.9330654544755816e-05
( O 0 8.367546655563274e-08
LBR O 0 3.193390148226172e-05
) O 0 9.56102841342954e-09
. O 0 2.099147167200499e-08

A O 0 2.8420419766916893e-05
panel O 0 3.861887876155379e-07
of O 0 1.8164875825732452e-07
16 O 0 2.1107786096763448e-07
monoclonal O 0 1.900360757645103e-08
antibodies O 0 1.8243958566088736e-09
( O 0 9.78651115701723e-09
mAbs O 0 1.4403488535208453e-07
) O 0 7.375712263169021e-10
has O 0 4.8908037342254573e-11
been O 0 1.1511144121234551e-10
mapped O 0 9.415900281695144e-10
to O 0 4.3667711807637843e-11
six O 0 1.0454441479179621e-10
specific O 0 3.0937478273651564e-11
sites O 0 5.40662237202838e-10
throughout O 0 4.5802428516594773e-10
the O 0 2.945025112666144e-09
emerin O 0 2.2945873467961064e-07
molecule O 0 4.174069090367993e-09
using O 0 1.6545858017025239e-09
phage O 0 6.856641476815639e-09
- O 0 1.7633006166306586e-09
displayed O 0 2.2098867180631032e-09
peptide O 0 9.378426923944971e-09
libraries O 0 8.8369764839058e-09
and O 0 1.5915326001536556e-10
has O 0 1.706960683911518e-10
been O 0 6.426857379615569e-10
used O 0 1.3675096610654691e-09
to O 0 3.375483670353674e-09
localize O 0 6.0571328504011035e-06
emerin O 0 1.71325373230502e-05
in O 0 5.643307687819288e-08
human O 0 9.765594199961924e-08
and O 0 3.6383710266818525e-08
rabbit O 0 3.645217020675773e-06
heart O 0 1.1439121408329811e-05
. O 0 5.5157780565195935e-08

Several O 0 8.421164920946467e-07
mAbs O 0 3.743787601706572e-06
against O 0 2.0586400140132355e-08
different O 0 1.0661685756474526e-08
emerin O 0 2.0418583517312072e-05
epitopes O 0 4.420133791427361e-06
did O 0 1.9098813197615527e-08
not O 0 9.573031256593367e-10
recognize O 0 5.0582880106730954e-09
intercalated O 0 2.9514567359001376e-06
discs O 0 1.078483023775334e-06
in O 0 1.6170721650610176e-08
the O 0 5.651052248367705e-08
heart O 0 2.0884060631942702e-06
, O 0 8.46179737390429e-10
though O 0 1.4778466228548837e-09
they O 0 4.378257478787617e-10
recognized O 0 6.953057685166186e-09
cardiomyocyte O 0 8.272677973764075e-07
nuclei O 0 3.2065187838270504e-07
strongly O 0 2.5703105421825967e-08
, O 0 1.6536961799928918e-09
both O 0 4.8543125075184435e-09
at O 0 4.0170377246795397e-07
the O 0 8.120908745468114e-08
rim O 0 2.932788163434452e-07
and O 0 7.73246688900997e-10
in O 0 1.0687379869978031e-08
intranuclear O 0 6.462538294726983e-06
spots O 0 4.696374276136339e-07
or O 0 1.5731116320694127e-07
channels O 0 4.009536098692479e-07
. O 0 8.381937988133359e-08

A O 0 4.583959889714606e-05
polyclonal O 0 7.464934606105089e-05
rabbit O 0 4.758427166962065e-06
antiserum O 0 6.2738949964114e-06
against O 0 8.38331359886979e-08
emerin O 0 1.8667797121452168e-05
did O 0 3.914779966862625e-08
recognize O 0 9.308319448564362e-09
both O 0 2.8538120755428054e-09
nuclear O 0 1.2615740843102685e-06
membrane O 0 6.572661277459702e-07
and O 0 1.222507428622066e-09
intercalated O 0 2.134414899046533e-06
discs O 0 1.1204085126337304e-07
but O 0 4.6112294538325216e-10
, O 0 4.679343024172056e-11
after O 0 4.354397675765398e-10
affinity O 0 3.6986269602579114e-09
purification O 0 1.173933483755718e-08
against O 0 8.943139562234137e-09
a O 0 3.142771731745597e-08
pure O 0 1.8289299532625591e-06
- O 0 2.95309376951991e-07
emerin O 0 3.824273335339967e-06
band O 0 8.579630161875684e-08
on O 0 2.422822475978137e-08
a O 0 2.42119639892735e-08
western O 0 1.6749783782188388e-08
blot O 0 1.120863203141198e-06
, O 0 3.7182836809535047e-09
it O 0 7.961489245644771e-10
stained O 0 1.9786901361840137e-07
only O 0 1.0815379702933114e-08
the O 0 2.223387518540676e-08
nuclear O 0 2.364341753491317e-06
membrane O 0 1.1633839676505886e-05
. O 0 2.5435707584620104e-07

These O 0 7.562822901263644e-08
results O 0 7.435478455164457e-09
would O 0 1.1853741321843358e-09
not O 0 3.994844732790881e-10
be O 0 1.3076298932546138e-09
expected O 0 3.783962032599675e-09
if O 0 9.8308508000855e-09
immunostaining O 0 2.0176289581286255e-06
at O 0 6.561463692378311e-07
intercalated O 0 3.226551052648574e-05
discs O 0 4.026202532259049e-06
were O 0 9.309085413633511e-08
due O 0 4.7950344139735535e-08
to O 0 2.1202959388233467e-09
a O 0 6.738350322166298e-09
product O 0 9.003293666154377e-10
of O 0 5.896584553966022e-09
the O 0 1.925216785991779e-08
emerin O 0 2.897936610679608e-06
gene O 0 1.2233868362798717e-09
and O 0 1.1889829398814555e-10
, O 0 1.3311203528321158e-10
therefore O 0 6.904052329836929e-10
, O 0 7.068258478515332e-11
cast O 0 6.643717798127113e-10
some O 0 5.842917816245574e-11
doubt O 0 9.200799566677631e-10
upon O 0 1.2751065758820346e-09
the O 0 1.1041907388431582e-09
hypothesis O 0 2.3972372531488872e-08
that O 0 3.3945410371494233e-10
cardiac B-Disease 0 0.08337247371673584
defects I-Disease 0 0.00019290813361294568
in O 0 2.4651681087561883e-06
EDMD B-Disease 1 1.0
are O 0 1.6526823287676962e-07
caused O 0 1.001807987677239e-07
by O 0 3.906513779128318e-09
absence O 0 1.9538549622666324e-06
of O 0 4.18214676756179e-06
emerin O 0 0.0001431635901099071
from O 0 8.857767284098372e-07
intercalated O 0 0.0016608014702796936
discs O 0 0.00011088977043982595
. O 0 4.5162263972997607e-07

Although O 0 1.0632400062604574e-06
emerin O 0 2.18261920963414e-05
was O 0 4.7261630697903456e-07
abundant O 0 1.0551514861845135e-07
in O 0 1.4358033872952092e-08
the O 0 3.0983052567989944e-08
membranes O 0 2.0744623441260046e-07
of O 0 4.4729944193022675e-07
cardiomyocyte O 0 1.4809796084591653e-05
nuclei O 0 2.602169615784078e-06
, O 0 6.993197576576904e-09
it O 0 6.62483790048185e-10
was O 0 2.1485585932623508e-07
absent O 0 4.389031360574336e-08
from O 0 2.0511294884784093e-09
many O 0 3.0339106227295076e-10
non O 0 3.619337007876311e-08
- O 0 4.608516945836527e-08
myocyte O 0 4.476355024962686e-05
cells O 0 2.6030400945842302e-08
in O 0 2.351030703451329e-09
the O 0 5.2649291149009514e-08
heart O 0 1.6576226698816754e-05
. O 0 1.6902279753594485e-07

This O 0 5.6223147026912557e-08
distribution O 0 4.309372414468271e-08
of O 0 2.857545666756778e-07
emerin O 0 3.568080865079537e-05
was O 0 8.171044783011894e-07
similar O 0 1.7429537813029583e-09
to O 0 1.403398730559502e-09
that O 0 4.020543897809148e-10
of O 0 3.471618725825465e-08
lamin O 0 5.5867562878120225e-06
A O 0 1.7610465192774427e-06
, O 0 1.0868229649574346e-09
a O 0 5.244330747444792e-09
candidate O 0 1.1459451165762857e-09
gene O 0 3.0258834327057116e-10
for O 0 4.16894324617445e-10
an O 0 3.5289247080072528e-09
autosomal O 0 7.806747959193672e-08
form O 0 7.58255325195023e-08
of O 1 0.9998520612716675
EDMD B-Disease 1 1.0
. O 0 1.80340648512356e-05

In O 0 5.090394665785425e-07
contrast O 0 2.1361935864661064e-07
, O 0 3.943904047787328e-08
lamin O 0 0.0003362054703757167
B1 O 0 0.001022224547341466
was O 0 1.5592894442306715e-06
absent O 0 9.55379277911561e-07
from O 0 4.7383029055936277e-08
cardiomyocyte O 0 4.079404789081309e-06
nuclei O 0 1.005684566734999e-06
, O 0 1.1234660313164113e-08
showing O 0 4.236525512624212e-07
that O 0 2.1722764032006125e-08
lamin O 0 9.15207783691585e-05
B1 O 0 0.00016309866623487324
is O 0 1.5866354896587609e-09
not O 0 3.9882058766593786e-10
essential O 0 1.2465152465779283e-08
for O 0 7.03763536336055e-09
localization O 0 3.7992272154951934e-06
of O 0 3.9610176827409305e-07
emerin O 0 1.697391053312458e-05
to O 0 5.592677609911334e-08
the O 0 2.311265632215509e-07
nuclear O 0 0.00011682450713124126
lamina O 1 0.9999874830245972
. O 0 2.5121114504145226e-06

Lamin O 1 0.999994158744812
B1 O 1 0.9982455968856812
is O 0 2.465872483981002e-08
also O 0 1.3073132576479907e-09
almost O 0 1.0735800692884823e-08
completely O 0 4.6761604721723415e-07
absent O 0 1.0908130434472696e-06
from O 0 2.1829428931141592e-07
skeletal O 0 0.10803277045488358
muscle O 0 5.071055056760088e-06
nuclei O 0 0.00023236779088620096
. O 0 8.474272590319742e-07

In O 0 2.208447767770849e-05
EDMD B-Disease 1 1.0
, O 0 1.0304765929447512e-08
the O 0 4.7775681188966246e-09
additional O 0 5.8379661105334435e-09
absence O 0 8.814456009531568e-08
of O 0 1.046348756972293e-06
lamin O 0 0.003426923882216215
B1 O 1 0.7394834756851196
from O 0 1.7418649349565385e-06
heart O 0 0.4766499996185303
and O 0 5.097733264847193e-06
skeletal O 1 1.0
muscle O 1 0.9775160551071167
nuclei O 1 0.999993085861206
which O 0 2.310599995780649e-07
already O 0 2.8210658697958024e-08
lack O 0 2.9589057248813333e-06
emerin O 0 7.700565220147837e-06
may O 0 3.122282210554772e-09
offer O 0 1.0872661798666527e-10
an O 0 3.990227592787221e-11
alternative O 0 1.40723627195527e-10
explanation O 0 6.238841443462206e-09
of O 0 7.694597181640006e-10
why O 0 5.697290972328517e-10
these O 0 1.7755566114607824e-11
tissues O 0 4.0078187990566505e-10
are O 0 5.5219061961819804e-11
particularly O 0 2.068935578414255e-10
affected O 0 3.0418967345013925e-09
. O 0 1.2070946464604049e-09
. O 0 2.8942961805000778e-08

Genetic O 0 2.8220509193488397e-05
mapping O 0 3.019106998181087e-06
of O 0 6.853564968878345e-07
the O 0 2.152600018234807e-06
copper B-Disease 1 0.8384937047958374
toxicosis I-Disease 1 0.9999997615814209
locus O 0 0.0006925284978933632
in O 0 1.037740844367363e-06
Bedlington O 1 0.7785547375679016
terriers O 0 3.388639015611261e-05
to O 0 3.1266463196288896e-08
dog O 0 8.43777527848033e-08
chromosome O 0 1.150715966957705e-08
10 O 0 3.3687623801625932e-09
, O 0 8.48386846885596e-11
in O 0 6.672201124935384e-10
a O 0 1.2336271559831857e-08
region O 0 5.232573130342644e-08
syntenic O 0 5.966098797216546e-06
to O 0 2.309748836637482e-08
human O 0 2.2853621217677755e-08
chromosome O 0 1.0525083382617595e-07
region O 0 1.635721780246513e-08
2p13 O 0 7.834648386051413e-06
- O 0 1.9822664398816414e-06
p16 O 0 4.555149189400254e-06
. O 0 6.19293842873958e-08

Abnormal O 1 1.0
hepatic B-Disease 1 1.0
copper I-Disease 1 0.9999995231628418
accumulation I-Disease 1 0.9999995231628418
is O 0 2.6105959705091664e-07
recognized O 0 1.9462394362790292e-08
as O 0 3.628604305916383e-09
an O 0 3.360113609574e-08
inherited B-Disease 1 1.0
disorder I-Disease 1 1.0
in O 0 0.014379151165485382
man O 0 0.0009292379836551845
, O 0 6.316287226582062e-08
mouse O 0 4.99630868944223e-06
, O 0 5.01595032176283e-08
rat O 0 3.2675488910172135e-05
and O 0 1.1143664124801944e-07
dog O 0 0.00016710595809854567
. O 0 4.7653526280555525e-07

The O 0 2.036931391558028e-06
major O 0 3.104673169218586e-06
cause O 0 4.1136732761515304e-05
of O 0 0.0016405353089794517
hepatic B-Disease 1 1.0
copper I-Disease 1 0.9999998807907104
accumulation I-Disease 1 1.0
in O 0 5.608555511571467e-05
man O 0 0.00013695927918888628
is O 0 3.7021152365923626e-08
a O 0 2.2478961625438387e-07
dysfunctional O 0 0.00010813263361342251
ATP7B O 0 0.0037520132027566433
gene O 0 6.525992546357884e-08
, O 0 2.6175768219616202e-09
causing O 0 1.419229533894395e-06
Wilson B-Disease 0 0.014514107257127762
disease I-Disease 1 0.9999998807907104
( O 0 0.00041019811760634184
WD B-Disease 1 0.999981164932251
) O 0 2.1302184904925525e-07
. O 0 6.245915784575118e-08

Mutations O 0 2.572513267296017e-06
in O 0 7.385531120007727e-08
the O 0 3.134223618417309e-07
ATP7B O 0 0.01055713091045618
genes O 0 1.7274103925046802e-07
have O 0 1.944854277624586e-09
also O 0 4.4484779748721337e-10
been O 0 3.92273857841019e-09
demonstrated O 0 2.901243689734656e-08
in O 0 1.570223275848548e-07
mouse O 0 2.2768269900552696e-06
and O 0 1.225327395104614e-07
rat O 0 2.7033673177356832e-05
. O 0 1.2090681877907627e-07

The O 0 9.940941708919127e-06
ATP7B O 0 0.016619233414530754
gene O 0 3.798028274104581e-07
has O 0 4.245538143266003e-09
been O 0 3.105687484961095e-09
excluded O 0 7.67591146200175e-09
in O 0 8.892515057645767e-10
the O 0 3.888902089244084e-09
much O 0 1.008752459341622e-08
rarer O 0 7.562850328213244e-07
human O 0 2.7425818416304537e-07
copper B-Disease 1 0.999993085861206
overload I-Disease 1 1.0
disease O 1 1.0
non B-Disease 1 0.9998123049736023
- I-Disease 0 1.3846664842276368e-05
Indian I-Disease 0 8.702058948983904e-06
childhood I-Disease 1 0.9996743202209473
cirrhosis I-Disease 1 1.0
, O 0 4.5873418952346867e-10
indicating O 0 5.95281797188818e-08
genetic O 0 2.104351040088659e-07
heterogeneity O 0 1.336389800599136e-06
. O 0 3.241723689484388e-08

By O 0 5.521851775824871e-08
investigating O 0 2.404207180006779e-07
the O 0 5.3048157866442125e-08
common O 0 2.223400770162698e-07
autosomal O 0 0.0006529368693009019
recessive O 0 0.0002075899246847257
copper B-Disease 1 0.9999984502792358
toxicosis I-Disease 1 1.0
( O 0 0.00019265100127086043
CT B-Disease 1 0.9999954700469971
) O 0 4.585072232998755e-08
in O 0 5.3394717980381756e-08
Bedlington O 1 0.9866103529930115
terriers O 0 9.691900049801916e-05
, O 0 8.711324994692404e-10
we O 0 1.0823753004984837e-09
have O 0 1.010286090896706e-10
identified O 0 5.527083235534747e-10
a O 0 4.334758385571291e-10
new O 0 7.974038096492109e-11
locus O 0 1.0170036368606361e-08
involved O 0 6.517456796473198e-09
in O 0 3.157456376357004e-07
progressive O 1 1.0
liver B-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 1.593510774000606e-06

We O 0 1.9594479283568944e-07
examined O 0 1.6454637830065622e-07
whether O 0 2.5309633500114614e-08
the O 0 3.9043854371811904e-07
WD B-Disease 0 0.0023149873595684767
gene O 0 2.2228580576211243e-07
ATP7B O 0 2.1699155695387162e-05
was O 0 3.5873719639312185e-07
also O 0 1.7020556075664217e-09
causative O 0 1.74603982827648e-07
for O 0 4.74870498479163e-09
CT B-Disease 0 1.1408463251427747e-05
by O 0 9.41915700991558e-09
investigating O 0 5.961680358268495e-07
the O 0 1.0661079130613871e-07
chromosomal O 0 1.0482582183612976e-05
co O 0 0.00010342746099922806
- O 0 0.00010974545875797048
localization O 0 0.002511131577193737
of O 0 3.590662117858301e-06
ATP7B O 0 0.0004956139018759131
and O 0 1.1009211320356371e-08
C04107 O 0 3.137552369025798e-07
, O 0 1.7469567459293955e-10
using O 0 2.939260501655383e-10
fluorescence O 0 6.5648411151641994e-09
in O 0 2.4642630158666634e-09
situ O 0 7.33872809632885e-07
hybridization O 0 2.32523316157085e-08
( O 0 2.5873769793349766e-09
FISH O 0 4.862646107994806e-08
) O 0 5.732466168417716e-10
. O 0 3.442853557800163e-09

C04107 O 0 8.924824942369014e-05
is O 0 4.3157715623465265e-08
an O 0 1.033809393646834e-08
anonymous O 0 8.238886266553891e-07
microsatellite O 0 1.418408464815002e-05
marker O 0 1.998251946133678e-06
closely O 0 7.968908448674483e-07
linked O 0 6.322570698102936e-06
to O 0 4.217799585148896e-07
CT B-Disease 1 0.9999915361404419
. O 0 9.215330010192702e-07

However O 0 1.929797690536361e-06
, O 0 1.8551043012848822e-07
BAC O 0 0.0006728608277626336
clones O 0 9.475684237258974e-07
containing O 0 3.3789223152780323e-07
ATP7B O 0 0.00014877434296067804
and O 0 2.1997950128138655e-08
C04107 O 0 2.5781080239539733e-06
mapped O 0 5.091991965855414e-07
to O 0 1.1940293198620111e-08
the O 0 3.9324191902778693e-08
canine O 0 8.495611041325901e-07
chromosome O 0 1.3069005433408165e-07
regions O 0 8.073876678338365e-09
CFA22q11 O 0 3.7224315747153014e-05
and O 0 1.2263989823679822e-08
CFA10q26 O 0 4.511643055593595e-05
, O 0 5.252356327645202e-10
respectively O 0 4.351435656246849e-09
, O 0 2.0910807807528187e-10
demonstrating O 0 1.0062217725703704e-08
that O 0 3.2615499190313813e-09
WD B-Disease 0 6.4550731622148305e-06
cannot O 0 1.298680096795124e-08
be O 0 2.110873698057958e-09
homologous O 0 1.2593939224814221e-08
to O 0 8.921110072890315e-09
CT B-Disease 0 0.00034144442179240286
. O 0 1.5614962478593952e-07

The O 0 1.5715440895291977e-05
copper O 0 7.603391713928431e-05
transport O 0 7.925277714093681e-06
genes O 0 5.0489543355070055e-06
CTR1 O 0 0.21475060284137726
and O 0 2.2828490386928024e-07
CTR2 O 1 0.8808794617652893
were O 0 2.136348342673955e-07
also O 0 2.1161263852320644e-09
excluded O 0 8.012069230289853e-09
as O 0 2.5306434725536064e-09
candidate O 0 5.176029826969852e-09
genes O 0 2.22412843697839e-09
for O 0 7.291468762105069e-09
CT B-Disease 0 0.05153203383088112
since O 0 1.1584891979055101e-07
they O 0 1.1759699880542485e-09
both O 0 7.75530195618046e-10
mapped O 0 1.1800266008776816e-07
to O 0 1.215342759763871e-08
canine O 0 1.3770345503871795e-06
chromosome O 0 3.574470213152381e-07
region O 0 1.8388185196727136e-07
CFA11q22 O 0 0.008381928317248821
. O 0 5.122076345287496e-07

2 O 0 1.6066023817984387e-05
- O 0 2.695286639209371e-06
22 O 0 1.0938746299871127e-06
. O 0 1.0146828088863913e-07

5 O 0 3.5717504943022504e-05
. O 0 6.2844304693499e-07

A O 0 5.333392437023576e-06
transcribed O 0 1.2678483471972868e-06
sequence O 0 3.8881101005472374e-08
identified O 0 1.4102632839296803e-08
from O 0 4.911786977146448e-09
the O 0 1.0529556782046257e-08
C04107 O 0 6.070041536077042e-07
- O 0 1.6901456945106474e-07
containing O 0 8.474403756508764e-08
BAC O 0 0.0006627987022511661
was O 0 3.3370386631759175e-07
found O 0 3.179688512489065e-09
to O 0 5.479062759050635e-10
be O 0 9.763500008475035e-10
homologous O 0 7.110373179131102e-09
to O 0 1.5671101083469807e-09
a O 0 1.855270070905135e-08
gene O 0 1.0040701603486468e-09
expressed O 0 5.823805326876652e-10
from O 0 7.60829355073156e-09
human O 0 2.1295660346254408e-08
chromosome O 0 4.566787481508072e-08
2p13 O 0 1.7634134508170973e-07
- O 0 5.032615391087347e-08
p16 O 0 4.600577696578512e-08
, O 0 1.7980777977655293e-10
a O 0 1.4795953351409707e-09
region O 0 2.4374218199341158e-09
devoid O 0 4.195406404505775e-07
of O 0 1.7229936588591954e-08
any O 0 1.2634938428845999e-08
positional O 0 1.567302945204574e-07
candidate O 0 1.000141196527693e-07
genes O 0 4.008212783901399e-08
. O 0 1.8940680135415278e-08

Molecular O 0 4.103393166587921e-06
analysis O 0 7.805140000982647e-08
of O 0 3.8462296458874334e-08
the O 0 5.929971891305286e-08
APC B-Disease 0 7.856729666855244e-08
gene O 0 1.179322889344192e-10
in O 0 1.7257152651328767e-10
205 O 0 8.901559489515876e-10
families O 0 3.527756906041013e-11
: O 0 4.152157090375752e-11
extended O 0 1.494280588154595e-09
genotype O 0 1.8213651031828704e-08
- O 0 3.1446603543372476e-08
phenotype O 0 1.980976094273501e-08
correlations O 0 2.0795688726593653e-07
in O 0 7.504237231614752e-09
FAP B-Disease 0 6.01265739419432e-08
and O 0 3.299067269368905e-11
evidence O 0 2.03691108424664e-09
for O 0 6.667961321982219e-11
the O 0 7.924417233518e-10
role O 0 6.434047961079159e-09
of O 0 4.4430468193468187e-08
APC B-Disease 0 4.655953489418607e-08
amino O 0 1.8587544836634606e-09
acid O 0 2.4857800262623186e-09
changes O 0 2.416268074512118e-09
in O 0 2.4926834157668054e-05
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
predisposition O 1 1.0
. O 0 3.442744400672382e-07

BACKGROUND O 0 0.0011548689799383283
/ O 0 3.508978625177406e-05
AIMS O 0 1.4422337244468508e-06
The O 0 4.422256694169846e-08
development O 0 1.5351207593994332e-06
of O 1 0.9801099300384521
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 7.046536687482785e-10
a O 0 1.3117085195801792e-10
variable O 0 3.8972683413796005e-10
range O 0 7.915802735514177e-11
of O 0 3.742601506484533e-10
extracolonic O 0 3.6017146953781776e-07
manifestations O 0 1.9641229300759733e-06
in O 0 1.1157546850881772e-06
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 0 1.374732528347522e-05
FAP B-Disease 0 1.0644321264408063e-06
) O 0 3.5802930065109706e-10
is O 0 7.315588412826202e-11
the O 0 1.8041859672912608e-10
result O 0 2.1164452412847368e-09
of O 0 2.633980145105852e-08
the O 0 4.1101106518226516e-08
dominant O 0 6.736875093338313e-07
inheritance O 0 4.7889247980492655e-06
of O 0 0.002660582307726145
adenomatous B-Disease 1 1.0
polyposis I-Disease 1 1.0
coli I-Disease 1 1.0
( O 0 1.2942845387442503e-05
APC B-Disease 0 1.2817686183552723e-06
) O 0 1.758267309526218e-08
gene O 0 2.5168057860014414e-08
mutations O 0 9.625825470038762e-08
. O 0 8.714407329080132e-08

In O 0 5.893483745467165e-08
this O 0 3.1301397585004054e-10
study O 0 3.3572788993296854e-10
, O 0 4.28853697345688e-12
direct O 0 8.146696511834861e-11
mutation O 0 3.085338581843011e-11
analysis O 0 1.7461039558686053e-10
of O 0 1.396738613657078e-09
the O 0 1.0938528305359796e-08
APC B-Disease 0 8.282295027584041e-08
gene O 0 1.3955723243697093e-09
was O 0 2.0172135961615822e-08
performed O 0 1.3879033478048086e-09
to O 0 2.057939096911099e-10
determine O 0 8.56576143348775e-09
genotype O 0 2.6151559495701804e-07
- O 0 1.0693479879364531e-07
phenotype O 0 5.2332520539266625e-08
correlations O 0 2.345330756270414e-07
for O 0 5.639614109043123e-09
nine O 0 2.4606251258774137e-07
extracolonic O 0 9.70359815255506e-06
manifestations O 0 2.0368556761241052e-06
and O 0 6.990232837011945e-10
to O 0 6.663298801612427e-10
investigate O 0 1.2378037261839836e-08
the O 0 4.303415401807342e-09
incidence O 0 1.046869783749571e-06
of O 0 8.260208517185674e-08
APC B-Disease 0 8.069768853147252e-08
mutations O 0 1.2594797427212256e-09
in O 0 4.89143392456981e-09
non O 0 0.02803262323141098
- O 1 0.9999992847442627
FAP O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 1.5756189668536535e-06

METHODS O 0 5.963824878563173e-05
The O 0 1.4775085901419516e-06
APC B-Disease 0 1.1554697039173334e-06
gene O 0 3.0279345697437066e-09
was O 0 1.4573100948211959e-08
analysed O 0 2.7474605701627297e-08
in O 0 4.5343933052777174e-09
190 O 0 9.70493090335367e-08
unrelated O 0 8.220099800837488e-08
FAP B-Disease 0 6.439133670710362e-08
and O 0 2.2192374327101305e-10
15 O 0 1.0765249669475452e-07
non O 1 0.6746159791946411
- O 1 0.9999997615814209
FAP O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 1.4780101764699793e-07
using O 0 1.942288996303887e-09
denaturing O 0 4.037796315969899e-06
gradient O 0 1.799054416551371e-07
gel O 0 1.9941913009802192e-08
electrophoresis O 0 5.8347080056364575e-08
, O 0 9.78937764184451e-11
the O 0 7.390850709221297e-10
protein O 0 9.823236668538016e-10
truncation O 0 1.4386104751906714e-08
test O 0 2.3731325238252055e-10
, O 0 9.961451802320553e-12
and O 0 1.72653748936602e-11
direct O 0 3.1078681850260637e-09
sequencing O 0 2.23824994094457e-08
. O 0 1.3800403486641244e-08

RESULTS O 0 5.254533243714832e-05
Chain O 0 1.4025990822119638e-05
terminating O 0 6.621445436394424e-07
signals O 0 3.5763857653137165e-08
were O 0 1.0238033754106368e-09
only O 0 1.6507926969833164e-10
identified O 0 1.3981567015264318e-09
in O 0 1.249876313558218e-09
patients O 0 1.1359976292979468e-09
belonging O 0 4.709641530098452e-07
to O 0 2.4804199583172704e-08
the O 0 5.584085442933429e-07
FAP B-Disease 0 2.3158115709520644e-06
group O 0 6.713962275028962e-09
( O 0 1.0951861639796334e-09
105 O 0 6.221387849336679e-08
patients O 0 2.2633110940972756e-09
) O 0 7.454559747266387e-10
. O 0 4.728279545673786e-09

Amino O 0 6.193686658662045e-06
acid O 0 3.371161483300966e-08
changes O 0 1.0279437301363714e-09
were O 0 2.394818343631755e-09
identified O 0 2.0163122282923496e-09
in O 0 1.4901678779821736e-09
four O 0 3.5028917544366323e-09
patients O 0 4.563978917015987e-10
, O 0 9.192445415973083e-11
three O 0 9.735569017621515e-10
of O 0 4.01697633378717e-07
whom O 0 2.0527554056570807e-07
belonged O 0 0.0010127148125320673
to O 0 1.7584426359462668e-07
the O 0 9.33563967464579e-07
non O 0 0.0024044171441346407
- O 0 8.296005944430362e-06
FAP O 0 5.246571618044982e-06
group O 0 9.530750411101963e-09
of O 0 5.557572148973122e-05
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 1 0.9998940229415894
. O 0 2.4559778211141747e-08

Genotype O 0 0.001073242980055511
- O 0 4.700398676504847e-06
phenotype O 0 1.6312081640990073e-07
correlations O 0 5.991146849737561e-07
identified O 0 3.509246582211745e-08
significant O 0 6.306197342098585e-09
differences O 0 7.594997519788649e-09
in O 0 4.638276873691893e-09
the O 0 3.626030586900697e-09
nature O 0 8.846504861992344e-09
of O 0 1.873843968880351e-09
certain O 0 1.1917715703191334e-09
extracolonic O 0 2.6603416358739196e-07
manifestations O 0 7.101363053152454e-08
in O 0 1.0188733412519468e-08
FAP B-Disease 0 2.3437344509602553e-07
patients O 0 4.710858370060578e-10
belonging O 0 3.6896292687771393e-09
to O 0 3.228645129027541e-10
three O 0 2.0081412088757133e-09
mutation O 0 9.855952498583065e-09
subgroups O 0 2.159455107175745e-06
. O 0 5.722236195992991e-08

CONCLUSIONS O 0 2.3839813366066664e-05
Extended O 0 4.83172061649384e-06
genotype O 0 4.029010597150773e-06
- O 0 4.977039793629956e-07
phenotype O 0 1.4572606232832186e-07
correlations O 0 2.902838787122164e-07
made O 0 4.3062313714870015e-09
in O 0 1.911039104740553e-09
this O 0 9.062630645928493e-10
study O 0 4.150023436011452e-09
may O 0 1.0322032117926483e-09
have O 0 1.567808938229831e-10
the O 0 8.555730568460262e-10
potential O 0 2.2054906789747974e-09
to O 0 2.5389190749791624e-10
determine O 0 2.0148516188811527e-09
the O 0 2.3232060719635683e-09
most O 0 4.741839559896377e-11
appropriate O 0 4.88954710053946e-10
surveillance O 0 5.961894089523412e-09
and O 0 4.718148788329657e-11
prophylactic O 0 3.3432692703172506e-07
treatment O 0 7.125741774416383e-09
regimens O 0 2.0666107047873084e-08
for O 0 7.88709236809737e-11
those O 0 2.301908143265141e-11
patients O 0 2.2105758196167002e-11
with O 0 6.160598507026771e-12
mutations O 0 7.983249061815911e-10
associated O 0 2.4939783571653606e-08
with O 0 1.9546981810947273e-09
life O 0 7.092208397807553e-05
threatening O 0 1.497169137110177e-06
conditions O 0 6.4196865423582494e-06
. O 0 1.467511197006388e-07

This O 0 4.516243734542513e-08
study O 0 7.240910981920479e-09
also O 0 5.108448733470716e-11
provided O 0 2.906169749294918e-10
evidence O 0 6.417805176184288e-10
for O 0 5.937399183419956e-11
the O 0 2.532951848266407e-09
pathological O 0 6.535735792567721e-06
nature O 0 1.1787305354005184e-08
of O 0 8.953960239921344e-09
amino O 0 3.7042535705467117e-09
acid O 0 6.179458056365661e-10
changes O 0 1.8253103195586817e-10
in O 0 2.6128579300177535e-09
APC O 0 1.7820735109808084e-08
associated O 0 1.3345656801888595e-09
with O 0 1.35409017332222e-10
both O 0 3.868793285732863e-09
FAP B-Disease 0 3.7391521345853107e-07
and O 0 3.755768585023134e-09
non O 1 0.9957433342933655
- O 1 1.0
FAP O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 2.749061241047457e-05
. O 0 2.722709557811953e-10
. O 0 1.854695952374641e-09

Inherited B-Disease 1 1.0
colorectal I-Disease 1 1.0
polyposis I-Disease 1 1.0
and O 0 2.8096847017877735e-06
cancer B-Disease 1 0.9998530149459839
risk O 1 0.5446747541427612
of O 0 0.1769428551197052
the O 0 2.663351006049197e-05
APC O 0 7.749888936814386e-06
I1307K O 0 4.7798084779060446e-06
polymorphism O 0 1.8224442328573787e-06
. O 0 3.96630142063259e-08

Germ O 0 0.002913812641054392
- O 0 7.574798928544624e-06
line O 0 9.385320254295948e-08
and O 0 7.331852347469692e-10
somatic O 0 7.928234424525726e-08
truncating O 0 7.873709364503156e-07
mutations O 0 5.227024146847725e-09
of O 0 4.444835255412727e-08
the O 0 3.5978828805127705e-08
APC B-Disease 0 1.6647835821004264e-07
gene O 0 1.6871358754499965e-09
are O 0 4.223436531058944e-11
thought O 0 9.860704475173065e-10
to O 0 7.310124172654753e-10
initiate O 0 2.1036807140717428e-07
colorectal B-Disease 1 1.0
tumor I-Disease 0 0.48329418897628784
formation O 0 3.698878572322428e-05
in O 0 0.07966340333223343
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
syndrome I-Disease 1 1.0
and O 0 1.1914130482182372e-06
sporadic O 1 1.0
colorectal O 1 1.0
carcinogenesis O 1 1.0
, O 0 4.595451912337012e-07
respectively O 0 1.842908932303544e-05
. O 0 4.910918391942687e-07

Recently O 0 2.3245672764460323e-06
, O 0 4.160961353250059e-09
an O 0 6.956745401964781e-09
isoleucine O 0 1.057668669091072e-06
- O 0 3.127224317722721e-06
- O 0 5.992774276819546e-06
> O 0 4.066291694471147e-06
lysine O 0 8.103546065285627e-07
polymorphism O 0 1.4700773931508593e-07
at O 0 6.257410944954245e-08
codon O 0 2.5836018835434515e-07
1307 O 0 2.4487428618158447e-06
( O 0 6.304634148079913e-09
I1307K O 0 6.394301976797578e-08
) O 0 6.532524521318805e-10
of O 0 9.541463619200385e-09
the O 0 6.279218922600194e-08
APC B-Disease 0 6.558347536156361e-07
gene O 0 3.431825934541166e-09
has O 0 1.4876878895453416e-10
been O 0 5.132104186067465e-10
identified O 0 5.032226302326137e-10
in O 0 6.385326156710391e-10
6 O 0 6.378540007290212e-08
% O 0 1.807545113585718e-09
- O 0 1.0902072578033994e-09
7 O 0 2.5837932682293285e-08
% O 0 7.776097543654714e-10
of O 0 1.6094036103808662e-09
the O 0 6.211508640774355e-09
Ashkenazi O 0 9.572163151005952e-08
Jewish O 0 5.348972109686656e-08
population O 0 3.178922958202435e-10
. O 0 1.379176550742045e-09

To O 0 1.1248366149629874e-07
assess O 0 2.759232700100256e-07
the O 0 8.228095538242997e-09
risk O 0 3.073578369594543e-08
of O 0 8.009959806543065e-09
this O 0 9.513836385366403e-10
common O 0 1.4796178726683706e-09
APC B-Disease 0 3.253573765960027e-08
allelic O 0 2.2536974952913624e-08
variant O 0 3.1820686530181774e-08
in O 0 1.641277549424558e-07
colorectal O 1 1.0
carcinogenesis O 1 1.0
, O 0 9.91811219819283e-08
we O 0 1.4280932880694763e-08
have O 0 7.714965333249779e-10
analyzed O 0 1.3938624476850237e-08
a O 0 1.6815266956626829e-09
large O 0 1.6512501366250376e-09
cohort O 0 2.1557256957294157e-07
of O 0 3.596805697725358e-08
unselected O 0 0.0018300460651516914
Ashkenazi O 0 1.7280875908909366e-05
Jewish O 0 8.928909096539428e-07
subjects O 0 1.2045306903019082e-06
with O 0 1.8816560753975864e-08
adenomatous B-Disease 0 0.0022483435459434986
polyps I-Disease 0 1.2911442581753363e-06
and O 0 5.660067081691977e-09
. O 0 1.8322849015817155e-08
or O 1 0.9999988079071045
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, I-Disease 0 1.550824464402467e-07
for O 0 1.433712704113077e-08
the O 0 5.175821229386202e-07
APC O 0 2.2209137569007e-06
I1307K O 0 3.251804400861147e-06
polymorphism O 0 1.409125388818211e-06
. O 0 2.360292050695989e-08

The O 0 1.6111192962853238e-05
APC O 0 9.252047675545327e-06
I1307K O 0 3.5720818232221063e-06
allele O 0 3.546936966358771e-08
was O 0 1.511325251613016e-07
identified O 0 1.5621301585611036e-08
in O 0 1.0399541672256873e-08
48 O 0 5.4406516625249424e-08
( O 0 1.4025476335888243e-09
10 O 0 6.583948386484906e-10
. O 0 3.133363707386039e-11
1 O 0 3.3799609777673822e-09
% O 0 1.1066759314504182e-10
) O 0 1.4930681691005532e-11
of O 0 4.478735160517999e-10
476 O 0 4.518182450397035e-08
patients O 0 5.891873655627933e-09
. O 0 1.1752463890957188e-08

Compared O 0 1.497503347991369e-07
with O 0 2.757899117411533e-11
the O 0 5.940142822069561e-10
frequency O 0 9.456522231943154e-10
in O 0 3.181274688124347e-11
two O 0 1.2358390352740223e-11
separate O 0 5.78562787956205e-11
population O 0 9.997921761317752e-12
control O 0 1.1527974408398478e-10
groups O 0 4.496939626230656e-11
, O 0 8.861728711950789e-11
the O 0 1.0023561536343095e-08
APC O 0 1.755510368184332e-07
I1307K O 0 1.2561115170228732e-07
allele O 0 3.238978196762332e-09
is O 0 2.6557298027363174e-10
associated O 0 4.5505840762238847e-10
with O 0 2.4713869839487757e-11
an O 0 3.9125142015095093e-10
estimated O 0 6.650233697058638e-10
relative O 0 1.4694747108023876e-07
risk O 0 9.380612908671537e-08
of O 0 3.5916235674449126e-07
1 O 0 3.574634320102632e-06
. O 0 5.85570099076449e-08

5 O 0 8.073969183897134e-06
- O 0 2.399365712335566e-06
1 O 0 1.3734462527281721e-06
. O 0 1.205785338243004e-07

7 O 0 6.871163350297138e-06
for O 0 2.8063726631444297e-07
colorectal B-Disease 1 1.0
neoplasia I-Disease 1 0.5523682832717896
( O 0 5.726942049477657e-07
both O 0 3.477026311315967e-08
P O 0 0.001082184724509716
= O 0 1.2867104715041933e-06
. O 0 1.8799404255531726e-09
01 O 0 7.204488383649732e-07
) O 0 3.947123072833847e-09
. O 0 6.01924110554819e-09

Furthermore O 0 1.2798655006918125e-06
, O 0 1.4978103202167858e-09
compared O 0 3.212828225684916e-09
with O 0 9.215816443308711e-10
noncarriers O 0 6.144758663140237e-05
, O 0 1.284593906802911e-07
APC O 0 2.279620957779116e-06
I1307K O 0 6.19343495600333e-07
carriers O 0 8.42514336074629e-10
had O 0 1.2622068945589149e-09
increased O 0 1.2507467284095242e-09
numbers O 0 2.8891047332280095e-09
of O 0 9.670782930015775e-08
adenomas B-Disease 1 0.9999896287918091
and O 0 1.9042978465222404e-06
colorectal B-Disease 1 1.0
cancers I-Disease 1 0.9997463822364807
per O 0 3.0920293738745386e-06
patient O 0 8.596762199886143e-07
( O 0 4.048440693793509e-09
P O 0 3.41407758241985e-06
= O 0 3.7598628210844254e-08
. O 0 1.9232952730430242e-10
03 O 0 9.522358368485584e-08
) O 0 1.237649011054387e-10
, O 0 3.377437912677195e-11
as O 0 1.5689068100233072e-10
well O 0 5.551975545969867e-10
as O 0 6.922539208531475e-10
a O 0 6.5710046293077085e-09
younger O 0 2.93314639243647e-09
age O 0 2.702967272227852e-08
at O 0 6.85056534166506e-07
diagnosis O 0 2.621751036713249e-06
. O 0 4.4451148539792484e-08

We O 0 9.411058385921933e-07
conclude O 0 3.967787961300928e-06
that O 0 1.0457064547608752e-08
the O 0 1.273838847737352e-07
APC O 0 1.9662370505102444e-06
I1307K O 0 1.8762947320283274e-06
variant O 0 1.1993481052741117e-07
leads O 0 4.498628314308917e-08
to O 0 6.553744213988466e-09
increased O 0 1.1330777169860085e-06
adenoma B-Disease 1 1.0
formation O 0 7.147079941205448e-07
and O 0 6.201328339727752e-09
directly O 0 8.842995669056108e-09
contributes O 0 1.7589877332468973e-09
to O 0 3.4935287995807585e-10
3 O 0 5.119768609063158e-09
% O 0 7.958190356704975e-11
- O 0 4.1176607262771725e-11
4 O 0 2.8053895317903255e-10
% O 0 1.2967698095889268e-11
of O 0 2.9152954356126415e-11
all O 0 2.309596819349835e-10
Ashkenazi O 0 3.22827781928936e-06
Jewish O 1 0.8275393843650818
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 7.214540573841077e-07

The O 0 3.395172853970507e-08
estimated O 0 3.6372520550997933e-09
relative O 0 8.363413428469357e-08
risk O 0 1.6486987775010675e-08
for O 0 4.127633512762685e-10
carriers O 0 2.806015697576214e-10
may O 0 9.477305606964137e-10
justify O 0 1.9451668720193993e-08
specific O 0 1.5862171298675065e-10
clinical O 0 4.1609773404616135e-09
screening O 0 2.021826039921848e-10
for O 0 8.294724629376304e-11
the O 0 2.16773488048716e-09
360 O 0 3.1215439122433963e-09
, O 0 2.1756565299346775e-11
000 O 0 3.0203726186783797e-09
Americans O 0 3.69113378750896e-10
expected O 0 2.2410029387742725e-10
to O 0 4.1950179441307966e-10
harbor O 0 5.8428149429801124e-08
this O 0 1.1218140305579993e-10
allele O 0 2.388253206309088e-10
, O 0 3.5009911636407764e-11
and O 0 1.4421055495594803e-11
genetic O 0 2.9717645011473337e-10
testing O 0 2.2959591172710958e-10
in O 0 5.775818157083279e-10
the O 0 7.0704233579022e-09
setting O 0 6.83152876490567e-08
of O 0 1.394775210883381e-07
long O 0 4.1271178474744374e-08
- O 0 2.6173534450890656e-08
term O 0 4.326214053662625e-08
- O 0 7.64821717069708e-09
outcome O 0 7.1537402668298e-09
studies O 0 2.711429081259098e-09
may O 0 1.31542152170816e-10
impact O 0 1.4984445906307542e-09
significantly O 0 5.493883570295566e-09
on O 0 1.236553998751333e-06
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
prevention O 0 2.4437584215775132e-05
in O 0 1.2712132735348547e-10
this O 0 5.048808246477243e-11
population O 0 2.8303965074472082e-11
. O 0 3.0820698770916977e-10

Localization O 0 0.0002755566674750298
of O 0 7.777437645017926e-07
human O 0 3.394111445231829e-07
BRCA1 O 0 6.808841845895586e-08
and O 0 2.5991886420939636e-09
its O 0 4.817758192388055e-09
loss O 0 1.5642655171177466e-07
in O 0 7.874549901032424e-09
high O 0 4.057627336351288e-07
- O 0 7.658833567347756e-08
grade O 0 1.2896015505248215e-05
, O 0 3.160824491033054e-08
non B-Disease 1 0.9753114581108093
- I-Disease 1 0.999573290348053
inherited I-Disease 1 1.0
breast I-Disease 1 1.0
carcinomas I-Disease 1 1.0
. O 0 2.559182576078456e-06

Although O 0 6.659251994278748e-08
the O 0 1.431417473440888e-08
link O 0 8.453964994714624e-08
between O 0 7.535206236752856e-08
the O 0 2.265437899495737e-07
BRCA1 O 0 8.91144372872077e-06
tumour B-Disease 1 1.0
- O 0 1.919884016388096e-05
suppressor O 0 1.031269675877411e-05
gene O 0 4.837601430551786e-09
and O 0 2.405774024438756e-09
hereditary B-Disease 1 1.0
breast I-Disease 1 1.0
and I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
is O 0 7.848832319723442e-05
established O 0 4.938986108982135e-08
, O 0 7.933971535312168e-11
the O 0 5.298995686686681e-10
role O 0 4.416194521184025e-09
, O 0 1.3742995630394716e-10
if O 0 1.451408437880275e-10
any O 0 1.3329146675289394e-09
, O 0 1.2234119273202282e-10
of O 0 5.433234306906343e-09
BRCA1 O 0 8.601845458144908e-09
in O 0 3.542832871517021e-08
non B-Disease 1 0.9998819828033447
- I-Disease 1 0.9487205743789673
familial I-Disease 1 0.9999977350234985
cancers I-Disease 1 0.9999815225601196
is O 0 3.338788800988368e-08
unclear O 0 3.002459720846673e-07
. O 0 2.984901215086211e-08

BRCA1 O 0 1.4687991097162012e-05
mutations O 0 2.6184819645891366e-08
are O 0 1.8880173813240475e-10
rare O 0 5.927896506996433e-10
in O 0 7.220788411643753e-09
sporadic B-Disease 0 0.05837177857756615
cancers I-Disease 1 0.9999339580535889
, O 0 1.0915123027643858e-08
but O 0 5.50820544731323e-09
loss O 0 5.685096311935922e-06
of O 0 8.848294896779407e-07
BRCA1 O 0 1.5617606763385083e-08
resulting O 0 1.054444309644964e-09
from O 0 2.384511754716101e-10
reduced O 0 9.22283249771283e-10
expression O 0 1.1632276253337182e-09
or O 0 6.965637511235911e-10
incorrect O 0 3.394810121903902e-08
subcellular O 0 2.074883013847284e-06
localization O 0 4.81798167584202e-07
is O 0 1.4248140445261015e-09
postulated O 0 4.949453824565353e-08
to O 0 3.81743692212666e-10
be O 0 3.0854580002070975e-10
important O 0 1.0550901263783885e-09
in O 0 5.82355319522776e-09
non B-Disease 0 0.0016104386886581779
- I-Disease 0 0.3550659120082855
familial I-Disease 1 1.0
breast I-Disease 1 1.0
and I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancers I-Disease 1 1.0
. O 0 1.8342052499065176e-05

Epigenetic O 0 0.017650505527853966
loss O 0 0.00010377638682257384
, O 0 1.8936164636329522e-08
however O 0 1.5280345877499713e-08
, O 0 1.1590927107008042e-09
has O 0 2.1047015519304324e-10
not O 0 6.763310050894589e-11
received O 0 4.1946018880523184e-10
general O 0 2.155757128363689e-09
acceptance O 0 7.291260484265649e-09
due O 0 3.1540853484557374e-08
to O 0 7.69844354930882e-10
controversy O 0 6.325158175002343e-09
regarding O 0 5.003106373635546e-09
the O 0 5.552942550224316e-09
subcellular O 0 1.4444180123973638e-05
localization O 0 1.150728962784342e-06
of O 0 1.690070838833435e-08
BRCA1 O 0 9.584619320435195e-09
proteins O 0 5.733910013461241e-10
, O 0 1.030780183430835e-10
reports O 0 2.120400965921476e-09
of O 0 1.3912701213314449e-08
which O 0 6.210249536842127e-10
have O 0 5.514780646032058e-11
ranged O 0 2.526545372916189e-08
from O 0 2.7717450556963286e-09
exclusively O 0 1.0976356712433244e-08
nuclear O 0 8.826685302665283e-07
, O 0 9.090693198210431e-10
to O 0 8.087234770748353e-10
conditionally O 0 4.674140541283123e-08
nuclear O 0 1.5656983975986805e-07
, O 0 5.184109808098469e-10
to O 0 1.6063796959286947e-09
the O 0 6.026066756703585e-08
ER O 0 0.0005083597498014569
/ O 0 1.0217358976660762e-06
golgi O 0 9.32248804019764e-06
, O 0 2.0851951276767977e-09
to O 0 3.904494949580339e-09
cytoplasmic O 0 2.413323045402649e-06
invaginations O 0 4.5389047045318875e-06
into O 0 5.180240236768441e-08
the O 0 1.22356070164642e-07
nucleus O 0 2.9922969133622246e-06
. O 0 2.1774457081846776e-07

In O 0 1.616420604477753e-06
an O 0 4.101566730696504e-08
attempt O 0 2.2889179263074766e-07
to O 0 7.513288657889916e-09
resolve O 0 1.5029414157652354e-07
this O 0 4.589873814353496e-09
issue O 0 1.692067463920921e-08
, O 0 4.266886566295369e-10
we O 0 1.8579462413015335e-09
have O 0 5.633870037158317e-10
comprehensively O 0 1.1804599608922217e-07
characterized O 0 2.9467178919162507e-08
19 O 0 1.7528887497064716e-07
anti O 0 6.824040355013494e-08
- O 0 5.065527375336387e-07
BRCA1 O 0 5.879595477153998e-08
antibodies O 0 5.049246354360548e-09
. O 0 1.750060008021137e-08

These O 0 2.8580952715628882e-08
reagents O 0 9.22108185363868e-08
detect O 0 5.4955840766979236e-08
a O 0 3.2512659231542784e-08
220 O 0 6.495591975408388e-08
- O 0 2.588489067534283e-08
kD O 0 4.532654656941304e-06
protein O 0 8.036234788733054e-09
localized O 0 3.709195617318528e-09
in O 0 4.1020944974157203e-10
discrete O 0 2.0128243960471082e-08
nuclear O 0 1.368308062410506e-07
foci O 0 6.052594471839257e-06
in O 0 2.139792787403394e-09
all O 0 1.3843000079560852e-09
epithelial O 0 7.252911871091783e-08
cell O 0 4.0114062471729994e-07
lines O 0 2.3751349775835706e-09
, O 0 3.236763634895112e-11
including O 0 3.5719354557484095e-11
those O 0 1.150890494017176e-10
derived O 0 1.4426744243678513e-08
from O 0 9.983858717532712e-08
breast B-Disease 0 0.0026830059941858053
malignancies I-Disease 0 0.0011331269051879644
. O 0 4.9020840720004344e-08

Immunohistochemical O 0 0.01601376011967659
staining O 0 1.7908047084347345e-05
of O 0 1.9541457731975242e-06
human O 0 1.2930258890264668e-06
breast O 0 3.195821409462951e-05
specimens O 0 3.290703489255975e-06
also O 0 6.193065615889282e-09
revealed O 0 3.424354986236722e-07
BRCA1 O 0 1.0722605026103338e-07
nuclear O 0 1.9867311493726447e-06
foci O 0 0.00011838698264909908
in O 0 1.6767650379279075e-08
benign O 1 0.8276932239532471
breast O 0 0.0027297385968267918
, O 0 6.156099630061362e-08
invasive B-Disease 1 0.8024647831916809
lobular I-Disease 1 1.0
cancers I-Disease 1 0.9999998807907104
and O 0 7.7633876571781e-07
low B-Disease 1 1.0
- I-Disease 1 1.0
grade I-Disease 1 1.0
ductal I-Disease 1 1.0
carcinomas I-Disease 1 1.0
. O 0 2.635553983054706e-06

Conversely O 0 6.455673428718e-05
, O 0 6.57292531514031e-08
BRCA1 O 0 1.754352183525043e-07
expression O 0 3.2639597691286326e-08
was O 0 2.7986798656343126e-08
reduced O 0 2.2561221779682228e-09
or O 0 1.7933213802834302e-09
undetectable O 0 1.4993775110383467e-08
in O 0 9.424920843770224e-10
the O 0 1.3535382814566788e-09
majority O 0 1.1988705861387672e-10
of O 0 2.077700678171368e-08
high O 0 8.357320666618762e-07
- O 0 1.3955963140688254e-06
grade O 0 0.04807286337018013
, O 0 7.307145097001921e-06
ductal B-Disease 1 1.0
carcinomas I-Disease 1 1.0
, O 0 1.3141690402562745e-08
suggesting O 0 5.137516012609922e-08
that O 0 2.257287412543718e-10
absence O 0 4.0718379779036695e-08
of O 0 8.390832562099604e-08
BRCA1 O 0 2.169775292770737e-08
may O 0 2.079892258421978e-09
contribute O 0 1.6936810842693717e-09
to O 0 1.301156293820327e-09
the O 0 7.406913749008481e-09
pathogenesis O 0 1.614590837561991e-05
of O 0 1.7036217769828e-08
a O 0 1.5658551122399444e-09
significant O 0 1.5812036124884798e-09
percentage O 0 3.300318596188845e-08
of O 0 2.8674925545146834e-08
sporadic B-Disease 0 0.005958678666502237
breast I-Disease 1 0.9999799728393555
cancers I-Disease 1 0.9924497604370117
. O 0 3.611799570535368e-08
. O 0 7.71694459444916e-08

